[
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03392"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03246"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07552"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08773"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07154"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07402"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00493"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03098"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07707"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12633"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00858"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06444"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09570"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02995"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16891"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13071"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08602"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04228"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00276"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08392"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03115"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08961"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04929"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14531"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00645"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05214"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16076"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01859"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15099"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14124"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07965"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07647"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07157"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06788"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12208"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02947"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03826"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05653"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04269"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11952"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01692"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00865"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04601"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08789"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03657"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04886"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07275"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12120"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15772"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07773"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08551"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01077"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01331"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15617"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00160"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03923"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08294"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03009"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00324"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01836"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12253"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05434"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13156"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13002"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03933"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02303"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03733"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02127"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09546"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07701"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00701"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04074"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07712"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01448"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08353"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08847"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15914"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04723"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03948"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04497"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08360"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08211"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05419"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08283"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13508"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02297"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09231"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02390"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03883"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02288"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08642"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12423"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07914"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04486"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08314"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07296"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01451"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05239"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06931"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05384"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11718"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11633"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04651"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13483"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07933"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13577"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02177"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14815"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13698"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01489"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11980"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07606"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03870"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07100"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07747"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12197"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02949"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01841"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00188"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04691"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15570"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01683"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03924"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16535"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06894"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02356"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16440"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04013"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07601"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08767"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05381"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08921"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14649"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03630"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01765"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18153"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15170"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15915"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06166"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03735"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08666"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02404"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18232"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00258"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08465"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04494"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00602"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08730"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08685"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12771"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12378"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11943"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08787"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03622"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11379"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08862"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01362"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03412"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03791"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12464"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05492"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03378"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01543"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08303"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00924"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08781"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11623"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13848"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08794"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07945"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06421"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03559"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12545"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16707"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03839"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04405"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08248"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07612"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08718"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01503"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08830"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02937"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08917"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09011"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04609"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13782"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02938"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13019"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02524"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07599"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13275"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16652"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02470"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06698"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07061"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13436"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07535"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03722"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05899"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06766"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05768"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16004"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08637"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07223"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02916"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17118"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01704"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07940"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08875"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16204"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08891"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15984"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11188"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07241"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08994"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07174"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07622"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15460"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06626"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06237"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02971"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17202"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18164"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13638"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02048"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12597"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18584"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07294"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02168"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16871"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03798"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03358"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03386"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01924"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14221"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04387"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01661"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15927"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14737"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02401"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07305"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03139"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02163"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00514"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03011"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04600"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16176"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01952"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17737"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02028"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01912"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04734"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00207"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00221"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01709"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08652"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07163"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17108"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08480"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03413"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06872"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08725"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09262"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00901"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00328"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02473"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16133"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11411"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06950"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15653"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03746"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05519"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04532"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13825"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06730"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02433"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01561"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02343"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06347"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06935"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03189"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14205"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08614"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06179"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04458"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01865"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07103"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02309"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08493"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02924"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03059"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16766"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08141"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17985"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08976"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01093"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15401"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03044"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13314"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05172"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04646"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01723"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00843"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14092"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08843"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03153"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02266"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17398"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07722"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00969"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13879"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15056"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17919"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07721"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03439"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07546"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08486"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08238"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08062"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01439"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01925"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06419"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08822"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04841"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04804"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08083"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03515"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06216"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07796"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03379"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05050"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04002"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14083"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08710"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03448"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14025"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16124"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14845"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11210"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00918"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07045"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09403"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04163"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12613"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02622"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02806"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15125"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07898"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01958"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01126"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02711"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13103"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08664"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12957"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01425"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03225"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12298"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08262"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07999"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11684"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18200"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07210"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09133"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04162"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14557"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01825"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07876"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08004"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03774"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02665"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06733"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12388"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15033"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08593"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13712"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06742"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12997"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04326"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00639"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00803"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00426"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02514"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16168"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08510"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05129"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15222"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02593"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02124"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07611"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00693"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16078"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09129"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02679"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14174"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03548"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01616"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03110"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15168"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07423"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07737"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03372"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14684"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14828"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08946"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03700"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04092"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11318"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02681"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08171"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11150"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01892"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08007"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02255"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04716"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04471"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00515"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05780"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14953"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02333"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11783"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15610"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02668"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05159"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07161"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06885"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08045"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03489"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18038"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15887"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15360"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13257"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06061"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13089"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11591"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07480"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08661"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17108"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02572"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08743"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03485"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02716"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02032"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00889"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05938"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03216"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02315"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00222"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08858"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00800"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07189"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18345"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07559"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06835"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01960"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01996"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04371"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08712"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00326"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13370"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04577"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04474"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08760"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01944"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00265"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13821"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02005"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15916"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15881"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06231"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04707"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01972"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17734"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18060"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02059"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03505"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07090"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08264"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16165"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00855"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15351"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04708"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03383"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13373"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07413"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08588"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08644"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07892"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07186"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17769"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14543"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00363"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13674"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07301"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07381"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13012"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07746"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00773"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01853"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04793"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13966"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05351"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07859"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08542"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17127"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05757"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02376"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04124"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02881"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07273"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00766"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04851"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15425"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00349"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04597"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06937"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02805"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02893"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13502"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08609"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04023"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01949"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12860"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04830"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02265"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03338"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03569"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07197"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13439"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15436"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00404"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09301"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00861"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12557"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01246"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13028"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12465"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13291"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13573"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02460"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14846"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16602"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15347"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02489"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05226"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01694"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15205"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13604"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12528"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07890"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13686"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15291"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14581"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04051"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02728"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17159"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11789"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06307"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12883"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12591"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16083"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05724"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14753"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04425"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02797"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00575"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02454"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07596"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00154"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02354"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01997"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13386"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02595"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08748"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01470"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15993"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12059"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18678"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03732"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14929"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02993"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08522"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01814"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13625"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07791"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13954"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00322"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11409"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04854"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00604"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01986"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11961"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08569"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07429"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04053"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04266"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06395"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00655"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00644"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16157"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18632"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03421"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12500"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15991"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07858"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04546"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07432"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03598"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01822"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08624"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03222"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15659"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13160"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18498"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11650"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06907"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07788"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01933"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02607"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03239"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04541"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02879"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07006"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08529"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02472"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03616"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01161"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05009"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02143"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04782"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13751"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07903"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01437"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11778"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14001"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03944"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07300"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08980"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06980"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05130"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00578"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02730"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04641"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03760"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00517"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01119"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06920"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12966"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04564"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08265"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02007"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01773"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00274"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05660"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03773"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08485"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03223"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02388"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02623"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02722"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04855"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02796"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03071"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17115"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11386"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06151"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01200"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04794"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02360"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04884"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09123"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05866"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03982"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08200"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02776"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08514"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07076"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12471"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12881"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04849"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08838"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04079"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07597"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07984"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07324"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11916"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07132"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03472"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13561"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01512"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06900"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15951"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07201"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12685"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03441"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07433"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11382"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03683"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15407"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13697"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04350"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03318"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02542"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04235"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01510"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16339"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03215"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07764"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11257"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03217"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08164"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15293"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12630"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03442"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07207"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13259"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03955"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07378"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06683"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07278"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17234"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08615"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04197"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08011"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07751"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03391"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02994"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00758"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01987"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15825"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02878"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07177"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03007"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16949"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12996"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05418"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18178"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05606"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01802"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00710"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18118"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03241"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01812"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08095"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01674"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08424"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05326"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03396"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08807"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08101"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03751"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01794"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04674"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05800"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16050"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07426"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07025"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02510"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07149"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08809"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03395"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12696"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04116"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04086"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01432"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07947"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08383"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11221"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02347"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05404"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13221"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12239"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04806"
    },
    {
        "smiles": "[OH-].[OH-].[OH-].[Mg++].[Cl-].[K++].[K++].[Ca++].[O-]C([O-])=O",
        "id": "DB14497",
        "molecule": "Calcium magnesium potassium carbonate chloride hydroxide",
        "cas": "1224727-39-2",
        "iupac_name": "calcium magnesium(2+) dipotassium(2+) chloride trihydroxide carbonate",
        "inchi": {
            "hash": "RUGQTQJQCSDUFS-UHFFFAOYSA-H",
            "id": "InChI=1S/CH2O3.Ca.ClH.2K.Mg.3H2O/c2-1(3)4;;;;;;;;/h(H2,2,3,4);;1H;;;;3*1H2/q;+2;;3*+2;;;/p-6"
        },
        "weight": [
            {
                "type": "average",
                "weight": 289.06,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 287.8357639,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14497",
        "type": "Small Molecule",
        "synonyms": [
            "Alka4-complex"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03302"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01565"
    },
    {
        "smiles": "NC1=NC2=C(N=C(CN3C4=CC=CC=C4C=CC4=CC=CC=C34)C=N2)C(N)=N1",
        "id": "DB08406",
        "molecule": "[N-(2,4-DIAMINOPTERIDIN-6-YL)-METHYL]-DIBENZ[B,F]AZEPINE",
        "iupac_name": "6-({2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}methyl)pteridine-2,4-diamine",
        "inchi": {
            "hash": "NXCCIJQEAKMFGW-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H17N7/c22-19-18-20(27-21(23)26-19)24-11-15(25-18)12-28-16-7-3-1-5-13(16)9-10-14-6-2-4-8-17(14)28/h1-11H,12H2,(H4,22,23,24,26,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 367.4066,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 367.154543579,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB08406",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07484"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14046"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12657"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02888"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08884"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01744"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06987"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08958"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12506"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04292"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04842"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06873"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12635"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04449"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01974"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05064"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01573"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16164"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07203"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17696"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03228"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04652"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13575"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08544"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18445"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03928"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15657"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02620"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13529"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03652"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11902"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14530"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03739"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02372"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07577"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01935"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17383"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06955"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08061"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05801"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01474"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07616"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16572"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16832"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17456"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07814"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13333"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05051"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01150"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13279"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05023"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05069"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15675"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15795"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02627"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02963"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12665"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01961"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02036"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12805"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13909"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07200"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00770"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02560"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00158"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08259"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07339"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05268"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03142"
    },
    {
        "smiles": "[H][C@](NC(=O)OCC1=CC=CC=C1)(C1=CC=C(C=C1)C(N)=N)P(O)(O)=O",
        "id": "DB08763",
        "molecule": "[N-(BENZYLOXYCARBONYL)AMINO](4-AMIDINOPHENYL)METHANE-PHOSPHONATE",
        "iupac_name": "[(R)-{[(benzyloxy)carbonyl]amino}(4-carbamimidoylphenyl)methyl]phosphonic acid",
        "inchi": {
            "hash": "FSNDLCSOLUMYRH-OAHLLOKOSA-N",
            "id": "InChI=1S/C16H18N3O5P/c17-14(18)12-6-8-13(9-7-12)15(25(21,22)23)19-16(20)24-10-11-4-2-1-3-5-11/h1-9,15H,10H2,(H3,17,18)(H,19,20)(H2,21,22,23)/t15-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 363.305,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 363.098407213,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzyloxycarbonyls. These are organic compounds containing a carbonyl group substituted with a benzyloxyl group.",
        "link": "https://go.drugbank.com/drugs/DB08763",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "OCCCC(O)=O",
        "id": "DB01440",
        "molecule": "gamma-Hydroxybutyric acid",
        "cas": "591-81-1",
        "iupac_name": "4-hydroxybutanoic acid",
        "background": "Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.\n",
        "inchi": {
            "hash": "SJZRECIVHVDYJC-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 104.1045,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 104.047344122,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB01440",
        "type": "Small Molecule",
        "synonyms": [
            "3-carboxypropoxy acid",
            "4-hydroxy-butyric acid",
            "4-hydroxybutanoate",
            "4-hydroxybutanoic acid",
            "4-Hydroxybutyric acid",
            "gamma-Hydroxybutyrate",
            "GHB",
            "oxy-n-butyric acid",
            "Oxybate",
            "-Hydroxybutyric acid"
        ],
        "indication": "Used as a general anesthetic, to treat conditions such as insomnia, clinical depression, narcolepsy, and alcoholism, and to improve athletic performance. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "GHB predominantly works at two distinct binding sites in the central nervous system: it works as an agonist at the newly-characterized excitatory GHB receptor, while acting as a weak agonist at the inhibitory GABAB receptor. Since it is a naturally occurring substance, its physiological action is similar to that of some endogenous neurotransmitters in mammalian brain. GHB is probably synthesized from GABA in GABAergic neurons, and released when the neurons fire.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AGamma-hydroxybutyrate (GHB) receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit beta-1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08761"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00586"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03877"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03443"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15350"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08701"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11140"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08316"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13565"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12475"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04891"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16209"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00689"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15763"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16660"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17160"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06864"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12671"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16117"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16622"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03206"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15647"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18023"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08897"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07517"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07342"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07866"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07141"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08971"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08172"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08304"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12505"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01560"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02263"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02836"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15903"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06743"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05308"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14680"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13582"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03400"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07262"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11275"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00378"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07821"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11408"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18124"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04547"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04380"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13871"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08058"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15348"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03374"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04947"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04813"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03312"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12732"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14201"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08663"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04144"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04719"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11743"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00637"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02794"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13379"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18172"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11417"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01099"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08533"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12242"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02402"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07345"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02217"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00411"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02659"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07896"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08120"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00986"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01780"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17521"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13470"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04718"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08345"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05249"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16752"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07379"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11978"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17025"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02862"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01905"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04202"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03849"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13316"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07585"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03320"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08356"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03201"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15565"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08972"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08129"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00547"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04069"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04569"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01714"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03886"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13694"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12004"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00298"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07572"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00979"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18208"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08857"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08333"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11935"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16525"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13516"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15448"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00356"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16183"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11239"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08017"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04010"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08423"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07078"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08536"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04367"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02535"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01824"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02758"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08525"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04227"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04453"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02948"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03284"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11105"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08662"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18011"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00712"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13382"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01531"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05015"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08044"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02778"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02606"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04596"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17756"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05108"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04576"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07268"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01762"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04745"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12393"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09235"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14914"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03809"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11936"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13810"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05932"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08540"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02780"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08627"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04463"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01942"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04769"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04696"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13350"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17494"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09088"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09065"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04549"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16683"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08871"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04714"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05310"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07209"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15618"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02301"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07409"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01611"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08671"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16403"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00523"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08695"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08046"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13970"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09495"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01193"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03112"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03968"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13796"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08583"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01197"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07343"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03993"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03231"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16838"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02104"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02661"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07314"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02364"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11921"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11617"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13648"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07857"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08033"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15411"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18175"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00958"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07732"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00317"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06744"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00998"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06923"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05973"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02696"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03860"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15374"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08982"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16319"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12707"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13338"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14665"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11074"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01329"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08987"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03607"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08153"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02161"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02442"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03469"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07794"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14844"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13908"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03663"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02743"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12126"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17261"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07397"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17259"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03737"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05395"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04818"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15797"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02200"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03523"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11392"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03670"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01240"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15418"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00609"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04699"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07578"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06133"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12322"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15051"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03550"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07299"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03624"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07570"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04683"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02278"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16063"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14634"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12789"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18170"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07064"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07131"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03100"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13865"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07757"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07961"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18464"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17399"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07091"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11874"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16144"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15309"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17257"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03258"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04264"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03588"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01460"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02619"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04807"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01953"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01064"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04011"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07680"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04470"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01766"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03357"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11944"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03756"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07460"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07510"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12680"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02373"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07669"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07027"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02866"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02294"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16874"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06926"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02898"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08461"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05812"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03087"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05444"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01587"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08090"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02133"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12938"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01862"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13101"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16759"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15011"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01540"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13435"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00587"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08165"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01275"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04510"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08759"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14598"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04298"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04920"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02076"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14653"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00311"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02096"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04566"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12354"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01031"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11254"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15156"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14668"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02721"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05127"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18600"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14701"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16132"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06919"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13100"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04286"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01598"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05284"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09083"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05103"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07949"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00928"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17493"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07043"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08255"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00242"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11982"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01697"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04366"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14766"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01245"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03813"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03869"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04551"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02429"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13240"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11717"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07009"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02532"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06299"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15391"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00828"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11573"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04746"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08435"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04668"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08984"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01248"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04643"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02052"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02657"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14080"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15435"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02135"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06881"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03156"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14934"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08197"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08206"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13626"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07052"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06696"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16087"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18689"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05869"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08472"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14795"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00228"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00985"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02798"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03180"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04119"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02006"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16856"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08575"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00597"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08376"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02861"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11284"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01242"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00027"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02853"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06512"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14572"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01800"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06888"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14951"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03422"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06543"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09214"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07837"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17851"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00294"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02021"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08323"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17312"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08990"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00529"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04130"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00751"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05025"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04888"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13696"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03445"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05263"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02946"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03178"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02339"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13018"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05166"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09000"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00565"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04218"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07852"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15902"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13258"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07567"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03237"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07437"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08608"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14093"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04647"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08015"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05971"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09223"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06677"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13102"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08213"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03986"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08154"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16171"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01294"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15422"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00651"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02504"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00846"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07353"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08503"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12806"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07556"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04226"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00798"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02740"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07986"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06261"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07855"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07172"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01936"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03843"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08591"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07206"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01213"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07818"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02663"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17143"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14719"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18069"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14045"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05048"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07851"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11208"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13006"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04239"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13789"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13919"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08952"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01939"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08949"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03832"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07521"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13560"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13297"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12596"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01689"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07610"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03384"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08110"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14969"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12438"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18007"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18588"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14552"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15058"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07087"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12459"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03140"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07376"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03769"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09305"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02456"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08273"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01469"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04679"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02041"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03164"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07809"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03420"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08595"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07580"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00180"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03725"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13423"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15646"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12931"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07972"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06597"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04419"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04544"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01742"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02907"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08927"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01746"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07724"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03269"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04360"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04246"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15637"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07469"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13277"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07130"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03185"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03980"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06986"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02699"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02704"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14526"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04499"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16107"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15833"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08367"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00438"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08526"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07409"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02966"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08354"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03623"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02426"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11516"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03679"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05188"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07102"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08791"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01160"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03166"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13709"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06774"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08175"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12074"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13548"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03711"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06871"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02585"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08319"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08420"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08079"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07831"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05369"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01322"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01614"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00362"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06274"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03475"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07083"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02162"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00283"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16130"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00303"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00278"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16866"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07453"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02549"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08386"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07421"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12980"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02371"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14528"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08962"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04457"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13178"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01546"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07883"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08523"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06860"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01717"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00719"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07793"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02914"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04378"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04306"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16189"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03339"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12305"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07688"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03508"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03043"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12664"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18220"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01806"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08887"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15012"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07416"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00365"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11168"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01635"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15597"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12767"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00430"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17546"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03506"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08384"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05683"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07319"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16075"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03353"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01712"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14722"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03554"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17033"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15189"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08556"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06887"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00142"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12740"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08572"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07908"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00535"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11123"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14807"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15918"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07739"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12358"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17027"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11242"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07110"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04174"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03824"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00887"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04838"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07179"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13317"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18442"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00872"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04139"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08648"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02508"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09166"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09382"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17198"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01112"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08363"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04030"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00700"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12237"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04362"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03141"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03909"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01175"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16297"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09188"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15287"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03066"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01466"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01547"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03192"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00204"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13402"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11171"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07718"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00681"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01494"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14086"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01538"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14917"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13874"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05936"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01418"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18061"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04248"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11561"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06728"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03567"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07806"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15440"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13861"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01060"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08438"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08470"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06946"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03336"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01539"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07832"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08288"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00429"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13788"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01427"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04179"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13841"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06699"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07911"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08740"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08973"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00513"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13780"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13206"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07192"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08158"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06772"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18400"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07990"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07539"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03979"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17030"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08675"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01354"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02469"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08820"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09284"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01633"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01527"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13209"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15424"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12618"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07133"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00804"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07596"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01902"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11758"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04313"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16142"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09393"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01152"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08579"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14637"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15492"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03676"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17567"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07635"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09060"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04802"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13854"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08443"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13990"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03004"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05424"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14823"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00436"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02864"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01965"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18077"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02632"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00270"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16025"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02618"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07836"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01484"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00613"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15380"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01932"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02573"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14755"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09255"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08127"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06977"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11522"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14866"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12508"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07440"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06938"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00927"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08088"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00947"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02828"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07066"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11810"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13473"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16354"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02548"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03499"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02755"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12259"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08180"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16835"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14860"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00783"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04373"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15649"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03718"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01786"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17506"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11796"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12009"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09563"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08245"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01023"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07075"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04049"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00676"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18493"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06925"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04303"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01740"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04459"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06842"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07053"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15123"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09425"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01984"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07060"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11831"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17408"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16037"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13755"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00636"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02450"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09055"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04742"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04722"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07213"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01473"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09333"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14529"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02854"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04446"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12730"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05057"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07607"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01771"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01701"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09093"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07762"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15670"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13837"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04059"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08698"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09204"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04260"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07042"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01351"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03961"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03942"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11932"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00201"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11383"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06622"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00301"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07593"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11885"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11348"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11075"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13285"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16635"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06143"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03208"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16102"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01326"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08077"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09480"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01176"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02691"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01050"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02987"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03366"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02019"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16536"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00756"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11847"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07912"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01613"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16058"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03322"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00569"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01340"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14638"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04062"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04315"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06248"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11203"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14547"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11587"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03176"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07403"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04311"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15268"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15203"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12819"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01167"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00143"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00442"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04177"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12028"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01497"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14803"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00354"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06914"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09002"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07664"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03581"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18393"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08611"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01253"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04076"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03771"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03682"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00192"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16122"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15341"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08957"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13269"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02972"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08379"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08216"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11880"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13256"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07355"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02260"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04784"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14655"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02520"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07026"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08668"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08617"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11350"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05659"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07558"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03688"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03603"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13645"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03641"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01019"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07758"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13446"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00915"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08739"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04560"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00316"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14763"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07471"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04448"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16527"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08457"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12333"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06263"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02852"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16872"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06879"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02563"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14674"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02413"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15132"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06447"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01756"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07321"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04517"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13276"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04791"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02788"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01850"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07823"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02367"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03116"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07407"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01959"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04478"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02232"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13863"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11367"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15669"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09007"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15138"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04254"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05894"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04816"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00456"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06888"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02537"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03091"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00841"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08993"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17735"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08709"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02545"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15587"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01177"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13940"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00813"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02438"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00290"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12800"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07040"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04006"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02420"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15202"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02613"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00240"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00625"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13389"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04045"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08049"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12731"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09257"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03341"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11372"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02119"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08212"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07290"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18056"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12993"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03781"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02727"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00450"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09293"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15684"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08926"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11404"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01373"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07513"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16120"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09086"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13545"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16822"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03995"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03708"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00950"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12968"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18236"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01625"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01567"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14715"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11841"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12725"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07966"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03137"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15392"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13493"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02666"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01843"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15875"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02205"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06616"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02847"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08204"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16101"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02087"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08856"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09401"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03971"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06767"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02566"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08596"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08309"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07717"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02274"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01544"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04374"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01681"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09232"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04027"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15638"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12289"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02683"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01095"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04711"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14810"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00845"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00225"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04480"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09115"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15689"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04554"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14038"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06973"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00573"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02090"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12161"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01872"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03646"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08916"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08597"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17602"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15096"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06224"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02253"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03270"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13286"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03064"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13636"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03257"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08484"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01515"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11519"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12915"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03643"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03252"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05873"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01849"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05016"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03287"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08096"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08389"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08214"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16887"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06580"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06445"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02203"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07237"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07266"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07644"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17307"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00470"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18033"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07162"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07638"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07660"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15908"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11757"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13231"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03947"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04308"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04164"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07494"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01212"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03530"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07023"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18407"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04277"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07789"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00131"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07495"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02051"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07829"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17621"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12610"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08402"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00690"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09501"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08005"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02236"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12776"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02331"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15462"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11089"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14207"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12869"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17936"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13098"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16894"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03929"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07459"
    },
    {
        "smiles": "[H][C@]1(CO)O[C@@]([H])(OC2=CC=CC=C2N(=O)=O)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O",
        "id": "DB01920",
        "molecule": "1-O-[O-Nitrophenyl]-Beta-D-Galactopyranose",
        "iupac_name": "(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(2-nitrophenoxy)oxane-3,4,5-triol",
        "background": "Includes ortho-, meta-, and para-nitrophenylgalactosides. [PubChem]\n",
        "inchi": {
            "hash": "KUWPCJHYPSUOFW-YBXAARCKSA-N",
            "id": "InChI=1S/C12H15NO8/c14-5-8-9(15)10(16)11(17)12(21-8)20-7-4-2-1-3-6(7)13(18)19/h1-4,8-12,14-17H,5H2/t8-,9+,10+,11-,12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 301.2494,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 301.079766461,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.",
        "link": "https://go.drugbank.com/drugs/DB01920",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-galactosidase"
            }
        ]
    },
    {
        "smiles": "CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl",
        "id": "DB01559",
        "molecule": "Clotiazepam",
        "cas": "33671-46-4",
        "iupac_name": "5-(2-chlorophenyl)-7-ethyl-1-methyl-1H,2H,3H-thieno[2,3-e][1,4]diazepin-2-one",
        "background": "Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.\n",
        "inchi": {
            "hash": "CHBRHODLKOZEPZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3"
        },
        "summary": "Clotiazepam is a thienodiazepine used to manage anxiety disorders and insomnia.",
        "weight": [
            {
                "type": "average",
                "weight": 318.821,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 318.059361509,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thienodiazepines. These are heteropolycyclic containing a thiophene ring fused to a diazepine ring. Thiophene is 5-membered ring consisting of four carbon and one sulfur atoms. Diazepine is a 7-membered ring consisting of five carbon and two nitrogen atoms.",
        "link": "https://go.drugbank.com/drugs/DB01559",
        "type": "Small Molecule",
        "synonyms": [
            "Clotiazepam",
            "Clotiazepamum"
        ],
        "indication": "For the treatment of anxiety disorders.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Clotiazepam is a thienodiazepine possessing anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It increases the stage 2 non-rapid eye movement sleep.\n",
        "moa": [
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "AGABA(A) Receptor Benzodiazepine Binding Site"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08408"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02280"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11958"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04864"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06197"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00937"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01754"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06112"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14524"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08186"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07954"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03618"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02609"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08305"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02641"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09508"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02942"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05953"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09448"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02031"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07958"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02645"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02953"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07404"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02592"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11946"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05814"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09261"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02786"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01223"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03471"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06090"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03430"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07497"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15931"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03724"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13800"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01249"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02225"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04133"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06470"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03328"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02038"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18313"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05463"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03820"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08078"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13650"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08358"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18083"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13472"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00452"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03158"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04211"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14726"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06844"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13682"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00132"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07685"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01602"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11894"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02362"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03887"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08495"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07465"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01761"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01998"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02941"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18003"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07012"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07666"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14489"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09026"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04438"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03793"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18603"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12946"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18267"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15583"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00475"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11504"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08013"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02503"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03370"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07899"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11290"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15230"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08375"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15286"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07489"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03960"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03355"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12412"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05036"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01296"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00465"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13569"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03516"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04941"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08177"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15932"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16560"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06943"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05676"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15183"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02459"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01537"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16623"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00823"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01429"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18514"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06486"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03361"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16036"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05417"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04565"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01462"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16080"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05170"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00945"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07185"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02228"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07595"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13617"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11651"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00369"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14535"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01644"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08618"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08531"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00632"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02541"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01370"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08570"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00941"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06918"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12319"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02616"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17137"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12567"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00492"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02654"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07723"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04528"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03162"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12263"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04845"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04450"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02279"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02565"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01556"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14070"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07277"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13935"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02923"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07360"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17545"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04573"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01788"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06127"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06780"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15832"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12196"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17817"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12745"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15619"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05541"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02611"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08577"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00942"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13630"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02697"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11750"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08532"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09215"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17654"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17742"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02013"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07151"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05198"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12063"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04665"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04206"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13721"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07853"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06852"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12029"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02092"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01251"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16052"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04036"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07211"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01086"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06071"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01239"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11285"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08397"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05710"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11374"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11674"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06362"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02837"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03124"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13060"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06721"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06837"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02252"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08312"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04180"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05205"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06829"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01477"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05750"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02676"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01926"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07575"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12380"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06781"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12429"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06855"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12313"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11577"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03342"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08473"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01144"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06581"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09218"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01852"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12941"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12810"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00327"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03637"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04789"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06954"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08966"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03354"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02636"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14188"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02275"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02441"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13960"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09279"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12348"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03925"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07371"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07348"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12878"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11782"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06990"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14639"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05076"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04089"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03584"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08268"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07283"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13745"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07694"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16048"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08955"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01216"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02970"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07466"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03454"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04839"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07745"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15873"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05494"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11682"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07038"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02227"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15760"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01010"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07874"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08307"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01914"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13044"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14656"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02710"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06782"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02359"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03595"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09378"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02060"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02045"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04887"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03234"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14002"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13428"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14063"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02152"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03163"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05217"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00608"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11583"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07880"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09375"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11769"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07949"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00407"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02108"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02571"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08463"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08160"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16125"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03210"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13345"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07450"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08126"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16290"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03716"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03303"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02582"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02985"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08826"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13505"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12760"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06754"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04660"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07579"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08003"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08357"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03981"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05806"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18100"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01564"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18303"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17135"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16962"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07815"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00091"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12316"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03943"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08060"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03434"
    },
    {
        "smiles": "OC1=C(CNC2CCN(CC2)S(=O)(=O)NC2=CC(OC3=CC=C(F)C=C3)=CC=C2)C=CC=C1",
        "id": "DB04632",
        "molecule": "4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE",
        "iupac_name": "N-[3-(4-fluorophenoxy)phenyl]-4-{[(2-hydroxyphenyl)methyl]amino}piperidine-1-sulfonamide",
        "inchi": {
            "hash": "JHHBGNIRSUTQAS-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H26FN3O4S/c25-19-8-10-22(11-9-19)32-23-6-3-5-21(16-23)27-33(30,31)28-14-12-20(13-15-28)26-17-18-4-1-2-7-24(18)29/h1-11,16,20,26-27,29H,12-15,17H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 471.544,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 471.16280523,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.",
        "link": "https://go.drugbank.com/drugs/DB04632",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 14"
            }
        ]
    },
    {
        "smiles": "CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O",
        "id": "DB14018",
        "molecule": "Bromotheophylline",
        "cas": "10381-75-6",
        "iupac_name": "8-bromo-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione",
        "background": "Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.1 Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.3 It is also approved by Health Canada to be used alone or in combination with Acetaminophen in OTC products.4\n",
        "inchi": {
            "hash": "SKTFQHRVFFOHTQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H7BrN4O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H,9,10)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 259.063,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 257.975238,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14018",
        "type": "Small Molecule",
        "synonyms": [
            "8-Bromotheophylline"
        ],
        "indication": "Bromotheophylline is used as a diuretic and also, in combination with Acetaminophen, it is used for the relief of temporary water weight gain, bloating, swelling and full feeling associated with the premenstrual and menstrual periods.5\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bromotheophylline diuretic action will produce an immediate increase in urination frequency. This effect aids in the relief of bloating and menstrual pain.1 This diuretic function is performed by the an increase in glomerular filtration and a potential effect in the tubular reabsorption as it is established that the administration of these agents produce a rise in the urinary concentration of sodium a chloride and thus, an increase in their rates of excretion.2\n",
        "drug_interactions": [
            [
                "\u003ca href=\"/drugs/DB08496\"\u003e(R)-warfarin\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with (R)-warfarin."
            ],
            [
                "\u003ca href=\"/drugs/DB12537\"\u003e1,2-Benzodiazepine\u003c/a\u003e",
                "The therapeutic efficacy of 1,2-Benzodiazepine can be decreased when used in combination with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB01467\"\u003e2,5-Dimethoxy-4-ethylamphetamine\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB13940\"\u003e2,5-Dimethoxy-4-ethylthioamphetamine\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB03374\"\u003e3,5-Diiodotyrosine\u003c/a\u003e",
                "3,5-Diiodotyrosine may decrease the excretion rate of Bromotheophylline which could result in a higher serum level."
            ],
            [
                "\u003ca href=\"/drugs/DB01484\"\u003e4-Bromo-2,5-dimethoxyamphetamine\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB04070\"\u003e6-Deoxyerythronolide B\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with 6-Deoxyerythronolide B."
            ],
            [
                "\u003ca href=\"/drugs/DB11919\"\u003e6-O-benzylguanine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with 6-O-benzylguanine."
            ],
            [
                "\u003ca href=\"/drugs/DB02207\"\u003e7-Nitroindazole\u003c/a\u003e",
                "7-Nitroindazole may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB01667\"\u003e8-azaguanine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with 8-azaguanine."
            ],
            [
                "\u003ca href=\"/drugs/DB14132\"\u003e8-chlorotheophylline\u003c/a\u003e",
                "The metabolism of 8-chlorotheophylline can be decreased when combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB04356\"\u003e9-Deazaguanine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with 9-Deazaguanine."
            ],
            [
                "\u003ca href=\"/drugs/DB02489\"\u003e9-Methylguanine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with 9-Methylguanine."
            ],
            [
                "\u003ca href=\"/drugs/DB01048\"\u003eAbacavir\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB11932\"\u003eAbametapir\u003c/a\u003e",
                "The serum concentration of Bromotheophylline can be increased when it is combined with Abametapir."
            ],
            [
                "\u003ca href=\"/drugs/DB01281\"\u003eAbatacept\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be increased when combined with Abatacept."
            ],
            [
                "\u003ca href=\"/drugs/DB12100\"\u003eAbediterol\u003c/a\u003e",
                "The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Abediterol."
            ],
            [
                "\u003ca href=\"/drugs/DB05812\"\u003eAbiraterone\u003c/a\u003e",
                "The serum concentration of Bromotheophylline can be increased when it is combined with Abiraterone."
            ],
            [
                "\u003ca href=\"/drugs/DB01193\"\u003eAcebutolol\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when Acebutolol is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB06736\"\u003eAceclofenac\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB13573\"\u003eAcefylline\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Acefylline."
            ],
            [
                "\u003ca href=\"/drugs/DB13783\"\u003eAcemetacin\u003c/a\u003e",
                "The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Acemetacin."
            ],
            [
                "\u003ca href=\"/drugs/DB01418\"\u003eAcenocoumarol\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Acenocoumarol."
            ],
            [
                "\u003ca href=\"/drugs/DB00819\"\u003eAcetazolamide\u003c/a\u003e",
                "Acetazolamide may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00945\"\u003eAcetylsalicylic acid\u003c/a\u003e",
                "Acetylsalicylic acid may decrease the excretion rate of Bromotheophylline which could result in a higher serum level."
            ],
            [
                "\u003ca href=\"/drugs/DB08897\"\u003eAclidinium\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB09488\"\u003eAcrivastine\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00787\"\u003eAcyclovir\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00051\"\u003eAdalimumab\u003c/a\u003e",
                "The serum concentration of Bromotheophylline can be decreased when it is combined with Adalimumab."
            ],
            [
                "\u003ca href=\"/drugs/DB00640\"\u003eAdenosine\u003c/a\u003e",
                "The therapeutic efficacy of Adenosine can be decreased when used in combination with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB00546\"\u003eAdinazolam\u003c/a\u003e",
                "The therapeutic efficacy of Adinazolam can be decreased when used in combination with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB04956\"\u003eAfelimomab\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be increased when combined with Afelimomab."
            ],
            [
                "\u003ca href=\"/drugs/DB06594\"\u003eAgomelatine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Agomelatine."
            ],
            [
                "\u003ca href=\"/drugs/DB00518\"\u003eAlbendazole\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be increased when combined with Albendazole."
            ],
            [
                "\u003ca href=\"/drugs/DB05396\"\u003eAlbinterferon Alfa-2B\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Albinterferon Alfa-2B."
            ],
            [
                "\u003ca href=\"/drugs/DB12950\"\u003eAlbusomatropin\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be increased when combined with Albusomatropin."
            ],
            [
                "\u003ca href=\"/drugs/DB13884\"\u003eAlbutrepenonacog alfa\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Albutrepenonacog alfa which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB13167\"\u003eAlclofenac\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Alclofenac which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00041\"\u003eAldesleukin\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00802\"\u003eAlfentanil\u003c/a\u003e",
                "The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Alfentanil."
            ],
            [
                "\u003ca href=\"/drugs/DB15477\"\u003eAlloin\u003c/a\u003e",
                "The risk or severity of dehydration can be increased when Bromotheophylline is combined with Alloin."
            ],
            [
                "\u003ca href=\"/drugs/DB00437\"\u003eAllopurinol\u003c/a\u003e",
                "The serum concentration of Bromotheophylline can be increased when it is combined with Allopurinol."
            ],
            [
                "\u003ca href=\"/drugs/DB01431\"\u003eAllylestrenol\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB13595\"\u003eAlmasilate\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00918\"\u003eAlmotriptan\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB06203\"\u003eAlogliptin\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00969\"\u003eAlosetron\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Alosetron."
            ],
            [
                "\u003ca href=\"/drugs/DB01555\"\u003eAlphacetylmethadol\u003c/a\u003e",
                "The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Alphacetylmethadol."
            ],
            [
                "\u003ca href=\"/drugs/DB13160\"\u003eAlphaprodine\u003c/a\u003e",
                "The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Alphaprodine."
            ],
            [
                "\u003ca href=\"/drugs/DB00404\"\u003eAlprazolam\u003c/a\u003e",
                "The therapeutic efficacy of Alprazolam can be decreased when used in combination with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB00866\"\u003eAlprenolol\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when Alprenolol is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB00915\"\u003eAmantadine\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB01424\"\u003eAminophenazone\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Aminophenazone."
            ],
            [
                "\u003ca href=\"/drugs/DB01223\"\u003eAminophylline\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Aminophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB01118\"\u003eAmiodarone\u003c/a\u003e",
                "The serum concentration of Bromotheophylline can be increased when it is combined with Amiodarone."
            ],
            [
                "\u003ca href=\"/drugs/DB00321\"\u003eAmitriptyline\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB06767\"\u003eAmmonium chloride\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB01351\"\u003eAmobarbital\u003c/a\u003e",
                "The serum concentration of Bromotheophylline can be decreased when it is combined with Amobarbital."
            ],
            [
                "\u003ca href=\"/drugs/DB01060\"\u003eAmoxicillin\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00182\"\u003eAmphetamine\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when Amphetamine is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB00415\"\u003eAmpicillin\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB01427\"\u003eAmrinone\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00261\"\u003eAnagrelide\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Anagrelide."
            ],
            [
                "\u003ca href=\"/drugs/DB00026\"\u003eAnakinra\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be increased when combined with Anakinra."
            ],
            [
                "\u003ca href=\"/drugs/DB09103\"\u003eAncestim\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB11785\"\u003eAnisodamine\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when Anisodamine is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB09329\"\u003eAntihemophilic factor (recombinant), PEGylated\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB01435\"\u003eAntipyrine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Antipyrine."
            ],
            [
                "\u003ca href=\"/drugs/DB11598\"\u003eAntithrombin III human\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB11901\"\u003eApalutamide\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Apalutamide which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB05676\"\u003eApremilast\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be increased when combined with Apremilast."
            ],
            [
                "\u003ca href=\"/drugs/DB01102\"\u003eArbutamine\u003c/a\u003e",
                "The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Arbutamine."
            ],
            [
                "\u003ca href=\"/drugs/DB01274\"\u003eArformoterol\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Arformoterol which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB06413\"\u003eArmodafinil\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be increased when combined with Armodafinil."
            ],
            [
                "\u003ca href=\"/drugs/DB09204\"\u003eArotinolol\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when Arotinolol is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB01169\"\u003eArsenic trioxide\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB06216\"\u003eAsenapine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Asenapine."
            ],
            [
                "\u003ca href=\"/drugs/DB01072\"\u003eAtazanavir\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Atazanavir."
            ],
            [
                "\u003ca href=\"/drugs/DB00335\"\u003eAtenolol\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when Atenolol is combined with Bromotheophylline."
            ],
            [
                "\u003ca href=\"/drugs/DB00289\"\u003eAtomoxetine\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00995\"\u003eAuranofin\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB09121\"\u003eAurothioglucose\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB06442\"\u003eAvasimibe\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Avasimibe."
            ],
            [
                "\u003ca href=\"/drugs/DB06318\"\u003eAVE9633\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with AVE9633."
            ],
            [
                "\u003ca href=\"/drugs/DB06626\"\u003eAxitinib\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Axitinib."
            ],
            [
                "\u003ca href=\"/drugs/DB00928\"\u003eAzacitidine\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00993\"\u003eAzathioprine\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00548\"\u003eAzelaic acid\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00972\"\u003eAzelastine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Azelastine."
            ],
            [
                "\u003ca href=\"/drugs/DB00355\"\u003eAztreonam\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB00181\"\u003eBaclofen\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB01408\"\u003eBambuterol\u003c/a\u003e",
                "The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Bambuterol."
            ],
            [
                "\u003ca href=\"/drugs/DB13203\"\u003eBamifylline\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Bamifylline."
            ],
            [
                "\u003ca href=\"/drugs/DB09001\"\u003eBarbexaclone\u003c/a\u003e",
                "The serum concentration of Bromotheophylline can be decreased when it is combined with Barbexaclone."
            ],
            [
                "\u003ca href=\"/drugs/DB01483\"\u003eBarbital\u003c/a\u003e",
                "The serum concentration of Bromotheophylline can be decreased when it is combined with Barbital."
            ],
            [
                "\u003ca href=\"/drugs/DB11817\"\u003eBaricitinib\u003c/a\u003e",
                "Bromotheophylline may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB12526\"\u003eBatefenterol\u003c/a\u003e",
                "The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Batefenterol."
            ],
            [
                "\u003ca href=\"/drugs/DB09011\"\u003eBeclamide\u003c/a\u003e",
                "Beclamide may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy."
            ],
            [
                "\u003ca href=\"/drugs/DB05015\"\u003eBelinostat\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be increased when combined with Belinostat."
            ],
            [
                "\u003ca href=\"/drugs/DB06769\"\u003eBendamustine\u003c/a\u003e",
                "The metabolism of Bromotheophylline can be decreased when combined with Bendamustine."
            ]
        ],
        "drug_interactions_raw": "This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. ApprovedVet approvedNutraceuticalIllicitWithdrawnInvestigationalExperimentalAll DrugsDrugInteractionIntegrate drug-drug interactions in your software\n\n\n1,2-BenzodiazepineThe therapeutic efficacy of 1,2-Benzodiazepine can be decreased when used in combination with Bromotheophylline.AbacavirBromotheophylline may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.AbametapirThe serum concentration of Bromotheophylline can be increased when it is combined with Abametapir.AbataceptThe metabolism of Bromotheophylline can be increased when combined with Abatacept.AbirateroneThe serum concentration of Bromotheophylline can be increased when it is combined with Abiraterone.AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Bromotheophylline.AceclofenacBromotheophylline may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.AcemetacinThe therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Acemetacin.AcenocoumarolThe metabolism of Bromotheophylline can be decreased when combined with Acenocoumarol.AcetazolamideAcetazolamide may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   ",
        "drug_interactions_link": "https://go.drugbank.com/drugs/DB14018/drug_interactions.json?start=0\u0026length=100\u0026_=1701097772",
        "drug_interactions_page": "{\"draw\":1,\"recordsTotal\":1116,\"recordsFiltered\":1116,\"data\":[[\"\\u003ca href=\\\"/drugs/DB08496\\\"\\u003e(R)-warfarin\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with (R)-warfarin.\"],[\"\\u003ca href=\\\"/drugs/DB12537\\\"\\u003e1,2-Benzodiazepine\\u003c/a\\u003e\",\"The therapeutic efficacy of 1,2-Benzodiazepine can be decreased when used in combination with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB01467\\\"\\u003e2,5-Dimethoxy-4-ethylamphetamine\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB13940\\\"\\u003e2,5-Dimethoxy-4-ethylthioamphetamine\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB03374\\\"\\u003e3,5-Diiodotyrosine\\u003c/a\\u003e\",\"3,5-Diiodotyrosine may decrease the excretion rate of Bromotheophylline which could result in a higher serum level.\"],[\"\\u003ca href=\\\"/drugs/DB01484\\\"\\u003e4-Bromo-2,5-dimethoxyamphetamine\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB04070\\\"\\u003e6-Deoxyerythronolide B\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with 6-Deoxyerythronolide B.\"],[\"\\u003ca href=\\\"/drugs/DB11919\\\"\\u003e6-O-benzylguanine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with 6-O-benzylguanine.\"],[\"\\u003ca href=\\\"/drugs/DB02207\\\"\\u003e7-Nitroindazole\\u003c/a\\u003e\",\"7-Nitroindazole may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB01667\\\"\\u003e8-azaguanine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with 8-azaguanine.\"],[\"\\u003ca href=\\\"/drugs/DB14132\\\"\\u003e8-chlorotheophylline\\u003c/a\\u003e\",\"The metabolism of 8-chlorotheophylline can be decreased when combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB04356\\\"\\u003e9-Deazaguanine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with 9-Deazaguanine.\"],[\"\\u003ca href=\\\"/drugs/DB02489\\\"\\u003e9-Methylguanine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with 9-Methylguanine.\"],[\"\\u003ca href=\\\"/drugs/DB01048\\\"\\u003eAbacavir\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB11932\\\"\\u003eAbametapir\\u003c/a\\u003e\",\"The serum concentration of Bromotheophylline can be increased when it is combined with Abametapir.\"],[\"\\u003ca href=\\\"/drugs/DB01281\\\"\\u003eAbatacept\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be increased when combined with Abatacept.\"],[\"\\u003ca href=\\\"/drugs/DB12100\\\"\\u003eAbediterol\\u003c/a\\u003e\",\"The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Abediterol.\"],[\"\\u003ca href=\\\"/drugs/DB05812\\\"\\u003eAbiraterone\\u003c/a\\u003e\",\"The serum concentration of Bromotheophylline can be increased when it is combined with Abiraterone.\"],[\"\\u003ca href=\\\"/drugs/DB01193\\\"\\u003eAcebutolol\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when Acebutolol is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB06736\\\"\\u003eAceclofenac\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB13573\\\"\\u003eAcefylline\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Acefylline.\"],[\"\\u003ca href=\\\"/drugs/DB13783\\\"\\u003eAcemetacin\\u003c/a\\u003e\",\"The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Acemetacin.\"],[\"\\u003ca href=\\\"/drugs/DB01418\\\"\\u003eAcenocoumarol\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Acenocoumarol.\"],[\"\\u003ca href=\\\"/drugs/DB00819\\\"\\u003eAcetazolamide\\u003c/a\\u003e\",\"Acetazolamide may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00945\\\"\\u003eAcetylsalicylic acid\\u003c/a\\u003e\",\"Acetylsalicylic acid may decrease the excretion rate of Bromotheophylline which could result in a higher serum level.\"],[\"\\u003ca href=\\\"/drugs/DB08897\\\"\\u003eAclidinium\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB09488\\\"\\u003eAcrivastine\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00787\\\"\\u003eAcyclovir\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00051\\\"\\u003eAdalimumab\\u003c/a\\u003e\",\"The serum concentration of Bromotheophylline can be decreased when it is combined with Adalimumab.\"],[\"\\u003ca href=\\\"/drugs/DB00640\\\"\\u003eAdenosine\\u003c/a\\u003e\",\"The therapeutic efficacy of Adenosine can be decreased when used in combination with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB00546\\\"\\u003eAdinazolam\\u003c/a\\u003e\",\"The therapeutic efficacy of Adinazolam can be decreased when used in combination with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB04956\\\"\\u003eAfelimomab\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be increased when combined with Afelimomab.\"],[\"\\u003ca href=\\\"/drugs/DB06594\\\"\\u003eAgomelatine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Agomelatine.\"],[\"\\u003ca href=\\\"/drugs/DB00518\\\"\\u003eAlbendazole\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be increased when combined with Albendazole.\"],[\"\\u003ca href=\\\"/drugs/DB05396\\\"\\u003eAlbinterferon Alfa-2B\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Albinterferon Alfa-2B.\"],[\"\\u003ca href=\\\"/drugs/DB12950\\\"\\u003eAlbusomatropin\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be increased when combined with Albusomatropin.\"],[\"\\u003ca href=\\\"/drugs/DB13884\\\"\\u003eAlbutrepenonacog alfa\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Albutrepenonacog alfa which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB13167\\\"\\u003eAlclofenac\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Alclofenac which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00041\\\"\\u003eAldesleukin\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00802\\\"\\u003eAlfentanil\\u003c/a\\u003e\",\"The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Alfentanil.\"],[\"\\u003ca href=\\\"/drugs/DB15477\\\"\\u003eAlloin\\u003c/a\\u003e\",\"The risk or severity of dehydration can be increased when Bromotheophylline is combined with Alloin.\"],[\"\\u003ca href=\\\"/drugs/DB00437\\\"\\u003eAllopurinol\\u003c/a\\u003e\",\"The serum concentration of Bromotheophylline can be increased when it is combined with Allopurinol.\"],[\"\\u003ca href=\\\"/drugs/DB01431\\\"\\u003eAllylestrenol\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB13595\\\"\\u003eAlmasilate\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00918\\\"\\u003eAlmotriptan\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB06203\\\"\\u003eAlogliptin\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00969\\\"\\u003eAlosetron\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Alosetron.\"],[\"\\u003ca href=\\\"/drugs/DB01555\\\"\\u003eAlphacetylmethadol\\u003c/a\\u003e\",\"The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Alphacetylmethadol.\"],[\"\\u003ca href=\\\"/drugs/DB13160\\\"\\u003eAlphaprodine\\u003c/a\\u003e\",\"The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Alphaprodine.\"],[\"\\u003ca href=\\\"/drugs/DB00404\\\"\\u003eAlprazolam\\u003c/a\\u003e\",\"The therapeutic efficacy of Alprazolam can be decreased when used in combination with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB00866\\\"\\u003eAlprenolol\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when Alprenolol is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB00915\\\"\\u003eAmantadine\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB01424\\\"\\u003eAminophenazone\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Aminophenazone.\"],[\"\\u003ca href=\\\"/drugs/DB01223\\\"\\u003eAminophylline\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Aminophylline.\"],[\"\\u003ca href=\\\"/drugs/DB01118\\\"\\u003eAmiodarone\\u003c/a\\u003e\",\"The serum concentration of Bromotheophylline can be increased when it is combined with Amiodarone.\"],[\"\\u003ca href=\\\"/drugs/DB00321\\\"\\u003eAmitriptyline\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB06767\\\"\\u003eAmmonium chloride\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB01351\\\"\\u003eAmobarbital\\u003c/a\\u003e\",\"The serum concentration of Bromotheophylline can be decreased when it is combined with Amobarbital.\"],[\"\\u003ca href=\\\"/drugs/DB01060\\\"\\u003eAmoxicillin\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00182\\\"\\u003eAmphetamine\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when Amphetamine is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB00415\\\"\\u003eAmpicillin\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB01427\\\"\\u003eAmrinone\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00261\\\"\\u003eAnagrelide\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Anagrelide.\"],[\"\\u003ca href=\\\"/drugs/DB00026\\\"\\u003eAnakinra\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be increased when combined with Anakinra.\"],[\"\\u003ca href=\\\"/drugs/DB09103\\\"\\u003eAncestim\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB11785\\\"\\u003eAnisodamine\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when Anisodamine is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB09329\\\"\\u003eAntihemophilic factor (recombinant), PEGylated\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB01435\\\"\\u003eAntipyrine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Antipyrine.\"],[\"\\u003ca href=\\\"/drugs/DB11598\\\"\\u003eAntithrombin III human\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB11901\\\"\\u003eApalutamide\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Apalutamide which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB05676\\\"\\u003eApremilast\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be increased when combined with Apremilast.\"],[\"\\u003ca href=\\\"/drugs/DB01102\\\"\\u003eArbutamine\\u003c/a\\u003e\",\"The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Arbutamine.\"],[\"\\u003ca href=\\\"/drugs/DB01274\\\"\\u003eArformoterol\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Arformoterol which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB06413\\\"\\u003eArmodafinil\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be increased when combined with Armodafinil.\"],[\"\\u003ca href=\\\"/drugs/DB09204\\\"\\u003eArotinolol\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when Arotinolol is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB01169\\\"\\u003eArsenic trioxide\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB06216\\\"\\u003eAsenapine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Asenapine.\"],[\"\\u003ca href=\\\"/drugs/DB01072\\\"\\u003eAtazanavir\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Atazanavir.\"],[\"\\u003ca href=\\\"/drugs/DB00335\\\"\\u003eAtenolol\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when Atenolol is combined with Bromotheophylline.\"],[\"\\u003ca href=\\\"/drugs/DB00289\\\"\\u003eAtomoxetine\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00995\\\"\\u003eAuranofin\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB09121\\\"\\u003eAurothioglucose\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB06442\\\"\\u003eAvasimibe\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Avasimibe.\"],[\"\\u003ca href=\\\"/drugs/DB06318\\\"\\u003eAVE9633\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with AVE9633.\"],[\"\\u003ca href=\\\"/drugs/DB06626\\\"\\u003eAxitinib\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Axitinib.\"],[\"\\u003ca href=\\\"/drugs/DB00928\\\"\\u003eAzacitidine\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00993\\\"\\u003eAzathioprine\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00548\\\"\\u003eAzelaic acid\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00972\\\"\\u003eAzelastine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Azelastine.\"],[\"\\u003ca href=\\\"/drugs/DB00355\\\"\\u003eAztreonam\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB00181\\\"\\u003eBaclofen\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB01408\\\"\\u003eBambuterol\\u003c/a\\u003e\",\"The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Bambuterol.\"],[\"\\u003ca href=\\\"/drugs/DB13203\\\"\\u003eBamifylline\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Bamifylline.\"],[\"\\u003ca href=\\\"/drugs/DB09001\\\"\\u003eBarbexaclone\\u003c/a\\u003e\",\"The serum concentration of Bromotheophylline can be decreased when it is combined with Barbexaclone.\"],[\"\\u003ca href=\\\"/drugs/DB01483\\\"\\u003eBarbital\\u003c/a\\u003e\",\"The serum concentration of Bromotheophylline can be decreased when it is combined with Barbital.\"],[\"\\u003ca href=\\\"/drugs/DB11817\\\"\\u003eBaricitinib\\u003c/a\\u003e\",\"Bromotheophylline may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB12526\\\"\\u003eBatefenterol\\u003c/a\\u003e\",\"The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Batefenterol.\"],[\"\\u003ca href=\\\"/drugs/DB09011\\\"\\u003eBeclamide\\u003c/a\\u003e\",\"Beclamide may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.\"],[\"\\u003ca href=\\\"/drugs/DB05015\\\"\\u003eBelinostat\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be increased when combined with Belinostat.\"],[\"\\u003ca href=\\\"/drugs/DB06769\\\"\\u003eBendamustine\\u003c/a\\u003e\",\"The metabolism of Bromotheophylline can be decreased when combined with Bendamustine.\"]]}"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12692"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15535"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02960"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14577"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13691"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13830"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02493"
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1",
        "id": "DB06586",
        "molecule": "Cetilistat",
        "cas": "282526-98-1",
        "iupac_name": "2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one",
        "background": "Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.\n",
        "inchi": {
            "hash": "MVCQKIKWYUURMU-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 401.5821,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 401.292994119,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).",
        "link": "https://go.drugbank.com/drugs/DB06586",
        "type": "Small Molecule",
        "synonyms": [
            "Cetilistat"
        ],
        "indication": "Investigated for use/treatment in obesity.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPancreatic triacylglycerol lipase"
            }
        ]
    },
    {
        "id": "DB17488",
        "molecule": "Divarasib",
        "cas": "2417987-45-0",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17488",
        "type": "Small Molecule",
        "synonyms": [
            "1-((3S)-4-((7M)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one",
            "2-propen-1-one, 1-((3S)-4-((7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl)-6-chloro-8-fluoro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)-4-quinazolinyl)-3-methyl-1-piperazinyl)-"
        ],
        "is_stub": true
    },
    {
        "id": "DB13302",
        "molecule": "Hachimycin",
        "cas": "1394-02-1",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13302",
        "type": "Small Molecule",
        "synonyms": [
            "Hachimycin"
        ],
        "is_stub": true,
        "drug_interactions_raw": "This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not Available",
        "drug_interactions_link": "https://go.drugbank.com/drugs/DB13302/drug_interactions.json?start=0\u0026length=100\u0026_=1701097772",
        "drug_interactions_page": "{\"draw\":1,\"recordsTotal\":0,\"recordsFiltered\":0,\"data\":[]}"
    },
    {
        "smiles": "CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N+]([O-])=O",
        "id": "DB06091",
        "molecule": "Evofosfamide",
        "cas": "918633-87-1",
        "iupac_name": "(2-bromoethyl)({[(2-bromoethyl)amino][(1-methyl-2-nitro-1H-imidazol-5-yl)methoxy]phosphoryl})amine",
        "background": "TH-302 is a novel cancer therapeutic specifically activated under the low oxygen or \"hypoxic\" conditions typical of solid tumor cancer cells. TH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide. TH-302 has been shown, in preclinical studies, to be both efficacious and well tolerated.\n",
        "inchi": {
            "hash": "UGJWRPJDTDGERK-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 449.04,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 446.930667,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06091",
        "type": "Small Molecule",
        "synonyms": [
            "(1-methyl-2-nitro-1H-imidazol-5-YL)methyl N,N'-bis(2-bromoethyl)diamidophosphate",
            "(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate",
            "Evofosfamide"
        ],
        "indication": "Investigated for use/treatment in solid tumors.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "id": "DB05021",
        "molecule": "EMZ702",
        "background": "EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency compared to interferon and ribavirin alone.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05021",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in hepatitis (viral, C).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "NC1=NC2=C(C(N)=N1)C(OCC1CCN(CC3=C(Cl)C(Cl)=CC=C3)CC1)=CC=C2",
        "id": "DB07643",
        "molecule": "5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine",
        "iupac_name": "5-({1-[(2,3-dichlorophenyl)methyl]piperidin-4-yl}methoxy)quinazoline-2,4-diamine",
        "inchi": {
            "hash": "XVLUVRFYGVJKGJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H23Cl2N5O/c22-15-4-1-3-14(19(15)23)11-28-9-7-13(8-10-28)12-29-17-6-2-5-16-18(17)20(24)27-21(25)26-16/h1-6,13H,7-12H2,(H4,24,25,26,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 432.346,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 431.127965797,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.",
        "link": "https://go.drugbank.com/drugs/DB07643",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "Um7GpppX diphosphatase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB06786",
        "molecule": "Halcinonide",
        "cas": "3093-35-4",
        "iupac_name": "(1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0,.0,.0,]icos-17-en-16-one",
        "background": "Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide.\n",
        "inchi": {
            "hash": "MUQNGPZZQDCDFT-JNQJZLCISA-N",
            "id": "InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1"
        },
        "summary": "Halcinonide is a corticosteroid used for the management and symptomatic relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.",
        "weight": [
            {
                "type": "average",
                "weight": 454.96,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 454.19223,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB06786",
        "type": "Small Molecule",
        "synonyms": [
            "(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-6b-(chloroacetyl)-4b-fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one",
            "Halcinonid",
            "Halcinonida",
            "Halcinonide",
            "Halcinonidum"
        ],
        "indication": "Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "agonistactivator",
                "organism": "Humans",
                "target": "USmoothened homolog"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=CC(O)=C2C(Cl)=CC(Cl)=CC2=N1",
        "id": "DB01931",
        "molecule": "5,7-Dichlorokynurenic acid",
        "cas": "131123-76-7",
        "iupac_name": "5,7-dichloro-4-hydroxyquinoline-2-carboxylic acid",
        "inchi": {
            "hash": "BGKFPRIGXAVYNX-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H5Cl2NO3/c11-4-1-5(12)9-6(2-4)13-7(10(15)16)3-8(9)14/h1-3H,(H,13,14)(H,15,16)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 258.058,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 256.964648445,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.",
        "link": "https://go.drugbank.com/drugs/DB01931",
        "type": "Small Molecule",
        "synonyms": [
            "5,7-Dcka",
            "5,7-Dichloroquinurenic acid",
            "5,7-Dichorokynurenic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, NMDA 1"
            }
        ]
    },
    {
        "smiles": "CC1=CCC2CC1C2(C)C",
        "id": "DB15573",
        "molecule": "alpha-Pinene",
        "cas": "80-56-8",
        "iupac_name": "2,6,6-trimethylbicyclo[3.1.1]hept-2-ene",
        "inchi": {
            "hash": "GRWFGVWFFZKLTI-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H16/c1-7-4-5-8-6-9(7)10(8,2)3/h4,8-9H,5-6H2,1-3H3"
        },
        "summary": "alpha-Pinene is a mono-terpene indicated in combination with other plant-derived compounds for the treatment of bladder, kidney, and urinary stones.",
        "weight": [
            {
                "type": "average",
                "weight": 136.238,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 136.125200515,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15573",
        "type": "Small Molecule",
        "synonyms": [
            "()-2-pinene",
            "()--pinene",
            "2-pinene",
            "Acintene A",
            "alpha-Pinene",
            "pin-2(3)-ene",
            "-pinene"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=CC=CC=C1F",
        "id": "DB02403",
        "molecule": "2-Fluoroaniline",
        "cas": "348-54-9",
        "iupac_name": "2-fluoroaniline",
        "inchi": {
            "hash": "FTZQXOJYPFINKJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H6FN/c7-5-3-1-2-4-6(5)8/h1-4H,8H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 111.1169,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 111.048427402,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB02403",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Enterobacteria phage T4",
                "target": "ULysozyme"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14175"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11513"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08991"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01927"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11329"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04493"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11380"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11262"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00810"
    },
    {
        "smiles": "[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na++].[Na++].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6]",
        "id": "DB17739",
        "molecule": "HPA-23",
        "cas": "89899-81-0",
        "iupac_name": "henicosatungsten(6+) nonaantimony(3+) disodium(2+) heptadecaammonium hexaoctacontaoxidandiide",
        "background": "HPA-23 is an investigational antiviral compound.1\n",
        "inchi": {
            "hash": "HIMFWDDKEANLEL-UHFFFAOYSA-A",
            "id": "InChI=1S/17H3N.2Na.86O.9Sb.21W/h17*1H3;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/q;;;;;;;;;;;;;;;;;2*+2;86*-2;9*+3;21*+6/p+17"
        },
        "weight": [
            {
                "type": "average",
                "weight": 6685.04,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 6679.2293,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17739",
        "type": "Small Molecule",
        "synonyms": [
            "Ammonium 21-tungsto-9-antimoniate",
            "Ammonium antimony sodium tungsten oxide ((nh4)17sb9na2w21o86)",
            "Tungstate(19-), hexaoctacontaoxononaantimonateheneicosa-, heptadecaammonium disodium"
        ],
        "is_stub": true
    },
    {
        "id": "DB17976",
        "molecule": "HOV-12020",
        "background": "HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).1\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17976",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCCCCC1=CC(O)=C(C\\C=C(/C)CCC=C(C)C)C(O)=C1",
        "id": "DB14734",
        "molecule": "Cannabigerol",
        "cas": "25654-31-3",
        "iupac_name": "2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-pentylbenzene-1,3-diol",
        "background": "A natural product found in Cannabis sativa and Helichrysum species.\n",
        "inchi": {
            "hash": "QXACEHWTBCFNSA-SFQUDFHCSA-N",
            "id": "InChI=1S/C21H32O2/c1-5-6-7-11-18-14-20(22)19(21(23)15-18)13-12-17(4)10-8-9-16(2)3/h9,12,14-15,22-23H,5-8,10-11,13H2,1-4H3/b17-12+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 316.485,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 316.24023027,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14734",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08564"
    },
    {
        "smiles": "BrC1=CC=CC(=C1)C1=NNC(=C1)C1=CC2=C(OCO2)C=C1",
        "id": "DB13927",
        "molecule": "Emrusolmin",
        "cas": "882697-00-9",
        "iupac_name": "5-(2H-1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole",
        "background": "Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology. 2\n",
        "inchi": {
            "hash": "RCQIIBJSUWYYFU-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H11BrN2O2/c17-12-3-1-2-10(6-12)13-8-14(19-18-13)11-4-5-15-16(7-11)21-9-20-15/h1-8H,9H2,(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 343.18,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 342.000391,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB13927",
        "type": "Small Molecule",
        "synonyms": [
            "1H-PYRAZOLE, 3-(1,3-BENZODIOXOL-5-YL)-5-(3-BROMOPHENYL)-",
            "3-(1,3-BENZODIOXOL-5-YL)-5-(3-BROMOPHENYL)-1H-PYRAZOLE"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@@H](OC(=O)NC1=C(ON=C1C)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(O)=O)C1=CC=CC=C1",
        "id": "DB14948",
        "molecule": "BMS-986020",
        "cas": "1257213-50-5",
        "iupac_name": "1-{4'-[3-methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]-[1,1'-biphenyl]-4-yl}cyclopropane-1-carboxylic acid",
        "background": "BMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers).\n",
        "inchi": {
            "hash": "GQBRZBHEPUQRPL-LJQANCHMSA-N",
            "id": "InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 482.536,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 482.184171945,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.",
        "link": "https://go.drugbank.com/drugs/DB14948",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07208"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06880"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12579"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07782"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07772"
    },
    {
        "smiles": "[Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O",
        "id": "DB05260",
        "molecule": "Gallium nitrate",
        "cas": "13494-90-1",
        "iupac_name": "gallium(3+) trinitrate",
        "background": "Gallium nitrate is a nitrate salt of Gallium cation, a heavy metal that has been used as a diagnostic agent.4 Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone.5 GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness.10\nApart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours.7\n",
        "inchi": {
            "hash": "CHPZKNULDCNCBW-UHFFFAOYSA-N",
            "id": "InChI=1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1"
        },
        "summary": "Gallium nitrate is a drug previously indicated to treat cancer-related hypercalcemia.",
        "weight": [
            {
                "type": "average",
                "weight": 255.738,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 254.889034525,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as post-transition metal nitrates. These are inorganic compounds in which the largest oxoanion is nitrate, and in which the heaviest atom not in an oxoanion is a post-transition metal.",
        "link": "https://go.drugbank.com/drugs/DB05260",
        "type": "Small Molecule",
        "synonyms": [
            "Gallium nitrate (anhydrous)",
            "Gallium nitrate injection",
            "Nitric acid, gallium salt, anhydrate"
        ],
        "indication": "Gallium nitrate does not currently have approved indications. It was previously used in the treatment of cancer-related hypercalcemia.9\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Gallium nitrate produces a hypocalcemic effect by inhibiting calcium resorption from bone, possibly blocking osteoclast activity and reducing increased bone turnover.9 Preclinical studies demonstrated that gallium dose-dependently accumulates in areas of high bone turnover, where it is incorporated into hydroxyapatite, making it less susceptible to dissolution and osteoclast-mediated resorption.4,5 No cytotoxic effects were observed on bone cells in drug-treated animals.9\nGallium nitrate exhibits antitumour activity, which is reported to be unrelated to the physiological mechanism involved in its bone turnover effects.4 Anti-inflammatory and immunosuppressant effects have also been documented.7\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "URibonucleoside-diphosphate reductase subunit M2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UV-type proton ATPase subunit B, brain isoform"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06911"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08899"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01798"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14132"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03802"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02975"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07862"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03867"
    },
    {
        "smiles": "CNC(=O)CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I",
        "id": "DB13701",
        "molecule": "Ioglicic acid",
        "cas": "49755-67-1",
        "iupac_name": "3-acetamido-2,4,6-triiodo-5-{[(methylcarbamoyl)methyl]carbamoyl}benzoic acid",
        "inchi": {
            "hash": "HHFIATHHSBFCBY-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H12I3N3O5/c1-4(20)19-11-9(15)6(12(22)18-3-5(21)17-2)8(14)7(10(11)16)13(23)24/h3H2,1-2H3,(H,17,21)(H,18,22)(H,19,20)(H,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 670.968,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 670.79111,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.",
        "link": "https://go.drugbank.com/drugs/DB13701",
        "type": "Small Molecule",
        "synonyms": [
            "Ioglicic acid"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06883"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07889"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13226"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03543"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12362"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11378"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02125"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11702"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16088"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04096"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07634"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07435"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01711"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01666"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05620"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12926"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07956"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07780"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07444"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05189"
    },
    {
        "smiles": "COC1=CC=C(COC2=CC=C(CN3C(N)=NC4=C3N=CC(=C4)C3=CN(C)N=C3)C=C2OC)C=C1",
        "id": "DB16056",
        "molecule": "GZ-389988",
        "cas": "1788906-96-6",
        "iupac_name": "3-({3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl}methyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine",
        "background": "GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee).\n",
        "inchi": {
            "hash": "HVRWZFQFSQUILC-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H26N6O3/c1-31-15-20(13-29-31)19-11-22-25(28-12-19)32(26(27)30-22)14-18-6-9-23(24(10-18)34-3)35-16-17-4-7-21(33-2)8-5-17/h4-13,15H,14,16H2,1-3H3,(H2,27,30)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 470.533,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 470.206638721,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16056",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "id": "DB04848",
        "molecule": "AZD0947",
        "background": "AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the companys development pipeline.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04848",
        "type": "Small Molecule",
        "indication": "Intended for the treatment of urinary incontinence.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "AZD0947 is a K+ channel opener.\n"
    },
    {
        "smiles": "[H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)N1CC(CCN2CCOCC2)C1)[C@@]1(C)O[C@@H]1CC=C(C)C",
        "id": "DB16079",
        "molecule": "Aclimostat",
        "cas": "2082752-83-6",
        "iupac_name": "(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl 3-[2-(morpholin-4-yl)ethyl]azetidine-1-carboxylate",
        "background": "Aclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes).\n",
        "inchi": {
            "hash": "QJWJPMLDQYEPPW-AUKZVGPFSA-N",
            "id": "InChI=1S/C26H42N2O6/c1-18(2)5-6-21-25(3,34-21)23-22(30-4)20(7-9-26(23)17-32-26)33-24(29)28-15-19(16-28)8-10-27-11-13-31-14-12-27/h5,19-23H,6-17H2,1-4H3/t20-,21-,22-,23-,25+,26+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 478.63,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 478.30428708,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16079",
        "type": "Small Molecule",
        "synonyms": [
            "Aclimostat"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02222"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04801"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12694"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12515"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08100"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02326"
    },
    {
        "smiles": "CCCC(=O)N1CCCN(CC1)C1=NC(N)=C2C=C(OC)C(OC)=CC2=N1",
        "id": "DB12230",
        "molecule": "Bunazosin",
        "cas": "80755-51-7",
        "iupac_name": "1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one",
        "background": "Bunazosin has been used in trials studying the treatment of High Blood Pressure.\n",
        "inchi": {
            "hash": "RHLJLALHBZGAFM-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 373.457,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 373.211389749,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB12230",
        "type": "Small Molecule",
        "synonyms": [
            "Bunazosin"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03918"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13230"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02484"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04307"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00668"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01447"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08168"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00647"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03846"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02409"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01672"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11737"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13294"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02043"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01835"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01465"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08252"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01029"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00521"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02474"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02453"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01889"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03755"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08783"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15645"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02436"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03083"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08878"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04603"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08205"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16200"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01898"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01978"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08396"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03092"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03102"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01777"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04312"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06196"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09050"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01716"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17120"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11878"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12452"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02873"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15193"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14122"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08722"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04451"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11174"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00893"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08651"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04088"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05087"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14501"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04661"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03552"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18296"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04883"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04837"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04624"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11306"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08395"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08000"
    },
    {
        "smiles": "COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C([O-])=O.CCCCCCCCCCCCCCCC[N+](C)(C)C",
        "id": "DB15877",
        "molecule": "Cetyltrimethylammonium naproxenate",
        "cas": "102580-74-5",
        "iupac_name": "hexadecyltrimethylazanium (2S)-2-(6-methoxynaphthalen-2-yl)propanoate",
        "inchi": {
            "hash": "RNQBLUNNAYFBIW-NPULLEENSA-M",
            "id": "InChI=1S/C19H42N.C14H14O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(2,3)4;1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h5-19H2,1-4H3;3-9H,1-2H3,(H,15,16)/q+1;/p-1/t;9-/m.0/s1"
        },
        "summary": "Cetyltrimethylammonium naproxenate is an anti-inflammatory and antiseptic agent indicated to treat mouth inflammation and pain , including that caused by tooth extraction.",
        "weight": [
            {
                "type": "average",
                "weight": 513.807,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 513.418194635,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15877",
        "type": "Small Molecule",
        "synonyms": [
            "Cetyl trimethylammonium naproxenate",
            "Cetyltrimethylammonium naproxenate"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03833"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01063"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00833"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03672"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15126"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07641"
    },
    {
        "smiles": "O[C@H]1C[C@@H](O[C@@H]1COP(O)(O)=O)N1C=C(F)C(=O)NC1=O",
        "id": "DB03761",
        "molecule": "5-fluoro-2'-deoxyuridine-5'-monophosphate",
        "cas": "134-46-3",
        "iupac_name": "{[(2R,3S,5R)-5-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "HFEKDTCAMMOLQP-RRKCRQDMSA-N",
            "id": "InChI=1S/C9H12FN2O8P/c10-4-2-12(9(15)11-8(4)14)7-1-5(13)6(20-7)3-19-21(16,17)18/h2,5-7,13H,1,3H2,(H,11,14,15)(H2,16,17,18)/t5-,6+,7+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 326.1723,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 326.031530087,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleoside monophosphates. These are pyrimidine nucleotides with a monophosphate group linked to the ribose moiety lacking a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB03761",
        "type": "Small Molecule",
        "synonyms": [
            "5-fluorodeoxyuridine monophosphate",
            "5FdUMP",
            "F-dUMP"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UThymidylate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Lactobacillus casei",
                "target": "UThymidylate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)",
                "target": "UThymidylate synthase ThyX"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UThymidylate synthase 1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08071"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01970"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08132"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17270"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01860"
    },
    {
        "smiles": "[H][C@@](O)(CNC(=O)C1=CC2=CC(Cl)=CC=C2N1)N(CCO)C1CCCC1",
        "id": "DB03288",
        "molecule": "5-Chloro-1h-Indole-2-Carboxylic Acid{[Cyclopentyl-(2-Hydroxy-Ethyl)-Carbamoyl]-Methyl}-Amide",
        "iupac_name": "5-chloro-N-[(2R)-2-[cyclopentyl(2-hydroxyethyl)amino]-2-hydroxyethyl]-1H-indole-2-carboxamide",
        "inchi": {
            "hash": "VXABTOCIIZSEPD-QGZVFWFLSA-N",
            "id": "InChI=1S/C18H24ClN3O3/c19-13-5-6-15-12(9-13)10-16(21-15)18(25)20-11-17(24)22(7-8-23)14-3-1-2-4-14/h5-6,9-10,14,17,21,23-24H,1-4,7-8,11H2,(H,20,25)/t17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 365.854,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 365.150619356,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.",
        "link": "https://go.drugbank.com/drugs/DB03288",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, liver form"
            }
        ]
    },
    {
        "smiles": "CS(=O)(=O)C1=CC=C(N2C=C(Cl)C(OC3CCN(CC3)C3=NC=C(Cl)C=N3)=CC2=O)C(F)=C1",
        "id": "DB11773",
        "molecule": "BMS-903452",
        "cas": "1339944-47-6",
        "iupac_name": "5-chloro-4-{[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]oxy}-1-(2-fluoro-4-methanesulfonylphenyl)-1,2-dihydropyridin-2-one",
        "background": "BMS-903452 has been used in trials studying the treatment of Diabetes.\n",
        "inchi": {
            "hash": "OGIAVRWXUPYGGC-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H19Cl2FN4O4S/c1-33(30,31)15-2-3-18(17(24)8-15)28-12-16(23)19(9-20(28)29)32-14-4-6-27(7-5-14)21-25-10-13(22)11-26-21/h2-3,8-12,14H,4-7H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 513.37,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 512.0488098,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.",
        "link": "https://go.drugbank.com/drugs/DB11773",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[13NH3]",
        "id": "DB09326",
        "molecule": "Ammonia N-13",
        "cas": "34819-78-8",
        "iupac_name": "(N)ammonia",
        "background": "Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02.\nAmmonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.\n",
        "inchi": {
            "hash": "QGZKDVFQNNGYKY-BJUDXGSMSA-N",
            "id": "InChI=1S/H3N/h1H3/i1-1"
        },
        "summary": "Ammonia N-13 is a radioactive diagnostic agent used in PET (positron emission tomography) scans.",
        "weight": [
            {
                "type": "average",
                "weight": 16.03,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 16.029213681,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous other non-metal compounds. These are inorganic non-metallic compounds in which the largest atom belongs to the class of 'other non-metals'.",
        "link": "https://go.drugbank.com/drugs/DB09326",
        "type": "Small Molecule",
        "synonyms": [
            "(13N)Ammonia",
            "Ammonia N 13"
        ],
        "indication": "For diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Following intravenous injection, ammonia N 13 enters the myocardium through the coronary arteries. The PET technique measures myocardial blood flow based on the assumption of a three-compartmental disposition of intravenous ammonia N 13 in the myocardium. In this model, the value of the rate constant, which represents the delivery of blood to myocardium, and the fraction of ammonia N 13 extracted into the myocardial cells, is a measure of myocardial blood flow. Optimal PET imaging of the myocardium is generally achieved between 10 to 20 minutes after administration.\n"
    },
    {
        "smiles": "O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1",
        "id": "DB12873",
        "molecule": "Dianhydrogalactitol",
        "cas": "23261-20-3",
        "iupac_name": "(1R,2S)-1-[(2R)-oxiran-2-yl]-2-[(2S)-oxiran-2-yl]ethane-1,2-diol",
        "background": "Dianhydrogalactitol has been used in trials studying the treatment of GBM, Glioma, Glioblastoma, Brain Cancer, and Glioblastoma Multiforme.\n",
        "inchi": {
            "hash": "AAFJXZWCNVJTMK-GUCUJZIJSA-N",
            "id": "InChI=1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2/t3-,4+,5+,6-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 146.142,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 146.057908802,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2-diols. These are polyols containing an alcohol group at two adjacent positions.",
        "link": "https://go.drugbank.com/drugs/DB12873",
        "type": "Small Molecule",
        "synonyms": [
            "1,2:5,6-Dianhdrogalactitol",
            "1,2:5,6-Dianhydrogalactitol",
            "Dianhydrogalactitol"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08622"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01632"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15934"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18294"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01048"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14143"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08558"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13476"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02277"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07070"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13237"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11400"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16950"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14062"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17778"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03996"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08664"
    },
    {
        "smiles": "C[N+]#[C-]",
        "id": "DB04337",
        "molecule": "Isocyanomethane",
        "cas": "593-75-9",
        "iupac_name": "isocyanomethane",
        "inchi": {
            "hash": "ZRKSVHFXTRFQFL-UHFFFAOYSA-N",
            "id": "InChI=1S/C2H3N/c1-3-2/h1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 41.0519,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 41.026549101,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organic isocyanides. These are organic compounds containing the isomer HN+#C- of hydrocyanic acid, HC#N, or its hydrocarbyl derivatives RNC (RN+#C-).",
        "link": "https://go.drugbank.com/drugs/DB04337",
        "type": "Small Molecule",
        "synonyms": [
            "Methyl isocyanide",
            "Methyl isonitrile",
            "Methylisonitrile"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMyoglobin"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03539"
    },
    {
        "smiles": "CC(C)CN1N=CC2=CC(OC3=CC=C(F)C=C3F)=C(C=C12)C(=O)N[C@@H](CCN(C)C)C(N)=O",
        "id": "DB17603",
        "molecule": "Emprumapimod",
        "cas": "765914-60-1",
        "iupac_name": "(2S)-2-{[5-(2,4-difluorophenoxy)-1-(2-methylpropyl)-1H-indazol-6-yl]formamido}-4-(dimethylamino)butanamide",
        "background": "Emprumapimod is a potent, orally active and selective inhibitor of p38 mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.\n",
        "inchi": {
            "hash": "JOOOJNJPZINWHM-IBGZPJMESA-N",
            "id": "InChI=1S/C24H29F2N5O3/c1-14(2)13-31-20-11-17(24(33)29-19(23(27)32)7-8-30(3)4)22(9-15(20)12-28-31)34-21-6-5-16(25)10-18(21)26/h5-6,9-12,14,19H,7-8,13H2,1-4H3,(H2,27,32)(H,29,33)/t19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 473.525,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 473.22384614,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17603",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCN(CC)CCNC(=O)C1=C(OC)C=C(NC(=O)C2=CC=C(F)C=C2)C([131I])=C1",
        "id": "DB17102",
        "molecule": "Ioflubenzamide I-131",
        "cas": "1214283-52-9",
        "iupac_name": "N-[2-(diethylamino)ethyl]-4-(4-fluorobenzamido)-5-(I)iodo-2-methoxybenzamide",
        "inchi": {
            "hash": "UPRRZQGAQRAODM-AWUWEVMDSA-N",
            "id": "InChI=1S/C21H25FIN3O3/c1-4-26(5-2)11-10-24-21(28)16-12-17(23)18(13-19(16)29-3)25-20(27)14-6-8-15(22)9-7-14/h6-9,12-13H,4-5,10-11H2,1-3H3,(H,24,28)(H,25,27)/i23+4"
        },
        "weight": [
            {
                "type": "average",
                "weight": 517.354,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 517.094119008,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17102",
        "type": "Small Molecule",
        "synonyms": [
            "(131i)-n-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide",
            "[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide",
            "Benzamide, n-(2-(diethylamino)ethyl)-4-((4-fluorobenzoyl)amino)-5-(iodo-131i)-2-methoxy-",
            "Ioflubenzamide (131 i)",
            "Ioflubenzamide (131i)",
            "Ioflubenzamide i 131",
            "Ioflubenzamide, I-131",
            "N-(2-(diethylamino)ethyl)-4-((4-fluorobenzoyl)amino)-5-((sup 131)i)iodo-2-methoxybenzamide",
            "N-(2-(diethylamino)ethyl)-4-((4-fluorobenzoyl)amino)-5-(iodo-131i)-2-methoxybenzamide"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14985"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08201"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08674"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03937"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07573"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09381"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12542"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07985"
    },
    {
        "smiles": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C(F)C(C)=C4CC[C@H](N)C3=C14)C2=O",
        "id": "DB12185",
        "molecule": "Exatecan",
        "cas": "171335-80-1",
        "iupac_name": "(10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.0^{2,14}.0^{4,13}.0^{6,11}.0^{20,24}]tetracosa-1(24),2(14),6(11),12,15,17,19-heptaene-5,9-dione",
        "background": "Exatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others.\n",
        "inchi": {
            "hash": "ZVYVPGLRVWUPMP-FYSMJZIKSA-N",
            "id": "InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 435.455,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 435.159434363,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).",
        "link": "https://go.drugbank.com/drugs/DB12185",
        "type": "Small Molecule",
        "synonyms": [
            "Exatecan"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13126"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12605"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02551"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04082"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15449"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11911"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02486"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04520"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14480"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15130"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02890"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00972"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08318"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06965"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01493"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09021"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04885"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05174"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00696"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13120"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03135"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01657"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03272"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07057"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03729"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09157"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03915"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03277"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06011"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03090"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09013"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04426"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03240"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05456"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08419"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00308"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03921"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13167"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01142"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17514"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18174"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04595"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04593"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02556"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12021"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02267"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02680"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04158"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16163"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01903"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03350"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07736"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07507"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07265"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07375"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16123"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11859"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08446"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03865"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03994"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15198"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07405"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03450"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03504"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08170"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09246"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04283"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12297"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14005"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14135"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03612"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14654"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14471"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09313"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04431"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18115"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03200"
    },
    {
        "smiles": "[H][C@]1(N)C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O",
        "id": "DB02120",
        "molecule": "6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol",
        "cas": "38231-86-6",
        "iupac_name": "(1S,2S,3R,6S)-6-amino-4-(hydroxymethyl)cyclohex-4-ene-1,2,3-triol",
        "inchi": {
            "hash": "XPHOBMULWMGEBA-VZFHVOOUSA-N",
            "id": "InChI=1S/C7H13NO4/c8-4-1-3(2-9)5(10)7(12)6(4)11/h1,4-7,9-12H,2,8H2/t4-,5+,6-,7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 175.1824,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 175.084457909,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cyclitols and derivatives. These are compounds containing a cycloalkane moiety with one hydroxyl group on each of three or more ring atoms. These of also include derivatives where the hydrogen atom of one or more of the hydroxyl groups is replaced with another atom.",
        "link": "https://go.drugbank.com/drugs/DB02120",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus sp. (strain 1011)",
                "target": "UCyclomaltodextrin glucanotransferase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus circulans",
                "target": "UCyclomaltodextrin glucanotransferase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus sp. (strain 707)",
                "target": "UGlucan 1,4-alpha-maltohexaosidase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UAlpha-amylase"
            },
            {
                "action": "Not Available",
                "organism": "Thermoactinomyces vulgaris",
                "target": "UNeopullulanase 1"
            }
        ]
    },
    {
        "smiles": "C[C@H](CNCC1=C(O)C(C)=NC=C1COP(O)(O)=O)OP(O)(O)=O",
        "id": "DB03433",
        "molecule": "{3-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-2-Methyl-Propyl}-Phosphonic Acid",
        "iupac_name": "{[(2R)-1-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]propan-2-yl]oxy}phosphonic acid",
        "inchi": {
            "hash": "JMZWWHLIKAYMPJ-SSDOTTSWSA-N",
            "id": "InChI=1S/C11H20N2O9P2/c1-7(22-24(18,19)20)3-12-5-10-9(6-21-23(15,16)17)4-13-8(2)11(10)14/h4,7,12,14H,3,5-6H2,1-2H3,(H2,15,16,17)(H2,18,19,20)/t7-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 386.232,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 386.064403272,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridoxamine 5'-phosphates. These are heterocyclic aromatic compounds containing a pyridoxamine that carries a phosphate group at the 5'-position.",
        "link": "https://go.drugbank.com/drugs/DB03433",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UThreonine-phosphate decarboxylase"
            }
        ]
    },
    {
        "smiles": "NC1=C2C=CC=C(C2=CC=C1)S(O)(=O)=O",
        "id": "DB07176",
        "molecule": "1-Naphthylamine-5-sulfonic acid",
        "cas": "84-89-9",
        "iupac_name": "5-aminonaphthalene-1-sulfonic acid",
        "inchi": {
            "hash": "DQNAQOYOSRJXFZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H9NO3S/c11-9-5-1-4-8-7(9)3-2-6-10(8)15(12,13)14/h1-6H,11H2,(H,12,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 223.248,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 223.030313849,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-naphthalene sulfonates. These are organic aromatic compounds that contain a naphthalene moiety that carries a sulfonic acid group at the 1-position. Naphthalene is a bicyclic compound that is made up of two fused benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB07176",
        "type": "Small Molecule",
        "synonyms": [
            "1-Amino-5-naphthalenesufonic acid",
            "1-Amino-5-sulfonaphthalene",
            "5-Naphthylamine-1-sulfonic acid",
            "Laurent acid"
        ]
    },
    {
        "smiles": "CC1O[C@@]2(CS1)CN1CCC2CC1",
        "id": "DB00185",
        "molecule": "Cevimeline",
        "cas": "107233-08-9",
        "iupac_name": "(2R)-5'-methyl-4-azaspiro[bicyclo[2.2.2]octane-2,2'-[1,4]oxathiolane]",
        "background": "Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjgren's syndrome.\n",
        "inchi": {
            "hash": "WUTYZMFRCNBCHQ-LHIURRSHSA-N",
            "id": "InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8?,10-/m1/s1"
        },
        "summary": "Cevimeline is a muscarinic agonist with parasympathomimetic activities that is used for the symptomatic treatment of dry mouth in patients with Sjgren's Syndrome.",
        "weight": [
            {
                "type": "average",
                "weight": 199.313,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 199.103084861,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as azaspirodecane derivatives. These are organic compounds containing a spirodecane moiety with at least one nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB00185",
        "type": "Small Molecule",
        "synonyms": [
            "2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine",
            "Cevimelina",
            "Cvimline",
            "Cevimeline",
            "Cevimelinum"
        ],
        "indication": "For the treatment of symptoms of dry mouth in patients with Sjgren's Syndrome.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M3"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M1"
            }
        ]
    },
    {
        "smiles": "C[C@H](N1CC[C@H](NS(=O)(=O)C2=CC3=C(N2)C=CC(Cl)=C3)C1=O)C(=O)N1CCOCC1",
        "id": "DB07848",
        "molecule": "5-Chloro-N-{(3S)-1-[(2S)-1-(4-morpholinyl)-1-oxo-2-propanyl]-2-oxo-3-pyrrolidinyl}-1H-indole-2-sulfonamide",
        "iupac_name": "5-chloro-N-[(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]-1H-indole-2-sulfonamide",
        "inchi": {
            "hash": "BHNMMFGOJRIAEZ-LRDDRELGSA-N",
            "id": "InChI=1S/C19H23ClN4O5S/c1-12(18(25)23-6-8-29-9-7-23)24-5-4-16(19(24)26)22-30(27,28)17-11-13-10-14(20)2-3-15(13)21-17/h2-3,10-12,16,21-22H,4-9H2,1H3/t12-,16-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 454.928,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 454.107768263,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB07848",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05810"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03914"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07309"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07439"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01459"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08334"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03891"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02105"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01225"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03613"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14189"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06255"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06618"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01645"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14886"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08378"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04330"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03541"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07592"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05112"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07564"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14140"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16242"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05755"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02248"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08492"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07861"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07317"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01463"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12307"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03221"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02838"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04636"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02867"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18046"
    },
    {
        "smiles": "NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1",
        "id": "DB00879",
        "molecule": "Emtricitabine",
        "cas": "143491-57-0",
        "iupac_name": "5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-4-imino-1,4-dihydropyrimidin-2-ol",
        "background": "Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults6 or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults.5 Emtricitabine is a cytidine analogue.6 The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.6\nEmtricitabine was granted FDA approval on 2 July 2003.6\n",
        "inchi": {
            "hash": "XQSPYNMVSIKCOC-NTSWFWBYSA-N",
            "id": "InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1"
        },
        "summary": "Emtricitabine is a nucleoside reverse transcriptase inhibitor used for the treatment and prophylaxis of HIV.",
        "weight": [
            {
                "type": "average",
                "weight": 247.247,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 247.042690096,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 3'-thia pyrimidine nucleosides. These are nucleoside analogues with a structure that consists of a pyrimidine base, which is N-substituted at the 1-position with a 3'-thia derivative (1,3-oxazolidine) of the ribose moiety that is characteristic of nucleosides.",
        "link": "https://go.drugbank.com/drugs/DB00879",
        "type": "Small Molecule",
        "synonyms": [
            "()-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine",
            "()-2'-deoxy-5-fluoro-3'-thiacytidine",
            "()-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one",
            "()-FTC",
            "()--2',3'-dideoxy-5-fluoro-3'-thiacytidine",
            "(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone",
            "4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one",
            "4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one",
            "5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine",
            "Emtricitabin",
            "Emtricitabina",
            "Emtricitabine",
            "Emtricitabinum"
        ],
        "indication": "Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections;6,10,17 treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients 35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex;7,5 treatment of HIV-1 infections in pediatric and adult patients 17kg, pre exposure prophylaxis in adolescents and adults 35kg;9 treatment of HIV-1 in patients 12 years and 35kg;11 treatment of HIV-1 in patients weighing 35kg;12,14 treatment of HIV-1 in patients weighing 25kg;13,15 and treatment of HIV-1 in patients weighing 40kg.16\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Emtricitabine is a cytidine analog that competes with the natural substrate of HIV-1 reverse transcriptase to be incorporated into newly formed DNA, terminating its transcription.6 It is administered once daily so it has a long duration of action. Patients should be counselled regarding the risk of lactic acidosis and hepatomegaly with steatosis.6\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Human immunodeficiency virus 1",
                "target": "AReverse transcriptase/RNaseH"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03281"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15149"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03842"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16451"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14090"
    },
    {
        "smiles": "CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)OC3=CC=CC=C3)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O",
        "id": "DB13506",
        "molecule": "Carfecillin",
        "cas": "27025-49-6",
        "iupac_name": "(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[2-phenyl-2-(phenyl carboxy)acetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",
        "inchi": {
            "hash": "NZDASSHFKWDBBU-KVMCETHSSA-N",
            "id": "InChI=1S/C23H22N2O6S/c1-23(2)17(21(28)29)25-19(27)16(20(25)32-23)24-18(26)15(13-9-5-3-6-10-13)22(30)31-14-11-7-4-8-12-14/h3-12,15-17,20H,1-2H3,(H,24,26)(H,28,29)/t15?,16-,17+,20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 454.5,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 454.11985761,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB13506",
        "type": "Small Molecule",
        "synonyms": [
            "Carbenicillin phenyl",
            "Carfecilina",
            "Carfecillin",
            "Carfecilline",
            "Carfecillinum"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03919"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07826"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12689"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07473"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04615"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08251"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08241"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12198"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12338"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02286"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13298"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02317"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08102"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07487"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14940"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00321"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08321"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00355"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13612"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02969"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04583"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11129"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08093"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06996"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04498"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00345"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02754"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07236"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04320"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11512"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08280"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02714"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05093"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12853"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08224"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09230"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07030"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08157"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06401"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04731"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06755"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04815"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05178"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07258"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13994"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15275"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12135"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02395"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08149"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15358"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03556"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12116"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02781"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11575"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00520"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07202"
    },
    {
        "smiles": "[H][C@]1(C)OC(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@]([H])(CC2=CC=C(C=C2)N2CCOCC2)OC(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@]([H])(C)OC(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@]([H])(CC2=CC=C(C=C2)N2CCOCC2)OC(=O)[C@]([H])(CC(C)C)N(C)C1=O",
        "id": "DB11403",
        "molecule": "Emodepside",
        "cas": "155030-63-0",
        "iupac_name": "(3S,6R,9S,12R,15S,18R,21S,24R)-4,6,10,16,18,22-hexamethyl-3,9,15,21-tetrakis(2-methylpropyl)-12,24-bis({[4-(morpholin-4-yl)phenyl]methyl})-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclotetracosan-2,5,8,11,14,17,20,23-octone",
        "background": "Emodepside is an anthelmintic drug that is effective against a number of gastrointestinal nematodes, is licensed for use in cats and belongs to the class of drugs known as the octadepsipeptides, a relatively new class of anthelmintic.\n",
        "inchi": {
            "hash": "ZMQMTKVVAMWKNY-YSXLEBCMSA-N",
            "id": "InChI=1S/C60H90N6O14/c1-37(2)31-47-57(71)77-41(9)53(67)61(11)50(34-40(7)8)60(74)80-52(36-44-17-21-46(22-18-44)66-25-29-76-30-26-66)56(70)64(14)48(32-38(3)4)58(72)78-42(10)54(68)62(12)49(33-39(5)6)59(73)79-51(55(69)63(47)13)35-43-15-19-45(20-16-43)65-23-27-75-28-24-65/h15-22,37-42,47-52H,23-36H2,1-14H3/t41-,42-,47+,48+,49+,50+,51-,52-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1119.408,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1118.651501602,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cyclic depsipeptides. These are natural or synthetic compounds having sequences of amino and hydroxy carboxylic acid residues (usually -amino and -hydroxy acids) connected in a ring. The residues are commonly but not necessarily regularly alternating.",
        "link": "https://go.drugbank.com/drugs/DB11403",
        "type": "Small Molecule",
        "synonyms": [
            "Emodepsida",
            "modepside",
            "Emodepside",
            "Emodepsidum"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12865"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01217"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03250"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13106"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04280"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00122"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04143"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09341"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02241"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06431"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07877"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13442"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02365"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06889"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11197"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05821"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00748"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12010"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08232"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08277"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08530"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11341"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01597"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04003"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07302"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04654"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01125"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03631"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03254"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11934"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07011"
    },
    {
        "smiles": "CC1=CC(=CC(OC2=C(Br)C=C(CC3=NNC4=NN=CC=C34)C=C2)=C1)C#N",
        "id": "DB08444",
        "molecule": "3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile",
        "iupac_name": "3-[2-bromo-4-({1H-pyrazolo[3,4-c]pyridazin-3-yl}methyl)phenoxy]-5-methylbenzonitrile",
        "inchi": {
            "hash": "YYGZQXRLQMFHDH-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H14BrN5O/c1-12-6-14(11-22)8-15(7-12)27-19-3-2-13(9-17(19)21)10-18-16-4-5-23-25-20(16)26-24-18/h2-9H,10H2,1H3,(H,24,25,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 420.262,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 419.038172742,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bromodiphenyl ethers. These are compounds that contain two benzene groups linked to each other via an ether bond, and where at least one ring is substituted with a bromo group.",
        "link": "https://go.drugbank.com/drugs/DB08444",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(CNC(=O)C1)C1=CC=C(OC)C(OC2CCCC2)=C1",
        "id": "DB03606",
        "molecule": "(S)-Rolipram",
        "cas": "85416-73-5",
        "iupac_name": "(4S)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one",
        "background": "A phosphodiesterase inhibitor with antidepressant properties. [PubChem]\n",
        "inchi": {
            "hash": "HJORMJIFDVBMOB-GFCCVEGCSA-N",
            "id": "InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)/t12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 275.348,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 275.15214354,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB03606",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-rolipram",
            "(S)-(+)-rolipram",
            "S-rolipram"
        ],
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4B"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4D"
            }
        ]
    },
    {
        "smiles": "BrC1=CC=C(\\C=C\\CNCCNS(=O)(=O)C2=CC=CC3=C2C=CN=C3)C=C1",
        "id": "DB07995",
        "molecule": "H-89",
        "cas": "127243-85-0",
        "iupac_name": "N-(2-{[(2E)-3-(4-bromophenyl)prop-2-en-1-yl]amino}ethyl)isoquinoline-5-sulfonamide",
        "inchi": {
            "hash": "ZKZXNDJNWUTGDK-NSCUHMNNSA-N",
            "id": "InChI=1S/C20H20BrN3O2S/c21-18-8-6-16(7-9-18)3-2-11-22-13-14-24-27(25,26)20-5-1-4-17-15-23-12-10-19(17)20/h1-10,12,15,22,24H,11,13-14H2/b3-2+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 446.361,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 445.045960236,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as isoquinolines and derivatives. These are aromatic polycyclic compounds containing an isoquinoline moiety, which consists of a benzene ring fused to a pyridine ring and forming benzo[c]pyridine.",
        "link": "https://go.drugbank.com/drugs/DB07995",
        "type": "Small Molecule",
        "synonyms": [
            "N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase catalytic subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase inhibitor alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein kinase haspin"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UInterferon-induced, double-stranded RNA-activated protein kinase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02449"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01501"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02427"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03253"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07031"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01767"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04339"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04271"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02588"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12379"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17032"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02447"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01691"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13383"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00835"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04055"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07754"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04772"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14099"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17018"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04110"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05398"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08537"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17023"
    },
    {
        "smiles": "CC(C)N1C=CC(=N1)S(=O)(=O)NC(=O)NC1=C2CCCC2=CC2=C1CCC2",
        "id": "DB18304",
        "molecule": "Emlenoflast",
        "cas": "1995067-59-8",
        "inchi": {
            "hash": "MTOUOUSKXWSTAX-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H24N4O3S/c1-12(2)23-10-9-17(21-23)27(25,26)22-19(24)20-18-15-7-3-5-13(15)11-14-6-4-8-16(14)18/h9-12H,3-8H2,1-2H3,(H2,20,22,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 388.49,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 388.156911823,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18304",
        "type": "Small Molecule",
        "synonyms": [
            "1h-pyrazole-3-sulfonamide, n-(((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino)carbonyl)-1-(1-methylethyl)-",
            "Inzomelid",
            "N-[[(1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL) AMINO]CARBONYL]-1-(1-METHYLETHYL)-1H-PYRAZOLE-3-SULFONAMIDE"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08388"
    },
    {
        "smiles": "CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C(NC(=O)C=C)=C1",
        "id": "DB15169",
        "molecule": "H3B-6527",
        "cas": "1702259-66-2",
        "iupac_name": "N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide",
        "background": "H3B-6527 is under investigation in clinical trial NCT03424577 (A Study to Evaluate the Food-Effect of H3B-6527).\n",
        "inchi": {
            "hash": "MBWRLLRCTIYXDW-UHFFFAOYSA-N",
            "id": "InChI=1S/C29H34Cl2N8O4/c1-6-25(40)35-20-14-18(39-12-10-38(7-2)11-13-39)8-9-19(20)34-23-16-24(33-17-32-23)37(3)29(41)36-28-26(30)21(42-4)15-22(43-5)27(28)31/h6,8-9,14-17H,1,7,10-13H2,2-5H3,(H,35,40)(H,36,41)(H,32,33,34)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 629.54,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 628.208007,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15169",
        "type": "Small Molecule",
        "synonyms": [
            "(N-{2-[(6-{[(2,6-Dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4- yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide)",
            "2-PROPENAMIDE, N-(2-((6-((((2,6-DICHLORO-3,5-DIMETHOXYPHENYL)AMINO)CARBONYL)METHYLAMINO)-4-PYRIMIDINYL)AMINO)-5-(4-ETHYL-1-PIPERAZINYL)PHENYL)-",
            "H3B 6527",
            "H3B6527",
            "N-(2-((6-(((2,6-DICHLORO-3,5 DIMETHOXYPHENYL) CARBAMOYL) (METHYL)AMINO)PYRIMIDIN-4-YL)AMINO)-5-(4-ETHYLPIPERAZIN-1-YL)PHENYL)PROP-2-ENAMIDE"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCN(CC)CCOC1=CC=C(C=C1)C1=NC2=CC(Cl)=CC=C2S1",
        "id": "DB15942",
        "molecule": "Haletazole",
        "cas": "15599-36-7",
        "iupac_name": "{2-[4-(5-chloro-1,3-benzothiazol-2-yl)phenoxy]ethyl}diethylamine",
        "inchi": {
            "hash": "TXOKWXJQVFUUDD-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H21ClN2OS/c1-3-22(4-2)11-12-23-16-8-5-14(6-9-16)19-21-17-13-15(20)7-10-18(17)24-19/h5-10,13H,3-4,11-12H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 360.9,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 360.1063122,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15942",
        "type": "Small Molecule",
        "synonyms": [
            "Haletazole",
            "Halethazole"
        ],
        "is_stub": true
    },
    {
        "smiles": "CNC(=O)C[C@@H](N)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)C1=CC=C(O)C=C1",
        "id": "DB13816",
        "molecule": "Aspoxicillin",
        "cas": "63358-49-6",
        "iupac_name": "(2S,5R,6R)-6-[(2R)-2-[(2R)-2-amino-3-(methylcarbamoyl)propanamido]-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",
        "inchi": {
            "hash": "BHELIUBJHYAEDK-OAIUPTLZSA-N",
            "id": "InChI=1S/C21H27N5O7S/c1-21(2)15(20(32)33)26-18(31)14(19(26)34-21)25-17(30)13(9-4-6-10(27)7-5-9)24-16(29)11(22)8-12(28)23-3/h4-7,11,13-15,19,27H,8,22H2,1-3H3,(H,23,28)(H,24,29)(H,25,30)(H,32,33)/t11-,13-,14-,15+,19-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 493.54,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 493.163119403,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.",
        "link": "https://go.drugbank.com/drugs/DB13816",
        "type": "Small Molecule",
        "synonyms": [
            "Aspoxicillin"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](O)(CO)C1=CC=C(NC(=O)C2=CC3=CC(Cl)=CC=C3N2)C=C1",
        "id": "DB07315",
        "molecule": "5-chloro-N-{4-[(1R)-1,2-dihydroxyethyl]phenyl}-1H-indole-2-carboxamide",
        "iupac_name": "5-chloro-N-{4-[(1R)-1,2-dihydroxyethyl]phenyl}-1H-indole-2-carboxamide",
        "inchi": {
            "hash": "SHCHFGSUYJUEBR-INIZCTEOSA-N",
            "id": "InChI=1S/C17H15ClN2O3/c18-12-3-6-14-11(7-12)8-15(20-14)17(23)19-13-4-1-10(2-5-13)16(22)9-21/h1-8,16,20-22H,9H2,(H,19,23)/t16-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 330.766,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 330.077120063,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.",
        "link": "https://go.drugbank.com/drugs/DB07315",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, liver form"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CCN(CC(=O)NC2=C(F)C=C(C=C2)N2C=CC=CC2=O)C1)NC(=O)C1=CC=C(Cl)S1",
        "id": "DB07872",
        "molecule": "5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide",
        "iupac_name": "5-chloro-N-[(3R)-1-({[2-fluoro-4-(2-oxo-1,2-dihydropyridin-1-yl)phenyl]carbamoyl}methyl)pyrrolidin-3-yl]thiophene-2-carboxamide",
        "inchi": {
            "hash": "IYGIXVNAMZPBDK-CQSZACIVSA-N",
            "id": "InChI=1S/C22H20ClFN4O3S/c23-19-7-6-18(32-19)22(31)25-14-8-10-27(12-14)13-20(29)26-17-5-4-15(11-16(17)24)28-9-2-1-3-21(28)30/h1-7,9,11,14H,8,10,12-13H2,(H,25,31)(H,26,29)/t14-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 474.936,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 474.092867128,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB07872",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "smiles": "CC(C)C1=NOC(=N1)N1CCC(COC2=CC=C(N=C2)C2=CC=C(C=C2)S(C)(=O)=O)CC1",
        "id": "DB12627",
        "molecule": "GSK-1292263",
        "cas": "1032823-75-8",
        "iupac_name": "2-(4-methanesulfonylphenyl)-5-({1-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-4-yl}methoxy)pyridine",
        "background": "GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.\n",
        "inchi": {
            "hash": "AYJRTVVIBJSSKN-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 456.56,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 456.183126572,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB12627",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11823"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06963"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02308"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02996"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08645"
    },
    {
        "smiles": "O=C(OCC1=CC=CC=C1)C1=CC=CN=C1",
        "id": "DB15764",
        "molecule": "Benzyl nicotinate",
        "cas": "94-44-0",
        "iupac_name": "benzyl pyridine-3-carboxylate",
        "inchi": {
            "hash": "KVYGGMBOZFWZBQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H11NO2/c15-13(12-7-4-8-14-9-12)16-10-11-5-2-1-3-6-11/h1-9H,10H2"
        },
        "summary": "Benzyl nicotinate is a rubefacient and vasodilator used in combination with analgesics in topical preparations.",
        "weight": [
            {
                "type": "average",
                "weight": 213.236,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 213.078978598,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15764",
        "type": "Small Molecule",
        "synonyms": [
            "Benzyl nicotinate",
            "Nicotinic acid benzyl ester",
            "Phenylmethyl 3-pyridinecarboxylate"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02037"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15279"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12276"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03660"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02715"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04727"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02492"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05104"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16015"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02407"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06976"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08036"
    },
    {
        "smiles": "O\\C(C1CC1)=C(\\C#N)C(=O)NC1=CC=C(C=C1)C1=CC=CC=C1",
        "id": "DB08169",
        "molecule": "(2Z)-N-biphenyl-4-yl-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide",
        "iupac_name": "(2Z)-N-{[1,1'-biphenyl]-4-yl}-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide",
        "inchi": {
            "hash": "CAGGGMPTWTUYHZ-ZCXUNETKSA-N",
            "id": "InChI=1S/C19H16N2O2/c20-12-17(18(22)15-6-7-15)19(23)21-16-10-8-14(9-11-16)13-4-2-1-3-5-13/h1-5,8-11,15,22H,6-7H2,(H,21,23)/b18-17-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 304.3425,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 304.121177766,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.",
        "link": "https://go.drugbank.com/drugs/DB08169",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydroorotate dehydrogenase (quinone), mitochondrial"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01260"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03212"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01262"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08721"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00249"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07036"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07618"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16862"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07550"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08924"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02425"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11376"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08581"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17387"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15581"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07077"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04365"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01541"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14971"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17351"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14518"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06250"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14927"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11520"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11602"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08775"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04717"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03936"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12078"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01528"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13869"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04016"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04604"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00746"
    },
    {
        "smiles": "[H]N1C(=O)C(CCC)=C(C2=C1C=CC(Cl)=C2)[S@](=O)C1CCCCC1",
        "id": "DB07869",
        "molecule": "6-Chloro-4-[(R)-cyclohexylsulfinyl]-3-propyl-2(1H)-quinolinone",
        "iupac_name": "6-chloro-4-[(R)-cyclohexanesulfinyl]-3-propyl-1,2-dihydroquinolin-2-one",
        "inchi": {
            "hash": "QRBUGQMJMFAHKS-HSZRJFAPSA-N",
            "id": "InChI=1S/C18H22ClNO2S/c1-2-6-14-17(23(22)13-7-4-3-5-8-13)15-11-12(19)9-10-16(15)20-18(14)21/h9-11,13H,2-8H2,1H3,(H,20,21)/t23-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 351.891,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 351.10597735,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroquinolones. These are compounds containing a hydrogenated quinoline bearing a ketone group.",
        "link": "https://go.drugbank.com/drugs/DB07869",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ],
        "drug_interactions_raw": "This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not Available",
        "drug_interactions_link": "https://go.drugbank.com/drugs/DB07869/drug_interactions.json?start=0\u0026length=100\u0026_=1701097776",
        "drug_interactions_page": "{\"draw\":1,\"recordsTotal\":0,\"recordsFiltered\":0,\"data\":[]}"
    },
    {
        "smiles": "[H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C(I)C=C1)C(=O)OC)N2CCC[18F]",
        "id": "DB16913",
        "molecule": "Ioflupane F-18",
        "cas": "186381-69-1",
        "iupac_name": "methyl (1R,2S,3S,5S)-8-[3-(F)fluoropropyl]-3-(4-iodophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate",
        "inchi": {
            "hash": "HXWLAJVUJSVENX-LNYNZGDVSA-N",
            "id": "InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i19-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 430.292,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 430.07829,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16913",
        "type": "Small Molecule",
        "synonyms": [
            "(18f)fp-cit",
            "18f-beta-cit-fp",
            "18f-cit-fp",
            "18f-fp-.beta.-cit",
            "18f-fpcit",
            "18f-ioflupane",
            "18fluorine-n-3-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) nortropane",
            "8-azabicyclo(3.2.1)octane-2-carboxylic acid, 8-(3-(fluoro-18f)propyl)-3-(4-iodophenyl)-, methyl ester, (1r,2s,3s,5s)-",
            "F-18-fpcit",
            "Methyl (1s,3s,4s,5r)-8-(3-fluoranylpropyl)-3-(4-iodophenyl)-8-azabicyclo(3.2.1)octane-4-carboxylate"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08956"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05934"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00822"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07098"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05090"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03586"
    },
    {
        "smiles": "FC1=CC=CC=C1C12OCCN1CC(=O)NC1=C2C=C(Br)C=C1",
        "id": "DB01476",
        "molecule": "Haloxazolam",
        "cas": "59128-97-1",
        "iupac_name": "13-bromo-2-(2-fluorophenyl)-3-oxa-6,9-diazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),11,13-trien-8-one",
        "inchi": {
            "hash": "XDKCGKQHVBOOHC-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H14BrFN2O2/c18-11-5-6-15-13(9-11)17(12-3-1-2-4-14(12)19)21(7-8-23-17)10-16(22)20-15/h1-6,9H,7-8,10H2,(H,20,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 377.208,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 376.022268554,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,3-oxazolobenzo-1,4-diazepines. These are aromatic heteropolycyclic compounds containing a 1,3-oxazole ring fused to the 1,-4-diazepine moiety of a 1,4-benzodiazepine ring system.",
        "link": "https://go.drugbank.com/drugs/DB01476",
        "type": "Small Molecule",
        "synonyms": [
            "Haloxazolam",
            "Haloxazolamum"
        ]
    },
    {
        "smiles": "OC(=O)C1=C(C2=CNC3=CC=CC=C23)C(=C(N1)C(O)=O)C1=CNC2=C1C=CC=C2",
        "id": "DB07588",
        "molecule": "3,4-DI-1H-INDOL-3-YL-1H-PYRROLE-2,5-DICARBOXYLIC ACID",
        "iupac_name": "3,4-bis(1H-indol-3-yl)-1H-pyrrole-2,5-dicarboxylic acid",
        "inchi": {
            "hash": "FZDVNXHYGMEEDT-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H15N3O4/c26-21(27)19-17(13-9-23-15-7-3-1-5-11(13)15)18(20(25-19)22(28)29)14-10-24-16-8-4-2-6-12(14)16/h1-10,23-25H,(H,26,27)(H,28,29)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 385.3722,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 385.106255983,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.",
        "link": "https://go.drugbank.com/drugs/DB07588",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces sp. TP-A0274",
                "target": "UCytochrome P450"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15300"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17140"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04889"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09130"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04221"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00215"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04389"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00320"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14079"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09347"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06867"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15207"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11501"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05212"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03852"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13318"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06833"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00672"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08905"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15648"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07770"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13599"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02245"
    },
    {
        "smiles": "CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C",
        "id": "DB12311",
        "molecule": "CP1-1189",
        "cas": "183619-38-7",
        "iupac_name": "N-tert-butyl-4-acetamidobenzamide",
        "background": "CPI-1189 has been used in trials studying the treatment of HIV Infections and AIDS Dementia Complex.\n",
        "inchi": {
            "hash": "DJKNRCWSXSZACF-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 234.299,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 234.136827828,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.",
        "link": "https://go.drugbank.com/drugs/DB12311",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07295"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13372"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11724"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01458"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07291"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17104"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12631"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08034"
    },
    {
        "smiles": "OC1=CC=C2C=C(C=C(C#N)C2=C1)C1=CC=C(O)C(F)=C1",
        "id": "DB06875",
        "molecule": "ERB-196",
        "cas": "550997-55-2",
        "iupac_name": "3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthalene-1-carbonitrile",
        "inchi": {
            "hash": "NSSOSHDCWCMNDM-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H10FNO2/c18-16-7-10(2-4-17(16)21)12-5-11-1-3-14(20)8-15(11)13(6-12)9-19/h1-8,20-21H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 279.2652,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 279.069556774,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylnaphthalenes. These are compounds containing a phenylnaphthalene skeleton, which consists of a naphthalene bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB06875",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor coactivator 1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04693"
    },
    {
        "smiles": "[H]N1C(OC)=C(Cl)C(=O)C(Cl)=C1C(Cl)(Cl)Cl",
        "id": "DB06331",
        "molecule": "4-O-Demethylpenclomedine",
        "cas": "176046-79-0",
        "iupac_name": "3,5-dichloro-2-methoxy-6-(trichloromethyl)-1,4-dihydropyridin-4-one",
        "inchi": {
            "hash": "GUYGGZGIKZIRFO-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H4Cl5NO2/c1-15-6-3(9)4(14)2(8)5(13-6)7(10,11)12/h1H3,(H,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 311.36,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 308.8684669,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as polyhalopyridines. These are organic compounds containing a pyridine ring substituted at two or more positions by a halogen atom.",
        "link": "https://go.drugbank.com/drugs/DB06331",
        "type": "Small Molecule",
        "synonyms": [
            "4-Demethylpenclomedine",
            "4-Dm-pen",
            "4-Dmpen",
            "DM-PEN",
            "DMPEN"
        ],
        "indication": "Investigated for use/treatment in solid tumors.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03259"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07139"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07910"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16825"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04152"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08765"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00876"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04032"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00584"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03295"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15580"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08431"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03811"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01044"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06958"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05842"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15477"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02804"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06884"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01455"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11960"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00926"
    },
    {
        "smiles": "FC1=CC(=CC(=C1)C(=O)NC1=CC=C2NC=C(CCC3=CC=NC=C3)C2=C1)N1CCOCC1",
        "id": "DB08091",
        "molecule": "3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE",
        "iupac_name": "3-fluoro-5-(morpholin-4-yl)-N-{3-[2-(pyridin-4-yl)ethyl]-1H-indol-5-yl}benzamide",
        "inchi": {
            "hash": "HIUFYIOMUILESI-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H25FN4O2/c27-21-13-20(14-23(15-21)31-9-11-33-12-10-31)26(32)30-22-3-4-25-24(16-22)19(17-29-25)2-1-18-5-7-28-8-6-18/h3-8,13-17,29H,1-2,9-12H2,(H,30,32)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 444.5007,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 444.196154269,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.",
        "link": "https://go.drugbank.com/drugs/DB08091",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 14"
            }
        ]
    },
    {
        "smiles": "COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC",
        "id": "DB00400",
        "molecule": "Griseofulvin",
        "cas": "126-07-8",
        "iupac_name": "(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[1-benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione",
        "background": "An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.\n",
        "inchi": {
            "hash": "DDUHZTYCFQRHIY-RBHXEPJQSA-N",
            "id": "InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1"
        },
        "summary": "Griseofulvin is an antifungal agent used to treat a variety of superficial tinea infections and fungal infections of the fingernails and toes.",
        "weight": [
            {
                "type": "average",
                "weight": 352.766,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 352.071365983,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.",
        "link": "https://go.drugbank.com/drugs/DB00400",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-griseofulvin",
            "Amudane",
            "Griseofulvin",
            "Griseofulvin, microcrystalline",
            "Griseofulvin, ultramicrosize",
            "Griseofulvina",
            "Grisofulvine",
            "Griseofulvinum"
        ],
        "indication": "For the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by Trichophyton or Microsporum fungi.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Griseofulvin is a mycotoxic metabolic product of Penicillium spp. It was the first available oral agent for the treatment of dermatophytoses and has now been used for more than forty years. Griseofulvin is fungistatic with in vitro activity against various species of Microsporum Epidermophyton, and Trichophyton. It has no effect on bacteria or on other genera of fungi. Following oral administration, griseofulvin is deposited in the keratin precursor cells and has a greater affinity for diseased tissue. The drug is tightly bound to the new keratin which becomes highly resistant to fungal invasions. Once the keratin-Griseofulvin complex reaches the skin site of action, it binds to fungal microtubules (tubulin) thus altering fungal mitosis.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Trichophyton rubrum",
                "target": "ATubulin beta chain"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "UKeratin, type I cytoskeletal 12"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02316"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13393"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08790"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07373"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05803"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11359"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16864"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14725"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12180"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00677"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16631"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09234"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17298"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11421"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12001"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03514"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07034"
    },
    {
        "smiles": "COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1",
        "id": "DB13510",
        "molecule": "Buflomedil",
        "cas": "55837-25-7",
        "iupac_name": "4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one",
        "inchi": {
            "hash": "OWYLAEYXIQKAOL-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 307.39,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 307.178358289,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB13510",
        "type": "Small Molecule",
        "synonyms": [
            "Buflomedil"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11100"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00343"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01486"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07978"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07150"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16883"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03807"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15254"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01995"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11752"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01981"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00629"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08422"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16100"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04437"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17507"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18176"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18149"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03810"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06747"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16166"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15571"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04415"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08393"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03510"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08702"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13494"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07354"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08041"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17277"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13135"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08412"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11957"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03403"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14888"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06598"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04626"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04004"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12432"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03076"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01937"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11809"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13549"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13989"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07569"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08727"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12945"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02198"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03368"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03079"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04516"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01838"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08810"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18408"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12461"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08979"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01760"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04614"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02363"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08398"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16908"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08162"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03872"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12551"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09201"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02445"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03690"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15886"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05881"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00995"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13799"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01382"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12990"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04704"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03632"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08786"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04060"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12784"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14578"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13917"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00537"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02872"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02451"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12781"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11487"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01049"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17026"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07156"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11502"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01431"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01140"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01444"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13742"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15029"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04631"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02498"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01829"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07401"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16040"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01122"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16831"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13731"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04543"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17818"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01731"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02738"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04489"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01909"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04472"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18683"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06087"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04753"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12144"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08713"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01395"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06702"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06582"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13763"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08655"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08043"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05735"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16110"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02599"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08944"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06562"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03600"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12645"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07222"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12466"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08998"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11817"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01811"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09202"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04142"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18010"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02860"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02897"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13425"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02328"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03609"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04540"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16241"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16033"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05851"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12032"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06932"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04461"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13759"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02079"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13504"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13177"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04796"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01876"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03082"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05714"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16547"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07137"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06005"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08872"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15041"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00269"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08753"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06472"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03427"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01649"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11205"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15398"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01013"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01684"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03814"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14550"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03286"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13540"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12174"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07704"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07856"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01415"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11634"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01700"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11274"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07740"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00631"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15796"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01430"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11735"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14074"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04557"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18698"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17721"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01005"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18573"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03196"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00458"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07697"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16126"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02811"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04418"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07420"
    },
    {
        "smiles": "[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O",
        "id": "DB09059",
        "molecule": "Atosiban",
        "cas": "90779-69-4",
        "iupac_name": "(2S)-5-amino-2-{[(2S)-1-[(4R,7S,10S,13S,16R)-13-[(2S)-butan-2-yl]-7-(carbamoylmethyl)-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)pentanamide",
        "background": "Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.\n",
        "inchi": {
            "hash": "VWXRQYYUEIYXCZ-OBIMUBPZSA-N",
            "id": "InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1"
        },
        "summary": "Atosiban is an inhibitor of oxytocin and vasopressin used to delay imminent preterm birth in pregnant adult women displaying specific clinical observations.",
        "weight": [
            {
                "type": "average",
                "weight": 994.19,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 993.441208989,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB09059",
        "type": "Small Molecule",
        "synonyms": [
            "Atosiban"
        ],
        "indication": "Atosiban is indicated for use in delaying imminent pre-term birth in pregnant adult women with: \n\nregular uterine contractions of at least 30 s duration at a rate of at least 4 per 30 min\na cervical dilation of 1-3cm (0-3cm for nulliparas) and effacement of at least 50%\na gestational age of 24-33 weeks\na normal fetal heart rate\n\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Atosiban reduces the frequency of uterine contractions to delay pre-term birth in adult females and induces uterine quiescence 5,1.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AOxytocin receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UVasopressin V1a receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UVasopressin V1b receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UVasopressin V2 receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04694"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17034"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02903"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07515"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06637"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00572"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06751"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11904"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08801"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01571"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01652"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04447"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03597"
    },
    {
        "smiles": "[H][C@]1(C)CC[C@@]([H])(CC1)C(=O)N(C(C)C)C1=C(SC(=C1)C1=CC=CC=C1)C(O)=O",
        "id": "DB08279",
        "molecule": "3-{ISOPROPYL[(TRANS-4-METHYLCYCLOHEXYL)CARBONYL]AMINO}-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID",
        "iupac_name": "5-phenyl-3-[N-(propan-2-yl)(1r,4r)-4-methylcyclohexaneamido]thiophene-2-carboxylic acid",
        "inchi": {
            "hash": "RZXQBIKGWSLVEK-JCNLHEQBSA-N",
            "id": "InChI=1S/C22H27NO3S/c1-14(2)23(21(24)17-11-9-15(3)10-12-17)18-13-19(27-20(18)22(25)26)16-7-5-4-6-8-16/h4-8,13-15,17H,9-12H2,1-3H3,(H,25,26)/t15-,17-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 385.52,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 385.171164425,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thiophene carboxylic acids. These are compounds containing a thiophene ring which bears a carboxylic acid group.",
        "link": "https://go.drugbank.com/drugs/DB08279",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Hepatitis C virus genotype 1b (isolate BK)",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16932"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11966"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04657"
    },
    {
        "id": "DB05061",
        "molecule": "GFT14",
        "background": "GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.\nGFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides) and on other risk factors such as hypertension or diabetes. Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based). The risks of medical interaction are weak and GFT14 may be easily combined with statins or other antidiabetic molecules (glitazones). \n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05061",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in cardiovascular disorders and hyperlipidemia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "C1[C@@H]2CNC[C@]12C1=CC=C2C=CC=CC2=C1",
        "id": "DB14841",
        "molecule": "Centanafadine",
        "cas": "924012-43-1",
        "iupac_name": "(1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane",
        "background": "Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects).\n",
        "inchi": {
            "hash": "HKHCSWPSUSWGLI-CABCVRRESA-N",
            "id": "InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 209.292,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 209.120449487,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB14841",
        "type": "Small Molecule",
        "synonyms": [
            "Centanafadine"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O",
        "id": "DB02353",
        "molecule": "Heparin Disaccharide Iii-S",
        "iupac_name": "(2R,3R,4S)-2-{[(2R,3S,4R,5R,6S)-4,6-dihydroxy-2-(hydroxymethyl)-5-(sulfonatoamino)oxan-3-yl]oxy}-4-hydroxy-3-(sulfonatooxy)-3,4-dihydro-2H-pyran-6-carboxylate",
        "inchi": {
            "hash": "GSYQGRODWXMUOO-GYBHJADLSA-K",
            "id": "InChI=1S/C12H19NO16S2/c14-2-5-9(7(16)6(11(19)26-5)13-30(20,21)22)28-12-8(29-31(23,24)25)3(15)1-4(27-12)10(17)18/h1,3,5-9,11-16,19H,2H2,(H,17,18)(H,20,21,22)(H,23,24,25)/p-3/t3-,5+,6+,7+,8+,9+,11-,12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 494.383,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 493.991049849,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as disaccharides. These are compounds containing two carbohydrate moieties linked to each to each other through a glycosidic bond, no set of three or more glycosidically linked carbohydrate units.",
        "link": "https://go.drugbank.com/drugs/DB02353",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UC-C motif chemokine 5"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02512"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14107"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13980"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04272"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04737"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18506"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14476"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05123"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03964"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08001"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14879"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17837"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08665"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04170"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01012"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00616"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03415"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14623"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07065"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06903"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04637"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03329"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00159"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17396"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07462"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05687"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13918"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07771"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07605"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03266"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04656"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04336"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02259"
    },
    {
        "smiles": "[H]N(OCC1=CC=CC=C1)S(=O)(=O)CC[C@H](CCC1=CC=CC=C1)N([H])C(=O)[C@H](CC1=CC=CC=C1)N([H])C(=O)N1CCN(C)CC1",
        "id": "DB04427",
        "molecule": "4-Methyl-N-[(2S)-1-oxo-3-phenyl-1-[[(3S)-1-phenyl-5-(phenylmethoxysulfamoyl)pentan-3-yl]amino]propan-2-yl]piperazine-1-carboxamide",
        "iupac_name": "(2S)-N-[(3S)-1-[(benzyloxy)sulfamoyl]-5-phenylpentan-3-yl]-2-[(4-methylpiperazine-1-carbonyl)amino]-3-phenylpropanamide",
        "inchi": {
            "hash": "PPIYQXGSPPWVLJ-CONSDPRKSA-N",
            "id": "InChI=1S/C33H43N5O5S/c1-37-20-22-38(23-21-37)33(40)35-31(25-28-13-7-3-8-14-28)32(39)34-30(18-17-27-11-5-2-6-12-27)19-24-44(41,42)36-43-26-29-15-9-4-10-16-29/h2-16,30-31,36H,17-26H2,1H3,(H,34,39)(H,35,40)/t30-,31-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 621.79,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 621.298490201,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB04427",
        "type": "Small Molecule",
        "synonyms": [
            "N-{(3S)-1-[(Benzyloxy)sulfamoyl]-5-phenyl-3-pentanyl}-N-[(4-methyl-1-piperazinyl)carbonyl]-L-phenylalaninamide"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Trypanosoma cruzi",
                "target": "UCruzipain"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07563"
    },
    {
        "smiles": "CC1=CC=C(C=C1)C1=NN(C2=C1C(N)=NC=N2)C(C)(C)C",
        "id": "DB01809",
        "molecule": "1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",
        "iupac_name": "1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",
        "inchi": {
            "hash": "ZVPDNRVYHLRXLX-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H19N5/c1-10-5-7-11(8-6-10)13-12-14(17)18-9-19-15(12)21(20-13)16(2,3)4/h5-9H,1-4H3,(H2,17,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 281.3556,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 281.164045633,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB01809",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProto-oncogene tyrosine-protein kinase receptor Ret"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein kinase HCK"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12925"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01994"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08050"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00546"
    },
    {
        "smiles": "CN(C\\C=C\\COC1=CC=C(C=C1)C(=O)C1=CC=C(Br)C=C1)C1CC1",
        "id": "DB08458",
        "molecule": "(4-BROMOPHENYL)[4-({(2E)-4-[CYCLOPROPYL(METHYL)AMINO]BUT-2-ENYL}OXY)PHENYL]METHANONE",
        "iupac_name": "N-[(2E)-4-[4-(4-bromobenzoyl)phenoxy]but-2-en-1-yl]-N-methylcyclopropanamine",
        "inchi": {
            "hash": "JAZMZJDLZUDIDG-NSCUHMNNSA-N",
            "id": "InChI=1S/C21H22BrNO2/c1-23(19-10-11-19)14-2-3-15-25-20-12-6-17(7-13-20)21(24)16-4-8-18(22)9-5-16/h2-9,12-13,19H,10-11,14-15H2,1H3/b3-2+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 400.309,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 399.0833916,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB08458",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Alicyclobacillus acidocaldarius subsp. acidocaldarius (strain ATCC 27009 / DSM 446 / 104-1A)",
                "target": "USqualene--hopene cyclase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00445"
    },
    {
        "smiles": "CC1=C(O)C2=C(C=N1)C(OC2)C1=CC=C(Cl)C=C1",
        "id": "DB12766",
        "molecule": "Cicletanine",
        "cas": "89943-82-8",
        "iupac_name": "3-(4-chlorophenyl)-6-methyl-1H,3H-furo[3,4-c]pyridin-7-ol",
        "background": "Cicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension.\n",
        "inchi": {
            "hash": "CVKNDPRBJVBDSS-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 261.71,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 261.0556563,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB12766",
        "type": "Small Molecule",
        "synonyms": [
            "Cicletanine"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07981"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16834"
    },
    {
        "smiles": "OC(=O)C(S)C(S)C(O)=O",
        "id": "DB14089",
        "molecule": "Dimercaptosuccinic acid",
        "cas": "2418-14-6",
        "iupac_name": "2,3-disulfanylbutanedioic acid",
        "inchi": {
            "hash": "ACTRVOBWPAIOHC-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 182.218,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 181.97075006,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thia fatty acids. These are fatty acid derivatives obtained by insertion of a sulfur atom at specific positions in the chain.",
        "link": "https://go.drugbank.com/drugs/DB14089",
        "type": "Small Molecule",
        "synonyms": [
            "2,3-Dimercaptobutanedioic acid",
            "2,3-Dimercaptosuccinic acid"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "chelator",
                "organism": "Humans",
                "target": "UMercury"
            },
            {
                "action": "chelator",
                "organism": "Humans",
                "target": "UArsenic"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06211"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16945"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11671"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01522"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02431"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05095"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07775"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06828"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02934"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08449"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04141"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15630"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05489"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11495"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08501"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08714"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11269"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03528"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00424"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02322"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17066"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06585"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05462"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12959"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15835"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06969"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01833"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07551"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07955"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04754"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15582"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05447"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05642"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14942"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02973"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11209"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02833"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00970"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11903"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00226"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02876"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01897"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00210"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15557"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11766"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04140"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07787"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00483"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14071"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11986"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04681"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03307"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12483"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03647"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07626"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16192"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07457"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13679"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08747"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13610"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06465"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15261"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00286"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01078"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06040"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17605"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14510"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09110"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02671"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00261"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08409"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07719"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15216"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02292"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04167"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12139"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04264"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14139"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07116"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13421"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16854"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01690"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04477"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03775"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06959"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04376"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04539"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17138"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15404"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03365"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02561"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17499"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03477"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07129"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07841"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02296"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13729"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04522"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04684"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13867"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18065"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11211"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05092"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07804"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08967"
    },
    {
        "smiles": "C[C@@H]([C@H](O)C1=CC=CC=C1)N(C)C",
        "id": "DB11278",
        "molecule": "DL-Methylephedrine",
        "cas": "1201-56-5",
        "iupac_name": "(1R,2S)-2-(dimethylamino)-1-phenylpropan-1-ol",
        "background": "Methylephedrine is a sympathomimetic amine that appears in various over-the-counter cough and cold medications throughout the world 9, 10, 11. The abuse of methylephedrine-containing medications has been reported in Japan. Methylephedrine is not legally available in the United States, but has been identified in cases of drug abuse 7.\n",
        "inchi": {
            "hash": "FMCGSUUBYTWNDP-ONGXEEELSA-N",
            "id": "InChI=1S/C11H17NO/c1-9(12(2)3)11(13)10-7-5-4-6-8-10/h4-9,11,13H,1-3H3/t9-,11-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 179.263,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 179.131014171,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.",
        "link": "https://go.drugbank.com/drugs/DB11278",
        "type": "Small Molecule",
        "synonyms": [
            "(+/-)-Methylephedrine",
            "(+/-)-N-methylephedrine",
            "Methylephedrine, (+/-)-",
            "Methylephedrine, DL-",
            "N-methylephedrine DL-form"
        ],
        "indication": "Used as an antitussive and decongestant 5.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "This drugs acts as an antitussive, bronchodilator, and adrenergic receptor agonist 5. It stimulates the alpha and beta adrenergic receptors, relieving cough and congestion 5.\nAs with other adrenomimetic amines, the drugs in this class are much less potent than norepinephrine itself. Members of this class of drugs increase both systolic and diastolic blood pressure, cardiac contractility, and cardiac output; in general, however, they do not increase heart rate. Bronchial smooth muscle relaxation of prolonged duration occurs, and pupils dilate 7.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ABeta-1 adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-2A adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ABeta adrenergic receptor"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC",
        "id": "DB15782",
        "molecule": "Cetyl palmitate",
        "cas": "540-10-3",
        "iupac_name": "hexadecyl hexadecanoate",
        "inchi": {
            "hash": "PXDJXZJSCPSGGI-UHFFFAOYSA-N",
            "id": "InChI=1S/C32H64O2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-34-32(33)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-31H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 480.862,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 480.490631301,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15782",
        "type": "Small Molecule",
        "synonyms": [
            "Hexadecanoic acid, hexadecyl ester",
            "Hexadecyl palmitate",
            "n-Hexadecyl hexadecanoate",
            "Palmityl palmitate"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14570"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13842"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15981"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03648"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16059"
    },
    {
        "smiles": "FC(F)(F)C1=CC(NC2=NOC3=C(C(=O)NC4=CN=CN=C4)C(Cl)=CC=C23)=CC=C1",
        "id": "DB07326",
        "molecule": "6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide",
        "iupac_name": "6-chloro-N-(pyrimidin-5-yl)-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzoxazole-7-carboxamide",
        "inchi": {
            "hash": "FEGRQUWSKADGSP-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H11ClF3N5O2/c20-14-5-4-13-16(15(14)18(29)27-12-7-24-9-25-8-12)30-28-17(13)26-11-3-1-2-10(6-11)19(21,22)23/h1-9H,(H,26,28)(H,27,29)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 433.771,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 433.055336943,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.",
        "link": "https://go.drugbank.com/drugs/DB07326",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UVascular endothelial growth factor receptor 2"
            }
        ]
    },
    {
        "id": "DB16964",
        "molecule": "HY-111996",
        "cas": "1380696-64-9",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16964",
        "type": "Small Molecule",
        "synonyms": [
            "5,5-Dimethyl-3-(2-((7-methyl-2H-spiro[benzofuran-3,1'-cyclopropan]-4-yl)oxy)pyrimidin-5-yl)imidazolidine-2,4-dione",
            "5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13110"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01135"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00671"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07692"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12301"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11981"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05513"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03230"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12420"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17893"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04918"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07830"
    },
    {
        "id": "DB05033",
        "molecule": "INCB7839",
        "background": "INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05033",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in breast cancer.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDisintegrin and metalloproteinase domain-containing protein 9"
            }
        ]
    },
    {
        "smiles": "CNCC1=CC(NC(=O)C2=CC=C(NC3=NC4=CC=CC=C4C(=N3)C3=CC=CC=C3)C=C2)=C(C)C=C1",
        "id": "DB16844",
        "molecule": "BMS-833923",
        "cas": "1059734-66-5",
        "iupac_name": "N-{2-methyl-5-[(methylamino)methyl]phenyl}-4-[(4-phenylquinazolin-2-yl)amino]benzamide",
        "inchi": {
            "hash": "KLRRGBHZCJLIEL-UHFFFAOYSA-N",
            "id": "InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 473.58,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 473.221560509,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16844",
        "type": "Small Molecule",
        "synonyms": [
            "BMS-833923 free base anhydrous"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC[C@@H](C)[C@@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC2=CC=CC=C2)N(C)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)C(NC1=O)C(C)C)[C@H](C)C(C)C",
        "id": "DB14058",
        "molecule": "Basifungin",
        "cas": "127785-64-2",
        "iupac_name": "(3R,6S,9S,12S,15S,21S,24S,29aS)-21,24-dibenzyl-15-[(2R)-butan-2-yl]-5,11,23-trimethyl-3-[(2R)-3-methylbutan-2-yl]-9-(2-methylpropyl)-6,12,18-tris(propan-2-yl)-octacosahydropyrrolo[1,2-m]1-oxa-4,7,10,13,16,19,22,25-octaazacycloheptacosane-1,4,7,10,13,16,19,22,25-nonone",
        "background": "Basifungin, also known as aureuobacidin A, is a phosphorylceramide synthase inhibitor 3, 1.\n",
        "inchi": {
            "hash": "YHSKJPXGXIYLHB-OTNPUQRPSA-N",
            "id": "InChI=1S/C60H92N8O10/c1-17-39(12)51-55(72)63-47(36(6)7)53(70)61-44(32-41-25-20-18-21-26-41)56(73)65(14)46(33-42-27-22-19-23-28-42)58(75)68-30-24-29-45(68)52(69)64-48(40(13)35(4)5)59(76)66(15)49(37(8)9)54(71)62-43(31-34(2)3)57(74)67(16)50(38(10)11)60(77)78-51/h18-23,25-28,34-40,43-51H,17,24,29-33H2,1-16H3,(H,61,70)(H,62,71)(H,63,72)(H,64,69)/t39-,40-,43+,44+,45+,46+,47?,48-,49+,50+,51+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1085.442,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1084.693641194,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14058",
        "type": "Small Molecule",
        "synonyms": [
            "Aureobasidin A",
            "Basifungin"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Yeast",
                "target": "AInositol phosphorylceramide synthase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07842"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15686"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02144"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00890"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08643"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05403"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13536"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06726"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04659"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08365"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08137"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16958"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12669"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07240"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00200"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00851"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18025"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06909"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05919"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13798"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13242"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09151"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12576"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00449"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03186"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04423"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03224"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12101"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05038"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07918"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14206"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12586"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15494"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08963"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12153"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05831"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14183"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01237"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02751"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12262"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14034"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13042"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02719"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16702"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16066"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06358"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06016"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06934"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06896"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02770"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02875"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04001"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13817"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02951"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05421"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00659"
    },
    {
        "smiles": "CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1",
        "id": "DB06719",
        "molecule": "Buserelin",
        "cas": "57982-77-1",
        "iupac_name": "(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-carbamimidamidopentanoyl]-N-ethylpyrrolidine-2-carboxamide",
        "background": "Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.\n",
        "inchi": {
            "hash": "CUWODFFVMXJOKD-UVLQAERKSA-N",
            "id": "InChI=1S/C60H86N16O13/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65)/t40-,41-,42-,43-,44-,45-,46-,47+,48-/m0/s1"
        },
        "summary": "Buserelin is a LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females.",
        "weight": [
            {
                "type": "average",
                "weight": 1239.447,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1238.656026893,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06719",
        "type": "Small Molecule",
        "synonyms": [
            "Buserelin",
            "Buserelina",
            "Busereline",
            "Buserelinum",
            "Etilamide",
            "Tiloryth"
        ],
        "indication": "Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The substitution of glycine in position 6 by D-serine, and that of glycinamide in position 10 by ethylamide, leads to a nonapeptide with a greatly enhanced LHRH effect. The effects of buserelin on FSH and LH release are 20 to 170 times greater than those of LHRH. Buserelin also has a longer duration of action than natural LHRH. Investigations in healthy adult males and females have demonstrated that the increase in plasma LH and FSH levels persist for at least 7 hours and that a return to basal values requires about 24 hours.\nClinical inhibition of gonadotropin release, and subsequent reduction of serum testosterone or estradiol to castration level, was found when large pharmacologic doses (50-500 mcg SC/day or 300-1200 mcg IN/day) were administered for periods greater than 1 to 3 months. Chronic administration of such doses of buserelin results in sustained inhibition of gonadotropin production, suppression of ovarian and testicular steroidogenesis and, ultimately, reduced circulating levels of gonadotropin and gonadal steroids. These effects form the basis for buserelin use in patients with hormone-dependent metastatic carcinoma of the prostate gland as well as in patients with endometriosis.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ALutropin-choriogonadotropic hormone receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AGonadotropin-releasing hormone receptor"
            }
        ]
    },
    {
        "smiles": "COC1=C(F)C=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)F",
        "id": "DB11395",
        "molecule": "Deracoxib",
        "cas": "169590-41-4",
        "iupac_name": "4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide",
        "background": "Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for \"the control of post operative pain and inflammation associated with orthopedic surgery in dogs.\n",
        "inchi": {
            "hash": "WAZQAZKAZLXFMK-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 397.37,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 397.070796986,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB11395",
        "type": "Small Molecule",
        "synonyms": [
            "Dracoxib",
            "Deracoxib",
            "Deracoxibum"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN(C)C(C)(C)COC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB13380",
        "molecule": "Difemerine",
        "cas": "80387-96-8",
        "iupac_name": "2-(dimethylamino)-2-methylpropyl 2-hydroxy-2,2-diphenylacetate",
        "inchi": {
            "hash": "GUONSMXZEYTWML-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H25NO3/c1-19(2,21(3)4)15-24-18(22)20(23,16-11-7-5-8-12-16)17-13-9-6-10-14-17/h5-14,23H,15H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 327.424,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 327.183443669,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB13380",
        "type": "Small Molecule",
        "synonyms": [
            "Difemerine"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=C(Cl)C2=NC(=CC(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCCCC[C@@H]3C[C@]3(NC4=O)P(O)(=O)CC3=C(F)C=CC=C3F)NC(=O)OC3CCCC3)=C2C=C1)C1=CSC(NC(C)C)=N1",
        "id": "DB12876",
        "molecule": "GS-9256",
        "cas": "1001094-46-7",
        "iupac_name": "[(1S,4S,6R,14S,18R)-18-[(8-chloro-7-methoxy-2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-14-{[(cyclopentyloxy)carbonyl]amino}-2,15-dioxo-3,16-diazatricyclo[14.3.0.0^{4,6}]nonadecan-4-yl][(2,6-difluorophenyl)methyl]phosphinic acid",
        "background": "GS-9256 has been used in trials studying the treatment of HCV Infection and Chronic Hepatitis C Infection.\n",
        "inchi": {
            "hash": "RFGUWOCFYCYEDM-ZOMNBDOOSA-N",
            "id": "InChI=1S/C46H56ClF2N6O8PS/c1-26(2)50-44-52-36(25-65-44)35-21-39(30-18-19-38(61-3)40(47)41(30)51-35)62-29-20-37-42(56)54-46(64(59,60)24-31-32(48)15-11-16-33(31)49)22-27(46)12-7-5-4-6-8-17-34(43(57)55(37)23-29)53-45(58)63-28-13-9-10-14-28/h11,15-16,18-19,21,25-29,34,37H,4-10,12-14,17,20,22-24H2,1-3H3,(H,50,52)(H,53,58)(H,54,56)(H,59,60)/t27-,29-,34+,37+,46+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 957.47,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 956.327455,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.",
        "link": "https://go.drugbank.com/drugs/DB12876",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18484"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15272"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11562"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04585"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15141"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03411"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07668"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09028"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08048"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14806"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13295"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08317"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07989"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07016"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07636"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13936"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03795"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08950"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01053"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18157"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04316"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13769"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04000"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08746"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00536"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03279"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04302"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00883"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12728"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01763"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18036"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00954"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14567"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08788"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01950"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08691"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01018"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08744"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01148"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01456"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01117"
    },
    {
        "smiles": "C\\C(N(CC1=CN=C(C)N=C1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)C1=CC=CC=C1",
        "id": "DB11748",
        "molecule": "Benfotiamine",
        "cas": "22457-89-2",
        "iupac_name": "{[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid",
        "background": "Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.\n",
        "inchi": {
            "hash": "BTNNPSLJPBRMLZ-LGMDPLHJSA-N",
            "id": "InChI=1S/C19H23N4O6PS/c1-13(23(12-24)11-16-10-21-14(2)22-18(16)20)17(8-9-29-30(26,27)28)31-19(25)15-6-4-3-5-7-15/h3-7,10,12H,8-9,11H2,1-2H3,(H2,20,21,22)(H2,26,27,28)/b17-13-"
        },
        "summary": "Benfotiamine is a derivative of thiamine thought to be useful in the management of diabetic neuropathy, although evidence is lacking.",
        "weight": [
            {
                "type": "average",
                "weight": 466.45,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 466.107592649,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11748",
        "type": "Small Molecule",
        "synonyms": [
            "Benfotiamina",
            "Benfotiamine",
            "Benphothiamine",
            "Benzoylthiamine monophosphate",
            "S-benzoylthiamine monophosphate"
        ],
        "is_stub": true
    },
    {
        "smiles": "N[C@@H](CCC(=O)N[C@@H](CS)C(O)=O)C(O)=O",
        "id": "DB03408",
        "molecule": "gamma-Glutamylcysteine",
        "cas": "636-58-8",
        "iupac_name": "(2S)-2-amino-4-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}butanoic acid",
        "inchi": {
            "hash": "RITKHVBHSGLULN-WHFBIAKZSA-N",
            "id": "InChI=1S/C8H14N2O5S/c9-4(7(12)13)1-2-6(11)10-5(3-16)8(14)15/h4-5,16H,1-3,9H2,(H,10,11)(H,12,13)(H,14,15)/t4-,5-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 250.272,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 250.062342258,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB03408",
        "type": "Small Molecule",
        "synonyms": [
            "5-L-Glutamyl-L-cysteine",
            "gamma-Glu-Cys",
            "gamma-L-Glutamyl-L-cysteine",
            "Glu(-Cys)",
            "L-gamma-glutamyl-L-cysteine",
            "L-gamma-Glutamylcysteine",
            "GluCys"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione synthetase"
            }
        ]
    },
    {
        "id": "DB05371",
        "molecule": "ACR-16",
        "background": "ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntingtons disease as well as in three Phase Ib studies within Huntingtons disease, Parkinsons disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05371",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in huntington's disease and schizophrenia and schizoaffective disorders.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "id": "DB15311",
        "molecule": "Davanat",
        "cas": "916851-14-4",
        "background": "Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15311",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCCCC#CC1=CC=C(O1)C(=O)NNC(=S)NC",
        "id": "DB07004",
        "molecule": "2-[(5-hex-1-yn-1-ylfuran-2-yl)carbonyl]-N-methylhydrazinecarbothioamide",
        "iupac_name": "5-(hex-1-yn-1-yl)-N-[(methylcarbamothioyl)amino]furan-2-carboxamide",
        "inchi": {
            "hash": "CUKZXTKQBXLMDO-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H17N3O2S/c1-3-4-5-6-7-10-8-9-11(18-10)12(17)15-16-13(19)14-2/h8-9H,3-5H2,1-2H3,(H,15,17)(H2,14,16,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 279.358,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 279.104147493,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as furoic acid and derivatives. These are aromatic heterocyclic compounds containing a furan ring, which carries a carboxyl group or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB07004",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein S100-B"
            }
        ]
    },
    {
        "smiles": "OS(=O)(=O)CCNC1=CC=CC=C1",
        "id": "DB02283",
        "molecule": "2-Phenylamino-Ethanesulfonic Acid",
        "iupac_name": "2-(phenylamino)ethane-1-sulfonic acid",
        "inchi": {
            "hash": "IAVHKMVGTPXJIC-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H11NO3S/c10-13(11,12)7-6-9-8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,10,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 201.243,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 201.045963913,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylalkylamines. These are organic amines where the amine group is secondary and linked on one end to a phenyl group and on the other end, to an alkyl group.",
        "link": "https://go.drugbank.com/drugs/DB02283",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus megaterium",
                "target": "UCatabolite control protein A"
            }
        ]
    },
    {
        "id": "DB17133",
        "molecule": "ADH-503",
        "cas": "2055362-74-6",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17133",
        "type": "Small Molecule",
        "synonyms": [
            "2-Hydroxy-N,N,N-trimethylethanaminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate"
        ],
        "is_stub": true
    },
    {
        "id": "DB17968",
        "molecule": "2-O-desulfated heparin",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17968",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08434"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00694"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14176"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00949"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13853"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01569"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04334"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05928"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11277"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07661"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02929"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01575"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02463"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01333"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00591"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04580"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15315"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08040"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03931"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00543"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16617"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04274"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08336"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11585"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07713"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02821"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03291"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01702"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08995"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13519"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02813"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02723"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09278"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12476"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03520"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13738"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16875"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00167"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11091"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02063"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06968"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02869"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02366"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13813"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07443"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11517"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07264"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07825"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15671"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14093"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05854"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12122"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06374"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00619"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09183"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03709"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15678"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03285"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07467"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08543"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04598"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16860"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07259"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07677"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11709"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04995"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13718"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08682"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07760"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09271"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13056"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06966"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02417"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01542"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13949"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17801"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13768"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02670"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07846"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11259"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15192"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07032"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02773"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00260"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08326"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01172"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12442"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17549"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07863"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15377"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02289"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13877"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17760"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02540"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00271"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09119"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03568"
    },
    {
        "smiles": "[O-][51Cr]([O-])(=O)=O",
        "id": "DB14537",
        "molecule": "Chromate ion Cr-51",
        "iupac_name": "dioxo(51Cr)chromiumbis(olate)",
        "inchi": {
            "hash": "ZCDOYSPFYFSLEW-HONVGLGOSA-N",
            "id": "InChI=1S/Cr.4O/q;;;2*-1/i1-1;;;;"
        },
        "weight": [
            {
                "type": "average",
                "weight": 114.942,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 114.925527407,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14537",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02299"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07798"
    },
    {
        "smiles": "N[C@@H](C\\N=C(/N)NO)C(O)=O",
        "id": "DB02499",
        "molecule": "Dinor-N(Omega)-Hydroxy-L-Arginine",
        "iupac_name": "(2S)-2-amino-3-[(E)-[amino(hydroxyamino)methylidene]amino]propanoic acid",
        "inchi": {
            "hash": "RPHCSGPGZUWMRV-REOHCLBHSA-N",
            "id": "InChI=1S/C4H10N4O3/c5-2(3(9)10)1-7-4(6)8-11/h2,11H,1,5H2,(H,9,10)(H3,6,7,8)/t2-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 162.1472,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 162.075290206,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB02499",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UArginase-1"
            }
        ]
    },
    {
        "smiles": "OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1",
        "id": "DB00341",
        "molecule": "Cetirizine",
        "cas": "83881-51-0",
        "iupac_name": "2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid",
        "background": "Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms 1, 2. \nOne of the most common uses for this drug is for a condition called allergic rhinitis. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals 3. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects 4. \nCetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects 2.\n",
        "inchi": {
            "hash": "ZKLPARSLTMPFCP-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)"
        },
        "summary": "Cetirizine is a selective Histamine-1 antagonist drug used in allergic rhinitis and chronic urticaria.",
        "weight": [
            {
                "type": "average",
                "weight": 388.888,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 388.155370383,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB00341",
        "type": "Small Molecule",
        "synonyms": [
            "Cetirizin",
            "Cetirizina",
            "Cetirizine",
            "Cetirizinum"
        ],
        "indication": "Seasonal Allergic Rhinitis: Indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and above. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes Label. \nPerennial allergic rhinitis: This drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds in adults and children 6 months of age and older. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing Label. \nChronic urticaria: Cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It markedly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus Label.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "General effects and respiratory effects\nCetirizine, the active metabolite of the piperazine H1-receptor antagonist hydroxyzine, minimizes or eliminates the symptoms of chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis.\nThe clinical efficacy of cetirizine for allergic respiratory diseases has been well established in numerous trials Label. \nEffects on urticaria/anti-inflammatory effects\nIt has anti-inflammatory properties that may play a role in asthma management 1. There is evidence that cetirizine improves symptoms of urticaria. Marked clinical inhibition of a wheal and flare response occurs in infants, children as well as adults within 20 minutes of one oral dose and lasts for 24 h 1. Concomitant use of cetirizine reduces the duration and dose of topical anti-inflammatory formulas used for the treatment of atopic dermatitis 1. \n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AHistamine H1 receptor"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCCCCCC[N+](C)(C)C",
        "id": "DB01718",
        "molecule": "Cetrimonium",
        "cas": "6899-10-1",
        "iupac_name": "hexadecyltrimethylazanium",
        "background": "Cetrimonium is a quaternary ammonium cation whose salts are used as antiseptics.\n",
        "inchi": {
            "hash": "RLGQACBPNDBWTB-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H42N/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(2,3)4/h5-19H2,1-4H3/q+1"
        },
        "summary": "Cetrimonium is a compound that can be used as a topical antiseptic.",
        "weight": [
            {
                "type": "average",
                "weight": 284.5435,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 284.331725349,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetraalkylammonium salts. These are organonitrogen compounds containing a quaternary ammonium substituted with four alkyl chains.",
        "link": "https://go.drugbank.com/drugs/DB01718",
        "type": "Small Molecule",
        "synonyms": [
            "Cetrimonium cation",
            "Cetrimonium ion",
            "Cetyl-Trimethyl-Ammonium",
            "Cetyltrimethylammonium",
            "Cetyltrimethylammonium cation",
            "Cetyltrimethylammonium ion",
            "Hexadecyltrimethylammonium",
            "Hexadecyltrimethylammonium cation",
            "Hexadecyltrimethylammonium ion",
            "N,N,N-Trimethyl-1-hexadecanaminium",
            "Trimethylhexadecylammonium"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UCyclopropane mycolic acid synthase 1"
            },
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UCyclopropane mycolic acid synthase MmaA2"
            }
        ]
    },
    {
        "smiles": "CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1)C(C)C)[C@@H](C)O)[C@H](O)CC)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O",
        "id": "DB06260",
        "molecule": "Aviptadil",
        "cas": "40077-57-4",
        "iupac_name": "(3S)-3-{[(1S)-1-{[(1S)-1-{[(1S,2R)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-{[(1S)-2-carbamoyl-1-{[(1S)-1-{[(1S,2S)-1-{[(1S)-1-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-methylbutyl]carbamoyl}-2-hydroxyethyl]carbamoyl}ethyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}pentyl]carbamoyl}pentyl]carbamoyl}-2-methylpropyl]carbamoyl}ethyl]carbamoyl}-3-(methylsulfanyl)propyl]carbamoyl}-3-carbamoylpropyl]carbamoyl}pentyl]carbamoyl}ethyl]carbamoyl}-3-methylbutyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-2-hydroxybutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-carbamoylethyl]carbamoyl}-3-[(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-5-yl)propanamido]-3-hydroxypropanamido]-3-carboxypropanamido]propanamido]-3-methylbutanamido]-3-phenylpropanamido]-3-hydroxybutanamido]propanoic acid",
        "inchi": {
            "hash": "OIDGWOIMPADMGM-GXSWRUKYSA-N",
            "id": "InChI=1S/C145H232N40O43S/c1-19-74(13)114(141(224)175-94(55-71(7)8)130(213)178-102(144(227)228)62-109(153)195)183-138(221)104(67-187)180-133(216)99(61-108(152)194)172-129(212)93(54-70(5)6)169-131(214)95(57-80-37-41-83(189)42-38-80)170-124(207)87(34-25-28-49-147)163-123(206)88(35-26-29-50-148)166-139(222)112(72(9)10)181-118(201)76(15)159-121(204)91(47-52-229-18)165-126(209)90(45-46-106(150)192)164-122(205)86(33-24-27-48-146)162-117(200)75(14)160-127(210)92(53-69(3)4)168-125(208)89(36-30-51-157-145(154)155)167-143(226)116(105(191)20-2)185-136(219)96(58-81-39-43-84(190)44-40-81)171-132(215)98(60-107(151)193)173-134(217)101(64-111(198)199)177-142(225)115(78(17)188)184-135(218)97(56-79-31-22-21-23-32-79)176-140(223)113(73(11)12)182-119(202)77(16)161-128(211)100(63-110(196)197)174-137(220)103(66-186)179-120(203)85(149)59-82-65-156-68-158-82/h21-23,31-32,37-44,65,68-78,85-105,112-116,186-191H,19-20,24-30,33-36,45-64,66-67,146-149H2,1-18H3,(H2,150,192)(H2,151,193)(H2,152,194)(H2,153,195)(H,156,158)(H,159,204)(H,160,210)(H,161,211)(H,162,200)(H,163,206)(H,164,205)(H,165,209)(H,166,222)(H,167,226)(H,168,208)(H,169,214)(H,170,207)(H,171,215)(H,172,212)(H,173,217)(H,174,220)(H,175,224)(H,176,223)(H,177,225)(H,178,213)(H,179,203)(H,180,216)(H,181,201)(H,182,202)(H,183,221)(H,184,218)(H,185,219)(H,196,197)(H,198,199)(H,227,228)(H4,154,155,157)/t74-,75-,76-,77-,78+,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105+,112-,113-,114-,115-,116-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 3255.75,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 3253.691767464,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06260",
        "type": "Small Molecule",
        "synonyms": [
            "Aviptadil",
            "Porcine vasoactive intestinal octacosapeptide",
            "Vasoactive intestinal octacosapeptide (pig)",
            "Vasoactive intestinal octacosapeptide (swine)"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(=O)NCC(O)=O",
        "id": "DB02713",
        "molecule": "Acetylamino-Acetic Acid",
        "cas": "543-24-8",
        "iupac_name": "2-acetamidoacetic acid",
        "inchi": {
            "hash": "OKJIRPAQVSHGFK-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H7NO3/c1-3(6)5-2-4(7)8/h2H2,1H3,(H,5,6)(H,7,8)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 117.1033,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 117.042593095,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB02713",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UGlycine oxidase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15052"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11687"
    },
    {
        "smiles": "CCC(C)(CC)OC(N)=O",
        "id": "DB13572",
        "molecule": "Emylcamate",
        "cas": "78-28-4",
        "iupac_name": "3-methylpentan-3-yl carbamate",
        "inchi": {
            "hash": "SLWGJZPKHAXZQL-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H15NO2/c1-4-7(3,5-2)10-6(8)9/h4-5H2,1-3H3,(H2,8,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 145.202,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 145.110278727,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.",
        "link": "https://go.drugbank.com/drugs/DB13572",
        "type": "Small Molecule",
        "synonyms": [
            "Emylcamate"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15880"
    },
    {
        "smiles": "COC1=C2C(NC=C2C(=O)C(=O)N2CCN(CC2)C(=O)C2=CC=CC=C2)=C(OC)N=C1",
        "id": "DB05532",
        "molecule": "BMS-488043",
        "cas": "452296-83-2",
        "iupac_name": "1-(4-benzoylpiperazin-1-yl)-2-{4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl}ethane-1,2-dione",
        "background": "BMS-488043 has been investigated as an anti-HIV agent.\n",
        "inchi": {
            "hash": "DBPMWRYLTBNCCE-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H22N4O5/c1-30-16-13-24-20(31-2)18-17(16)15(12-23-18)19(27)22(29)26-10-8-25(9-11-26)21(28)14-6-4-3-5-7-14/h3-7,12-13,23H,8-11H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 422.441,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 422.159019824,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolopyridines. These are compounds containing a pyrrolopyridine moiety, which consists of a pyrrole ring fused to a pyridine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.",
        "link": "https://go.drugbank.com/drugs/DB05532",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in HIV infection.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFree fatty acid receptor 4"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08846"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06370"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12809"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03750"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08249"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00739"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13828"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03127"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12593"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06415"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14716"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08912"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06878"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00898"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03293"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06947"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11505"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08676"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06890"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07937"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12588"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16028"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13266"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12666"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04592"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06993"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03297"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04608"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08065"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01548"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01234"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08978"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04273"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08516"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09040"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09156"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00561"
    },
    {
        "id": "DB05754",
        "molecule": "IPH 1101",
        "background": "IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the V9V2 T cell subset. IPH 1101 is the most advanced drug candidate of the  T cell platform\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05754",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in hepatitis (viral, C), leukemia (myeloid), and lymphoma (non-hodgkin's).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "IPH 1101 potentiates the direct cytotoxic activity of V9V2 T cells against a large number of tumor cell lines and also triggers the synthesis of pro-inflammatory cytokines - thus inducing the recruitment of other cell effectors and facilitating implementation of an adaptive response.\n"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04533"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15144"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14669"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08070"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06210"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03401"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03753"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12886"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09357"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08566"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05586"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18086"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01443"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04548"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04880"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01499"
    },
    {
        "smiles": "COC1=C(Cl)C(OC(=O)O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@H]5[C@@H]4CC=C3C2)[C@H](C)CCCC(C)C)=C(Cl)C(=N1)C(Cl)(Cl)Cl",
        "id": "DB15075",
        "molecule": "4-demethyl-4-cholesteryloxycarbonylpenclomedine",
        "cas": "942149-56-6",
        "iupac_name": "(1R,3aS,3bS,7S,9aR,9bS,11aR)-9a,11a-dimethyl-1-[(2R)-6-methylheptan-2-yl]-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl 3,5-dichloro-2-methoxy-6-(trichloromethyl)pyridin-4-yl carbonate",
        "background": "4-demethyl-4-cholesteryloxycarbonylpenclomedine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).\n",
        "inchi": {
            "hash": "ZJUUIXYKTPSIOH-LEZJFEBPSA-N",
            "id": "InChI=1S/C35H48Cl5NO4/c1-19(2)8-7-9-20(3)24-12-13-25-23-11-10-21-18-22(14-16-33(21,4)26(23)15-17-34(24,25)5)44-32(42)45-29-27(36)30(35(38,39)40)41-31(43-6)28(29)37/h10,19-20,22-26H,7-9,11-18H2,1-6H3/t20-,22+,23+,24-,25+,26+,33+,34-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 724.02,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 721.2025975,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15075",
        "type": "Small Molecule",
        "synonyms": [
            "4-DEMETHYLCHOLESTERYLOXYCARBONYLPENCLOMEDINE",
            "DM-CHOC-PEN"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04853"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02569"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08115"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00789"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02242"
    },
    {
        "id": "DB17631",
        "molecule": "Exaluren",
        "cas": "1375073-93-0",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17631",
        "type": "Small Molecule",
        "synonyms": [
            "6-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine",
            "6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine",
            "ELX 02",
            "ELX02",
            "Exaluren",
            "NB 124",
            "NB-124",
            "NB124"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07002"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04347"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03549"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06961"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07625"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07228"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05904"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04680"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07971"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17269"
    },
    {
        "smiles": "NC1=NN=C(SC2=NC=C(S2)[N+]([O-])=O)S1",
        "id": "DB15624",
        "molecule": "Halicin",
        "cas": "40045-50-9",
        "iupac_name": "5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine",
        "inchi": {
            "hash": "NQQBNZBOOHHVQP-UHFFFAOYSA-N",
            "id": "InChI=1S/C5H3N5O2S3/c6-3-8-9-5(14-3)15-4-7-1-2(13-4)10(11)12/h1H,(H2,6,8)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 261.29,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 260.944887879,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15624",
        "type": "Small Molecule",
        "synonyms": [
            "2-amino-5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazole"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "Uc-Jun N-terminal kinases"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03667"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12347"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08953"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00951"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08903"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15579"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07541"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08447"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08069"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03062"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11344"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11638"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02774"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03197"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12962"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02323"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03572"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02287"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02205"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02848"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11125"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04527"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06989"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07119"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07750"
    },
    {
        "smiles": "[NH4+].[NH4+].[S-][Mo]([S-])(=S)=S",
        "id": "DB17641",
        "molecule": "Ammonium tetrathiomolybdate",
        "cas": "15060-55-6",
        "iupac_name": "diammonium (sulfanidyldisulfanylidenemolybdenio)sulfanide",
        "inchi": {
            "hash": "PQNOIAHNKHBLRN-UHFFFAOYSA-P",
            "id": "InChI=1S/Mo.2H3N.4S/h;2*1H3;;;;/q;;;;;2*-1/p+2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 260.27,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 261.862438,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17641",
        "type": "Small Molecule",
        "synonyms": [
            "Ammonium molybdenum sulfide ((nh4)2mos4)",
            "Coprexa",
            "Diammonium tetrathiomolybdate",
            "Molybdate(2-), tetrathioxo-, ammonium (1:2), (t-4)-",
            "Molybdate(2-), tetrathioxo-, diammonium, (t-4)-",
            "Tiomolibdate diammonium"
        ],
        "is_stub": true
    },
    {
        "smiles": "CO[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB03879",
        "molecule": "alpha-L-methyl-fucose",
        "cas": "14687-15-1",
        "iupac_name": "(2R,3S,4R,5S,6S)-2-methoxy-6-methyloxane-3,4,5-triol",
        "inchi": {
            "hash": "OHWCAVRRXKJCRB-CXNFULCWSA-N",
            "id": "InChI=1S/C7H14O5/c1-3-4(8)5(9)6(10)7(11-2)12-3/h3-10H,1-2H3/t3-,4+,5+,6-,7+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 178.1831,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 178.084123558,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB03879",
        "type": "Small Molecule",
        "synonyms": [
            "alpha-L-1-Methyl-fucose",
            "Methyl alpha-L-fucopyranoside",
            "-L-Methyl-Fucose"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMannose-binding protein C"
            },
            {
                "action": "Not Available",
                "organism": "Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / NCIB 9290)",
                "target": "UChondroitinase-AC"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03704"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13956"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05531"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03557"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12890"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02517"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02648"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12729"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07088"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12619"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04505"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12526"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04171"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15533"
    },
    {
        "smiles": "[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(O)=O",
        "id": "DB14125",
        "molecule": "Benazeprilat",
        "cas": "86541-78-8",
        "iupac_name": "(2S)-2-{[(3S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}-4-phenylbutanoic acid",
        "inchi": {
            "hash": "MADRIHWFJGRSBP-ROUUACIJSA-N",
            "id": "InChI=1S/C22H24N2O5/c25-20(26)14-24-19-9-5-4-8-16(19)11-13-17(21(24)27)23-18(22(28)29)12-10-15-6-2-1-3-7-15/h1-9,17-18,23H,10-14H2,(H,25,26)(H,28,29)/t17-,18-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 396.4364,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 396.168521888,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB14125",
        "type": "Small Molecule",
        "synonyms": [
            "(3S)-3-(((1S)-1-Carboxy-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid",
            "Benazepril diacid",
            "Benazeprilat",
            "Bnazprilate",
            "Benazeprilatum"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04267"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17029"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05708"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13003"
    },
    {
        "smiles": "COC1=C(OP(O)(O)=O)C2=C(NC(=CC2=O)C2=CC(F)=CC=C2)C=C1",
        "id": "DB16172",
        "molecule": "Foslinanib",
        "cas": "1256037-60-1",
        "iupac_name": "{[2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl]oxy}phosphonic acid",
        "background": "Foslinanib is under investigation in clinical trial NCT03600233 (Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors).\n",
        "inchi": {
            "hash": "ZDWFMAHQGDEALT-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H13FNO6P/c1-23-14-6-5-11-15(16(14)24-25(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9/h2-8H,1H3,(H,18,19)(H2,20,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 365.253,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 365.046452304,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16172",
        "type": "Small Molecule",
        "synonyms": [
            "Foslinanib",
            "Trx-818 free acid"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOCN1C(=O)NC(=O)C(C(C)C)=C1CC1=CC=CC=C1",
        "id": "DB08188",
        "molecule": "Emivirine",
        "cas": "149950-60-7",
        "iupac_name": "6-benzyl-1-(ethoxymethyl)-5-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione",
        "background": "Emivirine has been used in trials studying the treatment of HIV Infections.\n",
        "inchi": {
            "hash": "MLILORUFDVLTSP-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 302.3682,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 302.16304258,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB08188",
        "type": "Small Molecule",
        "synonyms": [
            "1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1H,3H)-dione",
            "6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil",
            "Emivirine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "CC(C)C(O)=O",
        "id": "DB02531",
        "molecule": "Isobutyric acid",
        "cas": "79-31-2",
        "iupac_name": "2-methylpropanoic acid",
        "inchi": {
            "hash": "KQNPFQTWMSNSAP-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H8O2/c1-3(2)4(5)6/h3H,1-2H3,(H,5,6)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 88.1051,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 88.0524295,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.",
        "link": "https://go.drugbank.com/drugs/DB02531",
        "type": "Small Molecule",
        "synonyms": [
            "2-methyl-propionic acid",
            "2-Methylpropanoate",
            "2-Methylpropanoic acid",
            "2-Methylpropionsure",
            "2,2-dimethylacetic acid",
            "Dimethylacetic acid",
            "iso-butyric acid",
            "Isobutanoate",
            "Isobuttersure",
            "Isobutyrate",
            "Isopropylformic acid",
            "-isobutyric acid",
            "-methylpropanoic acid",
            "-methylpropionic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas fluorescens",
                "target": "U2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08258"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12234"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03577"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07427"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06345"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03714"
    },
    {
        "id": "DB13734",
        "molecule": "Biphenylol",
        "cas": "1322-20-9",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13734",
        "type": "Small Molecule",
        "synonyms": [
            "Biphenylol (mixed isomers)"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1=NC(C)=C(N=C1C1=CC=C(C=C1)[C@H]1CC[C@H](CC(O)=O)CC1)C(N)=O",
        "id": "DB14949",
        "molecule": "AZD-7687",
        "cas": "1166827-44-6",
        "iupac_name": "2-[(1r,4r)-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid",
        "background": "AZD-7687 is under investigation in clinical trial NCT01119352 (AZD7687 Multiple Ascending Dose Study).\n",
        "inchi": {
            "hash": "YXFNPRHZMOGREC-SHTZXODSSA-N",
            "id": "InChI=1S/C21H25N3O3/c1-12-19(24-20(21(22)27)13(2)23-12)17-9-7-16(8-10-17)15-5-3-14(4-6-15)11-18(25)26/h7-10,14-15H,3-6,11H2,1-2H3,(H2,22,27)(H,25,26)/t14-,15-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 367.449,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 367.189591677,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14949",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "C[C@H](CO)NC1=CC(=CC(=N1)N1CCOCC1)C1=CC(NC(=O)N2CC[C@@H](CC(F)(F)F)C2)=CC=C1C",
        "id": "DB17582",
        "molecule": "Exarafenib",
        "cas": "2639957-39-2",
        "iupac_name": "(3S)-N-[3-(2-{[(2R)-1-hydroxypropan-2-yl]amino}-6-(morpholin-4-yl)pyridin-4-yl)-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide",
        "inchi": {
            "hash": "GZMYLSJUNSCMTD-MOPGFXCFSA-N",
            "id": "InChI=1S/C26H34F3N5O3/c1-17-3-4-21(31-25(36)34-6-5-19(15-34)14-26(27,28)29)13-22(17)20-11-23(30-18(2)16-35)32-24(12-20)33-7-9-37-10-8-33/h3-4,11-13,18-19,35H,5-10,14-16H2,1-2H3,(H,30,32)(H,31,36)/t18-,19+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 521.585,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 521.261374464,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17582",
        "type": "Small Molecule",
        "synonyms": [
            "KIN-2787 free base"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]N([H])N(CC(O)=O)C(=O)CC([H])(O)C(=O)N(CC1=CC=CC=C1)CC1=CC=CC=C1",
        "id": "DB08229",
        "molecule": "[N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid",
        "iupac_name": "2-[N-amino-3-(dibenzylcarbamoyl)-3-hydroxypropanamido]acetic acid",
        "inchi": {
            "hash": "JGMMFVVACJREFE-KRWDZBQOSA-N",
            "id": "InChI=1S/C20H23N3O5/c21-23(14-19(26)27)18(25)11-17(24)20(28)22(12-15-7-3-1-4-8-15)13-16-9-5-2-6-10-16/h1-10,17,24H,11-14,21H2,(H,26,27)/t17-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 385.4137,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 385.163770861,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB08229",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCaspase-3"
            }
        ]
    },
    {
        "smiles": "C[C@H]1NCC2=CC(=CC=C12)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1OC(F)F)C(O)=O",
        "id": "DB06160",
        "molecule": "Garenoxacin",
        "cas": "194804-75-6",
        "iupac_name": "1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid",
        "background": "Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.\n",
        "inchi": {
            "hash": "NJDRXTDGYFKORP-LLVKDONJSA-N",
            "id": "InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 426.42,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 426.139113458,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.",
        "link": "https://go.drugbank.com/drugs/DB06160",
        "type": "Small Molecule",
        "synonyms": [
            "Garenoxacin",
            "Garnoxacine",
            "Garenoxacino",
            "Garenoxacinum"
        ],
        "indication": "Investigated for use/treatment in bacterial infection.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O",
        "id": "DB03989",
        "molecule": "D-Allopyranose",
        "cas": "2595-97-3",
        "iupac_name": "(3R,4R,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol",
        "inchi": {
            "hash": "WQZGKKKJIJFFOK-IVMDWMLBSA-N",
            "id": "InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4-,5-,6?/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 180.1559,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 180.063388116,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB03989",
        "type": "Small Molecule",
        "synonyms": [
            "D-Allose"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UD-allose-binding periplasmic protein"
            }
        ]
    },
    {
        "id": "DB05049",
        "molecule": "DDP733",
        "background": "DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD). It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. Preclinical studies of DDP733 established the compounds prokinetic properties (the ability to promote the motility of the GI tract).\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05049",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in constipation, gastroesophageal reflux disease (GERD), gastrointestinal diseases and disorders (miscellaneous), and irritable bowel syndrome (IBS).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 3A"
            }
        ]
    },
    {
        "smiles": "OC(=O)CC[C@H](NC(=O)N[C@@H](CSCC1=CC=C([18F])C=C1)C(O)=O)C(O)=O",
        "id": "DB14772",
        "molecule": "DCFBC F-18",
        "cas": "1169942-33-9",
        "iupac_name": "(2S)-2-({[(1R)-1-carboxy-2-({[4-(F)fluorophenyl]methyl}sulfanyl)ethyl]carbamoyl}amino)pentanedioic acid",
        "background": "DCFBC F-18 is under investigation in clinical trial NCT02190279 (18F-DCFBC PET/CT in Prostate Cancer).\n",
        "inchi": {
            "hash": "IDTMSHGCAZPVLC-STUNTBJNSA-N",
            "id": "InChI=1S/C16H19FN2O7S/c17-10-3-1-9(2-4-10)7-27-8-12(15(24)25)19-16(26)18-11(14(22)23)5-6-13(20)21/h1-4,11-12H,5-8H2,(H,20,21)(H,22,23)(H,24,25)(H2,18,19,26)/t11-,12-/m0/s1/i17-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 401.4,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 401.092234801,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14772",
        "type": "Small Molecule",
        "synonyms": [
            "18F DCFBC"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC(=O)CN1CC2=CC=CC=C2OC1=O",
        "id": "DB09254",
        "molecule": "Caroxazone",
        "cas": "18464-39-6",
        "iupac_name": "2-(2-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)acetamide",
        "background": "Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. However, it presents a five-fold preference for the MAO-B subtype.\n",
        "inchi": {
            "hash": "KYCBWEZLKCTALM-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H10N2O3/c11-9(13)6-12-5-7-3-1-2-4-8(7)15-10(12)14/h1-4H,5-6H2,(H2,11,13)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 206.201,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 206.06914219,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).",
        "link": "https://go.drugbank.com/drugs/DB09254",
        "type": "Small Molecule",
        "synonyms": [
            "Caroxazone"
        ],
        "indication": "For the treatment of depression.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13342"
    },
    {
        "id": "DB05082",
        "molecule": "ARX201",
        "background": "ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrxs patented ReCODE technology to achieve precise spatial positioning of the site of polyethylene glycol (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH). ARX201 has improved pharmacological properties, which should allow less frequent administration than the daily dosing regimen of currently available growth hormones.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05082",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in growth hormone deficiencies/abnormalities.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "id": "DB04997",
        "molecule": "ATL1102",
        "background": "ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04997",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in asthma and multiple sclerosis.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIntegrin alpha-4"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCCC(=O)OCC(CSSC1=CC=C(COC(=O)N2[C@H]3CN4C5=C([C@@H](COC(N)=O)[C@@]4(OC)[C@@H]23)C(=O)C(N)=C(C)C5=O)C=C1)OC(=O)CCCCCCCCCCCCCCCCC",
        "id": "DB15372",
        "molecule": "JNJ-27548547",
        "cas": "303983-00-8",
        "iupac_name": "(4-{[2,3-bis(octadecanoyloxy)propyl]disulfanyl}phenyl)methyl (4S,6S,7R,8S)-11-amino-8-[(carbamoyloxy)methyl]-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-diene-5-carboxylate",
        "background": "JNJ-27548547 is under investigation in clinical trial NCT01705002 (Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.).\n",
        "inchi": {
            "hash": "LIHIIWJRSSLKKX-YCTALCSSSA-N",
            "id": "InChI=1S/C62H98N4O11S2/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-52(67)74-43-48(77-53(68)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2)45-78-79-49-39-37-47(38-40-49)42-76-61(72)66-51-41-65-56-54(58(70)55(63)46(3)57(56)69)50(44-75-60(64)71)62(65,73-4)59(51)66/h37-40,48,50-51,59H,5-36,41-45,63H2,1-4H3,(H2,64,71)/t48?,50-,51+,59+,62-,66?/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1139.6,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1138.66735234,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as mitomycins. These are polycyclic compounds with a structure based on an aziridine ring linked to a 7-amino-6-methyl-cyclohexa[b]pyrrolizine-5,8-dione.",
        "link": "https://go.drugbank.com/drugs/DB15372",
        "type": "Small Molecule",
        "synonyms": [
            "PROMITIL"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1(CCCCC1)C1=CC=CC=C1",
        "id": "DB01506",
        "molecule": "1-Phenylcyclohexylamine",
        "cas": "2201-24-3",
        "iupac_name": "1-phenylcyclohexan-1-amine",
        "inchi": {
            "hash": "RGZGRPPQZUQUCR-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H17N/c13-12(9-5-2-6-10-12)11-7-3-1-4-8-11/h1,3-4,7-8H,2,5-6,9-10,13H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 175.2701,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 175.136099549,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.",
        "link": "https://go.drugbank.com/drugs/DB01506",
        "type": "Small Molecule"
    },
    {
        "smiles": "COC1=C(OCCC[18F])C=C2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3C2=C1",
        "id": "DB14945",
        "molecule": "Florbenazine F-18",
        "cas": "956903-29-0",
        "iupac_name": "(2R,3R,11bR)-9-[3-(F)fluoropropoxy]-10-methoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol",
        "background": "Florbenazine F-18 is under investigation in clinical trial NCT01515384 (A Trial of 18F-AV-133 Positron Emission Tomography (PET)).\n",
        "inchi": {
            "hash": "GNKGXQHHUUEYQV-WTHAECTESA-N",
            "id": "InChI=1S/C21H32FNO3/c1-14(2)9-16-13-23-7-5-15-10-21(26-8-4-6-22)20(25-3)11-17(15)18(23)12-19(16)24/h10-11,14,16,18-19,24H,4-9,12-13H2,1-3H3/t16-,18-,19-/m1/s1/i22-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 364.492,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 364.239156561,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14945",
        "type": "Small Molecule",
        "synonyms": [
            "18F-AV-133"
        ],
        "is_stub": true
    },
    {
        "smiles": "N[C@H](C(O)=O)C1=CC(Cl)=C(O)C=C1",
        "id": "DB03898",
        "molecule": "3-Chloro-4-Hydroxyphenylglycine",
        "iupac_name": "(2S)-2-amino-2-(3-chloro-4-hydroxyphenyl)acetic acid",
        "inchi": {
            "hash": "FLZDFFKRJPLFGS-ZETCQYMHSA-N",
            "id": "InChI=1S/C8H8ClNO3/c9-5-3-4(1-2-6(5)11)7(10)8(12)13/h1-3,7,11H,10H2,(H,12,13)/t7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 201.607,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 201.019270834,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB03898",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H][C@@]12CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H]",
        "id": "DB16141",
        "molecule": "Dimethandrolone Undecanoate",
        "cas": "366472-45-9",
        "iupac_name": "(1S,3aS,3bR,4R,9aR,9bS,10S,11aS)-4,10,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl undecanoate",
        "background": "Dimethandrolone Undecanoate is under investigation in clinical trial NCT03455075 (Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men).\n",
        "inchi": {
            "hash": "FVICENFBEMJOCE-RTFNQGFNSA-N",
            "id": "InChI=1S/C31H50O3/c1-5-6-7-8-9-10-11-12-13-28(33)34-27-17-16-26-30-21(2)18-23-19-24(32)14-15-25(23)29(30)22(3)20-31(26,27)4/h19,21-22,25-27,29-30H,5-18,20H2,1-4H3/t21-,22+,25+,26+,27+,29-,30+,31+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 470.738,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 470.37599547,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16141",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "COC(=O)[C@H](CC1=CC=C(C=C1)N1C(=O)N(C)C2=C(C=C(C=C2)N(C)C)C1=O)NC(=O)C1=C(Cl)C=CC=C1Cl",
        "id": "DB16119",
        "molecule": "Carotegrast methyl",
        "cas": "401905-67-7",
        "iupac_name": "methyl (2S)-2-[(2,6-dichlorophenyl)formamido]-3-{4-[6-(dimethylamino)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl]phenyl}propanoate",
        "background": "Carotegrast methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis).\n",
        "inchi": {
            "hash": "MMHHPKCJJIFLBQ-QFIPXVFZSA-N",
            "id": "InChI=1S/C28H26Cl2N4O5/c1-32(2)18-12-13-23-19(15-18)26(36)34(28(38)33(23)3)17-10-8-16(9-11-17)14-22(27(37)39-4)31-25(35)24-20(29)6-5-7-21(24)30/h5-13,15,22H,14H2,1-4H3,(H,31,35)/t22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 569.44,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 568.1280254,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16119",
        "type": "Small Molecule",
        "synonyms": [
            "Carotegrast methyl"
        ],
        "is_stub": true
    },
    {
        "smiles": "CNCCCOC1=CC(F)=C(C(F)=C1)C1=C(N[C@@H](C)C(F)(F)F)N2N=CN=C2N=C1Cl",
        "id": "DB12533",
        "molecule": "Cevipabulin",
        "cas": "849550-05-6",
        "iupac_name": "5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(2S)-1,1,1-trifluoropropan-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",
        "background": "Cevipabulin has been used in trials studying the treatment and educational/counseling/training of Tumors and Neoplasms.\n",
        "inchi": {
            "hash": "ZUZPCOQWSYNWLU-VIFPVBQESA-N",
            "id": "InChI=1S/C18H18ClF5N6O/c1-9(18(22,23)24)28-16-14(15(19)29-17-26-8-27-30(16)17)13-11(20)6-10(7-12(13)21)31-5-3-4-25-2/h6-9,25,28H,3-5H2,1-2H3/t9-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 464.83,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 464.1150777,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB12533",
        "type": "Small Molecule",
        "synonyms": [
            "Cevipabulin"
        ],
        "is_stub": true
    },
    {
        "smiles": "[O--].[O--].[Hf+4]",
        "id": "DB17508",
        "molecule": "Hafnium oxide",
        "cas": "12055-23-1",
        "iupac_name": "hafnium(4+) dioxidandiide",
        "inchi": {
            "hash": "WIHZLLGSGQNAGK-UHFFFAOYSA-N",
            "id": "InChI=1S/Hf.2O/q+4;2*-2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 210.49,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 211.93639,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17508",
        "type": "Small Molecule",
        "synonyms": [
            "Hafnium oxide-containing nanoparticles nbtxr3"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)COC1=CC=CC=C1\\C=N\\NC(=O)C1=CC=NC=C1",
        "id": "DB17731",
        "molecule": "Aconiazide",
        "cas": "13410-86-1",
        "iupac_name": "2-{2-[(E)-{[(pyridin-4-yl)formamido]imino}methyl]phenoxy}acetic acid",
        "inchi": {
            "hash": "MDFXJBQEWLCGHP-RQZCQDPDSA-N",
            "id": "InChI=1S/C15H13N3O4/c19-14(20)10-22-13-4-2-1-3-12(13)9-17-18-15(21)11-5-7-16-8-6-11/h1-9H,10H2,(H,18,21)(H,19,20)/b17-9+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 299.286,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 299.090605911,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17731",
        "type": "Small Molecule",
        "synonyms": [
            "Aconiazide",
            "Isonicophen",
            "Isonicotinic acid (2-(carboxymethoxy)benzylidene)hydrazide",
            "Isonicotinic acid (o-(carboxymethoxy)benzylidene)hydrazide",
            "Phenoxalid"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC(=CC=C1OC[C@H](OP(O)(O)=O)C1CC1)N1C=NC2=C(SC(=C2)C2=CC=C(Cl)C=C2)C1=O",
        "id": "DB14787",
        "molecule": "BMS-830216",
        "cas": "1197420-06-6",
        "iupac_name": "[(1R)-2-{4-[6-(4-chlorophenyl)-4-oxo-3H,4H-thieno[3,2-d]pyrimidin-3-yl]-2-methoxyphenoxy}-1-cyclopropylethoxy]phosphonic acid",
        "background": "BMS-830216 is under investigation in clinical trial NCT00909766 (Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects).\n",
        "inchi": {
            "hash": "YDTUJCNTIMWHPJ-NRFANRHFSA-N",
            "id": "InChI=1S/C24H22ClN2O7PS/c1-32-20-10-17(8-9-19(20)33-12-21(14-2-3-14)34-35(29,30)31)27-13-26-18-11-22(36-23(18)24(27)28)15-4-6-16(25)7-5-15/h4-11,13-14,21H,2-3,12H2,1H3,(H2,29,30,31)/t21-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 548.93,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 548.0573869,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thienopyrimidines. These are heterocyclic compounds containing a thiophene ring fused to a pyrimidine ring. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB14787",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "id": "DB05150",
        "molecule": "CAD106",
        "background": "CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients. \n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05150",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in alzheimer's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "CAD106 can block the formation of beta-amyloid plaques in the brain. Since the formation of such plaques is considered a hallmark of the disease, CAD106 may offer the potential to advance the treatment of Alzheimer's disease.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAmyloid beta A4 protein"
            }
        ]
    },
    {
        "smiles": "NCCO[N+]([O-])=O",
        "id": "DB13585",
        "molecule": "Aminoethyl nitrate",
        "cas": "646-02-6",
        "iupac_name": "2-aminoethyl nitrate",
        "inchi": {
            "hash": "KZTZJUQNSSLNAG-UHFFFAOYSA-N",
            "id": "InChI=1S/C2H6N2O3/c3-1-2-7-4(5)6/h1-3H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 106.081,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 106.037842061,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl nitrates. These are organic compounds containing a nitrate that is O-linked to an alkyl group.",
        "link": "https://go.drugbank.com/drugs/DB13585",
        "type": "Small Molecule",
        "synonyms": [
            "2-aminoethyl nitrate",
            "Aminoethyl nitrate",
            "Itramin"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(=O)C1=C(C)C2=CC3=C(C(O)=C)C(C)=C4C=C5N6C(=CC7=C(CCC(O)=O)C(C)=C8C=C1N2[Fe]6(N78)N34)C(CCC(O)=O)=C5C",
        "id": "DB03418",
        "molecule": "Diacetyldeuteroheme",
        "iupac_name": "3-[15-acetyl-20-(2-carboxyethyl)-10-(1-hydroxyethenyl)-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^{2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid",
        "inchi": {
            "hash": "YTEJZYYPHLALHQ-IDTMDVKXSA-K",
            "id": "InChI=1S/C34H35N4O6.Fe/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27;/h11-14H,5,7-10H2,1-4,6H3,(H6-,35,36,37,38,39,40,41,42,43,44);/q-1;+4/p-3/b23-11-,24-12-,25-11-,26-13-,27-14-,28-14-,29-12-,30-13-;"
        },
        "weight": [
            {
                "type": "average",
                "weight": 648.486,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 648.167126909,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB03418",
        "type": "Small Molecule"
    },
    {
        "smiles": "[Ca++].[O-]Cl.[O-]Cl",
        "id": "DB15912",
        "molecule": "Calcium hypochlorite",
        "cas": "7778-54-3",
        "iupac_name": "calcium dihypochlorite",
        "inchi": {
            "hash": "ZKQDCIXGCQPQNV-UHFFFAOYSA-N",
            "id": "InChI=1S/Ca.2ClO/c;2*1-2/q+2;2*-1"
        },
        "summary": "Calcium hypochlorite is an antiseptic indicated for wound care.",
        "weight": [
            {
                "type": "average",
                "weight": 142.98,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 141.8901255,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15912",
        "type": "Small Molecule",
        "synonyms": [
            "Chloride of lime",
            "Chlorinated lime",
            "Hipoclorito calcico",
            "Hypochlorite de calcium",
            "Hypochlorous acid, calcium salt"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN1C=C(C=N1)C1=CC=C(CNC2=CC(=NC=N2)C2=CN=C3C=C(OCCCN4CCCC4)C=CN23)C=C1",
        "id": "DB18087",
        "molecule": "IDRX-42",
        "cas": "2590556-80-0",
        "inchi": {
            "hash": "LVMAULGVWBINFP-UHFFFAOYSA-N",
            "id": "InChI=1S/C29H32N8O/c1-35-20-24(18-34-35)23-7-5-22(6-8-23)17-30-28-16-26(32-21-33-28)27-19-31-29-15-25(9-13-37(27)29)38-14-4-12-36-10-2-3-11-36/h5-9,13,15-16,18-21H,2-4,10-12,14,17H2,1H3,(H,30,32,33)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 508.63,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 508.269907682,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18087",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO",
        "id": "DB11250",
        "molecule": "Glyceryl monostearate",
        "cas": "31566-31-1",
        "iupac_name": "2,3-dihydroxypropyl octadecanoate",
        "background": "Glycerol monostearate, commonly known as GMS, is the glycerol ester of stearic acid . It is commonly used as an emulsifier in foods.\n",
        "inchi": {
            "hash": "VBICKXHEKHSIBG-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H42O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h20,22-23H,2-19H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 358.5558,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 358.308309832,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11250",
        "type": "Small Molecule",
        "synonyms": [
            "Geleol mono and diglycerides",
            "Glycerin monostearate",
            "Glycerol monostearate",
            "Glyceroli monostearas",
            "Glyceryl monooctadecanoate",
            "Glyceryl monopalmitostearate",
            "Glyceryl stearate",
            "Monoglyceryl stearate",
            "Monostearate (glyceride)",
            "Monostearin",
            "Stearic acid, monoester with glycerol",
            "Stearoylglycerol"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C3=C2C=CC(=O)N3)C=C1",
        "id": "DB15784",
        "molecule": "Carmoterol",
        "cas": "147568-66-9",
        "iupac_name": "8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one",
        "inchi": {
            "hash": "IHOXNOQMRZISPV-YJYMSZOUSA-N",
            "id": "InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1"
        },
        "summary": "Carmoterol is a long acting beta-2 agonist indicated in the treatment of COPD, asthma, and chronic bronchitis.",
        "weight": [
            {
                "type": "average",
                "weight": 368.433,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 368.173607261,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15784",
        "type": "Small Molecule",
        "synonyms": [
            "Carmoterol",
            "Quinoterol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN(C1CCCCC1)C(=S)NN=C(C1=CC=CC=N1)C1=NC=CC=C1",
        "id": "DB15235",
        "molecule": "Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone",
        "cas": "1382469-39-7",
        "iupac_name": "1-{[bis(pyridin-2-yl)methylidene]amino}-3-cyclohexyl-3-methylthiourea",
        "background": "Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors).\n",
        "inchi": {
            "hash": "GNLZNQJBZNOUBM-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H23N5S/c1-24(15-9-3-2-4-10-15)19(25)23-22-18(16-11-5-7-13-20-16)17-12-6-8-14-21-17/h5-8,11-15H,2-4,9-10H2,1H3,(H,23,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 353.49,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 353.167416935,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15235",
        "type": "Small Molecule",
        "synonyms": [
            "DP4CYCH4MT"
        ],
        "is_stub": true
    },
    {
        "smiles": "NS(=O)(=O)C1=C(Cl)C=C2NC(NC(=O)C2=C1)C1=CC=CC=C1",
        "id": "DB13708",
        "molecule": "Fenquizone",
        "cas": "20287-37-0",
        "iupac_name": "7-chloro-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinazoline-6-sulfonamide",
        "inchi": {
            "hash": "DBDTUXMDTSTPQZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H12ClN3O3S/c15-10-7-11-9(6-12(10)22(16,20)21)14(19)18-13(17-11)8-4-2-1-3-5-8/h1-7,13,17H,(H,18,19)(H2,16,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 337.78,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 337.0287901,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.",
        "link": "https://go.drugbank.com/drugs/DB13708",
        "type": "Small Molecule",
        "synonyms": [
            "Fenquizone"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1",
        "id": "DB12629",
        "molecule": "3,5-diiodothyropropionic acid",
        "cas": "1158-10-7",
        "iupac_name": "3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid",
        "background": "DITPA has been investigated in Congestive Heart Failure.\n",
        "inchi": {
            "hash": "WONYMNWUJVKVII-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 510.066,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 509.8825,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.",
        "link": "https://go.drugbank.com/drugs/DB12629",
        "type": "Small Molecule",
        "synonyms": [
            "DITPA"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(C)COC(=N1)C1=CC=C(OCCCCCC2=CC(C)=NO2)C=C1",
        "id": "DB08724",
        "molecule": "5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole",
        "iupac_name": "3-methyl-5-(5-{4-[(4S)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}pentyl)-1,2-oxazole",
        "background": "5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. This medication is known to target genome polyprotein.\n",
        "inchi": {
            "hash": "UXIYKMARWUSIKU-HNNXBMFYSA-N",
            "id": "InChI=1S/C19H24N2O3/c1-14-12-18(24-21-14)6-4-3-5-11-22-17-9-7-16(8-10-17)19-20-15(2)13-23-19/h7-10,12,15H,3-6,11,13H2,1-2H3/t15-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 328.4055,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 328.178692644,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08724",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "HRV-14",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "smiles": "O[C@@H]1CC2=C(O[C@@H]1C1=CC(O)=C(O)C(O)=C1)C=C(O)C=C2O",
        "id": "DB03823",
        "molecule": "Epigallocatechin",
        "cas": "970-74-1",
        "iupac_name": "(2R,3R)-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol",
        "inchi": {
            "hash": "XMOCLSLCDHWDHP-IUODEOHRSA-N",
            "id": "InChI=1S/C15H14O7/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6/h1-4,12,15-21H,5H2/t12-,15-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 306.2675,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 306.073952802,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as epigallocatechins. These are compounds containing epigallocatechin or a derivative. Epigallocatechin is a flavan-3-ol containing a benzopyran-3,5,7-triol linked to a 3,4,5-hydroxyphenyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB03823",
        "type": "Small Molecule",
        "synonyms": [
            "(-)-epi-gallocatechin",
            "(-)-epigallocatechin",
            "(-)-epigallocatechol",
            "()-epigallocatechin",
            "3,3',4',5,5',7-flavanhexol",
            "Antiscurvy factor C2",
            "EGC",
            "Epi-gallocatechin",
            "Galloepicatechin",
            "L-epigallocatechin"
        ]
    },
    {
        "smiles": "[H]\\C(CC\\C(C)=C(/[H])CCC(=O)OC\\C([H])=C(/C)CCC=C(C)C)=C(\\C)CCC=C(C)C",
        "id": "DB12079",
        "molecule": "Gefarnate",
        "cas": "51-77-4",
        "iupac_name": "(2E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate",
        "background": "Gefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and Cardio-cerebrovascular Disease.\n",
        "inchi": {
            "hash": "ZPACYDRSPFRDHO-ROBAGEODSA-N",
            "id": "InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 400.647,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 400.334130657,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as wax monoesters. These are waxes bearing an ester group at exactly one position.",
        "link": "https://go.drugbank.com/drugs/DB12079",
        "type": "Small Molecule",
        "synonyms": [
            "Gefarnate"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]12CCC3=C(C=CC(=C3)C(=O)NC3=C(C)N=CC=C3)[C@]1(CC1=CC=CC=C1)CC[C@@](O)(C2)C(F)(F)F",
        "id": "DB14676",
        "molecule": "Fagrocorat",
        "cas": "1044535-52-5",
        "iupac_name": "(4bS,7R,8aR)-4b-benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide",
        "inchi": {
            "hash": "QJJBNCHSWFGXML-KEKPKEOLSA-N",
            "id": "InChI=1S/C29H29F3N2O2/c1-19-25(8-5-15-33-19)34-26(35)22-10-12-24-21(16-22)9-11-23-18-28(36,29(30,31)32)14-13-27(23,24)17-20-6-3-2-4-7-20/h2-8,10,12,15-16,23,36H,9,11,13-14,17-18H2,1H3,(H,34,35)/t23-,27+,28-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 494.558,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 494.218112671,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14676",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CNC(=NS(=O)(=O)C1=CC=C(Cl)C=C1)N1C[C@@H](C(=N1)C1=CC=C(Cl)C=C1)C1=CC=CC=C1",
        "id": "DB12649",
        "molecule": "Ibipinabant",
        "cas": "464213-10-3",
        "iupac_name": "(4S)-N'-(4-chlorobenzenesulfonyl)-3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide",
        "background": "Ibipinabant has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.\n",
        "inchi": {
            "hash": "AXJQVVLKUYCICH-OAQYLSRUSA-N",
            "id": "InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)/t21-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 487.4,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 486.0684025,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.",
        "link": "https://go.drugbank.com/drugs/DB12649",
        "type": "Small Molecule",
        "synonyms": [
            "Ibipinabant",
            "Ibipinabantum"
        ],
        "is_stub": true
    },
    {
        "id": "DB13365",
        "molecule": "Calcium lactate gluconate",
        "cas": "11116-97-5",
        "inchi": {},
        "summary": "Calcium lactate gluconate is a calcium salt indicated in the treatment of rickets, osteomalacia, and the treatment and prevention of calcium deficiency",
        "link": "https://go.drugbank.com/drugs/DB13365",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "NC1=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C(C#N)C(C2=CC=C(OCCO)C=C2)=C1C#N",
        "id": "DB16118",
        "molecule": "Capadenoson",
        "cas": "544417-40-5",
        "iupac_name": "2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile",
        "background": "Capadenoson is under investigation in clinical trial NCT00518921 (Capadenoson in Angina Pectoris).\n",
        "inchi": {
            "hash": "CITWCLNVRIKQAF-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 520.02,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 519.0590449,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16118",
        "type": "Small Molecule",
        "synonyms": [
            "Capadenoson"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCC(CC)COC(=O)C1=CC=CC=C1",
        "id": "DB11291",
        "molecule": "2-ethylhexyl benzoate",
        "cas": "5444-75-7",
        "iupac_name": "2-ethylhexyl benzoate",
        "inchi": {
            "hash": "UADWUILHKRXHMM-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H22O2/c1-3-5-9-13(4-2)12-17-15(16)14-10-7-6-8-11-14/h6-8,10-11,13H,3-5,9,12H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 234.339,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 234.161979948,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.",
        "link": "https://go.drugbank.com/drugs/DB11291",
        "type": "Small Molecule",
        "synonyms": [
            "2-Ethyl-1-hexanol benzoate",
            "Ethylhexyl benzoate"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC=C(\\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1OP(O)(O)=O",
        "id": "DB12577",
        "molecule": "Fosbretabulin",
        "cas": "222030-63-9",
        "iupac_name": "{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxy}phosphonic acid",
        "background": "Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.\n",
        "inchi": {
            "hash": "WDOGQTQEKVLZIJ-WAYWQWQTSA-N",
            "id": "InChI=1S/C18H21O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H2,19,20,21)/b6-5-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 396.332,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 396.097404634,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.",
        "link": "https://go.drugbank.com/drugs/DB12577",
        "type": "Small Molecule",
        "synonyms": [
            "2-METHOXY-5-((Z)-2-(3,4,5-TRIMETHOXYPHENYL)VINYL)PHENYL DIHYDROGEN PHOSPHATE",
            "Combretastatin A-4 phosphate",
            "Combretastatin A4 phosphate",
            "Fosbretabulin",
            "PHENOL, 2-METHOXY-5-((1Z)-2-(3,4,5-TRIMETHOXYPHENYL)ETHENYL)-,1-(DIHYDROGEN PHOSPHATE)",
            "PHENOL, 2-METHOXY-5-((Z)-2-(3,4,5-TRIMETHOXYPHENYL)ETHENYL)-, DIHYDROGEN PHOSPHATE",
            "Phosbretabulin"
        ],
        "is_stub": true
    },
    {
        "id": "DB05367",
        "molecule": "Actelion-1",
        "background": "Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05367",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in cardiovascular disorders, hypertension, and pulmonary hypertension.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEndothelin-1 receptor"
            }
        ]
    },
    {
        "smiles": "CC1=C(NC(=O)C2=CC(=NC3=C2C=CC(F)=C3)C(N)=O)C(=NN1CC1=CC=C(C=C1)C#N)C(F)(F)F",
        "id": "DB16758",
        "molecule": "BAY-876",
        "cas": "1799753-84-6",
        "iupac_name": "N4-{1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl}-7-fluoroquinoline-2,4-dicarboxamide",
        "inchi": {
            "hash": "BKLJDIJJOOQUFG-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H16F4N6O2/c1-12-20(21(24(26,27)28)33-34(12)11-14-4-2-13(10-29)3-5-14)32-23(36)17-9-19(22(30)35)31-18-8-15(25)6-7-16(17)18/h2-9H,11H2,1H3,(H2,30,35)(H,32,36)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 496.426,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 496.127086431,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16758",
        "type": "Small Molecule",
        "synonyms": [
            "BAY 876",
            "BAY876"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCN",
        "id": "DB03659",
        "molecule": "Butylamine",
        "cas": "109-73-9",
        "iupac_name": "butan-1-amine",
        "background": "Butylamine is a colourless liquid which acquires a yellow colour upon storage in air. It is one of the four isomeric amines of butane. It is known to have the fishy, ammonia-like odor common to amines.\n",
        "inchi": {
            "hash": "HQABUPZFAYXKJW-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H11N/c1-2-3-4-5/h2-5H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 73.1368,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 73.089149357,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monoalkylamines. These are organic compounds containing an primary aliphatic amine group.",
        "link": "https://go.drugbank.com/drugs/DB03659",
        "type": "Small Molecule",
        "synonyms": [
            "1-aminobutane",
            "1-butanamine",
            "n-butylamine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Yeast",
                "target": "UCandidapepsin-2"
            }
        ]
    },
    {
        "smiles": "CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=C(C)N=C(C)N=C1N",
        "id": "DB01682",
        "molecule": "6'-Methyl-Thiamin Diphosphate",
        "iupac_name": "3-[(4-amino-2,6-dimethylpyrimidin-5-yl)methyl]-5-(2-{[(hydrogen phosphonatooxy)(hydroxy)phosphoryl]oxy}ethyl)-4-methyl-1,3-thiazol-3-ium",
        "inchi": {
            "hash": "XTYXJYCWAJSHCY-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H20N4O7P2S/c1-8-11(13(14)16-10(3)15-8)6-17-7-27-12(9(17)2)4-5-23-26(21,22)24-25(18,19)20/h7H,4-6H2,1-3H3,(H4-,14,15,16,18,19,20,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 438.333,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 438.052792728,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thiamine phosphates. These are thiamine derivatives in which the hydroxyl group of the ethanol moiety is substituted by a phosphate group.",
        "link": "https://go.drugbank.com/drugs/DB01682",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H][C@]12CC[C@]([H])(O1)[C@]1(C)C(=O)OC(=O)[C@]21C",
        "id": "DB12328",
        "molecule": "Cantharidin",
        "cas": "56-25-7",
        "iupac_name": "(1R,2S,6R,7S)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.0,]decane-3,5-dione",
        "background": "Cantharidin is a naturally occurring odorless, colorless fatty substance of the terpenoid class that is produced as an oral fluid in the alimentary canal of the male blister beetle.1,2 For its natural purpose, the male blister beetle secretes and presents the cantharidin to a female beetle as a copulatory gift during mating. Post-copulation, the female beetle places the cantharidin over her eggs as protection against any potential predators.1,2\nTopical cantharidin products do not necessarily demonstrate any particular better effectiveness at treating topical skin conditions like warts than other commonly available vesicant and/or keratolytics although various studies have also investigated the possibility of using cantharidin as an inflammatory model or in cancer treatment.2 Regardless, the ongoing lack of FDA approval is likely related to certain toxic effects that were observed following oral ingestion, which include ulceration of the gastrointestinal and genitourinary tracts, along with electrolyte and renal function disturbance in humans and animals 1.\nAvailable synthetically since the 1950s, topical applications of cantharidin have been used predominantly as a treatment for cutaneous warts since that time. 1,2 In 1962 however, marketers of cantharidin failed to produce sufficient efficacy data, resulting in the FDA revision of approval of cantharidin.2 Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients.8 The approval was based on positive results from 2 phase III trials, CAMP-1 and CAMP-2, where 46% and 52% of patients treated with cantharidin achieved complete molluscum clearance, respectively.8\n",
        "inchi": {
            "hash": "DHZBEENLJMYSHQ-XCVPVQRUSA-N",
            "id": "InChI=1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10-"
        },
        "summary": "Cantharidin is a natured product indicated to treat molluscum contagiosum",
        "weight": [
            {
                "type": "average",
                "weight": 196.202,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 196.073558866,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as furofurans. These are organic compounds containing a two furan rings fused to each other. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.",
        "link": "https://go.drugbank.com/drugs/DB12328",
        "type": "Small Molecule",
        "synonyms": [
            "1,2-Dimethyl-3,6-epoxyperhydrophthalic anhydride",
            "Cantharidin",
            "Cantharidine",
            "Cantharone",
            "exo-1,2-cis-Dimethyl-3,6-epoxyhexahydrophthalic anhydride",
            "Kantharidin"
        ],
        "indication": "Cantharidin is approved by the FDA for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.9 It has also been approved by Health Canada for the treatment of common warts (verruca vulgaris), periungual warts, and molluscum contagiosum as a standalone product and resistant and heavily keratinized plantar warts as a combination product with salicylic acid and podophyllin.10 \nAt the same time, such topical cantharidin applications have also been used for a number of off-label indications like callus removal, cutaneous leishmaniasis, herpes zoster, and acquired perforating dermatosis.2 Furthermore, since most topical cantharidin applications are most commonly available in a 0.7% formulation or a more potent 1% mixture, the 0.7% formulation is most commonly indicated for the treatment of common warts, periungual warts, and molluscum contagiosum while the more potent 1% mixture is typically limited only for use by healthcare professionals in a clinical setting for treating plantar warts and other more specialized off-label conditions.1,2,11\nMoreover, there have also been studies into whether or not cantharidin could be effective at being used as an inflammatory model or in cancer treatment - either of which has yet to elucidate any results formally.2\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cantharidin is a natural toxin produced by the blistering beetle that possesses both vesicant (blistering) and keratolytic effects.1,2 The substance elicits these effects by inducing acantholysis (loss of intercellular connections) through the targeting of the desmosomal dense plaque, resulting in the detachment of the desmosomes from the tonofilaments.1,2 Cantharidin's effectiveness against warts is proposed to be a result of the exfoliation of the wart body as a consequence of the compound's acantholytic action.11 This acantholytic action generally does not go beyond the epidermal cells so that the basal layer remains intact and minimal effect occurs on the corium. There is consequently no scarring from the topical application of cantharidin.11 \n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UAryl hydrocarbon receptor"
            }
        ]
    },
    {
        "smiles": "C[C@H](O)CO",
        "id": "DB04349",
        "molecule": "(S)-propane-1,2-diol",
        "cas": "4254-15-3",
        "iupac_name": "(2S)-propane-1,2-diol",
        "background": "(S)-propane-1,2-diol is a clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.\n",
        "inchi": {
            "hash": "DNIAPMSPPWPWGF-VKHMYHEASA-N",
            "id": "InChI=1S/C3H8O2/c1-3(5)2-4/h3-5H,2H2,1H3/t3-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 76.0944,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 76.0524295,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2-diols. These are polyols containing an alcohol group at two adjacent positions.",
        "link": "https://go.drugbank.com/drugs/DB04349",
        "type": "Small Molecule",
        "synonyms": [
            "(S)-1,2-Propanediol",
            "(S)-propane-1,2-diol",
            "(S)-Propylene glycol",
            "S-1,2-Propanediol"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UIsocitrate dehydrogenase [NADP]"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "USigma factor SigB regulation protein RsbQ"
            }
        ]
    },
    {
        "smiles": "O=[Bi]O[Bi]=O",
        "id": "DB15929",
        "molecule": "Bismuth oxide",
        "cas": "1304-76-3",
        "iupac_name": "[(oxobismuthanyl)oxy]bismuthanone",
        "inchi": {
            "hash": "WMWLMWRWZQELOS-UHFFFAOYSA-N",
            "id": "InChI=1S/2Bi.3O"
        },
        "weight": [
            {
                "type": "average",
                "weight": 465.958,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 465.94554,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15929",
        "type": "Small Molecule",
        "synonyms": [
            "Bismuth trioxide",
            "Bismuth yellow",
            "Bismuthous oxide",
            "Bismuthum oxydatum",
            "Dibismuth trioxide"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(CF)CN(C(=O)C1)[C@@]1([H])CN2CCC3=CC(OC)=C(OC)C=C3[C@]2([H])C[C@]1([H])N",
        "id": "DB12268",
        "molecule": "Carmegliptin",
        "cas": "813452-18-5",
        "iupac_name": "(4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one",
        "background": "Carmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.\n",
        "inchi": {
            "hash": "GUYMHFIHHOEFOA-ZCPGHIKRSA-N",
            "id": "InChI=1S/C20H28FN3O3/c1-26-18-6-13-3-4-23-11-17(24-10-12(9-21)5-20(24)25)15(22)8-16(23)14(13)7-19(18)27-2/h6-7,12,15-17H,3-5,8-11,22H2,1-2H3/t12-,15+,16+,17+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 377.453,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 377.211469982,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.",
        "link": "https://go.drugbank.com/drugs/DB12268",
        "type": "Small Molecule",
        "synonyms": [
            "Carmegliptin"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@H](NC1=NC=NC2=C1C=C(F)C(F)=C2)C(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB03678",
        "molecule": "(6,7-Difluoro-Quinazolin-4-Yl)-(1-Methyl-2,2-Diphenyl-Ethyl)-Amine",
        "iupac_name": "N-[(2S)-1,1-diphenylpropan-2-yl]-6,7-difluoroquinazolin-4-amine",
        "inchi": {
            "hash": "WVGZKPGUHOZIJQ-HNNXBMFYSA-N",
            "id": "InChI=1S/C23H19F2N3/c1-15(22(16-8-4-2-5-9-16)17-10-6-3-7-11-17)28-23-18-12-19(24)20(25)13-21(18)26-14-27-23/h2-15,22H,1H3,(H,26,27,28)/t15-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 375.4139,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 375.154704033,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB03678",
        "type": "Small Molecule"
    },
    {
        "smiles": "CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=CC=C2)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O",
        "id": "DB11628",
        "molecule": "Depreotide",
        "cas": "161982-62-3",
        "iupac_name": "(2S)-6-amino-2-[(2R)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-[2-({2-[(2S,5S,8S,11R,14S,17S)-14-(4-aminobutyl)-5-benzyl-8-[(4-hydroxyphenyl)methyl]-11-[(1H-indol-3-yl)methyl]-4-methyl-3,6,9,12,15,18-hexaoxo-17-(propan-2-yl)-1,4,7,10,13,16-hexaazacyclooctadecan-2-yl]ethyl}sulfanyl)acetamido]propanamido]hexanamido]-3-sulfanylpropanamido]hexanamide",
        "background": "Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.\n",
        "inchi": {
            "hash": "XXXSJQLZVNKRKX-YQRDHHIGSA-N",
            "id": "InChI=1S/C65H96N16O12S2/c1-38(2)55-64(92)76-49(26-30-95-37-54(83)72-35-44(69)57(85)74-47(20-10-13-28-67)58(86)79-52(36-94)62(90)73-46(56(70)84)19-9-12-27-66)65(93)81(3)53(32-39-15-5-4-6-16-39)63(91)78-50(31-40-22-24-42(82)25-23-40)60(88)77-51(33-41-34-71-45-18-8-7-17-43(41)45)61(89)75-48(59(87)80-55)21-11-14-29-68/h4-8,15-18,22-25,34,38,44,46-53,55,71,82,94H,9-14,19-21,26-33,35-37,66-69H2,1-3H3,(H2,70,84)(H,72,83)(H,73,90)(H,74,85)(H,75,89)(H,76,92)(H,77,88)(H,78,91)(H,79,86)(H,80,87)/t44-,46-,47-,48-,49-,50-,51+,52-,53-,55-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1357.7,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1356.683504943,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB11628",
        "type": "Small Molecule",
        "synonyms": [
            "Depreotide"
        ],
        "is_stub": true
    },
    {
        "smiles": "O=C(N1CCN(CC1)C1CC1)C1=CC=C(CN2CCOCC2)C=C1",
        "id": "DB12299",
        "molecule": "Bavisant",
        "cas": "929622-08-2",
        "iupac_name": "4-{[4-(4-cyclopropylpiperazine-1-carbonyl)phenyl]methyl}morpholine",
        "background": "Bavisant has been used in trials studying the basic science and treatment of Alcoholism, Pharmacokinetics, Drug Interactions, Attention Deficit Hyperactivity Disorder, and Attention Deficit Disorders With Hyperactivity.\n",
        "inchi": {
            "hash": "BGBVSGSIXIIREO-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 329.444,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 329.210327121,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzamides. These are organic compounds containing a carboxamido substituent attached to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB12299",
        "type": "Small Molecule",
        "synonyms": [
            "Bavisant"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1",
        "id": "DB07919",
        "molecule": "Harmine",
        "cas": "442-51-3",
        "iupac_name": "7-methoxy-1-methyl-9H-pyrido[3,4-b]indole",
        "inchi": {
            "hash": "BXNJHAXVSOCGBA-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 212.2472,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 212.094963016,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as harmala alkaloids. These are compounds with a structure based on harmaline, harmine, harmalol, harman or a derivative of those parents. These parents are beta-carbolines, consisting of a pyrimidine fused to the pyrrole moiety of an indole to form a pyrido[3,4-b]indole.",
        "link": "https://go.drugbank.com/drugs/DB07919",
        "type": "Small Molecule",
        "synonyms": [
            "Banisterine",
            "Leucoharmine",
            "Telepathine",
            "Yageine",
            "Yajeine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAmine oxidase [flavin-containing] A"
            }
        ]
    },
    {
        "smiles": "NC(=N)SCCCC#N",
        "id": "DB13010",
        "molecule": "4-isothioureidobutyronitrile",
        "cas": "500863-50-3",
        "iupac_name": "4-(carbamimidoylsulfanyl)butanenitrile",
        "background": "Thioureidobutyronitrile has been used in trials studying the treatment of Solid Tumors and Ovarian cancer.\n",
        "inchi": {
            "hash": "PRDJGNVQBVXXEO-UHFFFAOYSA-N",
            "id": "InChI=1S/C5H9N3S/c6-3-1-2-4-9-5(7)8/h1-2,4H2,(H3,7,8)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 143.21,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 143.051718476,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as isothioureas. These are organic compounds containing the isothiourea group, with the general structure R1SC(=NR2)N(R3)R4 (R1,R2,R3,R4=H, alkyl, aryl).",
        "link": "https://go.drugbank.com/drugs/DB13010",
        "type": "Small Molecule",
        "synonyms": [
            "Kevetrin",
            "Thioureidobutyronitrile"
        ],
        "is_stub": true
    },
    {
        "id": "DB09106",
        "molecule": "Hydroxyethyl Starch",
        "cas": "9005-27-0",
        "background": "Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume.\nHES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.\n",
        "inchi": {},
        "summary": "Hydroxyethyl Starch is a plasma volume substitute used to treat and prevent hypovolemia.",
        "link": "https://go.drugbank.com/drugs/DB09106",
        "type": "Small Molecule",
        "synonyms": [
            "HAES",
            "HES",
            "Hetastarch",
            "Hydroxyethylstarch"
        ],
        "indication": "An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "After isovolemic exchange of blood with 500 mL of HES in healthy volunteers, blood volume is maintained for at least 6 hours\n"
    },
    {
        "smiles": "CCCNC(=O)C1=NN=C2C(=CC=CC2=C1N)C1=CC(OC)=CC=C1OC",
        "id": "DB12210",
        "molecule": "AZD-6280",
        "cas": "942436-93-3",
        "iupac_name": "4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide",
        "background": "AZD6280 has been used in trials studying the basic science of Anxiety.\n",
        "inchi": {
            "hash": "NVWCZRPXYVDQEE-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H22N4O3/c1-4-10-22-20(25)19-17(21)14-7-5-6-13(18(14)23-24-19)15-11-12(26-2)8-9-16(15)27-3/h5-9,11H,4,10H2,1-3H3,(H2,21,23)(H,22,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 366.421,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 366.169190584,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cinnolines. These are organic aromatic compounds containing a benzene fused to a pyridazine ring.",
        "link": "https://go.drugbank.com/drugs/DB12210",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "C[C@@H]1CN(CCN1S(=O)(=O)C1=CC=CC(=C1)[C@@](C)(O)C(F)(F)F)C1=CC=C(F)C=C1C(F)(F)F",
        "id": "DB12419",
        "molecule": "HSD-016",
        "cas": "946396-92-5",
        "iupac_name": "(2R)-1,1,1-trifluoro-2-(3-{[(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonyl}phenyl)propan-2-ol",
        "background": "Hsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016).\n",
        "inchi": {
            "hash": "ZWASRJHIEFYJGL-BFUOFWGJSA-N",
            "id": "InChI=1S/C21H21F7N2O3S/c1-13-12-29(18-7-6-15(22)11-17(18)20(23,24)25)8-9-30(13)34(32,33)16-5-3-4-14(10-16)19(2,31)21(26,27)28/h3-7,10-11,13,31H,8-9,12H2,1-2H3/t13-,19-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 514.46,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 514.116110859,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB12419",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC1=NC(=CN1CC1=C(Cl)C=CC=C1Cl)C1=NC(N)=NC=C1",
        "id": "DB08076",
        "molecule": "4-[1-(2,6-dichlorobenzyl)-2-methyl-1H-imidazol-4-yl]pyrimidin-2-amine",
        "iupac_name": "4-{1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-imidazol-4-yl}pyrimidin-2-amine",
        "inchi": {
            "hash": "CKSSZTMRRVJNNG-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H13Cl2N5/c1-9-20-14(13-5-6-19-15(18)21-13)8-22(9)7-10-11(16)3-2-4-12(10)17/h2-6,8H,7H2,1H3,(H2,18,19,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 334.203,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 333.054800855,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2,4-trisubstituted imidazoles. These are imidazoles in which the imidazole ring is substituted at positions 1, 2, and 3.",
        "link": "https://go.drugbank.com/drugs/DB08076",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBiotin carboxylase"
            }
        ]
    },
    {
        "smiles": "OC1=NC2=CC=CC=C2N1C1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1",
        "id": "DB12867",
        "molecule": "Benperidol",
        "cas": "2062-84-2",
        "iupac_name": "1-(4-fluorophenyl)-4-[4-(2-hydroxy-1H-1,3-benzodiazol-1-yl)piperidin-1-yl]butan-1-one",
        "background": "Benperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.\n",
        "inchi": {
            "hash": "FEBOTPHFXYHVPL-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H24FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)"
        },
        "summary": "Benperidol is a neuroleptic butyrophenone derivative indicated in the treatment of psychoses, manic episodes, and psychomotor agitation.",
        "weight": [
            {
                "type": "average",
                "weight": 381.451,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 381.185255188,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB12867",
        "type": "Small Molecule",
        "synonyms": [
            "Benperidol",
            "Benperidolum"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCC[C@@H](O)\\C=C\\C1=CC=CC=C1\\C=C\\[C@@H](O)[C@@H](O)CCCC(O)=O",
        "id": "DB12133",
        "molecule": "BLXA4",
        "cas": "864516-86-9",
        "iupac_name": "(5S,6R,7E)-5,6-dihydroxy-8-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]phenyl}oct-7-enoic acid",
        "background": "BLXA4 has been used in trials studying the treatment of Gingival Inflammation.\n",
        "inchi": {
            "hash": "HEDVTGFTYROYFE-RREUNBNVSA-N",
            "id": "InChI=1S/C22H32O5/c1-2-3-4-10-19(23)15-13-17-8-5-6-9-18(17)14-16-21(25)20(24)11-7-12-22(26)27/h5-6,8-9,13-16,19-21,23-25H,2-4,7,10-12H2,1H3,(H,26,27)/b15-13+,16-14+/t19-,20+,21-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 376.493,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 376.22497413,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cinnamyl alcohols. These are aromatic alcohols containing a 3-phenylprop-2-en-1-ol moiety.",
        "link": "https://go.drugbank.com/drugs/DB12133",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(CCCN1C(=O)CCN1C(=O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C(=O)N1CCCC1",
        "id": "DB08738",
        "molecule": "1-{3-oxo-3-[(2S)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]propyl}-3-phenylquinoxalin-2(1H)-one",
        "iupac_name": "1-{3-oxo-3-[(2S)-2-(pyrrolidine-1-carbonyl)pyrrolidin-1-yl]propyl}-3-phenyl-1,2-dihydroquinoxalin-2-one",
        "inchi": {
            "hash": "KWCKZIJGKMCYCI-QFIPXVFZSA-N",
            "id": "InChI=1S/C26H28N4O3/c31-23(29-17-8-13-22(29)25(32)28-15-6-7-16-28)14-18-30-21-12-5-4-11-20(21)27-24(26(30)33)19-9-2-1-3-10-19/h1-5,9-12,22H,6-8,13-18H2/t22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 444.5255,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 444.216140782,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB08738",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProlyl endopeptidase"
            }
        ]
    },
    {
        "smiles": "[Co]",
        "id": "DB14574",
        "molecule": "Cobalt",
        "cas": "7440-48-4",
        "iupac_name": "cobalt",
        "background": "A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis. Except for radioactive forms of cobalt and cobalamin, the FDA withdrew its approval for the use of drug products containing cobalt salts.1\n",
        "inchi": {
            "hash": "GUTLYIVDDKVIGB-UHFFFAOYSA-N",
            "id": "InChI=1S/Co"
        },
        "summary": "Cobalt is a metal element used in various nutritional products.",
        "weight": [
            {
                "type": "average",
                "weight": 58.9332,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 58.933200194,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14574",
        "type": "Small Molecule",
        "synonyms": [
            "Cobalt",
            "Cobalt, elemental",
            "Cobalto",
            "Cobaltum",
            "Kobalt"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCC1=CC2=C(C=CC(C)(CCC=C(C)C)O2)C(O)=C1",
        "id": "DB14735",
        "molecule": "Cannabichromene",
        "cas": "20675-51-8",
        "iupac_name": "2-methyl-2-(4-methylpent-3-en-1-yl)-7-pentyl-2H-chromen-5-ol",
        "background": "A natural product found in Cannabis sativa and Helichrysum species.\n",
        "inchi": {
            "hash": "UVOLYTDXHDXWJU-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H30O2/c1-5-6-7-10-17-14-19(22)18-11-13-21(4,23-20(18)15-17)12-8-9-16(2)3/h9,11,13-15,22H,5-8,10,12H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 314.469,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 314.224580206,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14735",
        "type": "Small Molecule",
        "synonyms": [
            "2-Methyl-2-(4-methyl-3-pentenyl)-7-pentyl-2H-1-benzopyran-5-ol",
            "Cannabichrome",
            "Cannabinochromene",
            "Cannanbichromene",
            "Pentylcannabichromene"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1=CC=C2C=C(SC2=C1)C(=O)NC1(CCCC1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NCC1CCN(CC2CCOCC2)CC1",
        "id": "DB12042",
        "molecule": "Ibodutant",
        "cas": "522664-63-7",
        "iupac_name": "6-methyl-N-(1-{[(1R)-1-[({1-[(oxan-4-yl)methyl]piperidin-4-yl}methyl)carbamoyl]-2-phenylethyl]carbamoyl}cyclopentyl)-1-benzothiophene-2-carboxamide",
        "background": "Ibodutant has been used in trials studying the treatment of Irritable Bowel Syndrome and Irritable Bowel Syndrome With Diarrhea.\n",
        "inchi": {
            "hash": "YQYSVMKCMIUCHY-WJOKGBTCSA-N",
            "id": "InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 644.88,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 644.339627216,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB12042",
        "type": "Small Molecule",
        "synonyms": [
            "Ibodutant"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]C(=O)CC(C)CCCC(C)(C)O",
        "id": "DB14187",
        "molecule": "Hydroxycitronellal",
        "cas": "107-75-5",
        "iupac_name": "7-hydroxy-3,7-dimethyloctanal",
        "background": "Hydroxycitronellal is a synthetic fragrance that is widely used in many cosmetics and hygiene products such as deodorants, soaps, antiseptics, and other household items. It has the smell of lilac, lily, and lily of the valley 1. Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain only 0.1-3.6%.\nSensitivity to hydroxycitronellal may be identified with a clinical patch test.\n",
        "inchi": {
            "hash": "WPFVBOQKRVRMJB-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H20O2/c1-9(6-8-11)5-4-7-10(2,3)12/h8-9,12H,4-7H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 172.2646,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 172.146329884,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14187",
        "type": "Small Molecule",
        "synonyms": [
            "3,7-dimethyl-7-hydroxyoctan-1-al",
            "3,7-Dimethyl-7-hydroxyoctanal",
            "7-hydroxy-3,7-dimethyloctanal",
            "7-hydroxycitronellal",
            "Citronellal hydrate",
            "Cyclalia",
            "Cyclosia",
            "Fixol",
            "hydroxy citronellal",
            "Laurine",
            "Lilyl aldehyde",
            "Muguet synthetic",
            "Muguettine principle",
            "Oxydihydrocitronellal",
            "Phixia"
        ],
        "indication": "Hydroxycitronellal is approved by the FDA for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "[H]C1(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C1=O)C(C)C)C(C)C)C(C)C",
        "id": "DB08965",
        "molecule": "Fusafungine",
        "cas": "1393-87-9",
        "iupac_name": "(3S,9S,15S)-4,10,16-trimethyl-3,6,9,12,15,18-hexakis(propan-2-yl)-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone",
        "background": "Fusafungine is an antibiotic from Fusarium lateririum, and is used for the treatment of respiratory infections.\n",
        "inchi": {
            "hash": "MIZMDSVSLSIMSC-OGLSAIDSSA-N",
            "id": "InChI=1S/C33H57N3O9/c1-16(2)22-31(40)43-26(20(9)10)29(38)35(14)24(18(5)6)33(42)45-27(21(11)12)30(39)36(15)23(17(3)4)32(41)44-25(19(7)8)28(37)34(22)13/h16-27H,1-15H3/t22-,23-,24-,25?,26?,27?/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 639.8204,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 639.409480437,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cyclic depsipeptides. These are natural or synthetic compounds having sequences of amino and hydroxy carboxylic acid residues (usually -amino and -hydroxy acids) connected in a ring. The residues are commonly but not necessarily regularly alternating.",
        "link": "https://go.drugbank.com/drugs/DB08965",
        "type": "Small Molecule",
        "synonyms": [
            "Fusafungina",
            "Fusafungine"
        ]
    },
    {
        "smiles": "ONC(=O)\\C=C\\C1=CC=C(Cl)C=C1",
        "id": "DB07819",
        "molecule": "(2E)-3-(4-CHLOROPHENYL)-N-HYDROXYACRYLAMIDE",
        "iupac_name": "(2E)-3-(4-chlorophenyl)-N-hydroxyprop-2-enamide",
        "inchi": {
            "hash": "YPYUWBDOEMPXSK-ZZXKWVIFSA-N",
            "id": "InChI=1S/C9H8ClNO2/c10-8-4-1-7(2-5-8)3-6-9(12)11-13/h1-6,13H,(H,11,12)/b6-3+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 197.618,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 197.024356212,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cinnamic acids and derivatives. These are organic aromatic compounds containing a benzene and a carboxylic acid group (or a derivative thereof) forming 3-phenylprop-2-enoic acid.",
        "link": "https://go.drugbank.com/drugs/DB07819",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Clostridium botulinum",
                "target": "UBotulinum neurotoxin type A"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium botulinum",
                "target": "UBoNT/A"
            }
        ]
    },
    {
        "smiles": "CCC(O)(CC)\\C=C\\C[C@H](C)C1=CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@@](F)([H])C1=C",
        "id": "DB06194",
        "molecule": "Elocalcitol",
        "cas": "199798-84-0",
        "iupac_name": "(1R,3Z,5S)-3-{2-[(3aS,7E,7aS)-3-[(2S,4E)-6-ethyl-6-hydroxyoct-4-en-2-yl]-3a-methyl-3a,4,5,6,7,7a-hexahydro-1H-inden-7-ylidene]ethylidene}-5-fluoro-4-methylidenecyclohexan-1-ol",
        "background": "Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).\n",
        "inchi": {
            "hash": "LRLWXBHFPGSUOX-GJQYOBCGSA-N",
            "id": "InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 442.6489,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 442.324708825,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.",
        "link": "https://go.drugbank.com/drugs/DB06194",
        "type": "Small Molecule",
        "synonyms": [
            "Elocalcitol"
        ],
        "indication": "Investigated for use/treatment in benign prostatic hyperplasia, urinary incontinence, prostate disorders, and infertility.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UVitamin D3 receptor"
            }
        ]
    },
    {
        "smiles": "Cl.CCN(C\\C=C/C1=CC(Cl)=C(C=C1)C1CCCCC1)C1CCCCC1",
        "id": "DB05792",
        "molecule": "Arylacenamide",
        "cas": "132173-07-0",
        "iupac_name": "N-[(2Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-en-1-yl]-N-ethylcyclohexanamine hydrochloride",
        "background": "Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.\n",
        "inchi": {
            "hash": "HKHPCMBPASXYGP-KVVVOXFISA-N",
            "id": "InChI=1S/C23H34ClN.ClH/c1-2-25(21-13-7-4-8-14-21)17-9-10-19-15-16-22(23(24)18-19)20-11-5-3-6-12-20;/h9-10,15-16,18,20-21H,2-8,11-14,17H2,1H3;1H/b10-9-;"
        },
        "weight": [
            {
                "type": "average",
                "weight": 396.437,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 395.214655539,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB05792",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in cancer/tumors (unspecified), immunosuppressive, and prostate cancer.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHCG20471, isoform CRA_c"
            }
        ]
    },
    {
        "smiles": "ClC1=CC=C(C=C1)C1=NN\\C(SC1)=N\\CCC=C",
        "id": "DB08028",
        "molecule": "BUT-3-ENYL-[5-(4-CHLORO-PHENYL)-3,6-DIHYDRO-[1,3,4]THIADIAZIN-2-YLIDENE]-AMINE",
        "iupac_name": "N-[(2Z)-5-(4-chlorophenyl)-3,6-dihydro-2H-1,3,4-thiadiazin-2-ylidene]but-3-en-1-amine",
        "inchi": {
            "hash": "ZVZPCRKQNRRBOQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H14ClN3S/c1-2-3-8-15-13-17-16-12(9-18-13)10-4-6-11(14)7-5-10/h2,4-7H,1,3,8-9H2,(H,15,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 279.788,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 279.05969586,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB08028",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeutrophil collagenase"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CCC=O)C(O)=O",
        "id": "DB04388",
        "molecule": "4-Carboxy-4-Aminobutanal",
        "iupac_name": "(2S)-2-amino-5-oxopentanoic acid",
        "inchi": {
            "hash": "KABXUUFDPUOJMW-BYPYZUCNSA-N",
            "id": "InChI=1S/C5H9NO3/c6-4(5(8)9)2-1-3-7/h3-4H,1-2,6H2,(H,8,9)/t4-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 131.1299,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 131.058243159,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB04388",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida (strain KT2440)",
                "target": "UGlutaminase-asparaginase"
            }
        ]
    },
    {
        "smiles": "[H]N1CC[C@@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)C1=O",
        "id": "DB03717",
        "molecule": "3-Hydroxy-4-(3,4,5-trihydroxy-tetrahydro-pyran-2-yloxy)-piperidin-2-one",
        "cas": "284045-95-0",
        "iupac_name": "(3S,4R)-3-hydroxy-4-{[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}piperidin-2-one",
        "inchi": {
            "hash": "BHZMHPRIYUPDCT-BQWZOORQSA-N",
            "id": "InChI=1S/C10H17NO7/c12-4-3-17-10(8(15)6(4)13)18-5-1-2-11-9(16)7(5)14/h4-8,10,12-15H,1-3H2,(H,11,16)/t4-,5-,6+,7+,8-,10+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 263.2445,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 263.100501903,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB03717",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Cellulomonas fimi",
                "target": "UExoglucanase/xylanase"
            }
        ]
    },
    {
        "smiles": "[H][C@](C)(OC(C)=O)[C@@]([H])(C=O)[C@@]1([H])NC(=CS1)C(=O)OCC=C",
        "id": "DB06904",
        "molecule": "(5S,6S)-6-[(R)ACETOXYETH-2-YL]-PENEM-3-CARBOXYLATEPROPANE",
        "iupac_name": "prop-2-en-1-yl (2S)-2-[(2S,3R)-3-(acetyloxy)-1-oxobutan-2-yl]-2,3-dihydro-1,3-thiazole-4-carboxylate",
        "inchi": {
            "hash": "KYVQFVHQVGHNFK-UISBYWKRSA-N",
            "id": "InChI=1S/C13H17NO5S/c1-4-5-18-13(17)11-7-20-12(14-11)10(6-15)8(2)19-9(3)16/h4,6-8,10,12,14H,1,5H2,2-3H3/t8-,10-,12+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 299.343,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 299.082743349,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06904",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "USignal peptidase I"
            }
        ]
    },
    {
        "smiles": "NCC[C@@H](O)C1=CC(OCC2CCCCC2)=CC=C1",
        "id": "DB12608",
        "molecule": "Emixustat",
        "cas": "1141777-14-1",
        "iupac_name": "(1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol",
        "background": "Emixustat has been used in trials studying the treatment of Geographic Atrophy, Age-Related Macular Degeneration, and Dry Age-related Macular Degeneration.\n",
        "inchi": {
            "hash": "WJIGGYYSZBWCGC-MRXNPFEDSA-N",
            "id": "InChI=1S/C16H25NO2/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2/t16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 263.381,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 263.188529049,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB12608",
        "type": "Small Molecule",
        "synonyms": [
            "Emixustat"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](O)(COC(=O)CCCCC)COP(O)(O)=O",
        "id": "DB04199",
        "molecule": "1-Monohexanoyl-2-Hydroxy-Sn-Glycero-3-Phosphate",
        "iupac_name": "[(2S)-3-(hexanoyloxy)-2-hydroxypropoxy]phosphonic acid",
        "inchi": {
            "hash": "FIMVTNBZKNVWDN-QMMMGPOBSA-N",
            "id": "InChI=1S/C9H19O7P/c1-2-3-4-5-9(11)15-6-8(10)7-16-17(12,13)14/h8,10H,2-7H2,1H3,(H2,12,13,14)/t8-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 270.2167,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 270.086839474,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-acylglycerol-3-phosphates. These are lysophosphatidic acids where the glycerol is esterified with a fatty acid at O-1 position.",
        "link": "https://go.drugbank.com/drugs/DB04199",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Shigella flexneri",
                "target": "ULipoprotein MxiM"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli O157:H7",
                "target": "UGrlR"
            },
            {
                "action": "Not Available",
                "organism": "Shigella sonnei",
                "target": "ULipoprotein MxiM"
            }
        ]
    },
    {
        "smiles": "OC(=O)CN1C=CC(=O)N(CC2=NC3=CC(Cl)=CC=C3S2)C1=O",
        "id": "DB07093",
        "molecule": "{3-[(5-CHLORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL}ACETIC ACID",
        "iupac_name": "2-{3-[(5-chloro-1,3-benzothiazol-2-yl)methyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}acetic acid",
        "inchi": {
            "hash": "RQWICELTTDJODO-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H10ClN3O4S/c15-8-1-2-10-9(5-8)16-11(23-10)6-18-12(19)3-4-17(14(18)22)7-13(20)21/h1-5H,6-7H2,(H,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 351.765,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 351.00805422,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB07093",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAldose reductase"
            }
        ]
    },
    {
        "smiles": "CC(C)C1=CC=CC=C1OCC1=NCCN1",
        "id": "DB13736",
        "molecule": "Fenoxazoline",
        "cas": "4846-91-7",
        "iupac_name": "2-{[2-(propan-2-yl)phenoxy]methyl}-4,5-dihydro-1H-imidazole",
        "inchi": {
            "hash": "GFYSWQDCHLWRMQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H18N2O/c1-10(2)11-5-3-4-6-12(11)16-9-13-14-7-8-15-13/h3-6,10H,7-9H2,1-2H3,(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 218.3,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 218.141913208,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB13736",
        "type": "Small Molecule",
        "synonyms": [
            "Fenoxazoline"
        ],
        "is_stub": true
    },
    {
        "smiles": "N[C@@H](CS)C(N)=O",
        "id": "DB03275",
        "molecule": "Cysteinamide",
        "cas": "74401-72-2",
        "iupac_name": "(2R)-2-amino-3-sulfanylpropanamide",
        "inchi": {
            "hash": "YEDNBEGNKOANMB-REOHCLBHSA-N",
            "id": "InChI=1S/C3H8N2OS/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H2,5,6)/t2-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 120.173,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 120.035733578,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB03275",
        "type": "Small Molecule",
        "synonyms": [
            "2-amino-3-mercapto-propionamide",
            "L-Cysteinamide"
        ]
    },
    {
        "smiles": "CN(C)CCOCCOC(=O)N1C2=CC=CC=C2SC2=CC=CC=C12",
        "id": "DB13794",
        "molecule": "Dimethoxanate",
        "cas": "477-93-0",
        "iupac_name": "2-[2-(dimethylamino)ethoxy]ethyl 10H-phenothiazine-10-carboxylate",
        "inchi": {
            "hash": "OOVJCSPCMCAXEX-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H22N2O3S/c1-20(2)11-12-23-13-14-24-19(22)21-15-7-3-5-9-17(15)25-18-10-6-4-8-16(18)21/h3-10H,11-14H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 358.46,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 358.13511375,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.",
        "link": "https://go.drugbank.com/drugs/DB13794",
        "type": "Small Molecule",
        "synonyms": [
            "Dimethoxanate"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCl",
        "id": "DB11534",
        "molecule": "Butyl chloride",
        "cas": "109-69-3",
        "iupac_name": "1-chlorobutane",
        "inchi": {
            "hash": "VFWCMGCRMGJXDK-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H9Cl/c1-2-3-4-5/h2-4H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 92.57,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 92.039278,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organochlorides. These are compounds containing a chemical bond between a carbon atom and a chlorine atom.",
        "link": "https://go.drugbank.com/drugs/DB11534",
        "type": "Small Molecule",
        "synonyms": [
            "n-Butyl chloride",
            "n-Propylcarbinyl chloride"
        ],
        "is_stub": true
    },
    {
        "smiles": "O[C@@H]1O[C@H](COP(O)(O)=O)[C@H](O)[C@H](O)[C@H]1O",
        "id": "DB02312",
        "molecule": "beta-D-galactose 6-phosphate",
        "iupac_name": "{[(2R,3R,4S,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "NBSCHQHZLSJFNQ-FPRJBGLDSA-N",
            "id": "InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3+,4+,5-,6-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 260.1358,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 260.029718526,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexose phosphates. These are carbohydrate derivatives containing a hexose substituted by one or more phosphate groups.",
        "link": "https://go.drugbank.com/drugs/DB02312",
        "type": "Small Molecule",
        "synonyms": [
            "6-O-phosphono--D-galactopyranose",
            "beta-galactose-6-phosphate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Lactococcus lactis subsp. lactis",
                "target": "U6-phospho-beta-galactosidase"
            }
        ]
    },
    {
        "smiles": "OC(O)(C(F)(F)F)C(F)(F)F",
        "id": "DB02922",
        "molecule": "Hexafluoroacetone Hydrate",
        "iupac_name": "hexafluoropropane-2,2-diol",
        "inchi": {
            "hash": "AKVXSYUWYXOLMY-UHFFFAOYSA-N",
            "id": "InChI=1S/C3H2F6O2/c4-2(5,6)1(10,11)3(7,8)9/h10-11H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 184.0372,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 183.995898538,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fluorohydrins. These are alcohols substituted by a fluorine atom at a saturated carbon atom otherwise bearing only hydrogen or hydrocarbyl groups.",
        "link": "https://go.drugbank.com/drugs/DB02922",
        "type": "Small Molecule"
    },
    {
        "smiles": "CN(CC(N)=O)C(=O)N(CCCl)N=O",
        "id": "DB11688",
        "molecule": "2-chloroethyl-3-sarcosinamide-1-nitrosourea",
        "cas": "81965-43-7",
        "iupac_name": "2-{[N-(2-chloroethyl)-N'-oxohydrazinecarbonyl](methyl)amino}acetamide",
        "background": "2-chloroethyl-3-sarcosinamide-1-nitrosourea has been used in trials studying the treatment of Colorectal Cancer, Brain and Central Nervous System Tumors, and Unspecified Adult Solid Tumor, Protocol Specific.\n",
        "inchi": {
            "hash": "HYHJFNXFVPGMBI-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H11ClN4O3/c1-10(4-5(8)12)6(13)11(9-14)3-2-7/h2-4H2,1H3,(H2,8,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 222.63,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 222.0519679,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB11688",
        "type": "Small Molecule",
        "synonyms": [
            "2-chloroethyl-3-sarcosinamide-1-nitrosourea",
            "ACETAMIDE, 2-((((2-CHLOROETHYL)NITROSOAMINO)CARBONYL)METHYLAMINO)-",
            "SarCNU",
            "SARCOSINEAMIDE CHLOROETHYLNITROSOUREA",
            "Sarmustine"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=C(C)C(C)=C(C(C)=C1)S(=O)(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC1=CC=C(C=C1)C(N)=N)C(=O)N1CCCCC1",
        "id": "DB03081",
        "molecule": "[N-[N-(4-Methoxy-2,3,6-trimethylphenylsulfonyl)-L-aspartyl]-D-(4-amidino-phenylalanyl)]-piperidine",
        "cas": "146663-95-8",
        "iupac_name": "(3S)-3-{[(2R)-3-(4-carbamimidoylphenyl)-1-oxo-1-(piperidin-1-yl)propan-2-yl]carbamoyl}-3-(4-methoxy-2,3,6-trimethylbenzenesulfonamido)propanoic acid",
        "inchi": {
            "hash": "ZOXOKTJHZSUHRJ-XZOQPEGZSA-N",
            "id": "InChI=1S/C29H39N5O7S/c1-17-14-24(41-4)18(2)19(3)26(17)42(39,40)33-22(16-25(35)36)28(37)32-23(29(38)34-12-6-5-7-13-34)15-20-8-10-21(11-9-20)27(30)31/h8-11,14,22-23,33H,5-7,12-13,15-16H2,1-4H3,(H3,30,31)(H,32,37)(H,35,36)/t22-,23+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 601.714,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 601.257019317,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB03081",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "O=C(OCCN1CCCCCC1)C(C1CCCCC1)C1=CSC=C1",
        "id": "DB13753",
        "molecule": "Cetiedil",
        "cas": "14176-10-4",
        "iupac_name": "2-(azepan-1-yl)ethyl 2-cyclohexyl-2-(thiophen-3-yl)acetate",
        "inchi": {
            "hash": "MMNICIJVQJJHHF-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H31NO2S/c22-20(23-14-13-21-11-6-1-2-7-12-21)19(18-10-15-24-16-18)17-8-4-3-5-9-17/h10,15-17,19H,1-9,11-14H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 349.53,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 349.207550416,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as azepanes. These are organic compounds containing a saturated seven member heterocycle, with one nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB13753",
        "type": "Small Molecule",
        "synonyms": [
            "Cetiedil"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(CN)CN(CCO1)C1=C(C=NC2=C1C=NN2)C1=CC=CC=C1",
        "id": "DB08774",
        "molecule": "1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine",
        "iupac_name": "1-[(2S)-4-{5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl}morpholin-2-yl]methanamine",
        "inchi": {
            "hash": "YBRZCAKSBYWZTC-ZDUSSCGKSA-N",
            "id": "InChI=1S/C17H19N5O/c18-8-13-11-22(6-7-23-13)16-14(12-4-2-1-3-5-12)9-19-17-15(16)10-20-21-17/h1-5,9-10,13H,6-8,11,18H2,(H,19,20,21)/t13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 309.3657,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 309.158960255,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB08774",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein kinase Chk1"
            }
        ]
    },
    {
        "smiles": "COC1=CC(CN(C)C2=CN=C3N=C(N)N=C(N)C3=C2)=CC(OC)=C1OC",
        "id": "DB02919",
        "molecule": "2,4-Diamino-6-[N-(3',4',5'-Trimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",
        "iupac_name": "N6-methyl-N6-[(3,4,5-trimethoxyphenyl)methyl]pyrido[2,3-d]pyrimidine-2,4,6-triamine",
        "inchi": {
            "hash": "PUOZHLHNKHRTOW-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H22N6O3/c1-24(9-10-5-13(25-2)15(27-4)14(6-10)26-3)11-7-12-16(19)22-18(20)23-17(12)21-8-11/h5-8H,9H2,1-4H3,(H4,19,20,21,22,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 370.4057,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 370.1753386,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrido[2,3-d]pyrimidines. These are compounds containing the pyrido[2,3-d]pyrimidine ring system, which is a pyridopyrimidine isomer with three ring nitrogen atoms at the 1-, 3-, and 8- position.",
        "link": "https://go.drugbank.com/drugs/DB02919",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "CC(C)OC1=CC=C(C=C1)C1=NC2=C(OC3=C2C=CC=C3)C(O[C@@H]2C[C@@H]3N(C2)C(=O)[C@H](CCCCC\\C=C/[C@@H]2C[C@]2(NC3=O)C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)OC2CCCC2)=N1",
        "id": "DB12785",
        "molecule": "Furaprevir",
        "cas": "1435923-88-8",
        "iupac_name": "cyclopentyl N-[(1S,4R,6S,7Z,14S,18R)-4-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-2,15-dioxo-18-({4-[4-(propan-2-yloxy)phenyl]-8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl}oxy)-3,16-diazatricyclo[14.3.0.0^{4,6}]nonadec-7-en-14-yl]carbamate",
        "background": "Furaprevir is under investigation in clinical trial NCT01523990 (A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients).\n",
        "inchi": {
            "hash": "GZRNOYTVBWWFLJ-NTPALUMKSA-N",
            "id": "InChI=1S/C47H56N6O10S/c1-28(2)60-32-21-19-29(20-22-32)40-49-38-34-16-11-12-18-37(34)63-39(38)42(50-40)61-33-25-36-41(54)51-47(44(56)52-64(58,59)46(3)23-24-46)26-30(47)13-7-5-4-6-8-17-35(43(55)53(36)27-33)48-45(57)62-31-14-9-10-15-31/h7,11-13,16,18-22,28,30-31,33,35-36H,4-6,8-10,14-15,17,23-27H2,1-3H3,(H,48,57)(H,51,54)(H,52,56)/b13-7-/t30-,33-,35+,36+,47-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 897.06,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 896.377863201,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.",
        "link": "https://go.drugbank.com/drugs/DB12785",
        "type": "Small Molecule",
        "synonyms": [
            "Furaprevir"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCNC1=CC=CN=C1N1CCN(CC1)C(=O)C1=CC2=CC(OC)=CC=C2N1",
        "id": "DB12264",
        "molecule": "Atevirdine",
        "cas": "136816-75-6",
        "iupac_name": "N-ethyl-2-[4-(5-methoxy-1H-indole-2-carbonyl)piperazin-1-yl]pyridin-3-amine",
        "background": "Atevirdine has been used in trials studying the treatment of HIV Infections.\n",
        "inchi": {
            "hash": "UCPOMLWZWRTIAA-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H25N5O2/c1-3-22-18-5-4-8-23-20(18)25-9-11-26(12-10-25)21(27)19-14-15-13-16(28-2)6-7-17(15)24-19/h4-8,13-14,22,24H,3,9-12H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 379.464,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 379.200825065,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.",
        "link": "https://go.drugbank.com/drugs/DB12264",
        "type": "Small Molecule",
        "synonyms": [
            "Atevirdine"
        ],
        "is_stub": true,
        "drug_interactions": [
            [
                "\u003ca href=\"/drugs/DB14685\"\u003eAdenovirus type 7 vaccine live\u003c/a\u003e",
                "The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB11003\"\u003eAnthrax vaccine\u003c/a\u003e",
                "The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB10804\"\u003eBacillus calmette-guerin substrain connaught live antigen\u003c/a\u003e",
                "The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB16648\"\u003eBacillus calmette-guerin substrain russian BCG-I live antigen\u003c/a\u003e",
                "The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB10343\"\u003eBacillus calmette-guerin substrain tice live antigen\u003c/a\u003e",
                "The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB12768\"\u003eBCG vaccine\u003c/a\u003e",
                "The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB18701\"\u003eChikungunya vaccine (live, attenuated)\u003c/a\u003e",
                "The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB14409\"\u003eHuman adenovirus e serotype 4 strain cl-68578 antigen\u003c/a\u003e",
                "The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB10317\"\u003eRubella virus vaccine\u003c/a\u003e",
                "The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB11050\"\u003eTyphoid Vaccine Live\u003c/a\u003e",
                "The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB10318\"\u003eVaricella zoster vaccine (live/attenuated)\u003c/a\u003e",
                "The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB14443\"\u003eVibrio cholerae CVD 103-HgR strain live antigen\u003c/a\u003e",
                "The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Atevirdine."
            ],
            [
                "\u003ca href=\"/drugs/DB10805\"\u003eYellow fever vaccine\u003c/a\u003e",
                "The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Atevirdine."
            ]
        ],
        "drug_interactions_raw": "This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. ApprovedVet approvedNutraceuticalIllicitWithdrawnInvestigationalExperimentalAll DrugsDrugInteractionIntegrate drug-drug interactions in your software\n\n\nAdenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Atevirdine.Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Atevirdine.Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Atevirdine.Bacillus calmette-guerin substrain russian BCG-I live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Atevirdine.Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Atevirdine.BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Atevirdine.Chikungunya vaccine (live, attenuated)The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Atevirdine.Human adenovirus e serotype 4 strain cl-68578 antigenThe therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Atevirdine.Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Atevirdine.Typhoid Vaccine LiveThe therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Atevirdine.Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   ",
        "drug_interactions_link": "https://go.drugbank.com/drugs/DB12264/drug_interactions.json?start=0\u0026length=100\u0026_=1701097772",
        "drug_interactions_page": "{\"draw\":1,\"recordsTotal\":13,\"recordsFiltered\":13,\"data\":[[\"\\u003ca href=\\\"/drugs/DB14685\\\"\\u003eAdenovirus type 7 vaccine live\\u003c/a\\u003e\",\"The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB11003\\\"\\u003eAnthrax vaccine\\u003c/a\\u003e\",\"The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB10804\\\"\\u003eBacillus calmette-guerin substrain connaught live antigen\\u003c/a\\u003e\",\"The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB16648\\\"\\u003eBacillus calmette-guerin substrain russian BCG-I live antigen\\u003c/a\\u003e\",\"The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB10343\\\"\\u003eBacillus calmette-guerin substrain tice live antigen\\u003c/a\\u003e\",\"The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB12768\\\"\\u003eBCG vaccine\\u003c/a\\u003e\",\"The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB18701\\\"\\u003eChikungunya vaccine (live, attenuated)\\u003c/a\\u003e\",\"The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB14409\\\"\\u003eHuman adenovirus e serotype 4 strain cl-68578 antigen\\u003c/a\\u003e\",\"The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB10317\\\"\\u003eRubella virus vaccine\\u003c/a\\u003e\",\"The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB11050\\\"\\u003eTyphoid Vaccine Live\\u003c/a\\u003e\",\"The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB10318\\\"\\u003eVaricella zoster vaccine (live/attenuated)\\u003c/a\\u003e\",\"The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB14443\\\"\\u003eVibrio cholerae CVD 103-HgR strain live antigen\\u003c/a\\u003e\",\"The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Atevirdine.\"],[\"\\u003ca href=\\\"/drugs/DB10805\\\"\\u003eYellow fever vaccine\\u003c/a\\u003e\",\"The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Atevirdine.\"]]}"
    },
    {
        "smiles": "[H][C@@](C)(O)C[C@](C)(O)CO",
        "id": "DB01881",
        "molecule": "2-Methylpentane-1,2,4-Triol",
        "iupac_name": "(2S,4S)-2-methylpentane-1,2,4-triol",
        "inchi": {
            "hash": "OMXLSJPESIOAGG-WDSKDSINSA-N",
            "id": "InChI=1S/C6H14O3/c1-5(8)3-6(2,9)4-7/h5,7-9H,3-4H2,1-2H3/t5-,6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 134.1736,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 134.094294314,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tertiary alcohols. These are compounds in which a hydroxy group, -OH, is attached to a saturated carbon atom R3COH (R not H ).",
        "link": "https://go.drugbank.com/drugs/DB01881",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces rubiginosus",
                "target": "UXylose isomerase"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)CN(CC(=O)NC2=C(F)C=C(C=C2)N2C=CC=CC2=O)C[C@]1([H])NC(=O)C1=CC=C(Cl)S1",
        "id": "DB07875",
        "molecule": "5-Chloro-thiophene-2-carboxylic acid ((3S,4S)-1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-4-hydroxy-pyrrolidin-3-yl)-amide",
        "iupac_name": "5-chloro-N-[(3S,4S)-1-({[2-fluoro-4-(2-oxo-1,2-dihydropyridin-1-yl)phenyl]carbamoyl}methyl)-4-hydroxypyrrolidin-3-yl]thiophene-2-carboxamide",
        "inchi": {
            "hash": "ARAVOODWJJJNBY-IRXDYDNUSA-N",
            "id": "InChI=1S/C22H20ClFN4O4S/c23-19-7-6-18(33-19)22(32)26-16-10-27(11-17(16)29)12-20(30)25-15-5-4-13(9-14(15)24)28-8-2-1-3-21(28)31/h1-9,16-17,29H,10-12H2,(H,25,30)(H,26,32)/t16-,17-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 490.935,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 490.08778175,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB07875",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "smiles": "[H]N(C)C1=C(Br)C=C(C(=O)N([H])[C@@H]2CN(C)CCN(CC)C2)C(OC)=C1",
        "id": "DB09207",
        "molecule": "AS-8112",
        "iupac_name": "5-bromo-N-[(6R)-1-ethyl-4-methyl-1,4-diazepan-6-yl]-2-methoxy-4-(methylamino)benzamide",
        "background": "AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3. It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.\n",
        "inchi": {
            "hash": "DALSFUWTAOKVTF-GFCCVEGCSA-N",
            "id": "InChI=1S/C17H27BrN4O2/c1-5-22-7-6-21(3)10-12(11-22)20-17(23)13-8-14(18)15(19-2)9-16(13)24-4/h8-9,12,19H,5-7,10-11H2,1-4H3,(H,20,23)/t12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 399.333,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 398.131739,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminobenzamides. These are organic compounds containing a benzamide moiety with an amine group attached to the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB09207",
        "type": "Small Molecule",
        "is_stub": true,
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UDopamine D2 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UDopamine D3 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "U5HT3 serotonin receptor"
            }
        ]
    },
    {
        "smiles": "C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O",
        "id": "DB15236",
        "molecule": "Fucose",
        "cas": "2438-80-4",
        "iupac_name": "(2S,3R,4R,5S)-2,3,4,5-tetrahydroxyhexanal",
        "background": "Fucose is under investigation in clinical trial NCT03354533 (Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II).\n",
        "inchi": {
            "hash": "PNNNRSAQSRJVSB-KCDKBNATSA-N",
            "id": "InChI=1S/C6H12O5/c1-3(8)5(10)6(11)4(9)2-7/h2-6,8-11H,1H3/t3-,4+,5+,6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 164.157,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 164.068473486,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15236",
        "type": "Small Molecule",
        "synonyms": [
            "L-FUCOSE"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1=CC=CC(C)=C1N(CC(=O)NC1=CC=C(C=C1)C1=NOC=N1)C(=O)C1CCS(=O)(=O)CC1",
        "id": "DB11701",
        "molecule": "Amenamevir",
        "cas": "841301-32-4",
        "iupac_name": "2-[N-(2,6-dimethylphenyl)-1-(1,1-dioxo-1lambda6-thian-4-yl)formamido]-N-[4-(1,2,4-oxadiazol-3-yl)phenyl]acetamide",
        "background": "Amenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis, and Safety of Amenamevir.\n",
        "inchi": {
            "hash": "MNHNIVNAFBSLLX-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 482.56,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 482.162391127,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenyloxadiazoles. These are polycyclic aromatic compounds containing a benzene ring linked to a 1,2,4-oxadiazole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB11701",
        "type": "Small Molecule",
        "synonyms": [
            "Amenamevir"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)[C@H]1CC[C@H](C)C[C@@H]1O",
        "id": "DB11344",
        "molecule": "(+)-menthol",
        "cas": "15356-60-2",
        "iupac_name": "(1S,2R,5S)-5-methyl-2-(propan-2-yl)cyclohexan-1-ol",
        "inchi": {
            "hash": "NOOLISFMXDJSKH-AEJSXWLSSA-N",
            "id": "InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 156.269,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 156.151415264,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as menthane monoterpenoids. These are monoterpenoids with a structure based on the o-, m-, or p-menthane backbone. P-menthane consists of the cyclohexane ring with a methyl group and a (2-methyl)-propyl group at the 1 and 4 ring position, respectively. The o- and m- menthanes are much rarer, and presumably arise by alkyl migration of p-menthanes.",
        "link": "https://go.drugbank.com/drugs/DB11344",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-(1S,2R,5S)-menthol",
            "(+)-(1S,3S,4R)-menthol",
            "(1S,2R,5S)-(+)-menthol",
            "(1S,2R,5S)-menthol",
            "D-menthol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN(C)CC1=CC=C(CSCCNC(=O)NC2=CC=C(C)C(Cl)=C2)O1",
        "id": "DB08027",
        "molecule": "CAP-1",
        "cas": "564475-13-4",
        "iupac_name": "1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}urea",
        "inchi": {
            "hash": "WEYNBWVKOYCCQT-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H24ClN3O2S/c1-13-4-5-14(10-17(13)19)21-18(23)20-8-9-25-12-16-7-6-15(24-16)11-22(2)3/h4-7,10H,8-9,11-12H2,1-3H3,(H2,20,21,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 381.92,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 381.127775424,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-phenylureas. These are compounds containing a N-phenylurea moiety, which is structurally characterized by a phenyl group linked to one nitrogen atom of a urea group.",
        "link": "https://go.drugbank.com/drugs/DB08027",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "CC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C",
        "id": "DB16863",
        "molecule": "Butylated hydroxytoluene",
        "cas": "128-37-0",
        "iupac_name": "2,6-di-tert-butyl-4-methylphenol",
        "inchi": {
            "hash": "NLZUEZXRPGMBCV-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H24O/c1-10-8-11(14(2,3)4)13(16)12(9-10)15(5,6)7/h8-9,16H,1-7H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 220.356,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 220.182715393,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16863",
        "type": "Small Molecule",
        "synonyms": [
            "BHT",
            "Butylhydroxytoluene"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(F)C[C@@]([H])(O[C@]1([H])COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)N1C=CC(=O)NC1=O",
        "id": "DB04685",
        "molecule": "1-{(2S,5S)-4-FLUORO-5-[(TRITYLOXY)METHYL]TETRAHYDROFURAN-2-YL}PYRIMIDINE-2,4(1H,3H)-DIONE",
        "iupac_name": "1-[(2R,4S,5R)-4-fluoro-5-[(triphenylmethoxy)methyl]oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione",
        "inchi": {
            "hash": "GJNIPWYJQUGERM-BFLUCZKCSA-N",
            "id": "InChI=1S/C28H25FN2O4/c29-23-18-26(31-17-16-25(32)30-27(31)33)35-24(23)19-34-28(20-10-4-1-5-11-20,21-12-6-2-7-13-21)22-14-8-3-9-15-22/h1-17,23-24,26H,18-19H2,(H,30,32,33)/t23-,24+,26+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 472.5075,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 472.179835503,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as triphenyl compounds. These are aromatic compounds containing a triphenyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB04685",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Plasmodium falciparum (isolate 3D7)",
                "target": "UDeoxyuridine 5'-triphosphate nucleotidohydrolase, putative"
            }
        ]
    },
    {
        "smiles": "OCC(O)CNC(=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(N(CC(O)CN(C=O)C2=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C2I)C=O)=C1I",
        "id": "DB12439",
        "molecule": "Ioforminol",
        "cas": "1095110-48-7",
        "iupac_name": "5-{N-[3-(N-{3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}formamido)-2-hydroxypropyl]formamido}-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide",
        "background": "Ioforminol has been used in trials studying the diagnostic of Cardio Renal Safety in High-risk Elderly Subjects Undergoing a Coronary CATH With or Without PCI.\n",
        "inchi": {
            "hash": "BFVVDRUCXCIALU-UHFFFAOYSA-N",
            "id": "InChI=1S/C33H40I6N6O15/c34-22-18(30(57)40-1-13(52)7-46)24(36)28(25(37)19(22)31(58)41-2-14(53)8-47)44(11-50)5-17(56)6-45(12-51)29-26(38)20(32(59)42-3-15(54)9-48)23(35)21(27(29)39)33(60)43-4-16(55)10-49/h11-17,46-49,52-56H,1-10H2,(H,40,57)(H,41,58)(H,42,59)(H,43,60)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1522.137,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1521.68198,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.",
        "link": "https://go.drugbank.com/drugs/DB12439",
        "type": "Small Molecule",
        "synonyms": [
            "Ioforminol"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC(N)=NNC(=O)N(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB07120",
        "molecule": "3-Carbamimidamido-1,1-diphenylurea",
        "iupac_name": "3-[(diaminomethylidene)amino]-1,1-diphenylurea",
        "inchi": {
            "hash": "QLXOHIUDKNRVBZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H15N5O/c15-13(16)17-18-14(20)19(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H,18,20)(H4,15,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 269.3018,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 269.127660127,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-phenylureas. These are compounds containing a N-phenylurea moiety, which is structurally characterized by a phenyl group linked to one nitrogen atom of a urea group.",
        "link": "https://go.drugbank.com/drugs/DB07120",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N)N=C(F)N=C23)[C@]([H])(O)[C@]1([H])O",
        "id": "DB04441",
        "molecule": "2-Fluoroadenosine",
        "cas": "146-78-1",
        "iupac_name": "(2R,3R,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol",
        "inchi": {
            "hash": "HBUBKKRHXORPQB-UUOKFMHZSA-N",
            "id": "InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6-,9-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 285.2318,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 285.087332102,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB04441",
        "type": "Small Molecule",
        "synonyms": [
            "2-(6-amino-2-fluoro-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol",
            "6-amino-2-fluoro-9--D-ribofuranosylpurine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPurine nucleoside phosphorylase DeoD-type"
            }
        ]
    },
    {
        "smiles": "CCN(C)CC1=CN=C(C)N=C1N",
        "id": "DB03653",
        "molecule": "5-{[Ethyl(Methyl)Amino]Methyl}-2-Methyl-5,6-Dihydropyrimidin-4-Amine",
        "iupac_name": "5-{[ethyl(methyl)amino]methyl}-2-methylpyrimidin-4-amine",
        "inchi": {
            "hash": "UMZINNCUCWRLDQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H16N4/c1-4-13(3)6-8-5-11-7(2)12-9(8)10/h5H,4,6H2,1-3H3,(H2,10,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 180.2501,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 180.137496532,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminopyrimidines and derivatives. These are organic compounds containing an amino group attached to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB03653",
        "type": "Small Molecule"
    },
    {
        "smiles": "CCOCCOCCOCCOCCOCCO",
        "id": "DB07344",
        "molecule": "3,6,9,12,15-PENTAOXAHEPTADECAN-1-OL",
        "iupac_name": "3,6,9,12,15-pentaoxaheptadecan-1-ol",
        "inchi": {
            "hash": "NJRFAMBTWHGSDE-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H26O6/c1-2-14-5-6-16-9-10-18-12-11-17-8-7-15-4-3-13/h13H,2-12H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 266.3312,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 266.172938564,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as polyethylene glycols. These are oligomers or polymers of ethylene oxide, with the general formula (C2H4O)n (with n\u003e=3).",
        "link": "https://go.drugbank.com/drugs/DB07344",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMalonyl-CoA-acyl carrier protein transacylase, mitochondrial"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB14544",
        "molecule": "Hydrocortisone valerate",
        "cas": "57524-89-7",
        "iupac_name": "(1R,3aS,3bS,9aR,9bS,10S,11aS)-10-hydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl pentanoate",
        "inchi": {
            "hash": "FZCHYNWYXKICIO-FZNHGJLXSA-N",
            "id": "InChI=1S/C26H38O6/c1-4-5-6-22(31)32-26(21(30)15-27)12-10-19-18-8-7-16-13-17(28)9-11-24(16,2)23(18)20(29)14-25(19,26)3/h13,18-20,23,27,29H,4-12,14-15H2,1-3H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1"
        },
        "summary": "Hydrocortisone valerate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.",
        "weight": [
            {
                "type": "average",
                "weight": 446.5763,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 446.266838948,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.",
        "link": "https://go.drugbank.com/drugs/DB14544",
        "type": "Small Molecule",
        "synonyms": [
            "Cortisol 17-valerate",
            "Hydrocortisone 17-valerate",
            "Hydrocortisone valerate"
        ],
        "indication": "For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AAnnexin A1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AGlucocorticoid receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U3 beta-hydroxysteroid dehydrogenase/Delta 5--\u003e4-isomerase type 1"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=C(I)C(NC(=O)COCCOCCOCC(=O)NC2=C(I)C(C(O)=O)=C(I)C=C2I)=C(I)C=C1I",
        "id": "DB08945",
        "molecule": "Iotroxic acid",
        "cas": "51022-74-3",
        "iupac_name": "3-{2-[2-(2-{[(3-carboxy-2,4,6-triiodophenyl)carbamoyl]methoxy}ethoxy)ethoxy]acetamido}-2,4,6-triiodobenzoic acid",
        "background": "Iotroxic acid is a contrast medium molecule.\n",
        "inchi": {
            "hash": "JXMIBUGMYLQZGO-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H18I6N2O9/c23-9-5-11(25)19(17(27)15(9)21(33)34)29-13(31)7-38-3-1-37-2-4-39-8-14(32)30-20-12(26)6-10(24)16(18(20)28)22(35)36/h5-6H,1-4,7-8H2,(H,29,31)(H,30,32)(H,33,34)(H,35,36)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1215.8131,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1215.528040704,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.",
        "link": "https://go.drugbank.com/drugs/DB08945",
        "type": "Small Molecule",
        "synonyms": [
            "Acide iotroxique",
            "Acido iotroxico",
            "Acidum iotroxicum",
            "Iotroxic acid",
            "Iotroxinsaeure"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC(=N)NCC1COC2=C(O1)C=CC=C2",
        "id": "DB13211",
        "molecule": "Guanoxan",
        "cas": "2165-19-7",
        "iupac_name": "N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]guanidine",
        "background": "Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.\nGuanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.\n",
        "inchi": {
            "hash": "HIUVKVDQFXDZHU-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 207.233,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 207.100776671,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzo-1,4-dioxanes. These are heterocyclic compounds containing a benzene ring fused to a 1,4-dioxane ring.",
        "link": "https://go.drugbank.com/drugs/DB13211",
        "type": "Small Molecule",
        "synonyms": [
            "Guanoxan",
            "Guanoxano",
            "Guanoxanum"
        ],
        "is_stub": true
    },
    {
        "smiles": "N[C@@H](CCC\\[NH+]=C(/N)NCC=C)C(O)=O",
        "id": "DB03892",
        "molecule": "5-N-Allyl-arginine",
        "iupac_name": "(E)-[(4S)-4-amino-4-carboxybutyl]({amino[(prop-2-en-1-yl)amino]methylidene})azanium",
        "inchi": {
            "hash": "ZPQWZDPOLXVMOU-ZETCQYMHSA-O",
            "id": "InChI=1S/C9H18N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h2,7H,1,3-6,10H2,(H,14,15)(H3,11,12,13)/p+1/t7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 215.2728,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 215.150800872,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as arginine and derivatives. These are compounds containing arginine or a derivative thereof resulting from reaction of arginine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB03892",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, brain"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(F)CN(CC(=O)NC2=CC=C(C=C2F)N2C=CC=CC2=O)C[C@]1([H])NC(=O)C1=CC=C(Cl)S1",
        "id": "DB08143",
        "molecule": "5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE",
        "iupac_name": "5-chloro-N-[(3S,4S)-4-fluoro-1-({[2-fluoro-4-(2-oxo-1,2-dihydropyridin-1-yl)phenyl]carbamoyl}methyl)pyrrolidin-3-yl]thiophene-2-carboxamide",
        "inchi": {
            "hash": "SXIYSYYSKHUTQQ-RDJZCZTQSA-N",
            "id": "InChI=1S/C22H19ClF2N4O3S/c23-19-7-6-18(33-19)22(32)27-17-11-28(10-15(17)25)12-20(30)26-16-5-4-13(9-14(16)24)29-8-2-1-3-21(29)31/h1-9,15,17H,10-12H2,(H,26,30)(H,27,32)/t15-,17-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 492.926,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 492.083445301,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB08143",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "smiles": "O[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O",
        "id": "DB04352",
        "molecule": "beta-D-Ribose-5-phosphate",
        "cas": "34980-66-0",
        "iupac_name": "{[(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "KTVPXOYAKDPRHY-TXICZTDVSA-N",
            "id": "InChI=1S/C5H11O8P/c6-3-2(1-12-14(9,10)11)13-5(8)4(3)7/h2-8H,1H2,(H2,9,10,11)/t2-,3-,4-,5-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 230.1098,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 230.01915384,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.",
        "link": "https://go.drugbank.com/drugs/DB04352",
        "type": "Small Molecule",
        "synonyms": [
            "5-O-phosphono-beta-D-ribofuranose",
            "5-O-phosphono--D-ribofuranose",
            "-D-ribofuranose 5-phosphate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UD-ribose pyranase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UADP-ribose pyrophosphatase, mitochondrial"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1O[C@H](O)[C@@H](F)[C@@H](O)[C@@H]1O",
        "id": "DB04084",
        "molecule": "2-deoxy-2-fluoro--D-mannose",
        "cas": "62182-14-3",
        "iupac_name": "(2S,3S,4S,5S,6R)-3-fluoro-6-(hydroxymethyl)oxane-2,4,5-triol",
        "inchi": {
            "hash": "ZCXUVYAZINUVJD-RXRWUWDJSA-N",
            "id": "InChI=1S/C6H11FO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1H2/t2-,3+,4-,5-,6+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 182.147,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 182.059051617,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB04084",
        "type": "Small Molecule",
        "synonyms": [
            "2-deoxy-2-fluoro-alpha-D-mannose"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Cellvibrio japonicus (strain Ueda107)",
                "target": "UMannan endo-1,4-beta-mannosidase"
            }
        ]
    },
    {
        "smiles": "CN1C=NC2=C1[N+](C)=CN=C2N",
        "id": "DB03730",
        "molecule": "3,9-Dimethyladenine",
        "iupac_name": "6-amino-3,9-dimethyl-9H-purin-3-ium",
        "inchi": {
            "hash": "YXTNRNJPEDJTNF-UHFFFAOYSA-O",
            "id": "InChI=1S/C7H9N5/c1-11-3-9-5-6(8)10-4-12(2)7(5)11/h3-4,8H,1-2H3/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 164.1878,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 164.093620345,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.",
        "link": "https://go.drugbank.com/drugs/DB03730",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Helicobacter pylori (strain ATCC 700392 / 26695)",
                "target": "UEndonuclease III"
            }
        ]
    },
    {
        "smiles": "[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)C(O)=O",
        "id": "DB03042",
        "molecule": "5-Phosphoarabinonic Acid",
        "iupac_name": "(2S,3R,4R)-2,3,4-trihydroxy-5-(phosphonooxy)pentanoic acid",
        "inchi": {
            "hash": "HNECGPFIYSOYHF-JJYYJPOSSA-N",
            "id": "InChI=1S/C5H11O9P/c6-2(1-14-15(11,12)13)3(7)4(8)5(9)10/h2-4,6-8H,1H2,(H,9,10)(H2,11,12,13)/t2-,3-,4+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 246.1092,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 246.014068462,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB03042",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Geobacillus stearothermophilus",
                "target": "UGlucose-6-phosphate isomerase B"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlucose-6-phosphate isomerase"
            }
        ]
    },
    {
        "smiles": "NC1=C(C2=C(N)N=C(N)N=C2C=C1)[Cl](=O)=O",
        "id": "DB01929",
        "molecule": "5-Chloryl-2,4,6-quinazolinetriamine",
        "iupac_name": "5-chlorylquinazoline-2,4,6-triamine",
        "inchi": {
            "hash": "AOIWFGJNGXKHGL-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H8ClN5O2/c10-3-1-2-4-5(6(3)9(15)16)7(11)14-8(12)13-4/h1-2H,10H2,(H4,11,12,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 241.634,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 241.036652232,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB01929",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydrofolate reductase, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Yeast",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "CC(=O)N[C@H]([C@@H](O)CC(=O)C(O)=O)[C@@H](O)[C@H](O)[C@H](O)CO",
        "id": "DB11797",
        "molecule": "Aceneuramic acid",
        "cas": "131-48-6",
        "iupac_name": "(4S,5R,6R,7S,8R)-5-acetamido-4,6,7,8,9-pentahydroxy-2-oxononanoic acid",
        "background": "Aceneuramic acid has been used in trials studying the treatment of Distal Myopathy, Nonaka Type, Hereditary Inclusion Body Myopathy, and Distal Myopathy With Rimmed Vacuoles.\n",
        "inchi": {
            "hash": "KBGAYAKRZNYFFG-BOHATCBPSA-N",
            "id": "InChI=1S/C11H19NO9/c1-4(14)12-8(5(15)2-6(16)11(20)21)10(19)9(18)7(17)3-13/h5,7-10,13,15,17-19H,2-3H2,1H3,(H,12,14)(H,20,21)/t5-,7+,8+,9+,10+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 309.2699,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 309.105981211,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.",
        "link": "https://go.drugbank.com/drugs/DB11797",
        "type": "Small Molecule",
        "synonyms": [
            "Aceneuramic acid",
            "Acidium aceneuramicum",
            "Acido aceneuramico"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN1SC(=O)C2=CC(=CC=C12)S(N)(=O)=O",
        "id": "DB03294",
        "molecule": "1-Methyl-3-Oxo-1,3-Dihydro-Benzo[C]Isothiazole-5-Sulfonic Acid Amide",
        "iupac_name": "1-methyl-3-oxo-1,3-dihydro-2,1-benzothiazole-5-sulfonamide",
        "inchi": {
            "hash": "DFPYCCVFXMWMJM-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H8N2O3S2/c1-10-7-3-2-5(15(9,12)13)4-6(7)8(11)14-10/h2-4H,1H3,(H2,9,12,13)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 244.291,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 243.997633512,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenoids. These are aromatic compounds containing one or more benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB03294",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "CN1CCN(CC1)C1=C(C\\N=N/C(N)=S)C=CC=C1",
        "id": "DB06941",
        "molecule": "(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide",
        "iupac_name": "(Z)-({[2-(4-methylpiperazin-1-yl)phenyl]methyl}imino)thiourea",
        "background": "(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide is a solid. This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.\n",
        "inchi": {
            "hash": "KAASZVAHBVMHCO-NXVVXOECSA-N",
            "id": "InChI=1S/C13H19N5S/c1-17-6-8-18(9-7-17)12-5-3-2-4-11(12)10-15-16-13(14)19/h2-5H,6-10H2,1H3,(H2,14,19)/b16-15-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 277.388,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 277.136116323,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB06941",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein S100-B"
            }
        ]
    },
    {
        "smiles": "[H]N(CC1=C(F)C=CC=N1)C(=O)CN1C(C)=CN=C(N([H])CC(F)(F)C2=CC=CC=N2)C1=O",
        "id": "DB07548",
        "molecule": "2-(6-Chloro-3-{[2,2-difluoro-2-(2-pyridinyl)ethyl]amino}-2-oxo-1(2H)-pyrazinyl)-N-[(2-fluoro-6-pyridinyl)methyl]acetamide",
        "cas": "312904-60-2",
        "iupac_name": "2-(3-{[2,2-difluoro-2-(pyridin-2-yl)ethyl]amino}-6-methyl-2-oxo-1,2-dihydropyrazin-1-yl)-N-[(3-fluoropyridin-2-yl)methyl]acetamide",
        "inchi": {
            "hash": "JXHWVKOKYDAROD-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H19F3N6O2/c1-13-9-27-18(28-12-20(22,23)16-6-2-3-7-25-16)19(31)29(13)11-17(30)26-10-15-14(21)5-4-8-24-15/h2-9H,10-12H2,1H3,(H,26,30)(H,27,28)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 432.3991,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 432.152158497,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminopyrazines. These are organic compounds containing an amino group attached to a pyrazine ring.",
        "link": "https://go.drugbank.com/drugs/DB07548",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "CC(C)(CO)[C@@H](O)C(=O)NCCCC(O)=O",
        "id": "DB14044",
        "molecule": "Hopantenic acid",
        "cas": "18679-90-8",
        "iupac_name": "4-[(2R)-2,4-dihydroxy-3,3-dimethylbutanamido]butanoic acid",
        "background": "Hopantenic acid (Pantogam) is a central nervous system depressant. Hopantenic acid has a unique spectrum of pharmacological effects (nootropic, anticonvulsant, mild activating) in the absence of addiction, hyperstimulation or withdrawal syndrome. 1\n",
        "inchi": {
            "hash": "SBBDHANTMHIRGW-QMMMGPOBSA-N",
            "id": "InChI=1S/C10H19NO5/c1-10(2,6-12)8(15)9(16)11-5-3-4-7(13)14/h8,12,15H,3-6H2,1-2H3,(H,11,16)(H,13,14)/t8-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 233.264,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 233.126322716,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14044",
        "type": "Small Molecule",
        "synonyms": [
            "Acide hopantenique",
            "Acido hopantenico",
            "Acidum hopantenicum",
            "D-Homopantothenic acid",
            "Hopantenic acid",
            "Hopanteninsaeure",
            "N-pantoyl-GABA",
            "Pantocalcin"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[Te]CC([O-])=O",
        "id": "DB01918",
        "molecule": "[Methyltelluro]Acetate",
        "iupac_name": "2-(methyltellanyl)acetate",
        "background": "[methyltelluro]acetate is a solid. This compound belongs to the organic oxoanionic compounds. These are organic compounds containing an oxoanion. This medication targets the protein monomeric sarcosine oxidase.\n",
        "inchi": {
            "hash": "OKJWQADPGUWQAJ-UHFFFAOYSA-M",
            "id": "InChI=1S/C3H6O2Te/c1-6-2-3(4)5/h2H2,1H3,(H,4,5)/p-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 200.7,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 202.935177157,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organic oxoanionic compounds. These are organic compounds containing an oxoanion.",
        "link": "https://go.drugbank.com/drugs/DB01918",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus sp. (strain B-0618)",
                "target": "UMonomeric sarcosine oxidase"
            }
        ]
    },
    {
        "smiles": "[H]N([H])C(=O)C1=CN([C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]3O[C@H]([C@H](OP(O)(O)=O)[C@@H]3O)N3C=NC4=C(N=CN=C34)N([H])[H])[C@@H](O)[C@H]2O)[C@@H](O)[C@@H](O)C1",
        "id": "DB02319",
        "molecule": "5,6-dihydroxy-NADP",
        "iupac_name": "{[(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-[({[({[(2R,3S,4R,5R)-5-[(2S,3S)-5-carbamoyl-2,3-dihydroxy-1,2,3,4-tetrahydropyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-4-hydroxyoxolan-3-yl]oxy}phosphonic acid",
        "inchi": {
            "hash": "LRAVAOPKUBJONV-IVCJQJMGSA-N",
            "id": "InChI=1S/C21H32N7O19P3/c22-16-11-18(25-5-24-16)28(6-26-11)21-15(46-48(35,36)37)13(31)10(45-21)4-43-50(40,41)47-49(38,39)42-3-9-12(30)14(32)20(44-9)27-2-7(17(23)33)1-8(29)19(27)34/h2,5-6,8-10,12-15,19-21,29-32,34H,1,3-4H2,(H2,23,33)(H,38,39)(H,40,41)(H2,22,24,25)(H2,35,36,37)/t8-,9+,10+,12+,13+,14+,15+,19-,20+,21+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 779.4356,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 779.096581413,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleotide sugars. These are purine nucleotides bound to a saccharide derivative through the terminal phosphate group.",
        "link": "https://go.drugbank.com/drugs/DB02319",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAlcohol dehydrogenase YqhD"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O",
        "id": "DB02763",
        "molecule": "5-Mercapto-2-Nitro-Benzoic Acid",
        "cas": "15139-21-6",
        "iupac_name": "2-nitro-5-sulfanylbenzoic acid",
        "inchi": {
            "hash": "GANZODCWZFAEGN-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H5NO4S/c9-7(10)5-3-4(13)1-2-6(5)8(11)12/h1-3,13H,(H,9,10)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 199.184,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 198.993928343,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitrobenzoic acids and derivatives. These are compounds containing a nitrobenzoic acid moiety, which consists of a benzene ring bearing both a carboxylic acid group and a nitro group on two different ring carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB02763",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UInterleukin-12 subunit beta"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus",
                "target": "UProtein ArsC"
            }
        ]
    },
    {
        "smiles": "[H]\\C(C1=CC(OC)=C(C=C1)N1C=NC(C)=C1)=C1\\CCCN(C1=O)[C@@]([H])(C)C1=CC=C(F)C=C1",
        "id": "DB05171",
        "molecule": "E-2012",
        "cas": "870843-42-8",
        "iupac_name": "(3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-{[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene}piperidin-2-one",
        "background": "E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.\n",
        "inchi": {
            "hash": "PUOAETJYKQITMO-LANLRWRYSA-N",
            "id": "InChI=1S/C25H26FN3O2/c1-17-15-28(16-27-17)23-11-6-19(14-24(23)31-3)13-21-5-4-12-29(25(21)30)18(2)20-7-9-22(26)10-8-20/h6-11,13-16,18H,4-5,12H2,1-3H3/b21-13+/t18-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 419.5,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 419.200905252,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB05171",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in alzheimer's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGamma-secretase subunit APH-1A"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGamma-secretase subunit PEN-2"
            }
        ]
    },
    {
        "smiles": "CCCC(=O)C1=C(O)C=C(OC)C(CC2=C(O)C(C)(C)C(O)=C(C(=O)CCC)C2=O)=C1O",
        "id": "DB13567",
        "molecule": "Desaspidin",
        "cas": "114-43-2",
        "iupac_name": "2-butanoyl-6-[(3-butanoyl-2,4-dihydroxy-6-methoxyphenyl)methyl]-3,5-dihydroxy-4,4-dimethylcyclohexa-2,5-dien-1-one",
        "inchi": {
            "hash": "GAHOBHHMYUYJDT-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H30O8/c1-6-8-14(25)18-16(27)11-17(32-5)12(20(18)28)10-13-21(29)19(15(26)9-7-2)23(31)24(3,4)22(13)30/h11,27-28,30-31H,6-10H2,1-5H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 446.496,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 446.194067926,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB13567",
        "type": "Small Molecule",
        "synonyms": [
            "Desaspidin",
            "Desaspidina",
            "Desaspidine",
            "Desaspidinum",
            "Rosapin"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCN(CC)CCN1C(=O)C(CC2=CC=C(OC)C=C2)=NC2=CC=CC=C12",
        "id": "DB13835",
        "molecule": "Caroverine",
        "cas": "23465-76-1",
        "iupac_name": "1-[2-(diethylamino)ethyl]-3-[(4-methoxyphenyl)methyl]-1,2-dihydroquinoxalin-2-one",
        "inchi": {
            "hash": "MSPRUJDUTKRMLM-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3"
        },
        "summary": "Caroverine is a calcium channel blocker indicated in the treatment of smooth muscle spasms, alcohol and drug withdrawal, and tinnitus.",
        "weight": [
            {
                "type": "average",
                "weight": 365.477,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 365.210327121,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring.",
        "link": "https://go.drugbank.com/drugs/DB13835",
        "type": "Small Molecule",
        "synonyms": [
            "Caroverine"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCCCCCC[P+](C)(C)CC(P(O)(O)=O)P(O)(O)=O",
        "id": "DB07221",
        "molecule": "(2,2-DIPHOSPHONOETHYL)(DODECYL)DIMETHYLPHOSPHONIUM",
        "iupac_name": "[2-(dodecyldimethylphosphaniumyl)-1-phosphonoethyl]phosphonic acid",
        "inchi": {
            "hash": "QCMHKGWUOSRYCF-UHFFFAOYSA-O",
            "id": "InChI=1S/C16H37O6P3/c1-4-5-6-7-8-9-10-11-12-13-14-23(2,3)15-16(24(17,18)19)25(20,21)22/h16H,4-15H2,1-3H3,(H3-,17,18,19,20,21,22)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 419.3906,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 419.188123484,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB07221",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGeranylgeranyl pyrophosphate synthase"
            }
        ]
    },
    {
        "smiles": "OC(=O)COC1=CC=CC2=CC=CC=C12",
        "id": "DB08286",
        "molecule": "1-Naphthoxyacetic acid",
        "cas": "2976-75-2",
        "iupac_name": "2-(naphthalen-1-yloxy)acetic acid",
        "inchi": {
            "hash": "GHRYSOFWKRRLMI-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H10O3/c13-12(14)8-15-11-7-3-5-9-4-1-2-6-10(9)11/h1-7H,8H2,(H,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 202.206,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 202.062994186,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.",
        "link": "https://go.drugbank.com/drugs/DB08286",
        "type": "Small Molecule",
        "synonyms": [
            "(1-naphthalenyloxy)acetic acid",
            "(1-naphthyloxy)acetic acid",
            "1-naphthyloxyacetic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            },
            {
                "action": "Not Available",
                "organism": "HIV-2",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1",
        "id": "DB08639",
        "molecule": "Dapivirine",
        "cas": "244767-67-7",
        "iupac_name": "4-({4-[(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl}amino)benzonitrile",
        "background": "Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.\n",
        "inchi": {
            "hash": "ILAYIAGXTHKHNT-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H19N5/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17/h4-11H,1-3H3,(H2,22,23,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 329.3984,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 329.164045633,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzonitriles. These are organic compounds containing a benzene bearing a nitrile substituent.",
        "link": "https://go.drugbank.com/drugs/DB08639",
        "type": "Small Molecule",
        "synonyms": [
            "Dapivirine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "CN1C=CC(N)=NC1=O",
        "id": "DB04314",
        "molecule": "1-Methylcytosine",
        "cas": "1122-47-0",
        "iupac_name": "4-amino-1-methyl-1,2-dihydropyrimidin-2-one",
        "inchi": {
            "hash": "HWPZZUQOWRWFDB-UHFFFAOYSA-N",
            "id": "InChI=1S/C5H7N3O/c1-8-3-2-4(6)7-5(8)9/h2-3H,1H3,(H2,6,7,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 125.1286,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 125.058911861,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB04314",
        "type": "Small Molecule",
        "synonyms": [
            "N-Methylcytosine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "VACV",
                "target": "UCap-specific mRNA (nucleoside-2'-O-)-methyltransferase"
            }
        ]
    },
    {
        "smiles": "CN1CCN(CC1)C1=NC2=C(C=C(C=C2N=C1)C(F)(F)F)C1=CC(O)=CC=C1",
        "id": "DB07969",
        "molecule": "3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol",
        "iupac_name": "3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol",
        "inchi": {
            "hash": "QNCYYRHIUFGGJX-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H19F3N4O/c1-26-5-7-27(8-6-26)18-12-24-17-11-14(20(21,22)23)10-16(19(17)25-18)13-3-2-4-15(28)9-13/h2-4,9-12,28H,5-8H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 388.3863,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 388.151095865,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB07969",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHepatocyte growth factor receptor"
            }
        ]
    },
    {
        "smiles": "COC1=C2C=CC(=O)OC2=CC2=C1C=CO2",
        "id": "DB12216",
        "molecule": "Bergapten",
        "cas": "484-20-8",
        "iupac_name": "4-methoxy-7H-furo[3,2-g]chromen-7-one",
        "background": "Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).\n",
        "inchi": {
            "hash": "BGEBZHIAGXMEMV-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 216.192,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 216.042258738,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 5-methoxypsoralens. These are psoralens containing a methoxy group attached at the C5 position of the psoralen group.",
        "link": "https://go.drugbank.com/drugs/DB12216",
        "type": "Small Molecule",
        "synonyms": [
            "5 methoxypsoralen",
            "5-methoxypsoralen"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCC(=O)N(CC(C)N(C)CCC1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB01502",
        "molecule": "Diampromide",
        "cas": "552-25-0",
        "iupac_name": "N-{2-[methyl(2-phenylethyl)amino]propyl}-N-phenylpropanamide",
        "inchi": {
            "hash": "RXTHKWVSXOIHJS-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H28N2O/c1-4-21(24)23(20-13-9-6-10-14-20)17-18(2)22(3)16-15-19-11-7-5-8-12-19/h5-14,18H,4,15-17H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 324.4598,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 324.220163528,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.",
        "link": "https://go.drugbank.com/drugs/DB01502",
        "type": "Small Molecule",
        "synonyms": [
            "Diampromide"
        ]
    },
    {
        "smiles": "CC1=CC(O)=C2C(=O)C3=C(C=C(O)C=C3O)C(=O)C2=C1",
        "id": "DB07715",
        "molecule": "Emodin",
        "cas": "518-82-1",
        "iupac_name": "1,3,8-trihydroxy-6-methyl-9,10-dihydroanthracene-9,10-dione",
        "background": "Emodin has been investigated for the treatment of Polycystic Kidney.\n",
        "inchi": {
            "hash": "RHMXXJGYXNZAPX-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H10O5/c1-6-2-8-12(10(17)3-6)15(20)13-9(14(8)19)4-7(16)5-11(13)18/h2-5,16-18H,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 270.2369,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 270.05282343,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxyanthraquinones. These are compounds containing a hydroxyanthraquinone moiety, which consists of an anthracene bearing a quinone, and hydroxyl group.",
        "link": "https://go.drugbank.com/drugs/DB07715",
        "type": "Small Molecule",
        "synonyms": [
            "1,3,8-trihydroxy-6-methyl-9,10-anthracenedione",
            "1,3,8-trihydroxy-6-methyl-9,10-anthraquinone",
            "Schuttgelb"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCasein kinase II subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145)",
                "target": "UPutative ketoacyl reductase"
            },
            {
                "action": "Not Available",
                "organism": "Helicobacter pylori",
                "target": "U3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UAryl hydrocarbon receptor"
            }
        ]
    },
    {
        "smiles": "CC(C)[C@@]1(C)N=C(NC1=O)C1=NC2=CC=CC=C2C=C1C(O)=O",
        "id": "DB04582",
        "molecule": "Imazaquin",
        "iupac_name": "2-[(4R)-4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]quinoline-3-carboxylic acid",
        "inchi": {
            "hash": "CABMTIJINOIHOD-QGZVFWFLSA-N",
            "id": "InChI=1S/C17H17N3O3/c1-9(2)17(3)16(23)19-14(20-17)13-11(15(21)22)8-10-6-4-5-7-12(10)18-13/h4-9H,1-3H3,(H,21,22)(H,19,20,23)/t17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 311.3352,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 311.126991425,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.",
        "link": "https://go.drugbank.com/drugs/DB04582",
        "type": "Small Molecule",
        "synonyms": [
            "(R)-imazaquin"
        ]
    },
    {
        "smiles": "[H][C@@]1(C)CNC2=C(SC3=C2C2=C(C=C3)N=C(C=C2)C2=CN=C(C)C=C2)C(=O)N1",
        "id": "DB07430",
        "molecule": "(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one",
        "iupac_name": "(15R)-15-methyl-5-(6-methylpyridin-3-yl)-11-thia-6,14,17-triazatetracyclo[8.8.0.0^{2,7}.0^{12,18}]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one",
        "inchi": {
            "hash": "CMWRPDHVGMHLSZ-GFCCVEGCSA-N",
            "id": "InChI=1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 374.459,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 374.120131908,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.",
        "link": "https://go.drugbank.com/drugs/DB07430",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMAP kinase-activated protein kinase 2"
            }
        ]
    },
    {
        "smiles": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)CCC[C@@H](N)C(O)=O)C(O)=O",
        "id": "DB03938",
        "molecule": "Deacetoxycephalosporin C",
        "cas": "26924-74-3",
        "iupac_name": "(6R,7R)-7-[(5R)-5-amino-5-carboxypentanamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",
        "inchi": {
            "hash": "NNQIJOYQWYKBOW-JWKOBGCHSA-N",
            "id": "InChI=1S/C14H19N3O6S/c1-6-5-24-12-9(11(19)17(12)10(6)14(22)23)16-8(18)4-2-3-7(15)13(20)21/h7,9,12H,2-5,15H2,1H3,(H,16,18)(H,20,21)(H,22,23)/t7-,9-,12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 357.382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 357.099456045,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]Oct-2-ene-2-carboxylic acid moiety or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB03938",
        "type": "Small Molecule",
        "synonyms": [
            "DAOC",
            "De(acetyloxy)cephalosporin C",
            "Deacetoxycephalosporin C",
            "Deacetoxycephalosporin-C"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces clavuligerus (strain ATCC 27064 / DSM 738 / JCM 4710 / NBRC 13307 / NCIMB 12785 / NRRL 3585 / VKM Ac-602)",
                "target": "UDeacetoxycephalosporin C synthase"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CO)O[C@@]([H])(C2=C3N=CNC(=O)C3=NN2)[C@]([H])(O)[C@]1([H])O",
        "id": "DB04198",
        "molecule": "Formycin B",
        "iupac_name": "3-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2H,6H,7H-pyrazolo[4,3-d]pyrimidin-7-one",
        "inchi": {
            "hash": "MTCJZZBQNCXKAP-KSYZLYKTSA-N",
            "id": "InChI=1S/C10H12N4O5/c15-1-3-7(16)8(17)9(19-3)5-4-6(14-13-5)10(18)12-2-11-4/h2-3,7-9,15-17H,1H2,(H,13,14)(H,11,12,18)/t3-,7-,8-,9+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 268.2261,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 268.080769514,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as c-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a C-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB04198",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPurine nucleoside phosphorylase DeoD-type"
            },
            {
                "action": "Not Available",
                "organism": "Trypanosoma cruzi",
                "target": "UHypoxanthine-guanine phosphoribosyltransferase"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)C[N@]2[C@@]([H])(C1)[C@]1([H])C(=O)N(CC3=CC=C4OCOC4=C3)C(=O)[C@]1([H])[C@]2([H])C1=CC=C(C=C1)C(N)=N",
        "id": "DB08546",
        "molecule": "4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE",
        "iupac_name": "4-[(3aS,4R,7R,8aS,8bR)-2-[(2H-1,3-benzodioxol-5-yl)methyl]-7-hydroxy-1,3-dioxo-decahydropyrrolo[3,4-a]pyrrolizin-4-yl]benzene-1-carboximidamide",
        "inchi": {
            "hash": "CETLUACQMGBMFH-ZALSBGIRSA-N",
            "id": "InChI=1S/C24H24N4O5/c25-22(26)14-4-2-13(3-5-14)21-20-19(16-8-15(29)10-27(16)21)23(30)28(24(20)31)9-12-1-6-17-18(7-12)33-11-32-17/h1-7,15-16,19-21,29H,8-11H2,(H3,25,26)/t15-,16+,19+,20+,21+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 448.4712,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 448.174669898,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB08546",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "NC(=N)C1=CC2=C(C=C1)N=C(N2)C(O)(O)C1=NC2=C(N1)C=C(C=C2)C([NH3+])=[NH2+]",
        "id": "DB04301",
        "molecule": "Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone Hydrate",
        "iupac_name": "[azaniumyl({2-[(6-carbamimidoyl-1H-1,3-benzodiazol-2-yl)dihydroxymethyl]-1H-1,3-benzodiazol-6-yl})methylidene]azanium",
        "inchi": {
            "hash": "ZLAHDRAQCSQPOC-UHFFFAOYSA-P",
            "id": "InChI=1S/C17H16N8O2/c18-13(19)7-1-3-9-11(5-7)24-15(22-9)17(26,27)16-23-10-4-2-8(14(20)21)6-12(10)25-16/h1-6,26-27H,(H3,18,19)(H3,20,21)(H,22,24)(H,23,25)/p+2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 366.3772,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 366.15527186,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB04301",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NON=C3C[C@]12C",
        "id": "DB01514",
        "molecule": "Furazabol",
        "cas": "1239-29-8",
        "iupac_name": "(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6-oxa-5,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4,7-dien-17-ol",
        "inchi": {
            "hash": "RGLLOUBXMOGLDQ-IVEVATEUSA-N",
            "id": "InChI=1S/C20H30N2O2/c1-18-11-17-16(21-24-22-17)10-12(18)4-5-13-14(18)6-8-19(2)15(13)7-9-20(19,3)23/h12-15,23H,4-11H2,1-3H3/t12-,13+,14-,15-,18-,19-,20-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 330.4644,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 330.230728214,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton.",
        "link": "https://go.drugbank.com/drugs/DB01514",
        "type": "Small Molecule",
        "synonyms": [
            "Furazabol"
        ]
    },
    {
        "smiles": "CC(C)OC(=S)NC1=CC(C(=O)OC(C)C)=C(Cl)C=C1",
        "id": "DB08681",
        "molecule": "1-METHYL ETHYL 2-CHLORO-5-[[[(1-METHYLETHOXY)THIOOXO]METHYL]AMINO]-BENZOATE",
        "iupac_name": "propan-2-yl 2-chloro-5-{[(propan-2-yloxy)methanethioyl]amino}benzoate",
        "inchi": {
            "hash": "AXTNFJKQZPETJA-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H18ClNO3S/c1-8(2)18-13(17)11-7-10(5-6-12(11)15)16-14(20)19-9(3)4/h5-9H,1-4H3,(H,16,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 315.816,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 315.069591844,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.",
        "link": "https://go.drugbank.com/drugs/DB08681",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)C2=CC3=C(S2)C=C(Cl)C=C3)C1=O)C(=O)N1CCOCC1",
        "id": "DB07844",
        "molecule": "6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE",
        "iupac_name": "6-chloro-N-[(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]-1-benzothiophene-2-sulfonamide",
        "inchi": {
            "hash": "PHLKBODTBJLXRD-WFASDCNBSA-N",
            "id": "InChI=1S/C19H22ClN3O5S2/c1-12(18(24)22-6-8-28-9-7-22)23-5-4-15(19(23)25)21-30(26,27)17-10-13-2-3-14(20)11-16(13)29-17/h2-3,10-12,15,21H,4-9H2,1H3/t12-,15-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 471.978,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 471.068939916,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB07844",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CO)O[C@@]([H])(C2=C3N=CN=C(N)C3=NN2)[C@]([H])(O)[C@]1([H])O",
        "id": "DB02281",
        "molecule": "Formycin",
        "cas": "6742-12-7",
        "iupac_name": "(2S,3R,4S,5R)-2-{7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl}-5-(hydroxymethyl)oxolane-3,4-diol",
        "inchi": {
            "hash": "KBHMEHLJSZMEMI-KSYZLYKTSA-N",
            "id": "InChI=1S/C10H13N5O4/c11-10-6-4(12-2-13-10)5(14-15-6)9-8(18)7(17)3(1-16)19-9/h2-3,7-9,16-18H,1H2,(H,14,15)(H2,11,12,13)/t3-,7-,8-,9+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 267.2413,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 267.096753929,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as c-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a C-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB02281",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "US-methyl-5'-thioadenosine phosphorylase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "U5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase"
            }
        ]
    },
    {
        "smiles": "COC(=O)N1CCC(CC#CC2=NC(N)=C3N=CN([C@@H]4O[C@@H]([C@@H](O)[C@H]4O)C(=O)NC4CC4)C3=N2)CC1",
        "id": "DB12295",
        "molecule": "Evodenoson",
        "cas": "844873-47-8",
        "iupac_name": "methyl 4-(3-{6-amino-9-[(2R,3R,4S,5S)-5-(cyclopropylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-9H-purin-2-yl}prop-2-yn-1-yl)piperidine-1-carboxylate",
        "background": "Evodenoson has been used in trials studying the treatment of Open-angle Glaucoma and Ocular Hypertension.\n",
        "inchi": {
            "hash": "SQJXTUJMBYVDBB-RQXXJAGISA-N",
            "id": "InChI=1S/C23H29N7O6/c1-35-23(34)29-9-7-12(8-10-29)3-2-4-14-27-19(24)15-20(28-14)30(11-25-15)22-17(32)16(31)18(36-22)21(33)26-13-5-6-13/h11-13,16-18,22,31-32H,3,5-10H2,1H3,(H,26,33)(H2,24,27,28)/t16-,17+,18-,22+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 499.528,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 499.217931682,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB12295",
        "type": "Small Molecule",
        "synonyms": [
            "Evodenoson"
        ],
        "is_stub": true
    },
    {
        "smiles": "O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O",
        "id": "DB04300",
        "molecule": "(1s,3r,4r,6s)-1,3,4,6-Tetrapkisphosphate",
        "iupac_name": "{[(1R,2s,3S,4S,5r,6R)-2,5-dihydroxy-3,4,6-tris(phosphonooxy)cyclohexyl]oxy}phosphonic acid",
        "inchi": {
            "hash": "ZAWIXNGTTZTBKV-JMVOWJSSSA-N",
            "id": "InChI=1S/C6H16O18P4/c7-1-3(21-25(9,10)11)5(23-27(15,16)17)2(8)6(24-28(18,19)20)4(1)22-26(12,13)14/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2+,3-,4+,5-,6+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 500.0755,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 499.928709756,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as inositol phosphates. These are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety.",
        "link": "https://go.drugbank.com/drugs/DB04300",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H]N(C1=CC=C(OC[C@H](O)CN(C)C)C=C1)C1=NC=C(Br)C(=N1)N([H])C1=CC=CC=C1",
        "id": "DB07504",
        "molecule": "(2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol",
        "iupac_name": "(2R)-1-(4-{[5-bromo-6-(phenylimino)-1,6-dihydropyrimidin-2-yl]amino}phenoxy)-3-(dimethylamino)propan-2-ol",
        "inchi": {
            "hash": "MEIJADBULOETOV-QGZVFWFLSA-N",
            "id": "InChI=1S/C21H24BrN5O2/c1-27(2)13-17(28)14-29-18-10-8-16(9-11-18)25-21-23-12-19(22)20(26-21)24-15-6-4-3-5-7-15/h3-12,17,28H,13-14H2,1-2H3,(H2,23,24,25,26)/t17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 458.352,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 457.111337684,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB07504",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "COC1=CC=CC(=C1)C1=CC=C(NC(=O)C2=C(SC=C2)C(O)=O)C(F)=C1",
        "id": "DB07976",
        "molecule": "3-{[(3-FLUORO-3'-METHOXYBIPHENYL-4-YL)AMINO]CARBONYL}THIOPHENE-2-CARBOXYLIC ACID",
        "iupac_name": "3-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}carbamoyl)thiophene-2-carboxylic acid",
        "inchi": {
            "hash": "GIUMGVUBDBDTDX-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H14FNO4S/c1-25-13-4-2-3-11(9-13)12-5-6-16(15(20)10-12)21-18(22)14-7-8-26-17(14)19(23)24/h2-10H,1H3,(H,21,22)(H,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 371.382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 371.062756836,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.",
        "link": "https://go.drugbank.com/drugs/DB07976",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydroorotate dehydrogenase (quinone), mitochondrial"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@@]11C[C@]([H])(C(C)(C)O)[C@]2(OC)C=C1",
        "id": "DB01480",
        "molecule": "Cyprenorphine",
        "cas": "4406-22-8",
        "iupac_name": "(1R,2R,6S,14R,15R,19R)-3-(cyclopropylmethyl)-19-(2-hydroxypropan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1,.0,.0,.0,]icosa-7,9,11,16-tetraen-11-ol",
        "inchi": {
            "hash": "VSKIOMHXEUHYSI-KNLIIKEYSA-N",
            "id": "InChI=1S/C26H33NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-9,15,18-19,22,28-29H,4-5,10-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 423.553,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 423.240958547,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.",
        "link": "https://go.drugbank.com/drugs/DB01480",
        "type": "Small Molecule",
        "synonyms": [
            "Cyprenorphine"
        ]
    },
    {
        "smiles": "O=C(NC1=CC=CC(=C1)C1=NCCN1)NC1=CC=CC(=C1)C1=NCCN1",
        "id": "DB11521",
        "molecule": "Imidocarb",
        "cas": "27885-92-3",
        "iupac_name": "1,3-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea",
        "background": "Imidocarb is a urea derivative used in veterinary medicine as an antiprotozoal agent for the treatment of infection with Babesia and other parasites.\n",
        "inchi": {
            "hash": "SCEVFJUWLLRELN-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H20N6O/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 348.41,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 348.169859288,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-phenylureas. These are compounds containing a N-phenylurea moiety, which is structurally characterized by a phenyl group linked to one nitrogen atom of a urea group.",
        "link": "https://go.drugbank.com/drugs/DB11521",
        "type": "Small Molecule",
        "synonyms": [
            "1,3-Bis(3-(2-imidazolin-2-yl)phenyl)harnstoff",
            "1,3-bis(3-(2-imidazolin-2-yl)phenyl)urea",
            "Imidocarb",
            "Imidocarbe",
            "Imidocarbo",
            "Imidocarbum",
            "N,N'-bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)urea"
        ],
        "is_stub": true
    },
    {
        "smiles": "BrC1=C2N=C(C=C(NCC3=CC=CN=C3)N2N=C1)C1=CC=CC=C1",
        "id": "DB08535",
        "molecule": "3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",
        "iupac_name": "3-bromo-5-phenyl-N-[(pyridin-3-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine",
        "inchi": {
            "hash": "SMIZFGZXFDGISG-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H14BrN5/c19-15-12-22-24-17(21-11-13-5-4-8-20-10-13)9-16(23-18(15)24)14-6-2-1-3-7-14/h1-10,12,21H,11H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 380.241,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 379.04325812,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB08535",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "CC1=CC(Br)=C([O-])C(=C1)C1=CC2=CC(=CC=C2N1)C(N)=[NH2+]",
        "id": "DB04215",
        "molecule": "CRA_9076",
        "iupac_name": "2-{5-[amino(iminiumyl)methyl]-1H-indol-2-yl}-6-bromo-4-methylbenzen-1-olate",
        "inchi": {
            "hash": "BVTBOJXEAPSOEB-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H14BrN3O/c1-8-4-11(15(21)12(17)5-8)14-7-10-6-9(16(18)19)2-3-13(10)20-14/h2-7,20-21H,1H3,(H3,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 344.206,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 343.032024732,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-phenylindoles. These are indoles substituted at the 2-position with a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB04215",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "CCCCC(O)CO",
        "id": "DB14108",
        "molecule": "1,2-Hexanediol",
        "cas": "6920-22-5",
        "iupac_name": "hexane-1,2-diol",
        "inchi": {
            "hash": "FHKSXSQHXQEMOK-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H14O2/c1-2-3-4-6(8)5-7/h6-8H,2-5H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 118.176,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 118.099379691,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fatty alcohols. These are aliphatic alcohols consisting of a chain of a least six carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB14108",
        "type": "Small Molecule",
        "synonyms": [
            "1,2-Dihydroxyhexane",
            "5,6-Dihydroxyhexane",
            "DL-1,2-Hexanediol",
            "DL-Hexane-1,2-diol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1",
        "id": "DB11073",
        "molecule": "Cetylpyridinium",
        "cas": "7773-52-6",
        "iupac_name": "1-hexadecylpyridin-1-ium",
        "background": "Cetylpyridinium is a quaternary ammonium with broad-spectrum antiseptic properties. Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays. In these products, it generally mediates an antiseptic activity and protective action against dental plaque and reducing gingivitis.\n",
        "inchi": {
            "hash": "NEUSVAOJNUQRTM-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H38N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22/h15,17-18,20-21H,2-14,16,19H2,1H3/q+1"
        },
        "summary": "Cetylpyridinium is a compound used to reduce plaque and gingivitis, as well as whiten teeth.",
        "weight": [
            {
                "type": "average",
                "weight": 304.541,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 304.299876648,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinium derivatives. These are compounds containing a pyridinium ring, which is the cationic form of pyridine.",
        "link": "https://go.drugbank.com/drugs/DB11073",
        "type": "Small Molecule",
        "synonyms": [
            "1-hexadecylpyridinium"
        ],
        "indication": "Typically employed as the cetylpyridinium chloride salt, this compound is commonly used as an active ingredient in various over-the-counter mouthwashes, toothpastes, lozenges, and mouth sprays where it is generally indicated for antiseptic actions, gingivitis and plaque prevention, as well as action or prevention against some other oropharyngeal bacterial infections 1,3,4.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cetylpyridinium chloride is considered a cationic disinfectant with properties and uses similar to other such cationic surfactants 5. In particular, cetylpyridinium chloride has demonstrated a rapid bactericidal and fungicide effect on gram-positive pathogens and yeasts, respectively 1. Cetylpyridinium chloride is subsequently utilized in a variety of preparations for the local treatment of minor infections 5. Despite the variety of formulations in which cetylpyridinium chloride may appear as an active ingredient, it is generally accepted that it only elicits a local effect 5 owing to the compound's relatively poor absorption by route of exposure 6.\n"
    },
    {
        "smiles": "NCCC(=O)N[C@@H](CC1=CN=CN1)C(O)=O",
        "id": "DB11695",
        "molecule": "Carnosine",
        "cas": "305-84-0",
        "iupac_name": "(2S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl)propanoic acid",
        "background": "Carnosine has been investigated for the treatment of Gulf War Illness.\n",
        "inchi": {
            "hash": "CQOVPNPJLQNMDC-ZETCQYMHSA-N",
            "id": "InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/t7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 226.2325,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 226.106590334,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB11695",
        "type": "Small Molecule",
        "synonyms": [
            "L-Carnosine"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC1=C(\\C=C2/SC(=S)N(CC3=CC=CC=C3)C2=O)C=CC=C1[N+]([O-])=O",
        "id": "DB07838",
        "molecule": "(Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE",
        "iupac_name": "(5Z)-3-benzyl-5-[(2-hydroxy-3-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one",
        "inchi": {
            "hash": "ZTWBCEZQPRYIGY-ZROIWOOFSA-N",
            "id": "InChI=1S/C17H12N2O4S2/c20-15-12(7-4-8-13(15)19(22)23)9-14-16(21)18(17(24)25-14)10-11-5-2-1-3-6-11/h1-9,20H,10H2/b14-9-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 372.418,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 372.023848262,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitrophenols. These are compounds containing a nitrophenol moiety, which consists of a benzene ring bearing both a hydroxyl group and a nitro group on two different ring carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB07838",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycylpeptide N-tetradecanoyltransferase 2"
            }
        ]
    },
    {
        "smiles": "CC[C@H](C)[C@@H]1NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)CCSCC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC1=O)[C@H](C)CC)C(=O)N(C)[C@H](CO)CCCN",
        "id": "DB12292",
        "molecule": "Barusiban",
        "cas": "285571-64-4",
        "iupac_name": "(4S,7S,10S,13S,16R)-N-[(2S)-5-amino-1-hydroxypentan-2-yl]-10-[(2R)-butan-2-yl]-13-[(2S)-butan-2-yl]-7-(carbamoylmethyl)-16-[(1H-indol-3-yl)methyl]-N-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide",
        "background": "Barusiban has been used in trials studying the treatment of Infertility and In Vitro Fertilisation (IVF) Treatment.\n",
        "inchi": {
            "hash": "UGNGRKKDUVKQDF-IHOMMZCZSA-N",
            "id": "InChI=1S/C40H63N9O8S/c1-6-23(3)34-38(55)46-31(20-32(42)51)36(53)45-29(40(57)49(5)26(22-50)11-10-16-41)14-17-58-18-15-33(52)44-30(19-25-21-43-28-13-9-8-12-27(25)28)37(54)47-35(24(4)7-2)39(56)48-34/h8-9,12-13,21,23-24,26,29-31,34-35,43,50H,6-7,10-11,14-20,22,41H2,1-5H3,(H2,42,51)(H,44,52)(H,45,53)(H,46,55)(H,47,54)(H,48,56)/t23-,24+,26+,29+,30-,31+,34+,35+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 830.06,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 829.452031199,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB12292",
        "type": "Small Molecule",
        "synonyms": [
            "Barusiban"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]N1C(=O)\\C(C2=C1C=CC(Br)=C2)=C1/N([H])C2=CC=CC=C2C1=O",
        "id": "DB07493",
        "molecule": "5-Bromoindirubin",
        "cas": "60874-72-8",
        "iupac_name": "(Z)-5'-bromo-1',2'-dihydro-1H,3H-[2,3'-biindolylidene]-2',3-dione",
        "inchi": {
            "hash": "IEQQJQHHJMQETK-YPKPFQOOSA-N",
            "id": "InChI=1S/C16H9BrN2O2/c17-8-5-6-12-10(7-8)13(16(21)19-12)14-15(20)9-3-1-2-4-11(9)18-14/h1-7,18H,(H,19,21)/b14-13-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 341.159,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 339.984740189,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.",
        "link": "https://go.drugbank.com/drugs/DB07493",
        "type": "Small Molecule",
        "synonyms": [
            "(2Z)-5'-bromo-2,3'-biindole-2',3(1H,1'H)-dione ammoniate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "CC(=O)NC1=C(N)C=C(C=C1)C(O)=O",
        "id": "DB02268",
        "molecule": "4-(Acetylamino)-3-Amino Benzoic Acid",
        "iupac_name": "3-amino-4-acetamidobenzoic acid",
        "inchi": {
            "hash": "MJMLUICFHWSBQZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H10N2O3/c1-5(12)11-8-3-2-6(9(13)14)4-7(8)10/h2-4H,10H2,1H3,(H,11,12)(H,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 194.1873,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 194.069142196,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.",
        "link": "https://go.drugbank.com/drugs/DB02268",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Influenza A virus (strain A/Tokyo/3/1967 H2N2)",
                "target": "UNeuraminidase"
            }
        ]
    },
    {
        "smiles": "CC(C)(C)NC1=NC(N)=C(S1)C(=O)C1=CC=CC=C1",
        "id": "DB08778",
        "molecule": "[4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone",
        "iupac_name": "5-benzoyl-N2-tert-butyl-1,3-thiazole-2,4-diamine",
        "inchi": {
            "hash": "KEHNGAHNKVLUSC-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H17N3OS/c1-14(2,3)17-13-16-12(15)11(19-13)10(18)9-7-5-4-6-8-9/h4-8H,15H2,1-3H3,(H,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 275.369,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 275.109232871,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB08778",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein kinase Chk1"
            }
        ]
    },
    {
        "smiles": "CC1=CC(CC2=NN(C3=C2C(N)=NC=N3)C(C)(C)C)=CC=C1",
        "id": "DB08699",
        "molecule": "1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",
        "iupac_name": "1-tert-butyl-3-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine",
        "inchi": {
            "hash": "FYCOTGCSHZKHPR-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H21N5/c1-11-6-5-7-12(8-11)9-13-14-15(18)19-10-20-16(14)22(21-13)17(2,3)4/h5-8,10H,9H2,1-4H3,(H2,18,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 295.3821,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 295.179695697,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrazolo[3,4-d]pyrimidines. These are aromatic heterocyclic compounds containing a pyrazolo[3,4-d]pyrimidine ring system, which consists of a pyrazole ring fused to but and not sharing a nitrogen atom with a pyrimidine ring.",
        "link": "https://go.drugbank.com/drugs/DB08699",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCalcium/calmodulin-dependent protein kinase type II subunit gamma"
            }
        ]
    },
    {
        "smiles": "CN1N=CC(Cl)=C1C1=C(Cl)SC(=C1)C(=O)N[C@H](CN)CC1=CC=CC(F)=C1",
        "id": "DB11648",
        "molecule": "Afuresertib",
        "cas": "1047644-62-1",
        "iupac_name": "N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide",
        "background": "Afuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.\n",
        "inchi": {
            "hash": "AFJRDFWMXUECEW-LBPRGKRZSA-N",
            "id": "InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 427.32,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 426.0484159,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.",
        "link": "https://go.drugbank.com/drugs/DB11648",
        "type": "Small Molecule",
        "synonyms": [
            "Afuresertib"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=C(F)C(=O)NC1=O",
        "id": "DB01629",
        "molecule": "5-fluorouridine",
        "cas": "316-46-1",
        "iupac_name": "1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione",
        "background": "5-fluorouridine is also known as FUrd, 5-Fluorouracil 1-beta-D-ribofuranoside, 5-Fur, or 5-Fluoro-uridine. 5-fluorouridine is a solid. This compound belongs to the pyrimidine nucleosides and analogues. These are compounds comprising a pyrimidine base attached to a sugar. 5-fluorouridine is known to target uridine phosphorylase. FUrd is often used in chemical and biochemical comparison studies with fluorouracil and thymine analogs.\n",
        "inchi": {
            "hash": "FHIDNBAQOFJWCA-UAKXSSHOSA-N",
            "id": "InChI=1S/C9H11FN2O6/c10-3-1-12(9(17)11-7(3)16)8-6(15)5(14)4(2-13)18-8/h1,4-6,8,13-15H,2H2,(H,11,16,17)/t4-,5-,6-,8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 262.1918,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 262.060114299,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine nucleosides. These are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB01629",
        "type": "Small Molecule",
        "synonyms": [
            "5-Fluoro-uridine",
            "5-Fluorouracil 1beta-D-ribofuranoside",
            "5-Fur"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USuperoxide dismutase [Cu-Zn]"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UUridine phosphorylase"
            }
        ]
    },
    {
        "smiles": "C[C@H](NC(=O)C(=O)NC1=C(C=CC=C1)C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F",
        "id": "DB05408",
        "molecule": "Emricasan",
        "cas": "254750-02-2",
        "iupac_name": "(3S)-3-[(2S)-2-{[(2-tert-butylphenyl)carbamoyl]formamido}propanamido]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid",
        "background": "Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.\n",
        "inchi": {
            "hash": "SCVHJVCATBPIHN-SJCJKPOMSA-N",
            "id": "InChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 569.51,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 569.178512873,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB05408",
        "type": "Small Molecule",
        "synonyms": [
            "Emricasan",
            "Emricasn",
            "Emricasanum"
        ],
        "indication": "Investigated for use/treatment in hepatitis (viral, C), liver disease, and transplantation (organ or tissue).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCaspase-1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCaspase-3"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCaspase-7"
            }
        ]
    },
    {
        "smiles": "OC1=CC=C(C=C1)[C@@H]1CC(=O)C2=CC=C(O)C=C2O1",
        "id": "DB03601",
        "molecule": "5-deoxyflavanone",
        "cas": "578-86-9",
        "iupac_name": "(2S)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one",
        "background": "5-deoxyflavanone is a solid. This compound belongs to the flavanones. These are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.\n",
        "inchi": {
            "hash": "FURUXTVZLHCCNA-AWEZNQCLSA-N",
            "id": "InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2/t14-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 256.2534,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 256.073558872,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as flavanones. These are compounds containing a flavan-3-one moiety, with a structure characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.",
        "link": "https://go.drugbank.com/drugs/DB03601",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H][C@]12CC[C@](C)(CC1)C2(C)C",
        "id": "DB04501",
        "molecule": "Camphane",
        "cas": "464-15-3",
        "iupac_name": "(1s,4s)-1,7,7-trimethylbicyclo[2.2.1]heptane",
        "inchi": {
            "hash": "BEWYHVAWEKZDPP-WAAGHKOSSA-N",
            "id": "InChI=1S/C10H18/c1-9(2)8-4-6-10(9,3)7-5-8/h8H,4-7H2,1-3H3/t8-,10+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 138.2499,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 138.140850576,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.",
        "link": "https://go.drugbank.com/drugs/DB04501",
        "type": "Small Molecule",
        "synonyms": [
            "(1s,4s)-1,7,7-trimethylbicyclo[2.2.1]heptane",
            "1,4-bornane",
            "Bornane",
            "Bornylane"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "UCamphor 5-monooxygenase"
            }
        ]
    },
    {
        "smiles": "C[C@@H](NCC(C)(C)CN[C@H](C)C(\\C)=N\\O)C(\\C)=N\\O",
        "id": "DB11179",
        "molecule": "Exametazime",
        "cas": "105613-48-7",
        "iupac_name": "(E)-N-[(3R)-3-[(3-{[(2R,3E)-3-(hydroxyimino)butan-2-yl]amino}-2,2-dimethylpropyl)amino]butan-2-ylidene]hydroxylamine",
        "background": "Exametazime is a diagnostic radiopharmaceutical agent commonly used for the preparation of Tc99m Exametazime injection. It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex. It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes.\n",
        "inchi": {
            "hash": "BPNZYADGDZPRTK-UDUYQYQQSA-N",
            "id": "InChI=1S/C13H28N4O2/c1-9(11(3)16-18)14-7-13(5,6)8-15-10(2)12(4)17-19/h9-10,14-15,18-19H,7-8H2,1-6H3/b16-11+,17-12+/t9-,10-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 272.393,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 272.221226158,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11179",
        "type": "Small Molecule",
        "synonyms": [
            "Exametazima",
            "Exametazime"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(CO)C[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)O1",
        "id": "DB02065",
        "molecule": "4-Deoxylactose",
        "iupac_name": "(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,6S)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol",
        "inchi": {
            "hash": "DSYGIMVFFQCOQZ-KYYLAPRMSA-N",
            "id": "InChI=1S/C12H22O10/c13-2-4-1-5(15)7(16)12(20-4)22-10-6(3-14)21-11(19)9(18)8(10)17/h4-19H,1-3H2/t4-,5-,6+,7+,8+,9+,10+,11+,12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 326.2971,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 326.121296924,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monosaccharides. These are compounds containing one carbohydrate unit not glycosidically linked to another such unit, and no set of two or more glycosidically linked carbohydrate units. Monosaccharides have the general formula CnH2nOn.",
        "link": "https://go.drugbank.com/drugs/DB02065",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Neisseria meningitidis",
                "target": "UGlycosyl transferase"
            }
        ]
    },
    {
        "smiles": "CCCC1=NN(C)C2=C1N=C(NC2=O)C1=C(OCC)SC(=C1)S(N)(=O)=O",
        "id": "DB08729",
        "molecule": "5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)thiophene-2-sulfonamide",
        "iupac_name": "5-ethoxy-4-{1-methyl-7-oxo-3-propyl-1H,6H,7H-pyrazolo[4,3-d]pyrimidin-5-yl}thiophene-2-sulfonamide",
        "inchi": {
            "hash": "FENWRHVHBZQJGW-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H19N5O4S2/c1-4-6-9-11-12(20(3)19-9)14(21)18-13(17-11)8-7-10(26(16,22)23)25-15(8)24-5-2/h7H,4-6H2,1-3H3,(H2,16,22,23)(H,17,18,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 397.472,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 397.087845501,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrazolopyrimidines. These are compounds containing a pyrazolopyrimidine skeleton, which consists of a pyrazole fused to a pyrimidine. Pyrazole is 5-membered ring consisting of three carbon atoms and two adjacent nitrogen centers. Pyrimidine is 6-membered ring consisting of four carbon atoms and two adjacent nitrogen atoms at the 1- and 3- ring position.",
        "link": "https://go.drugbank.com/drugs/DB08729",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcGMP-specific 3',5'-cyclic phosphodiesterase"
            }
        ]
    },
    {
        "smiles": "CCN(CCCOC1=CC=C2C(NC3=CC(CC(=O)NC4=CC=CC(F)=C4)=NN3)=NC=NC2=C1)CCOP(O)(O)=O",
        "id": "DB11747",
        "molecule": "Barasertib",
        "cas": "722543-31-9",
        "iupac_name": "(2-{ethyl[3-({4-[(3-{[(3-fluorophenyl)carbamoyl]methyl}-1H-pyrazol-5-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethoxy)phosphonic acid",
        "background": "Barasertib has been used in trials studying the treatment of Tumors, Lymphoma, Solid Tumors, Solid Tumours, and Myeloid Leukemia, among others.\n",
        "inchi": {
            "hash": "GBJVVSCPOBPEIT-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H31FN7O6P/c1-2-34(10-12-40-41(36,37)38)9-4-11-39-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(35)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17H,2,4,9-12,15H2,1H3,(H,30,35)(H2,36,37,38)(H2,28,29,31,32,33)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 587.549,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 587.205746907,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB11747",
        "type": "Small Molecule",
        "synonyms": [
            "Barasertib"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]N([H])[C@@H](CS)C(=O)N([H])S(=O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N=CN=C12)N([H])[H]",
        "id": "DB02684",
        "molecule": "5'-O-(L-Cysteinylsulfamoyl)adenosine",
        "iupac_name": "(2R)-2-amino-1-[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}sulfonyl)amino]-3-sulfanylpropan-1-one",
        "inchi": {
            "hash": "FTSDEWPMACCNGN-YTMOPEAISA-N",
            "id": "InChI=1S/C13H19N7O7S2/c14-5(2-28)12(23)19-29(24,25)26-1-6-8(21)9(22)13(27-6)20-4-18-7-10(15)16-3-17-11(7)20/h3-6,8-9,13,21-22,28H,1-2,14H2,(H,19,23)(H2,15,16,17)/t5-,6+,8+,9+,13+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 449.463,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 449.078737377,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB02684",
        "type": "Small Molecule",
        "synonyms": [
            "5'-O-(N-(L-Cysteinyl)-sulfamoyl)adenosine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UBifunctional glutamate/proline--tRNA ligase"
            }
        ]
    },
    {
        "smiles": "ONC(=O)CCOC1=CC=C(C=C1)C1=CC=C(C=C1)C#N",
        "id": "DB08030",
        "molecule": "3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide",
        "iupac_name": "3-({4'-cyano-[1,1'-biphenyl]-4-yl}oxy)-N-hydroxypropanamide",
        "inchi": {
            "hash": "XZWFHJUEAVOHHG-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H14N2O3/c17-11-12-1-3-13(4-2-12)14-5-7-15(8-6-14)21-10-9-16(19)18-20/h1-8,20H,9-10H2,(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 282.294,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 282.100442324,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenylcarbonitriles. These are organic compounds containing an acetonitrile with one hydrogen replaced by a biphenyl group.",
        "link": "https://go.drugbank.com/drugs/DB08030",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UStromelysin-1"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)C[C@]([H])(CC[C@]1([H])C1=CC=C(C=C1)C(=O)NCCCC(O)=O)C1=CC=CC=C1",
        "id": "DB07909",
        "molecule": "(1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL",
        "iupac_name": "4-({4-[(1R,2S,4S)-2-hydroxy-4-phenylcyclohexyl]phenyl}formamido)butanoic acid",
        "inchi": {
            "hash": "OBWILOKKNDYPLX-HBMCJLEFSA-N",
            "id": "InChI=1S/C23H27NO4/c25-21-15-19(16-5-2-1-3-6-16)12-13-20(21)17-8-10-18(11-9-17)23(28)24-14-4-7-22(26)27/h1-3,5-6,8-11,19-21,25H,4,7,12-15H2,(H,24,28)(H,26,27)/t19-,20+,21-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 381.4648,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 381.194008357,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB07909",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UUncharacterized protein"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIg gamma-1 chain C region"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIg kappa chain C region"
            }
        ]
    },
    {
        "smiles": "C[C@H]1C[C@@]2(OC(C)=O)[C@H]([C@H]1OC(=O)C1=CC=CC=C1)[C@@H](OC(C)=O)C(=C)CC[C@H]1[C@@H](\\C=C(C)\\C2=O)C1(C)C",
        "id": "DB11260",
        "molecule": "Diacetyl benzoyl lathyrol",
        "cas": "218916-52-0",
        "iupac_name": "(1R,3E,5R,7S,11R,12R,13S,14S)-1,11-bis(acetyloxy)-3,6,6,14-tetramethyl-10-methylidene-2-oxotricyclo[10.3.0.0^{5,7}]pentadec-3-en-13-yl benzoate",
        "background": "Diacetyl benzoyl lathyrol is an active ingredient in whitening creams. It is also reported to be a skin conditioning agent.\n",
        "inchi": {
            "hash": "JPYYWXPAHJBKJX-VWSFRBHVSA-N",
            "id": "InChI=1S/C31H38O7/c1-17-13-14-23-24(30(23,6)7)15-18(2)28(34)31(38-21(5)33)16-19(3)27(25(31)26(17)36-20(4)32)37-29(35)22-11-9-8-10-12-22/h8-12,15,19,23-27H,1,13-14,16H2,2-7H3/b18-15+/t19-,23-,24+,25-,26-,27-,31+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 522.638,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 522.261753564,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diterpenoids. These are terpene compounds formed by four isoprene units.",
        "link": "https://go.drugbank.com/drugs/DB11260",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC(C)(C)N1[NH+]=C(C2=C1N=CN=C2N)C1=CC=C(Cl)C=C1",
        "id": "DB03023",
        "molecule": "1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",
        "iupac_name": "4-amino-1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-2-ium",
        "inchi": {
            "hash": "PBBRWFOVCUAONR-UHFFFAOYSA-O",
            "id": "InChI=1S/C15H16ClN5/c1-15(2,3)21-14-11(13(17)18-8-19-14)12(20-21)9-4-6-10(16)7-5-9/h4-8H,1-3H3,(H2,17,18,19)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 302.782,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 302.117248276,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB03023",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein kinase Lyn"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProto-oncogene tyrosine-protein kinase Src"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein kinase Lck"
            }
        ]
    },
    {
        "smiles": "[H][C@]12CCCN[C@]11CC(C)=C[C@H]2CC2=C1C=CC(=O)N2",
        "id": "DB03348",
        "molecule": "Huperzine B",
        "cas": "103548-82-9",
        "iupac_name": "(1R,9R,10R)-16-methyl-6,14-diazatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,16-trien-5-one",
        "background": "Huperzine B is a novel acetylcholinesterase inhibitor.\n",
        "inchi": {
            "hash": "YYWGABLTRMRUIT-HWWQOWPSSA-N",
            "id": "InChI=1S/C16H20N2O/c1-10-7-11-8-14-13(4-5-15(19)18-14)16(9-10)12(11)3-2-6-17-16/h4-5,7,11-12,17H,2-3,6,8-9H2,1H3,(H,18,19)/t11-,12+,16+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 256.3428,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 256.157563272,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenanthrolines. These are aromatic polycyclic compounds containing the phenanthroline skeleton, which is a derivative of phenanthrene, and consists of two pyridine rings non-linearly joined by a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB03348",
        "type": "Small Molecule",
        "synonyms": [
            "HupB"
        ],
        "indication": "Under investigation for the treatment of Alzheimer's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Huperzine B is an alkaloid derived from Huperzia serrata (which is available as an herbal product in the US). It is under investigation as an acetylcholinesterase inhibitor. Clinical trials in China have shown that huperzine B is comparably effective to the drugs currently on the market, and may even be somewhat safer in terms of side effects.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAcetylcholinesterase"
            }
        ]
    },
    {
        "id": "DB00375",
        "molecule": "Colestipol",
        "cas": "26658-42-4",
        "background": "Bile acid sequestrants like colestipol have been in use since the 1970s.Label,5,7,3 And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness.Label,5,7,3\nIn particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut.Label,5,7,3\nAlternatively, colestipol predominantly elicits its activities within the gut environment because it undergoes little absorption and metabolism.Label,5,7,3 The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.Label,5,7,3\n",
        "inchi": {},
        "summary": "Colestipol is a bile acid sequestrant used as an adjunct to diet and exercise to reduce LDL-C cholesterol levels in patients with primary hypercholesterolemia.",
        "link": "https://go.drugbank.com/drugs/DB00375",
        "type": "Small Molecule",
        "synonyms": [
            "Colestipol",
            "Colestipolum",
            "Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane",
            "Epichlorohydrin-tetraethylenepentamine polymer"
        ],
        "indication": "Colestipol is indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia (a condition that features elevated LDL-C) who do not respond adequately to dietary changes .Label,1,5\nTherapy with lipid-altering agents like colestipol should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia Label,1,5. Treatment should begin and continue with dietary therapy Label,1,5. In general, a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy such as that with colestipol Label,5. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite coronary heart disease Label,5.\nAlthough colestipol is effective in all types of hypercholesterolemia, some regional prescribing information note in particular that it is medically most appropriate in patients with Fredrickson's type II hyperlipoproteinemia 1. Nevertheless, in patients with combined hypercholesterolemia and hypertriglyceridemia, although colestipol may be helpful in reducing elevated cholesterol, it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern 7.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cholesterol is the major, and probably the sole precursor of bile acids Label,5. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines Label,5. Bile acids emulsify the fat and lipid materials present in food, thus facilitating absorption Label,5. A major portion of the bile acids secreted is reabsorbed from the intestines and returned via the portal circulation to the liver, thus completing the enterohepatic cycle Label,5. Only very small amounts of bile acids are found in normal serum Label,5.\nColestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces Label,5. This nonsystemic action results in a partial removal of the bile acids from the enterohepatic circulation, preventing their reabsorption Label,5. Since colestipol hydrochloride is an anion exchange resin, the chloride anions of the resin can be replaced by other anions, usually those with a greater affinity for the resin than the chloride ion Label,5.\n",
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "ABile acids"
            }
        ]
    },
    {
        "smiles": "O=N(=O)C1=CC=CC2=CNN=C12",
        "id": "DB02207",
        "molecule": "7-Nitroindazole",
        "cas": "2942-42-9",
        "iupac_name": "7-nitro-2H-indazole",
        "inchi": {
            "hash": "PQCAUHUKTBHUSA-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 163.1335,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 163.038176419,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.",
        "link": "https://go.drugbank.com/drugs/DB02207",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, endothelial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, inducible"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UNitric oxide synthase, brain"
            }
        ]
    },
    {
        "smiles": "OC(=O)C(=O)\\C=C\\C1=CC=CC=C1O",
        "id": "DB08636",
        "molecule": "2-Hydroxybenzalpyruvate",
        "cas": "90293-62-2",
        "iupac_name": "(3E)-4-(2-hydroxyphenyl)-2-oxobut-3-enoic acid",
        "inchi": {
            "hash": "HMXOGGUFCBUALL-AATRIKPKSA-N",
            "id": "InChI=1S/C10H8O4/c11-8-4-2-1-3-7(8)5-6-9(12)10(13)14/h1-6,11H,(H,13,14)/b6-5+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 192.1681,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 192.042258744,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxycinnamic acids and derivatives. These are compounds containing an cinnamic acid (or a derivative thereof) where the benzene ring is hydroxylated.",
        "link": "https://go.drugbank.com/drugs/DB08636",
        "type": "Small Molecule",
        "synonyms": [
            "(3E)-4-(2-Hydroxyphenyl)-2-oxobut-3-enoate",
            "(3E)-4-(2-hydroxyphenyl)-2-oxobut-3-enoic acid",
            "4-(2-Hydroxyphenyl)-2-oxo-3-butenoic acid",
            "ortho-Hydroxybenzalpyruvate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "U2-hydroxychromene-2-carboxylate isomerase"
            }
        ]
    },
    {
        "smiles": "OC(=O)[C@@]1(O)OC2=CC=CC=C2C=C1",
        "id": "DB06952",
        "molecule": "(2S)-2-HYDROXY-2H-CHROMENE-2-CARBOXYLIC ACID",
        "iupac_name": "(2S)-2-hydroxy-2H-chromene-2-carboxylic acid",
        "inchi": {
            "hash": "LGYIZQLNYONEFJ-JTQLQIEISA-N",
            "id": "InChI=1S/C10H8O4/c11-9(12)10(13)6-5-7-3-1-2-4-8(7)14-10/h1-6,13H,(H,11,12)/t10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 192.1681,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 192.042258744,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-benzopyrans. These are organic aromatic compounds that 1-benzopyran, a bicyclic compound made up of a benzene ring fused to a pyran, so that the oxygen atom is at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB06952",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "U2-hydroxychromene-2-carboxylate isomerase"
            }
        ]
    },
    {
        "smiles": "O=N(=O)C1=CC=CC(=C1)\\N=C1\\N=CCC(=N1)C1=CC=CC(CN2C=NC=N2)=C1",
        "id": "DB08218",
        "molecule": "HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM",
        "iupac_name": "(2Z)-N-(3-nitrophenyl)-4-{3-[(1H-1,2,4-triazol-1-yl)methyl]phenyl}-2,5-dihydropyrimidin-2-imine",
        "inchi": {
            "hash": "PLQVWKCQWFFUFJ-NMWGTECJSA-N",
            "id": "InChI=1S/C19H15N7O2/c27-26(28)17-6-2-5-16(10-17)23-19-21-8-7-18(24-19)15-4-1-3-14(9-15)11-25-13-20-12-22-25/h1-6,8-10,12-13H,7,11H2/b23-19-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 373.3681,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 373.128722759,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB08218",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-A2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "CCOC1=NC(=CC=C1C#N)C(=O)NCC1=CC(OC)=CC=C1OC",
        "id": "DB07276",
        "molecule": "5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE",
        "iupac_name": "5-cyano-N-[(2,5-dimethoxyphenyl)methyl]-6-ethoxypyridine-2-carboxamide",
        "inchi": {
            "hash": "VEGKZYFYGCWXMN-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H19N3O4/c1-4-25-18-12(10-19)5-7-15(21-18)17(22)20-11-13-9-14(23-2)6-8-16(13)24-3/h5-9H,4,11H2,1-3H3,(H,20,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 341.3612,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 341.137556111,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.",
        "link": "https://go.drugbank.com/drugs/DB07276",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UC-Jun-amino-terminal kinase-interacting protein 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 8"
            }
        ]
    },
    {
        "smiles": "NC1=NC2=CC=CC(OCC3CCN(CC4=CC=CC=C4F)CC3)=C2C(N)=N1",
        "id": "DB07642",
        "molecule": "5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine",
        "iupac_name": "5-({1-[(2-fluorophenyl)methyl]piperidin-4-yl}methoxy)quinazoline-2,4-diamine",
        "inchi": {
            "hash": "GYKIQIOWVKCVBP-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H24FN5O/c22-16-5-2-1-4-15(16)12-27-10-8-14(9-11-27)13-28-18-7-3-6-17-19(18)20(23)26-21(24)25-17/h1-7,14H,8-13H2,(H4,23,24,25,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 381.4466,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 381.19648862,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.",
        "link": "https://go.drugbank.com/drugs/DB07642",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "Um7GpppX diphosphatase"
            }
        ]
    },
    {
        "smiles": "[H]N([H])C1=NC(=CS1)C(=N\\OC)\\C(=O)N([H])[C@H](C=O)[C@@]1([H])SC(C)(C)[C@@H](N1[H])C(O)=O",
        "id": "DB03437",
        "molecule": "(2R,4S)-2-[(1R)-1-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-oxoethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid",
        "iupac_name": "(2R,4S)-2-[(1R)-1-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-oxoethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid",
        "inchi": {
            "hash": "YVNKGXXVZIQNIV-RKMXGKDGSA-N",
            "id": "InChI=1S/C14H19N5O5S2/c1-14(2)9(12(22)23)18-11(26-14)6(4-20)16-10(21)8(19-24-3)7-5-25-13(15)17-7/h4-6,9,11,18H,1-3H3,(H2,15,17)(H,16,21)(H,22,23)/b19-8-/t6-,9+,11-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 401.461,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 401.082760123,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as d-alpha-amino acids. These are alpha amino acids which have the D-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB03437",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "COC1=CC(OCC2=CC=NC=C2)=C(C)C=C1",
        "id": "DB07428",
        "molecule": "4-[(5-methoxy-2-methylphenoxy)methyl]pyridine",
        "iupac_name": "4-[(5-methoxy-2-methylphenoxy)methyl]pyridine",
        "inchi": {
            "hash": "MBHBRRBLXCXQKV-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H15NO2/c1-11-3-4-13(16-2)9-14(11)17-10-12-5-7-15-8-6-12/h3-9H,10H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 229.2744,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 229.110278729,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB07428",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHemoglobin subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHemoglobin subunit beta"
            }
        ]
    },
    {
        "smiles": "CC1=C(Cl)C(NCCC2=CC=CC=C2)=NC(=N1)C1=NC=CC=C1",
        "id": "DB07901",
        "molecule": "5-CHLORO-6-METHYL-N-(2-PHENYLETHYL)-2-PYRIDIN-2-YLPYRIMIDIN-4-AMINE",
        "iupac_name": "5-chloro-6-methyl-N-(2-phenylethyl)-2-(pyridin-2-yl)pyrimidin-4-amine",
        "inchi": {
            "hash": "HIUOABSWQSUEGK-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H17ClN4/c1-13-16(19)18(21-12-10-14-7-3-2-4-8-14)23-17(22-13)15-9-5-6-11-20-15/h2-9,11H,10,12H2,1H3,(H,21,22,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 324.807,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 324.114174271,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.",
        "link": "https://go.drugbank.com/drugs/DB07901",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMethionine aminopeptidase 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
        "id": "DB01434",
        "molecule": "19-norandrostenedione",
        "cas": "734-32-7",
        "iupac_name": "(3aS,3bR,9aR,9bS,11aS)-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione",
        "background": "19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. \nIn the body 19-norandrostenedione is rapidly metabolized into nandrolone, also known as nortestosterone.\n",
        "inchi": {
            "hash": "JRIZOGLBRPZBLQ-QXUSFIETSA-N",
            "id": "InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 272.382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 272.177630012,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.",
        "link": "https://go.drugbank.com/drugs/DB01434",
        "type": "Small Molecule",
        "synonyms": [
            "delta,4-Estrene-3,17-dione",
            "delta4-Estrene-3,17-dione"
        ],
        "indication": "The claim that supplemental 19-norandrostenedione has anabolic effects is unsubstantiated.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO)N1C=C(C2=CC=C(Br)S2)C(=O)NC1=O",
        "id": "DB03804",
        "molecule": "5-Bromothienyldeoxyuridine",
        "iupac_name": "5-(5-bromothiophen-2-yl)-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione",
        "inchi": {
            "hash": "IGUZFFOBAZCVRK-VAOFZXAKSA-N",
            "id": "InChI=1S/C13H13BrN2O5S/c14-10-2-1-9(22-10)6-4-16(13(20)15-12(6)19)11-3-7(18)8(5-17)21-11/h1-2,4,7-8,11,17-18H,3,5H2,(H,15,19,20)/t7-,8+,11+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 389.222,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 387.972854873,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB03804",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "ligand",
                "organism": "HHV-1",
                "target": "UThymidine kinase"
            }
        ]
    },
    {
        "smiles": "[Ga+3].CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1",
        "id": "DB05420",
        "molecule": "Gallium maltolate",
        "cas": "108560-70-9",
        "iupac_name": "gallium(3+) ion tris(2-methyl-4-oxo-4H-pyran-3-olate)",
        "background": "Gallium maltolate is Titans novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.\n",
        "inchi": {
            "hash": "ASYYOZSDALANRF-UHFFFAOYSA-K",
            "id": "InChI=1S/3C6H6O3.Ga/c3*1-4-6(8)5(7)2-3-9-4;/h3*2-3,8H,1H3;/q;;;+3/p-3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 445.032,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 443.997181,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyranones and derivatives. These are compounds containing a pyran ring which bears a ketone.",
        "link": "https://go.drugbank.com/drugs/DB05420",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in bladder cancer, lymphoma (unspecified), multiple myeloma, paget's disease, and prostate cancer.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URibonucleoside-diphosphate reductase large subunit"
            }
        ]
    },
    {
        "smiles": "CCC1(C)CC(=O)NC(=O)C1",
        "id": "DB13740",
        "molecule": "Bemegride",
        "cas": "64-65-3",
        "iupac_name": "4-ethyl-4-methylpiperidine-2,6-dione",
        "background": "Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.\n",
        "inchi": {
            "hash": "ORRZGUBHBVWWOP-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H13NO2/c1-3-8(2)4-6(10)9-7(11)5-8/h3-5H2,1-2H3,(H,9,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 155.197,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 155.094628663,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as piperidinediones. These are compounds containing a piperidine ring which bears two ketones.",
        "link": "https://go.drugbank.com/drugs/DB13740",
        "type": "Small Molecule",
        "synonyms": [
            "Bemegrida",
            "Bemegride",
            "Bemegridum"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=NC2=C(N(CO)[C@@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=N2)C(=O)N1",
        "id": "DB02800",
        "molecule": "5-hydroxymethyl-5,6-dihydrofolic acid",
        "iupac_name": "(2S)-2-{[4-({[(6S)-2-amino-5-(hydroxymethyl)-4-oxo-3,4,5,6-tetrahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid",
        "inchi": {
            "hash": "IIEPLRAFVCMHQF-STQMWFEESA-N",
            "id": "InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,8,12-13,22,28H,5-7,9H2,(H,24,31)(H,29,30)(H,33,34)(H3,21,25,26,32)/t12-,13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 473.4393,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 473.165896125,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB02800",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine hydroxymethyltransferase, cytosolic"
            },
            {
                "action": "Not Available",
                "organism": "Mycoplasma pneumoniae (strain ATCC 29342 / M129)",
                "target": "UProbable 5-formyltetrahydrofolate cyclo-ligase"
            }
        ]
    },
    {
        "smiles": "[H][C@@](COC(=O)CCCCCCCCCCCCCCCCC)(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC",
        "id": "DB04178",
        "molecule": "Di-Stearoyl-3-Sn-Phosphatidylcholine",
        "iupac_name": "[(2R)-2,3-bis(octadecanoyloxy)propoxy][2-(trimethylazaniumyl)ethoxy]phosphinic acid",
        "inchi": {
            "hash": "NRJAVPSFFCBXDT-HUESYALOSA-O",
            "id": "InChI=1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3/p+1/t42-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 791.1531,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 790.632580341,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phosphatidylcholines. These are glycerophosphocholines in which the two free -OH are attached to one fatty acid each through an ester linkage.",
        "link": "https://go.drugbank.com/drugs/DB04178",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UBactericidal permeability-increasing protein"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UADP/ATP translocase 1"
            }
        ]
    },
    {
        "smiles": "CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1",
        "id": "DB05786",
        "molecule": "Irofulven",
        "cas": "158440-71-2",
        "iupac_name": "(6'R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-6',7'-dihydrospiro[cyclopropane-1,5'-inden]-7'-one",
        "background": "A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted fast track status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers. \nMGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.\n",
        "inchi": {
            "hash": "NICJCIQSJJKZAH-AWEZNQCLSA-N",
            "id": "InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 246.3016,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 246.125594442,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cyclohexenones. These are compounds containing a cylohexenone moiety, which is a six-membered aliphatic ring that carries a ketone and has one endocyclic double bond.",
        "link": "https://go.drugbank.com/drugs/DB05786",
        "type": "Small Molecule",
        "synonyms": [
            "6-hydroxymethylacylfulvene",
            "HMAF",
            "Irofulven"
        ],
        "indication": "Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFar upstream element-binding protein 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C",
        "id": "DB11416",
        "molecule": "Gamithromycin",
        "cas": "145435-72-9",
        "iupac_name": "(2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,8,10,12,14-hexamethyl-7-propyl-1-oxa-7-azacyclopentadecan-15-one",
        "background": "Gamithromycin is an antibiotic used in cattle.\n",
        "inchi": {
            "hash": "VWAMTBXLZPEDQO-UZSBJOJWSA-N",
            "id": "InChI=1S/C40H76N2O12/c1-15-17-42-21-22(3)33(44)40(11,48)29(16-2)52-36(46)26(7)32(53-30-20-39(10,49-14)34(45)27(8)51-30)25(6)35(38(9,47)19-23(42)4)54-37-31(43)28(41(12)13)18-24(5)50-37/h22-35,37,43-45,47-48H,15-21H2,1-14H3/t22-,23+,24+,25-,26+,27-,28-,29+,30-,31+,32-,33+,34-,35+,37-,38+,39+,40+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 777.05,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 776.539825895,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.",
        "link": "https://go.drugbank.com/drugs/DB11416",
        "type": "Small Molecule",
        "synonyms": [
            "Gamithromycin"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC(OC)=CC(CN(C)C2=CN=C3N=C(N)N=C(N)C3=C2)=C1",
        "id": "DB03987",
        "molecule": "2,4-Diamino-6-[N-(3',5'-Dimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",
        "iupac_name": "N6-[(3,5-dimethoxyphenyl)methyl]-N6-methylpyrido[2,3-d]pyrimidine-2,4,6-triamine",
        "inchi": {
            "hash": "XWCCXDBXMCTZPW-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H20N6O2/c1-23(9-10-4-12(24-2)7-13(5-10)25-3)11-6-14-15(18)21-17(19)22-16(14)20-8-11/h4-8H,9H2,1-3H3,(H4,18,19,20,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 340.3797,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 340.164773914,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrido[2,3-d]pyrimidines. These are compounds containing the pyrido[2,3-d]pyrimidine ring system, which is a pyridopyrimidine isomer with three ring nitrogen atoms at the 1-, 3-, and 8- position.",
        "link": "https://go.drugbank.com/drugs/DB03987",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydrofolate reductase"
            },
            {
                "action": "Not Available",
                "organism": "Pneumocystis carinii",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(CO)CC[C@@]([H])(O1)N1C=NC2=C1N=C(Cl)N=C2N",
        "id": "DB02103",
        "molecule": "2-Chlorodideoxyadenosine",
        "cas": "114849-58-0",
        "iupac_name": "[(2S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)oxolan-2-yl]methanol",
        "inchi": {
            "hash": "FNLILOONPKMGST-NTSWFWBYSA-N",
            "id": "InChI=1S/C10H12ClN5O2/c11-10-14-8(12)7-9(15-10)16(4-13-7)6-2-1-5(3-17)18-6/h4-6,17H,1-3H2,(H2,12,14,15)/t5-,6+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 269.688,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 269.06795236,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine 2',3'-dideoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at positions 2 and 3.",
        "link": "https://go.drugbank.com/drugs/DB02103",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEndoplasmin"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=CC=CC(O)=C21)C1=CC=C(O)C=C1",
        "id": "DB08737",
        "molecule": "(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL",
        "iupac_name": "(2R,6S,7R)-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(13),9,11-trien-13-ol",
        "inchi": {
            "hash": "FSYFYSFYUHBIHE-GLJUWKHASA-N",
            "id": "InChI=1S/C18H18O3/c19-12-9-7-11(8-10-12)18-14-4-1-3-13(14)17-15(20)5-2-6-16(17)21-18/h2,5-10,13-14,18-20H,1,3-4H2/t13-,14+,18+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 282.3337,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 282.125594442,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 5-hydroxyflavonoids. These are flavonoids that bear one hydroxyl group at the C-5 position of the flavonoid skeleton.",
        "link": "https://go.drugbank.com/drugs/DB08737",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor alpha"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB00769",
        "molecule": "Hydrocortamate",
        "cas": "76-47-1",
        "iupac_name": "2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl 2-(diethylamino)acetate",
        "background": "Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects.\n",
        "inchi": {
            "hash": "FWFVLWGEFDIZMJ-FOMYWIRZSA-N",
            "id": "InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 475.6175,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 475.293388049,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB00769",
        "type": "Small Molecule",
        "synonyms": [
            "17-Hydroxycorticosterone, 21-(diethylamino)acetate",
            "Hidrocortamato",
            "Hydrocortamate",
            "Hydrocortamatum"
        ],
        "indication": "Used topically as an antiinflammatory in the treatment of steroid-responsive dermatoses\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AGlucocorticoid receptor"
            }
        ]
    },
    {
        "smiles": "O[C@@H]1C[C@@](O)(CC(=O)[C@H]1O)C(O)=O",
        "id": "DB03868",
        "molecule": "3-Dehydroquinic Acid",
        "iupac_name": "(1R,3R,4S)-1,3,4-trihydroxy-5-oxocyclohexane-1-carboxylic acid",
        "inchi": {
            "hash": "WVMWZWGZRAXUBK-SYTVJDICSA-N",
            "id": "InChI=1S/C7H10O6/c8-3-1-7(13,6(11)12)2-4(9)5(3)10/h3,5,8,10,13H,1-2H2,(H,11,12)/t3-,5+,7-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 190.1507,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 190.047738052,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha hydroxy acids and derivatives. These are organic compounds containing a carboxylic acid substituted with a hydroxyl group on the adjacent carbon.",
        "link": "https://go.drugbank.com/drugs/DB03868",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Helicobacter pylori (strain ATCC 700392 / 26695)",
                "target": "U3-dehydroquinate dehydratase"
            }
        ]
    },
    {
        "smiles": "CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F",
        "id": "DB12625",
        "molecule": "Evogliptin",
        "cas": "1222102-29-5",
        "iupac_name": "(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(tert-butoxy)methyl]piperazin-2-one",
        "background": "Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.\n",
        "inchi": {
            "hash": "LCDDAGSJHKEABN-MLGOLLRUSA-N",
            "id": "InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 401.43,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 401.192626198,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB12625",
        "type": "Small Molecule",
        "synonyms": [
            "Evogliptin"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)N1CCC(CC2=CC(OC3=NC=C(C=C3)C(F)(F)F)=CC=C2)CC1",
        "id": "DB08400",
        "molecule": "4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acid",
        "iupac_name": "4-[(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)methyl]piperidine-1-carboxylic acid",
        "inchi": {
            "hash": "KUEKMTNOUPAOBS-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H19F3N2O3/c20-19(21,22)15-4-5-17(23-12-15)27-16-3-1-2-14(11-16)10-13-6-8-24(9-7-13)18(25)26/h1-5,11-13H,6-10H2,(H,25,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 380.361,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 380.134777099,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4-benzylpiperidines. These are organic compounds containing a benzyl group attached to the 4-position of a piperidine.",
        "link": "https://go.drugbank.com/drugs/DB08400",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFatty-acid amide hydrolase 1"
            }
        ]
    },
    {
        "smiles": "C[C@H](CN)C([O-])=O",
        "id": "DB03432",
        "molecule": "Beta-Amino Isobutyrate",
        "iupac_name": "(2R)-3-amino-2-methylpropanoate",
        "inchi": {
            "hash": "QCHPKSFMDHPSNR-GSVOUGTGSA-M",
            "id": "InChI=1S/C4H9NO2/c1-3(2-5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/p-1/t3-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 102.1118,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 102.055503505,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB03432",
        "type": "Small Molecule"
    },
    {
        "smiles": "OC(=O)C1=C(NC(=O)N2CCC(CC2)C2=C(C=CC=C2)C(F)(F)F)C=CC=C1",
        "id": "DB06985",
        "molecule": "2-[({4-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)amino]benzoic acid",
        "iupac_name": "2-({4-[2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}amino)benzoic acid",
        "inchi": {
            "hash": "MEAQCLPMSVEOQF-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H19F3N2O3/c21-20(22,23)16-7-3-1-5-14(16)13-9-11-25(12-10-13)19(28)24-17-8-4-2-6-15(17)18(26)27/h1-8,13H,9-12H2,(H,24,28)(H,26,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 392.3717,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 392.134777099,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB06985",
        "type": "Small Molecule"
    },
    {
        "smiles": "CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C",
        "id": "DB00307",
        "molecule": "Bexarotene",
        "cas": "153559-49-0",
        "iupac_name": "4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid",
        "background": "Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.\n",
        "inchi": {
            "hash": "NAVMQTYZDKMPEU-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)"
        },
        "summary": "Bexarotene is a retinoid drug used for cutaneous manifestations of T-cell lymphoma in patients who have not responded well to previous systemic therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 348.4779,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 348.20893014,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.",
        "link": "https://go.drugbank.com/drugs/DB00307",
        "type": "Small Molecule",
        "synonyms": [
            "4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid",
            "4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid",
            "Bexaroten",
            "Bexarotne",
            "Bexarotene",
            "Bexaroteno",
            "Bexarotenum",
            "p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid"
        ],
        "indication": "Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR, RXR, RXR). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor RXR-alpha"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor RXR-beta"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor RXR-gamma"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CCCN1)C1=NC2=C(OC3=C2C=C(Cl)C=C3)C(=O)N1",
        "id": "DB12357",
        "molecule": "BMS-863233",
        "cas": "1169558-38-6",
        "iupac_name": "12-chloro-4-[(2S)-pyrrolidin-2-yl]-8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,10,12-pentaen-6-one",
        "background": "BMS-863233 has been investigated for the treatment of Refractory Hematologic Cancer.\n",
        "inchi": {
            "hash": "JJWLXRKVUJDJKG-VIFPVBQESA-N",
            "id": "InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 289.717,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 289.06180435,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.",
        "link": "https://go.drugbank.com/drugs/DB12357",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@]12CCC(=C)[C@@H](C\\C=C3/[C@H](O)COC3=O)[C@]1(C)CC[C@@H](O)[C@@]2(C)CO",
        "id": "DB05767",
        "molecule": "Andrographolide",
        "cas": "5508-58-7",
        "iupac_name": "(3E,4S)-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-decahydronaphthalen-1-yl]ethylidene}-4-hydroxyoxolan-2-one",
        "background": "Andrographolide (HMPL-004) is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.\n",
        "inchi": {
            "hash": "BOJKULTULYSRAS-OTESTREVSA-N",
            "id": "InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 350.455,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 350.209324066,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gamma butyrolactones. These are compounds containing a gamma butyrolactone moiety, which consists of an aliphatic five-member ring with four carbon atoms, one oxygen atom, and bears a ketone group on the carbon adjacent to the oxygen atom.",
        "link": "https://go.drugbank.com/drugs/DB05767",
        "type": "Small Molecule",
        "synonyms": [
            "3,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid -Lactone"
        ],
        "indication": "Investigated for use/treatment in ulcerative colitis.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTumor necrosis factor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UInterleukin-1 beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UInterleukin-6"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear factor NF-kappa-B p100 subunit"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear factor NF-kappa-B p105 subunit"
            }
        ]
    },
    {
        "smiles": "NCC1=CC=C2OCC3(CCN(CC3)C(=O)C3=CC=C(O3)C#CC3=CC=CC=C3)C2=C1",
        "id": "DB06962",
        "molecule": "JNJ-27390467",
        "cas": "1025795-11-2",
        "iupac_name": "1-{1'-[5-(2-phenylethynyl)furan-2-carbonyl]-2H-spiro[1-benzofuran-3,4'-piperidin]-5-yl}methanamine",
        "background": "JNJ-27390467 is a potent, nonpeptide inhibitor of human mast cell tryptase.\n",
        "inchi": {
            "hash": "YKTUSHSSKIWDRY-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H24N2O3/c27-17-20-7-10-23-22(16-20)26(18-30-23)12-14-28(15-13-26)25(29)24-11-9-21(31-24)8-6-19-4-2-1-3-5-19/h1-5,7,9-11,16H,12-15,17-18,27H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 412.4804,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 412.178692644,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.",
        "link": "https://go.drugbank.com/drugs/DB06962",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTryptase beta-2"
            }
        ]
    },
    {
        "smiles": "CC[C@@H](OP(O)(O)=O)C(O)=O",
        "id": "DB03248",
        "molecule": "2-(Phosphonooxy)Butanoic Acid",
        "iupac_name": "(2R)-2-(phosphonooxy)butanoic acid",
        "inchi": {
            "hash": "OETAGSCBSKODFW-GSVOUGTGSA-N",
            "id": "InChI=1S/C4H9O6P/c1-2-3(4(5)6)10-11(7,8)9/h3H,2H2,1H3,(H,5,6)(H2,7,8,9)/t3-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 184.0844,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 184.013674532,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monoalkyl phosphates. These are organic compounds containing a phosphate group that is linked to exactly one alkyl chain.",
        "link": "https://go.drugbank.com/drugs/DB03248",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Aquifex aeolicus (strain VF5)",
                "target": "U2-dehydro-3-deoxyphosphooctonate aldolase"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CC1=CC(N)=C(O)C=C1O)C(O)=O",
        "id": "DB02928",
        "molecule": "3-Amino-6-Hydroxy-Tyrosine",
        "iupac_name": "(2S)-2-amino-3-(5-amino-2,4-dihydroxyphenyl)propanoic acid",
        "inchi": {
            "hash": "OIXIYIGKZVEKPI-LURJTMIESA-N",
            "id": "InChI=1S/C9H12N2O4/c10-5-1-4(2-6(11)9(14)15)7(12)3-8(5)13/h1,3,6,12-13H,2,10-11H2,(H,14,15)/t6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 212.2026,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 212.079706882,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB02928",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPrimary amine oxidase"
            }
        ]
    },
    {
        "smiles": "CN(CCCOC1=CC=C(Cl)C=C1Cl)CC#C",
        "id": "DB04017",
        "molecule": "Clorgiline",
        "cas": "17780-72-2",
        "iupac_name": "[3-(2,4-dichlorophenoxy)propyl](methyl)(prop-2-yn-1-yl)amine",
        "background": "An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.\n",
        "inchi": {
            "hash": "BTFHLQRNAMSNLC-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H15Cl2NO/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15/h1,5-6,10H,4,7-9H2,2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 272.17,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 271.053069521,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.",
        "link": "https://go.drugbank.com/drugs/DB04017",
        "type": "Small Molecule",
        "synonyms": [
            "Clorgilina",
            "Clorgiline",
            "Clorgilinum",
            "Clorgyline"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAmine oxidase [flavin-containing] A"
            }
        ]
    },
    {
        "smiles": "OC(=O)COC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12",
        "id": "DB13501",
        "molecule": "Bendazac",
        "cas": "20187-55-7",
        "iupac_name": "2-[(1-benzyl-1H-indazol-3-yl)oxy]acetic acid",
        "background": "Bendazac is an oxyacetic acid 1,2. Despite possessing anti-inflammatory, anti-necrotic, choleretic, and anti-lipidemic characteristics, most research has revolved around studying and demonstrating the agent's principal action in inhibiting the denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts 1,1. Bendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity 4,5,6,10 in patients although a small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation.\n",
        "inchi": {
            "hash": "BYFMCKSPFYVMOU-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H14N2O3/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12/h1-9H,10-11H2,(H,19,20)"
        },
        "summary": "Bendazac is a non-steroidal anti-inflammatory drug (NSAID) available as an eye drop for the treatment of cataracts and as a topical cream for the treatment of dermatitis, eczema, hives, skin ulcers and other inflammatory skin conditions.",
        "weight": [
            {
                "type": "average",
                "weight": 282.299,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 282.100442319,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.",
        "link": "https://go.drugbank.com/drugs/DB13501",
        "type": "Small Molecule",
        "synonyms": [
            "Bendazac",
            "bendazaco"
        ],
        "indication": "Prior to the withdrawal of bendazac from various international regions of use due to concerns for hepatotoxicity 4,5,6,10 the chemical had demonstrated potential usefulness predominantly as the prescription medication bendazac lysine for the indication of managing the level of vision in patients with mild to moderate cataracts to facilitate delaying the need for surgical intervention 1,2,3.\nElsewhere bendazac may still be available in a limited capacity as a non-prescription topical cream product for treating conditions like local pain, inflammation, dermatitis, eczema, pruritis, hives, insect bites, burns, erythema, and others 11 - although such products may also be facing general discontinuation 12.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bendazac principally demonstrates an antidenaturant action on proteins 1,2. This effect has been shown to inhibit the denaturation of various proteins like ocular lens proteins by heat, ultraviolet radiation, free radicals, and other chemicals 1,2. The medication may be administered to patients via a number of different formulations, including orally as the lysine salt, as eye drops, or even topical applications for the skin 1,2.\nSome preliminary studies have suggested that an apparent improvement of the blood-retinal barrier had been observed in diabetic patients using bendazac lysine 500 mg three times a day for three to six months 2. Moreover, the use of topical bendazac has also been shown to demonstrate anti-inflammatory effects in animal models and clinical studies to effectively treat varied dermatoses, especially those involving a necrotic component 2.\nAdditionally, bendazac has also demonstrated choleretic and antilipidaemic activities that have resulted in substantial reductions in beta/alpha lipoprotein ratio, and total lipid, total cholesterol, and triglyceride levels in patients with dyslipidaemia using oral bendazac lysine 500 mg three times daily 1,2. The medication has also elicited the inhibition of phytohaemagglutinin induced lymphocyte transformation in vitro 1,2.\n",
        "moa": [
            {
                "action": "blocker",
                "organism": "Humans",
                "target": "UFree radicals"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 2"
            }
        ]
    },
    {
        "smiles": "[H]N([C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@H]1O)C(C)=O",
        "id": "DB03109",
        "molecule": "2-acetylamino-2-deoxy-b-D-allopyranose",
        "iupac_name": "N-[(2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide",
        "inchi": {
            "hash": "OVRNDRQMDRJTHS-UIAUGNHASA-N",
            "id": "InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7+,8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 221.2078,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 221.089937217,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group.",
        "link": "https://go.drugbank.com/drugs/DB03109",
        "type": "Small Molecule",
        "synonyms": [
            "N-acetyl-D-allosamine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UChitotriosidase-1"
            },
            {
                "action": "Not Available",
                "organism": "Serratia marcescens",
                "target": "UChitinase B"
            },
            {
                "action": "Not Available",
                "organism": "Serratia marcescens",
                "target": "UChitinase A"
            }
        ]
    },
    {
        "smiles": "[H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF",
        "id": "DB08824",
        "molecule": "Ioflupane I-123",
        "cas": "155798-07-5",
        "iupac_name": "methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-[4-(I)iodophenyl]-8-azabicyclo[3.2.1]octane-2-carboxylate",
        "background": "Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes.\n",
        "inchi": {
            "hash": "HXWLAJVUJSVENX-HFIFKADTSA-N",
            "id": "InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4"
        },
        "summary": "Ioflupane I-123 is a radiopharmaceutical used in single photon emission computed tomography (SPECT) brain imaging to help diagnose patients with suspected Parkinsonian syndromes.",
        "weight": [
            {
                "type": "average",
                "weight": 427.291,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 427.076880092,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenyltropanes. These are compounds containing a phenyl group linked to a tropane moiety. Tropane is an organonitrogenous [3.2.1] Bicyclic organic compound.",
        "link": "https://go.drugbank.com/drugs/DB08824",
        "type": "Small Molecule",
        "synonyms": [
            "123I-FP-CIT",
            "123I-Ioflupane",
            "Iodine ioflupane (123I)",
            "Ioflupane ((123)I)",
            "Ioflupane (123I)",
            "Ioflupane I 123",
            "Ioflupane I(123)",
            "Ioflupano (123I)",
            "Ioflupanum (123I)"
        ],
        "indication": "Ioflupane I-123 is a SPECT (single photon emission computerized tomography) agent used to distinguish between Parkinsons syndrome tremors and essential tremor. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "iodine-123 labeled ioflupanebinds selectively to striatal presynaptic dopamine neurons by binding reversibly to presynaptic dopamine transporters.\n"
    },
    {
        "smiles": "C[C@@H](O[C@H]1OCCN(CC2=NC(=O)N(N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F",
        "id": "DB06717",
        "molecule": "Fosaprepitant",
        "cas": "172673-20-0",
        "iupac_name": "(3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid",
        "background": "Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.\n",
        "inchi": {
            "hash": "BARDROPHSZEBKC-OITMNORJSA-N",
            "id": "InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1"
        },
        "summary": "Fosaprepitant is an antiemetic drug used in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting caused by chemotherapy.",
        "weight": [
            {
                "type": "average",
                "weight": 614.4066,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 614.116518403,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.",
        "link": "https://go.drugbank.com/drugs/DB06717",
        "type": "Small Molecule",
        "synonyms": [
            "Fosaprpitant",
            "Fosaprepitant",
            "Fosaprepitantum"
        ],
        "indication": "Fosaprepitant is indicated in adult and pediatric patients 6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.1 It is also indicated for the treatment of delayed nausea and vomiting with initial and repeat courses of moderately emetogenic cancer chemotherapy.1\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fosaprepitant is a prodrug of Aprepitant. Once biologically activated, the drug acts as a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).\n"
    },
    {
        "smiles": "CC1CCN(CC1)C1=CC=C(CO)C=C1NC(=O)C1=CC=C(O1)C#N",
        "id": "DB07167",
        "molecule": "5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE",
        "iupac_name": "5-cyano-N-[5-(hydroxymethyl)-2-(4-methylpiperidin-1-yl)phenyl]furan-2-carboxamide",
        "inchi": {
            "hash": "NNPCFFIJVKYGHR-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H21N3O3/c1-13-6-8-22(9-7-13)17-4-2-14(12-23)10-16(17)21-19(24)18-5-3-15(11-20)25-18/h2-5,10,13,23H,6-9,12H2,1H3,(H,21,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 339.3883,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 339.158291553,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-furanilides. These are aromatic heterocyclic compounds contaning a furan ring that is substituted at the 2-position with an anilide.",
        "link": "https://go.drugbank.com/drugs/DB07167",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMacrophage colony-stimulating factor 1 receptor"
            }
        ]
    },
    {
        "smiles": "NC1=C2N=CN([C@@H]3O[C@H](CO[P@](O)(=O)O[P@](O)(=O)O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](O)[C@H]3O)C2=NC=N1",
        "id": "DB01774",
        "molecule": "Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester",
        "iupac_name": "{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({[hydroxy({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphoryl]oxy})phosphinic acid",
        "background": "Serves as the glycosyl donor for formation of bacterial glycogen, amylose in green algae, and amylopectin in higher plants. [PubChem]\n",
        "inchi": {
            "hash": "WFPZSXYXPSUOPY-ROYWQJLOSA-N",
            "id": "InChI=1S/C16H25N5O15P2/c17-13-7-14(19-3-18-13)21(4-20-7)15-11(26)9(24)6(33-15)2-32-37(28,29)36-38(30,31)35-16-12(27)10(25)8(23)5(1-22)34-16/h3-6,8-12,15-16,22-27H,1-2H2,(H,28,29)(H,30,31)(H2,17,18,19)/t5-,6-,8-,9-,10+,11-,12-,15-,16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 589.3417,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 589.082238179,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleotide sugars. These are purine nucleotides bound to a saccharide derivative through the terminal phosphate group.",
        "link": "https://go.drugbank.com/drugs/DB01774",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UADP-L-glycero-D-manno-heptose-6-epimerase"
            }
        ]
    },
    {
        "smiles": "CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1",
        "id": "DB04812",
        "molecule": "Benoxaprofen",
        "cas": "51234-28-7",
        "iupac_name": "2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid",
        "background": "The use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions. The holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.\n",
        "inchi": {
            "hash": "MITFXPHMIHQXPI-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 301.724,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 301.050570962,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenyl-1,3-oxazoles. These are aromatic heterocyclic compounds containing a 1,3-oxazole substituted at one or more positions by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB04812",
        "type": "Small Molecule",
        "synonyms": [
            "()-benoxaprofen",
            "(1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid",
            "2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid",
            "2-(4-chlorophenyl)--methyl-5-benzoxazoleacetic acid",
            "2-(p-chlorophenyl)--methyl-5-benzoxazoleacetic acid",
            "Benoxaprofen",
            "Benoxaprofene",
            "Benoxaprofeno",
            "Benoxaprofenum",
            "DL-benoxaprofen"
        ]
    },
    {
        "smiles": "N[C@]1(C[C@H]([18F])C1)C(O)=O",
        "id": "DB13146",
        "molecule": "Fluciclovine (18F)",
        "cas": "222727-39-1",
        "iupac_name": "(1r,3r)-1-amino-3-(F)fluorocyclobutane-1-carboxylic acid",
        "background": "Fluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging.2 The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body.3 Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.7\n",
        "inchi": {
            "hash": "NTEDWGYJNHZKQW-DGMDOPGDSA-N",
            "id": "InChI=1S/C5H8FNO2/c6-3-1-5(7,2-3)4(8)9/h3H,1-2,7H2,(H,8,9)/t3-,5-/i6-1"
        },
        "summary": "Fluciclovine (18F) is a radiolabelled L-leucine derivative used to image tumors, especially in the prostate.",
        "weight": [
            {
                "type": "average",
                "weight": 132.125,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 132.056441169,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB13146",
        "type": "Small Molecule",
        "synonyms": [
            "(18F)FACBC",
            "(1R,3R)-1-amino-3(18F)fluorocyclobutane-1-carboxylic acid",
            "Anti-1-amino-3-(18F)fluorocyclobutane-1-carboxylic acid",
            "FACBC F-18",
            "Fluciclovine (18F)",
            "Fluciclovine F 18",
            "Fluciclovine F-18"
        ],
        "indication": "Fluciclovine is indicated as a detection agent for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.4 The overexpression of L-type amino acid transporters such as LAT1 and LAT3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growth.5\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Following intravenous administration, the tumor-to-normal tissue contrast is highest between 2 and 10 minutes after injection, with a 63% reduction in mean tumor uptake at 90 minutes after injection.6 The scanning time point should be evaluated carefully as an early scanning can present an increased blood pool and a late scanning will translate into an increased muscle uptake. These variations should always be considered in the image interpretation.8\n",
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "ANeutral amino acid transporter B(0)"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "AY+L amino acid transporter 1"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "ACationic amino acid transporter 3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NGlutamate (NMDA) receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NGlutamate receptor 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NGlutamate receptor 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NGlutamate receptor 3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NGlutamate receptor 4"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CCCN1C(=O)CNC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N",
        "id": "DB06850",
        "molecule": "(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide",
        "iupac_name": "(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[2-(cyclohexylamino)acetyl]pyrrolidine-2-carboxamide",
        "inchi": {
            "hash": "RYKFVFFOIYLADT-SFHVURJKSA-N",
            "id": "InChI=1S/C21H31N5O2/c22-20(23)16-10-8-15(9-11-16)13-25-21(28)18-7-4-12-26(18)19(27)14-24-17-5-2-1-3-6-17/h8-11,17-18,24H,1-7,12-14H2,(H3,22,23)(H,25,28)/t18-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 385.5031,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 385.247775261,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB06850",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CCS)C(O)=O",
        "id": "DB04422",
        "molecule": "Homocysteine",
        "cas": "6027-13-0",
        "iupac_name": "(2S)-2-amino-4-sulfanylbutanoic acid",
        "background": "Homocysteine is a thiol-containing amino acid formed by a demethylation of methionine.\n",
        "inchi": {
            "hash": "FFFHZYDWPBMWHY-VKHMYHEASA-N",
            "id": "InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 135.185,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 135.035399227,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB04422",
        "type": "Small Molecule",
        "synonyms": [
            "L-2-amino-4-mercaptobutyric acid",
            "L-Homocysteine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "US-ribosylhomocysteine lyase"
            },
            {
                "action": "Not Available",
                "organism": "Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)",
                "target": "U5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase"
            },
            {
                "action": "Not Available",
                "organism": "Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)",
                "target": "U5-methyltetrahydrofolate S-homocysteine methyltransferase"
            }
        ]
    },
    {
        "smiles": "CN(C)CCO\\N=C(\\C=C\\C1=CC=C(O)C=C1)/C1=CC=CC=C1F",
        "id": "DB12177",
        "molecule": "Eplivanserin",
        "cas": "130579-75-8",
        "iupac_name": "4-[(1E,3Z)-3-{[2-(dimethylamino)ethoxy]imino}-3-(2-fluorophenyl)prop-1-en-1-yl]phenol",
        "background": "Eplivanserin has been used in trials studying the treatment of Sleep, Insomnia, Chronic Pain, Fibromyalgia, and Primary Insomnia, among others.\n",
        "inchi": {
            "hash": "VAIOZOCLKVMIMN-PRJWTAEASA-N",
            "id": "InChI=1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 328.387,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 328.158706087,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cinnamylphenols. These are organic compounds containing the 1,3-diphenylpropene moiety with one benzene ring bearing one or more hydroxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB12177",
        "type": "Small Molecule",
        "synonyms": [
            "Eplivanserin",
            "Eplivanserine"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2C"
            }
        ]
    },
    {
        "smiles": "CCC1=C(C(N)=NC(N)=N1)C1=CC=C(NCC2=CC(F)=CC(F)=C2)C=C1",
        "id": "DB07244",
        "molecule": "5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE",
        "iupac_name": "5-(4-{[(3,5-difluorophenyl)methyl]amino}phenyl)-6-ethylpyrimidine-2,4-diamine",
        "inchi": {
            "hash": "SRRWXMSVQYQCRX-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H19F2N5/c1-2-16-17(18(22)26-19(23)25-16)12-3-5-15(6-4-12)24-10-11-7-13(20)9-14(21)8-11/h3-9,24H,2,10H2,1H3,(H4,22,23,25,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 355.3845,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 355.160852043,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.",
        "link": "https://go.drugbank.com/drugs/DB07244",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, endothelial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URenin"
            }
        ]
    },
    {
        "smiles": "NC(=[NH2+])C1=CC2=C(S1)C=CC=C2I",
        "id": "DB03136",
        "molecule": "4-Iodobenzo[B]Thiophene-2-Carboxamidine",
        "iupac_name": "[amino(4-iodo-1-benzothiophen-2-yl)methylidene]azanium",
        "inchi": {
            "hash": "YERQOXAYAFWFEJ-UHFFFAOYSA-O",
            "id": "InChI=1S/C9H7IN2S/c10-6-2-1-3-7-5(6)4-8(13-7)9(11)12/h1-4H,(H3,11,12)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 303.143,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 302.945287376,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-benzothiophenes. These are aromatic heterocyclic compound containing the Benzo[b]thiophene ring system.",
        "link": "https://go.drugbank.com/drugs/DB03136",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UUrokinase-type plasminogen activator"
            }
        ]
    },
    {
        "smiles": "[H]OP([O-])(=O)O[H]",
        "id": "DB02831",
        "molecule": "Dihydrogenphosphate",
        "cas": "29505-79-1",
        "iupac_name": "dihydrogen phosphate",
        "inchi": {
            "hash": "NBIIXXVUZAFLBC-UHFFFAOYSA-M",
            "id": "InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 96.9872,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 96.969070064,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as non-metal phosphates. These are inorganic non-metallic compounds containing a phosphate as its largest oxoanion.",
        "link": "https://go.drugbank.com/drugs/DB02831",
        "type": "Small Molecule",
        "synonyms": [
            "Dihydrogenphosphate ion"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UL-xylulose reductase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPhosphate-binding protein PstS"
            }
        ]
    },
    {
        "smiles": "CC1=CC(C)=[N+](CCC2=CC=C(C=C2)S(N)(=O)=O)C(C)=C1",
        "id": "DB04763",
        "molecule": "1-N-(4-SULFAMOYLPHENYL-ETHYL)-2,4,6-TRIMETHYLPYRIDINIUM",
        "iupac_name": "2,4,6-trimethyl-1-[2-(4-sulfamoylphenyl)ethyl]pyridin-1-ium",
        "inchi": {
            "hash": "UXBCHTZINZNVRG-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H21N2O2S/c1-12-10-13(2)18(14(3)11-12)9-8-15-4-6-16(7-5-15)21(17,19)20/h4-7,10-11H,8-9H2,1-3H3,(H2,17,19,20)/q+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 305.415,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 305.132373616,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB04763",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "OC(=O)CCCNC(=O)NC1CCCCC1",
        "id": "DB08257",
        "molecule": "4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID",
        "iupac_name": "4-[(cyclohexylcarbamoyl)amino]butanoic acid",
        "inchi": {
            "hash": "WSVFRGGLURJIMG-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H20N2O3/c14-10(15)7-4-8-12-11(16)13-9-5-2-1-3-6-9/h9H,1-8H2,(H,14,15)(H2,12,13,16)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 228.2881,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 228.147392516,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB08257",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UBifunctional epoxide hydrolase 2"
            }
        ]
    },
    {
        "smiles": "[H][C@@](COCCCCCCCC)(COP(O)(=O)OCCN)OP(O)(=O)CCCCCCC",
        "id": "DB03565",
        "molecule": "1-O-Octyl-2-Heptylphosphonyl-Sn-Glycero-3-Phosphoethanolamine",
        "iupac_name": "(2-aminoethoxy)[(2R)-2-{[heptyl(hydroxy)phosphoryl]oxy}-3-(octyloxy)propoxy]phosphinic acid",
        "inchi": {
            "hash": "RCCNUBYROFOKAU-HXUWFJFHSA-N",
            "id": "InChI=1S/C20H45NO8P2/c1-3-5-7-9-10-12-15-26-18-20(19-28-31(24,25)27-16-14-21)29-30(22,23)17-13-11-8-6-4-2/h20H,3-19,21H2,1-2H3,(H,22,23)(H,24,25)/t20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 489.5207,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 489.262040445,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glycerophosphoethanolamines. These are glycerolipids characterized by an ethanolamine ester of glycerophosphoric acid. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 atoms.",
        "link": "https://go.drugbank.com/drugs/DB03565",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPhospholipase A2"
            }
        ]
    },
    {
        "smiles": "CCC1=C(C)NC(=O)C(N(C)CCOC)=C1CC1=CC=CC(C)=C1",
        "id": "DB07018",
        "molecule": "5-ETHYL-3-[(2-METHOXYETHYL)METHYLAMINO]-6-METHYL-4-(3-METHYLBENZYL)PYRIDIN-2(1H)-ONE",
        "iupac_name": "5-ethyl-3-[(2-methoxyethyl)(methyl)amino]-6-methyl-4-[(3-methylphenyl)methyl]-1,2-dihydropyridin-2-one",
        "inchi": {
            "hash": "USWKTQVAABDFSY-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H28N2O2/c1-6-17-15(3)21-20(23)19(22(4)10-11-24-5)18(17)13-16-9-7-8-14(2)12-16/h7-9,12H,6,10-11,13H2,1-5H3,(H,21,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 328.4485,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 328.21507815,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.",
        "link": "https://go.drugbank.com/drugs/DB07018",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "NCCCC(O)=O",
        "id": "DB02530",
        "molecule": "gamma-Aminobutyric acid",
        "cas": "56-12-2",
        "iupac_name": "4-aminobutanoic acid",
        "background": "The most common inhibitory neurotransmitter in the central nervous system.\n",
        "inchi": {
            "hash": "BTCSSZJGUNDROE-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 103.1198,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 103.063328537,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB02530",
        "type": "Small Molecule",
        "synonyms": [
            "4-aminobutanoic acid",
            "4-aminobutyric acid",
            "4Abu",
            "GABA",
            "gamma-Aminobutyric acid",
            "piperidic acid",
            "piperidinic acid",
            "-amino-n-butyric acid",
            "-aminobutanoic acid",
            "-Aminobuttersure",
            "-aminobutyric acid",
            "-aminobutyric acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGamma-aminobutyric acid type B receptor subunit 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGamma-aminobutyric acid type B receptor subunit 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycine amidinotransferase, mitochondrial"
            }
        ]
    },
    {
        "smiles": "CC1=C(CC(O)=O)C2=CC(F)=CC=C2\\C1=C/C1=CC=C(C=C1)S(C)(=O)=O",
        "id": "DB06246",
        "molecule": "Exisulind",
        "cas": "59973-80-7",
        "iupac_name": "2-[(1Z)-5-fluoro-1-[(4-methanesulfonylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid",
        "inchi": {
            "hash": "MVGSNCBCUWPVDA-MFOYZWKCSA-N",
            "id": "InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 372.41,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 372.083158364,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06246",
        "type": "Small Molecule",
        "synonyms": [
            "5-Fluoro-2-methyl-1-((Z)-p-(methylsulfonyl)benzylidene)indene-3-acetic acid",
            "cis-5-Fluoro-2-methyl-1-(p-methylsulfonylbenzylidenyl)indene-3-acetic acid",
            "Exisulind",
            "Sulindac sulfone"
        ],
        "indication": "Investigated for use/treatment in adenomatous polyposis coli, lung cancer, prostate cancer, colon polyps, Barrett's esophagus disease, and pediatric indications.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UGlutathione S-transferase P"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UAldose reductase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UAldo-keto reductase family 1 member B10"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4D"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4C"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcGMP-specific 3',5'-cyclic phosphodiesterase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcGMP-dependent 3',5'-cyclic phosphodiesterase"
            }
        ]
    },
    {
        "smiles": "COC1=CC(NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C2=C(OC)C=CC=C2F)=CC=C1C(O)=O",
        "id": "DB05220",
        "molecule": "Alisertib",
        "cas": "1028486-01-2",
        "iupac_name": "4-{[13-chloro-10-(2-fluoro-6-methoxyphenyl)-3,5,9-triazatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2,4,6,9,11,13-heptaen-4-yl]amino}-2-methoxybenzoic acid",
        "background": "Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.\n",
        "inchi": {
            "hash": "ZLHFILGSQDJULK-UHFFFAOYSA-N",
            "id": "InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 518.93,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 518.115711,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).",
        "link": "https://go.drugbank.com/drugs/DB05220",
        "type": "Small Molecule",
        "synonyms": [
            "Alisertib"
        ],
        "indication": "For the treatment of various forms of cancer.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "inhibitorregulator",
                "organism": "Humans",
                "target": "UAurora kinase A"
            }
        ]
    },
    {
        "smiles": "CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1",
        "id": "DB01355",
        "molecule": "Hexobarbital",
        "cas": "56-29-1",
        "iupac_name": "5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione",
        "background": "A barbiturate that is effective as a hypnotic and sedative.\n",
        "inchi": {
            "hash": "UYXAWHWODHRRMR-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 236.267,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 236.116092388,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB01355",
        "type": "Small Molecule",
        "synonyms": [
            "5-(1-cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione",
            "5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid",
            "5-Cyclohex-1-enyl-1,5-dimethyl-pyrimidine-2,4,6-trione",
            "Hexobarbital",
            "Hexobarbitone",
            "Methexenyl",
            "Methylhexabital"
        ],
        "indication": "For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was subsequently used in the 1940s and 1950s as an anesthetic for surgery. Furthermore, the agent also demonstrates a fairly quick onset of action that also possesses a short duration of action. However it can be difficult to control the depth of anesthesia with hexobarbital which makes it quite dangerous, and it has now been replaced by safer drugs in human medicine, usually thiopental would be the barbiturate of choice for this application these days.\n",
        "moa": [
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-2"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-3"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-4"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-5"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-6"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-7"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor 2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 2"
            }
        ]
    },
    {
        "smiles": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",
        "id": "DB00050",
        "molecule": "Cetrorelix",
        "cas": "120287-85-6",
        "iupac_name": "(2S)-N-[(2S)-5-carbamimidamido-1-[(2S)-2-{[(1R)-1-carbamoylethyl]carbamoyl}pyrrolidin-1-yl]-1-oxopentan-2-yl]-2-[(2R)-5-(carbamoylamino)-2-[(2S)-2-[(2S)-2-[(2R)-2-[(2R)-3-(4-chlorophenyl)-2-[(2R)-2-acetamido-3-(naphthalen-2-yl)propanamido]propanamido]-3-(pyridin-3-yl)propanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]pentanamido]-4-methylpentanamide",
        "background": "Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.\n",
        "inchi": {
            "hash": "SBNPWPIBESPSIF-MHWMIDJBSA-N",
            "id": "InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1"
        },
        "summary": "Cetrorelix is a synthetic peptide antagonist of gonadotropin releasing hormone used to prevent luteinizing hormone surges in women undergoing assisted reproduction therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 1431.038,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1429.669818444,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.",
        "link": "https://go.drugbank.com/drugs/DB00050",
        "type": "Small Molecule",
        "synonyms": [
            "Cetrorelix",
            "Cetrorelixum"
        ],
        "indication": "For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AGonadotropin-releasing hormone receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULutropin-choriogonadotropic hormone receptor"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)CCCN[C@]1([H])CC(=O)CN1C=NC2=C(C=C(Cl)C(Br)=C2)C1=O",
        "id": "DB04866",
        "molecule": "Halofuginone",
        "cas": "55837-20-2",
        "iupac_name": "7-bromo-6-chloro-3-{3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl}-3,4-dihydroquinazolin-4-one",
        "background": "Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.\n",
        "inchi": {
            "hash": "LVASCWIMLIKXLA-CABCVRRESA-N",
            "id": "InChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2/t14-,15+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 414.681,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 413.014181779,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.",
        "link": "https://go.drugbank.com/drugs/DB04866",
        "type": "Small Molecule",
        "synonyms": [
            "(+/-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3H)-quinazolinone",
            "Halofuginone"
        ],
        "indication": "For the treatment of scleroderma, cancer, and restenosis.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Halofuginone, a fully synthetic small molecule, is a potent and selective regulator of stromal cell activation, cell migration and Collagen type I synthesis, a process that has been identified as a 'master switch' in the body's tissue repair process.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCollagen alpha-1(I) chain"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U72 kDa type IV collagenase"
            }
        ],
        "drug_interactions": [
            [
                "\u003ca href=\"/drugs/DB00630\"\u003eAlendronic acid\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Alendronic acid."
            ],
            [
                "\u003ca href=\"/drugs/DB06742\"\u003eAmbroxol\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ambroxol."
            ],
            [
                "\u003ca href=\"/drugs/DB09009\"\u003eArticaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Articaine."
            ],
            [
                "\u003ca href=\"/drugs/DB01086\"\u003eBenzocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Benzocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB06770\"\u003eBenzyl alcohol\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Benzyl alcohol."
            ],
            [
                "\u003ca href=\"/drugs/DB00297\"\u003eBupivacaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Bupivacaine."
            ],
            [
                "\u003ca href=\"/drugs/DB11502\"\u003eButacaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butacaine."
            ],
            [
                "\u003ca href=\"/drugs/DB11148\"\u003eButamben\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butamben."
            ],
            [
                "\u003ca href=\"/drugs/DB13328\"\u003eButanilicaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butanilicaine."
            ],
            [
                "\u003ca href=\"/drugs/DB06774\"\u003eCapsaicin\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Capsaicin."
            ],
            [
                "\u003ca href=\"/drugs/DB01161\"\u003eChloroprocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Chloroprocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00527\"\u003eCinchocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Cinchocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00720\"\u003eClodronic acid\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Clodronic acid."
            ],
            [
                "\u003ca href=\"/drugs/DB00907\"\u003eCocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Cocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00012\"\u003eDarbepoetin alfa\u003c/a\u003e",
                "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Halofuginone."
            ],
            [
                "\u003ca href=\"/drugs/DB01075\"\u003eDiphenhydramine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Diphenhydramine."
            ],
            [
                "\u003ca href=\"/drugs/DB00645\"\u003eDyclonine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Dyclonine."
            ],
            [
                "\u003ca href=\"/drugs/DB00016\"\u003eErythropoietin\u003c/a\u003e",
                "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Halofuginone."
            ],
            [
                "\u003ca href=\"/drugs/DB13259\"\u003eEthyl chloride\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ethyl chloride."
            ],
            [
                "\u003ca href=\"/drugs/DB08987\"\u003eEtidocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Etidocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB01077\"\u003eEtidronic acid\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Etidronic acid."
            ],
            [
                "\u003ca href=\"/drugs/DB14766\"\u003eEtrasimod\u003c/a\u003e",
                "The risk or severity of immunosuppression can be increased when Halofuginone is combined with Etrasimod."
            ],
            [
                "\u003ca href=\"/drugs/DB00710\"\u003eIbandronate\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Ibandronate."
            ],
            [
                "\u003ca href=\"/drugs/DB06255\"\u003eIncadronic acid\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Incadronic acid."
            ],
            [
                "\u003ca href=\"/drugs/DB01002\"\u003eLevobupivacaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Levobupivacaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00281\"\u003eLidocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Lidocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00814\"\u003eMeloxicam\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Meloxicam."
            ],
            [
                "\u003ca href=\"/drugs/DB00961\"\u003eMepivacaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Mepivacaine."
            ],
            [
                "\u003ca href=\"/drugs/DB13578\"\u003eMetabutethamine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Metabutethamine."
            ],
            [
                "\u003ca href=\"/drugs/DB09107\"\u003eMethoxy polyethylene glycol-epoetin beta\u003c/a\u003e",
                "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Halofuginone."
            ],
            [
                "\u003ca href=\"/drugs/DB01280\"\u003eNelarabine\u003c/a\u003e",
                "The risk or severity of adverse effects can be increased when Nelarabine is combined with Halofuginone."
            ],
            [
                "\u003ca href=\"/drugs/DB12532\"\u003eOxetacaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Oxetacaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00892\"\u003eOxybuprocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Oxybuprocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00282\"\u003ePamidronic acid\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Pamidronic acid."
            ],
            [
                "\u003ca href=\"/drugs/DB08894\"\u003ePeginesatide\u003c/a\u003e",
                "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Halofuginone."
            ],
            [
                "\u003ca href=\"/drugs/DB03255\"\u003ePhenol\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Phenol."
            ],
            [
                "\u003ca href=\"/drugs/DB09345\"\u003ePramocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Pramocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00750\"\u003ePrilocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Prilocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00721\"\u003eProcaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Procaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00807\"\u003eProparacaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Proparacaine."
            ],
            [
                "\u003ca href=\"/drugs/DB09342\"\u003ePropoxycaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Propoxycaine."
            ],
            [
                "\u003ca href=\"/drugs/DB13683\"\u003eQuinisocaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Quinisocaine."
            ],
            [
                "\u003ca href=\"/drugs/DB00884\"\u003eRisedronic acid\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Risedronic acid."
            ],
            [
                "\u003ca href=\"/drugs/DB00296\"\u003eRopivacaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ropivacaine."
            ],
            [
                "\u003ca href=\"/drugs/DB09085\"\u003eTetracaine\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Tetracaine."
            ],
            [
                "\u003ca href=\"/drugs/DB05232\"\u003eTetrodotoxin\u003c/a\u003e",
                "The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Tetrodotoxin."
            ],
            [
                "\u003ca href=\"/drugs/DB01133\"\u003eTiludronic acid\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Tiludronic acid."
            ],
            [
                "\u003ca href=\"/drugs/DB00399\"\u003eZoledronic acid\u003c/a\u003e",
                "The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Zoledronic acid."
            ]
        ],
        "drug_interactions_raw": "This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. ApprovedVet approvedNutraceuticalIllicitWithdrawnInvestigationalExperimentalAll DrugsDrugInteractionIntegrate drug-drug interactions in your software\n\n\nAlendronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Alendronic acid.AmbroxolThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ambroxol.ArticaineThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Articaine.BenzocaineThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Benzocaine.Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Benzyl alcohol.BupivacaineThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Bupivacaine.ButacaineThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butacaine.ButambenThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butamben.CapsaicinThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Capsaicin.ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Chloroprocaine.Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   ",
        "drug_interactions_link": "https://go.drugbank.com/drugs/DB04866/drug_interactions.json?start=0\u0026length=100\u0026_=1701097777",
        "drug_interactions_page": "{\"draw\":1,\"recordsTotal\":48,\"recordsFiltered\":48,\"data\":[[\"\\u003ca href=\\\"/drugs/DB00630\\\"\\u003eAlendronic acid\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Alendronic acid.\"],[\"\\u003ca href=\\\"/drugs/DB06742\\\"\\u003eAmbroxol\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ambroxol.\"],[\"\\u003ca href=\\\"/drugs/DB09009\\\"\\u003eArticaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Articaine.\"],[\"\\u003ca href=\\\"/drugs/DB01086\\\"\\u003eBenzocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Benzocaine.\"],[\"\\u003ca href=\\\"/drugs/DB06770\\\"\\u003eBenzyl alcohol\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Benzyl alcohol.\"],[\"\\u003ca href=\\\"/drugs/DB00297\\\"\\u003eBupivacaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Bupivacaine.\"],[\"\\u003ca href=\\\"/drugs/DB11502\\\"\\u003eButacaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butacaine.\"],[\"\\u003ca href=\\\"/drugs/DB11148\\\"\\u003eButamben\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butamben.\"],[\"\\u003ca href=\\\"/drugs/DB13328\\\"\\u003eButanilicaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Butanilicaine.\"],[\"\\u003ca href=\\\"/drugs/DB06774\\\"\\u003eCapsaicin\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Capsaicin.\"],[\"\\u003ca href=\\\"/drugs/DB01161\\\"\\u003eChloroprocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Chloroprocaine.\"],[\"\\u003ca href=\\\"/drugs/DB00527\\\"\\u003eCinchocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Cinchocaine.\"],[\"\\u003ca href=\\\"/drugs/DB00720\\\"\\u003eClodronic acid\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Clodronic acid.\"],[\"\\u003ca href=\\\"/drugs/DB00907\\\"\\u003eCocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Cocaine.\"],[\"\\u003ca href=\\\"/drugs/DB00012\\\"\\u003eDarbepoetin alfa\\u003c/a\\u003e\",\"The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Halofuginone.\"],[\"\\u003ca href=\\\"/drugs/DB01075\\\"\\u003eDiphenhydramine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Diphenhydramine.\"],[\"\\u003ca href=\\\"/drugs/DB00645\\\"\\u003eDyclonine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Dyclonine.\"],[\"\\u003ca href=\\\"/drugs/DB00016\\\"\\u003eErythropoietin\\u003c/a\\u003e\",\"The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Halofuginone.\"],[\"\\u003ca href=\\\"/drugs/DB13259\\\"\\u003eEthyl chloride\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ethyl chloride.\"],[\"\\u003ca href=\\\"/drugs/DB08987\\\"\\u003eEtidocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Etidocaine.\"],[\"\\u003ca href=\\\"/drugs/DB01077\\\"\\u003eEtidronic acid\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Etidronic acid.\"],[\"\\u003ca href=\\\"/drugs/DB14766\\\"\\u003eEtrasimod\\u003c/a\\u003e\",\"The risk or severity of immunosuppression can be increased when Halofuginone is combined with Etrasimod.\"],[\"\\u003ca href=\\\"/drugs/DB00710\\\"\\u003eIbandronate\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Ibandronate.\"],[\"\\u003ca href=\\\"/drugs/DB06255\\\"\\u003eIncadronic acid\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Incadronic acid.\"],[\"\\u003ca href=\\\"/drugs/DB01002\\\"\\u003eLevobupivacaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Levobupivacaine.\"],[\"\\u003ca href=\\\"/drugs/DB00281\\\"\\u003eLidocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Lidocaine.\"],[\"\\u003ca href=\\\"/drugs/DB00814\\\"\\u003eMeloxicam\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Meloxicam.\"],[\"\\u003ca href=\\\"/drugs/DB00961\\\"\\u003eMepivacaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Mepivacaine.\"],[\"\\u003ca href=\\\"/drugs/DB13578\\\"\\u003eMetabutethamine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Metabutethamine.\"],[\"\\u003ca href=\\\"/drugs/DB09107\\\"\\u003eMethoxy polyethylene glycol-epoetin beta\\u003c/a\\u003e\",\"The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Halofuginone.\"],[\"\\u003ca href=\\\"/drugs/DB01280\\\"\\u003eNelarabine\\u003c/a\\u003e\",\"The risk or severity of adverse effects can be increased when Nelarabine is combined with Halofuginone.\"],[\"\\u003ca href=\\\"/drugs/DB12532\\\"\\u003eOxetacaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Oxetacaine.\"],[\"\\u003ca href=\\\"/drugs/DB00892\\\"\\u003eOxybuprocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Oxybuprocaine.\"],[\"\\u003ca href=\\\"/drugs/DB00282\\\"\\u003ePamidronic acid\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Pamidronic acid.\"],[\"\\u003ca href=\\\"/drugs/DB08894\\\"\\u003ePeginesatide\\u003c/a\\u003e\",\"The risk or severity of Thrombosis can be increased when Peginesatide is combined with Halofuginone.\"],[\"\\u003ca href=\\\"/drugs/DB03255\\\"\\u003ePhenol\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Phenol.\"],[\"\\u003ca href=\\\"/drugs/DB09345\\\"\\u003ePramocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Pramocaine.\"],[\"\\u003ca href=\\\"/drugs/DB00750\\\"\\u003ePrilocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Prilocaine.\"],[\"\\u003ca href=\\\"/drugs/DB00721\\\"\\u003eProcaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Procaine.\"],[\"\\u003ca href=\\\"/drugs/DB00807\\\"\\u003eProparacaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Proparacaine.\"],[\"\\u003ca href=\\\"/drugs/DB09342\\\"\\u003ePropoxycaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Propoxycaine.\"],[\"\\u003ca href=\\\"/drugs/DB13683\\\"\\u003eQuinisocaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Quinisocaine.\"],[\"\\u003ca href=\\\"/drugs/DB00884\\\"\\u003eRisedronic acid\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Risedronic acid.\"],[\"\\u003ca href=\\\"/drugs/DB00296\\\"\\u003eRopivacaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Ropivacaine.\"],[\"\\u003ca href=\\\"/drugs/DB09085\\\"\\u003eTetracaine\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Tetracaine.\"],[\"\\u003ca href=\\\"/drugs/DB05232\\\"\\u003eTetrodotoxin\\u003c/a\\u003e\",\"The risk or severity of methemoglobinemia can be increased when Halofuginone is combined with Tetrodotoxin.\"],[\"\\u003ca href=\\\"/drugs/DB01133\\\"\\u003eTiludronic acid\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Tiludronic acid.\"],[\"\\u003ca href=\\\"/drugs/DB00399\\\"\\u003eZoledronic acid\\u003c/a\\u003e\",\"The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Zoledronic acid.\"]]}"
    },
    {
        "smiles": "COC1=CC=C2C3=C(C4CCCCC4)C4=CC=C(C=C4N3C[C@]3(C[C@H]3C2=C1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C",
        "id": "DB12225",
        "molecule": "Beclabuvir",
        "cas": "958002-33-0",
        "iupac_name": "(8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-[(1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl]-12-azapentacyclo[10.7.0.0^{2,7}.0^{8,10}.0^{13,18}]nonadeca-1(19),2,4,6,13,15,17-heptaene-15-carboxamide",
        "background": "Beclabuvir has been used in trials studying the treatment of Hepatitis C, Chronic.\n",
        "inchi": {
            "hash": "ZTTKEBYSXUCBSE-QDFUAKMASA-N",
            "id": "InChI=1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24-,25+,30-,36-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 659.838,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 659.314140265,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.",
        "link": "https://go.drugbank.com/drugs/DB12225",
        "type": "Small Molecule",
        "synonyms": [
            "Beclabuvir"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](C)(\\C=C(/C)\\C=C\\[C@]([H])(N)[C@]([H])(C)C(O)=O)[C@]([H])(CC1=CC=CC=C1)OC",
        "id": "DB06905",
        "molecule": "(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid",
        "iupac_name": "(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid",
        "inchi": {
            "hash": "HJVCHYDYCYBBQX-HLTLHRPFSA-N",
            "id": "InChI=1S/C20H29NO3/c1-14(10-11-18(21)16(3)20(22)23)12-15(2)19(24-4)13-17-8-6-5-7-9-17/h5-12,15-16,18-19H,13,21H2,1-4H3,(H,22,23)/b11-10+,14-12+/t15-,16-,18-,19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 331.4492,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 331.214743799,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB06905",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein phosphatase 2A catalytic subunit alpha isoform"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform"
            }
        ]
    },
    {
        "smiles": "[H]N1C(=O)\\C(C2=C1C=CC(=C2)S(O)(=O)=O)=C1/N([H])C2=CC=CC=C2C1=O",
        "id": "DB02519",
        "molecule": "Indirubin-5-sulphonate",
        "cas": "244021-67-8",
        "iupac_name": "(Z)-2',3-dioxo-1',2'-dihydro-1H,3H-[2,3'-biindolylidene]-5'-sulfonic acid",
        "inchi": {
            "hash": "IHBOEHLUIBMBMY-YPKPFQOOSA-N",
            "id": "InChI=1S/C16H10N2O5S/c19-15-9-3-1-2-4-11(9)17-14(15)13-10-7-8(24(21,22)23)5-6-12(10)18-16(13)20/h1-7,17H,(H,18,20)(H,21,22,23)/b14-13-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 342.326,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 342.03104213,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.",
        "link": "https://go.drugbank.com/drugs/DB02519",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, muscle form"
            },
            {
                "action": "Not Available",
                "organism": "Plasmodium falciparum (isolate K1 / Thailand)",
                "target": "UCell division control protein 2 homolog"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCC1=C(O)C(=O)C2=C(N=CS2)C1=O",
        "id": "DB04799",
        "molecule": "6-Hydroxy-5-undecyl-4,7-benzothiazoledione",
        "cas": "43152-58-5",
        "iupac_name": "6-hydroxy-5-undecyl-4,7-dihydro-1,3-benzothiazole-4,7-dione",
        "inchi": {
            "hash": "QCWGBMWYLYKEIU-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H25NO3S/c1-2-3-4-5-6-7-8-9-10-11-13-15(20)14-18(23-12-19-14)17(22)16(13)21/h12,21H,2-11H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 335.461,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 335.155514361,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aryl ketones. These are organic aromatic compounds that contain a ketone group substituted at one C-atom with an aryl group. They have the generic structure RC(=O)R', where R = aryl group and R'=organyl group.",
        "link": "https://go.drugbank.com/drugs/DB04799",
        "type": "Small Molecule",
        "synonyms": [
            "5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole",
            "6-hydroxy-5-undecyl-1,3-benzothiazole-4,7-dione",
            "6-Hydroxy-5-undecyl-4,7-benzothiazoledione",
            "UHDBT"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome c1, heme protein, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 1, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 2, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 6, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 8"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit Rieske, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 10"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 7"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 9"
            }
        ]
    },
    {
        "smiles": "O=C1C=C(OC2=CC=CC=C12)C1=CC=CC=C1",
        "id": "DB07776",
        "molecule": "Flavone",
        "cas": "525-82-6",
        "iupac_name": "2-phenyl-4H-chromen-4-one",
        "inchi": {
            "hash": "VHBFFQKBGNRLFZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H10O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-10H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 222.2387,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 222.068079564,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as flavones. These are flavonoids with a structure based on the backbone of 2-phenylchromen-4-one (2-phenyl-1-benzopyran-4-one).",
        "link": "https://go.drugbank.com/drugs/DB07776",
        "type": "Small Molecule",
        "synonyms": [
            "2-Phenyl-4-benzopyron",
            "2-Phenyl-4-chromone",
            "2-phenyl-4H-1-benzopyran-4-one",
            "2-phenyl-4H-benzopyran-4-one",
            "2-phenyl--benzopyrone",
            "2-Phenylbenzopyran-4-one",
            "2-phenylchromone",
            "Flavon"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces carzinostaticus",
                "target": "UNeocarzinostatin"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "USteroid hormone receptor ERR1"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "USteroid hormone receptor ERR2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome P450 1B1"
            }
        ]
    },
    {
        "smiles": "CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@@H](C(=O)OCC)C1=CC=CC=C1",
        "id": "DB05460",
        "molecule": "Ezatiostat",
        "cas": "168682-53-9",
        "iupac_name": "ethyl (2S)-2-amino-4-{[(1R)-2-(benzylsulfanyl)-1-{[(1R)-2-ethoxy-2-oxo-1-phenylethyl]carbamoyl}ethyl]carbamoyl}butanoate",
        "background": "Ezatiostat is investigated in clinical trials for treating myelodysplastic syndrome. This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another. This medication is known to target Glutathione S-transferase P. Ezatiostat is a small molecule drug that is an analog inhibitor of glutathione S-transferase P1-1. It acts intracellularly on the MAPK signaling pathway by activating ERK2. Ezatiostat has myelostimulant activity in preclinical rodent models and human bone marrow cultures, and differentiates granulocytes and monocytes in HL60 cells. Ezatiostat is a candidate designed to stimulate the formation of bone marrow cells that are precursors to granulocytes and monocytes (white blood cells), erythrocytes (red blood cells) and platelets. Many conditions are characterized by depleted bone marrow, including myelodysplastic syndrome (MDS), a form of pre-leukemia in which the bone marrow produces insufficient levels of one or more of the 3 major blood elements (white blood cells, red blood cells and platelets). It might also be relevant as an adjunct therapy since a reduction in blood cell levels is also a common, toxic effect of many standard chemotherapeutic drugs.\n",
        "inchi": {
            "hash": "GWEJFLVSOGNLSS-WPFOTENUSA-N",
            "id": "InChI=1S/C27H35N3O6S/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32)/t21-,22-,24+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 529.648,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 529.224656557,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB05460",
        "type": "Small Molecule",
        "synonyms": [
            "Ezatiostat",
            "gamma-Glutamyl-S-(benzyl)-cysteinyl-R(-)-phenylglycine diethyl ester"
        ],
        "indication": "Investigated for use/treatment in myelodysplastic syndrome.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione S-transferase P"
            }
        ]
    },
    {
        "smiles": "[H][C@](N)(CCSCC)[C@]([H])(O)C(=O)N[C@@]([H])(C)C1=C2C=CC=CC2=CC=C1",
        "id": "DB04108",
        "molecule": "(2s,3r)-3-Amino-2-Hydroxy-5-(Ethylsulfanyl)Pentanoyl-((S)-(-)-(1-Naphthyl)Ethyl)Amide",
        "iupac_name": "(2S,3S)-3-amino-5-(ethylsulfanyl)-2-hydroxy-N-[(1S)-1-(naphthalen-1-yl)ethyl]pentanamide",
        "inchi": {
            "hash": "AIIOXZPEXXZCML-KKXDTOCCSA-N",
            "id": "InChI=1S/C19H26N2O2S/c1-3-24-12-11-17(20)18(22)19(23)21-13(2)15-10-6-8-14-7-4-5-9-16(14)15/h4-10,13,17-18,22H,3,11-12,20H2,1-2H3,(H,21,23)/t13-,17-,18-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 346.487,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 346.171498776,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB04108",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMethionine aminopeptidase 2"
            }
        ]
    },
    {
        "smiles": "[H][C@@](C)(NC(=O)[C@@]([H])(CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)\\C=C\\C(=O)C=O",
        "id": "DB01810",
        "molecule": "[1-(1-Methyl-4,5-Dioxo-Pent-2-Enylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester",
        "iupac_name": "benzyl N-[(1R)-1-{[(2S,3E)-5,6-dioxohex-3-en-2-yl]carbamoyl}-2-phenylethyl]carbamate",
        "inchi": {
            "hash": "NOXVWFAAXREWMI-GURWAVDKSA-N",
            "id": "InChI=1S/C23H24N2O5/c1-17(12-13-20(27)15-26)24-22(28)21(14-18-8-4-2-5-9-18)25-23(29)30-16-19-10-6-3-7-11-19/h2-13,15,17,21H,14,16H2,1H3,(H,24,28)(H,25,29)/b13-12+/t17-,21+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 408.4471,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 408.168521888,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB01810",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCathepsin F"
            },
            {
                "action": "Not Available",
                "organism": "Trypanosoma cruzi",
                "target": "UCruzipain"
            }
        ]
    },
    {
        "smiles": "[H]N([C@H]1N([H])C[C@H](CO)[C@H](O)[C@@H]1O)C(C)=O",
        "id": "DB03861",
        "molecule": "(2R,3R,4S,5R)-2-acetamido-3,4-dihydroxy-5-hydroxymethyl-piperidine",
        "cas": "176246-06-3",
        "iupac_name": "N-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)piperidin-2-yl]acetamide",
        "inchi": {
            "hash": "IWVRQJNSUOIUFV-VGRMVHKJSA-N",
            "id": "InChI=1S/C8H16N2O4/c1-4(12)10-8-7(14)6(13)5(3-11)2-9-8/h5-9,11,13-14H,2-3H2,1H3,(H,10,12)/t5-,6+,7+,8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 204.2236,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 204.11100701,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as piperidines. These are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB03861",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UBeta-hexosaminidase subunit beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCalcium-activated potassium channel subunit beta-2"
            }
        ]
    },
    {
        "smiles": "NC1=CC=C2C(=O)NC(=O)C3=CC=CC1=C23",
        "id": "DB07096",
        "molecule": "6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE",
        "iupac_name": "8-amino-3-azatricyclo[7.3.1.0^{5,13}]trideca-1(12),5,7,9(13),10-pentaene-2,4-dione",
        "inchi": {
            "hash": "SSMIFVHARFVINF-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H8N2O2/c13-9-5-4-8-10-6(9)2-1-3-7(10)11(15)14-12(8)16/h1-5H,13H2,(H,14,15,16)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 212.2041,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 212.05857751,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as isoquinolones and derivatives. These are aromatic polycyclic compounds containing a ketone bearing isoquinoline moiety.",
        "link": "https://go.drugbank.com/drugs/DB07096",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPoly [ADP-ribose] polymerase 1"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB09121",
        "molecule": "Aurothioglucose",
        "cas": "12192-57-3",
        "iupac_name": "{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}gold",
        "background": "Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis.\nContemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis 2. The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action. Many if not most gold compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far more effective.\n",
        "inchi": {
            "hash": "XHVAWZZCDCWGBK-WYRLRVFGSA-M",
            "id": "InChI=1S/C6H12O5S.Au/c7-1-2-3(8)4(9)5(10)6(12)11-2;/h2-10,12H,1H2;/q;+1/p-1/t2-,3-,4+,5-,6-;/m1./s1"
        },
        "summary": "Aurothioglucose is a gold compound used in the treatment of rheumatoid arthritis.",
        "weight": [
            {
                "type": "average",
                "weight": 392.18,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 391.999289,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB09121",
        "type": "Small Molecule",
        "synonyms": [
            "Auromyose",
            "Aurothioglucose",
            "Gold thioglucose"
        ],
        "indication": "Aurothioglucose is indicated for the adjunctive treatment of early active adult and juvenile type rheumatoid arthritis that is not adequately controlled by other anti-inflammatory agents and conservative measures like salicylate, glucocorticoids, etc. 5,6. In chronic, advanced cases of rheumatoid arthritis, such gold therapy is not demonstrated to be as valuable 6.\nAntirheumatic measures such as salicylate and other anti-inflammatory drugs (both steroidal and non steroidal) may be continued after initiation of gold therapy 6. After improvement commences, these measures may be discontinued slowly as symptoms permit 6.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "After administration, patient serum levels of gold rise sharply but decline over the following week 6. Peak levels with aqueous preparations are higher and decline faster than those with oily preparations 6. Regular weekly administration produces a continuous rise in the basal value for several months, after which the serum level becomes relatively stable 6. After a standard weekly dose, considerable individual variation in the levels of gold can be observed 6. A steady decline in gold levels occurs when the interval between injections is lengthened, and small amounts may be found in the serum for months after discontinuation of therapy 6. The incidence of toxic reactions is seemingly unrelated to the plasma level of gold, but may perhaps be more associated with the total cumulative content of gold in the body 6.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenylate cyclase type 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenylate cyclase type 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenylate cyclase type 5"
            }
        ]
    },
    {
        "smiles": "N[C@@H]1CCOC1=O",
        "id": "DB02624",
        "molecule": "Homoserine Lactone",
        "cas": "1192-20-7",
        "iupac_name": "(3R)-3-aminooxolan-2-one",
        "inchi": {
            "hash": "QJPWUUJVYOJNMH-GSVOUGTGSA-N",
            "id": "InChI=1S/C4H7NO2/c5-3-1-2-7-4(3)6/h3H,1-2,5H2/t3-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 101.1039,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 101.047678473,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB02624",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USodium/hydrogen exchanger 1"
            }
        ]
    },
    {
        "smiles": "[O-][N+](=O)C1=CC=C(O1)\\C=C\\C=N\\N1CC(=O)NC1=O",
        "id": "DB13475",
        "molecule": "Furazidin",
        "cas": "1672-88-4",
        "iupac_name": "1-[(E)-[(2E)-3-(5-nitrofuran-2-yl)prop-2-en-1-ylidene]amino]imidazolidine-2,4-dione",
        "inchi": {
            "hash": "DECBQELQORZLLP-UAIOPKHMSA-N",
            "id": "InChI=1S/C10H8N4O5/c15-8-6-13(10(16)12-8)11-5-1-2-7-3-4-9(19-7)14(17)18/h1-5H,6H2,(H,12,15,16)/b2-1+,11-5+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 264.197,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 264.049469374,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydantoins. These are heterocyclic compounds containing an imidazolidine substituted by ketone group at positions 2 and 4.",
        "link": "https://go.drugbank.com/drugs/DB13475",
        "type": "Small Molecule",
        "synonyms": [
            "Furazidine"
        ],
        "is_stub": true
    },
    {
        "smiles": "NS(=O)(=O)C1=CC=C(NC2=NC(=CC=N2)C2=CN=C3C=CC=CN23)C=C1",
        "id": "DB02197",
        "molecule": "4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide",
        "iupac_name": "4-[(4-{imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]benzene-1-sulfonamide",
        "inchi": {
            "hash": "NKORVPQBJCGYEC-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H14N6O2S/c18-26(24,25)13-6-4-12(5-7-13)21-17-19-9-8-14(22-17)15-11-20-16-3-1-2-10-23(15)16/h1-11H,(H2,18,24,25)(H,19,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 366.397,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 366.089894412,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB02197",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "OC(=O)C=C",
        "id": "DB02579",
        "molecule": "Acrylic Acid",
        "cas": "79-10-7",
        "iupac_name": "prop-2-enoic acid",
        "background": "A ,-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.\n",
        "inchi": {
            "hash": "NIXOWILDQLNWCW-UHFFFAOYSA-N",
            "id": "InChI=1S/C3H4O2/c1-2-3(4)5/h2H,1H2,(H,4,5)"
        },
        "summary": "Acrylic Acid is a drug used in combination with benzalkonium for eye disinfection and lubrication.",
        "weight": [
            {
                "type": "average",
                "weight": 72.0627,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 72.021129372,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acrylic acids. These are organic compounds containing acrylic acid CH2=CHCO2H.",
        "link": "https://go.drugbank.com/drugs/DB02579",
        "type": "Small Molecule",
        "synonyms": [
            "2-Propenoic acid",
            "acroleic acid",
            "Acrylate",
            "ethylenecarboxylic acid",
            "Propenoate",
            "Propenoic acid",
            "Vinylformic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UBeta-lactamase SHV-1"
            }
        ]
    },
    {
        "smiles": "[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)N2C",
        "id": "DB11181",
        "molecule": "Homatropine",
        "cas": "87-00-3",
        "iupac_name": "(1R,3S,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-2-phenylacetate",
        "background": "Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions. Homatropine is included in subtherapeutic amounts as homatropine methylbromide to discourage deliberate overdosage. Homatropine hydrobromide has been administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic use has not been approved by the FDA to be safe and effective.\n",
        "inchi": {
            "hash": "ZTVIKZXZYLEVOL-MCOXGKPRSA-N",
            "id": "InChI=1S/C16H21NO3/c1-17-12-7-8-13(17)10-14(9-12)20-16(19)15(18)11-5-3-2-4-6-11/h2-6,12-15,18H,7-10H2,1H3/t12-,13+,14+,15?"
        },
        "summary": "Homatropine is an anticholinergic agent used to dilate the pupil, treat inflammation of the uveal tract, and suppress a cough.",
        "weight": [
            {
                "type": "average",
                "weight": 275.348,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 275.15214354,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11181",
        "type": "Small Molecule",
        "synonyms": [
            "Homatropina",
            "Omatropina"
        ],
        "indication": "Indicated as an overdose-rescuing agent in combination with hydrocodone antitussive Label.\nIndicated for the induction of mydriasis in ophthalmic solutions. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Homatropine is an anticholinergic drug that produces typical anticholinergic effects inducing mydriasis and cycloplegia. Other effects of structurally-related atropine that could also apply to homatropine include inhibition of secretions, tachycardia, relaxation of smooth muscle and central nervous effects including excitation 1.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M3"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M5"
            }
        ]
    },
    {
        "smiles": "COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@H]1CCN(CC2=CC=CC=C2)C1",
        "id": "DB09227",
        "molecule": "Barnidipine",
        "cas": "104713-75-9",
        "iupac_name": "3-(3S)-1-benzylpyrrolidin-3-yl 5-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate",
        "background": "Barnidipine is a long-acting novel calcium antagonist that belongs to the dihydropyridine (DHP) group of calcium channel blockers. Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the smooth muscle cells in the vascular wall 8 and selectivity against cardiovascular L-type calcium channels 1. Barnidipine contains two chiral centres thus can have four possible enantiomers. The active component is composed of a single optical isomer (3'S, 4S configuration), which is the most potent and longest-acting of the four enantiomers 3. Compared to several other calcium antagonists which are racemates, the barnidipine compound consisting of a single enantiomer may offer a high degree of pharmacological selectivity 3.\nAccording to a dose-ranging, multicentre, placebo-controlled, double-blind study in patients with mild to moderate hypertension, the antihypertensive response from barnidipine treatment was maintained after a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug 1. In two European multicentre randomized, double-blind trials, barnidipine was shown to possess equivalent antihypertensive efficacy to amlodipine and nitrendipine, but produced fewer class-specific side-effects 4. It also demonstrated clinical efficacy which is similar to that of atenolol, enalapril and hydrochlorothiazide 1. \nIt is available in modified-release oral tablets under the brand name Vasexten to be taken once daily in the morning. Barnidipine has a gradual onset of action and is shown to be well tolerated in patients. It does not produce reflex tachycardia 1.\n",
        "inchi": {
            "hash": "VXMOONUMYLCFJD-DHLKQENFSA-N",
            "id": "InChI=1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1"
        },
        "summary": "Barnidipine is a calcium channel blocker used to treat various forms of hypertension.",
        "weight": [
            {
                "type": "average",
                "weight": 491.544,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 491.205635666,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.",
        "link": "https://go.drugbank.com/drugs/DB09227",
        "type": "Small Molecule",
        "synonyms": [
            "Barnidipine",
            "Barnidipino",
            "Mepirodipine"
        ],
        "indication": "Indicated for the treatment of mild to moderate essential hypertension and management of chronic stable angina.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Barnidipine reduces peripheral resistance and lowers blood pressure. The chronic use of the drug is not reported to lead to an increase in basic heart frequency. The antihypertensive effects of barnidipine are reported to remain during the entire 24-hour dose interval. Barnidipine does not exert any negative effect on serum lipids profile, glucose level or blood electrolytes 8. \n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AVoltage-dependent L-type calcium channel subunit alpha-1C"
            },
            {
                "action": "antagonistinhibitor",
                "organism": "Humans",
                "target": "UVoltage-dependent T-type calcium channel subunit alpha-1G"
            },
            {
                "action": "antagonistinhibitor",
                "organism": "Humans",
                "target": "UVoltage-dependent T-type calcium channel subunit alpha-1H"
            }
        ]
    },
    {
        "smiles": "CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O",
        "id": "DB08915",
        "molecule": "Aleglitazar",
        "cas": "475479-34-6",
        "iupac_name": "(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid",
        "background": "Aleglitazar is an investigational drug from the company HoffmannLa Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPAR and PPAR receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity.\n",
        "inchi": {
            "hash": "DAYKLWSKQJBGCS-NRFANRHFSA-N",
            "id": "InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 437.508,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 437.129693541,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenyl-1,3-oxazoles. These are aromatic heterocyclic compounds containing a 1,3-oxazole substituted at one or more positions by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB08915",
        "type": "Small Molecule",
        "synonyms": [
            "Aleglitazar"
        ],
        "indication": "Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "APeroxisome proliferator-activated receptor alpha"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "APeroxisome proliferator-activated receptor gamma"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor coactivator 1"
            }
        ]
    },
    {
        "smiles": "CC(C)C[C@H](NC(=O)[C@@H](O)CC(O)=O)C(=O)NCCCC[NH+]=C(N)N",
        "id": "DB04276",
        "molecule": "4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium",
        "iupac_name": "{4-[(2S)-2-[(2S)-3-carboxy-2-hydroxypropanamido]-4-methylpentanamido]butyl}(diaminomethylidene)azanium",
        "inchi": {
            "hash": "QPQNJAXBPHVASB-QWRGUYRKSA-O",
            "id": "InChI=1S/C15H29N5O5/c1-9(2)7-10(20-14(25)11(21)8-12(22)23)13(24)18-5-3-4-6-19-15(16)17/h9-11,21H,3-8H2,1-2H3,(H,18,24)(H,20,25)(H,22,23)(H4,16,17,19)/p+1/t10-,11-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 360.4292,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 360.224694095,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as leucine and derivatives. These are compounds containing leucine or a derivative thereof resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB04276",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus (strain MW2)",
                "target": "UNPQTN specific sortase B"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCalpain-1 catalytic subunit"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4",
        "id": "DB09274",
        "molecule": "Artesunate",
        "cas": "88495-63-0",
        "iupac_name": "4-oxo-4-{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0,.0,]hexadecan-10-yl]oxy}butanoic acid",
        "background": "Artesunate is indicated for the initial treatment of severe malaria.8 The World Health Organization recommends artesunate as first line treatment for severe malaria.6 Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin.5\nArtesunate was granted FDA approval on 26 May 2020.8\n",
        "inchi": {
            "hash": "FIHJKUPKCHIPAT-AHIGJZGOSA-N",
            "id": "InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1"
        },
        "summary": "Artesunate is artesunate is an artemesinin derivative indicated for the initial treatment of severe malaria.",
        "weight": [
            {
                "type": "average",
                "weight": 384.425,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 384.178417862,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as artemisinins. These are sesquiterpenoids originally isolated from the herb Artemisia annua. Their structure is based on artemisinin, a tetracyclic compound that contains a 1,2-dioxepane fused to an octahydrobenzopyran moiety. The internal peroxide bridge is believed to be a key to the mode of action of artemisinins.",
        "link": "https://go.drugbank.com/drugs/DB09274",
        "type": "Small Molecule",
        "synonyms": [
            "Artesunate",
            "Artesunato",
            "Artesunatum",
            "Artesunic acid",
            "AS",
            "butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester",
            "dihydroqinghasu hemsuccinate",
            "Succinyl dihydroartemisinin"
        ],
        "indication": "Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients.8\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Artesunate is an artemisinin derivative that is metabolized to DHA, which generates free radicals to inhibit normal function of Plasmodium parasites.1,7,8 It has a short duration of action due to its short half life, and a moderate therapeutic index.7,8 Patients should be counselled regarding the risk of post treatment hemolytic anemia and hypersenstivity.8\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Plasmodium falciparum",
                "target": "AMalaria protein EXP-1"
            }
        ]
    },
    {
        "smiles": "COC1=C(C)C(C)=C(\\C=C\\C(\\C)=C\\C=C\\C(\\C)=C\\C(O)=O)C(C)=C1",
        "id": "DB00459",
        "molecule": "Acitretin",
        "cas": "55079-83-9",
        "iupac_name": "(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid",
        "background": "An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.\n",
        "inchi": {
            "hash": "IHUNBGSDBOWDMA-AQFIFDHZSA-N",
            "id": "InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+"
        },
        "summary": "Acitretin is an oral retinoid used in the treatment of severe psoriasis.",
        "weight": [
            {
                "type": "average",
                "weight": 326.4293,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 326.188194698,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.",
        "link": "https://go.drugbank.com/drugs/DB00459",
        "type": "Small Molecule",
        "synonyms": [
            "(all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid",
            "Acitretin",
            "Acitretina",
            "Acitretine",
            "Acitretinum",
            "all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid",
            "Etretin"
        ],
        "indication": "For the treatment of severe psoriasis in adults.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Acitretin is a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation (process by which skin cells become thickened due to the deposition of a protein within them) seen in psoriasis. It therefore reduces the thickening of the skin, plaque formation and scaling.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor RXR-alpha"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor alpha"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor beta"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor gamma"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor RXR-beta"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ARetinoic acid receptor RXR-gamma"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "URetinol-binding protein 1"
            },
            {
                "action": "Not Available",
                "organism": "",
                "target": "URetinoic acid receptor RXR"
            }
        ]
    },
    {
        "smiles": "C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1",
        "id": "DB08799",
        "molecule": "Antazoline",
        "cas": "91-75-8",
        "iupac_name": "N-benzyl-N-[(4,5-dihydro-1H-imidazol-2-yl)methyl]aniline",
        "background": "Antazoline is a 1st generation antihistamine with anticholinergic activity. It is used to relieve nasal congestion. It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.\n",
        "inchi": {
            "hash": "REYFJDPCWQRWAA-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)"
        },
        "summary": "Antazoline is an antihistamine agent used for the symptomatic treatment of nasal congestion and allergic conjunctivitis.",
        "weight": [
            {
                "type": "average",
                "weight": 265.3529,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 265.157897623,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.",
        "link": "https://go.drugbank.com/drugs/DB08799",
        "type": "Small Molecule",
        "synonyms": [
            "2-(N-Benzylanilinomethyl)-2-imidazoline",
            "2-(N-Phenyl-N-benzylaminomethyl)imidazoline",
            "4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine",
            "Antazolina",
            "Antazoline",
            "Antazolinum"
        ],
        "indication": "Used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Antazoline is a histamine H1 receptor antagonist. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AHistamine H1 receptor"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CCC(C)=C[C@H]1C1=C(O)C=C(CCC)C=C1O)C(C)=C",
        "id": "DB14050",
        "molecule": "Cannabidivarin",
        "cas": "24274-48-4",
        "iupac_name": "2-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol",
        "background": "Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within Medical Cannabis. It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana 3. Compared to its homolog, Cannabidiol, CBDV is shortened by two methyl (CH2) groups on its side chain. Notably, both Cannabidiol and CBDV have demonstrated anticonvulsant activity in animal and human models and are demonstrating promising clinical trial results 2,4,5,6. Other cannabinoids with some evidence of anti-epileptic activity include Tetrahydrocannabivarin (THCV) and 9-tetrahydrocannabinolic acid.\nWhile the primary components of cannabis, CBD and THC, have been shown to modulate many of their physiological effects through their binding to the cannabinoid-1 (CB1R) and cannabinoid-2 (CB2R) receptors, the investigational cannabinoids with anticonvulsant action mostly use mechanisms that do not involve these two endocannabinoid receptors.\nThe anti-epileptic activity of CBD and CBDV is thought to be modulated by their effects on transient receptor potential cation channel subfamily V member 1 (TRPV1), also known as the capsaicin receptor, which is a member of a large family of ion channels that are involved in the onset and progression of several types of epilepsy. CBD and CBDV have been shown to dose-dependently activate and then desensitize TRPV1 as well as TRPV2 and TRPA1 channels 4,7,8. Desensitization of these ion channels is a potential mechanism by which these molecules cause a reduction of neuronal hyperexcitability that contributes to epileptic activity and seizures. \nCBDV has also been shown to inhibit the activity of diacylglycerol (DAG) lipase-, the primary enzyme responsible for the synthesis of the endocannabinoid, 2-arachidonoylglycerol (2-AG) 1,10. The clinical implications of this are unclear however, as this interaction has not been shown to affect CBDV's anticonvulsant activity.\nCannabidivarin is being actively developed by GW Pharmaceuticals as the experimental compound GWP42006 as it has \"shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs\" 13. Unfortunately, as of February 2018, GW Pharmaceuticals announced that their Phase 2a placebo-controlled study of CBDV for focal seizure did not reach its primary endpoints. They will continue to study its use in epilepsy, however, and are expanding their investigations to include its potential use in Autism Spectrum Disorder, Rett syndrome and Fragile X among others 12. \nIn October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome 15 and again in February 2018 for treatment of Fragile X Syndrome 14.\n",
        "inchi": {
            "hash": "REOZWEGFPHTFEI-JKSUJKDBSA-N",
            "id": "InChI=1S/C19H26O2/c1-5-6-14-10-17(20)19(18(21)11-14)16-9-13(4)7-8-15(16)12(2)3/h9-11,15-16,20-21H,2,5-8H2,1,3-4H3/t15-,16+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 286.415,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 286.193280077,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14050",
        "type": "Small Molecule",
        "synonyms": [
            "2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol",
            "cannabidivarine",
            "Cannabidivarol",
            "CBD-V",
            "CBDV"
        ],
        "indication": "Cannabidivarin does not currently have any FDA or Health Canada approved indications, however in October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome 15 and again in February 2018 for treatment of Fragile X Syndrome 14.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ATransient receptor potential cation channel subfamily V member 1"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ATransient receptor potential cation channel subfamily V member 2"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ATransient receptor potential cation channel subfamily A member 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "USn1-specific diacylglycerol lipase alpha"
            }
        ]
    },
    {
        "smiles": "NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1",
        "id": "DB12783",
        "molecule": "Benserazide",
        "cas": "322-35-0",
        "iupac_name": "2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide",
        "background": "When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the blood and to various extracerebral tissues. This can result in a number of side effects like nausea, vomiting, or even cardiac arrhythmias that may diminish patient adherence 3,2. A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation of dopamine from levadopa in extracerebral tissues - thereby acting to minimize the occurrence of extracerebral side effects 3,2.\nLevodopa/benserazide combination products are used commonly worldwide for the management of Parkinson's disease. In particular, although the specific levodopa/benserazide combination is formally approved for use in Canada and much of Europe, the FDA has approved another similar levodopa/dopa decarboxylase inhibitor combination in the form of levodopa and carbidopa.\nMoreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well 4.\n",
        "inchi": {
            "hash": "BNQDCRGUHNALGH-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)"
        },
        "summary": "Benserazide is a medication used to treat Parkinson's disease, parkinsonism, and restless leg syndrome.",
        "weight": [
            {
                "type": "average",
                "weight": 257.246,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 257.101170595,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as serine and derivatives. These are compounds containing serine or a derivative thereof resulting from reaction of serine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB12783",
        "type": "Small Molecule",
        "synonyms": [
            "benserazida",
            "Benserazide",
            "benserazidum"
        ],
        "indication": "The primary therapeutic use for which benserazide is currently indicated for is as a combination therapy with levadopa for the treatment of Parkinson's disease in adults \u003e 25 years of age, with the exception of drug-induced parkinsonism 3,2.\nAt certain doses, the combination product of levodopa and benserazide may also be used to treat restless legs syndrome, which is sometimes associated with Parkinson's disease 2,1.\nThere have also been some studies that have prompted the European Medicines Agency to confer orphan designation upon benserazide hydrochloride as a potential therapy for beta thalassaemia 4. Although studies are ongoing, no evidence has been formally elucidated as of yet 4.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "When used as a therapy for treating Parkinson's disease, levadopa's specific mechanism of action revolves around its metabolism into dopamine in the body 3,2. Unfortunately, the resultant increase in the levels of circulating dopamine in the blood and to various extracerebral tissues can result in a number of side effects like nausea, vomiting, or even cardiac arrhythmias that may diminish patient adherence 3,2. A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself and therefore allows levadopa to elicit its primary action in the central nervous system, but will prevent the formation of dopamine from levadopa in extracerebral tissues - thereby acting to minimize the occurrence of extracerebral side effects 3,2.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AAromatic-L-amino-acid decarboxylase"
            }
        ]
    },
    {
        "smiles": "NC1(CCN(CC1)C1=C2C=CNC2=NC=N1)C(=O)N[C@@H](CCO)C1=CC=C(Cl)C=C1",
        "id": "DB12218",
        "molecule": "Capivasertib",
        "cas": "1143532-39-1",
        "iupac_name": "4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperidine-4-carboxamide",
        "background": "Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually. Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. Therefore, significant research has been put into developing genetically targeted treatments.1\nThe PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative regulator of the PIK3/AKT pathway, or PIK3CA mutations. Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor.1,2,3\nOn November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with fulvestrant. This approval is based on favorable results obtained from the CAPItello-291 trial, where the combination of capivasertib and fulvestrant reduced the risk of disease progression or death by 50% versus fulvestrant alone.5\n",
        "inchi": {
            "hash": "JDUBGYFRJFOXQC-KRWDZBQOSA-N",
            "id": "InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1"
        },
        "summary": "Capivasertib is a serine/threonine kinase inhibitor used to treat hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",
        "weight": [
            {
                "type": "average",
                "weight": 428.915,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 428.172751781,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB12218",
        "type": "Small Molecule",
        "synonyms": [
            "Capivasertib",
            "Capivasertibum"
        ],
        "indication": "Capivasertib, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.4\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "In vitro, capivasertib reduced the growth of breast cancer cell lines including those with relevant PIK3CA or AKT1 mutations or PTEN alteration. In vivo, capivasertib alone and in combination with fulvestrant inhibited tumor growth of mouse xenograft models including estrogen receptor-positive breast cancer models with alterations in PIK3CA, AKT1, and PTEN.4\nThe exposure-response relationship and time course of pharmacodynamic response for the effectiveness of capivasertib has not been fully characterized. Exposure-response relationships were observed for diarrhea (CTCAE Grade 2 to 4), rash (CTCAE Grade 2 to 4), and hyperglycemia (CTCAE Grades 3 or 4) at doses of 80 to 800 mg (0.2 to 2 times the approved recommended dosage).4\nAt the recommended capivasertib dose, a mean increase in the QTc interval \u003e 20 ms was not observed.4 \n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ARAC-alpha serine/threonine-protein kinase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ARAC-beta serine/threonine-protein kinase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ARAC-gamma serine/threonine-protein kinase"
            }
        ]
    },
    {
        "smiles": "COC1=C(C=C(OC2=CN=C(N)N=C2N)C(=C1)C(C)C)S(N)(=O)=O",
        "id": "DB15097",
        "molecule": "Gefapixant",
        "cas": "1015787-98-0",
        "iupac_name": "5-[(2,4-diaminopyrimidin-5-yl)oxy]-2-methoxy-4-(propan-2-yl)benzene-1-sulfonamide",
        "background": "It has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks.4 A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment or unexplained chronic cough (UCC) when no diagnosable cause for the cough can be determined.3 Existing treatments for chronic cough have been associated with considerable side effects, in particular opioids such as codeine or dextromethorphan.3\nGefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough. It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.3,2 It is the first therapy to be approved for the treatment of RCC or UCC in the EU.4\n",
        "inchi": {
            "hash": "HLWURFKMDLAKOD-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)"
        },
        "summary": "Gefapixant is a P2X3 receptor antagonist that reduces the cough reflex in patients with refractory or unexplained chronic cough.",
        "weight": [
            {
                "type": "average",
                "weight": 353.4,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 353.115775286,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15097",
        "type": "Small Molecule",
        "synonyms": [
            "Gefapixant"
        ],
        "indication": "Gefapixant is indicated in adult patients for the treatment of refractory or unexplained chronic cough.2\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Gefapixant exerts its therapeutic effects via suppressing the cough reflex initiated by sensory C fibers of the vagus nerve.2 In clinical studies, patients experienced a significant reduction in 24-hour cough frequency compared to placebo - this reduction was apparent by Week 4 and persisted throughout the remainder of the primary efficacy period.2\nAs renal excretion is the primary route of elimination for gefapixant, patients with severe renal impairment (eGFR \u003c 30 mL/min/1.73m2) may require dose adjustment to maintain appropriate systemic exposures.2\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AP2X purinoceptor 3"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UP2X purinoceptor 2"
            }
        ]
    },
    {
        "smiles": "CCC1=NC(N)=NC(N)=C1C#CCC1=CC(OC)=CC=C1OC",
        "id": "DB08234",
        "molecule": "5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine",
        "iupac_name": "5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine",
        "inchi": {
            "hash": "NNFDQABYXZBKRK-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H20N4O2/c1-4-14-13(16(18)21-17(19)20-14)7-5-6-11-10-12(22-2)8-9-15(11)23-3/h8-10H,4,6H2,1-3H3,(H4,18,19,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 312.3663,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 312.158625904,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.",
        "link": "https://go.drugbank.com/drugs/DB08234",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus anthracis",
                "target": "UDihydrofolate reductase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydrofolate reductase"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus (strain bovine RF122 / ET3-1)",
                "target": "UDihydrofolate reductase (dfrB)"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "CN1CCN(CCCCN2C(=O)CN(N=CC3=CC=C(O3)C3=CC=C(Cl)C=C3)C2=O)CC1",
        "id": "DB04957",
        "molecule": "Azimilide",
        "cas": "149908-53-2",
        "iupac_name": "1-({[5-(4-chlorophenyl)furan-2-yl]methylidene}amino)-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione",
        "background": "Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. It is not approved for use in any country, but is currently in clinical trials in the United States.\n",
        "inchi": {
            "hash": "MREBEPTUUMTTIA-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 457.96,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 457.1880675,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydantoins. These are heterocyclic compounds containing an imidazolidine substituted by ketone group at positions 2 and 4.",
        "link": "https://go.drugbank.com/drugs/DB04957",
        "type": "Small Molecule",
        "synonyms": [
            "Azimilide"
        ],
        "indication": "Investigated for use/treatment in arrhythmia and atrial fibrillation.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Azimilide is a new class III anti-arrhythmic agent. It is distinguished by a relative lack of reverse use-dependence, excellent oral absorption, no need for dose titration, an option for out-patient initiation, no need for adjustment associated with renal or liver failure and a lack of interaction with warfarin or digoxin. It carries some risk of torsade de pointes and rarely, neutropoenia.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPotassium voltage-gated channel subfamily E member 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPotassium voltage-gated channel subfamily KQT member 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPotassium voltage-gated channel subfamily H member 2"
            }
        ]
    },
    {
        "smiles": "NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1",
        "id": "DB00999",
        "molecule": "Hydrochlorothiazide",
        "cas": "58-93-5",
        "iupac_name": "6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide",
        "background": "Hydrochlorothiazide is the most commonly prescribed thiazide diuretic.2 It is indicated to treat edema and hypertension.2,10,11 Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors.2 Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors14,15 or angiotensin II receptor blockers.12,13\nHydrochlorothiazide was granted FDA approval on 12 February 1959.9\n",
        "inchi": {
            "hash": "JZUFKLXOESDKRF-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)"
        },
        "summary": "Hydrochlorothiazide is a thiazide diuretic used to treat edema associated with a number of conditions, and hypertension.",
        "weight": [
            {
                "type": "average",
                "weight": 297.739,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 296.964474846,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB00999",
        "type": "Small Molecule",
        "synonyms": [
            "HCTZ",
            "Hidroclorotiazida",
            "Hydrochlorothiazide",
            "Hydrochlorothiazidum"
        ],
        "indication": "Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy.10,11 Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.2,10,11,16\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrochlorothiazide prevents the reabsorption of sodium and water from the distal convoluted tubule, allowing for the increased elimination of water in the urine.2,3,4,10,11 Hydrochlorothiazide has a wide therapeutic window as dosing is individualized and can range from 25-100mg.10,11 Hydrochlorothiazide should be used with caution in patients with reduced kidney or liver function.10,11\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASolute carrier family 12 member 3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACalcium-activated potassium channel subunit alpha-1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2",
        "id": "DB00757",
        "molecule": "Dolasetron",
        "cas": "115956-12-2",
        "iupac_name": "(1s,3R,5r,7S)-10-oxo-8-azatricyclo[5.3.1.0,]undecan-5-yl 1H-indole-3-carboxylate",
        "background": "Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.\n",
        "inchi": {
            "hash": "UKTAZPQNNNJVKR-KJGYPYNMSA-N",
            "id": "InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11-,12-,13+,14+"
        },
        "summary": "Dolasetron is an antinauseant and antiemetic used in chemotherapy and postoperatively.",
        "weight": [
            {
                "type": "average",
                "weight": 324.38,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 324.147392512,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indolecarboxylic acids and derivatives. These are compounds containing a carboxylic acid group (or a derivative thereof) linked to an indole.",
        "link": "https://go.drugbank.com/drugs/DB00757",
        "type": "Small Molecule",
        "synonyms": [
            "Dolasetron",
            "Dolastron",
            "Dolasetronum"
        ],
        "indication": "For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. It is structurally and pharmacologically related to other 5-HT3 receptor agonists. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. It is suggested that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 3A"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1",
        "id": "DB08907",
        "molecule": "Canagliflozin",
        "cas": "842133-18-0",
        "iupac_name": "(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol",
        "background": "Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise Label.\nIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus 8, Label. \nCanagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes 8. Cardiovascular disease is the most common cause of death in these patients 4.\n",
        "inchi": {
            "hash": "XTNGUQKDFGDXSJ-ZXGKGEBGSA-N",
            "id": "InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1"
        },
        "summary": "Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage hyperglycemia in type 2 diabetes mellitus (DM). Also used to reduce the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 DM.",
        "weight": [
            {
                "type": "average",
                "weight": 444.516,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 444.140672805,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.",
        "link": "https://go.drugbank.com/drugs/DB08907",
        "type": "Small Molecule",
        "synonyms": [
            "Canagliflozin",
            "Canagliflozin anhydrous",
            "Canagliflozina"
        ],
        "indication": "This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus Label.\nAnother indication for canagliflozin is the prevention of major cardiovascular events (myocardial infarction, stroke, or death due to a cardiovascular cause) in patients with type 2 diabetes, as well as hospitalization for heart failure in patients with type 2 diabetes8,10.\nIn addition to the above, canagliflozin can be used to lower the risk of end-stage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus, diabetic nephropathy, and albuminuria.10\nIt is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis Label. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "This drug increases urinary glucose excretion and decreases the renal threshold for glucose (RTG) in a dose-dependent manner Label. The renal threshold is defined as the lowest level of blood glucose associated with the appearance of detectable glucose in the urine 2,7. The end result of canagliflozin administration is increased urinary excretion of glucose and less renal absorption of glucose, decreasing glucose concentration in the blood and improving glycemic control. \nA note on type 2 diabetes and cardiovascular disease\nThe risk of cardiovascular events in diabetes type 2 is increased due to the damaging effects of diabetes on blood vessels and nerves in the cardiovascular system. In particular, there is a tendency for hyperglycemia to create pro-atherogenic (plaque forming) lesions in blood vessels, leading to various fatal and non-fatal events including stroke and myocardial infarction 5,9. Long-term glycemic control has been proven to be effective in the prevention of cardiovascular events such as myocardial infarction and stroke in patients with type 2 diabetes 6.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium/glucose cotransporter 2"
            }
        ]
    },
    {
        "smiles": "CCCCCCCC(O)=O",
        "id": "DB04519",
        "molecule": "Caprylic acid",
        "cas": "124-07-2",
        "iupac_name": "octanoic acid",
        "background": "Caprylic acid is an eight-carbon chain fatty acid, also known systematically as octanoic acid. It is found naturally in coconuts and breast milk. It is an oily liquid with a slightly unpleasant rancid-like smell that is minimally soluble in water.\n",
        "inchi": {
            "hash": "WWZKQHOCKIZLMA-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H16O2/c1-2-3-4-5-6-7-8(9)10/h2-7H2,1H3,(H,9,10)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 144.2114,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 144.115029756,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB04519",
        "type": "Small Molecule",
        "synonyms": [
            "1-heptanecarboxylic acid",
            "Acide octanoque",
            "Acide octanoique",
            "cido octanoico",
            "Acidum octanocium",
            "Acidum octanoicum",
            "C8:0",
            "Caprylic acid",
            "Kaprylsure",
            "n-caprylic acid",
            "n-octanoic acid",
            "n-Octoic acid",
            "n-octylic acid",
            "Octanoic acid",
            "Octoic acid",
            "Octylic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPeroxisome proliferator-activated receptor alpha"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "U3-oxoacyl-[acyl-carrier-protein] synthase 1"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAcyl-CoA thioesterase I"
            }
        ]
    },
    {
        "smiles": "CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1",
        "id": "DB01319",
        "molecule": "Fosamprenavir",
        "cas": "226700-79-4",
        "iupac_name": "{[(2R,3S)-1-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-3-({[(3S)-oxolan-3-yloxy]carbonyl}amino)-4-phenylbutan-2-yl]oxy}phosphonic acid",
        "background": "Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.\n",
        "inchi": {
            "hash": "MLBVMOWEQCZNCC-OEMFJLHTSA-N",
            "id": "InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1"
        },
        "summary": "Fosamprenavir is an antiretroviral agent used for the treatment and postexposure prophylaxis of human immunodeficiency virus (HIV-1) infection.",
        "weight": [
            {
                "type": "average",
                "weight": 585.607,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 585.190986967,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB01319",
        "type": "Small Molecule",
        "synonyms": [
            "FOS-APV",
            "Fosamprenavir"
        ],
        "indication": "Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fosamprenavir is hydrolyzed by cellular phosphatases to the antiretroviral protease inhibitor amprenavir. This hydrolysis allows for the slow release of amprenavir, reducing the number of pills a patient must take.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Human immunodeficiency virus 1",
                "target": "AHuman immunodeficiency virus type 1 protease"
            }
        ]
    },
    {
        "smiles": "NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F",
        "id": "DB00774",
        "molecule": "Hydroflumethiazide",
        "cas": "135-09-1",
        "iupac_name": "1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide",
        "background": "A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)\n",
        "inchi": {
            "hash": "DMDGGSIALPNSEE-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)"
        },
        "summary": "Hydroflumethiazide is a thiazide diuretic used to treat hypertension as well as edema due to congestive heart failure and liver cirrhosis.",
        "weight": [
            {
                "type": "average",
                "weight": 331.292,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 330.990831754,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB00774",
        "type": "Small Molecule",
        "synonyms": [
            "Dihydroflumethazide",
            "Hidroflumetiazid",
            "Hidroflumetiazida",
            "Hydroflumthiazide",
            "Hydroflumethiazide",
            "Hydroflumethiazidum",
            "Idroflumetiazide",
            "Metforylthiadiazin"
        ],
        "indication": "Used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydroflumethiazide is an oral thiazide used to treat hypertension and edema. High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. Like other thiazides, Hydroflumethiazide promotes water loss from the body (diuretics). Thiazides inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASolute carrier family 12 member 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 7"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 9"
            },
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "USodium/potassium-transporting ATPase subunit alpha-1"
            },
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "UCalcium-activated potassium channel subunit alpha-1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 4"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 12"
            }
        ]
    },
    {
        "smiles": "CCCC(C)(COC(N)=O)COC(=O)NC(C)C",
        "id": "DB00395",
        "molecule": "Carisoprodol",
        "cas": "78-44-4",
        "iupac_name": "2-[(carbamoyloxy)methyl]-2-methylpentyl N-(propan-2-yl)carbamate",
        "background": "Originally approved by the FDA in 1959 Label, carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications 4. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine Label,16,17.\nIn January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse 5,8 despite having a low potential for abuse in addition to a low risk of dependence 13.\n",
        "inchi": {
            "hash": "OFZCIYFFPZCNJE-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)"
        },
        "summary": "Carisoprodol is a centrally acting muscle relaxant used to relieve the discomfort associated with various musculoskeletal conditions.",
        "weight": [
            {
                "type": "average",
                "weight": 260.33,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 260.173607266,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.",
        "link": "https://go.drugbank.com/drugs/DB00395",
        "type": "Small Molecule",
        "synonyms": [
            "()-2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate",
            "(1-methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester",
            "(RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate",
            "2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate",
            "2-methyl-2-propyltrimethylene carbamate isopropylcarbamate",
            "carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester",
            "Carisoprodol",
            "Carisoprodolo",
            "Carisoprodolum",
            "Isobamate",
            "Isomeprobamate",
            "Isopropyl meprobamate",
            "Isopropylmeprobamate",
            "N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate"
        ],
        "indication": "Carisoprodol is indicated for the relief of discomfort related to acute, painful musculoskeletal conditions Label.\nImportant limitations of use Label:\n Should only be used for acute treatment periods up to two or three weeks \n Adequate evidence of effectiveness for more prolonged use has not been established \n Not recommended in pediatric patients less than 16 years of age\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Carisoprodol is a centrally acting skeletal muscle relaxant that does not act directly on skeletal muscle but acts directly on the central nervous system (CNS). This drug relieves the painful effects of muscle spasm 12,19. A metabolite of carisoprodol, meprobamate, possesses both anxiolytic and sedative properties Label. Clinical studies have shown that this drug causes impairment of psychomotor performance in neuropsychological tests.5,10\n",
        "moa": [
            {
                "action": "activatormodulator",
                "organism": "Humans",
                "target": "UGamma-aminobutyric acid receptor subunit alpha-1"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "UGamma-aminobutyric acid receptor subunit beta-2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGamma-aminobutyric acid receptor subunit gamma-2"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "UGamma-aminobutyric acid receptor subunit alpha-5"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "UGamma-aminobutyric acid receptor subunit alpha-3"
            }
        ]
    },
    {
        "smiles": "NCCCC(O)(P(O)(O)=O)P(O)(O)=O",
        "id": "DB00630",
        "molecule": "Alendronic acid",
        "cas": "66376-36-1",
        "iupac_name": "(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid",
        "background": "Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's diseaseLabel1,5. It functions by preventing resorption of boneLabel1.\n",
        "inchi": {
            "hash": "OGSPWJRAVKPPFI-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)"
        },
        "summary": "Alendronic acid is a bisphosphonate drug that prevents osteoclastic bone resorption which is used for the prevention and treatment of osteoporosis.",
        "weight": [
            {
                "type": "average",
                "weight": 249.096,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 249.016724799,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB00630",
        "type": "Small Molecule",
        "synonyms": [
            "(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)",
            "(4-amino-1-hydroxybutylidene)bisphosphonic acid",
            "4-amino-1-hydroxybutane-1,1-diphosphonic acid",
            "ABDP",
            "Acide Alendronique",
            "Acido Alendronico",
            "Acidum Alendronicum",
            "Alendronate",
            "Alendronic acid"
        ],
        "indication": "Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of boneLabel1,2. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance \u003c35mL/minLabel.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Alendronic acid tablets have a very low oral bioavialabilityLabel2. After administration it distributes into soft tissue and bone or is excreted in the urineLabel. Alendronic acid does not undergo metabolismLabel.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AFarnesyl pyrophosphate synthase"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AHydroxylapatite"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UTyrosine-protein phosphatase non-receptor type 4"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UReceptor-type tyrosine-protein phosphatase S"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UReceptor-type tyrosine-protein phosphatase epsilon"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UV-type proton ATPase catalytic subunit A"
            }
        ]
    },
    {
        "smiles": "CCCCC1(CC)C(=O)NC(=O)NC1=O",
        "id": "DB01353",
        "molecule": "Butobarbital",
        "cas": "77-28-1",
        "iupac_name": "5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione",
        "background": "Butobarbital is a sedative and a hypnotic drug.\n",
        "inchi": {
            "hash": "STDBAQMTJLUMFW-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 212.2456,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 212.116092388,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.",
        "link": "https://go.drugbank.com/drugs/DB01353",
        "type": "Small Molecule",
        "synonyms": [
            "Butethal",
            "Butobarbital",
            "Butobarbitone"
        ],
        "indication": "For the treatment of insomnia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Butethal (also known as butobarbitone and butobarbital) belongs to a group of medicines called the barbiturates. It is thought to act on receptors in the brain (GABA receptors) causing the release of the chemical GABA. This chemical inhibits certain areas of the brain resulting in sleepiness. \n",
        "moa": [
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-2"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-3"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-4"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-5"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-6"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-7"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor 2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 2"
            }
        ]
    },
    {
        "smiles": "CS(=O)(=O)OCCCCOS(C)(=O)=O",
        "id": "DB01008",
        "molecule": "Busulfan",
        "cas": "55-98-1",
        "iupac_name": "4-(methanesulfonyloxy)butyl methanesulfonate",
        "background": "Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.\n",
        "inchi": {
            "hash": "COVZYZSDYWQREU-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3"
        },
        "summary": "Busulfan is an alkylating agent used to treat chronic myelogenous leukemia.",
        "weight": [
            {
                "type": "average",
                "weight": 246.302,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 246.02317956,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organosulfonic acid esters. These are esters of sulfonic acid, which have the general structure RS(=O)2OR' (R,R' = organyl, not H).",
        "link": "https://go.drugbank.com/drugs/DB01008",
        "type": "Small Molecule",
        "synonyms": [
            "1,4-Bis(methanesulfonoxy)butane",
            "1,4-Butanediol dimethanesulfonate",
            "1,4-Dimesyloxybutane",
            "1,4-Dimethanesulfonoxybutane",
            "Busulfan",
            "Busulfano",
            "Busulfanum",
            "Busulphan",
            "Tetramethylene bis(methanesulfonate)"
        ],
        "indication": "For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Busulfan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn leads to a miscoding of DNA. Alkylating agents are cell cycle-nonspecific and work by three different mechanisms, all of which achieve the same end result - disruption of DNA function and cell death. Overexpression of MGST2, a glutathione s-transferase, is thought to confer resistance to busulfan. The role of MGST2 in the metabolism of busulfan is unknown however. \n",
        "moa": [
            {
                "action": "cross-linking/alkylation",
                "organism": "Humans",
                "target": "ADNA"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CCCNC(N)=N)C(O)=O",
        "id": "DB00125",
        "molecule": "Arginine",
        "cas": "74-79-3",
        "iupac_name": "(2S)-2-amino-5-carbamimidamidopentanoic acid",
        "background": "An essential amino acid that is physiologically active in the L-form.\n",
        "inchi": {
            "hash": "ODKSFYDXXFIFQN-BYPYZUCNSA-N",
            "id": "InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1"
        },
        "summary": "Arginine is an amino acid commonly found as a component of total parenteral nutrition.",
        "weight": [
            {
                "type": "average",
                "weight": 174.201,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 174.111675712,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB00125",
        "type": "Small Molecule",
        "synonyms": [
            "(2S)-2-amino-5-(carbamimidamido)pentanoic acid",
            "(2S)-2-amino-5-guanidinopentanoic acid",
            "(S)-2-amino-5-guanidinopentanoic acid",
            "(S)-2-Amino-5-guanidinovaleric acid",
            "Arg",
            "Arginina",
            "Arginine",
            "L-(+)-Arginine",
            "L-Arg",
            "L-Arginin",
            "L-arginine",
            "R"
        ],
        "indication": "Used for nutritional supplementation, also for treating dietary shortage or imbalance.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCationic amino acid transporter 3"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UArginine decarboxylase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UArgininosuccinate lyase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, inducible"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHigh affinity cationic amino acid transporter 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UArginase-2, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCationic amino acid transporter 4"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UArgininosuccinate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, endothelial"
            }
        ]
    },
    {
        "smiles": "CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1",
        "id": "DB06695",
        "molecule": "Dabigatran etexilate",
        "cas": "211915-06-9",
        "iupac_name": "ethyl 3-(1-{2-[({4-[(1E)-amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate",
        "background": "Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran.5,16,18,19 Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated.5 In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.5 Dabigatran etexilate was approved by the FDA in 2010.17\n",
        "inchi": {
            "hash": "KSGXQBZTULBEEQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)"
        },
        "summary": "Dabigatran etexilate is an anticoagulant used for the prevention of venous thromboembolic events or stroke in patients with recent elective hip or knee replacement surgery and atrial fibrillation.",
        "weight": [
            {
                "type": "average",
                "weight": 627.7332,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 627.316917457,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB06695",
        "type": "Small Molecule",
        "synonyms": [
            "Dabigatran etexilate"
        ],
        "indication": "Dabigatran etexilate is available in both oral pellet and capsule form. Dabigatran etexilate pellets are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients between three months and 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. They are also indicated in the same age group to reduce the risk of recurrence of VTE in patients who have been previously treated.18\nIn capsule form, dabigatran etexilate is indicated in adults to reduce the risk of stroke and systemic embolism associated with non-valvular atrial fibrillation and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days. It is also indicated in adults to reduce the risk of recurrence of DVT and PE in patients who have been previously treated and for the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery. Lastly, it is indicated in pediatric patients between eight and 18 years of age for the treatment of venous thromboembolic events (VTE) in patients who have been treated with a parenteral anticoagulant for at least 5 days and to reduce the risk of recurrence of VTE in patients who have been previously treated.19\nDabigatran etexilate is also approved by the EMA to prevent VTE in adult patients. For pediatric patients, Dabigatran etexilate is used to treat TVE and prevent recurrent TVE for patients from birth to less than 18 years of age.20\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dabigatran etexilate is a double prodrug that is hydrolyzed to the active dabigatran by intestinal and hepatic carboxylesterases.12,13,14 Dabigatran is a reversible competitive thrombin inhibitor that directly inhibits the conversion by thrombin of fibrinogen to fibrin, impairing the clotting process and acting as an anticoagulant.4,7,8,18,19 Dabigatran use prolongs coagulation markers such as the activated partial thromboplastin time (aPTT), ecarin clotting time (ECT), thrombin time (TT), and dilute thrombin time (dTT), but not the international normalized ratio (INR), which cannot be used in this context as it can in warfarin monitoring.18,19\nAs with all anticoagulant therapies, dabigatran carries a risk of bleeding, which may increase with concomitant use of antiplatelet agents, fibrinolytic therapy, heparins, or chronic NSAID use, and should be monitored for. Premature discontinuation of dabigatran, in the absence of an alternative anticoagulant, also carries an increased risk of thromboembolic events. Due to the risk of an epidural or spinal hematoma, dabigatran should generally not be used in the context of neuraxial anesthesia or spinal puncture; if such use is unavoidable, careful monitoring should be employed. Dabigatran should not be used in patients with prosthetic heart valves due to an increased occurrence of major bleeding and thromboembolic events. Dabigatran is a substrate of the P-gp transporter and should generally not be administered together with P-gp inhibitors or inducers, especially in patients with impaired renal function. Lastly, dabigatran or any other direct-acting oral anticoagulant should not be administered in patients with triple-positive antiphospholipid syndrome (APS) due to an increased risk of recurrent thrombotic events. In case of the need for emergency reversal, idarucizumab is available for use in adult patients; the safety and efficacy of idarucizumab has not been established in pediatric patients yet, for whom reversal may be achieved through hemodialysis, prothrombin complex concentrates, or recombinant FVIIa. However, none of these have been sufficiently evaluated in clinical trials.18,19\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AProthrombin"
            }
        ]
    },
    {
        "smiles": "OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1",
        "id": "DB00623",
        "molecule": "Fluphenazine",
        "cas": "69-23-8",
        "iupac_name": "2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol",
        "background": "A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.\n",
        "inchi": {
            "hash": "PLDUPXSUYLZYBN-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2"
        },
        "summary": "Fluphenazine is a phenothiazine used to treat patients requiring long-term neuroleptic therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 437.522,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 437.174867774,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.",
        "link": "https://go.drugbank.com/drugs/DB00623",
        "type": "Small Molecule",
        "synonyms": [
            "1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine",
            "10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine",
            "10-(3'-(4''-(-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine",
            "2-(4-(3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol",
            "2-(trifluoromethyl)-10-(3-(1-(-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine",
            "4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol",
            "4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol",
            "4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol",
            "Flufenazina",
            "Fluorfenazine",
            "Fluorophenazine",
            "Fluorphenazine",
            "Fluphenazin",
            "Fluphnazine",
            "Fluphenazine",
            "Fluphenazinum",
            "Triflumethazine"
        ],
        "indication": "For management of manifestations of psychotic disorders.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D1 receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCalmodulin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAndrogen receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2C"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB14542",
        "molecule": "Hydrocortisone phosphate",
        "cas": "3863-59-0",
        "iupac_name": "{2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}phosphonic acid",
        "inchi": {
            "hash": "BGSOJVFOEQLVMH-VWUMJDOOSA-N",
            "id": "InChI=1S/C21H31O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1"
        },
        "summary": "Hydrocortisone phosphate is a corticosteroid used to treat congenital adrenal hyperplasia, for emergency asthma treatment, hypersensitivity, and inflammation.",
        "weight": [
            {
                "type": "average",
                "weight": 442.445,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 442.175654956,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB14542",
        "type": "Small Molecule",
        "synonyms": [
            "Cortisol 21-phosphate",
            "Hydrocortisone 21-phosphate"
        ],
        "indication": "For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AAnnexin A1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AGlucocorticoid receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U3 beta-hydroxysteroid dehydrogenase/Delta 5--\u003e4-isomerase type 1"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2N=C(SC)N=C3NCCC(C)C)[C@]([H])(O)[C@]1([H])O",
        "id": "DB08185",
        "molecule": "2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE",
        "iupac_name": "{[(2R,3S,4R,5R)-3,4-dihydroxy-5-{6-[(3-methylbutyl)amino]-2-(methylsulfanyl)-9H-purin-9-yl}oxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "LCHGAOHLDYRACA-SDBHATRESA-N",
            "id": "InChI=1S/C16H26N5O7PS/c1-8(2)4-5-17-13-10-14(20-16(19-13)30-3)21(7-18-10)15-12(23)11(22)9(28-15)6-27-29(24,25)26/h7-9,11-12,15,22-23H,4-6H2,1-3H3,(H,17,19,20)(H2,24,25,26)/t9-,11-,12-,15-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 463.446,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 463.129055413,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine ribonucleoside monophosphates. These are nucleotides consisting of a purine base linked to a ribose to which one monophosphate group is attached.",
        "link": "https://go.drugbank.com/drugs/DB08185",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Thermus aquaticus",
                "target": "UElongation factor Tu"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S12"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S10"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S11"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S13"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S14 type Z"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S15"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S16"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S17"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S18"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S19"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S20"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S4"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S5"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S6"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S7"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S8"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S9"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein Thx"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)",
                "target": "U30S ribosomal protein S17"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)",
                "target": "U30S ribosomal protein S20"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)",
                "target": "U30S ribosomal protein S2"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)",
                "target": "U30S ribosomal protein S3"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)",
                "target": "U30S ribosomal protein S9"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)",
                "target": "U30S ribosomal protein S19"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S2"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "U30S ribosomal protein S3"
            }
        ]
    },
    {
        "smiles": "[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23",
        "id": "DB00714",
        "molecule": "Apomorphine",
        "cas": "58-00-4",
        "iupac_name": "(9R)-10-methyl-10-azatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadeca-1(16),2(7),3,5,13(17),14-hexaene-3,4-diol",
        "background": "Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.10 Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.9,10\nApomorphine was granted FDA approval on 20 April 2004.11\n",
        "inchi": {
            "hash": "VMWNQDUVQKEIOC-CYBMUJFWSA-N",
            "id": "InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1"
        },
        "summary": "Apomorphine is a morphine derivative D2 dopamine agonist used to treat hypomobile \"off\" episodes of advanced Parkinson's disease.",
        "weight": [
            {
                "type": "average",
                "weight": 267.3224,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 267.125928793,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aporphines. These are quinoline alkaloids containing the dibenzo[de,g]quinoline ring system or a dehydrogenated derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB00714",
        "type": "Small Molecule",
        "synonyms": [
            "()-10,11-dihydroxyaporphine",
            "(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol",
            "(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol",
            "Apomorfina",
            "Apomorphin",
            "Apomorphine",
            "R-()-apomorphine"
        ],
        "indication": "Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.11,12\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Apomorphine is a dopaminergic agonist that may stimulate regions of the brain involved in motor control.8,11,12 It has a short duration of action and a wide therapeutic index as large overdoses are necessary for significant toxicity.11,12 Patients should be counselled regarding the risk of nausea, vomiting, daytime somnolence, hypotension, oral mucosal irritation, falls, hallucinations, psychotic-like behaviour, impulsive behaviour, withdrawal hyperpyrexia, and prolongation of the QT interval.11,12\nGiven the incidence of nausea and vomiting in patients taking apomorphine, treatment with trimethobenzamide may be recommended prior to or during therapy. Antiemetic pretreatment may be started three days prior to beginning therapy with apomorphine - it should only be continued as long as is necessary and generally for no longer than two months.15\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ADopamine D4 receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ADopamine D3 receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UDopamine D5 receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UDopamine D1 receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UAlpha-2C adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UAlpha-2B adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1A"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2B"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2C"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UAlpha-2A adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1D"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1B"
            }
        ]
    },
    {
        "smiles": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1",
        "id": "DB01076",
        "molecule": "Atorvastatin",
        "cas": "134523-00-5",
        "iupac_name": "(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid",
        "background": "Atorvastatin (Lipitor), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,8 which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as \"bad cholesterol\"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal side effects and long term benefits, has resulted in wide use of this medication in North America.9,10\nAtorvastatin and other statins including lovastatin, pravastatin, rosuvastatin, fluvastatin, and simvastatin are considered first-line treatment options for dyslipidemia.9,10 The increasing use of this class of drugs is largely attributed to the rise in cardiovascular diseases (CVD) (such as heart attack, atherosclerosis, angina, peripheral artery disease, and stroke) in many countries.11 An elevated cholesterol level (elevated low-density lipoprotein (LDL) levels in particular) is a significant risk factor for the development of CVD.9,12 Several landmark studies demonstrate that the use of statins is associated with both a reduction in LDL levels and CVD risk.13,14,15,16,17,18 Statins were shown to reduce the incidences of all-cause mortality, including fatal and non-fatal CVD, as well as the need for surgical revascularization or angioplasty following a heart attack.9,10 Some evidence has shown that even for low-risk individuals (with \u003c10% risk of a major vascular event occurring within five years) statin use leads to a 20%-22% relative reduction in the number of major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.19,20\nAtorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996.34 It is a pentasubstituted pyrrole 3 formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound.35 Unlike other members of the statin group, atorvastatin is an active compound and therefore does not require activation.4\n",
        "inchi": {
            "hash": "XUKUURHRXDUEBC-KAYWLYCHSA-N",
            "id": "InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1"
        },
        "summary": "Atorvastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.",
        "weight": [
            {
                "type": "average",
                "weight": 558.6398,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 558.253000445,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylpyrroles. These are aromatic heterocyclic compounds with a structure based on a pyrrole ring linked to exactly two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB01076",
        "type": "Small Molecule",
        "synonyms": [
            "Atorvastatin",
            "atorvastatina",
            "atorvastatine",
            "atorvastatinum"
        ],
        "indication": "Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.2\nDyslipidemia describes an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.36 \nAtorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.2\nAtorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.2\nAtorvastatin may be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.2\nPrescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.9,10\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Atorvastatin is an oral antilipemic agent that reversibly inhibits HMG-CoA reductase. It lowers total cholesterol, low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), non-high density lipoprotein-cholesterol (non-HDL-C), and triglyceride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease, and high ratios are associated with a higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality.21,9,10,27 \nElevated cholesterol levels (and high low-density lipoprotein (LDL) levels in particular) are an important risk factor for the development of CVD.9 Clinical studies have shown that atorvastatin reduces LDL-C and total cholesterol by 36-53%.3 In patients with dysbetalipoproteinemia, atorvastatin reduced the levels of intermediate-density lipoprotein cholesterol.2 It has also been suggested that atorvastatin can limit the extent of angiogenesis, which can be useful in the treatment of chronic subdural hematoma.1\nMyopathy/Rhabdomyolysis\nAtorvastatin, like other HMG-CoA reductase inhibitors, is associated with a risk of drug-induced myopathy characterized by muscle pain, tenderness, or weakness in conjunction with elevated levels of creatine kinase (CK). Myopathy often manifests as rhabdomyolysis with or without acute renal failure secondary to myoglobinuria. The risk of statin-induced myopathy is dose-related, and the symptoms of myopathy are typically resolved upon drug discontinuation. Results from observational studies suggest that 10-15% of people taking statins may experience muscle aches at some point during treatment.30\nLiver Dysfunction\nStatins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (\u003e 3 times the upper limit of normal [ULN] occurring on two or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. This effect appears to be dose-related.41,42\nEndocrine Effects\nStatins are associated with a risk of increased serum HbA1c and glucose levels. An in vitro study demonstrated a dose-dependent cytotoxic effect on human pancreatic islet  cells following treatment with atorvastatin. Moreover, insulin secretion rates decreased relative to control.7\nHMG-CoA reductase inhibitors interfere with cholesterol synthesis and may theoretically interfere with the production of adrenal and/or gonadal steroids. Clinical studies with atorvastatin and other HMG-CoA reductase inhibitors have suggested that these agents do not affect plasma cortisol concentrations, basal plasma testosterone concentration, or adrenal reserve. However, the effect of statins on male fertility has not been fully investigated. The effects of statins on the pituitary-gonadal axis in premenopausal women are unknown.42\nCardiovascular\nSignificant decreases in circulating ubiquinone levels in patients treated with atorvastatin and other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure.42\nLipoprotein A\nIn some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by the concomitant increase in Lp(a) lipoprotein concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease.42 Further studies have demonstrated statins affect Lp(a) levels differently in patients with dyslipidemia depending on their apo(a) phenotype; statins increase Lp(a) levels exclusively in patients with the low molecular weight apo(a) phenotype.28\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "A3-hydroxy-3-methylglutaryl-coenzyme A reductase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UDipeptidyl peptidase 4"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UAryl hydrocarbon receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UHistone deacetylase 2"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UNuclear receptor subfamily 1 group I member 3"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCC[N+](C)(C)[O-]",
        "id": "DB04147",
        "molecule": "Dodecyldimethylamine N-oxide",
        "cas": "1643-20-5",
        "iupac_name": "N,N-dimethyldodecanamine oxide",
        "inchi": {
            "hash": "SYELZBGXAIXKHU-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H31NO/c1-4-5-6-7-8-9-10-11-12-13-14-15(2,3)16/h4-14H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 229.402,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 229.240564619,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as long-chain alkyl amine oxides. These are aminoxides that carry an alkyl chain ranging from C10 to C24.",
        "link": "https://go.drugbank.com/drugs/DB04147",
        "type": "Small Molecule",
        "synonyms": [
            "Dimethylaurylamine oxide",
            "Dimethyldodecylamine N-oxide",
            "Dimethyldodecylamine oxide",
            "Dodecyl(dimethyl)amine oxide",
            "Dodecyldimethylamine oxide",
            "Lauramine oxide",
            "Lauryl dimethylamine-N-oxide",
            "lauryldimethylamine N-oxide",
            "Lauryldimethylamine oxide",
            "n-Dodecyldimethylamine oxide",
            "N,N-Dimethyldodecylamine oxide"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides",
                "target": "UReaction center protein L chain"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides",
                "target": "UReaction center protein M chain"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides",
                "target": "UReaction center protein H chain"
            },
            {
                "action": "Not Available",
                "organism": "Paracoccus denitrificans",
                "target": "UCytochrome c oxidase subunit 1-beta"
            },
            {
                "action": "Not Available",
                "organism": "Paracoccus denitrificans",
                "target": "UCytochrome c oxidase subunit 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIg kappa chain V-I region Bi"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIg heavy chain V-III region VH26"
            },
            {
                "action": "Not Available",
                "organism": "Rhodopseudomonas viridis",
                "target": "UPhotosynthetic reaction center cytochrome c subunit"
            },
            {
                "action": "Not Available",
                "organism": "Rhodopseudomonas viridis",
                "target": "UReaction center protein H chain"
            },
            {
                "action": "Not Available",
                "organism": "Rhodopseudomonas viridis",
                "target": "UReaction center protein L chain"
            },
            {
                "action": "Not Available",
                "organism": "Rhodopseudomonas viridis",
                "target": "UReaction center protein M chain"
            },
            {
                "action": "Not Available",
                "organism": "Thermochromatium tepidum",
                "target": "UH subunit of photosynthetic reaction center complex"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDestrin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URhodopsin"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides",
                "target": "UCytochrome c2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear factor erythroid 2-related factor 1"
            },
            {
                "action": "Not Available",
                "organism": "Alicyclobacillus acidocaldarius subsp. acidocaldarius (strain ATCC 27009 / DSM 446 / 104-1A)",
                "target": "USqualene--hopene cyclase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UVitamin B12 transporter BtuB"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UColicin-E3"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UFe(3+)-pyochelin receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMyelin P2 protein"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UOuter membrane protein W"
            },
            {
                "action": "Not Available",
                "organism": "Rhodopseudomonas acidophila",
                "target": "ULight-harvesting protein B-800/850 alpha chain"
            },
            {
                "action": "Not Available",
                "organism": "Rhodopseudomonas acidophila",
                "target": "ULight-harvesting protein B-800/850 beta chain"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UProtein TonB"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UColicin I receptor"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UColicin-Ia"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCofilin-1"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "URhomboid protease GlpG"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UOuter membrane protein G"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UOuter membrane usher protein PapC"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UProbable N-acetylneuraminic acid outer membrane channel protein NanC"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides (strain ATCC 17023 / 2.4.1 / NCIB 8253 / DSM 158)",
                "target": "UReaction center protein H chain"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides (strain ATCC 17023 / 2.4.1 / NCIB 8253 / DSM 158)",
                "target": "UReaction center protein L chain"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides (strain ATCC 17023 / 2.4.1 / NCIB 8253 / DSM 158)",
                "target": "UReaction center protein M chain"
            },
            {
                "action": "Not Available",
                "organism": "Neisseria meningitidis",
                "target": "UOuter membrane protein II"
            },
            {
                "action": "Not Available",
                "organism": "Rhizobium loti (strain MAFF303099)",
                "target": "UCyclic nucleotide-gated potassium channel mll3241"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAmmonia channel"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus (strain COL)",
                "target": "UPenicillin-binding protein 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydroorotate dehydrogenase (quinone), mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UTraO protein"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UTraF protein"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UTraN protein"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas fluorescens (strain Pf-5 / ATCC BAA-477)",
                "target": "UOuter membrane porin, OprD family"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UFe(3+) dicitrate transport protein FecA"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "ULong-chain fatty acid transport protein"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "ULipid A palmitoyltransferase PagP"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAcyl-CoA thioesterase 2"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UAmine oxidase [flavin-containing] B"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13677"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03104"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16879"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04567"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04733"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11977"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03881"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12651"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07492"
    },
    {
        "smiles": "C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O",
        "id": "DB15302",
        "molecule": "2-fluorofucose",
        "cas": "70763-62-1",
        "iupac_name": "(2S,3R,4R,5S)-2-fluoro-3,4,5-trihydroxyhexanal",
        "background": "2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).\n",
        "inchi": {
            "hash": "SQTFKIKSQNCWGJ-KCDKBNATSA-N",
            "id": "InChI=1S/C6H11FO4/c1-3(9)5(10)6(11)4(7)2-8/h2-6,9-11H,1H3/t3-,4+,5+,6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 166.148,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 166.064136997,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15302",
        "type": "Small Molecule",
        "synonyms": [
            "SGN-2FF"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC(=O)C1=CN=CC(Br)=C1",
        "id": "DB01854",
        "molecule": "5-Bromonicotinamide",
        "cas": "28733-43-9",
        "iupac_name": "5-bromopyridine-3-carboxamide",
        "inchi": {
            "hash": "YOQRXZIMSKLRCY-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H5BrN2O/c7-5-1-4(6(8)10)2-9-3-5/h1-3H,(H2,8,10)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 201.021,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 199.958525439,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nicotinamides. These are heterocyclic aromatic compounds containing a pyridine ring substituted at position 3 by a carboxamide group.",
        "link": "https://go.drugbank.com/drugs/DB01854",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)[C@]([H])(O)[C@]([H])(CP(O)(O)=O)O[C@]1([H])COP(O)(O)=O",
        "id": "DB02393",
        "molecule": "D-Gluco-2,5-Anhydro-1-Deoxy-1-Phosphonohexitol-6-Phosphate",
        "iupac_name": "{[(2R,3S,4S,5R)-3,4-dihydroxy-5-(phosphonomethyl)oxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "YBOWGOLYQKBCFB-JGWLITMVSA-N",
            "id": "InChI=1S/C6H14O10P2/c7-5-3(1-15-18(12,13)14)16-4(6(5)8)2-17(9,10)11/h3-8H,1-2H2,(H2,9,10,11)(H2,12,13,14)/t3-,4+,5-,6-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 308.1169,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 308.006219692,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.",
        "link": "https://go.drugbank.com/drugs/DB02393",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1"
            }
        ]
    },
    {
        "smiles": "CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=C(N)C=C(C)N=C1",
        "id": "DB02814",
        "molecule": "3'-Deazo-Thiamin Diphosphate",
        "iupac_name": "3-[(4-amino-6-methylpyridin-3-yl)methyl]-5-(2-{[(hydrogen phosphonatooxy)(hydroxy)phosphoryl]oxy}ethyl)-4-methyl-1,3-thiazol-3-ium",
        "inchi": {
            "hash": "NWZZJKMZTWGIFE-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H19N3O7P2S/c1-9-5-12(14)11(6-15-9)7-16-8-26-13(10(16)2)3-4-22-25(20,21)23-24(17,18)19/h5-6,8H,3-4,7H2,1-2H3,(H4-,14,15,17,18,19,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 423.318,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 423.041893691,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organic pyrophosphates. These are organic compounds containing the pyrophosphate oxoanion, with the structure OP([O-])(=O)OP(O)([O-])=O.",
        "link": "https://go.drugbank.com/drugs/DB02814",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H][C@@](C[P@](O)(=O)[C@@]([H])(NS(=O)(=O)C1=CC=CC=C1)C(C)C)(C(O)=O)C1=CC(CN)=CC=C1",
        "id": "DB06921",
        "molecule": "(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-HYDROXY{(1R)-2-METHYL-1-[(PHENYLSULFONYL)AMINO]PROPYL}PHOSPHORYL]PROPANOIC ACID",
        "iupac_name": "(2S)-2-[3-(aminomethyl)phenyl]-3-{[(1R)-1-benzenesulfonamido-2-methylpropyl](hydroxy)phosphoryl}propanoic acid",
        "inchi": {
            "hash": "FNZHLCNFXRRIIC-RBUKOAKNSA-N",
            "id": "InChI=1S/C20H27N2O6PS/c1-14(2)19(22-30(27,28)17-9-4-3-5-10-17)29(25,26)13-18(20(23)24)16-8-6-7-15(11-16)12-21/h3-11,14,18-19,22H,12-13,21H2,1-2H3,(H,23,24)(H,25,26)/t18-,19+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 454.477,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 454.132743808,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB06921",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarboxypeptidase B"
            }
        ]
    },
    {
        "smiles": "CCCCCCC(O)(P(O)(O)=O)P(O)(O)=O",
        "id": "DB06830",
        "molecule": "(1-HYDROXYHEPTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",
        "iupac_name": "(1-hydroxy-1-phosphonoheptyl)phosphonic acid",
        "inchi": {
            "hash": "IJEGNOYPWRBKAE-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H18O7P2/c1-2-3-4-5-6-7(8,15(9,10)11)16(12,13)14/h8H,2-6H2,1H3,(H2,9,10,11)(H2,12,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 276.1611,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 276.052775954,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB06830",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGeranylgeranyl pyrophosphate synthase"
            }
        ]
    },
    {
        "smiles": "CCCCB(O)O",
        "id": "DB02664",
        "molecule": "1-Butane Boronic Acid",
        "iupac_name": "butylboronic acid",
        "inchi": {
            "hash": "QPKFVRWIISEVCW-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H11BO2/c1-2-3-4-5(6)7/h6-7H,2-4H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 101.94,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 102.085210062,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as boronic acids. These are compounds comprising the boronic acid functional group RB(O)O (R,R'=alkyl, aryl).",
        "link": "https://go.drugbank.com/drugs/DB02664",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Vibrio proteolyticus",
                "target": "UBacterial leucyl aminopeptidase"
            }
        ]
    },
    {
        "smiles": "CC(=O)N[C@@H](CC1=CC=C(C(=C1)P(O)(O)=O)P(O)(O)=O)C(=O)N[C@H]1CCCCC2=CC(OCC3CCCCC3)=C(C=C12)C(N)=O",
        "id": "DB01830",
        "molecule": "AP-22408",
        "cas": "268741-43-1",
        "iupac_name": "{5-[(2S)-2-{[(5S)-3-carbamoyl-2-(cyclohexylmethoxy)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl]carbamoyl}-2-acetamidoethyl]-2-phosphonophenyl}phosphonic acid",
        "inchi": {
            "hash": "SPSGYTWOIGAABK-DQEYMECFSA-N",
            "id": "InChI=1S/C30H41N3O10P2/c1-18(34)32-25(13-20-11-12-27(44(37,38)39)28(14-20)45(40,41)42)30(36)33-24-10-6-5-9-21-15-26(23(29(31)35)16-22(21)24)43-17-19-7-3-2-4-8-19/h11-12,14-16,19,24-25H,2-10,13,17H2,1H3,(H2,31,35)(H,32,34)(H,33,36)(H2,37,38,39)(H2,40,41,42)/t24-,25-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 665.6082,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 665.226717571,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB01830",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein kinase Lck"
            }
        ]
    },
    {
        "smiles": "[H][C@@](C)(O)[C@@]([H])(O)[C@@]([H])(O)[C@]([H])(O)CO",
        "id": "DB03815",
        "molecule": "Fucitol",
        "cas": "13074-06-1",
        "iupac_name": "(2R,3S,4R,5S)-hexane-1,2,3,4,5-pentol",
        "inchi": {
            "hash": "SKCKOFZKJLZSFA-KCDKBNATSA-N",
            "id": "InChI=1S/C6H14O5/c1-3(8)5(10)6(11)4(9)2-7/h3-11H,2H2,1H3/t3-,4+,5+,6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 166.1724,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 166.084123558,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB03815",
        "type": "Small Molecule",
        "synonyms": [
            "L-Fucitol"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Shigella flexneri",
                "target": "UL-fucose isomerase"
            }
        ]
    },
    {
        "smiles": "CC1=CC=C(C)C(CC2=NN(C3=C2C(N)=NC=N3)C(C)(C)C)=C1",
        "id": "DB08035",
        "molecule": "1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE",
        "iupac_name": "1-tert-butyl-3-[(2,5-dimethylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine",
        "inchi": {
            "hash": "QUPXEJURIFFVSX-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H23N5/c1-11-6-7-12(2)13(8-11)9-14-15-16(19)20-10-21-17(15)23(22-14)18(3,4)5/h6-8,10H,9H2,1-5H3,(H2,19,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 309.4087,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 309.195345761,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrazolo[3,4-d]pyrimidines. These are aromatic heterocyclic compounds containing a pyrazolo[3,4-d]pyrimidine ring system, which consists of a pyrazole ring fused to but and not sharing a nitrogen atom with a pyrimidine ring.",
        "link": "https://go.drugbank.com/drugs/DB08035",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAndrogen receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11898"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07867"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07728"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03152"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16027"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08344"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13207"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07125"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06376"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02313"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15344"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02840"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01790"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09056"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03093"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02895"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02935"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08163"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15774"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09012"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08337"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02911"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08364"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04061"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00531"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06704"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01094"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06700"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01870"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02342"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12507"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07464"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07916"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05078"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12081"
    },
    {
        "id": "DB18027",
        "molecule": "DI-87",
        "cas": "2107280-55-5",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18027",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "id": "DB17319",
        "molecule": "Aroplatin",
        "cas": "114488-24-3",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17319",
        "type": "Small Molecule",
        "synonyms": [
            "cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)",
            "L-NDDP",
            "Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=C(OC)C(=CC(CCCF)=C1)C(=O)NC[C@@H]1CCCN1CC=C",
        "id": "DB15167",
        "molecule": "Fallypride",
        "cas": "166173-78-0",
        "iupac_name": "5-(3-fluoropropyl)-2,3-dimethoxy-N-{[(2S)-1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}benzamide",
        "background": "Fallypride is under investigation in clinical trial NCT02310360 (Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans).\n",
        "inchi": {
            "hash": "OABRYNHZQBZDMG-INIZCTEOSA-N",
            "id": "InChI=1S/C20H29FN2O3/c1-4-10-23-11-6-8-16(23)14-22-20(24)17-12-15(7-5-9-21)13-18(25-2)19(17)26-3/h4,12-13,16H,1,5-11,14H2,2-3H3,(H,22,24)/t16-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 364.461,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 364.216220965,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15167",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@](N)(CSSC[C@]([H])(N)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=NCC(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=O)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=NCC(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(C)C)C(O)=O",
        "id": "DB05560",
        "molecule": "Delcasertib",
        "cas": "949100-39-4",
        "iupac_name": "(2S)-2-{[(2S)-2-[(2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2R)-2-amino-3-{[(2R)-2-amino-2-{[(1S)-1-[({[(1S)-1-{[(1S)-5-amino-1-{[(1S)-5-amino-1-{[(1S)-4-carbamimidamido-1-{[(1S)-4-carbamimidamido-1-{[(1S)-1-{[(1S)-4-carbamimidamido-1-{[(1S)-4-carbamimidamido-1-{[(1S)-4-carbamimidamido-1-carboxybutyl]-C-hydroxycarbonimidoyl}butyl]-C-hydroxycarbonimidoyl}butyl]-C-hydroxycarbonimidoyl}-3-(C-hydroxycarbonimidoyl)propyl]-C-hydroxycarbonimidoyl}butyl]-C-hydroxycarbonimidoyl}butyl]-C-hydroxycarbonimidoyl}pentyl]-C-hydroxycarbonimidoyl}pentyl]-C-hydroxycarbonimidoyl}-4-carbamimidamidobutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}ethyl]disulfanyl}-1-hydroxypropylidene]amino}-1,3-dihydroxypropylidene]amino}-1-hydroxy-3-phenylpropylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-1,3-dihydroxypropylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-carboxy-1-hydroxybutylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-1-hydroxyethylidene)amino]-1,3-dihydroxypropylidene]amino}-4-methylpentanoic acid",
        "inchi": {
            "hash": "XPXZTVWPRKJTAA-PJKOMPQUSA-N",
            "id": "InChI=1S/C120H199N45O34S2/c1-61(2)48-80(96(179)145-55-92(174)148-86(56-166)110(193)163-85(114(198)199)49-62(3)4)159-106(189)78(37-39-93(175)176)156-107(190)83(52-65-30-34-67(170)35-31-65)161-112(195)88(58-168)165-109(192)84(53-90(126)172)162-108(191)82(50-63-18-6-5-7-19-63)160-111(194)87(57-167)164-95(178)69(124)60-201-200-59-68(123)94(177)158-81(51-64-28-32-66(169)33-29-64)97(180)146-54-91(173)147-70(22-12-42-139-115(127)128)98(181)149-71(20-8-10-40-121)99(182)150-72(21-9-11-41-122)100(183)151-73(23-13-43-140-116(129)130)101(184)152-75(25-15-45-142-118(133)134)103(186)155-77(36-38-89(125)171)105(188)154-74(24-14-44-141-117(131)132)102(185)153-76(26-16-46-143-119(135)136)104(187)157-79(113(196)197)27-17-47-144-120(137)138/h5-7,18-19,28-35,61-62,68-88,166-170H,8-17,20-27,36-60,121-124H2,1-4H3,(H2,125,171)(H2,126,172)(H,145,179)(H,146,180)(H,147,173)(H,148,174)(H,149,181)(H,150,182)(H,151,183)(H,152,184)(H,153,185)(H,154,188)(H,155,186)(H,156,190)(H,157,187)(H,158,177)(H,159,189)(H,160,194)(H,161,195)(H,162,191)(H,163,193)(H,164,178)(H,165,192)(H,175,176)(H,196,197)(H,198,199)(H4,127,128,139)(H4,129,130,140)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)/t68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 2880.31,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 2878.466751016,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.",
        "link": "https://go.drugbank.com/drugs/DB05560",
        "type": "Small Molecule",
        "synonyms": [
            "Delcasertib"
        ],
        "indication": "Investigated for use/treatment in myocardial infarction.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "id": "DB05177",
        "molecule": "DG051",
        "background": "DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation. \n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05177",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in myocardial infarction.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULeukotriene A-4 hydrolase"
            }
        ]
    },
    {
        "smiles": "C[C@H](OC(N)=O)[C@@H](O)C1=CC=CC=C1Cl",
        "id": "DB16034",
        "molecule": "JBPOS0101",
        "cas": "1353949-71-9",
        "iupac_name": "(1S,2S)-1-(2-chlorophenyl)-1-hydroxypropan-2-yl carbamate",
        "background": "JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).\n",
        "inchi": {
            "hash": "TZOWVYPYWJLZTK-IMTBSYHQSA-N",
            "id": "InChI=1S/C10H12ClNO3/c1-6(15-10(12)14)9(13)7-4-2-3-5-8(7)11/h2-6,9,13H,1H3,(H2,12,14)/t6-,9+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 229.66,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 229.050571,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16034",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "id": "DB05856",
        "molecule": "CPD 923",
        "background": "CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile. \n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05856",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in metabolic disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "CC(C)(C)NC1CCN(CC1)C1=CC(NCC2=CC=C(Cl)C=C2)=NC2=CC=CC=C12",
        "id": "DB16458",
        "molecule": "Ezurpimtrostat",
        "cas": "1914148-72-3",
        "iupac_name": "4-[4-(tert-butylamino)piperidin-1-yl]-N-[(4-chlorophenyl)methyl]quinolin-2-amine",
        "inchi": {
            "hash": "QVXSJSXAVQJXOV-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H31ClN4/c1-25(2,3)29-20-12-14-30(15-13-20)23-16-24(28-22-7-5-4-6-21(22)23)27-17-18-8-10-19(26)11-9-18/h4-11,16,20,29H,12-15,17H2,1-3H3,(H,27,28)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 423,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 422.2237247,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16458",
        "type": "Small Molecule",
        "synonyms": [
            "Chloroquine analog"
        ],
        "is_stub": true
    },
    {
        "id": "DB05292",
        "molecule": "IDM-1",
        "background": "IDM-1 is IDMs most advanced antibody-based Cell drug for the treatment of cancer. It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05292",
        "type": "Small Molecule",
        "indication": "Ovarian cancer\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "C[C@@H](CC1=CC=CC=C1)C(O)=O",
        "id": "DB07673",
        "molecule": "(2S)-2-Methyl-3-phenylpropanoic acid",
        "cas": "14367-54-5",
        "iupac_name": "(2S)-2-methyl-3-phenylpropanoic acid",
        "inchi": {
            "hash": "MCIIDRLDHRQKPH-QMMMGPOBSA-N",
            "id": "InChI=1S/C10H12O2/c1-8(10(11)12)7-9-5-3-2-4-6-9/h2-6,8H,7H2,1H3,(H,11,12)/t8-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 164.2011,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 164.083729628,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.",
        "link": "https://go.drugbank.com/drugs/DB07673",
        "type": "Small Molecule",
        "synonyms": [
            "(S)-2-Benzylpropanoic acid",
            "Deamino-methyl-phenylalanine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus thermoproteolyticus",
                "target": "UThermolysin"
            }
        ]
    },
    {
        "smiles": "N[C@H](CC1=CC=C(OC[18F])C=C1)C(O)=O",
        "id": "DB15296",
        "molecule": "D-fluoromethyltyrosine F-18",
        "cas": "870452-26-9",
        "iupac_name": "(2R)-2-amino-3-{4-[(F)fluoromethoxy]phenyl}propanoic acid",
        "background": "D-fluoromethyltyrosine F-18 is under investigation in clinical trial NCT01089998 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations).\n",
        "inchi": {
            "hash": "GEBHVOHKNWLITQ-DEVVULMSSA-N",
            "id": "InChI=1S/C10H12FNO3/c11-6-15-8-3-1-7(2-4-8)5-9(12)10(13)14/h1-4,9H,5-6,12H2,(H,13,14)/t9-/m1/s1/i11-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 212.211,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 212.082655917,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15296",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC(C(O)=O)C1=CC=CC2=C1OC=C2C1=CC=CC=C1",
        "id": "DB06499",
        "molecule": "Furaprofen",
        "cas": "67700-30-5",
        "iupac_name": "2-(3-phenyl-1-benzofuran-7-yl)propanoic acid",
        "inchi": {
            "hash": "ODZUWQAFWMLWCF-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H14O3/c1-11(17(18)19)13-8-5-9-14-15(10-20-16(13)14)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 266.296,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 266.094294311,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06499",
        "type": "Small Molecule",
        "synonyms": [
            "alpha-Methyl-3-phenyl-7-benzofuranacetic acid",
            "Furaprofen",
            "Furaprofeno",
            "Furaprofenum"
        ],
        "indication": "Investigated for use/treatment in hepatitis (viral, C).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "CNC(=O)C1=C(OC2=CC(NS(C)(=O)=O)=C(OC(C)C)C=C12)C1=CC=C(F)C=C1",
        "id": "DB05884",
        "molecule": "HCV-086",
        "iupac_name": "2-(4-fluorophenyl)-6-methanesulfonamido-N-methyl-5-(propan-2-yloxy)-1-benzofuran-3-carboxamide",
        "background": "HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.\n",
        "inchi": {
            "hash": "VBRUONUESYTIDA-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H21FN2O5S/c1-11(2)27-17-9-14-16(10-15(17)23-29(4,25)26)28-19(18(14)20(24)22-3)12-5-7-13(21)8-6-12/h5-11,23H,1-4H3,(H,22,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 420.455,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 420.115520687,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-arylbenzofuran flavonoids. These are phenylpropanoids containing the 2-phenylbenzofuran moiety.",
        "link": "https://go.drugbank.com/drugs/DB05884",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in hepatitis (viral, C).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "COC1=CC=C(\\C=C\\C(=O)C(CC2CCC2)C(=O)\\C=C\\C2=CC=C(OC)C(OC)=C2)C=C1OC",
        "id": "DB16931",
        "molecule": "ASC-JM-17",
        "cas": "1039760-91-2",
        "iupac_name": "(1E,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione",
        "inchi": {
            "hash": "PJOSHEDKRPRCAE-QHKWOANTSA-N",
            "id": "InChI=1S/C28H32O6/c1-31-25-14-10-20(17-27(25)33-3)8-12-23(29)22(16-19-6-5-7-19)24(30)13-9-21-11-15-26(32-2)28(18-21)34-4/h8-15,17-19,22H,5-7,16H2,1-4H3/b12-8+,13-9+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 464.558,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 464.21988875,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16931",
        "type": "Small Molecule",
        "synonyms": [
            "(1e,6e)-1,7-bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione",
            "(1e,6e)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-1,6-heptadiene-3,5-dione",
            "1,6-heptadiene-3,5-dione, 4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-, (1e,6e)-"
        ],
        "is_stub": true
    },
    {
        "smiles": "COCCN(CCCCC1=CC=C2CCCNC2=N1)CC[C@H](NC1=NC=NC2=CC=CC=C12)C(O)=O",
        "id": "DB18444",
        "molecule": "Bexotegrast",
        "cas": "2376257-44-0",
        "inchi": {
            "hash": "CWOFQJBATWQSHL-DEOSSOPVSA-N",
            "id": "InChI=1S/C27H36N6O3/c1-36-18-17-33(15-5-4-8-21-12-11-20-7-6-14-28-25(20)31-21)16-13-24(27(34)35)32-26-22-9-2-3-10-23(22)29-19-30-26/h2-3,9-12,19,24H,4-8,13-18H2,1H3,(H,28,31)(H,34,35)(H,29,30,32)/t24-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 492.624,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 492.284889043,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18444",
        "type": "Small Molecule",
        "synonyms": [
            "(2S)-4-(2-METHOXYETHYL-(4-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)BUTYL)AMINO)-2-(QUINAZOLIN-4-YLAMINO)BUTANOIC ACID",
            "(S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acid",
            "Butanoic acid, 4-[(2-methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(4-quinazolinylamino)-, (2S)-"
        ],
        "is_stub": true
    },
    {
        "smiles": "CS(=O)(=O)C1=CC=CC=C1S(=O)(=O)NO",
        "id": "DB15326",
        "molecule": "CXL-1020",
        "cas": "950834-06-7",
        "iupac_name": "N-hydroxy-2-methanesulfonylbenzene-1-sulfonamide",
        "background": "CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).\n",
        "inchi": {
            "hash": "RZRWBKKAFHXNEQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H9NO5S2/c1-14(10,11)6-4-2-3-5-7(6)15(12,13)8-9/h2-5,8-9H,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 251.27,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 250.992214742,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB15326",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "C\\C(\\C=C\\[C@@]1(O)C(C)=CC(=O)CC1(C)C)=C\\C(O)=O",
        "id": "DB16829",
        "molecule": "Abscisic Acid",
        "cas": "21293-29-8",
        "iupac_name": "(2Z,4E)-5-[(1S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]-3-methylpenta-2,4-dienoic acid",
        "inchi": {
            "hash": "JLIDBLDQVAYHNE-YKALOCIXSA-N",
            "id": "InChI=1S/C15H20O4/c1-10(7-13(17)18)5-6-15(19)11(2)8-12(16)9-14(15,3)4/h5-8,19H,9H2,1-4H3,(H,17,18)/b6-5+,10-7-/t15-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 264.321,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 264.136159124,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16829",
        "type": "Small Molecule",
        "synonyms": [
            "Abscisin II",
            "Acide abscisique"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB09023",
        "molecule": "Benactyzine",
        "cas": "302-40-9",
        "iupac_name": "2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate",
        "background": "Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.\nBenactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.\n",
        "inchi": {
            "hash": "IVQOFBKHQCTVQV-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 327.4174,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 327.183443671,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB09023",
        "type": "Small Molecule",
        "synonyms": [
            "Benactyzine"
        ]
    },
    {
        "smiles": "C[C@H]1O[C@H](C[C@H](OC=O)[C@@H]1OC=O)O[C@@H]1[C@@H](C)O[C@H](C[C@@H]1OC=O)O[C@@H]1[C@@H](C)O[C@H](C[C@@H]1OC=O)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@H]([C@H](C[C@]32O)OC=O)C2=CC(=O)OC2)C1",
        "id": "DB13537",
        "molecule": "Gitoformate",
        "cas": "10176-39-3",
        "iupac_name": "(1S,2S,5S,7R,10R,11S,13S,14R,15R)-5-{[(2R,4S,5R,6R)-5-{[(2S,4S,5R,6R)-5-{[(2S,4S,5R,6R)-4,5-bis(formyloxy)-6-methyloxan-2-yl]oxy}-4-(formyloxy)-6-methyloxan-2-yl]oxy}-4-(formyloxy)-6-methyloxan-2-yl]oxy}-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl formate",
        "inchi": {
            "hash": "DOMHWKQEPDYUQX-LJAQBGIBSA-N",
            "id": "InChI=1S/C46H64O19/c1-24-41(59-23-51)32(55-19-47)14-38(60-24)64-43-26(3)62-39(16-34(43)57-21-49)65-42-25(2)61-37(15-33(42)56-20-48)63-29-8-10-44(4)28(13-29)6-7-31-30(44)9-11-45(5)40(27-12-36(52)54-18-27)35(58-22-50)17-46(31,45)53/h12,19-26,28-35,37-43,53H,6-11,13-18H2,1-5H3/t24-,25-,26-,28-,29+,30+,31-,32+,33+,34+,35+,37+,38+,39+,40+,41-,42-,43-,44+,45-,46+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 920.999,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 920.404179841,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.",
        "link": "https://go.drugbank.com/drugs/DB13537",
        "type": "Small Molecule",
        "synonyms": [
            "Gitoformate"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCC1=CC(O)=C2C(OC(C)(C)C3=C2C=C(C)C=C3)=C1",
        "id": "DB14736",
        "molecule": "Cannabivarin",
        "cas": "33745-21-0",
        "iupac_name": "6,6,9-trimethyl-3-propyl-6H-benzo[c]chromen-1-ol",
        "background": "A natural product found in Cannabis sativa.\n",
        "inchi": {
            "hash": "SVTKBAIRFMXQQF-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H22O2/c1-5-6-13-10-16(20)18-14-9-12(2)7-8-15(14)19(3,4)21-17(18)11-13/h7-11,20H,5-6H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 282.383,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 282.161979948,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14736",
        "type": "Small Molecule",
        "synonyms": [
            "Cannabivarol",
            "CBV"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](O)(CO)[C@@]([H])(O)[C@@]([H])(O)CN1C(O)=C(CCC(O)=O)N=C2C(O)=NC(=O)N=C12",
        "id": "DB04262",
        "molecule": "3-(7-hydroxy-8-ribityllumazine-6-yl) propionic acid",
        "iupac_name": "3-{4,7-dihydroxy-2-oxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-2,8-dihydropteridin-6-yl}propanoic acid",
        "inchi": {
            "hash": "ZUXCIPRCLKZSHS-PJKMHFRUSA-N",
            "id": "InChI=1S/C14H18N4O9/c19-4-7(21)10(24)6(20)3-18-11-9(12(25)17-14(27)16-11)15-5(13(18)26)1-2-8(22)23/h6-7,10,19-21,24,26H,1-4H2,(H,22,23)(H,17,25,27)/t6-,7+,10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 386.3141,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 386.107378194,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB04262",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Aquifex aeolicus (strain VF5)",
                "target": "U6,7-dimethyl-8-ribityllumazine synthase"
            }
        ]
    },
    {
        "smiles": "[H][C@]12COC(O[C@@H]3O[C@H](COC)[C@@H](O[C@@H]4O[C@H](C)[C@H](OC)[C@H](O[C@H]5C[C@@]6(C)OC7(C[C@@H](O)[C@H](O[C@H]8C[C@@H](O)[C@H](OC(=O)C9=C(C)C(Cl)=C(O)C(Cl)=C9OC)[C@@H](C)O8)[C@@H](C)O7)O[C@]6([H])[C@@H](C)O5)[C@H]4O)[C@H](O)[C@@H]3OC)[C@H](OC(=O)C(C)C)[C@]1([H])O[C@@]1(O2)O[C@H](C)[C@@](O)(C(C)=O)[C@]2([H])OCO[C@@]12[H]",
        "id": "DB11375",
        "molecule": "Avilamycin",
        "cas": "11051-71-1",
        "iupac_name": "(2R,3S,4R,6S)-6-[(3aR,4R,4'R,5'S,6S,6'R,7aR)-6-{[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4S,5S,6S)-6-[(2R,3aS,3'aR,6'R,7R,7'S,7aR,7'aR)-7'-acetyl-6'-methyl-7-[(2-methylpropanoyl)oxy]-octahydro-2'H,3aH-2,4'-spirobi[[1,3]dioxolo[4,5-c]pyran]-7'-oloxy]-4-hydroxy-5-methoxy-2-(methoxymethyl)oxan-3-yl]oxy}-3-hydroxy-5-methoxy-6-methyloxan-4-yl]oxy}-4,6',7a-trimethyl-tetrahydro-3aH-spiro[[1,3]dioxolo[4,5-c]pyran-2,2'-oxan]-4'-oloxy]-4-hydroxy-2-methyloxan-3-yl 3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoate",
        "inchi": {
            "hash": "XIRGHRXBGGPPKY-OTPQUNEMSA-N",
            "id": "InChI=1S/C61H88Cl2O32/c1-21(2)53(70)87-49-45-32(92-61(93-45)52-51(78-20-79-52)60(72,27(8)64)28(9)91-61)19-77-56(49)89-57-48(76-14)39(68)44(31(83-57)18-73-11)88-55-40(69)47(43(74-12)24(5)82-55)85-34-17-58(10)50(26(7)81-34)94-59(95-58)16-30(66)42(25(6)90-59)84-33-15-29(65)41(23(4)80-33)86-54(71)35-22(3)36(62)38(67)37(63)46(35)75-13/h21,23-26,28-34,39-45,47-52,55-57,65-69,72H,15-20H2,1-14H3/t23-,24-,25-,26-,28-,29-,30-,31-,32+,33+,34+,39+,40-,41-,42-,43+,44-,45-,47-,48+,49-,50-,51-,52-,55+,56?,57+,58-,59?,60+,61-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1404.24,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1402.4635761,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11375",
        "type": "Small Molecule",
        "synonyms": [
            "Avilamycin",
            "Avilamycina",
            "Avilamycine",
            "Avilamycinum"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O",
        "id": "DB14554",
        "molecule": "Dotatate",
        "cas": "177943-88-3",
        "iupac_name": "(2S,3R)-2-{[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-19-[(2R)-3-phenyl-2-{2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetamido}propanamido]-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]formamido}-3-hydroxybutanoic acid",
        "inchi": {
            "hash": "QVFLVLMYXXNJDT-CSBVGUNJSA-N",
            "id": "InChI=1S/C65H90N14O19S2/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98)/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1435.63,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1434.594809082,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14554",
        "type": "Small Molecule",
        "synonyms": [
            "DOTA-octreotate",
            "DOTA-TATE",
            "Oxodotreotide"
        ],
        "is_stub": true
    },
    {
        "smiles": "O[C@H](C[C@@H](OCC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12)[C@@H](OCC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12",
        "id": "DB04190",
        "molecule": "2,5-dibenzyloxy-3-hydroxy-hexanedioic acid bis-[(2-hydroxy-indan-1-yl)-amide]",
        "iupac_name": "(2R,3R,5R)-2,5-bis(benzyloxy)-3-hydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide",
        "inchi": {
            "hash": "AHAVBKNGKPWROK-UMFPTGFGSA-N",
            "id": "InChI=1S/C38H40N2O7/c41-30-19-26-15-7-9-17-28(26)34(30)39-37(44)33(46-22-24-11-3-1-4-12-24)21-32(43)36(47-23-25-13-5-2-6-14-25)38(45)40-35-29-18-10-8-16-27(29)20-31(35)42/h1-18,30-36,41-43H,19-23H2,(H,39,44)(H,40,45)/t30-,31-,32-,33-,34+,35+,36-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 636.7334,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 636.283551644,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB04190",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "CC1=CC=C(NS(=O)(=O)C2=CC=CC=C2)C(=C1)C(O)=O",
        "id": "DB07313",
        "molecule": "5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID",
        "iupac_name": "2-benzenesulfonamido-5-methylbenzoic acid",
        "inchi": {
            "hash": "HXQLTRSIZRSFTR-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H13NO4S/c1-10-7-8-13(12(9-10)14(16)17)15-20(18,19)11-5-3-2-4-6-11/h2-9,15H,1H3,(H,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 291.322,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 291.056528599,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.",
        "link": "https://go.drugbank.com/drugs/DB07313",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMethionine aminopeptidase 2"
            }
        ]
    },
    {
        "smiles": "CCOC1=CC=C(NC(=O)CC(C)O)C=C1",
        "id": "DB13278",
        "molecule": "Bucetin",
        "cas": "1083-57-4",
        "iupac_name": "N-(4-ethoxyphenyl)-3-hydroxybutanamide",
        "background": "Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.1\n",
        "inchi": {
            "hash": "LIAWQASKBFCRNR-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H17NO3/c1-3-16-11-6-4-10(5-7-11)13-12(15)8-9(2)14/h4-7,9,14H,3,8H2,1-2H3,(H,13,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 223.272,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 223.120843411,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.",
        "link": "https://go.drugbank.com/drugs/DB13278",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](N)(C(O)=O)[C@@]([H])(O)OP(O)(O)=O",
        "id": "DB03821",
        "molecule": "2-Amino-3-Hydroxy-3-Phosphonooxy-Propionic Acid",
        "iupac_name": "(2S,3S)-2-amino-3-hydroxy-3-(phosphonooxy)propanoic acid",
        "inchi": {
            "hash": "JVLKWZAWYDOHCD-GPKNORDASA-N",
            "id": "InChI=1S/C3H8NO7P/c4-1(2(5)6)3(7)11-12(8,9)10/h1,3,7H,4H2,(H,5,6)(H2,8,9,10)/t1-,3+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 201.0719,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 201.003838127,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as serine and derivatives. These are compounds containing serine or a derivative thereof resulting from reaction of serine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB03821",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UArylsulfatase A"
            }
        ]
    },
    {
        "smiles": "CCOC(=O)\\C=C\\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)C1=COC=C1",
        "id": "DB04613",
        "molecule": "(E)-(4S,6S)-6-((S)-2-{(S)-2-[(FURAN-2-CARBONYL)-AMINO]-3-METHYL-BUTYRYLAMINO}-3-METHYL-BUTYRYLAMINO)-8-METHYL-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID ETHYL ESTER",
        "iupac_name": "ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-[(2S)-2-[(furan-3-yl)formamido]-3-methylbutanamido]-3-methylbutanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate",
        "inchi": {
            "hash": "JQGYBVLTABWBOF-VTQXMFKGSA-N",
            "id": "InChI=1S/C32H49N5O8/c1-8-45-25(38)10-9-23(16-21-11-13-33-28(21)39)34-30(41)24(15-18(2)3)35-31(42)26(19(4)5)37-32(43)27(20(6)7)36-29(40)22-12-14-44-17-22/h9-10,12,14,17-21,23-24,26-27H,8,11,13,15-16H2,1-7H3,(H,33,39)(H,34,41)(H,35,42)(H,36,40)(H,37,43)/b10-9+/t21-,23+,24-,26-,27-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 631.7602,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 631.358113569,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB04613",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H]N(C)CCCC1(C)CN(C2=CC=CC=C12)C1=CC=CC=C1",
        "id": "DB09189",
        "molecule": "Daledalin",
        "cas": "22136-27-2",
        "iupac_name": "methyl[3-(3-methyl-1-phenyl-2,3-dihydro-1H-indol-3-yl)propyl]amine",
        "background": "Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.\n",
        "inchi": {
            "hash": "YFAIJBZEDDOCAN-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H24N2/c1-19(13-8-14-20-2)15-21(16-9-4-3-5-10-16)18-12-7-6-11-17(18)19/h3-7,9-12,20H,8,13-15H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 280.415,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 280.193948781,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.",
        "link": "https://go.drugbank.com/drugs/DB09189",
        "type": "Small Molecule",
        "synonyms": [
            "Daledalin"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC=CC(NC2=NC=NN3C=CC(CN4CC[C@@H](N)[C@H](O)C4)=C23)=C1",
        "id": "DB11665",
        "molecule": "BMS-690514",
        "cas": "859853-30-8",
        "iupac_name": "(3R,4R)-4-amino-1-({4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperidin-3-ol",
        "background": "BMS-690514 has been investigated for the treatment of Breast Cancer.\n",
        "inchi": {
            "hash": "CSGQVNMSRKWUSH-IAGOWNOFSA-N",
            "id": "InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)/t16-,17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 368.441,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 368.196074037,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolo[2,1-f][1,2,4]triazines. These are aromatic heterocyclic compounds containing a pyrrolo[2,1-f][1,2,4]triazine ring system. Pyrrolo[2,1-f][1,2,4]triazine consists of a 1,2,4-triazine ring fused to and sharing the N2-atom with a pyrrole ring.",
        "link": "https://go.drugbank.com/drugs/DB11665",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C=CC(N)=NC1=O",
        "id": "DB13921",
        "molecule": "2'-C-methylcytidine",
        "cas": "20724-73-6",
        "iupac_name": "4-amino-1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-1,2-dihydropyrimidin-2-one",
        "background": "A nucleoside analog with anti-hepatitis C virus (HCV) activity. Upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus viral replication.\n",
        "inchi": {
            "hash": "PPUDLEUZKVJXSZ-VPCXQMTMSA-N",
            "id": "InChI=1S/C10H15N3O5/c1-10(17)7(15)5(4-14)18-8(10)13-3-2-6(11)12-9(13)16/h2-3,5,7-8,14-15,17H,4H2,1H3,(H2,11,12,16)/t5-,7-,8-,10-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 257.246,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 257.101170595,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB13921",
        "type": "Small Molecule",
        "synonyms": [
            "2'-C-Mecytosin",
            "2'C-Me-C"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC",
        "id": "DB11283",
        "molecule": "DL-dimyristoylphosphatidylcholine",
        "cas": "18656-38-7",
        "iupac_name": "(2-{[2,3-bis(tetradecanoyloxy)propyl phosphono]oxy}ethyl)trimethylazanium",
        "background": "A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial drug preparations to solubilize drugs for injection 1\n",
        "inchi": {
            "hash": "CITHEXJVPOWHKC-UHFFFAOYSA-N",
            "id": "InChI=1S/C36H72NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-35(38)42-32-34(33-44-46(40,41)43-31-30-37(3,4)5)45-36(39)29-27-25-23-21-19-17-15-13-11-9-7-2/h34H,6-33H2,1-5H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 677.945,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 677.49955528,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phosphatidylcholines. These are glycerophosphocholines in which the two free -OH are attached to one fatty acid each through an ester linkage.",
        "link": "https://go.drugbank.com/drugs/DB11283",
        "type": "Small Molecule",
        "synonyms": [
            "dimyristoyl phosphatidylcholine",
            "dimyristoyl-phosphatidylcholine",
            "Dimyristoylphosphatidylcholine",
            "Dimyristoylphosphatidylcholine, DL-",
            "DMPC",
            "l--dimyristoylphosphatidylcholine"
        ],
        "indication": "DL-dimyristoylphosphatidylcholine is not an active pharmaceutical agent and has no indication.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "DL-dimyristoylphosphatidylcholine is a water soluble phospholipid used to solubilize drugs for injection 1.\n"
    },
    {
        "smiles": "C[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](NC(C)=O)[C@H](O[C@H]3[C@@H](OP(O)(=O)OC[C@@H](O)C(=O)OCC\\C=C(/C)CC\\C=C\\C(C)(C)CCC(=C)C\\C=C(/C)CCC=C(C)C)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]3OC(N)=O)O[C@@H]2CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](NC(C)=O)[C@@H](O)[C@@H]1O[C@@H]1O[C@@H]([C@H](O)[C@H](O)[C@H]1O)C(=O)NC1=C(O)CCC1=O",
        "id": "DB11377",
        "molecule": "Bambermycins",
        "cas": "11015-37-5",
        "iupac_name": "(2S,3S,4R,5R,6R)-4-(carbamoyloxy)-5-{[(2S,3R,4R,5S,6R)-3-acetamido-5-{[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-methyl-5-{[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)carbamoyl]oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3-hydroxy-6-({hydroxy[(2R)-2-hydroxy-3-oxo-3-{[(3E,7E,14E)-4,9,9,15,19-pentamethyl-12-methylideneicosa-3,7,14,18-tetraen-1-yl]oxy}propoxy]phosphoryl}oxy)-3-methyloxane-2-carboxylic acid",
        "background": "Bambermycins are antibiotic complexes which are retrieved from the organism, Streptomyces bambergiensis. They are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.\n",
        "inchi": {
            "hash": "FUIOWSNNCWZETH-NAMXWVJMSA-N",
            "id": "InChI=1S/C70H109N4O35P/c1-31(2)16-14-18-33(4)20-21-34(5)24-26-69(9,10)25-13-12-17-32(3)19-15-27-97-62(92)40(80)29-99-110(95,96)109-67-57(58(108-68(71)93)70(11,94)59(107-67)61(90)91)106-64-45(73-37(8)77)48(83)55(42(102-64)30-98-65-52(87)49(84)46(81)41(28-75)101-65)104-63-44(72-36(7)76)47(82)54(35(6)100-63)103-66-53(88)50(85)51(86)56(105-66)60(89)74-43-38(78)22-23-39(43)79/h13,16,19-20,25,35,40-42,44-59,63-67,75,78,80-88,94H,5,12,14-15,17-18,21-24,26-30H2,1-4,6-11H3,(H2,71,93)(H,72,76)(H,73,77)(H,74,89)(H,90,91)(H,95,96)/b25-13+,32-19+,33-20+/t35-,40-,41-,42-,44-,45-,46-,47-,48-,49+,50+,51-,52-,53-,54-,55-,56+,57-,58-,59-,63+,64+,65-,66-,67-,70+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1597.609,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1596.660998224,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as terpene glycosides. These are prenol lipids containing a carbohydrate moiety glycosidically bound to a terpene backbone.",
        "link": "https://go.drugbank.com/drugs/DB11377",
        "type": "Small Molecule",
        "synonyms": [
            "Bambermicina",
            "Bambermycin",
            "Bambermycine",
            "Bambermycins",
            "Bambermycinum",
            "Flavofosfolipol",
            "Moenomycin",
            "Moenomycin A"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O",
        "id": "DB09010",
        "molecule": "Carmofur",
        "cas": "61422-45-5",
        "iupac_name": "5-fluoro-N-hexyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-1-carboxamide",
        "background": "Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.\n",
        "inchi": {
            "hash": "AOCCBINRVIKJHY-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 257.2614,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 257.117569598,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB09010",
        "type": "Small Molecule",
        "synonyms": [
            "Carmofur"
        ]
    },
    {
        "smiles": "[Mn+3].CCCCOCC[N+]1=CC=CC=C1\\C1=C2/C=CC(=N2)\\C(=C2/[N-]\\C(\\C=C2)=C(/C2=N/C(/C=C2)=C(\\C2=CC=C1[N-]2)C1=CC=CC=[N+]1CCOCCCC)C1=CC=CC=[N+]1CCOCCCC)\\C1=CC=CC=[N+]1CCOCCCC",
        "id": "DB17516",
        "molecule": "BMX-001 free base",
        "cas": "1379866-50-8",
        "iupac_name": "manganese(3+) 2,7,12,17-tetrakis[1-(2-butoxyethyl)pyridin-1-ium-2-yl]-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(20),2,4,6(24),7,9,11,13(22),14,16,18-undecaene-21,23-diide",
        "inchi": {
            "hash": "CZXJDWRMJZZOTQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C64H76N8O4.Mn/c1-5-9-41-73-45-37-69-33-17-13-21-57(69)61-49-25-27-51(65-49)62(58-22-14-18-34-70(58)38-46-74-42-10-6-2)53-29-31-55(67-53)64(60-24-16-20-36-72(60)40-48-76-44-12-8-4)56-32-30-54(68-56)63(52-28-26-50(61)66-52)59-23-15-19-35-71(59)39-47-75-43-11-7-3;/h13-36H,5-12,37-48H2,1-4H3;/q+2;+3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1076.299,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1075.534254,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17516",
        "type": "Small Molecule",
        "synonyms": [
            "Manganese(5+), ((2,2',2'',2'''-(21h,23h-porphine-5,10,15,20-tetrayl-.kappa.n21,.kappa.n22,.kappa.n23,.kappa.n24)tetrakis(1-(2-butoxyethyl)pyridiniumato))(2-))-, (sp-4-1)-"
        ],
        "is_stub": true
    },
    {
        "smiles": "[In]",
        "id": "DB11659",
        "molecule": "Indium",
        "cas": "7440-74-6",
        "iupac_name": "indigane",
        "background": "Indium has been used in trials studying the basic science of Clear Cell Renal Cell Carcinoma.\n",
        "inchi": {
            "hash": "APFVFJFRJDLVQX-UHFFFAOYSA-N",
            "id": "InChI=1S/In"
        },
        "weight": [
            {
                "type": "average",
                "weight": 114.818,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 114.90387878,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous post-transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a post-transition metal atom.",
        "link": "https://go.drugbank.com/drugs/DB11659",
        "type": "Small Molecule",
        "synonyms": [
            "indio"
        ],
        "is_stub": true
    },
    {
        "smiles": "NCCC(=O)NCC[C@H](N)C(O)=O",
        "id": "DB03236",
        "molecule": "(2s)-4-(Beta-Alanylamino)-2-Aminobutanoic Acid",
        "iupac_name": "(2S)-2-amino-4-(3-aminopropanamido)butanoic acid",
        "inchi": {
            "hash": "ZTTQHTAQUGLWNQ-YFKPBYRVSA-N",
            "id": "InChI=1S/C7H15N3O3/c8-3-1-6(11)10-4-2-5(9)7(12)13/h5H,1-4,8-9H2,(H,10,11)(H,12,13)/t5-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 189.2123,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 189.111341361,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB03236",
        "type": "Small Molecule"
    },
    {
        "smiles": "OC(=O)C1=CC=C(CC2=CC=CC=C2Cl)O1",
        "id": "DB07308",
        "molecule": "5-(2-CHLOROBENZYL)-2-FUROIC ACID",
        "iupac_name": "5-[(2-chlorophenyl)methyl]furan-2-carboxylic acid",
        "inchi": {
            "hash": "YRUPEIZURHOLHV-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H9ClO3/c13-10-4-2-1-3-8(10)7-9-5-6-11(16-9)12(14)15/h1-6H,7H2,(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 236.651,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 236.024021861,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as furoic acids. These are organic compounds containing a furoic acid moiety, with a structure characterized by a furan ring bearing a carboxylic acid group at the C2 or C3 carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB07308",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMethionine aminopeptidase"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(C=C1)S([O-])=O",
        "id": "DB03033",
        "molecule": "4-methoxybenzenesulfinate",
        "iupac_name": "4-methoxybenzene-1-sulfinate",
        "inchi": {
            "hash": "YVZWQPOTHRMEQW-UHFFFAOYSA-M",
            "id": "InChI=1S/C7H8O3S/c1-10-6-2-4-7(5-3-6)11(8)9/h2-5H,1H3,(H,8,9)/p-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 171.19,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 171.012138839,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB03033",
        "type": "Small Molecule",
        "synonyms": [
            "1-methyloxy-4-sulfone-benzene"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCollagenase 3"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UStromelysin-1"
            }
        ]
    },
    {
        "smiles": "C[N+](C)([O-])CCNC1=CC=C(NCC[N+](C)(C)[O-])C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O",
        "id": "DB04975",
        "molecule": "Banoxantrone",
        "cas": "136470-65-0",
        "iupac_name": "2-[(4-{[2-(dimethyl-oxo-$l^{5}-azanyl)ethyl]amino}-5,8-dihydroxy-9,10-dioxo-9,10-dihydroanthracen-1-yl)amino]-N,N-dimethylethanamine oxide",
        "background": "Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of tumours compared to administration of either banoxantrone or radiation alone. Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. 5\n",
        "inchi": {
            "hash": "YZBAXVICWUUHGG-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H28N4O6/c1-25(2,31)11-9-23-13-5-6-14(24-10-12-26(3,4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30/h5-8,23-24,27-28H,9-12H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 444.488,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 444.200884638,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anthraquinones. These are organic compounds containing either anthracene-9,10-quinone, 1,4-anthraquinone, or 1,2-anthraquinone.",
        "link": "https://go.drugbank.com/drugs/DB04975",
        "type": "Small Molecule",
        "synonyms": [
            "Banoxantrone"
        ],
        "indication": "For the treatment of various forms of cancer.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "AQ4N was rationally designed to have anti-tumor activity following bioreduction by tissue cytochrome P450 to AQ4, an active DNA topoisomerase II inhibitor. Preclinical studies demonstrated AQ4N selectively targets lymphoid tissues and hypoxic tumor tissues.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA topoisomerase 2-alpha"
            }
        ]
    },
    {
        "smiles": "OC1=CC=C(C=C1O)[N+]([O-])=O",
        "id": "DB03407",
        "molecule": "4-Nitrocatechol",
        "cas": "3316-09-4",
        "iupac_name": "4-nitrobenzene-1,2-diol",
        "inchi": {
            "hash": "XJNPNXSISMKQEX-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H5NO4/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,8-9H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 155.1082,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 155.021857653,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitrophenols. These are compounds containing a nitrophenol moiety, which consists of a benzene ring bearing both a hydroxyl group and a nitro group on two different ring carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB03407",
        "type": "Small Molecule"
    },
    {
        "smiles": "OC[C@H]1O[C@]2(NC(=O)NC2=O)[C@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB01823",
        "molecule": "Beta-D-Glucopyranose Spirohydantoin",
        "iupac_name": "(5R,7R,8S,9S,10R)-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione",
        "inchi": {
            "hash": "QRXBDPYWCAAAAI-UXDJRKLDSA-N",
            "id": "InChI=1S/C8H12N2O7/c11-1-2-3(12)4(13)5(14)8(17-2)6(15)9-7(16)10-8/h2-5,11-14H,1H2,(H2,9,10,15,16)/t2-,3-,4+,5-,8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 248.1901,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 248.064450748,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as c-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a C-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB01823",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, muscle form"
            }
        ]
    },
    {
        "smiles": "CSCC([O-])=O",
        "id": "DB03517",
        "molecule": "[Methylthio]Acetate",
        "iupac_name": "2-(methylsulfanyl)acetate",
        "inchi": {
            "hash": "HGTBAIVLETUVCG-UHFFFAOYSA-M",
            "id": "InChI=1S/C3H6O2S/c1-6-2-3(4)5/h2H2,1H3,(H,4,5)/p-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 105.136,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 105.001025094,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as straight chain fatty acids. These are fatty acids with a straight aliphatic chain.",
        "link": "https://go.drugbank.com/drugs/DB03517",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus sp. (strain B-0618)",
                "target": "UMonomeric sarcosine oxidase"
            }
        ]
    },
    {
        "smiles": "CC1=CN([C@H]2CC[C@@H](COP(O)(O)=O)O2)C(=O)NC1=O",
        "id": "DB03150",
        "molecule": "2',3'-Dideoxythymidine-5'-Monophosphate",
        "iupac_name": "{[(2S,5R)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "WVNRRNJFRREKAR-JGVFFNPUSA-N",
            "id": "InChI=1S/C10H15N2O7P/c1-6-4-12(10(14)11-9(6)13)8-3-2-7(19-8)5-18-20(15,16)17/h4,7-8H,2-3,5H2,1H3,(H,11,13,14)(H2,15,16,17)/t7-,8+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 306.2091,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 306.061687356,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2',3'-dideoxyribonucleoside monophosphates. These are pyrimidine nucleotides with monophosphate group linked to the ribose moiety lacking a hydroxyl group at positions 2 and 3.",
        "link": "https://go.drugbank.com/drugs/DB03150",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UThymidylate kinase"
            }
        ]
    },
    {
        "smiles": "O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O",
        "id": "DB13322",
        "molecule": "Hydrotalcite",
        "cas": "12304-65-3",
        "iupac_name": "dialuminium(3+) ion hexamagnesium(2+) ion dodecahydrate carbonate nonaoxidandiide",
        "inchi": {
            "hash": "BEBILBPAQKONJS-UHFFFAOYSA-L",
            "id": "InChI=1S/CH2O3.2Al.6Mg.12H2O.9O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;;;12*1H2;;;;;;;;;/q;2*+3;6*+2;;;;;;;;;;;;;9*-2/p-2"
        },
        "summary": "Hydrotalcite is an antacid indicated in the treatment of heartburn and excess gastric acid.",
        "weight": [
            {
                "type": "average",
                "weight": 619.973,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 617.940176,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.",
        "link": "https://go.drugbank.com/drugs/DB13322",
        "type": "Small Molecule",
        "synonyms": [
            "Hydrotalcite"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCN1C2=C(NC(CC3=CC=C(NC(C)=O)C=C3)=N2)C(=O)N(CC=C)C1=O",
        "id": "DB03267",
        "molecule": "1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine",
        "iupac_name": "N-(4-{[3-butyl-2,6-dioxo-1-(prop-2-en-1-yl)-2,3,6,7-tetrahydro-1H-purin-8-yl]methyl}phenyl)acetamide",
        "inchi": {
            "hash": "XFOWZKUTPKXWIE-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H25N5O3/c1-4-6-12-25-19-18(20(28)26(11-5-2)21(25)29)23-17(24-19)13-15-7-9-16(10-8-15)22-14(3)27/h5,7-10H,2,4,6,11-13H2,1,3H3,(H,22,27)(H,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 395.4549,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 395.195739691,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.",
        "link": "https://go.drugbank.com/drugs/DB03267",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPhosphoenolpyruvate carboxykinase, cytosolic [GTP]"
            }
        ]
    },
    {
        "smiles": "[H]N(CC1=CC=CC=C1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@]1([H])SC",
        "id": "DB06984",
        "molecule": "(1R,2R,3R,4S,5R)-4-(Benzylamino)-5-(methylthio)cyclopentane-1,2,3-triol",
        "iupac_name": "(1R,2R,3R,4S,5R)-4-(benzylamino)-5-(methylsulfanyl)cyclopentane-1,2,3-triol",
        "inchi": {
            "hash": "CHTYSDQNKZIWBZ-ZOLYEBIHSA-N",
            "id": "InChI=1S/C13H19NO3S/c1-18-13-9(10(15)11(16)12(13)17)14-7-8-5-3-2-4-6-8/h2-6,9-17H,7H2,1H3/t9-,10+,11+,12+,13+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 269.36,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 269.108564169,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.",
        "link": "https://go.drugbank.com/drugs/DB06984",
        "type": "Small Molecule",
        "synonyms": [
            "Benzylation of mannostatin A, 1b"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-mannosidase 2"
            }
        ]
    },
    {
        "smiles": "OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2",
        "id": "DB11157",
        "molecule": "Anthralin",
        "cas": "1143-38-0",
        "iupac_name": "1,8-dihydroxy-9,10-dihydroanthracen-9-one",
        "background": "Anthralin (1,8dihydroxy9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include irritation and discoloration of the skin 2.\nThis specific property of the molecule inspired workers to study details of its pharmacology. It is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical therapies for psoriasis 9. \nAnthralin is also known as dithranol. It is a main active ingredient in topical skin formulations for the treatment of psoriasis. Various formulations of the drug are available, including solutions, foams, and shampoos 13. The chemical structure of anthralin allows for dual solubility, permitting the compound to be absorbed well through the epidermis 1. \nAnthralin has also been studied in the treatment of warts, showing promising results 3. Salicylic acid is frequently added to anthralin to augment the stability of anthralin and to increase its penetration and efficacy 13.\n",
        "inchi": {
            "hash": "NUZWLKWWNNJHPT-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H10O3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-6,15-16H,7H2"
        },
        "summary": "Anthralin is an anthracene used to treat stable plaque psoriasis.",
        "weight": [
            {
                "type": "average",
                "weight": 226.231,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 226.062994182,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anthracenes. These are organic compounds containing a system of three linearly fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB11157",
        "type": "Small Molecule",
        "synonyms": [
            "Anthralin",
            "Dithranol",
            "Ditranol"
        ],
        "indication": "Stable plaque psoriasis of the skin and scalp 8.\nIt is also used topically in the management of psoriasis, dermatoses, and alopecia areata. Anthralin is also used in biomedical research due to its effect on EGFR autophosphorylation 10.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Anthralin is a natural anthraquinone derivative, anti-psoriatic and anti-inflammatory agent. It controls skin growth by reducing the synthesis of DNA and the mitotic activity in the hyperplastic epidermis, normalizing the rate of cell proliferation and keratinization 10.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AKeratin, type II cytoskeletal 2 epidermal"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AKeratin, type I cytoskeletal 12"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UC-Jun-amino-terminal kinase-interacting protein 1"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2",
        "id": "DB06249",
        "molecule": "Arzoxifene",
        "cas": "182133-25-1",
        "iupac_name": "2-(4-methoxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]phenoxy}-1-benzothiophen-6-ol",
        "inchi": {
            "hash": "MCGDSOGUHLTADD-UHFFFAOYSA-N",
            "id": "InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 475.6,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 475.181729592,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.",
        "link": "https://go.drugbank.com/drugs/DB06249",
        "type": "Small Molecule",
        "synonyms": [
            "Arzoxifene"
        ],
        "indication": "Investigated for use/treatment in breast cancer, osteoporosis, and endometrial cancer.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor beta"
            }
        ]
    },
    {
        "smiles": "[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)C(=O)NO)C(=O)NCC(=O)NC1=CC=C(C=C1)[N+]([O-])=O",
        "id": "DB07434",
        "molecule": "HONH-BENZYLMALONYL-L-ALANYLGLYCINE-P-NITROANILIDE",
        "iupac_name": "(2S)-2-benzyl-N-hydroxy-N'-[(1S)-1-({[(4-nitrophenyl)carbamoyl]methyl}carbamoyl)ethyl]propanediamide",
        "inchi": {
            "hash": "TZWQPWGUQCSKDW-GUYCJALGSA-N",
            "id": "InChI=1S/C21H23N5O7/c1-13(23-20(29)17(21(30)25-31)11-14-5-3-2-4-6-14)19(28)22-12-18(27)24-15-7-9-16(10-8-15)26(32)33/h2-10,13,17,31H,11-12H2,1H3,(H,22,28)(H,23,29)(H,24,27)(H,25,30)/t13-,17-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 457.4366,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 457.159748115,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB07434",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus thermoproteolyticus",
                "target": "UThermolysin"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=CC=C(O1)C1=C(OC(F)(F)F)C=CC=C1",
        "id": "DB07304",
        "molecule": "5-[2-(TRIFLUOROMETHOXY)PHENYL]-2-FUROIC ACID",
        "iupac_name": "5-[2-(trifluoromethoxy)phenyl]furan-2-carboxylic acid",
        "inchi": {
            "hash": "PSLFQKRPFOCZHR-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H7F3O4/c13-12(14,15)19-9-4-2-1-3-7(9)8-5-6-10(18-8)11(16)17/h1-6H,(H,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 272.1768,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 272.029643327,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as furoic acids. These are organic compounds containing a furoic acid moiety, with a structure characterized by a furan ring bearing a carboxylic acid group at the C2 or C3 carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB07304",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMethionine aminopeptidase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(C)CN(CCN1S(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(C=C1)[N+]([O-])=O",
        "id": "DB07049",
        "molecule": "(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine",
        "iupac_name": "(2R)-1-(4-tert-butylbenzenesulfonyl)-2-methyl-4-(4-nitrophenyl)piperazine",
        "inchi": {
            "hash": "SOFGQQQVQZQJFS-MRXNPFEDSA-N",
            "id": "InChI=1S/C21H27N3O4S/c1-16-15-22(18-7-9-19(10-8-18)24(25)26)13-14-23(16)29(27,28)20-11-5-17(6-12-20)21(2,3)4/h5-12,16H,13-15H2,1-4H3/t16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 417.522,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 417.172227057,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07049",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 1"
            }
        ]
    },
    {
        "smiles": "CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1",
        "id": "DB06623",
        "molecule": "Flupirtine",
        "cas": "56995-20-1",
        "iupac_name": "ethyl N-(2-amino-6-{[(4-fluorophenyl)methyl]amino}pyridin-3-yl)carbamate",
        "background": "Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.\n",
        "inchi": {
            "hash": "JUUFBMODXQKSTD-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H17FN4O2/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 304.3195,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 304.133554013,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-benzylaminopyridines. These are aromatic compounds containing pyridine ring substituted at the 2-position by a benzylamine group.",
        "link": "https://go.drugbank.com/drugs/DB06623",
        "type": "Small Molecule",
        "synonyms": [
            "Flupirtine",
            "Flupirtino",
            "Flupirtinum"
        ],
        "indication": "Investigated for use/treatment in fibromyalgia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-2A adrenergic receptor"
            }
        ]
    },
    {
        "smiles": "BrC1=C2NCCCNS(=O)(=O)C3=CC=CC(NC(N=C1)=N2)=C3",
        "id": "DB08441",
        "molecule": "6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE",
        "iupac_name": "6-bromo-13lambda6-thia-2,4,8,12,19-pentaazatricyclo[12.3.1.1^{3,7}]nonadeca-1(18),3(19),4,6,14,16-hexaene-13,13-dione",
        "inchi": {
            "hash": "AWSQADBSXFTFKL-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H14BrN5O2S/c14-11-8-16-13-18-9-3-1-4-10(7-9)22(20,21)17-6-2-5-15-12(11)19-13/h1,3-4,7-8,17H,2,5-6H2,(H2,15,16,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 384.252,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 383.005158054,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB08441",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02747"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07975"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04666"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01475"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07748"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13182"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13829"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11807"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03132"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06874"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01453"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15666"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18041"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14483"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03788"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14098"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13665"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03053"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06861"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04210"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07287"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16106"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02437"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07714"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09116"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14875"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17738"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04724"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08936"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06756"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08986"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14664"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17263"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03051"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13652"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11326"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12415"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04777"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08524"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08515"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07015"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02655"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17984"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06405"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02529"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03935"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05432"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04581"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14091"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03635"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03204"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08560"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11647"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12504"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13499"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05442"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09477"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02494"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06998"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01408"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07731"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04117"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00434"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01764"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04201"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12803"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03536"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07306"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05611"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13030"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17119"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11397"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17478"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03436"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00280"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06106"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06117"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13771"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13328"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04650"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01066"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05959"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07514"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08800"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16203"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18026"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07686"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01647"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00476"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02526"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01221"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00771"
    },
    {
        "smiles": "C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1",
        "id": "DB08941",
        "molecule": "Isoxsuprine",
        "cas": "395-28-8",
        "iupac_name": "4-[(1S,2R)-1-hydroxy-2-{[(2R)-1-phenoxypropan-2-yl]amino}propyl]phenol",
        "background": "A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.\n",
        "inchi": {
            "hash": "BMUKKTUHUDJSNZ-HBUWYVDXSA-N",
            "id": "InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3/t13-,14-,18-/m1/s1"
        },
        "summary": "Isoxsuprine is a beta-adrenergic agonist used in the symptomatic treatment of cerebrovascular insufficiency, peripheral vascular disease of arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease) and Raynaud's disease.",
        "weight": [
            {
                "type": "average",
                "weight": 301.386,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 301.167793605,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.",
        "link": "https://go.drugbank.com/drugs/DB08941",
        "type": "Small Molecule",
        "synonyms": [
            "Isoxsuprine"
        ]
    },
    {
        "smiles": "CC1=C(NC(=O)NC(=O)C2=CC=C(Cl)C=C2Cl)C=CC=C1OCCCCC(O)=O",
        "id": "DB04645",
        "molecule": "5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID",
        "iupac_name": "5-(3-{[(2,4-dichlorobenzoyl)carbamoyl]amino}-2-methylphenoxy)pentanoic acid",
        "inchi": {
            "hash": "NJJIFGCFUDDBSP-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H20Cl2N2O5/c1-12-16(5-4-6-17(12)29-10-3-2-7-18(25)26)23-20(28)24-19(27)14-9-8-13(21)11-15(14)22/h4-6,8-9,11H,2-3,7,10H2,1H3,(H,25,26)(H2,23,24,27,28)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 439.289,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 438.074927174,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-benzoyl-n'-phenylureas. These are n-acyl-phenylureas that have the acyl group substituted by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB04645",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, muscle form"
            }
        ]
    },
    {
        "smiles": "COC(=O)C1=CC=CC=C1C(=O)OC",
        "id": "DB13336",
        "molecule": "Dimethylphthalate",
        "cas": "131-11-3",
        "iupac_name": "1,2-dimethyl benzene-1,2-dicarboxylate",
        "inchi": {
            "hash": "NIQCNGHVCWTJSM-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H10O4/c1-13-9(11)7-5-3-4-6-8(7)10(12)14-2/h3-6H,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 194.184,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 194.057908808,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.",
        "link": "https://go.drugbank.com/drugs/DB13336",
        "type": "Small Molecule",
        "synonyms": [
            "Dimethyl phthalate"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)CC1=C2C=CC=CC2=CC=C1",
        "id": "DB01750",
        "molecule": "1-naphthaleneacetic acid",
        "cas": "86-87-3",
        "iupac_name": "2-(naphthalen-1-yl)acetic acid",
        "inchi": {
            "hash": "PRPINYUDVPFIRX-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H10O2/c13-12(14)8-10-6-3-5-9-4-1-2-7-11(9)10/h1-7H,8H2,(H,13,14)"
        },
        "summary": "1-naphthaleneacetic acid is a drug used to treat digestive problems from excessive fat consumption and functional disorders of the gallbladder and bile ducts.",
        "weight": [
            {
                "type": "average",
                "weight": 186.2066,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 186.068079564,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB01750",
        "type": "Small Molecule",
        "synonyms": [
            "1-Naphthylacetic acid",
            "NAA",
            "naphthalen-1-yl-acetic acid",
            "naphthalene-1-acetic acid",
            "-NAA",
            "-naphthaleneacetic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "US-phase kinase-associated protein 1"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=C(C=CS1)S(=O)(=O)NC1=C(O)C=C(C=C1)C(O)=O",
        "id": "DB07927",
        "molecule": "3-[(4-Carboxy-2-hydroxyphenyl)sulfamoyl]-2-thiophenecarboxylic acid",
        "iupac_name": "3-[(4-carboxy-2-hydroxyphenyl)sulfamoyl]thiophene-2-carboxylic acid",
        "inchi": {
            "hash": "RDPXXOOKKRIKFN-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H9NO7S2/c14-8-5-6(11(15)16)1-2-7(8)13-22(19,20)9-3-4-21-10(9)12(17)18/h1-5,13-14H,(H,15,16)(H,17,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 343.332,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 342.982043027,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.",
        "link": "https://go.drugbank.com/drugs/DB07927",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CC1=CC=CC2=C1C=CC=C2)C(O)=O",
        "id": "DB07365",
        "molecule": "1-Naphthyl-L-alanine",
        "cas": "55516-54-6",
        "iupac_name": "(2S)-2-amino-3-(naphthalen-1-yl)propanoic acid",
        "inchi": {
            "hash": "OFYAYGJCPXRNBL-LBPRGKRZSA-N",
            "id": "InChI=1S/C13H13NO2/c14-12(13(15)16)8-10-6-3-5-9-4-1-2-7-11(9)10/h1-7,12H,8,14H2,(H,15,16)/t12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 215.2478,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 215.094628665,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB07365",
        "type": "Small Molecule",
        "synonyms": [
            "(S)-2-Amino-3-(naphthalen-1-yl)propanoic acid",
            "L-beta-(1-Naphthyl)alanine",
            "Naphthalen-2-yl-3-alanine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UPeriplasmic oligopeptide-binding protein"
            },
            {
                "action": "Not Available",
                "organism": "FIV",
                "target": "UPol polyprotein"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12C[C@@H](O)[C@@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3",
        "id": "DB07702",
        "molecule": "17alpha-Estriol",
        "cas": "1228-72-4",
        "iupac_name": "(1S,2R,3aS,3bR,9bS,11aS)-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,2,7-triol",
        "inchi": {
            "hash": "PROQIPRRNZUXQM-PNVOZDDCSA-N",
            "id": "InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17-,18+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 288.3814,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 288.172544634,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.",
        "link": "https://go.drugbank.com/drugs/DB07702",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor coactivator 5"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor beta"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCC(=O)NCCC[N+](C)(C)[O-]",
        "id": "DB01736",
        "molecule": "[3-(Dodecanoylamino)Propyl](Hydroxy)Dimethylammonium",
        "iupac_name": "N-[3-(dimethyl-oxo-$l^{5}-azanyl)propyl]dodecanamide",
        "inchi": {
            "hash": "JNGWKQJZIUZUPR-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H36N2O2/c1-4-5-6-7-8-9-10-11-12-14-17(20)18-15-13-16-19(2,3)21/h4-16H2,1-3H3,(H,18,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 300.4799,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 300.277678406,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl amines. These are compounds containing a fatty acid moiety linked to an amine group through an ester linkage.",
        "link": "https://go.drugbank.com/drugs/DB01736",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UADP/ATP translocase 1"
            }
        ]
    },
    {
        "smiles": "OC(=O)COC1=CC(F)=CC=C1C(=O)NCC1=NC2=C(S1)C(F)=CC(F)=C2F",
        "id": "DB02834",
        "molecule": "IDD552",
        "iupac_name": "2-(5-fluoro-2-{[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]carbamoyl}phenoxy)acetic acid",
        "inchi": {
            "hash": "ZCAGEXZTORJQDZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H10F4N2O4S/c18-7-1-2-8(11(3-7)27-6-13(24)25)17(26)22-5-12-23-15-14(21)9(19)4-10(20)16(15)28-12/h1-4H,5-6H2,(H,22,26)(H,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 414.331,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 414.029740328,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.",
        "link": "https://go.drugbank.com/drugs/DB02834",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAldose reductase"
            }
        ]
    },
    {
        "smiles": "NC1=NC2=C(N1)C=C1C(=O)NC(N)=NC1=C2",
        "id": "DB07452",
        "molecule": "2,6-diamino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",
        "iupac_name": "2,6-diamino-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one",
        "inchi": {
            "hash": "WFECBOHPSURSGU-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H8N6O/c10-8-13-5-1-3-4(2-6(5)14-8)12-9(11)15-7(3)16/h1-2H,(H3,10,13,14)(H3,11,12,15,16)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 216.1994,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 216.075958908,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB07452",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)",
                "target": "UQueuine tRNA-ribosyltransferase"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(Br)C=C1NC(=O)NC1=C2C=CN(CC3=CC=NC(N)=C3)C2=CC=C1",
        "id": "DB12744",
        "molecule": "CGI-1842",
        "cas": "900573-88-8",
        "iupac_name": "3-{1-[(2-aminopyridin-4-yl)methyl]-1H-indol-4-yl}-1-(5-bromo-2-methoxyphenyl)urea",
        "background": "JI-101 has been used in trials studying the treatment of Cancer, Colon Cancer, Neuroendocrine, Ovarian Cancer, and Advanced Solid Tumors.\n",
        "inchi": {
            "hash": "ZXBFYBLSJMEBEP-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H20BrN5O2/c1-30-20-6-5-15(23)12-18(20)27-22(29)26-17-3-2-4-19-16(17)8-10-28(19)13-14-7-9-25-21(24)11-14/h2-12H,13H2,1H3,(H2,24,25)(H2,26,27,29)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 466.339,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 465.080038,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-phenylureas. These are compounds containing a N-phenylurea moiety, which is structurally characterized by a phenyl group linked to one nitrogen atom of a urea group.",
        "link": "https://go.drugbank.com/drugs/DB12744",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1",
        "id": "DB00366",
        "molecule": "Doxylamine",
        "cas": "469-21-6",
        "iupac_name": "dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine",
        "background": "Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.\n",
        "inchi": {
            "hash": "HCFDWZZGGLSKEP-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3"
        },
        "summary": "Doxylamine is an antihistamine used to treat insomnia and allergy symptoms and is used with pyridoxine in the treatment of nausea and vomiting in pregnancy.",
        "weight": [
            {
                "type": "average",
                "weight": 270.3694,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 270.173213336,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).",
        "link": "https://go.drugbank.com/drugs/DB00366",
        "type": "Small Molecule",
        "synonyms": [
            "2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine",
            "2-Dimethylaminoethoxyphenylmethyl-2-picoline",
            "Dossilamina",
            "Doxilamina",
            "Doxilminio",
            "Doxylamine",
            "Doxylaminum",
            "N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine",
            "Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether"
        ],
        "indication": "Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AHistamine H1 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor subfamily 1 group I member 3"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor"
            }
        ]
    },
    {
        "smiles": "COC1=C(Br)C2=C(C=C1)C(O[C@@H]1C[C@H](N(C1)C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)C(=O)N[C@@]1(C[C@H]1C=C)C(O)=O)=CC(=N2)C1=CSC(NC(=O)C(C)C)=N1",
        "id": "DB11808",
        "molecule": "Faldaprevir",
        "cas": "801283-95-4",
        "iupac_name": "(1R,2S)-1-[(2S,4R)-4-({8-bromo-7-methoxy-2-[2-(2-methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl}oxy)-1-[(2S)-2-{[(cyclopentyloxy)carbonyl]amino}-3,3-dimethylbutanoyl]pyrrolidine-2-amido]-2-ethenylcyclopropane-1-carboxylic acid",
        "background": "Faldaprevir has been investigated for the treatment of Chronic Hepatitis C.\n",
        "inchi": {
            "hash": "LLGDPTDZOVKFDU-XUHJSTDZSA-N",
            "id": "InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 869.821,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 868.246510533,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB11808",
        "type": "Small Molecule",
        "synonyms": [
            "Faldaprvir",
            "Faldaprevir",
            "Faldaprevirum"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01143"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18668"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13783"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03639"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17174"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08549"
    },
    {
        "smiles": "[Cl-].C[N+](C)([11CH3])CCO",
        "id": "DB09277",
        "molecule": "Choline C 11",
        "cas": "87591-54-6",
        "iupac_name": "(2-hydroxyethyl)((C)methyl)dimethylazanium chloride",
        "background": "Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.4 It was developed by MCPRF and FDA first approved in September 2012.\n",
        "inchi": {
            "hash": "SGMZJAMFUVOLNK-ULWFUOSBSA-M",
            "id": "InChI=1S/C5H14NO.ClH/c1-6(2,3)4-5-7;/h7H,4-5H2,1-3H3;1H/q+1;/p-1/i1-1;"
        },
        "weight": [
            {
                "type": "average",
                "weight": 138.62,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 138.0878256,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cholines. These are organic compounds containing a N,N,N-trimethylethanolammonium cation.",
        "link": "https://go.drugbank.com/drugs/DB09277",
        "type": "Small Molecule",
        "synonyms": [
            "11C-choline",
            "11C-choline chloride"
        ],
        "indication": "Choline C11 is indicated for its use in positron emission tomography (PET) imaging in patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography or magnetic resonance imaging.Label,2\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Choline is phosphorylated by choline kinase into phosphorylcholine. This phosphorylated form gets trapped inside the cell. Cancer cells exhibit an increased cell wall membrane synthesis as well as an increased activity of choline kinase. Choline C11 presents a small tracer activity in the urinary collecting system and this property makes it a very noble compound in the evaluation of ureters and bladder.3\n"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06521"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04122"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17028"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08322"
    },
    {
        "smiles": "CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I",
        "id": "DB09487",
        "molecule": "Iotrolan",
        "cas": "79770-24-4",
        "iupac_name": "2,4,6-triiodo-5-{N-methyl-2-[methyl({2,4,6-triiodo-3,5-bis[(1,3,4-trihydroxybutan-2-yl)carbamoyl]phenyl})carbamoyl]acetamido}-N1,N3-bis(1,3,4-trihydroxybutan-2-yl)benzene-1,3-dicarboxamide",
        "background": "Nonionic, isotonic contrast medium designed for intrathecal use.\n",
        "inchi": {
            "hash": "XUHXFSYUBXNTHU-UHFFFAOYSA-N",
            "id": "InChI=1S/C37H48I6N6O18/c1-48(32-28(40)22(34(64)44-12(4-50)16(58)8-54)26(38)23(29(32)41)35(65)45-13(5-51)17(59)9-55)20(62)3-21(63)49(2)33-30(42)24(36(66)46-14(6-52)18(60)10-56)27(39)25(31(33)43)37(67)47-15(7-53)19(61)11-57/h12-19,50-61H,3-11H2,1-2H3,(H,44,64)(H,45,65)(H,46,66)(H,47,67)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1626.242,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1625.72933,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB09487",
        "type": "Small Molecule",
        "synonyms": [
            "Iotrolan",
            "Iotrolanum",
            "Iotrolum"
        ],
        "is_stub": true
    },
    {
        "smiles": "O[C@H]1C[C@@H](O[C@@H]1COP(O)(O)=O)N1C=CC(=O)NC1=O",
        "id": "DB03800",
        "molecule": "Deoxyuridine monophosphate",
        "cas": "964-26-1",
        "iupac_name": "{[(2R,3S,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "JSRLJPSBLDHEIO-SHYZEUOFSA-N",
            "id": "InChI=1S/C9H13N2O8P/c12-5-3-8(11-2-1-7(13)10-9(11)14)19-6(5)4-18-20(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,10,13,14)(H2,15,16,17)/t5-,6+,8+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 308.1819,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 308.040951914,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleoside monophosphates. These are pyrimidine nucleotides with a monophosphate group linked to the ribose moiety lacking a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB03800",
        "type": "Small Molecule",
        "synonyms": [
            "2'-deoxyuridine 5'-monophosphate",
            "2'-Deoxyuridine 5'-phosphate",
            "Deoxyuridine 5'-phosphate",
            "Deoxyuridylate",
            "Deoxyuridylic acid",
            "dUMP"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UDeoxyuridine 5'-triphosphate nucleotidohydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Lactobacillus casei",
                "target": "UThymidylate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UThymidylate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UThymidylate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)",
                "target": "UThymidylate synthase ThyX"
            },
            {
                "action": "Not Available",
                "organism": "FIV",
                "target": "UPol polyprotein"
            },
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UDeoxyuridine 5'-triphosphate nucleotidohydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Pneumocystis carinii",
                "target": "UThymidylate synthase"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C1",
        "id": "DB09038",
        "molecule": "Empagliflozin",
        "cas": "864070-44-0",
        "iupac_name": "(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol",
        "background": "Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.10 It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,15,16,13 for the management of type 2 diabetes mellitus.18\nThe first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects.12 Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. remogliflozin etabonate), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of canagliflozin in 2013 and both dapagliflozin and empagliflozin in 2014.12 As the most recently approved of the \"flozin\" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.22,19\n",
        "inchi": {
            "hash": "OBWASQILIWPZMG-QZMOQZSNSA-N",
            "id": "InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1"
        },
        "summary": "Empagliflozin is an SGLT2 inhibitor used to manage type 2 diabetes mellitus.",
        "weight": [
            {
                "type": "average",
                "weight": 450.91,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 450.1445309,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.",
        "link": "https://go.drugbank.com/drugs/DB09038",
        "type": "Small Molecule",
        "synonyms": [
            "(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol",
            "1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene",
            "Empagliflozin",
            "Empagliflozina",
            "Empagliflozine",
            "Empagliflozinum"
        ],
        "indication": "Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin.16,15,18 It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or as a combination product with metformin.18,21\nAn extended-release combination product containing empagliflozin, metformin, and linagliptin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.13\nEmpagliflozin is also approved to reduce the risk of cardiovascular mortality and hospitalization due to heart failure in adult patients with heart failure, either alone or in combination with metformin.18,23 It is also indicated in adults to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.21,24\nEmpagliflozin is not approved for use in patients with type 1 diabetes.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Empagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, thereby increasing the amount of glucose excreted in the urine.18 It has a relatively long duration of action requiring only once-daily dosing. Patients should be monitored closely for signs and symptoms of ketoacidosis regardless of blood glucose level as empagliflozin may precipitate diabetic ketoacidosis in the absence of hyperglycemia.18 As its mechanism of action is contingent on the renal excretion of glucose, empagliflozin may be held in cases of acute kidney injury and/or discontinued in patients who develop chronic renal disease. \nThe overexcretion of glucose creates a sugar-rich urogenital environment which increases the risk of urogenital infections in both male and female patients - monitor closely for signs and symptoms of developing infection.18\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium/glucose cotransporter 2"
            }
        ]
    },
    {
        "smiles": "OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1",
        "id": "DB00975",
        "molecule": "Dipyridamole",
        "cas": "58-32-2",
        "iupac_name": "2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol",
        "background": "A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)\n",
        "inchi": {
            "hash": "IZEKFCXSFNUWAM-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2"
        },
        "summary": "Dipyridamole is a phosphodiesterase inhibitor used to prevent postoperative thromboembolic events.",
        "weight": [
            {
                "type": "average",
                "weight": 504.6256,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 504.317251808,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.",
        "link": "https://go.drugbank.com/drugs/DB00975",
        "type": "Small Molecule",
        "synonyms": [
            "Dipiridamol",
            "Dipyridamine",
            "Dipyridamole",
            "Dipyridamolum",
            "Dipyudamine",
            "Dypyridamol"
        ],
        "indication": "For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AcGMP-specific 3',5'-cyclic phosphodiesterase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AcAMP-specific 3',5'-cyclic phosphodiesterase 4A"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AAdenosine deaminase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCalcipressin-1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-1-acid glycoprotein 1"
            }
        ]
    },
    {
        "smiles": "NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O",
        "id": "DB00695",
        "molecule": "Furosemide",
        "cas": "54-31-9",
        "iupac_name": "4-chloro-2-{[(furan-2-yl)methyl]amino}-5-sulfamoylbenzoic acid",
        "background": "Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative.9 Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure.10 It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients.1 The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.9\n",
        "inchi": {
            "hash": "ZZUFCTLCJUWOSV-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)"
        },
        "summary": "Furosemide is a loop diuretic used to treat hypertension and edema in congestive heart failure, liver cirrhosis, renal disease, and hypertension.",
        "weight": [
            {
                "type": "average",
                "weight": 330.744,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 330.007719869,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB00695",
        "type": "Small Molecule",
        "synonyms": [
            "2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid",
            "4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid",
            "4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid",
            "4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid",
            "Frusemide",
            "Furosemid",
            "Furosemida",
            "Furosemide",
            "Furosemidu",
            "Furosemidum"
        ],
        "indication": "Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.9 \nOral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.12\nIntravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.9\nSubcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.13\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Furosemide manages hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Furosemide is a potent loop diuretic that works to increase the excretion of Na+ and water by the kidneys by inhibiting their reabsorption from the proximal and distal tubules, as well as the loop of Henle.9 It works directly acts on the cells of the nephron and indirectly modifies the content of the renal filtrate.8 Ultimately, furosemide increases the urine output by the kidney. Protein-bound furosemide is delivered to its site of action in the kidneys and secreted via active secretion by nonspecific organic transporters expressed at the luminal site of action.4,9 \nFollowing oral administration, the onset of the diuretic effect is about 1 and 1.5 hours 9, and the peak effect is reached within the first 2 hours.10 The duration of effect following oral administration is about 4-6 hours but may last up to 8 hours.12 Following intravenous administration, the onset of effect is within 5 minutes, and the peak effect is reached within 30 minutes. The duration of action following intravenous administration is approximately 2 hours. Following intramuscular administration, the onset of action is somewhat delayed.9\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASolute carrier family 12 member 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NCarbonic anhydrase 2"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UG-protein coupled receptor 35"
            }
        ]
    },
    {
        "smiles": "CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1",
        "id": "DB00472",
        "molecule": "Fluoxetine",
        "cas": "54910-89-3",
        "iupac_name": "methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine",
        "background": "Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI).2 It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.13\n",
        "inchi": {
            "hash": "RTHCYVBBDHJXIQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3"
        },
        "summary": "Fluoxetine is a selective serotonin reuptake inhibitor used to treat major depressive disorder, bulimia, OCD, premenstrual dysphoric disorder, panic disorder, and bipolar I.",
        "weight": [
            {
                "type": "average",
                "weight": 309.3261,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 309.134048818,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.",
        "link": "https://go.drugbank.com/drugs/DB00472",
        "type": "Small Molecule",
        "synonyms": [
            "(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine",
            "(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine",
            "Fluoxetin",
            "Fluoxetina",
            "Fluoxtine",
            "Fluoxetine",
            "Fluoxetinum"
        ],
        "indication": "Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.12 Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression.12 Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).18\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fluoxetine blocks the serotonin reuptake transporter in the presynaptic terminal, which ultimately results in sustained levels of 5-hydroxytryptamine (5-HT) in certain brain areas.13 However, fluoxetine binds with relatively poor affinity to 5-HT, dopaminergic, adrenergic, cholinergic, muscarinic, and histamine receptors which explains why it has a far more desirable adverse effect profile compared to earlier developed classes of antidepressants such as tricyclic antidepressants.132 \n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent serotonin transporter"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2C"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-3"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit beta-4"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinases regulatory subunit 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UPotassium voltage-gated channel subfamily H member 2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07733"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18505"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07293"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03107"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05070"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05719"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03999"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06770"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12417"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07044"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03133"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00390"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00245"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00439"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07180"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14775"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01441"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04469"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15237"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01178"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13790"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02464"
    },
    {
        "smiles": "OS(O)(O)C1=CC=C(C=C1)C-1=C2\\C=CC(=N2)\\C(=C2/N\\C(\\C=C2)=C(/C2=N/C(/C=C2)=C(\\C2=CC=C\\-1N2)C1=CC=C(C=C1)S(O)(O)O)C1=CC=C(C=C1)S([O-])([O-])[O-])\\C1=CC=C(C=C1)S(O)(O)[O-]",
        "id": "DB01999",
        "molecule": "5,10,15,20-Tetrakis(4-Sulpfonatophenyl)-21h,23h-Porphine",
        "iupac_name": "[4-(17-{4-[dihydroxy(oxido)-lambda4-sulfanyl]phenyl}-7,12-bis[4-(trihydroxy-lambda4-sulfanyl)phenyl]-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1,3(24),4,6,8,10,12,14,16(22),17,19-undecaen-2-yl)phenyl]-lambda4-sulfanetris(olate)",
        "inchi": {
            "hash": "OVPFWIRROXFHGQ-LWQDQPMZSA-J",
            "id": "InChI=1S/C44H38N4O12S4/c49-61(50,51)29-9-1-25(2-10-29)41-33-17-19-35(45-33)42(26-3-11-30(12-4-26)62(52,53)54)37-21-23-39(47-37)44(28-7-15-32(16-8-28)64(58,59)60)40-24-22-38(48-40)43(36-20-18-34(41)46-36)27-5-13-31(14-6-27)63(55,56)57/h1-24,45,48-60H/p-4/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 939.02,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 938.105605332,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB01999",
        "type": "Small Molecule"
    },
    {
        "smiles": "CN1CCCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1",
        "id": "DB15979",
        "molecule": "Homochlorcyclizine",
        "cas": "848-53-3",
        "iupac_name": "1-[(4-chlorophenyl)(phenyl)methyl]-4-methyl-1,4-diazepane",
        "inchi": {
            "hash": "WEUCDJCFJHYFRL-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H23ClN2/c1-21-12-5-13-22(15-14-21)19(16-6-3-2-4-7-16)17-8-10-18(20)11-9-17/h2-4,6-11,19H,5,12-15H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 314.86,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 314.1549764,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15979",
        "type": "Small Molecule",
        "synonyms": [
            "Homochlorcyclizine",
            "Homochlorcyclizinum",
            "Homoclorociclizina"
        ],
        "is_stub": true
    },
    {
        "id": "DB17569",
        "molecule": "2-O, 3-O desulfated heparin",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17569",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCCCCCOC1=CC(C)=C(O)C(C)=C1C",
        "id": "DB12162",
        "molecule": "HX-1171",
        "cas": "148081-72-5",
        "iupac_name": "4-(hexyloxy)-2,3,6-trimethylphenol",
        "background": "Hx 1171 is under investigation in clinical trial NCT01548391 (A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects).\n",
        "inchi": {
            "hash": "ATMNQRRJNBCQJO-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H24O2/c1-5-6-7-8-9-17-14-10-11(2)15(16)13(4)12(14)3/h10,16H,5-9H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 236.355,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 236.177630013,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4-alkoxyphenols. These are phenols that carry an alkoxy group at the 4-position of the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB12162",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(C=C(OC)C(OS(N)(=O)=O)=C4)[C@@]3([H])CC[C@]12C)OS(N)(=O)=O",
        "id": "DB08416",
        "molecule": "(9BETA,13ALPHA,14BETA,17ALPHA)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIYL DISULFAMATE",
        "iupac_name": "(1S,3aS,3bR,9bS,11aS)-8-methoxy-11a-methyl-7-(sulfamoyloxy)-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl sulfamate",
        "inchi": {
            "hash": "AQSNIXKAKUZPSI-SSTWWWIQSA-N",
            "id": "InChI=1S/C19H28N2O7S2/c1-19-8-7-12-13(15(19)5-6-18(19)28-30(21,24)25)4-3-11-9-17(27-29(20,22)23)16(26-2)10-14(11)12/h9-10,12-13,15,18H,3-8H2,1-2H3,(H2,20,22,23)(H2,21,24,25)/t12-,13+,15-,18-,19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 460.565,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 460.13379264,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton.",
        "link": "https://go.drugbank.com/drugs/DB08416",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "[H][C@](N)(CC1=CC(Br)=C(O)C(Br)=C1)C(O)=O",
        "id": "DB07637",
        "molecule": "Dibromotyrosine",
        "cas": "300-38-9",
        "iupac_name": "(2S)-2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid",
        "inchi": {
            "hash": "COESHZUDRKCEPA-ZETCQYMHSA-N",
            "id": "InChI=1S/C9H9Br2NO3/c10-5-1-4(2-6(11)8(5)13)3-7(12)9(14)15/h1-2,7,13H,3,12H2,(H,14,15)/t7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 338.981,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 336.894918453,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB07637",
        "type": "Small Molecule",
        "synonyms": [
            "3,5-dibromo-L-tyrosine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UErythropoietin receptor"
            }
        ]
    },
    {
        "smiles": "CCN1C(=O)C2=C(NN=C2C)C2=C1C=CC=C2",
        "id": "DB07158",
        "molecule": "5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE",
        "iupac_name": "5-ethyl-3-methyl-1H,4H,5H-pyrazolo[4,3-c]quinolin-4-one",
        "inchi": {
            "hash": "ASEHARDUZDZEKS-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H13N3O/c1-3-16-10-7-5-4-6-9(10)12-11(13(16)17)8(2)14-15-12/h4-7H,3H2,1-2H3,(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 227.2618,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 227.105862053,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroquinolones. These are compounds containing a hydrogenated quinoline bearing a ketone group.",
        "link": "https://go.drugbank.com/drugs/DB07158",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein kinase Chk1"
            }
        ]
    },
    {
        "smiles": "CN1N=C(C)C2=C1N(O)C1=C(C=C(Cl)C=C1)C2=O",
        "id": "DB07218",
        "molecule": "6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE",
        "iupac_name": "6-chloro-9-hydroxy-1,3-dimethyl-1H,4H,9H-pyrazolo[3,4-b]quinolin-4-one",
        "inchi": {
            "hash": "AYKGPCNWPACUQV-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H10ClN3O2/c1-6-10-11(17)8-5-7(13)3-4-9(8)16(18)12(10)15(2)14-6/h3-5,18H,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 263.68,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 263.046154286,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroquinolones. These are compounds containing a hydrogenated quinoline bearing a ketone group.",
        "link": "https://go.drugbank.com/drugs/DB07218",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UC-Jun-amino-terminal kinase-interacting protein 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 8"
            }
        ]
    },
    {
        "id": "DB06093",
        "molecule": "ABT-560",
        "background": "ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06093",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in neurologic disorders.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[Cl-].[Cl-].CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C",
        "id": "DB13705",
        "molecule": "Decamethoxine",
        "cas": "38146-42-8",
        "iupac_name": "{10-[dimethyl(2-{[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy}-2-oxoethyl)azaniumyl]decyl}dimethyl(2-{[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy}-2-oxoethyl)azanium dichloride",
        "inchi": {
            "hash": "LRQIWRXCHWNNEA-MWZFJMJKSA-L",
            "id": "InChI=1S/C38H74N2O4.2ClH/c1-29(2)33-21-19-31(5)25-35(33)43-37(41)27-39(7,8)23-17-15-13-11-12-14-16-18-24-40(9,10)28-38(42)44-36-26-32(6)20-22-34(36)30(3)4;;/h29-36H,11-28H2,1-10H3;2*1H/q+2;;/p-2/t31-,32-,33+,34+,35-,36-;;/m1../s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 693.92,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 692.5025643,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB13705",
        "type": "Small Molecule",
        "synonyms": [
            "Decamethoxin"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](CO)(CCN1C=CC2=C1C=C(NC(=O)NCC1=CC=CC=C1)C=C2)N1C=NC(=C1)C(N)=O",
        "id": "DB02830",
        "molecule": "FR236913",
        "iupac_name": "1-[(2R)-4-{6-[(benzylcarbamoyl)amino]-1H-indol-1-yl}-1-hydroxybutan-2-yl]-1H-imidazole-4-carboxamide",
        "inchi": {
            "hash": "KCCUBLLGAMGDJL-HXUWFJFHSA-N",
            "id": "InChI=1S/C24H26N6O3/c25-23(32)21-14-30(16-27-21)20(15-31)9-11-29-10-8-18-6-7-19(12-22(18)29)28-24(33)26-13-17-4-2-1-3-5-17/h1-8,10,12,14,16,20,31H,9,11,13,15H2,(H2,25,32)(H2,26,28,33)/t20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 446.5016,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 446.206638728,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB02830",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenosine deaminase"
            }
        ]
    },
    {
        "smiles": "[H][C@@](CO\\N=C(/CCC(O)=O)C(O)=O)(NC(=O)COC1=CC=CC=C1)C(O)=O",
        "id": "DB08401",
        "molecule": "(2E)-2-({(2S)-2-CARBOXY-2-[(PHENOXYACETYL)AMINO]ETHOXY}IMINO)PENTANEDIOIC ACID",
        "iupac_name": "(2E)-2-{[(2S)-2-carboxy-2-(2-phenoxyacetamido)ethoxy]imino}pentanedioic acid",
        "inchi": {
            "hash": "LDNKNKRRFZRLIG-HWQJWEFDSA-N",
            "id": "InChI=1S/C16H18N2O9/c19-13(9-26-10-4-2-1-3-5-10)17-12(16(24)25)8-27-18-11(15(22)23)6-7-14(20)21/h1-5,12H,6-9H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/b18-11+/t12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 382.3221,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 382.101230184,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-l-alpha-amino acids. These are n-acylated alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB08401",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptococcus pneumoniae",
                "target": "UPenicillin-binding protein 1B"
            }
        ]
    },
    {
        "smiles": "NC1=NC(NC2=CC=C3CC[C@@H](CCC3=C2)N2CCCC2)=NN1C1=CC2=C(N=N1)C1=CC=CC=C1CCC2",
        "id": "DB12411",
        "molecule": "Bemcentinib",
        "cas": "1037624-75-1",
        "iupac_name": "1-{3,4-diazatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2(7),3,5,11,13-hexaen-5-yl}-N3-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine",
        "background": "Bemcentinib has been investigated for the treatment of Non-Small Cell Lung Cancer.\n",
        "inchi": {
            "hash": "KXMZDGSRSGHMMK-VWLOTQADSA-N",
            "id": "InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 506.658,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 506.290643127,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.",
        "link": "https://go.drugbank.com/drugs/DB12411",
        "type": "Small Molecule",
        "synonyms": [
            "(S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)- 6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine",
            "Bemcentinib"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "SARS-CoV-2",
                "target": "ASpike glycoprotein"
            }
        ]
    },
    {
        "smiles": "[O-][N+](=O)C1=CC(=CC=C1)C1=CC2=C(S1)C=C1N2C(=S)N(CCCN2CCOCC2)C1=O",
        "id": "DB03507",
        "molecule": "6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One",
        "iupac_name": "10-[3-(morpholin-4-yl)propyl]-4-(3-nitrophenyl)-11-sulfanylidene-5-thia-1,10-diazatricyclo[6.3.0.0^{2,6}]undeca-2(6),3,7-trien-9-one",
        "inchi": {
            "hash": "UXGUZFZBZPPZGL-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H20N4O4S2/c26-20-17-13-19-16(12-18(31-19)14-3-1-4-15(11-14)25(27)28)24(17)21(30)23(20)6-2-5-22-7-9-29-10-8-22/h1,3-4,11-13H,2,5-10H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 456.538,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 456.092596528,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitrobenzenes. These are compounds containing a nitrobenzene moiety, which consists of a benzene ring with a carbon bearing a nitro group.",
        "link": "https://go.drugbank.com/drugs/DB03507",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTumor necrosis factor receptor superfamily member 1A"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(O)C[C@@]2(C)C(=O)C[C@]1([H])C2(C)C",
        "id": "DB02817",
        "molecule": "5-Exo-Hydroxycamphor",
        "iupac_name": "(1R,4R,5R)-5-hydroxy-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one",
        "inchi": {
            "hash": "DJQYBVLXBVJHMU-PJKMHFRUSA-N",
            "id": "InChI=1S/C10H16O2/c1-9(2)6-4-8(12)10(9,3)5-7(6)11/h6-7,11H,4-5H2,1-3H3/t6-,7+,10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 168.2328,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 168.115029756,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.",
        "link": "https://go.drugbank.com/drugs/DB02817",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "UCamphor 5-monooxygenase"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1O[C@@H](S)[C@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB03859",
        "molecule": "1-thio-beta-D-glucopyranose",
        "cas": "7534-35-2",
        "iupac_name": "(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-sulfanyloxane-3,4,5-triol",
        "inchi": {
            "hash": "JUSMHIGDXPKSID-DVKNGEFBSA-N",
            "id": "InChI=1S/C6H12O5S/c7-1-2-3(8)4(9)5(10)6(12)11-2/h2-10,12H,1H2/t2-,3-,4+,5-,6+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 196.221,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 196.040544184,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB03859",
        "type": "Small Molecule",
        "synonyms": [
            "1-thio-b-D-glucose",
            "1-thio--D-glucose",
            "beta-D-Thioglucose",
            "-D-Glc-SH",
            "-D-Glcp-SH"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Clostridium cellulolyticum (strain ATCC 35319 / DSM 5812 / JCM 6584 / H10)",
                "target": "UEndoglucanase G"
            }
        ]
    },
    {
        "smiles": "CCCCCC[C@@H](CCC)C(O)=O",
        "id": "DB05343",
        "molecule": "Arundic acid",
        "cas": "185517-21-9",
        "iupac_name": "(2R)-2-propyloctanoic acid",
        "background": "Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).\n",
        "inchi": {
            "hash": "YCYMCMYLORLIJX-SNVBAGLBSA-N",
            "id": "InChI=1S/C11H22O2/c1-3-5-6-7-9-10(8-4-2)11(12)13/h10H,3-9H2,1-2H3,(H,12,13)/t10-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 186.2912,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 186.161979948,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB05343",
        "type": "Small Molecule",
        "synonyms": [
            "(2R)-2-propyloctanoic acid",
            "Arundic acid"
        ],
        "indication": "Investigated for use/treatment in cerebral ischemia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein S100-B"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07959"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01555"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07586"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07808"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08770"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17021"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15816"
    },
    {
        "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12C",
        "id": "DB06257",
        "molecule": "HE-2200",
        "cas": "2697-85-0",
        "iupac_name": "(1S,3aS,3bR,4R,7S,9aR,9bS,11aS)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,4,7-triol",
        "inchi": {
            "hash": "OEVZKEVBDIDVOI-YSZCXEEOSA-N",
            "id": "InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-17,20-22H,3-9H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 306.446,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 306.219494826,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06257",
        "type": "Small Molecule",
        "synonyms": [
            "beta-Aet"
        ],
        "indication": "Investigated for use/treatment in adverse effects (chemotherapy), hyperlipidemia, autoimmune diseases, and hepatitis (viral, B).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "CC1=NC=C(COP(O)(O)=O)C(CNOCC(O)=O)=C1O",
        "id": "DB02783",
        "molecule": "4'-Deoxy-4'-Acetylyamino-Pyridoxal-5'-Phosphate",
        "iupac_name": "2-{[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]oxy}acetic acid",
        "inchi": {
            "hash": "QYKRUCBLHROXCK-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H15N2O8P/c1-6-10(15)8(3-12-19-5-9(13)14)7(2-11-6)4-20-21(16,17)18/h2,12,15H,3-5H2,1H3,(H,13,14)(H2,16,17,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 322.2085,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 322.056601978,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridoxamine 5'-phosphates. These are heterocyclic aromatic compounds containing a pyridoxamine that carries a phosphate group at the 5'-position.",
        "link": "https://go.drugbank.com/drugs/DB02783",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "U4-aminobutyrate aminotransferase GabT"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAspartate aminotransferase, mitochondrial"
            }
        ]
    },
    {
        "smiles": "[166Ho++].OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP([O-])([O-])=O)CCN(CP(O)(O)=O)CC1",
        "id": "DB05380",
        "molecule": "DOTMP HO-166",
        "cas": "633308-23-3",
        "iupac_name": "lambda2-(166Ho)holmium(2+) ion {[4,7,10-tris(phosphonomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]methyl}phosphonate",
        "background": "DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in the bone marrow. It is an experimental therapy that is being developed by NeoRx Corporation.\n",
        "inchi": {
            "hash": "UOWMQDYQGKHTKV-IEOVAKBOSA-L",
            "id": "InChI=1S/C12H32N4O12P4.Ho/c17-29(18,19)9-13-1-2-14(10-30(20,21)22)5-6-16(12-32(26,27)28)8-7-15(4-3-13)11-31(23,24)25;/h1-12H2,(H2,17,18,19)(H2,20,21,22)(H2,23,24,25)(H2,26,27,28);/q;+2/p-2/i;1+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 712.215,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 712.013351681,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organic phosphonic acids. These are organic compounds containing phosphonic acid.",
        "link": "https://go.drugbank.com/drugs/DB05380",
        "type": "Small Molecule",
        "synonyms": [
            "166Ho-DOTMP",
            "Chelating agent delivering Holmium-166",
            "Holmium Ho-166 DOTMP",
            "Holmium-166 DOTMP"
        ],
        "indication": "Investigated for use/treatment in multiple myeloma.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C1=CC=CC=C1",
        "id": "DB09022",
        "molecule": "Benfluorex",
        "cas": "23602-78-0",
        "iupac_name": "2-({1-[3-(trifluoromethyl)phenyl]propan-2-yl}amino)ethyl benzoate",
        "background": "Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009. This recommendation was based on the risks (especially fenfluramine-like cardiovascular side-effects) outweighing the benefits.\n",
        "inchi": {
            "hash": "CJAVTWRYCDNHSM-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H20F3NO2/c1-14(12-15-6-5-9-17(13-15)19(20,21)22)23-10-11-25-18(24)16-7-3-2-4-8-16/h2-9,13-14,23H,10-12H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 351.3628,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 351.144613504,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.",
        "link": "https://go.drugbank.com/drugs/DB09022",
        "type": "Small Molecule",
        "synonyms": [
            "Benfluorex",
            "Benfluorexum"
        ]
    },
    {
        "smiles": "CCOC1=CC=C2NC(SCCN3CCOCC3)=NC2=C1",
        "id": "DB13623",
        "molecule": "Fabomotizole",
        "cas": "173352-21-1",
        "iupac_name": "5-ethoxy-2-{[2-(morpholin-4-yl)ethyl]sulfanyl}-1H-1,3-benzodiazole",
        "inchi": {
            "hash": "WWNUCVSRRUDYPP-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 307.41,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 307.135448102,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB13623",
        "type": "Small Molecule",
        "synonyms": [
            "Fabomotizole"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(COC1=CC=CC=C1CC1=CC=CC=C1)N1CCCCC1",
        "id": "DB13309",
        "molecule": "Benproperine",
        "cas": "2156-27-6",
        "iupac_name": "1-[1-(2-benzylphenoxy)propan-2-yl]piperidine",
        "inchi": {
            "hash": "JTUQXGZRVLWBCR-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H27NO/c1-18(22-14-8-3-9-15-22)17-23-21-13-7-6-12-20(21)16-19-10-4-2-5-11-19/h2,4-7,10-13,18H,3,8-9,14-17H2,1H3"
        },
        "summary": "Benproperine is an antitussive indicated in the treatment of acute and dry cough, especially dry cough.",
        "weight": [
            {
                "type": "average",
                "weight": 309.453,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 309.209264493,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB13309",
        "type": "Small Molecule",
        "synonyms": [
            "Bemproperina",
            "Benproperine",
            "Benproperinum"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(N)CCCCCCCCCCNC1=O",
        "id": "DB08476",
        "molecule": "3-AMINO-AZACYCLOTRIDECAN-2-ONE",
        "iupac_name": "(3S)-3-amino-1-azacyclotridecan-2-one",
        "inchi": {
            "hash": "CQZLEYBEPASILI-NSHDSACASA-N",
            "id": "InChI=1S/C12H24N2O/c13-11-9-7-5-3-1-2-4-6-8-10-14-12(11)15/h11H,1-10,13H2,(H,14,15)/t11-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 212.3318,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 212.1888634,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides.",
        "link": "https://go.drugbank.com/drugs/DB08476",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeutrophil collagenase"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)C2=C(N1)N(C=N2)[C@@H]1O[C@H](CO)[C@H]2O[C@@H](O[C@@H]12)P(O)(O)=O",
        "id": "DB04757",
        "molecule": "GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE",
        "iupac_name": "[(2S,3aR,4R,6R,6aR)-4-(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)-6-(hydroxymethyl)-tetrahydro-2H-furo[3,4-d][1,3]dioxol-2-yl]phosphonic acid",
        "inchi": {
            "hash": "GKAPYWCOOQBBHV-KXSYMAMXSA-N",
            "id": "InChI=1S/C11H14N5O8P/c12-10-14-7-4(8(18)15-10)13-2-16(7)9-6-5(3(1-17)22-9)23-11(24-6)25(19,20)21/h2-3,5-6,9,11,17H,1H2,(H2,19,20,21)(H3,12,14,15,18)/t3-,5-,6-,9-,11+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 375.2313,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 375.057998961,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB04757",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPurine nucleoside phosphorylase"
            }
        ]
    },
    {
        "smiles": "O=C1NC2=CC=CC=C2C1=O",
        "id": "DB02095",
        "molecule": "Isatin",
        "cas": "91-56-5",
        "iupac_name": "2,3-dihydro-1H-indole-2,3-dione",
        "background": "Isatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids. The compound is found in many plants and Schiff bases of Isatin are have been investigated for pharmaceutical applications.\n",
        "inchi": {
            "hash": "JXDYKVIHCLTXOP-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H5NO2/c10-7-5-3-1-2-4-6(5)9-8(7)11/h1-4H,(H,9,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 147.1308,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 147.032028409,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.",
        "link": "https://go.drugbank.com/drugs/DB02095",
        "type": "Small Molecule",
        "synonyms": [
            "1H-indole-2,3-dione"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAmine oxidase [flavin-containing] B"
            }
        ]
    },
    {
        "smiles": "COC1=CC(=O)C2=C(C(COC3=CC=CC=C3)=C(C)N2C)C1=O",
        "id": "DB03626",
        "molecule": "5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione",
        "iupac_name": "5-methoxy-1,2-dimethyl-3-(phenoxymethyl)-4,7-dihydro-1H-indole-4,7-dione",
        "inchi": {
            "hash": "JRPJCFILHCLEJI-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H17NO4/c1-11-13(10-23-12-7-5-4-6-8-12)16-17(19(11)2)14(20)9-15(22-3)18(16)21/h4-9H,10H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 311.3319,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 311.115758037,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indoles and derivatives. These are organic compounds containing an indole, which is a bicyclic ring system made up of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring.",
        "link": "https://go.drugbank.com/drugs/DB03626",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNAD(P)H dehydrogenase [quinone] 1"
            }
        ]
    },
    {
        "smiles": "[H]\\C(C[C@@]([H])(OC)[C@@]([H])(C)C(=O)CC[C@]([H])(C)[C@]([H])(C[C@]1([H])OC(=O)C[C@@]([H])(O)C[C@]([H])(O)CC(=O)[C@]([H])(C)[C@]([H])(OC)C2=COC(=N2)C2=COC(=N2)C2=COC(=N2)\\C([H])=C([H])\\CC[C@@]1([H])C)OC)=C(\\[H])N(C)CO",
        "id": "DB03850",
        "molecule": "Jaspisamide A",
        "iupac_name": "(10S,11R,14S,16S,20S,21R,24E)-14,16-dihydroxy-20-[(2S,3S,7R,8R,10E)-11-[(hydroxymethyl)(methyl)amino]-2,8-dimethoxy-3,7-dimethyl-6-oxoundec-10-en-1-yl]-10-methoxy-11,21-dimethyl-3,7,19,27-tetraoxa-29,30,31-triazatetracyclo[24.2.1.1^{2,5}.1^{6,9}]hentriaconta-1(28),2(31),4,6(30),8,24,26(29)-heptaene-12,18-dione",
        "inchi": {
            "hash": "VMTDLKOWOZYTPX-RZKNNNBGSA-N",
            "id": "InChI=1S/C44H64N4O13/c1-26-12-9-10-14-40-45-33(23-58-40)43-47-34(24-60-43)44-46-32(22-59-44)42(57-8)29(4)36(53)19-30(50)18-31(51)20-41(54)61-39(26)21-38(56-7)27(2)15-16-35(52)28(3)37(55-6)13-11-17-48(5)25-49/h10-11,14,17,22-24,26-31,37-39,42,49-51H,9,12-13,15-16,18-21,25H2,1-8H3/b14-10+,17-11+/t26-,27+,28+,29+,30+,31+,37-,38+,39+,42+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 856.998,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 856.446988154,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diterpene lactones. These are diterpenoids containing a lactone moiety.",
        "link": "https://go.drugbank.com/drugs/DB03850",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UActin, alpha skeletal muscle"
            }
        ]
    },
    {
        "smiles": "C1CCC2=C(P(C(=C2C1)C1=NC=CC=C1)C1=CC=CC=C1)C1=NC=CC=C1",
        "id": "DB07393",
        "molecule": "2-(2-PHENYL-3-PYRIDIN-2-YL-4,5,6,7-TETRAHYDRO-2H-ISOPHOSPHINDOL-1-YL)PYRIDINE",
        "iupac_name": "2-[2-phenyl-3-(pyridin-2-yl)-4,5,6,7-tetrahydro-2H-isophosphindol-1-yl]pyridine",
        "inchi": {
            "hash": "GSKNNHAAFLPYHG-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H21N2P/c1-2-10-18(11-3-1)27-23(21-14-6-8-16-25-21)19-12-4-5-13-20(19)24(27)22-15-7-9-17-26-22/h1-3,6-11,14-17H,4-5,12-13H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 368.4107,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 368.144235194,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridines and derivatives. These are compounds containing a pyridine ring, which is a six-member aromatic heterocycle which consists of one nitrogen atom and five carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB07393",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione reductase, mitochondrial"
            }
        ]
    },
    {
        "smiles": "FC1=CC=C(C=C1)C1=CNN=C1C1=CC(F)=NC=C1",
        "id": "DB07942",
        "molecule": "2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine",
        "iupac_name": "2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine",
        "inchi": {
            "hash": "YJCHZVXSPFPKMX-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H9F2N3/c15-11-3-1-9(2-4-11)12-8-18-19-14(12)10-5-6-17-13(16)7-10/h1-8H,(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 257.2382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 257.076453713,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07942",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 14"
            }
        ]
    },
    {
        "smiles": "OC(=O)C(=O)NC1=CC2=C(C=CC=C2)C=C1C(O)=O",
        "id": "DB01734",
        "molecule": "3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid",
        "iupac_name": "3-(carboxyformamido)naphthalene-2-carboxylic acid",
        "inchi": {
            "hash": "DQBLKSRRWDWNKQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H9NO5/c15-11(13(18)19)14-10-6-8-4-2-1-3-7(8)5-9(10)12(16)17/h1-6H,(H,14,15)(H,16,17)(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 259.2143,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 259.048072403,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenecarboxylic acids. These are compounds containing a naphthalene moiety, which bears a carboxylic acid group one or more positions. Naphthalene is a bicyclic compound that is made up of two fused benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB01734",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein phosphatase non-receptor type 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@](O)(CO)[C@]([H])(O)[C@]([H])(O)COP(O)(O)=O",
        "id": "DB03745",
        "molecule": "Arabinose-5-phosphate",
        "iupac_name": "{[(2R,3S,4R)-2,3,4,5-tetrahydroxypentyl]oxy}phosphonic acid",
        "inchi": {
            "hash": "VJDOAZKNBQCAGE-WDCZJNDASA-N",
            "id": "InChI=1S/C5H13O8P/c6-1-3(7)5(9)4(8)2-13-14(10,11)12/h3-9H,1-2H2,(H2,10,11,12)/t3-,4-,5+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 232.1257,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 232.034803904,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monosaccharide phosphates. These are monosaccharides comprising a phosphated group linked to the carbohydrate unit.",
        "link": "https://go.drugbank.com/drugs/DB03745",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Aquifex aeolicus (strain VF5)",
                "target": "U2-dehydro-3-deoxyphosphooctonate aldolase"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)",
                "target": "URibose-5-phosphate isomerase A"
            }
        ]
    },
    {
        "smiles": "O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O",
        "id": "DB02900",
        "molecule": "alpha-D-mannose 6-phosphate",
        "cas": "40436-60-0",
        "iupac_name": "{[(2R,3S,4S,5S,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "NBSCHQHZLSJFNQ-PQMKYFCFSA-N",
            "id": "InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5+,6+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 260.1358,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 260.029718526,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexose phosphates. These are carbohydrate derivatives containing a hexose substituted by one or more phosphate groups.",
        "link": "https://go.drugbank.com/drugs/DB02900",
        "type": "Small Molecule",
        "synonyms": [
            "(6P)Mana",
            "(6P)Man",
            "6-H2PO3Man",
            "6-O-phosphono--D-mannopyranose",
            "alpha-D-Mannopyranose 6-phosphate",
            "Man6P",
            "-D-mannose 6-phosphate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UPhosphomannomutase/phosphoglucomutase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCation-independent mannose-6-phosphate receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCation-dependent mannose-6-phosphate receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05506"
    },
    {
        "smiles": "ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1",
        "id": "DB00878",
        "molecule": "Chlorhexidine",
        "cas": "55-56-1",
        "iupac_name": "N-(4-chlorophenyl)-1-{N'-[6-(N-{[N'-(4-chlorophenyl)carbamimidamido]methanimidoyl}amino)hexyl]carbamimidamido}methanimidamide",
        "background": "Chlorhexidine is a broad-spectrum antimicrobial biguanide used as a topical antiseptic and in dental practice for the treatment of inflammatory dental conditions caused by microorganisms.11 It is one of the most common skin and mucous membrane antiseptic agents in use today.2 The molecule itself is a cationic bis-guanide consisting of two 4-chlorophenyl rings and two biguanide groups joined by a central hexamethylene chain.7 Topical chlorhexidine for disinfection, as well as oral rinses for dental use, carries activity against a broad range of pathogens including bacteria, yeasts, and viruses.12,11,7\nChlorhexidine was developed in the UK by Imperial Chemical Industries in the early 1950s9 and was introduced to the US in the 1970s.18 The FDA withdrew its approval for the use of chlorhexidine gluconate topical tincture 0.5%, due to a significant number of reports concerning chemical and thermal burns associated with the use of this product.19,20 Other formulations of chlorhexidine continue to be available.\n",
        "inchi": {
            "hash": "GHXZTYHSJHQHIJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)"
        },
        "summary": "Chlorhexidine is an antiseptic used to sterilize for surgeries and in healthcare practice, to reduce pocket depth in periodontitis, and to treat gingivitis.",
        "weight": [
            {
                "type": "average",
                "weight": 505.447,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 504.203196424,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB00878",
        "type": "Small Molecule",
        "synonyms": [
            "1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)",
            "Chlorhexidin",
            "Chlorhexidine",
            "Chlorhexidinum",
            "Cloresidina",
            "Clorhexidina",
            "N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide"
        ],
        "indication": "Chlorhexidine is available over-the-counter in various formulations (e.g. solution, sponge, cloth, swab) as a topical antiseptic to sanitize prior to surgeries and/or medical procedures.12,13,14,15 Dental formulations, available by prescription only, include an oral rinse indicated for the treatment of gingivitis11 and a slow-release \"chip\" which is inserted into periodontal pockets and is indicated for the reduction of pocket depth in adult patients with periodontitis as an adjunct therapy to dental scaling and root planing procedures.16\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Chlorhexidine is a broad-spectrum antimicrobial with demonstrated activity against both gram-positive and gram-negative bacteria, yeasts, and viruses.2 Antimicrobial activity is dose-dependent - chlorhexidine is bacteriostatic at lower concentrations (0.02%-0.06%) and bactericidal at higher concentrations (\u003e0.12%).2 Pharmacokinetic studies of oral chlorhexidine rinses indicate that approximately 30% of the active ingredient is retained in the mouth following rinsing, which is subsequently slowly released into oral fluids.11 This ability to adsorb to dentine, shared with tetracycline antibiotics such as doxycycline, is known as \"substantivity\" and is the result of chlorhexidine's positive charge - it is likely that this substantivity plays at least some role in chlorhexidine's antimicrobial activity, as its persistence on surfaces such as dentine prevent microbial colonization.7\nDental chlorhexidine rinses may result in staining of oral surfaces, such as teeth. This effect is not ubiquitous and appears to be more significant with extended therapy (i.e. up to 6 months) - nevertheless, patients for whom oral staining is unacceptable should use chlorhexidine rinse with caution and for the shortest effective interval.11 Allergic reactions to chlorhexidine have been associated with the development of anaphylaxis.8\n",
        "moa": [
            {
                "action": "incorporation into and destabilization",
                "organism": "Bacteria",
                "target": "ABacterial outer membrane"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14635"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08697"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03327"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16880"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04758"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12015"
    },
    {
        "smiles": "CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C1=C2C=CNC2=NC=N1",
        "id": "DB14973",
        "molecule": "Abrocitinib",
        "cas": "1622902-68-4",
        "iupac_name": "N-[(1s,3s)-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]cyclobutyl]propane-1-sulfonamide",
        "background": "Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function.6 The Janus kinase (JAK)signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases, including atopic dermatitis, a chronic inflammatory skin disease with complex pathogenesis. Atopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and the aberrant activation of immune cells. Patients with moderate-to-severe atopic dermatitis report reduced quality of life and often face limited treatment options. JAK inhibitors recently attracted more attention as potential treatments for inflammatory disorders, as JAK inhibition is associated with rapid and sustained anti-inflammatory efects.2\nAbrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.8 On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable.7 Health Canada also approved the use of abrocitinib in pediatric patients 12 years and older.9\n",
        "inchi": {
            "hash": "IUEWXNHSKRWHDY-PHIMTYICSA-N",
            "id": "InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+"
        },
        "summary": "Abrocitinib is a kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults.",
        "weight": [
            {
                "type": "average",
                "weight": 323.42,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 323.14159611,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14973",
        "type": "Small Molecule",
        "synonyms": [
            "Abrocitinib",
            "PF-04965842"
        ],
        "indication": "Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.6 In the US, it is indicated to treat refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable.5\nAbrocitinib is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.5\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Abrocitinib mediates anti-inflammatory effects by blocking the signalling of pro-inflammatory cytokines implicated in atopic dermatitis.4 It dose-dependently reduces the serum markers of inflammation in atopic dermatitis, including high sensitivity C-reactive protein (hsCRP), interleukin-31 (IL-31), and thymus and activation regulated chemokine (TARC). These changes returned to near baseline within four weeks following drug discontinuation.5 At two weeks of treatment, the mean absolute lymphocyte count increased, which returned to baseline by nine months of treatment. Treatment with abrocitinib was associated with a dose-related increase in B cell counts and a dose-related decrease in NK cell counts: the clinical significance of these changes is unknown.6\nTreatment with 200 mg abrocitinib once-daily was associated with a transient, dose-dependent decrease in platelet count with the nadir occurring at a median of 24 days. Recovery of platelet count (~40% recovery by 12 weeks) occurred without discontinuation of the treatment.5\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ATyrosine-protein kinase JAK1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UTyrosine-protein kinase JAK2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UTyrosine-protein kinase JAK3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UNon-receptor tyrosine-protein kinase TYK2"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB14538",
        "molecule": "Hydrocortisone aceponate",
        "cas": "74050-20-7",
        "iupac_name": "(1R,3aS,3bS,9aR,9bS,10S,11aS)-1-[2-(acetyloxy)acetyl]-10-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl propanoate",
        "inchi": {
            "hash": "MFBMYAOAMQLLPK-FZNHGJLXSA-N",
            "id": "InChI=1S/C26H36O7/c1-5-22(31)33-26(21(30)14-32-15(2)27)11-9-19-18-7-6-16-12-17(28)8-10-24(16,3)23(18)20(29)13-25(19,26)4/h12,18-20,23,29H,5-11,13-14H2,1-4H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 460.567,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 460.246103499,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB14538",
        "type": "Small Molecule",
        "synonyms": [
            "Hydrocortisone aceponate"
        ],
        "indication": "For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AAnnexin A1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AGlucocorticoid receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U3 beta-hydroxysteroid dehydrogenase/Delta 5--\u003e4-isomerase type 1"
            }
        ]
    },
    {
        "smiles": "OC[C@H](O)[C@@H](O)CO",
        "id": "DB03278",
        "molecule": "D-Treitol",
        "iupac_name": "(2S,3S)-butane-1,2,3,4-tetrol",
        "background": "A four-carbon sugar that is found in algae, fungi, and lichens. It is twice as sweet as sucrose and can be used as a coronary vasodilator. [PubChem]\n",
        "inchi": {
            "hash": "UNXHWFMMPAWVPI-IMJSIDKUSA-N",
            "id": "InChI=1S/C4H10O4/c5-1-3(7)4(8)2-6/h3-8H,1-2H2/t3-,4-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 122.1198,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 122.057908808,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.",
        "link": "https://go.drugbank.com/drugs/DB03278",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UFormate acetyltransferase 1"
            }
        ]
    },
    {
        "smiles": "[O-][N+]1=CC=CC=C1SSC1=CC=CC=[N+]1[O-]",
        "id": "DB11327",
        "molecule": "Dipyrithione",
        "cas": "3696-28-4",
        "iupac_name": "2-[(1-oxidopyridin-1-ium-2-yl)disulfanyl]pyridin-1-ium-1-olate",
        "background": "Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available.6 It is currently used as a pesticide, and not used in any FDA approved drug products.3\nInterestingly, dipyrithione has been studied and shown to have cytotoxic and potent broad-spectrum antitumor activity, which suggests a potential basis for an anticancer drug development.1\nPyrithione derivatives, such as Pyrithione and sodium pyrithione, are widely used as cosmetic preservatives and as anti-dandruff agents in shampoos.1 It may be combined with other ingredients, such as triclosan to serve as antifungal and antibacterial skin treatments.9\nDandruff is a common scalp disease affecting \u003e40% of the world's adult population, and may be caused by fungi such as Malassezia globosa and M. restricta.4\n",
        "inchi": {
            "hash": "ZHDBTKPXEJDTTQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H8N2O2S2/c13-11-7-3-1-5-9(11)15-16-10-6-2-4-8-12(10)14/h1-8H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 252.31,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 252.002719854,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinium derivatives. These are compounds containing a pyridinium ring, which is the cationic form of pyridine.",
        "link": "https://go.drugbank.com/drugs/DB11327",
        "type": "Small Molecule",
        "synonyms": [
            "Bispyrithione",
            "Dipiritiona",
            "Dipyrithione",
            "Dipyrithionum",
            "Omadine disulfide",
            "OMDS",
            "Pyrithione disulfide",
            "Pyrithione disulphide"
        ],
        "indication": "Scalp dandruff 5\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "This drug decreases or eliminates dandruff from the scalp, which is caused by various types of fungi.6, 9\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNitric oxide synthase, inducible"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 2"
            }
        ]
    },
    {
        "smiles": "CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1",
        "id": "DB00829",
        "molecule": "Diazepam",
        "cas": "439-14-5",
        "iupac_name": "7-chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one",
        "background": "A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589)\nGiven diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016 7. Combining diazepam, a proven effective therapy for acute repetitive seizures, with an auto-injector designed for subcutaneous administration that is quickly and easily administered offers the potential for complete, consistent drug absorption and rapid onset of effect 7. This current development is subsequently an important addition to the rescue therapy tool chest for patients with epilepsy 7.\n",
        "inchi": {
            "hash": "AAOVKJBEBIDNHE-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3"
        },
        "summary": "Diazepam is a long-acting benzodiazepine with rapid onset commonly used to treat panic disorders, severe anxiety, alcohol withdrawal, and seizures.",
        "weight": [
            {
                "type": "average",
                "weight": 284.74,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 284.071640755,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.",
        "link": "https://go.drugbank.com/drugs/DB00829",
        "type": "Small Molecule",
        "synonyms": [
            "7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one",
            "Diazepam",
            "Methyl diazepinone",
            "NRL-1"
        ],
        "indication": "In general, diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression.16\nMoreover, in acute alcoholic withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, and impending acute delirium tremens.16\nFurthermore, diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare \"stiff man syndrome\".16\nParticular label information from the United Kingdom also lists particular age-specific indications, including for adults: (1) The short-term relief (2-4 weeks) only, of anxiety which is severe, disabling, or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness, (2) cerebral palsy, (3) muscle spasm, (4) as an adjunct to certain types of epilepsy (eg. myoclonus), (5) symptomatic treatment of acute alcohol withdrawal, (6) as oral premedication for the nervous dental patient, and (7) for premedication before surgery.6\nIn the same UK label information, diazepam is indicated in children for: (1) control of tension and irritability in cerebral spasticity in selected cases, (2) as an adjunct to the control of muscle spasm in tetanus, and for (3) oral premedication.6\nA diazepam nasal spray is indicated in patients 6 years and older to treat intermittent, stereotypic episodes of frequent seizure activity that are different than the patient's usual seizure pattern.8\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Diazepam is a benzodiazepine that exerts anxiolytic, sedative, muscle- relaxant, anticonvulsant and amnestic effects 15,16,6. Most of these effects are thought to result from facilitation of the action of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system 15,16,6.\n",
        "moa": [
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "AGABA(A) Receptor Benzodiazepine Binding Site"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13293"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03847"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15488"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08448"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02411"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00869"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09003"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01254"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03314"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01057"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03402"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01562"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04256"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08296"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04137"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07127"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01895"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07813"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01521"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18095"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09053"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00963"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13802"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02118"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01855"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04214"
    },
    {
        "smiles": "COC1=CC(\\C=N\\N(C(=O)C(F)(F)F)C2=C(C)C=C(C)C=C2)=CC=C1",
        "id": "DB13957",
        "molecule": "J147",
        "cas": "1146963-51-0",
        "iupac_name": "N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(1E)-(3-methoxyphenyl)methylidene]acetohydrazide",
        "background": "J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. 1,2,3 It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy. 5\n",
        "inchi": {
            "hash": "HYMZAYGFKNNHDN-SSDVNMTOSA-N",
            "id": "InChI=1S/C18H17F3N2O2/c1-12-7-8-16(13(2)9-12)23(17(24)18(19,20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H,1-3H3/b22-11+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 350.341,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 350.124212284,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB13957",
        "type": "Small Molecule",
        "synonyms": [
            "N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide"
        ],
        "is_stub": true
    },
    {
        "smiles": "[O-][N+](=O)C1=CC=C(O1)\\C=N\\N1CC(CN2CCOCC2)OC1=O",
        "id": "DB16567",
        "molecule": "Furaltadone",
        "cas": "139-91-3",
        "iupac_name": "5-[(morpholin-4-yl)methyl]-3-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one",
        "inchi": {
            "hash": "YVQVOQKFMFRVGR-VGOFMYFVSA-N",
            "id": "InChI=1S/C13H16N4O6/c18-13-16(14-7-10-1-2-12(22-10)17(19)20)9-11(23-13)8-15-3-5-21-6-4-15/h1-2,7,11H,3-6,8-9H2/b14-7+"
        },
        "summary": "Furaltadone is indicated in combination with other drugs for the treatment of otitis media and externa.",
        "weight": [
            {
                "type": "average",
                "weight": 324.293,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 324.106984251,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16567",
        "type": "Small Molecule",
        "synonyms": [
            "Furaltadona",
            "Furaltadone"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN1CCN(CC1)C1=C(F)C=C(NC2=NC(OC3=CC=CC(NC(=O)C=C)=C3)=C3C=CNC3=N2)C=C1",
        "id": "DB15327",
        "molecule": "Abivertinib",
        "cas": "1557267-42-1",
        "iupac_name": "N-{3-[(2-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide",
        "background": "Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).1 It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).2\nAbivertinib's potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19.2,3 The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors). The study is expected to be completed in March 2021.4\n",
        "inchi": {
            "hash": "UOFYSRZSLXWIQB-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 487.539,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 487.213201268,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15327",
        "type": "Small Molecule",
        "synonyms": [
            "Abivertinib"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AEpidermal growth factor receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ATyrosine-protein kinase BTK"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=C(C)C(=O)NC2=O)[C@]([H])(OC)[C@]1([H])C",
        "id": "DB03249",
        "molecule": "2'-O-Methyl-3'-Methyl-3'-Deoxy-Arabinofuranosyl-Thymine-5'-Phosphate",
        "iupac_name": "{[(2S,3R,4R,5R)-4-methoxy-3-methyl-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "MCXXETKRWYMFCI-TURQNECASA-N",
            "id": "InChI=1S/C12H19N2O8P/c1-6-4-14(12(16)13-10(6)15)11-9(20-3)7(2)8(22-11)5-21-23(17,18)19/h4,7-9,11H,5H2,1-3H3,(H,13,15,16)(H2,17,18,19)/t7-,8-,9-,11-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 350.2616,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 350.087902106,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 3'-deoxyribonucleoside monophosphates. These are pyrimidine nucleotides with monophosphate group linked to the ribose moiety lacking a hydroxyl group at position 3.",
        "link": "https://go.drugbank.com/drugs/DB03249",
        "type": "Small Molecule"
    },
    {
        "id": "DB05950",
        "molecule": "Contulakin-G",
        "cas": "229180-41-0",
        "background": "Contulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05950",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in pain (acute or chronic).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UVoltage-dependent N-type calcium channel subunit alpha-1B"
            }
        ]
    },
    {
        "smiles": "[Cl-].C[N+]1=C2C=C(N)C=CC2=CC2=C1C=C(N)C=C2",
        "id": "DB13326",
        "molecule": "Euflavine",
        "cas": "86-40-8",
        "iupac_name": "3,6-diamino-10-methylacridin-10-ium chloride",
        "inchi": {
            "hash": "KKAJSJJFBSOMGS-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H13N3.ClH/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17;/h2-8H,1H3,(H3,15,16);1H"
        },
        "summary": "Euflavine is a topical disinfectant indicated in the treatment of wounds, blisters, insect bites, and infected wounds.",
        "weight": [
            {
                "type": "average",
                "weight": 259.74,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 259.0876252,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring.",
        "link": "https://go.drugbank.com/drugs/DB13326",
        "type": "Small Molecule",
        "synonyms": [
            "3,6-diamino-10-methylacridinium chloride"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC2=NC=NC(NC3=CC(SC)=CC=C3)=C2C=C1OC",
        "id": "DB02984",
        "molecule": "4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline",
        "iupac_name": "6,7-dimethoxy-N-[3-(methylsulfanyl)phenyl]quinazolin-4-amine",
        "inchi": {
            "hash": "FUSDVOSGGMBSMK-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H17N3O2S/c1-21-15-8-13-14(9-16(15)22-2)18-10-19-17(13)20-11-5-4-6-12(7-11)23-3/h4-10H,1-3H3,(H,18,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 327.401,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 327.104147493,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB02984",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 14"
            }
        ]
    },
    {
        "smiles": "OC(=O)\\C=C\\C1=CC=C(C=C1)C(O)=O",
        "id": "DB02126",
        "molecule": "4-Carboxycinnamic Acid",
        "iupac_name": "4-[(1E)-2-carboxyeth-1-en-1-yl]benzoic acid",
        "inchi": {
            "hash": "HAEJSGLKJYIYTB-ZZXKWVIFSA-N",
            "id": "InChI=1S/C10H8O4/c11-9(12)6-3-7-1-4-8(5-2-7)10(13)14/h1-6H,(H,11,12)(H,13,14)/b6-3+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 192.1681,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 192.042258744,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cinnamic acids. These are organic aromatic compounds containing a benzene and a carboxylic acid group forming 3-phenylprop-2-enoic acid.",
        "link": "https://go.drugbank.com/drugs/DB02126",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHemoglobin subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHemoglobin subunit beta"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18042"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03262"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01968"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01061"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12903"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14804"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06917"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03321"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09319"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13329"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03108"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11865"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07216"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03710"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12632"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00840"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09102"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15985"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04840"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13444"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16012"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00189"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06891"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07650"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02101"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13715"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07802"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09016"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02380"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00618"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08892"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12672"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18058"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18064"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04605"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07086"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01875"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00499"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05723"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04836"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08928"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06928"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04381"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13387"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02276"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14527"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01687"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15288"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00318"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04545"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14791"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01530"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06203"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07778"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12960"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01330"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08063"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09131"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03069"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04138"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15926"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06605"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04776"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03483"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08074"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15080"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01341"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00900"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12397"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13797"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13339"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02091"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07639"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01375"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12113"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12921"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01158"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13424"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07124"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07204"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01495"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17079"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07330"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13229"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12267"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03571"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04270"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13826"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12963"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14652"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07557"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11126"
    },
    {
        "smiles": "[H][C@@]12CCN(C[C@]1(CC1=C(C2)N(N=C1)C1=CC=C(F)C=C1)C(=O)C1=CC(=CC=N1)C(F)(F)F)S(=O)(=O)C1=NN(C)N=C1",
        "id": "DB16162",
        "molecule": "Exicorilant",
        "cas": "1781244-77-6",
        "iupac_name": "2-[(4aR,8aS)-1-(4-fluorophenyl)-6-[(2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl]-1H,4H,4aH,5H,6H,7H,8H,8aH,9H-pyrido[3,4-f]indazole-4a-carbonyl]-4-(trifluoromethyl)pyridine",
        "background": "Exicorilant is under investigation in clinical trial NCT03437941 (Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With Mcrpc).\n",
        "inchi": {
            "hash": "HWJYJKAURRIWJM-GKVSMKOHSA-N",
            "id": "InChI=1S/C26H23F4N7O3S/c1-35-32-14-23(34-35)41(39,40)36-9-7-17-11-22-16(13-33-37(22)20-4-2-19(27)3-5-20)12-25(17,15-36)24(38)21-10-18(6-8-31-21)26(28,29)30/h2-6,8,10,13-14,17H,7,9,11-12,15H2,1H3/t17-,25-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 589.57,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 589.151921455,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16162",
        "type": "Small Molecule",
        "synonyms": [
            "Exicorilant"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(O)CCO",
        "id": "DB14110",
        "molecule": "Butylene glycol",
        "cas": "107-88-0",
        "iupac_name": "butane-1,3-diol",
        "inchi": {
            "hash": "PUPZLCDOIYMWBV-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H10O2/c1-4(6)2-3-5/h4-6H,2-3H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 90.121,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 90.068079564,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14110",
        "type": "Small Molecule",
        "synonyms": [
            "(RS)-1,3-Butandiol",
            "1,3 Butylene glycol",
            "1,3-Butandiol",
            "1,3-Butanediol",
            "1,3-Butylene glycol",
            "1,3-Butylenglykol",
            "BD",
            "beta-Butylene glycol",
            "Butane-1,3-diol",
            "Methyltrimethylene glycol"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=NC=NC2=C1N=CN2[C@@H]1C=C[C@H](O)[C@H]1O",
        "id": "DB03216",
        "molecule": "(1'R,2'S)-9-(2-Hydroxy-3'-Keto-Cyclopenten-1-yl)Adenine",
        "iupac_name": "(1S,2S,5R)-5-(6-amino-9H-purin-9-yl)cyclopent-3-ene-1,2-diol",
        "inchi": {
            "hash": "RQPALADHFYHEHK-CHKWXVPMSA-N",
            "id": "InChI=1S/C10H11N5O2/c11-9-7-10(13-3-12-9)15(4-14-7)5-1-2-6(16)8(5)17/h1-6,8,16-17H,(H2,11,12,13)/t5-,6+,8+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 233.2266,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 233.091274621,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,3-substituted cyclopentyl purine nucleosides. These are nucleoside analogues with a structure that consists of a cyclobutane that is substituted a the 1-position with a hydroxyl group and at the 3-position with either a purine base.",
        "link": "https://go.drugbank.com/drugs/DB03216",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenosylhomocysteinase"
            }
        ]
    },
    {
        "smiles": "CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCS",
        "id": "DB03170",
        "molecule": "Dephospho Coenzyme A",
        "iupac_name": "{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(3R)-3-hydroxy-2,2-dimethyl-3-({2-[(2-sulfanylethyl)carbamoyl]ethyl}carbamoyl)propoxy]phosphoryl}oxy)phosphinic acid",
        "inchi": {
            "hash": "KDTSHFARGAKYJN-IBOSZNHHSA-N",
            "id": "InChI=1S/C21H35N7O13P2S/c1-21(2,16(32)19(33)24-4-3-12(29)23-5-6-44)8-39-43(36,37)41-42(34,35)38-7-11-14(30)15(31)20(40-11)28-10-27-13-17(22)25-9-26-18(13)28/h9-11,14-16,20,30-32,44H,3-8H2,1-2H3,(H,23,29)(H,24,33)(H,34,35)(H,36,37)(H2,22,25,26)/t11-,14-,15-,16+,20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 687.554,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 687.148877955,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine ribonucleoside diphosphates. These are purine ribobucleotides with diphosphate group linked to the ribose moiety.",
        "link": "https://go.drugbank.com/drugs/DB03170",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Shigella flexneri",
                "target": "UPhosphopantetheine adenylyltransferase"
            }
        ]
    },
    {
        "smiles": "CC(C)C1=C(SC2=CC(Cl)=CC(Cl)=C2)N(CC2=CC=NC=C2)C(COC(N)=O)=N1",
        "id": "DB08502",
        "molecule": "Capravirine",
        "cas": "178979-85-6",
        "iupac_name": "{5-[(3,5-dichlorophenyl)sulfanyl]-4-(propan-2-yl)-1-[(pyridin-4-yl)methyl]-1H-imidazol-2-yl}methyl carbamate",
        "inchi": {
            "hash": "YQXCVAGCMNFUMQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 451.369,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 450.068402008,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diarylthioethers. These are organosulfur compounds containing a thioether group that is substituted by two aryl groups.",
        "link": "https://go.drugbank.com/drugs/DB08502",
        "type": "Small Molecule",
        "synonyms": [
            "Capravirina",
            "Capravirine",
            "Capravirinum"
        ],
        "indication": "Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            },
            {
                "action": "inhibitor",
                "organism": "Human immunodeficiency virus 1",
                "target": "UReverse transcriptase/RNaseH"
            }
        ]
    },
    {
        "smiles": "CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1",
        "id": "DB00903",
        "molecule": "Etacrynic acid",
        "cas": "58-54-8",
        "iupac_name": "2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid",
        "background": "A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.\n",
        "inchi": {
            "hash": "AVOLMBLBETYQHX-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)"
        },
        "summary": "Etacrynic acid is a diuretic used to treat ascites and edema in congestive heart failure, liver cirrhosis, and renal disease.",
        "weight": [
            {
                "type": "average",
                "weight": 303.138,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 302.011264286,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as chlorophenoxyacetates. These are compounds containing a phenoxyacetate that carries one or more chlorine atoms on the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB00903",
        "type": "Small Molecule",
        "synonyms": [
            "(2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid",
            "Acide tacrynique",
            "cido etacrnico",
            "Acidum etacrynicum",
            "Etacrinic acid",
            "Etacrynic acid",
            "Ethacrynate",
            "Ethacrynic acid",
            "Methylenebutyrylphenoxyacetic acid"
        ],
        "indication": "For the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Ethacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASolute carrier family 12 member 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium/potassium-transporting ATPase subunit alpha-1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULymphoid enhancer-binding factor 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UGlutathione S-transferase P"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02889"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03099"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03764"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02194"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05775"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03292"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08237"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17395"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06848"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12123"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07292"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08299"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07269"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06680"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07543"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03273"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14909"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07871"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14894"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08373"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13158"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05540"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07336"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12795"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11890"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01778"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08550"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02483"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15292"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07323"
    },
    {
        "smiles": "OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1",
        "id": "DB08784",
        "molecule": "2-(4-CHLORO-PHENYLAMINO)-NICOTINIC ACID",
        "iupac_name": "2-[(4-chlorophenyl)amino]pyridine-3-carboxylic acid",
        "inchi": {
            "hash": "YEXIXVLEDGNAKM-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H9ClN2O2/c13-8-3-5-9(6-4-8)15-11-10(12(16)17)2-1-7-14-11/h1-7H,(H,14,15)(H,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 248.665,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 248.035255249,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.",
        "link": "https://go.drugbank.com/drugs/DB08784",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNmrA-like family domain-containing protein 1"
            }
        ]
    },
    {
        "smiles": "CC(=O)N[C@H](CC1=CC=CC2=C1C=CC=C2)[B-](O)(O)OC[C@H](N)C(O)=O",
        "id": "DB02677",
        "molecule": "D-naphthyl-1-acetamido boronic acid alanine",
        "iupac_name": "[(2S)-2-amino-2-carboxyethoxy][(1S)-1-acetamido-2-(naphthalen-1-yl)ethyl]dihydroxyboranuide",
        "inchi": {
            "hash": "KJSNEFAXFLDDDR-JKSUJKDBSA-N",
            "id": "InChI=1S/C17H22BN2O6/c1-11(21)20-16(18(24,25)26-10-15(19)17(22)23)9-13-7-4-6-12-5-2-3-8-14(12)13/h2-8,15-16,24-25H,9-10,19H2,1H3,(H,20,21)(H,22,23)/q-1/t15-,16+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 361.177,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 361.157091912,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB02677",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus licheniformis",
                "target": "USubtilisin Carlsberg"
            }
        ]
    },
    {
        "smiles": "CCOC(=O)[C@H](CCC1=CC=CC=C1)CC1(CCCC1)C(=O)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O",
        "id": "DB05796",
        "molecule": "Daglutril",
        "cas": "182821-27-8",
        "iupac_name": "2-[(3S)-3-{1-[(2R)-3-ethoxy-3-oxo-2-(2-phenylethyl)propyl]cyclopentaneamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid",
        "background": "Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.\n",
        "inchi": {
            "hash": "XMQODGUTLZXUGZ-RPBOFIJWSA-N",
            "id": "InChI=1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 534.6432,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 534.272986958,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB05796",
        "type": "Small Molecule",
        "synonyms": [
            "((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acid",
            "Daglutril"
        ],
        "indication": "Investigated for use/treatment in congestive heart failure and hypertension.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeprilysin"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)(C)O",
        "id": "DB04705",
        "molecule": "25-Hydroxycholesterol",
        "cas": "2140-46-7",
        "iupac_name": "(1R,3aS,3bS,7S,9aR,9bS,11aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-ol",
        "inchi": {
            "hash": "INBGSXNNRGWLJU-ZHHJOTBYSA-N",
            "id": "InChI=1S/C27H46O2/c1-18(7-6-14-25(2,3)29)22-10-11-23-21-9-8-19-17-20(28)12-15-26(19,4)24(21)13-16-27(22,23)5/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t18-,20+,21+,22-,23+,24+,26+,27-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 402.6529,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 402.349780716,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cholesterols and derivatives. These are compounds containing a 3-hydroxylated cholestane core.",
        "link": "https://go.drugbank.com/drugs/DB04705",
        "type": "Small Molecule",
        "synonyms": [
            "5-Cholestene-3beta,25-diol",
            "Cholest-5-ene-3beta,25-diol"
        ]
    },
    {
        "smiles": "CC(=O)NO",
        "id": "DB00551",
        "molecule": "Acetohydroxamic acid",
        "cas": "546-88-3",
        "iupac_name": "N-hydroxyacetamide",
        "background": "Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.\n",
        "inchi": {
            "hash": "RRUDCFGSUDOHDG-UHFFFAOYSA-N",
            "id": "InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)"
        },
        "summary": "Acetohydroxamic acid is a synthetic urea derivative used to treat urea splitting bacterial infections of the urinary tract.",
        "weight": [
            {
                "type": "average",
                "weight": 75.0666,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 75.032028409,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acetohydroxamic acids. These are organic compounds that contain a hydroxamic acid group carrying a methyl group attached to its carbon center.",
        "link": "https://go.drugbank.com/drugs/DB00551",
        "type": "Small Molecule",
        "synonyms": [
            "Acethydroxamsaeure",
            "Acetic acid, oxime",
            "Acetohydroxamate",
            "Acetohydroxamic acid",
            "Acetohydroximic acid",
            "Acetyl hydroxyamino",
            "Acetylhydroxamic acid",
            "Acide acetohydroxamique",
            "Acido acetohidroxamico",
            "Acidum acetohydroxamicum",
            "AHA",
            "Cetohyroxamic acid",
            "Methylhydroxamic acid",
            "N-Acetyl hydroxyacetamide",
            "N-Acetylhydroxylamine",
            "N-Hydroxyacetamide"
        ],
        "indication": "Used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Enterobacter aerogenes",
                "target": "AUrease subunit alpha"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UMacrophage metalloelastase"
            }
        ]
    },
    {
        "smiles": "NCCS",
        "id": "DB00847",
        "molecule": "Cysteamine",
        "cas": "60-23-1",
        "iupac_name": "2-aminoethane-1-thiol",
        "background": "Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.2\nSeveral preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form.10,12 In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour.11\nOn August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval.10 Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis. Marketed by Recordati Rare Diseases Inc., CYSTADROPS reduce the burden of multiple frequent medications normally administered to those with cystinosis.9\n",
        "inchi": {
            "hash": "UFULAYFCSOUIOV-UHFFFAOYSA-N",
            "id": "InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2"
        },
        "summary": "Cysteamine is a cystine depleting agent used to treat the effects of cystinosis.",
        "weight": [
            {
                "type": "average",
                "weight": 77.149,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 77.029919919,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkylthiols. These are organic compounds containing the thiol functional group linked to an alkyl chain.",
        "link": "https://go.drugbank.com/drugs/DB00847",
        "type": "Small Molecule",
        "synonyms": [
            "2-amino-1-ethanethiol",
            "2-amino-ethanethiol",
            "2-aminoethanethiol",
            "beta-aminoethanethiol",
            "beta-Mercaptoethylamine",
            "Cysteamine",
            "MEA",
            "Mercaptamina",
            "Mercaptamine",
            "Mercaptaminum",
            "Thioethanolamine",
            "-aminoethylthiol",
            "-MEA"
        ],
        "indication": "The bitartrate salt of cysteamine is used for the oral treatment of nephropathic cystinosis and cystinuria in adults and children 6 years old.12 The hydrochloride salt, used in eye drop preparations, is indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.9,10\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cystine accumulation is the cause of organ damage in cystinosis. Cysteamine prevents the accumulation of cystine crystals in the body and is specifically prescribed to prevent kidney and eye damage.4,9,12 Cysteamine converts cystine into a form that may easily exit cells, preventing harmful accumulation.10\n",
        "moa": [
            {
                "action": "cleavage",
                "organism": "Humans",
                "target": "UCystine"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "UNeuropeptide Y receptor type 2"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)CCC(C)(C)[C@]2([H])[C@]([H])(O)[C@]([H])(OC(C)=O)[C@@]3(C)O[C@](C)(CC(=O)[C@]3(O)[C@@]12C)C=C",
        "id": "DB02587",
        "molecule": "Colforsin",
        "cas": "66575-29-9",
        "iupac_name": "(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-dodecahydro-1H-naphtho[2,1-b]pyran-5-yl acetate",
        "background": "Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant Coleus forskohlii. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.\n",
        "inchi": {
            "hash": "OHCQJHSOBUTRHG-KGGHGJDLSA-N",
            "id": "InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 410.5012,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 410.230453442,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as triterpenoids. These are terpene molecules containing six isoprene units.",
        "link": "https://go.drugbank.com/drugs/DB02587",
        "type": "Small Molecule",
        "synonyms": [
            "7-acetoxy-8,13-epoxy-1,6,9-trihydroxylabd-14-en-11-one",
            "Coleonolk",
            "Colforsin",
            "colforsina",
            "colforsine",
            "colforsinum",
            "Forskolin"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenylate cyclase type 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGuanine nucleotide-binding protein G(s) subunit alpha isoforms short"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenylate cyclase type 5"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCystic fibrosis transmembrane conductance regulator"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "AAdenylate cyclase"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UCalcium-activated potassium channel"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UCREB-binding protein"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UExtracellular signal-regulated kinase (ERK)"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UMucin-2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UPlasminogen activator inhibitor 1"
            }
        ]
    },
    {
        "smiles": "NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1",
        "id": "DB00250",
        "molecule": "Dapsone",
        "cas": "80-08-0",
        "iupac_name": "4-(4-aminobenzenesulfonyl)aniline",
        "background": "A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)\n",
        "inchi": {
            "hash": "MQJKPEGWNLWLTK-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2"
        },
        "summary": "Dapsone is a sulfone drug used to treat acne vulgaris, Hansen's disease, and dermatitis herpetiformis.",
        "weight": [
            {
                "type": "average",
                "weight": 248.301,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 248.061948328,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.",
        "link": "https://go.drugbank.com/drugs/DB00250",
        "type": "Small Molecule",
        "synonyms": [
            "1,1'-sulfonylbis(4-aminobenzene)",
            "1,1'-Sulfonylbis[4-aminobenzene]",
            "4-(4-amino-benzenesulfonyl)-phenylamine",
            "4-(4-aminophenylsulfonyl)aniline",
            "4-(4-aminophenylsulfonyl)benzenamine",
            "4-aminophenyl sulfone",
            "4,4'-dapsone",
            "4,4'-diaminodiphenyl sulfone",
            "4,4'-Diaminodiphenyl sulphone",
            "4,4'-Diaminodiphenylsulfone",
            "4,4'-sulfonylbisaniline",
            "4,4'-Sulfonylbisbenzenamine",
            "4,4'-Sulfonylbisbenzeneamine",
            "4,4'-Sulfonyldianilin",
            "4,4'-sulfonyldianiline",
            "bis(4-aminophenyl)sulfone",
            "Bis(p-aminophenyl) sulfone",
            "DADPS",
            "Dapsona",
            "Dapsone",
            "Dapsonum",
            "DDS",
            "Diaphenylsulfone",
            "p-aminophenyl sulfone",
            "p,p-sulphonylbisbenzamine",
            "p,p-sulphonylbisbenzenamine",
            "p,p'-diaminodiphenyl sulfone"
        ],
        "indication": "For the treatment and management of leprosy and dermatitis herpetiformis.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Mycobacterium leprae (strain TN)",
                "target": "AInactive dihydropteroate synthase 2"
            },
            {
                "action": "inhibitor",
                "organism": "Mycobacterium leprae (strain TN)",
                "target": "ADihydropteroate synthase 1"
            }
        ]
    },
    {
        "smiles": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12",
        "id": "DB00762",
        "molecule": "Irinotecan",
        "cas": "97682-44-5",
        "iupac_name": "(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate",
        "background": "Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).\n",
        "inchi": {
            "hash": "UWKQSNNFCGGAFS-XIFFEERXSA-N",
            "id": "InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1"
        },
        "summary": "Irinotecan is an antineoplastic enzyme inhibitor used to treat metastatic carcinoma of the colon or rectum.",
        "weight": [
            {
                "type": "average",
                "weight": 586.678,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 586.279134968,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).",
        "link": "https://go.drugbank.com/drugs/DB00762",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-Irinotecan",
            "(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl)ethyl)piperidine-1-carboxylate",
            "Irinotecan",
            "Irinotecan lactone",
            "Irinotecan liposome injection",
            "Irinotecanum"
        ],
        "indication": "For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a semisynthetic derivative of camptothecin. Camptothecins interact specifically with topoisomerase I, an enzyme in the cell nucleus that regulates DNA topology and facilitates nuclear processes such as DNA replication, recombination, and repair. During these processes, topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks, allowing single DNA strands to pass through the break. The 3'-DNA terminus of the broken DNA strands bind covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After the DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the chemically unaltered topoisomers that allow transcription to proceed. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ADNA topoisomerase I, mitochondrial"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ADNA topoisomerase 1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08250"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03966"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06508"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07805"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12158"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08780"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07970"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01758"
    },
    {
        "smiles": "C[C@@H](CCCC(C)(C)O)C=C",
        "id": "DB02273",
        "molecule": "2,6-Dimethyl-7-Octen-2-Ol",
        "cas": "18479-58-8",
        "iupac_name": "(6S)-2,6-dimethyloct-7-en-2-ol",
        "inchi": {
            "hash": "XSNQECSCDATQEL-SECBINFHSA-N",
            "id": "InChI=1S/C10H20O/c1-5-9(2)7-6-8-10(3,4)11/h5,9,11H,1,6-8H2,2-4H3/t9-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 156.2652,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 156.151415262,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tertiary alcohols. These are compounds in which a hydroxy group, -OH, is attached to a saturated carbon atom R3COH (R not H ).",
        "link": "https://go.drugbank.com/drugs/DB02273",
        "type": "Small Molecule"
    },
    {
        "smiles": "CC(CC1=CC=CC=C1)NCCC#N",
        "id": "DB01550",
        "molecule": "Fenproporex",
        "cas": "16397-28-7",
        "iupac_name": "3-[(1-phenylpropan-2-yl)amino]propanenitrile",
        "background": "Fenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. It is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency. Structurally, fenproporex (N-2-cyanoethylamphetamine) falls within the phenylethamine and amphetamine chemical class of drugs. The N-2-cyanoethyl substituent was once believed to be resistant to cleavage, because fenproporex -- once recommended as an obesity treatment for patients with cardiovascular disease -- was originally claimed to lack stimulant properties. Contrary to the claim, research has demonstrated easy in vivo cleavage of the N-2-cyanothyl substituent to yield amphetamine as a metabolite. [5] However, in clinical practice, central nervous system stimulative effects are less notorious than with some other agents such as diethylpropion and mazindol. [7]\nIn the United States fenproporex was never approved by the FDA for clinical use due to a lack of efficacy and safety data, and is listed as a drug in Schedule IV of the Controlled Substances Act. In 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers.\nDespite being banned in the United States, fenproporex has been described as the second most commonly consumed appetite suppressant worldwide, [6] with fenproporex containing anorectics still being commonly prescribed in South America. Little is known about the specific hazards of amphetamine based diet pills, however case reports have noted side effects such as chest pain, palpitations, headaches, and insomnia. In addition, placebo controlled studies have shown that participants using fenproporex experience more joint pain, sweating, blurred vision and tremor. [2]\n",
        "inchi": {
            "hash": "IQUFSXIQAFPIMR-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H16N2/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,9-10H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 188.2688,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 188.131348522,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.",
        "link": "https://go.drugbank.com/drugs/DB01550",
        "type": "Small Molecule",
        "synonyms": [
            "Femproporex",
            "Fenproporex",
            "Fenproporexum"
        ],
        "indication": "Fenproporex is used as an appetite suppressant, and anti-obesity agent [2]; however, due to substance abuse potential, it is an illicit substance in many countries. In some countries, such as Brazil, it is still prescribed -- often in the form of diet pills (ie. Brazilian Diet Pills) which combine amphetamines, benzodiazepines, antidepressants, diuretics and laxatives. \nIn the United States the sale of such diet pills has been banned due to concerns over side effects, and the risk of potentially fatal overdose.\nHowever, internet sales and illicit markets has lead to international availability. It has been found by primary care physicians that Brazilian immigrant women utilized imported diet pills at particularly high rates, and sometimes suffered from side effects requiring hospitalization or experienced a loss of employment. [3]\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fenproporex was first claimed to not exert a stimulant effect on the body, however research into its metabolism has shown that it is converted into a considerable amount of amphetamine in the body, which leads to stimulant effects. [9]\n"
    },
    {
        "smiles": "OC1=CC=CC=C1[S@](=O)CCCCP(O)(O)=O",
        "id": "DB07925",
        "molecule": "4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID",
        "iupac_name": "{4-[(R)-2-hydroxybenzenesulfinyl]butyl}phosphonic acid",
        "inchi": {
            "hash": "FFIGWLBWBXCVHW-QGZVFWFLSA-N",
            "id": "InChI=1S/C10H15O5PS/c11-9-5-1-2-6-10(9)17(15)8-4-3-7-16(12,13)14/h1-2,5-6,11H,3-4,7-8H2,(H2,12,13,14)/t17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 278.262,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 278.037780792,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenyl sulfoxides. These are organosulfur compounds containing a sulfoxide group substituted with a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07925",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UTryptophan synthase alpha chain"
            },
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UTryptophan synthase beta chain"
            }
        ]
    },
    {
        "smiles": "NCCC1=CC=C(C=C1)S(N)(=O)=O",
        "id": "DB08782",
        "molecule": "4-(2-AMINOETHYL)BENZENESULFONAMIDE",
        "iupac_name": "4-(2-aminoethyl)benzene-1-sulfonamide",
        "inchi": {
            "hash": "FXNSVEQMUYPYJS-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H12N2O2S/c9-6-5-7-1-3-8(4-2-7)13(10,11)12/h1-4H,5-6,9H2,(H2,10,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 200.258,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 200.061948328,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08782",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "CC1=CC=C(C=C1)S(O)(=O)=O.CC1=CC=C(C=C1)S(O)(=O)=O.CN1CCN(CC1)C(C)(C)C#CC1=C(NC(=O)C=C)C=C2C(NC3=CC=C(F)C(Cl)=C3)=NC=NC2=C1",
        "id": "DB06021",
        "molecule": "AV-412",
        "cas": "451493-31-5",
        "iupac_name": "bis(4-methylbenzene-1-sulfonic acid); N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl]quinazolin-6-yl}prop-2-enamide",
        "inchi": {
            "hash": "GTWJVFFZCKODEV-UHFFFAOYSA-N",
            "id": "InChI=1S/C27H28ClFN6O.2C7H8O3S/c1-5-25(36)33-23-16-20-24(30-17-31-26(20)32-19-6-7-22(29)21(28)15-19)14-18(23)8-9-27(2,3)35-12-10-34(4)11-13-35;2*1-6-2-4-7(5-3-6)11(8,9)10/h5-7,14-17H,1,10-13H2,2-4H3,(H,33,36)(H,30,31,32);2*2-5H,1H3,(H,8,9,10)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 851.41,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 850.238546,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB06021",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in cancer/tumors (unspecified).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEpidermal growth factor receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UReceptor tyrosine-protein kinase erbB-2"
            }
        ]
    },
    {
        "smiles": "[K+].[K+].OP([O-])([O-])=O",
        "id": "DB09414",
        "molecule": "Dipotassium phosphate",
        "cas": "7758-11-4",
        "iupac_name": "dipotassium hydrogen phosphate",
        "background": "Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.\n",
        "inchi": {
            "hash": "ZPWVASYFFYYZEW-UHFFFAOYSA-L",
            "id": "InChI=1S/2K.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2"
        },
        "summary": "Dipotassium phosphate is an ionic compound used for electrolyte replenishment and total parenteral nutrition (TPN) therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 174.1759,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 173.888658754,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.",
        "link": "https://go.drugbank.com/drugs/DB09414",
        "type": "Small Molecule",
        "synonyms": [
            "Di-potassium hydrogen phosphate",
            "Dibasic potassium phosphate",
            "Dipotassium acid phosphate",
            "Dipotassium hydrogen monophosphate",
            "Dipotassium hydrogen orthophosphate",
            "Dipotassium hydrogen phosphate",
            "Dipotassium monophosphate",
            "Kali phosphoricum",
            "Phosphoric acid, dipotassium salt",
            "Phosphoric acid, potassium salt (1:2)",
            "Potassium phosphate dibasic",
            "Potassium phosphate, dibasic",
            "Potassium phosphate,dibasic",
            "Secondary potassium phosphate"
        ],
        "indication": "Dipotassium phosphate is used in imitation dairy creamers, dry powder beverages, mineral supplements, and starter cultures as an additive. It is used in non-dairy creamers to prevent coagulation. Dipotassium phosphate is also used to make buffer solutions and it is used in the production of trypticase soy agar which is used to make agar plates for culturing bacteria.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues. Phosphate exerts a modifying influence on calcium concentrations, a buffering effect on acid-base equilibrium, and has a major role in the renal excretion of hydrogen ions.\n"
    },
    {
        "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]",
        "id": "DB00304",
        "molecule": "Desogestrel",
        "cas": "54024-22-5",
        "iupac_name": "(1R,3aS,3bS,9aR,9bS,11aS)-11a-ethyl-1-ethynyl-10-methylidene-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-ol",
        "background": "Desogestrel, a prodrug, is a third generation progestogen1 and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada.4 It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activity.10 Desogestrel is now produced semi-synthetically from naturally occurred plant steroids.14 In the US, desogestrel is found only in combination with ethinyl estradiol.5 The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.11\n",
        "inchi": {
            "hash": "RPLCPCMSCLEKRS-BPIQYHPVSA-N",
            "id": "InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1"
        },
        "summary": "Desogestrel is a synthetic progestin used in contraception, often in combination with ethinyl estradiol.",
        "weight": [
            {
                "type": "average",
                "weight": 310.473,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 310.229665582,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton.",
        "link": "https://go.drugbank.com/drugs/DB00304",
        "type": "Small Molecule",
        "synonyms": [
            "13-Ethyl-11-methylene-18,19-dinor-17-pregn-4-en-20-yn-17-ol",
            "Desogestrel",
            "Dsogestrel",
            "Desogestrelum"
        ],
        "indication": "Oral desogestrel is used in combination with ethinylestradiol as a contraceptive agent for the prevention of pregnancy.Label\nDesogestrel is part of the combined oral contraceptives that contain a mix of estrogen and progestin which inhibit ovulation.12\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The effects of desogestrel are divided on reproductive including modification of luteinizing hormone and follicle stimulating hormone, declines on the onset of menstruation, and increases the viscosity of the vaginal fluid; and on metabolic that includes increase insulin secretion and resistance, increased lipase activity, and increased fat deposition.9 The effect of desogestrel on the lipids has been studied extensively and the results are contradictory.\nDesogestrel main therapeutic effect due to its mechanism of action is known to be related to the inhibition of the ovulation in 97% of the cycles. This effect was proven in clinical trials in non-breastfeeding women from which the Pearl failure rate was reported to be of 0.17 per 100 women-years. This result indicated that desogestrel is more efficient when compared to other progestogen-only pills.6 All the therapeutic effect is produced by a transformation of the endometrium followed by an inhibition of the ovulation due to the suppression of other hormones.10\nDesogestrel has been widely confirmed to be related to an increase in the risk of venous thromboembolism due to the driven increased in blood coagulation factors, leading to a pronounced prothrombotic state.1 However, the effects of desogestrel are known to not impact significantly the level of total cholesterol remaining in the range of change of 10% which allows it to be a molecule that presents a favorable lipid profile.4\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProgesterone receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AEstrogen receptor alpha"
            }
        ]
    },
    {
        "smiles": "C[C@H](N)CC1=CC=CC=C1",
        "id": "DB01576",
        "molecule": "Dextroamphetamine",
        "cas": "51-64-9",
        "iupac_name": "(2S)-1-phenylpropan-2-amine",
        "background": "Dextroamphetamine is the dextrorotary enantiomer of amphetamine5. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder6,Label.\n",
        "inchi": {
            "hash": "KWTSXDURSIMDCE-QMMMGPOBSA-N",
            "id": "InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1"
        },
        "summary": "Dextroamphetamine is a sympathomimetic agent used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.",
        "weight": [
            {
                "type": "average",
                "weight": 135.2062,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 135.104799421,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.",
        "link": "https://go.drugbank.com/drugs/DB01576",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-(S)-amphetamine",
            "(+)-amphetamine",
            "(+)--methylphenethylamine",
            "(+)--methylphenylethylamine",
            "(S)-(+)-amphetamine",
            "(S)-(+)--phenylisopropylamine",
            "(S)-1-phenyl-2-aminopropane",
            "(S)-1-phenyl-2-propylamine",
            "(S)-amphetamine",
            "(S)--methylbenzeneethanamine",
            "(S)--methylbenzeneethanamine",
            "d-amphetamine",
            "Desamfetamina",
            "Dexamfetamina",
            "Dexamfetamine",
            "Dexamfetaminum",
            "Dexamphetamine",
            "Dexanfetamina",
            "Dextroamphetamine"
        ],
        "indication": "Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).Label\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dextroamphetamine is a noncatecholamine, sympathomimetic amine that acts as a CNS stimulant.Label Dextroamphetamine raises systolic and diastolic blood pressure, acts as a weak bronchodilator, and also acts as a respiratory stimulant.Label The general mechanism of action of dextroamphetamine has not been well established.Label\n",
        "moa": [
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "ASynaptic vesicular amine transporter"
            },
            {
                "action": "negative modulator",
                "organism": "Humans",
                "target": "ASodium-dependent noradrenaline transporter"
            },
            {
                "action": "negative modulator",
                "organism": "Humans",
                "target": "ASodium-dependent dopamine transporter"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UTrace amine-associated receptor 1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UAlpha-1B adrenergic receptor"
            },
            {
                "action": "inhibitorinducer",
                "organism": "Humans",
                "target": "UAlpha adrenergic receptor"
            }
        ]
    },
    {
        "smiles": "OC(=O)CCCC(O)=O",
        "id": "DB03553",
        "molecule": "Glutaric Acid",
        "cas": "110-94-1",
        "iupac_name": "pentanedioic acid",
        "inchi": {
            "hash": "JFCQEDHGNNZCLN-UHFFFAOYSA-N",
            "id": "InChI=1S/C5H8O4/c6-4(7)2-1-3-5(8)9/h1-3H2,(H,6,7)(H,8,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 132.1146,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 132.042258744,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dicarboxylic acids and derivatives. These are organic compounds containing exactly two carboxylic acid groups.",
        "link": "https://go.drugbank.com/drugs/DB03553",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAspartate aminotransferase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBranched-chain-amino-acid aminotransferase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UGlutamate decarboxylase alpha"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00224"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07022"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04278"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12537"
    },
    {
        "smiles": "[H][C@]1(N)C[C@@]([H])(C)[C@@]([H])(N1)C(O)=O",
        "id": "DB03184",
        "molecule": "5-Amino-3-Methyl-Pyrrolidine-2-Carboxylic Acid",
        "iupac_name": "(2R,3R,5R)-5-amino-3-methylpyrrolidine-2-carboxylic acid",
        "inchi": {
            "hash": "ZELPFFKOULVLMW-UOWFLXDJSA-N",
            "id": "InChI=1S/C6H12N2O2/c1-3-2-4(7)8-5(3)6(9)10/h3-5,8H,2,7H2,1H3,(H,9,10)/t3-,4-,5-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 144.1717,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 144.089877638,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB03184",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H][C@]1(CC)O[C@]2(C)[C@]([H])(OC(C)=O)[C@@]1(C)O[C@@]([H])(\\C=C\\C=C\\C=C\\C1=C(C)C(OC)=CC(=O)O1)[C@]2([H])O",
        "id": "DB07394",
        "molecule": "AUROVERTIN B",
        "iupac_name": "(1S,3S,4S,5S,7R,8S)-7-ethyl-4-hydroxy-3-[(1E,3E,5E)-6-(4-methoxy-5-methyl-2-oxo-2H-pyran-6-yl)hexa-1,3,5-trien-1-yl]-1,5-dimethyl-2,6-dioxabicyclo[3.2.1]octan-8-yl acetate",
        "inchi": {
            "hash": "QXCOFYWOWZJFEA-YJMRODJJSA-N",
            "id": "InChI=1S/C25H32O8/c1-7-20-24(4)23(30-16(3)26)25(5,33-20)22(28)18(32-24)13-11-9-8-10-12-17-15(2)19(29-6)14-21(27)31-17/h8-14,18,20,22-23,28H,7H2,1-6H3/b9-8+,12-10+,13-11+/t18-,20+,22-,23+,24-,25-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 460.5168,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 460.209718,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as c-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a C-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB07394",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UATP synthase subunit alpha, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UATP synthase subunit beta, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UATP synthase subunit gamma, mitochondrial"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02298"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11368"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06734"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18390"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07768"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02270"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02025"
    },
    {
        "smiles": "[H][C@@]1(O[C@H]2[C@@H](O)[C@@H](CO)O[C@@]([H])(O[C@H]3[C@@H](CO)O[C@@]([H])(O[C@H]4[C@H](O)[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\\C=C\\CCCCCCCCCCCCC)O[C@@H]4CO)[C@H](O)[C@H]3O[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@@]([H])(O3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H]2NC(C)=O)O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O",
        "id": "DB16948",
        "molecule": "Ganglioside GM1",
        "cas": "116950-37-9",
        "iupac_name": "(2S,4S,5R,6R)-2-{[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4R,5R,6R)-4,5-dihydroxy-6-{[(2S,3R,4E)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl]oxy}-2-(hydroxymethyl)oxan-3-yl]oxy}-5-{[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-{[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-5-acetamido-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid",
        "inchi": {
            "hash": "QPJBWNIQKHGLAU-IQZHVAEDSA-N",
            "id": "InChI=1S/C73H131N3O31/c1-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-52(87)76-44(45(84)33-31-29-27-25-23-21-18-16-14-12-10-8-6-2)41-98-69-61(94)59(92)63(50(39-80)101-69)103-71-62(95)67(107-73(72(96)97)35-46(85)53(74-42(3)82)66(106-73)55(88)47(86)36-77)64(51(40-81)102-71)104-68-54(75-43(4)83)65(57(90)49(38-79)99-68)105-70-60(93)58(91)56(89)48(37-78)100-70/h31,33,44-51,53-71,77-81,84-86,88-95H,5-30,32,34-41H2,1-4H3,(H,74,82)(H,75,83)(H,76,87)(H,96,97)/b33-31+/t44-,45+,46-,47+,48+,49+,50+,51+,53+,54+,55+,56-,57-,58-,59+,60+,61+,62+,63+,64-,65+,66+,67+,68-,69+,70-,71-,73-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1546.841,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1545.87665445,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16948",
        "type": "Small Molecule",
        "synonyms": [
            "Ganglioside gm1 (d18:1/18:0)",
            "Monosialotetrahexosyl ganglioside (GM1)",
            "Monosialotetrahexosylganglioside",
            "Monosialotetrahexosylganglioside (d18:1/18:0)",
            "Porcine GM1 ganglioside"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04800"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11799"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11851"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01380"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15340"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13434"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04392"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02355"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01467"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12991"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05155"
    },
    {
        "id": "DB05741",
        "molecule": "AGS-005",
        "background": "AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05741",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in leukemia (lymphoid).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[H][C@@]1(NC(=O)C(=N/O)\\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\\C=C1/CCN(C1=O)[C@]1([H])CCN(C1)C(=O)OCC1=C(C)OC(=O)O1",
        "id": "DB14733",
        "molecule": "Ceftobiprole medocaril",
        "cas": "376653-43-9",
        "iupac_name": "(6R,7R)-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(N-hydroxyimino)acetamido]-3-{[(3E,3'R)-1'-{[(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methoxy]carbonyl}-2-oxo-[1,3'-bipyrrolidin]-3-ylidene]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",
        "background": "Ceftobiprole medocaril is a ceftobiprole prodrug.\n",
        "inchi": {
            "hash": "HFTSMHTWUFCYMJ-YIOMYIDASA-N",
            "id": "InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15-/t13-,16-,22-/m1/s1"
        },
        "summary": "Ceftobiprole medocaril is a cephalosporin indicated in the treatment of pneumonia.",
        "weight": [
            {
                "type": "average",
                "weight": 690.66,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 690.116246037,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14733",
        "type": "Small Molecule",
        "synonyms": [
            "Ceftobiprole medocaril",
            "Ceftobiprole medocaril free acid"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=NN(C)C=C1NC1=NC=CC(=N1)C1=CNC2=C(NC(=O)[C@@H](C)N3CCN(C)CC3)C=CC=C12",
        "id": "DB18057",
        "molecule": "Golidocitinib",
        "cas": "2091134-68-6",
        "inchi": {
            "hash": "CVCVOSPZEVINRM-MRXNPFEDSA-N",
            "id": "InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 489.584,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 489.260071274,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18057",
        "type": "Small Molecule",
        "synonyms": [
            "(.alpha.r)-n-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-1-piperazineacetamide",
            "1-piperazineacetamide, n-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-, (.alpha.r)-"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)CNC(=O)C1=C(O)C2=CC=CC=C2N(OCC2CC2)C1=O",
        "id": "DB16135",
        "molecule": "Desidustat",
        "cas": "1616690-16-4",
        "iupac_name": "2-{[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]formamido}acetic acid",
        "background": "Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).\n",
        "inchi": {
            "hash": "IKRKQQLJYBAPQT-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H16N2O6/c19-12(20)7-17-15(22)13-14(21)10-3-1-2-4-11(10)18(16(13)23)24-8-9-5-6-9/h1-4,9,21H,5-8H2,(H,17,22)(H,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 332.312,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 332.100836243,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16135",
        "type": "Small Molecule",
        "synonyms": [
            "Desidustat"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@@H](NC1=CC=CC=C1C(O)=O)C1=CC(C)=CN2C(=O)C=C(N=C12)N1CCOCC1",
        "id": "DB14980",
        "molecule": "AZD-6482",
        "cas": "1173900-33-8",
        "iupac_name": "2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid",
        "background": "AZD-6482 is under investigation in clinical trial NCT00688714 (Study to Investigate Safety and Tolerability of a Single Dose of AZD6482).\n",
        "inchi": {
            "hash": "IRTDIKMSKMREGO-OAHLLOKOSA-N",
            "id": "InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 408.458,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 408.179755269,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14980",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "id": "DB00516",
        "molecule": "Bentoquatam",
        "cas": "1340-69-8",
        "background": "Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. Bentoquatam contains bentonite, a clay, and is only effective as long as the film is visible on the skin.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00516",
        "type": "Small Molecule",
        "synonyms": [
            "Bentoquatam"
        ],
        "indication": "Used to prevent or reduce the severity of allergic contact dermatitis due to urushiol, the allergenic resin of poison ivy, poison oak, and poison sumac.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bentoquatam protects the skin like a shield against poison ivy, poison oak, and poison sumac by physically blocking skin contact with their resin. The best protection against getting these conditions is to avoid contact with these plants. This medicine does not dry oozing and weeping caused by the rash of poison ivy, poison oak, or poison sumac.\n"
    },
    {
        "smiles": "OC1=CC=C(C=C1O)[As+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB02086",
        "molecule": "(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium",
        "iupac_name": "(3,4-dihydroxyphenyl)triphenylarsanium",
        "inchi": {
            "hash": "AYGYLFIDAXGERM-UHFFFAOYSA-O",
            "id": "InChI=1S/C24H19AsO2/c26-23-17-16-22(18-24(23)27)25(19-10-4-1-5-11-19,20-12-6-2-7-13-20)21-14-8-3-9-15-21/h1-18H,(H-,26,27)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 415.336,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 415.067926301,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as catechols. These are compounds containing a 1,2-benzenediol moiety.",
        "link": "https://go.drugbank.com/drugs/DB02086",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1",
        "id": "DB06636",
        "molecule": "Isavuconazonium",
        "cas": "742049-41-8",
        "iupac_name": "1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4-[1-({methyl[3-({[2-(methylamino)acetyl]oxy}methyl)pyridin-2-yl]carbamoyl}oxy)ethyl]-1H-1,2,4-triazol-4-ium",
        "background": "Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA for the treatment of invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.\n",
        "inchi": {
            "hash": "RSWOJTICKMKTER-QXLBVTBOSA-N",
            "id": "InChI=1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1"
        },
        "summary": "Isavuconazonium is a triazole antifungal used for the treatment of invasive aspergillosis and mucormycosis.",
        "weight": [
            {
                "type": "average",
                "weight": 717.77,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 717.241370179,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB06636",
        "type": "Small Molecule",
        "synonyms": [
            "Isavuconazonium"
        ],
        "indication": "Indicated in the treatment of invasive aspergillosis and invasive mucormycosis.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "OC1=CC=C(O)C=C1",
        "id": "DB09526",
        "molecule": "Hydroquinone",
        "cas": "123-31-9",
        "iupac_name": "benzene-1,4-diol",
        "background": "Hydroquinone is a topical lightening product found in OTC products, and is used to correct skin discoloration associated with disorders of hyperpigmentation including melasma, post-inflammatory hyperpigmention, sunspots, and freckles. It can be used alone, but is more frequently found in combination with other agents such as alpha-hydroxy acids, corticosteroids, retinoids, or sunscreen. \nHydroquinone has come under scrutiny due to several complications associated with its use, including dermal irritation, exogenous onchronosis, and carginogenicity. As a result of these concerns, hydroquinone has been banned in the EU and UK.\n",
        "inchi": {
            "hash": "QIGBRXMKCJKVMJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H"
        },
        "summary": "Hydroquinone is a topical brightening agent used for the treatment of skin disorders associated with hyperpigmentation including melasma, post-inflammatory hyperpigmentation, sunspots, and freckles.",
        "weight": [
            {
                "type": "average",
                "weight": 110.1106,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 110.036779436,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroquinones. These are compounds containing a hydroquinone moiety, which consists of a benzene ring with a hydroxyl groups at positions 1 and 4.",
        "link": "https://go.drugbank.com/drugs/DB09526",
        "type": "Small Molecule",
        "synonyms": [
            "1,4-benzenediol",
            "1,4-dihydroxybenzene",
            "4-Hydroxyphenol",
            "benzene-1,4-diol",
            "Hydroquinone",
            "p-Benzenediol",
            "p-Hydroquinone",
            "p-hydroxyphenol",
            "Quinol"
        ],
        "indication": "Hydroquinone is used as an OTC topical lightening agent for disorders of hyperpigmentation including melasma, post-inflammatory hyperpigmention, sunspots and freckles. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ATyrosinase"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UCysteinyl leukotriene receptor 1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07756"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15423"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04098"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01139"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02871"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01003"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01445"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04095"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08459"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18047"
    },
    {
        "id": "DB17956",
        "molecule": "FB-101",
        "background": "FB-101 is a c-Abl inhibitor. Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).1\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17956",
        "type": "Small Molecule",
        "synonyms": [
            "FB 101",
            "FB101"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04946"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14987"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00437"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01188"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08287"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09387"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05071"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17820"
    },
    {
        "id": "DB16744",
        "molecule": "CP-96345",
        "cas": "132746-60-2",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16744",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "OC1=CC=C(C=C1)C(C1=CC=C(O)C=C1)C1=CC=CC=N1",
        "id": "DB14232",
        "molecule": "Deacetylbisacodyl",
        "cas": "603-41-8",
        "iupac_name": "4-[(4-hydroxyphenyl)(pyridin-2-yl)methyl]phenol",
        "inchi": {
            "hash": "LJROKJGQSPMTKB-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H15NO2/c20-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(21)11-7-14/h1-12,18,20-21H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 277.323,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 277.110278727,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14232",
        "type": "Small Molecule",
        "synonyms": [
            "BHPM",
            "DDPM",
            "Dihydroxydiphenyl-pyridyl methane"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](C)(C[C@]([H])(N)C(O)=O)C([O-])=O",
        "id": "DB03425",
        "molecule": "2s,4r-4-Methylglutamate",
        "iupac_name": "(2R,4S)-4-amino-4-carboxy-2-methylbutanoate",
        "inchi": {
            "hash": "KRKRAOXTGDJWNI-DMTCNVIQSA-M",
            "id": "InChI=1S/C6H11NO4/c1-3(5(8)9)2-4(7)6(10)11/h3-4H,2,7H2,1H3,(H,8,9)(H,10,11)/p-1/t3-,4+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 160.1479,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 160.060982813,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB03425",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 2"
            }
        ]
    },
    {
        "smiles": "[H][C@](CC1=CC(Br)=C(C=C1)C(F)(F)P(O)(O)=O)(C(=O)C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB07263",
        "molecule": "[{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid",
        "iupac_name": "({2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}difluoromethyl)phosphonic acid",
        "inchi": {
            "hash": "WDTMVBQZDFMOIK-GOSISDBHSA-N",
            "id": "InChI=1S/C22H18BrF2O4P/c23-20-14-15(11-12-19(20)22(24,25)30(27,28)29)13-18(16-7-3-1-4-8-16)21(26)17-9-5-2-6-10-17/h1-12,14,18H,13H2,(H2,27,28,29)/t18-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 495.25,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 494.009414633,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as retro-dihydrochalcones. These are a form of normal dihydrochalcones that are structurally distinguished by the lack of oxygen functionalities at the C2'- and C6'-positions.",
        "link": "https://go.drugbank.com/drugs/DB07263",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein phosphatase non-receptor type 1"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB02843",
        "molecule": "alpha-D-glucose-1-phosphate",
        "cas": "59-56-3",
        "iupac_name": "{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phosphonic acid",
        "inchi": {
            "hash": "HXXFSFRBOHSIMQ-VFUOTHLCSA-N",
            "id": "InChI=1S/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6-/m1/s1"
        },
        "summary": "alpha-D-glucose-1-phosphate is a type of glucose used for total parenteral nutrition and phosphate replacement therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 260.1358,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 260.029718526,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monosaccharide phosphates. These are monosaccharides comprising a phosphated group linked to the carbohydrate unit.",
        "link": "https://go.drugbank.com/drugs/DB02843",
        "type": "Small Molecule",
        "synonyms": [
            "glucose-1-phosphate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UPhosphomannomutase/phosphoglucomutase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, muscle form"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMaltodextrin phosphorylase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UGlucose-1-phosphatase"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UGlucose-1-phosphate thymidylyltransferase"
            }
        ]
    },
    {
        "smiles": "CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1",
        "id": "DB01009",
        "molecule": "Ketoprofen",
        "cas": "22071-15-4",
        "iupac_name": "2-(3-benzoylphenyl)propanoic acid",
        "background": "Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.\n",
        "inchi": {
            "hash": "DKYWVDODHFEZIM-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)"
        },
        "summary": "Ketoprofen is an NSAID used to treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, dysmenorrhea, mild to moderate muscle pain, postoperative pain, and postpartum pain.",
        "weight": [
            {
                "type": "average",
                "weight": 254.2806,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 254.094294314,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB01009",
        "type": "Small Molecule",
        "synonyms": [
            "2-(3-Benzoylphenyl)propionic acid",
            "3-Benzoyl-alpha-methylbenzeneacetic acid",
            "3-Benzoyl--methylbenzeneacetic acid",
            "3-Benzoylhydratropic acid",
            "Ketoprofen",
            "Ketoprofeno",
            "L'acide (benzoyl-3-phenyl)-2-propionique",
            "m-Benzoylhydratropic acid"
        ],
        "indication": "For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AProstaglandin G/H synthase 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 1"
            },
            {
                "action": "other",
                "organism": "Humans",
                "target": "UC-X-C chemokine receptor type 1"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12",
        "id": "DB14185",
        "molecule": "Aripiprazole lauroxil",
        "cas": "1259305-29-7",
        "iupac_name": "(7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-1,2,3,4-tetrahydroquinolin-1-yl)methyl dodecanoate",
        "background": "Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of aripiprazole, which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors 1. \nAffecting about 1% of the adult population in the United States and approximately 26 million people worldwide, schizophrenia is a chronic neurological disorder that may result in impairments in cognition and executive functions 1. The quality of life in patients is greatly reduced due to negative health outcomes, and oftentimes the patients are faced with social stigma and discriminations. Schizophrenia is characterized by positive symptoms such as delusions, hallucinations, thought disorders, and catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of emotional responses 7. D2 receptors have been the most common target for antipsychotic agents used in the treatment of schizophrenia: the positive symptoms are thought to arise from overactivity in the mesolimbic dopaminergic pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating 7. In a randomized, double-blind clinical trial, treatment of aripiprazole lauroxil in adult patients with schizophrenia resulted in improvement of positive and negative symptoms scores at day 85 of treatment 1,3. \nAripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. It is administered via intramuscular injection, and requires the establishment of tolerability prior to dosing in treatment-nave patients Label. On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose. The patients may receive Aristada Initio in combination with a single 30 mg oral dose of aripiprazole to achieve appropriate levels of aripiprazole more rapidly. Long-acting injectable aripiprazole lauroxil displayed comparable efficacy and safety to aripiprazole 3, and reduced dosing frequency improves patient adherence.\n",
        "inchi": {
            "hash": "DDINXHAORAAYAD-UHFFFAOYSA-N",
            "id": "InChI=1S/C36H51Cl2N3O4/c1-2-3-4-5-6-7-8-9-10-16-35(43)45-28-41-33-27-30(19-17-29(33)18-20-34(41)42)44-26-12-11-21-39-22-24-40(25-23-39)32-15-13-14-31(37)36(32)38/h13-15,17,19,27H,2-12,16,18,20-26,28H2,1H3"
        },
        "summary": "Aripiprazole lauroxil is an antipsychotic used to treat schizophrenia in adults.",
        "weight": [
            {
                "type": "average",
                "weight": 660.72,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 659.3256625,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB14185",
        "type": "Small Molecule",
        "synonyms": [
            "Aripiprazole lauroxil"
        ],
        "indication": "Aripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Aripiprazole, which is a major pharmacological metabolite of aripiprazole lauroxil, serves to improve the positive and negative symptoms of schizophrenia by modulating dopaminergic signalling pathways. Aripiprazole lauroxil is reported to have minimal effects on sexual function or prolactin levels 7. \n",
        "moa": [
            {
                "action": "partial agonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            },
            {
                "action": "partial agonist",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 1A"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1B"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1D"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1E"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDopamine D1 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDopamine D5 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDopamine D3 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDopamine D4 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2C"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 3A"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 6"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 7"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "NHistamine H1 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "NAlpha-1A adrenergic receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "NAlpha-1B adrenergic receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "NAlpha-2A adrenergic receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "NAlpha-2B adrenergic receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "NAlpha-2C adrenergic receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "NMuscarinic acetylcholine receptor M1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "NMuscarinic acetylcholine receptor M2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "NMuscarinic acetylcholine receptor M3"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "NMuscarinic acetylcholine receptor M4"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "NMuscarinic acetylcholine receptor M5"
            }
        ]
    },
    {
        "smiles": "CN1CCN(CC1)NC(=S)NC1=CC=C(C=C1)S(N)(=O)=O",
        "id": "DB08202",
        "molecule": "4-({[(4-METHYLPIPERAZIN-1-YL)AMINO]CARBONOTHIOYL}AMINO)BENZENESULFONAMIDE",
        "iupac_name": "1-(4-methylpiperazin-1-yl)-3-(4-sulfamoylphenyl)thiourea",
        "inchi": {
            "hash": "BPPLIZHQOIGRPZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H19N5O2S2/c1-16-6-8-17(9-7-16)15-12(20)14-10-2-4-11(5-3-10)21(13,18)19/h2-5H,6-9H2,1H3,(H2,13,18,19)(H2,14,15,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 329.442,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 329.098016257,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08202",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "CN1C=C(CCO)C2=C1C=C(C1=C2C(=O)NC1=O)C1=CC=CC=C1Cl",
        "id": "DB07257",
        "molecule": "4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione",
        "iupac_name": "4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methyl-1H,2H,3H,6H-pyrrolo[3,4-e]indole-1,3-dione",
        "inchi": {
            "hash": "WHMQZCPGFZBLBG-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H15ClN2O3/c1-22-9-10(6-7-23)15-14(22)8-12(11-4-2-3-5-13(11)20)16-17(15)19(25)21-18(16)24/h2-5,8-9,23H,6-7H2,1H3,(H,21,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 354.787,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 354.077120063,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrroloindoles. These are compounds containing a pyrroloindole moiety, which is a tricyclic heterocycle which consists of a pyrrole ring fused to an indole. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Indole is a bicyclic compound consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring.",
        "link": "https://go.drugbank.com/drugs/DB07257",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UWee1-like protein kinase"
            }
        ]
    },
    {
        "smiles": "O=C1COC(=O)CO1",
        "id": "DB16177",
        "molecule": "ABH001",
        "cas": "502-97-6",
        "iupac_name": "1,4-dioxane-2,5-dione",
        "background": "ABH001 is under investigation in clinical trial NCT01749306 (A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing).\n",
        "inchi": {
            "hash": "RKDVKSZUMVYZHH-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H4O4/c5-3-1-7-4(6)2-8-3/h1-2H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 116.072,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 116.010958609,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16177",
        "type": "Small Molecule",
        "synonyms": [
            "Glycolide"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)COC1=C(SC(=C1Br)C1=CC=CC(NCC2=CC=CC=C2)=C1)C(O)=O",
        "id": "DB07289",
        "molecule": "5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID",
        "iupac_name": "5-[3-(benzylamino)phenyl]-4-bromo-3-(carboxymethoxy)thiophene-2-carboxylic acid",
        "inchi": {
            "hash": "XEQPGVUGYAUMSA-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H16BrNO5S/c21-16-17(27-11-15(23)24)19(20(25)26)28-18(16)13-7-4-8-14(9-13)22-10-12-5-2-1-3-6-12/h1-9,22H,10-11H2,(H,23,24)(H,25,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 462.314,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 460.993255964,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.",
        "link": "https://go.drugbank.com/drugs/DB07289",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein phosphatase non-receptor type 1"
            }
        ]
    },
    {
        "smiles": "[H]N(C1=CC(=CC=C1)[N+]([O-])=O)S(=O)(=O)C1=C(SC=C1)C(O)=O",
        "id": "DB08306",
        "molecule": "3-[(3-Nitrophenyl)sulfamoyl]-2-thiophenecarboxylic acid",
        "cas": "850635-41-5",
        "iupac_name": "3-[(3-nitrophenyl)sulfamoyl]thiophene-2-carboxylic acid",
        "inchi": {
            "hash": "CITCNTPVKZFUAJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H8N2O6S2/c14-11(15)10-9(4-5-20-10)21(18,19)12-7-2-1-3-8(6-7)13(16)17/h1-6,12H,(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 328.321,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 327.982377378,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.",
        "link": "https://go.drugbank.com/drugs/DB08306",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "NC1=N[C@@](C2=CC=CC(F)=C12)(C1=CC=CC(=C1)C1=CN=CN=C1)C1=CC=NC(=C1)C(F)F",
        "id": "DB12368",
        "molecule": "AZD-3839",
        "cas": "1227163-84-9",
        "iupac_name": "(1S)-1-[2-(difluoromethyl)pyridin-4-yl]-4-fluoro-1-[3-(pyrimidin-5-yl)phenyl]-1H-isoindol-3-amine",
        "background": "AZD3839 has been used in trials studying the basic science of Safety, Tolerability, Alzheimer's Disease, and Blood Concentration.\n",
        "inchi": {
            "hash": "MRXBCEQZNKUUIP-DEOSSOPVSA-N",
            "id": "InChI=1S/C24H16F3N5/c25-19-6-2-5-18-21(19)23(28)32-24(18,17-7-8-31-20(10-17)22(26)27)16-4-1-3-14(9-16)15-11-29-13-30-12-15/h1-13,22H,(H2,28,32)/t24-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 431.422,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 431.135780024,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB12368",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C",
        "id": "DB13528",
        "molecule": "Chlormadinone",
        "cas": "1961-77-9",
        "iupac_name": "(1S,2R,10R,11S,14R,15S)-14-acetyl-8-chloro-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadeca-6,8-dien-5-one",
        "inchi": {
            "hash": "VUHJZBBCZGVNDZ-TTYLFXKOSA-N",
            "id": "InChI=1S/C21H27ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h10-11,14-16,25H,4-9H2,1-3H3/t14-,15+,16+,19-,20+,21+/m1/s1"
        },
        "summary": "Chlormadinone is a progestin indicated in combination with an estrogen for oral combined hormonal contraceptive therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 362.89,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 362.1648724,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB13528",
        "type": "Small Molecule",
        "synonyms": [
            "Chlormadinone"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)C1=CC(C(C)C)=C(CC(=O)NS(=O)(=O)OC2=C(C=CC=C2C(C)C)C(C)C)C(=C1)C(C)C",
        "id": "DB06442",
        "molecule": "Avasimibe",
        "cas": "166518-60-1",
        "iupac_name": "1-({[2,6-bis(propan-2-yl)phenoxy]sulfonyl}amino)-2-[2,4,6-tris(propan-2-yl)phenyl]ethan-1-one",
        "inchi": {
            "hash": "PTQXTEKSNBVPQJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32,33)34-29-23(18(3)4)12-11-13-24(29)19(5)6/h11-15,17-21H,16H2,1-10H3,(H,30,31)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 501.73,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 501.291280043,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aromatic monoterpenoids. These are monoterpenoids containing at least one aromatic ring.",
        "link": "https://go.drugbank.com/drugs/DB06442",
        "type": "Small Molecule",
        "synonyms": [
            "Avasimibe"
        ],
        "indication": "Investigated for use/treatment in peripheral vascular disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULiver carboxylesterase 1"
            }
        ]
    },
    {
        "smiles": "NC1=NC2=C(C(N)=N1)C(SC1=CC=C(C=C1)N1CCOCC1)=CC=C2",
        "id": "DB02001",
        "molecule": "5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine",
        "iupac_name": "5-{[4-(morpholin-4-yl)phenyl]sulfanyl}quinazoline-2,4-diamine",
        "inchi": {
            "hash": "CZLWCJRHDBTCGQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H19N5OS/c19-17-16-14(21-18(20)22-17)2-1-3-15(16)25-13-6-4-12(5-7-13)23-8-10-24-11-9-23/h1-7H,8-11H2,(H4,19,20,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 353.441,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 353.131030945,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.",
        "link": "https://go.drugbank.com/drugs/DB02001",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydrofolate reductase, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Yeast",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07679"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04159"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01735"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05712"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09064"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12453"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07140"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16143"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18486"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07347"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02936"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11059"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15919"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13925"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01609"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04736"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15639"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02736"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00291"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01075"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02172"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15690"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07367"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06892"
    },
    {
        "smiles": "CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)NC1=C(N=C(S1)C1=NC=CO1)C1=CC=CC=C1",
        "id": "DB12336",
        "molecule": "GDC-0917",
        "cas": "1446182-94-0",
        "iupac_name": "(2S)-1-[(2S)-2-cyclohexyl-2-[(2S)-2-(methylamino)propanamido]acetyl]-N-[2-(1,3-oxazol-2-yl)-4-phenyl-1,3-thiazol-5-yl]pyrrolidine-2-carboxamide",
        "background": "CUDC-427 has been used in trials studying the treatment of LYMPHOMA and Solid Cancers.\n",
        "inchi": {
            "hash": "HSHPBORBOJIXSQ-HARLFGEKSA-N",
            "id": "InChI=1S/C29H36N6O4S/c1-18(30-2)24(36)32-23(20-12-7-4-8-13-20)29(38)35-16-9-14-21(35)25(37)34-27-22(19-10-5-3-6-11-19)33-28(40-27)26-31-15-17-39-26/h3,5-6,10-11,15,17-18,20-21,23,30H,4,7-9,12-14,16H2,1-2H3,(H,32,36)(H,34,37)/t18-,21-,23-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 564.71,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 564.251874837,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB12336",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(CCCN1C(=O)CCC)C(=O)NCC1=CC=C(C=C1)C(N)=N",
        "id": "DB06929",
        "molecule": "1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
        "iupac_name": "(2S)-1-butanoyl-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide",
        "inchi": {
            "hash": "RYAZZWWVNUWKNB-AWEZNQCLSA-N",
            "id": "InChI=1S/C17H24N4O2/c1-2-4-15(22)21-10-3-5-14(21)17(23)20-11-12-6-8-13(9-7-12)16(18)19/h6-9,14H,2-5,10-11H2,1H3,(H3,18,19)(H,20,23)/t14-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 316.3981,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 316.189926032,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB06929",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1",
        "id": "DB11896",
        "molecule": "Gedatolisib",
        "cas": "1197160-78-3",
        "iupac_name": "1-{4-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}urea",
        "background": "Gedatolisib has been used in trials studying the basic science and treatment of Neoplasm, Ovary Cancer, Breast Cancer, Advanced Cancer, and Endometrial Cancer, among others.\n",
        "inchi": {
            "hash": "DWZAEMINVBZMHQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 615.739,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 615.328150836,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-benzoylpiperidines. These are compounds containing a piperidine ring substituted at the 1-position with a benzoyl group.",
        "link": "https://go.drugbank.com/drugs/DB11896",
        "type": "Small Molecule",
        "synonyms": [
            "Gedatolisib"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](CC1=CC=CC=C1)(N(CC1=CC(=CC=C1)C(F)(F)F)C(=O)C1=C(Cl)C=C(Cl)C=C1)C(O)=O",
        "id": "DB03605",
        "molecule": "(2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid",
        "iupac_name": "(2S)-2-[1-(2,4-dichlorophenyl)-N-{[3-(trifluoromethyl)phenyl]methyl}formamido]-3-phenylpropanoic acid",
        "inchi": {
            "hash": "LAJJKGIZTCCOHY-NRFANRHFSA-N",
            "id": "InChI=1S/C24H18Cl2F3NO3/c25-18-9-10-19(20(26)13-18)22(31)30(14-16-7-4-8-17(11-16)24(27,28)29)21(23(32)33)12-15-5-2-1-3-6-15/h1-11,13,21H,12,14H2,(H,32,33)/t21-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 496.306,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 495.061583476,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB03605",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Hepatitis C virus genotype 1b (isolate BK)",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "smiles": "CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS([O-])(=O)=O)C3=CC=C4C=CC=CC4=C3C2(C)C)N(CCCCS(O)(=O)=O)C2=CC=C3C=CC=CC3=C12",
        "id": "DB09374",
        "molecule": "Indocyanine green acid formCommonly known or available as Indocyanine green",
        "cas": "28782-33-4",
        "iupac_name": "2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-1H,2H,3H-benzo[e]indol-2-ylidene]hepta-1,3,5-trien-1-yl}-1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-3-ium",
        "background": "Indocyanine Green is a water soluble, tricarbocyanine dye with a peak spectral absorption at 800 nm. The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide, inner salt, sodium salt. Indocyanine Green for Injection USP has a pH of approximately 6.5 when reconstituted. Each vial of Indocyanine Green for Injection USP contains 25 mg of Indocyanine Green as a sterile lyophilized powder with no more than 5% sodium iodide.\n",
        "inchi": {
            "hash": "BDBMLMBYCXNVMC-UHFFFAOYSA-N",
            "id": "InChI=1S/C43H48N2O6S2/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51)"
        },
        "summary": "Indocyanine green is a diagnostic agent used for the determination of cardiac output, hepatic function and liver blood flow, and for ophthalmic angiography.",
        "weight": [
            {
                "type": "average",
                "weight": 752.99,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 752.295379622,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB09374",
        "type": "Small Molecule",
        "indication": "For Determining Cardiac Output, Hepatic Function and Liver Blood Flow\nFor ophthalmic angiography\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O",
        "id": "DB11938",
        "molecule": "Difelikefalin",
        "cas": "1024828-77-0",
        "iupac_name": "4-amino-1-[(2R)-6-amino-2-[(2R)-2-[(2R)-2-[(2R)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-4-methylpentanamido]hexanoyl]piperidine-4-carboxylic acid",
        "background": "Difelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984.1 Further investigations revealed that dynorphins, endogenous agonists of KORs, work to inhibit the itching sensation at the spinal cord level, and scratching could be elicited in mouse models with the administration of KOR antagonists.1 These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.\nPruritus associated with chronic kidney disease (also called uremic pruritus) affects 50-60% of all patients on dialysis and 25% of non-dialysis patients with chronic kidney disease.2,3 The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes, and even mortality.3 Options for therapy are limited - with no FDA-approved treatments, off-label gabapentin was the most evidence-based and widely available treatment.3\nDifelikefalin received FDA approval in August 2021 (under the brand name Korsuva), becoming the first FDA-approved therapy for patients with chronic kidney disease suffering from uremic pruritus.5,4 Difelikefalin was later approved by the EMA in April 2022 for the same indication.7\n",
        "inchi": {
            "hash": "FWMNVWWHGCHHJJ-SKKKGAJSSA-N",
            "id": "InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1"
        },
        "summary": "Difelikefalin is a kappa opioid receptor agonist used in the treatment of pruritus associated with chronic kidney disease in patients undergoing hemodialysis.",
        "weight": [
            {
                "type": "average",
                "weight": 679.863,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 679.405732455,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB11938",
        "type": "Small Molecule",
        "synonyms": [
            "Difelikefalin"
        ],
        "indication": "Difelikefalin is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP; uremic pruritus) in adults undergoing hemodialysis.4,6\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Difelikefalin is administered to patients undergoing hemodialysis for chronic kidney disease (CKD) to prevent and treat the pruritus often associated with CKD. It is administered via bolus intravenous injection at the end of each hemodialysis treatment.4 As it works on opioid receptors, difelikefalin can cause dizziness, somnolence, and other CNS depressant effects that may impair mental or physical abilities - as such, patients should be advised to avoid operating dangerous machinery until the effect of difelikefalin on that patient is known.4\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AKappa-type opioid receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08520"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07987"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11072"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08678"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07239"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04296"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15304"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13461"
    },
    {
        "smiles": "CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F",
        "id": "DB01218",
        "molecule": "Halofantrine",
        "cas": "69756-53-2",
        "iupac_name": "3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol",
        "background": "Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme \"heme polymerase\"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.\n",
        "inchi": {
            "hash": "FOHHNHSLJDZUGQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3"
        },
        "summary": "Halofantrine is an antimalarial used for the treatment of severe malaria.",
        "weight": [
            {
                "type": "average",
                "weight": 500.424,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 499.165654616,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.",
        "link": "https://go.drugbank.com/drugs/DB01218",
        "type": "Small Molecule",
        "synonyms": [
            "Halofantrina",
            "Halofantrine",
            "Halofantrinum"
        ],
        "indication": "For treatment of Severe malaria\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Halofantrine is a synthetic antimalarial which acts as a blood schizonticide. It is effective against multi drug resistant (including mefloquine resistant) P. falciparum malaria.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Plasmodium falciparum",
                "target": "AFe(II)-protoporphyrin IX"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "APotassium voltage-gated channel subfamily H member 2"
            },
            {
                "action": "inhibitor",
                "organism": "Plasmodium falciparum",
                "target": "UPlasmepsin-2"
            }
        ]
    },
    {
        "smiles": "[H]C(Cl)(Br)C(F)(F)F",
        "id": "DB01159",
        "molecule": "Halothane",
        "cas": "151-67-7",
        "iupac_name": "2-bromo-2-chloro-1,1,1-trifluoroethane",
        "background": "A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)\n",
        "inchi": {
            "hash": "BCQZXOMGPXTTIC-UHFFFAOYSA-N",
            "id": "InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H"
        },
        "summary": "Halothane is a general inhalation anesthetic used for the induction and maintenance of general anesthesia.",
        "weight": [
            {
                "type": "average",
                "weight": 197.382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 195.890225001,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.",
        "link": "https://go.drugbank.com/drugs/DB01159",
        "type": "Small Molecule",
        "synonyms": [
            "1-bromo-1-chloro-2,2,2-trifluoroethane",
            "1,1,1-trifluoro-2-bromo-2-chloroethane",
            "1,1,1-trifluoro-2-chloro-2-bromoethane",
            "2-bromo-2-chloro-1,1,1-trifluoroethane",
            "2,2,2-trifluoro-1-chloro-1-bromoethane",
            "Alotano",
            "Bromochlorotrifluoroethane",
            "Halotano",
            "Halothane",
            "Halothanum"
        ],
        "indication": "For the induction and maintenance of general anesthesia\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Halothane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It reduces the blood pressure and frequently decreases the pulse rate and depresses respiration. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.\n",
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "APotassium channel subfamily K member 3"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "APotassium channel subfamily K member 9"
            },
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "APlasma membrane calcium-transporting ATPase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCalcium-activated potassium channel subunit alpha-1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, NMDA 3A"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, NMDA 3B"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, NMDA 2A"
            },
            {
                "action": "allosteric modulator",
                "organism": "Humans",
                "target": "UGlycine receptor subunit alpha-1"
            },
            {
                "action": "other",
                "organism": "Humans",
                "target": "URhodopsin"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UG protein-activated inward rectifier potassium channel 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UG protein-activated inward rectifier potassium channel 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UNADH-ubiquinone oxidoreductase chain 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UIntermediate conductance calcium-activated potassium channel protein 4"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "UGamma-aminobutyric acid receptor subunit alpha-1"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "UGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "UNeuropeptide S receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03998"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00467"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12758"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02202"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01416"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03028"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09096"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08571"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11164"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13618"
    },
    {
        "smiles": "CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1",
        "id": "DB09061",
        "molecule": "Cannabidiol",
        "cas": "13956-29-1",
        "iupac_name": "2-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol",
        "background": "Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses 6,5. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy.\nFrom a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body 11. Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)12,8. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals 9.\nTetrahydrocannabinol (THC) and cannabidiol (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors that are found throughout the body. Although THC and CBD have been the most studied cannabinoids, there are many others identified to date including cannabinol (CBN), cannabigerol (CBG), Cannabidivarin (CBDV), and Tetrahydrocannabivarin (THCV) that can be found within the medical cannabis 10. While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms of THC like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.\nThe primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body 5. Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site which is clinically significant as direct agonists (such as THC) are limited by their psychomimetic effects such as changes to mood, memory, and anxiety5. \nIn addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV12 vanilloid receptors, antagonizes alpha-1 adrenergic and -opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) 1,2.\nCBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as \"nabiximols\") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer 18.\nIn April 2018, a Food and Drug Administration advisory panel unanimously recommended approval of Epidiolex (cannabidiol oral solution) for the treatment of two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome, which are among the two most difficult types of epilepsy to treat 21,19. Epidiolex was granted Orphan Drug designation as well as Fast Track Approval from the FDA for further study in these hard to treat conditions. Notably, phase 3 clinical trials of Epidiolex have demonstrated clinically significant improvement in Lennox-Gastaut syndrome and Dravet syndrome 20. On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market.\n",
        "inchi": {
            "hash": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
            "id": "InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1"
        },
        "summary": "Cannabidiol is an active cannabinoid used as an adjunctive treatment for the management of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome and symptomatic relief of moderate to severe neuropathic pain or other painful conditions, like cancer.",
        "weight": [
            {
                "type": "average",
                "weight": 314.469,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 314.224580206,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aromatic monoterpenoids. These are monoterpenoids containing at least one aromatic ring.",
        "link": "https://go.drugbank.com/drugs/DB09061",
        "type": "Small Molecule",
        "synonyms": [
            ".DELTA.1(2)-TRANS-CANNABIDIOL",
            "()-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol",
            "()-trans-cannabidiol",
            "(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol",
            "Cannabidiol",
            "CBD",
            "1(2)-trans-cannabidiol"
        ],
        "indication": "When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:\n1) as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy 18;\nDue to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence, Sativex was also given a Notice of Compliance with Conditions (NOC/c) by Health Canada for the following indications:\n1) as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis;\n2) as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain 18.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Although the exact mechanism and magnitude of effects of THC and CBD are not fully understood, CBD has been shown to have analgesic, anticonvulsant, muscle relaxant, anxiolytic, neuroprotective, anti-oxidant, and anti-psychotic activity. This wide variety of effects is likely due to it's complex pharmacological mechanisms. In addition to binding to CB1 and CB2 receptors of the endocannabinoid system, there is evidence that CBD activates 5-HT1A serotonergic and TRPV12 vanilloid receptors, antagonizes alpha-1 adrenergic and -opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gaminobutyric acid and cellular uptake of anandamide, acts on mitochondria Ca2 stores, blocks low-voltage-activated (T-type) Ca2 channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) 1,2.\n",
        "moa": [
            {
                "action": "antagonistmodulator",
                "organism": "Humans",
                "target": "ACannabinoid receptor 1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UCannabinoid receptor 2"
            },
            {
                "action": "inverse agonist",
                "organism": "Humans",
                "target": "UG-protein coupled receptor 12"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycine receptor subunit alpha-1"
            },
            {
                "action": "allosteric modulator",
                "organism": "Humans",
                "target": "UGlycine receptor (alpha-1/beta)"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "UGlycine receptor subunit alpha-3"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UN-arachidonyl glycine receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UG-protein coupled receptor 55"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1A"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-7"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDelta-type opioid receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMu-type opioid receptor"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UPeroxisome proliferator-activated receptor gamma"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UTransient receptor potential cation channel subfamily V member 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UVoltage-dependent T-type calcium channel subunit alpha-1G"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UVoltage-dependent T-type calcium channel subunit alpha-1H"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UVoltage-dependent T-type calcium channel subunit alpha-1I"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UTransient receptor potential cation channel subfamily A member 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTransient receptor potential cation channel subfamily M member 8"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UTransient receptor potential cation channel subfamily V member 2"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UTransient receptor potential cation channel subfamily V member 3"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UTransient receptor potential cation channel subfamily V member 4"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UVoltage-dependent anion-selective channel protein 1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 3A"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UAdenosine receptor A1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UAcetyl-CoA acetyltransferase, mitochondrial"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "USteroid 17-alpha-hydroxylase/17,20 lyase"
            },
            {
                "action": "stimulator",
                "organism": "Humans",
                "target": "U3-hydroxy-3-methylglutaryl-coenzyme A reductase"
            },
            {
                "action": "stimulator",
                "organism": "Humans",
                "target": "UGlutathione reductase, mitochondrial"
            },
            {
                "action": "stimulator",
                "organism": "Humans",
                "target": "UGlutathione peroxidase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UIndoleamine 2,3-dioxygenase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 1B1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UNAD(P)H dehydrogenase [quinone] 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCatalase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 3A5"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 2D6"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "USuperoxide dismutase [Cu-Zn]"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 1A2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 3A7"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UArylalkylamine N-acetyltransferase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UN-acylethanolamine-hydrolyzing acid amidase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08777"
    },
    {
        "smiles": "CCCCCCCC\\C=C/CCCCCCC(O)C(O)=O",
        "id": "DB18213",
        "molecule": "Idroxioleic acid",
        "cas": "56472-29-8",
        "inchi": {
            "hash": "JBSOOFITVPOOSY-KTKRTIGZSA-N",
            "id": "InChI=1S/C18H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h9-10,17,19H,2-8,11-16H2,1H3,(H,20,21)/b10-9-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 298.467,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 298.250794955,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18213",
        "type": "Small Molecule",
        "synonyms": [
            "(z)-2-hydroxyoctadec-9-enoic acid",
            "2-hydroxyoleic acid",
            "9-octadecenoic acid, 2-hydroxy-, (9z)-",
            "Alpha-hydroxyoleic acid",
            "Cis-2-hydroxy-9-octadecenoic acid",
            "Minerval",
            "Rac-(2r,9z)-2-hydroxyoctadec-9-enoic acid"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](N)(C(O)=O)[C@@]([H])(O)OS(O)(=O)=O",
        "id": "DB02735",
        "molecule": "2-Amino-3-Oxo-4-Sulfo-Butyric Acid",
        "iupac_name": "(2S,3S)-2-amino-3-hydroxy-3-(sulfooxy)propanoic acid",
        "inchi": {
            "hash": "MNJOBAOHZQQXIK-GPKNORDASA-N",
            "id": "InChI=1S/C3H7NO7S/c4-1(2(5)6)3(7)11-12(8,9)10/h1,3,7H,4H2,(H,5,6)(H,8,9,10)/t1-,3+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 201.15,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 200.994322743,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as serine and derivatives. These are compounds containing serine or a derivative thereof resulting from reaction of serine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB02735",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USteryl-sulfatase"
            }
        ]
    },
    {
        "smiles": "COC(=O)[C@H]1[C@@H]2C[C@@H](C=C2)[C@H]1C(=O)OC",
        "id": "DB13204",
        "molecule": "Dimethyl carbate",
        "cas": "39589-98-5",
        "iupac_name": "2,3-dimethyl (1R,2S,3R,4S)-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate",
        "background": "Dimethyl carbate is used as an insect repellant.\n",
        "inchi": {
            "hash": "VGQLNJWOULYVFV-SPJNRGJMSA-N",
            "id": "InChI=1S/C11H14O4/c1-14-10(12)8-6-3-4-7(5-6)9(8)11(13)15-2/h3-4,6-9H,5H2,1-2H3/t6-,7+,8-,9+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 210.229,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 210.089208931,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dicarboxylic acids and derivatives. These are organic compounds containing exactly two carboxylic acid groups.",
        "link": "https://go.drugbank.com/drugs/DB13204",
        "type": "Small Molecule",
        "synonyms": [
            "Dimethylcarbate"
        ],
        "is_stub": true
    },
    {
        "smiles": "[123I-]",
        "id": "DB09420",
        "molecule": "Iodide I-123",
        "cas": "69239-56-1",
        "iupac_name": "(123I)iodide",
        "background": "Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123.\nIodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131.\n",
        "inchi": {
            "hash": "XMBWDFGMSWQBCA-AHCXROLUSA-M",
            "id": "InChI=1S/HI/h1H/p-1/i1-4"
        },
        "summary": "Iodide I-123 is a radiopharmaceutical diagnostic agent used for the evaluation of the thyroid function and/or morphology.",
        "weight": [
            {
                "type": "average",
                "weight": 122.9061,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 122.906146524,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous halogens. These are inorganic non-metallic compounds in which the largest atom is a nobel gas.",
        "link": "https://go.drugbank.com/drugs/DB09420",
        "type": "Small Molecule",
        "synonyms": [
            "123I",
            "I 123",
            "I-123",
            "Iodide ion i-123",
            "Iodine 123",
            "Iodine-123"
        ],
        "indication": "Administration of Sodium Iodide I 123 Capsules is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[H]N(CCC)C(=O)[C@H](O)[C@@H](O)C(O)=O",
        "id": "DB03390",
        "molecule": "(2R,3R)-2,3-Dihydroxy-4-oxo-4-(propylamino)butanoic acid",
        "iupac_name": "(2R,3R)-2,3-dihydroxy-3-(propylcarbamoyl)propanoic acid",
        "inchi": {
            "hash": "LNEZKQHJUNIZIS-RFZPGFLSSA-N",
            "id": "InChI=1S/C7H13NO5/c1-2-3-8-6(11)4(9)5(10)7(12)13/h4-5,9-10H,2-3H2,1H3,(H,8,11)(H,12,13)/t4-,5-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 191.1818,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 191.079372531,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB03390",
        "type": "Small Molecule",
        "synonyms": [
            "N-Propyl-L-tartramate",
            "N-Propyl-tartramic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProstatic acid phosphatase"
            }
        ]
    },
    {
        "smiles": "[H][C@](N)(CC1=CC=C(C=C1)C1=CC=CC=C1)C(O)=O",
        "id": "DB04639",
        "molecule": "Biphenylalanine",
        "iupac_name": "(2S)-2-amino-3-{[1,1'-biphenyl]-4-yl}propanoic acid",
        "inchi": {
            "hash": "JCZLABDVDPYLRZ-AWEZNQCLSA-N",
            "id": "InChI=1S/C15H15NO2/c16-14(15(17)18)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9,14H,10,16H2,(H,17,18)/t14-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 241.2851,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 241.110278729,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB04639",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIg gamma-1 chain C region"
            },
            {
                "action": "Not Available",
                "organism": "",
                "target": "UEnvelope glycoprotein gp160"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CCC(=O)N[C@@H](C[S@](O)=O)C(=O)NCC(O)=O)C(O)=O",
        "id": "DB04700",
        "molecule": "GLUTATHIONE SULFINATE",
        "iupac_name": "(2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-[(S)-sulfino]ethyl]carbamoyl}butanoic acid",
        "inchi": {
            "hash": "DMAPAHUEYHXRFI-WDSKDSINSA-N",
            "id": "InChI=1S/C10H17N3O8S/c11-5(10(18)19)1-2-7(14)13-6(4-22(20)21)9(17)12-3-8(15)16/h5-6H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)(H,20,21)/t5-,6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 339.322,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 339.073635225,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB04700",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione S-transferase kappa 1"
            }
        ]
    },
    {
        "smiles": "C[C@H](OC1=CC=C(C=C1C(=O)N1CCN(CC1)C1=C(F)C=C(C=N1)C(F)(F)F)S(C)(=O)=O)C(F)(F)F",
        "id": "DB12426",
        "molecule": "Bitopertin",
        "cas": "845614-11-1",
        "iupac_name": "1-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-4-(5-methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzoyl)piperazine",
        "background": "Bitopertin has been used in trials studying the treatment of Schizophrenia and Obsessive-Compulsive Disorder.\n",
        "inchi": {
            "hash": "YUUGYIUSCYNSQR-LBPRGKRZSA-N",
            "id": "InChI=1S/C21H20F7N3O4S/c1-12(20(23,24)25)35-17-4-3-14(36(2,33)34)10-15(17)19(32)31-7-5-30(6-8-31)18-16(22)9-13(11-29-18)21(26,27)28/h3-4,9-12H,5-8H2,1-2H3/t12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 543.46,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 543.106274451,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.",
        "link": "https://go.drugbank.com/drugs/DB12426",
        "type": "Small Molecule",
        "synonyms": [
            "Bitopertin"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCOCC(CN1C(=O)NC(=O)C(CC)(C1=O)C1=CC=CC=C1)OC(N)=O",
        "id": "DB13303",
        "molecule": "Febarbamate",
        "cas": "13246-02-1",
        "iupac_name": "1-butoxy-3-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)propan-2-yl carbamate",
        "inchi": {
            "hash": "QHZQILHUJDRDAI-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H27N3O6/c1-3-5-11-28-13-15(29-18(21)26)12-23-17(25)20(4-2,16(24)22-19(23)27)14-9-7-6-8-10-14/h6-10,15H,3-5,11-13H2,1-2H3,(H2,21,26)(H,22,24,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 405.451,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 405.189985601,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.",
        "link": "https://go.drugbank.com/drugs/DB13303",
        "type": "Small Molecule",
        "synonyms": [
            "Febarbamate",
            "Febarbamato",
            "Febarbamatum",
            "Phebarbamate",
            "Phenobamate"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]N1C(C)=C([C@@H](C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCCN2CCC(CC2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C)C(=O)OC",
        "id": "DB14068",
        "molecule": "Dexniguldipine",
        "cas": "120054-86-6",
        "iupac_name": "3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate",
        "inchi": {
            "hash": "SVJMLYUFVDMUHP-MGBGTMOVSA-N",
            "id": "InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3/t33-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 609.723,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 609.283885988,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14068",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-niguldipine",
            "(R)-niguldipine",
            "Dexniguldipine"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UP-glycoprotein 1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02238"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04368"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08733"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15445"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08889"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07698"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08865"
    },
    {
        "smiles": "[H]N([H])S(=O)(=O)C1=CC=C(C=C1)C(=O)N([H])C[C@H](C)CN1C=CC2=CC=CC=C12",
        "id": "DB03950",
        "molecule": "(S)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide",
        "iupac_name": "N-[(2S)-3-(1H-indol-1-yl)-2-methylpropyl]-4-sulfamoylbenzamide",
        "inchi": {
            "hash": "ZFWHOUCRVSOZJE-AWEZNQCLSA-N",
            "id": "InChI=1S/C19H21N3O3S/c1-14(13-22-11-10-15-4-2-3-5-18(15)22)12-21-19(23)16-6-8-17(9-7-16)26(20,24)25/h2-11,14H,12-13H2,1H3,(H,21,23)(H2,20,24,25)/t14-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 371.453,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 371.130362243,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB03950",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O",
        "id": "DB06705",
        "molecule": "Gadofosveset trisodium",
        "cas": "193901-90-5",
        "background": "Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.\n",
        "inchi": {
            "hash": "XGOSYNSWSRUASG-SSMZTGFVSA-H",
            "id": "InChI=1S/C33H44N3O14P.Gd.3Na/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;;;;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);;;;/q;+3;3*+1/p-6/t26-;;;;/m1..../s1"
        },
        "summary": "Gadofosveset trisodium is an intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease.",
        "weight": [
            {
                "type": "average",
                "weight": 1003.85,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1004.081,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06705",
        "type": "Small Molecule",
        "synonyms": [
            "Gadofosveset"
        ],
        "indication": "Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Gadofosveset causes signal enhancement by shortening the T1 of water molecules that interact with it. The contrast agent complex's rotation rate is the primary factor determining the magnitude of relaxation enhancement. This relaxation enhancement increase only occurs when bound to human serum albumin. \n"
    },
    {
        "smiles": "C[C@H](NC1=NC(=O)[C@](C)(S1)C(F)(F)F)C1=C(F)C=CC=C1",
        "id": "DB07310",
        "molecule": "(5S)-2-{[(1S)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one",
        "iupac_name": "(5S)-2-{[(1S)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-4,5-dihydro-1,3-thiazol-4-one",
        "inchi": {
            "hash": "KNHNFKZUNFPPQE-MADCSZMMSA-N",
            "id": "InChI=1S/C13H12F4N2OS/c1-7(8-5-3-4-6-9(8)14)18-11-19-10(20)12(2,21-11)13(15,16)17/h3-7H,1-2H3,(H,18,19,20)/t7-,12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 320.306,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 320.060646526,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB07310",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 1"
            }
        ]
    },
    {
        "smiles": "[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O",
        "id": "DB09275",
        "molecule": "Bismuth subcitrate potassium",
        "cas": "880149-29-1",
        "iupac_name": "bismuth(3+) pentapotassium bis(2-oxidopropane-1,2,3-tricarboxylate)",
        "background": "A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).\n",
        "inchi": {
            "hash": "YDDTTXDPCSCLKY-UHFFFAOYSA-H",
            "id": "InChI=1S/2C6H7O7.Bi.5K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;/h2*1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;;/q2*-1;+3;5*+1/p-6"
        },
        "summary": "Bismuth subcitrate potassium is a colloid used for the treatment of peptic ulcer and gastro-esophageal reflux disease (GERD).",
        "weight": [
            {
                "type": "average",
                "weight": 780.654,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 779.79034,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB09275",
        "type": "Small Molecule",
        "synonyms": [
            "Bismuth subcitrate potassium anhydrous"
        ],
        "indication": "For the treatment of peptic ulcer and gastro-oesophageal reflux disease (GORD).\nTreatment of inflammatory and erosive-ulcerous diseases of gastric and duodenal mucosa: gastritis, ulcer disease of the stomach and duodenum, functional non-ulcerous dyspepsia, erosive duodenitis, post-operative inflammatory and erosive changes  anastomositis, peptic ulcer of anastomosis\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bismuth subcitrate is very effective in the treatment of gastroduodenal disorders and appears to act via several mechanisms. It has little acid-neutralizing effect and does not affect acid secretion.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Helicobacter pylori (strain ATCC 700392 / 26695)",
                "target": "UATP-dependent Clp protease ATP-binding subunit ClpX"
            }
        ]
    },
    {
        "smiles": "CC1=CC(=O)OC2=C1C=CC(O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=C2",
        "id": "DB02639",
        "molecule": "7-(alpha-D-Glucopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one",
        "cas": "17833-43-1",
        "iupac_name": "4-methyl-7-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2H-chromen-2-one",
        "inchi": {
            "hash": "YUDPTGPSBJVHCN-JZYAIQKZSA-N",
            "id": "InChI=1S/C16H18O8/c1-7-4-12(18)23-10-5-8(2-3-9(7)10)22-16-15(21)14(20)13(19)11(6-17)24-16/h2-5,11,13-17,19-21H,6H2,1H3/t11-,13-,14+,15-,16+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 338.3093,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 338.100167552,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as coumarin glycosides. These are aromatic compounds containing a carbohydrate moiety glycosidically bound to a coumarin moiety.",
        "link": "https://go.drugbank.com/drugs/DB02639",
        "type": "Small Molecule",
        "synonyms": [
            "4-Methylumbelliferyl a-D-glucopyranoside",
            "4-Methylumbelliferyl -D-glucoside",
            "7-(alpha-D-Glucopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one",
            "7-(-D-glucopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one"
        ]
    },
    {
        "smiles": "CCC1=CC=C(O1)\\C=C1/SC(N[C@H](C(O)=O)C2=CC=C(F)C=C2)=NC1=O",
        "id": "DB08706",
        "molecule": "(2S)-({(5Z)-5-[(5-Ethyl-2-furyl)methylene]-4-oxo-4,5-dihydro-1,3-thiazol-2-yl}amino)(4-fluorophenyl)acetic acid",
        "iupac_name": "(2S)-2-{[(5Z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}-2-(4-fluorophenyl)acetic acid",
        "inchi": {
            "hash": "RNEACARJKXYVND-MZLJFPOFSA-N",
            "id": "InChI=1S/C18H15FN2O4S/c1-2-12-7-8-13(25-12)9-14-16(22)21-18(26-14)20-15(17(23)24)10-3-5-11(19)6-4-10/h3-9,15H,2H2,1H3,(H,23,24)(H,20,21,22)/b14-9-/t15-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 374.386,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 374.073655873,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB08706",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Hepatitis C virus genotype 1b (isolate BK)",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04369"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03315"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15907"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03096"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08236"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02158"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07766"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00612"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01525"
    },
    {
        "smiles": "CCC1=NC2=C(C)N=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1",
        "id": "DB12836",
        "molecule": "Grapiprant",
        "cas": "415903-37-6",
        "iupac_name": "3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-(4-methylbenzenesulfonyl)urea",
        "background": "Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin receptor antagonists.7 This type of molecules is currently in development for veterinary patients.1 This class of drugs was defined in 2013 by the World Health Organization.11 \nGrapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.5\n",
        "inchi": {
            "hash": "HZVLFTCYCLXTGV-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H29N5O3S/c1-5-24-29-25-19(4)28-18(3)16-23(25)31(24)21-10-8-20(9-11-21)14-15-27-26(32)30-35(33,34)22-12-6-17(2)7-13-22/h6-13,16H,5,14-15H2,1-4H3,(H2,27,30,32)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 491.61,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 491.199110988,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB12836",
        "type": "Small Molecule",
        "synonyms": [
            "Grapiprant"
        ],
        "indication": "The effects of grapiprant have been investigated in the area of analgesia and anti-inflammation due to the effects that have been reported about this molecule.1\nThis molecule has been approved and widely accepted to be used in veterinary for pain reduction in arthritis.4 In humans, it has been researched to be used in the control of pain and inflammation associated with osteoarthritis.10,9\nThe effect of grapiprant can be explained through the function of prostaglandin E2 (PGE2) which is a key mediator of swelling redness and pain which are classic signs of inflammation. The effect of PGE2 results from its action through four receptor EP1, EP2, EP3 and EP4 from which the EP4 is the primary mediator of PGE2-driven inflammation.2\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Preclinical studies have shown that grapiprant is very effective to reduce acute and chronic pain and inflammation. The effect of grapiprant seems to be dose-dependent and it is comparable to the effect of rofecoxib and piroxicam.3\nThe effects of grapiprant have been reported to be effective in the relief from arthritic pain in canine patients. 1\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP4 subtype"
            }
        ]
    },
    {
        "smiles": "CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1",
        "id": "DB08808",
        "molecule": "Bupranolol",
        "cas": "14556-46-8",
        "iupac_name": "1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol",
        "background": "Bupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.\n",
        "inchi": {
            "hash": "HQIRNZOQPUAHHV-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 271.783,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 271.13390666,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08808",
        "type": "Small Molecule",
        "synonyms": [
            "Bupranolol",
            "Bupranololum"
        ],
        "indication": "Used to manage hypertension and tachycardia. Also used to treat glaucoma.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bupranolol is a competitive, nonselective beta-blocker similar to propanolol without intrinsic sympathomimetic activity.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ABeta-1 adrenergic receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UBeta-2 adrenergic receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UBeta-3 adrenergic receptor"
            }
        ]
    },
    {
        "smiles": "CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC",
        "id": "DB00381",
        "molecule": "Amlodipine",
        "cas": "88150-42-9",
        "iupac_name": "3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate",
        "background": "Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers 5.\nAmlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure 3. The option for single daily dosing of amlodipine is an attractive feature of this drug Label.\n",
        "inchi": {
            "hash": "HTIQEAQVCYTUBX-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3"
        },
        "summary": "Amlodipine is a calcium channel blocker used to treat hypertension and angina.",
        "weight": [
            {
                "type": "average",
                "weight": 408.876,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 408.145199627,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.",
        "link": "https://go.drugbank.com/drugs/DB00381",
        "type": "Small Molecule",
        "synonyms": [
            "(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate",
            "3-Ethyl 5-methylester, ()-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate",
            "Amlodipine",
            "Amlodipine free base",
            "Amlodipino",
            "Amlodipinum"
        ],
        "indication": "Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions Label:\n Hypertension \n Coronary artery disease\n Chronic stable angina\n Vasospastic angina (Prinzmetals or Variant angina) \n Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction \u003c 40%\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "General pharmacodynamic effects\nAmlodipine has a strong affinity for cell membranes, modulating calcium influx by inhibiting selected membrane calcium channels. This drug's unique binding properties allow for its long-acting action and less frequent dosing regimen 1, Label. \nHemodynamic effects\nAfter the administration of therapeutic doses of amlodipine to patients diagnosed with hypertension, amlodipine causes vasodilation, which results in a reduction of supine and standing blood pressure. During these blood pressure reductions, there are no clinically significant changes in heart rate or plasma catecholamine levels with long-term use. Acute intravenous administration of amlodipine reduces arterial blood pressure and increases heart rate in patients with chronic stable angina, however, chronic oral administration of amlodipine in clinical studies did not cause clinically significant alterations in heart rate or blood pressures in patients diagnosed with angina and normal blood pressure. With long-term, once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours Label. \nElectrophysiologic effects\nAmlodipine does not change sinoatrial (SA) nodal function or atrioventricular (AV) conduction in animals or humans. In patients who were diagnosed with chronic stable angina, the intravenous administration of 10 mg of amlodipine did not cause clinically significant alterations A-H and H-V conduction and sinus node recovery time after cardiac pacing. Patients administered amlodipine with concomitant beta-blockers produced similar results. In clinical trials in which amlodipine was given in combination with beta-blockers to patients diagnosed with hypertension or angina, no adverse effects on electrocardiographic parameters were noted. In clinical studies comprised of angina patients alone, amlodipine did not change electrocardiographic intervals or produce high degrees of AV block Label. \nEffects on angina\nAmlodipine relieves the symptoms of chest pain associated with angina. In patients diagnosed with angina, daily administration of a single amlodipine dose increases total exercise time, the time to angina onset, and the time to 1 mm ST-segment depression on ECG studies, decreases anginal attack frequency, and decreases the requirement for nitroglycerin tablets 9. \n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AVoltage-dependent L-type calcium channel subunit alpha-1C"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AVoltage-dependent T-type calcium channel subunit alpha-1I"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UVoltage-dependent N-type calcium channel subunit alpha-1B"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UVoltage-dependent L-type calcium channel subunit beta-1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UVoltage-dependent calcium channel subunit alpha-2/delta-3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "USphingomyelin phosphodiesterase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UVoltage-dependent N-type calcium channel"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB14541",
        "molecule": "Hydrocortisone cypionate",
        "cas": "508-99-6",
        "iupac_name": "2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl 3-cyclopentylpropanoate",
        "inchi": {
            "hash": "DLVOSEUFIRPIRM-KAQKJVHQSA-N",
            "id": "InChI=1S/C29H42O6/c1-27-13-11-20(30)15-19(27)8-9-21-22-12-14-29(34,28(22,2)16-23(31)26(21)27)24(32)17-35-25(33)10-7-18-5-3-4-6-18/h15,18,21-23,26,31,34H,3-14,16-17H2,1-2H3/t21-,22-,23-,26+,27-,28-,29-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 486.649,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 486.298139072,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB14541",
        "type": "Small Molecule",
        "synonyms": [
            "Cortisol 21-cyclopentanepropionate",
            "Hydrocortisone cipionate"
        ],
        "indication": "For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AAnnexin A1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AGlucocorticoid receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U3 beta-hydroxysteroid dehydrogenase/Delta 5--\u003e4-isomerase type 1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01446"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09168"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12115"
    },
    {
        "smiles": "CCN(C)C(=O)C1=CC=C(C=C1F)C1=NC2=C(C=C1)[C@H](C1=CC=CC=C1O2)C(C)(C)C(=O)NC1=NN=CS1",
        "id": "DB15023",
        "molecule": "BMS-791826",
        "cas": "1008116-73-1",
        "iupac_name": "N-ethyl-2-fluoro-N-methyl-4-[(5S)-5-{1-methyl-1-[(1,3,4-thiadiazol-2-yl)carbamoyl]ethyl}-5H-chromeno[2,3-b]pyridin-2-yl]benzamide",
        "background": "BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).\n",
        "inchi": {
            "hash": "DZBKAUMYTFPJIS-QHCPKHFHSA-N",
            "id": "InChI=1S/C28H26FN5O3S/c1-5-34(4)25(35)17-11-10-16(14-20(17)29)21-13-12-19-23(18-8-6-7-9-22(18)37-24(19)31-21)28(2,3)26(36)32-27-33-30-15-38-27/h6-15,23H,5H2,1-4H3,(H,32,33,36)/t23-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 531.61,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 531.174039054,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15023",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[I-]",
        "id": "DB12754",
        "molecule": "Iodide",
        "cas": "20461-54-5",
        "iupac_name": "iodide",
        "background": "Iodide has been investigated for the treatment of Goiter, Nodular.\n",
        "inchi": {
            "hash": "XMBWDFGMSWQBCA-UHFFFAOYSA-M",
            "id": "InChI=1S/HI/h1H/p-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 126.9045,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 126.90446842,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous halogens. These are inorganic non-metallic compounds in which the largest atom is a nobel gas.",
        "link": "https://go.drugbank.com/drugs/DB12754",
        "type": "Small Molecule",
        "synonyms": [
            "Iodide ion"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC(=[NH2+])C1=CC2=C(NC(=N2)C2=CC=CNC2=O)C=C1",
        "id": "DB04442",
        "molecule": "Imino[2-(2-oxo-1,2-dihydro-3-pyridinyl)-1H-benzimidazol-5-yl]methanaminium",
        "iupac_name": "{amino[2-(2-oxo-1,2-dihydropyridin-3-yl)-1H-1,3-benzodiazol-5-yl]methylidene}azanium",
        "inchi": {
            "hash": "PUOKYJMONGPAIM-UHFFFAOYSA-O",
            "id": "InChI=1S/C13H11N5O/c14-11(15)7-3-4-9-10(6-7)18-12(17-9)8-2-1-5-16-13(8)19/h1-6H,(H3,14,15)(H,16,19)(H,17,18)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 254.2673,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 254.104185031,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB04442",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "COC1=C2C(NC=C2C2=NC(N)=NC=C2)=NC=C1",
        "id": "DB08178",
        "molecule": "4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",
        "iupac_name": "4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine",
        "inchi": {
            "hash": "GGEWEQJWGGJUHO-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H11N5O/c1-18-9-3-5-14-11-10(9)7(6-16-11)8-2-4-15-12(13)17-8/h2-6H,1H3,(H,14,16)(H2,13,15,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 241.2486,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 241.096359999,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolopyridines. These are compounds containing a pyrrolopyridine moiety, which consists of a pyrrole ring fused to a pyridine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.",
        "link": "https://go.drugbank.com/drugs/DB08178",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-A2"
            }
        ]
    },
    {
        "smiles": "CN1C=CN=C1C(=O)C1=C(C)C2=C(O1)C=CC=C2OCCCNCC1=CN=CC=C1",
        "id": "DB03062",
        "molecule": "(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone",
        "iupac_name": "(3-{[3-methyl-2-(1-methyl-1H-imidazole-2-carbonyl)-1-benzofuran-4-yl]oxy}propyl)[(pyridin-3-yl)methyl]amine",
        "inchi": {
            "hash": "VZBQJKIOAOUYJL-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H24N4O3/c1-16-20-18(29-13-5-10-25-15-17-6-4-9-24-14-17)7-3-8-19(20)30-22(16)21(28)23-26-11-12-27(23)2/h3-4,6-9,11-12,14,25H,5,10,13,15H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 404.4617,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 404.184840654,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.",
        "link": "https://go.drugbank.com/drugs/DB03062",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycylpeptide N-tetradecanoyltransferase 1"
            },
            {
                "action": "Not Available",
                "organism": "Yeast",
                "target": "UGlycylpeptide N-tetradecanoyltransferase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03608"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03874"
    },
    {
        "smiles": "CC\\C=C/C\\C=C/C[C@@H](O)\\C=C\\C=C/C\\C=C/CCCC(O)=O",
        "id": "DB15571",
        "molecule": "(12R)-12-hydroxyeicosapentaenoic acid",
        "cas": "109430-12-8",
        "iupac_name": "(5Z,8Z,10E,12R,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoic acid",
        "inchi": {
            "hash": "MCRJLMXYVFDXLS-IHWYZUJNSA-N",
            "id": "InChI=1S/C20H30O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h3-4,7-11,13-14,17,19,21H,2,5-6,12,15-16,18H2,1H3,(H,22,23)/b4-3-,9-7-,11-8-,13-10-,17-14+/t19-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 318.457,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 318.219494826,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15571",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[198Au]",
        "id": "DB13427",
        "molecule": "Gold Au-198",
        "cas": "10043-49-9",
        "iupac_name": "(198Au)gold",
        "inchi": {
            "hash": "PCHJSUWPFVWCPO-OUBTZVSYSA-N",
            "id": "InChI=1S/Au/i1+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 197.9682,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 197.968225244,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.",
        "link": "https://go.drugbank.com/drugs/DB13427",
        "type": "Small Molecule",
        "synonyms": [
            "Aureotope",
            "Gold (198 Au)",
            "Gold (198 Au) colloidal",
            "Gold (198Au) colloidal",
            "Gold Au 198",
            "Gold-198",
            "Gold, Au-198",
            "Gold, radioactive, colloidal"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC(CC(C)N)=CC(OC)=C1OC",
        "id": "DB01516",
        "molecule": "3,4,5-Trimethoxyamphetamine",
        "cas": "1082-88-8",
        "iupac_name": "1-(3,4,5-trimethoxyphenyl)propan-2-amine",
        "inchi": {
            "hash": "WGTASENVNYJZBK-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H19NO3/c1-8(13)5-9-6-10(14-2)12(16-4)11(7-9)15-3/h6-8H,5,13H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 225.2842,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 225.136493479,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.",
        "link": "https://go.drugbank.com/drugs/DB01516",
        "type": "Small Molecule"
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1",
        "id": "DB11860",
        "molecule": "Aramchol",
        "cas": "246529-22-6",
        "iupac_name": "(4R)-4-[(1S,2S,5S,7S,9R,10R,11S,14R,15R,16S)-9,16-dihydroxy-5-icosanamido-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid",
        "background": "Aramchol has been used in trials studying the treatment of HIV, Gallstones, Fatty Liver, Metabolic Syndrome, and Nonalcoholic Steatohepatitis, among others.\n",
        "inchi": {
            "hash": "SHKXZIQNFMOPBS-OOMQYRRCSA-N",
            "id": "InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 702.118,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 701.595824648,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dihydroxy bile acids, alcohols and derivatives. These are compounds containing or derived from a bile acid or alcohol, and which bears exactly two carboxylic acid groups.",
        "link": "https://go.drugbank.com/drugs/DB11860",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "OC1=CC=C(C=C1)C(F)(F)F",
        "id": "DB03610",
        "molecule": "4-(trifluoromethyl)phenol",
        "cas": "402-45-9",
        "iupac_name": "4-(trifluoromethyl)phenol",
        "inchi": {
            "hash": "BAYGVMXZJBFEMB-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H5F3O/c8-7(9,10)5-1-3-6(11)4-2-5/h1-4,11H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 162.1092,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 162.029249397,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.",
        "link": "https://go.drugbank.com/drugs/DB03610",
        "type": "Small Molecule",
        "synonyms": [
            "4-hydroxybenzotrifluoride",
            "4-trifluoromethylphenol",
            ",,-trifluoro-p-cresol"
        ]
    },
    {
        "smiles": "CC1CC(CC(C)(C)C1)OC(=O)C1=C(O)C=CC=C1",
        "id": "DB11064",
        "molecule": "Homosalate",
        "cas": "118-56-9",
        "iupac_name": "3,3,5-trimethylcyclohexyl 2-hydroxybenzoate",
        "background": "Homosalate is an organic compound that belongs to salicylates. It is an ester formed from salicylic acid and 3,3,5-trimethylcyclohexanol, a derivative of cyclohexanol. Salicylates prevent direct skin exposure to the suns harmful rays by absorbing ultraviolet (UV) light. Homosalate specifically absorbs short-wave UVB rays, which are associated with DNA damage and increased risk of skin cancer. \nIt is a common ingredient in many commercially available sunscreens. There are no reported adverse effects from homosalate.\n",
        "inchi": {
            "hash": "WSSJONWNBBTCMG-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H22O3/c1-11-8-12(10-16(2,3)9-11)19-15(18)13-6-4-5-7-14(13)17/h4-7,11-12,17H,8-10H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 262.349,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 262.156894568,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as o-hydroxybenzoic acid esters. These are benzoic acid esters where the benzene ring is ortho-substituted with a hydroxy group.",
        "link": "https://go.drugbank.com/drugs/DB11064",
        "type": "Small Molecule",
        "synonyms": [
            "3,3,5-Trimethylcyclohexyl 2-hydroxybenzoate",
            "Homosalate",
            "Homosalato",
            "Homosalatum"
        ],
        "indication": "As ingredient in many sunscreen for protection against sunburn, skin aging and skin cancer. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Acts as UV filters. \n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UProgesterone receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UAndrogen receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor alpha"
            }
        ]
    },
    {
        "smiles": "NC1=NC2=C(NC=C2)C(=O)N1",
        "id": "DB04356",
        "molecule": "9-Deazaguanine",
        "cas": "65996-58-9",
        "iupac_name": "2-amino-3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one",
        "inchi": {
            "hash": "FFYPRJYSJODFFD-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H6N4O/c7-6-9-3-1-2-8-4(3)5(11)10-6/h1-2,8H,(H3,7,9,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 150.138,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 150.054160834,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB04356",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHypoxanthine-guanine phosphoribosyltransferase"
            }
        ]
    },
    {
        "smiles": "CCN(CC)C(=O)C(=C\\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\\C#N",
        "id": "DB00494",
        "molecule": "Entacapone",
        "cas": "130929-57-6",
        "iupac_name": "(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide",
        "background": "Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.\n",
        "inchi": {
            "hash": "JRURYQJSLYLRLN-BJMVGYQFSA-N",
            "id": "InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+"
        },
        "summary": "Entacapone is a selective reversible catechol-O-methyltransferase inhibitor for the treatment of Parkinson's disease.",
        "weight": [
            {
                "type": "average",
                "weight": 305.286,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 305.101170605,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxycinnamic acids and derivatives. These are compounds containing an cinnamic acid (or a derivative thereof) where the benzene ring is hydroxylated.",
        "link": "https://go.drugbank.com/drugs/DB00494",
        "type": "Small Molecule",
        "synonyms": [
            "(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide",
            "Entacapona",
            "Entacapone",
            "Entacaponum",
            "N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide"
        ],
        "indication": "Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose \"wearing-off\".\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Entacapone is structurally and pharmacologically related to tolcapone, but unlike tolcapone, is not associated with hepatotoxicity. Entacapone is used in the treatment of Parkinsons disease as an adjunct to levodopa/carbidopa therapy. Entacapone selectively and reversiblly inhibits catechol-O-methyltransferase (COMT). In mammals, COMT is distributed throughout various organs with the highest activities in the liver and kidney. COMT also occurs in the heart, lung, smooth and skeletal muscles, intestinal tract, reproductive organs, various glands, adipose tissue, skin, blood cells and neuronal tissues, especially in glial cells. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa, catalyzing the it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACatechol O-methyltransferase"
            }
        ]
    },
    {
        "smiles": "[H]\\C(C)=C(/N)CCC(O)=O",
        "id": "DB01699",
        "molecule": "(4e)-4-Aminohex-4-Enoic Acid",
        "iupac_name": "(4E)-4-aminohex-4-enoic acid",
        "inchi": {
            "hash": "KQFBUAIXCIGKAP-GORDUTHDSA-N",
            "id": "InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2H,3-4,7H2,1H3,(H,8,9)/b5-2+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 129.157,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 129.078978601,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB01699",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U4-aminobutyrate aminotransferase, mitochondrial"
            }
        ]
    },
    {
        "smiles": "CO[C@H]1C[C@H](C)CC2=C(N)C(=O)C=C(NC(=O)\\C(C)=C\\C=C/[C@H](OC)[C@@H](OC(N)=O)\\C(C)=C\\[C@H](C)[C@H]1O)C2=O",
        "id": "DB13023",
        "molecule": "IPI-493",
        "cas": "64202-81-9",
        "iupac_name": "(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-amino-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate",
        "background": "IPI-493 has been used in trials studying the treatment of Advanced Malignancies.\n",
        "inchi": {
            "hash": "XYFFWTYOFPSZRM-TWNAANEASA-N",
            "id": "InChI=1S/C28H39N3O8/c1-14-10-18-23(29)20(32)13-19(25(18)34)31-27(35)15(2)8-7-9-21(37-5)26(39-28(30)36)17(4)12-16(3)24(33)22(11-14)38-6/h7-9,12-14,16,21-22,24,26,33H,10-11,29H2,1-6H3,(H2,30,36)(H,31,35)/b9-7-,15-8+,17-12+/t14-,16+,21+,22+,24-,26+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 545.633,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 545.273715228,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides.",
        "link": "https://go.drugbank.com/drugs/DB13023",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@](O)(CN)CNC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O",
        "id": "DB07037",
        "molecule": "(2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL",
        "iupac_name": "(2S)-1-amino-3-[(5-nitroquinolin-8-yl)amino]propan-2-ol",
        "inchi": {
            "hash": "MBZPCTWLFNYBND-QMMMGPOBSA-N",
            "id": "InChI=1S/C12H14N4O3/c13-6-8(17)7-15-10-3-4-11(16(18)19)9-2-1-5-14-12(9)10/h1-5,8,15,17H,6-7,13H2/t8-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 262.2646,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 262.106590334,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitroquinolines and derivatives. These are compounds containing a nitro group attached to a quinoline moiety.",
        "link": "https://go.drugbank.com/drugs/DB07037",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein kinase Chk1"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C2NC=C(CCN(C)C)C2=C1",
        "id": "DB14010",
        "molecule": "5-methoxy-N,N-dimethyltryptamine",
        "cas": "1019-45-0",
        "iupac_name": "[2-(5-methoxy-1H-indol-3-yl)ethyl]dimethylamine",
        "background": "5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a tryptamine with psychedelic properties. It is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad. This drug, as well as dimethyltryptamine and bufotenin, have been registered to be used in South America in religious and spiritual rituals.\n",
        "inchi": {
            "hash": "ZSTKHSQDNIGFLM-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H18N2O/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13/h4-5,8-9,14H,6-7H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 218.2948,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 218.141913208,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14010",
        "type": "Small Molecule",
        "synonyms": [
            "3-(2-dimethylaminoethyl)-5-methoxyindole",
            "3-[2-(N,N-Dimethylamino)ethyl]-5-methoxy-indole",
            "5-MeO-DMT",
            "5-methoxy-N,N-dimethyl-1H-indole-3-ethanamine",
            "MeODMT",
            "Methoxybufotenin",
            "N,N-dimethyl-5-methoxytryptamine",
            "O-methylbufotenine"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1A"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2A"
            }
        ]
    },
    {
        "smiles": "[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[Si+4].[O-][H].[H]O[H].[H]O[H].[H]O[H].[H]O[H]",
        "id": "DB01574",
        "molecule": "Attapulgite",
        "cas": "12174-11-7",
        "iupac_name": "tetrasilicon(4+) ion aluminium(3+) ion magnesium(2+) ion tetrahydrate hydroxide decaoxidandiide",
        "background": "Attapulgite is a magnesium aluminium phyllosilicate which occurs in a type of clay soil common to the Southeastern United States. When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract. For that reason, it has often been used in antidiarrheal medications. Until 2003, it was the active ingredient used in Kaopectate, before that product was reformulated with bismuth subsalicylate.\n",
        "inchi": {
            "hash": "IXWIAFSBWGYQOE-UHFFFAOYSA-M",
            "id": "InChI=1S/Al.Mg.5H2O.10O.4Si/h;;5*1H2;;;;;;;;;;;;;;/q+3;+2;;;;;;10*-2;4*+4/p-1"
        },
        "summary": "Attapulgite is a veterinary antidiarrheal agent used to treat non-infectious diarrhea in animals.",
        "weight": [
            {
                "type": "average",
                "weight": 412.684,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 411.8684309,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.",
        "link": "https://go.drugbank.com/drugs/DB01574",
        "type": "Small Molecule",
        "synonyms": [
            "Activated attapulgite",
            "Aluminium magnesium silicate (attapulgite)",
            "Attapulgite (activated)",
            "Attapulgite, activated",
            "Attapulgite,activated",
            "Attapulgus clay"
        ],
        "indication": "When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract. For that reason, it has often been used in antidiarrheal medications. Attapulgite is an adsorbent. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Attapulgite is an adsorptive magnesium aluminium phyllosilicate which binds to toxins, bacteria and water. \n"
    },
    {
        "smiles": "[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSC[C@@H](N)C(O)=O)OC)C(O)=O",
        "id": "DB09062",
        "molecule": "Cefminox",
        "cas": "84305-41-9",
        "iupac_name": "(6R,7S)-7-(2-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetamido)-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",
        "background": "Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.\n",
        "inchi": {
            "hash": "JSDXOWVAHXDYCU-VXSYNFHWSA-N",
            "id": "InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 519.57,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 519.066459566,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cephamycins. These are compounds containing a the cephalosporin (oxo-5-thia-1-azabicyclo[4.2.0]Oct-2-ene-2-carboxylic acid) nucleus, with an alkyloxy group attached to the C6 carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB09062",
        "type": "Small Molecule",
        "synonyms": [
            "Cefminox",
            "cefminoxum",
            "CMNX"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16942"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13656"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07135"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13142"
    },
    {
        "smiles": "CN(C)N(C)C(=O)[C@@]1(CC2=CC=CC=C2)CCCN(C1)C(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)C(C)(C)N",
        "id": "DB06645",
        "molecule": "Anamorelin",
        "cas": "249921-19-5",
        "iupac_name": "2-amino-N-[(2R)-1-[(3R)-3-benzyl-3-(N,N',N'-trimethylhydrazinecarbonyl)piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide",
        "inchi": {
            "hash": "VQPFSIRUEPQQPP-MXBOTTGLSA-N",
            "id": "InChI=1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 546.716,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 546.331839236,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB06645",
        "type": "Small Molecule",
        "synonyms": [
            "Anamorelin"
        ],
        "indication": "Investigated for use/treatment in cachexia and anorexia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "[Fe++].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O",
        "id": "DB13639",
        "molecule": "Ferrous tartrate",
        "cas": "2944-65-2",
        "iupac_name": "lambda2-iron(2+) ion (2R,3R)-2,3-dihydroxybutanedioate",
        "inchi": {
            "hash": "OHZCFWMJMWFNFP-ZVGUSBNCSA-L",
            "id": "InChI=1S/C4H6O6.Fe/c5-1(3(7)8)2(6)4(9)10;/h1-2,5-6H,(H,7,8)(H,9,10);/q;+2/p-2/t1-,2-;/m1./s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 203.915,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 203.935724,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB13639",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "ClC1=CC=C(C=C1)C1=CN=CN1",
        "id": "DB02974",
        "molecule": "4-(4-Chlorophenyl)Imidazole",
        "iupac_name": "5-(4-chlorophenyl)-1H-imidazole",
        "inchi": {
            "hash": "DVKIFCXVRCGAEE-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H7ClN2/c10-8-3-1-7(2-4-8)9-5-11-6-12-9/h1-6H,(H,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 178.618,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 178.029775941,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB02974",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome P450 2B6"
            }
        ]
    },
    {
        "smiles": "NC1=C(C=C(C(=C1)C(Cl)=C(Cl)Cl)S(N)(=O)=O)S(N)(=O)=O",
        "id": "DB11389",
        "molecule": "Clorsulon",
        "cas": "60200-06-8",
        "iupac_name": "4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide",
        "inchi": {
            "hash": "QOVTVIYTBRHADL-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H8Cl3N3O4S2/c9-7(8(10)11)3-1-4(12)6(20(14,17)18)2-5(3)19(13,15)16/h1-2H,12H2,(H2,13,15,16)(H2,14,17,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 380.64,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 378.9021812,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB11389",
        "type": "Small Molecule",
        "synonyms": [
            "Clorsulon"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](CC1=CC=CC=C1)(C[P@](O)(=O)[C@]([H])(N)CCC1=CC=CC=C1)C(O)=O",
        "id": "DB07448",
        "molecule": "(2S)-3-[(R)-[(1S)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid",
        "iupac_name": "(2S)-3-{[(1S)-1-amino-3-phenylpropyl](hydroxy)phosphoryl}-2-benzylpropanoic acid",
        "inchi": {
            "hash": "QELOIXSGJMIHBZ-MSOLQXFVSA-N",
            "id": "InChI=1S/C19H24NO4P/c20-18(12-11-15-7-3-1-4-8-15)25(23,24)14-17(19(21)22)13-16-9-5-2-6-10-16/h1-10,17-18H,11-14,20H2,(H,21,22)(H,23,24)/t17-,18+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 361.3719,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 361.144294773,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.",
        "link": "https://go.drugbank.com/drugs/DB07448",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytosol aminopeptidase"
            }
        ]
    },
    {
        "smiles": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl",
        "id": "DB06769",
        "molecule": "Bendamustine",
        "cas": "16506-27-7",
        "iupac_name": "4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-1,3-benzodiazol-2-yl}butanoic acid",
        "background": "Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.\n",
        "inchi": {
            "hash": "YTKUWDBFDASYHO-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)"
        },
        "summary": "Bendamustine is an antineoplastic agent used for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 358.263,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 357.101082345,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB06769",
        "type": "Small Molecule",
        "synonyms": [
            "Bendamustina",
            "Bendamustine",
            "Ribomustine"
        ],
        "indication": "Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "No mean changes in QTc interval greater than 20 milliseconds were detected up to one hour post-infusion.\n"
    },
    {
        "smiles": "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O",
        "id": "DB04335",
        "molecule": "Inosine",
        "cas": "58-63-9",
        "iupac_name": "9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one",
        "background": "A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)\n",
        "inchi": {
            "hash": "UGQMRVRMYYASKQ-KQYNXXCUSA-N",
            "id": "InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1"
        },
        "summary": "Inosine is a nutritional supplement touted to improve athletic performance and a drug used in vitro as a red blood cell rejuvenator for a unit of red blood cells that will be used in a clinical setting.",
        "weight": [
            {
                "type": "average",
                "weight": 268.2261,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 268.080769514,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB04335",
        "type": "Small Molecule",
        "synonyms": [
            "9--D-ribofuranosyl-9H-purin-6-ol",
            "9--D-ribofuranosylhypoxanthine",
            "beta-Inosine",
            "hypoxanthine D-riboside",
            "Hypoxanthosine",
            "INO",
            "Inosin",
            "Inosina",
            "Inosine",
            "Inosinum"
        ],
        "indication": "The primary popular claim made for inosine, that it enhances exercise and athletic performance, is refuted by the available research data. There is some preliminary evidence that inosine may have some neurorestorative, anti-inflammatory, immunomodulatory and cardioprotective effects.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Inosine may have neuroprotective, cardioprotective, anti-inflammatory and immunomodulatory activities.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPurine nucleoside phosphorylase"
            },
            {
                "action": "Not Available",
                "organism": "Trypanosoma vivax",
                "target": "UIAG-nucleoside hydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPurine nucleoside phosphorylase DeoD-type"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3",
        "id": "DB00977",
        "molecule": "Ethinylestradiol",
        "cas": "57-63-6",
        "iupac_name": "(1R,3aS,3bR,9bS,11aS)-1-ethynyl-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-diol",
        "background": "Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.1 It was developed in an effort to create an estrogen with greater oral bioavailability.1 These properties were achieved by the substitution of an ethinyl group at carbon 17 of estradiol.1 Ethinylestradiol soon replaced mestranol in contraceptive pills.1\nEthinylestradiol was granted FDA approval on 25 June 1943.14\n",
        "inchi": {
            "hash": "BFPYWIDHMRZLRN-SLHNCBLASA-N",
            "id": "InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1"
        },
        "summary": "Ethinylestradiol is an estradiol used as a contraceptive.",
        "weight": [
            {
                "type": "average",
                "weight": 296.4034,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 296.177630012,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.",
        "link": "https://go.drugbank.com/drugs/DB00977",
        "type": "Small Molecule",
        "synonyms": [
            "17-ethinyl-3,17-estradiol",
            "17-ethinyl-3,17-oestradiol",
            "17-ethinylestradiol",
            "17alpha-Ethinyl estradiol",
            "17-ethynylestradiol",
            "Ethinyl estradiol",
            "Ethinylestradiol",
            "Ethinylestradiolum",
            "Ethinyloestradiol",
            "Ethynyl estradiol",
            "Etinilestradiol"
        ],
        "indication": "Ethinylestradiol is combined with other drugs for use as a contraceptive, premenstrual dysphoric disorder, moderate acne, moderate to severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis.15,25,16,17,24,18,19,20,21,22,23\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Ethinylestradiol is a synthetic estrogen that decreases luteinizing hormone to decrease endometrial vascularization, and decreases gonadotrophic hormone to prevent ovulation.13,12,15 It has a long duration of action as it is taken once daily, and a wide therapeutic index as overdoses are generally not associated with serious adverse effects.15 Patients should be counselled regarding the risks of thrombotic events.15\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AEstrogen receptor alpha"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UNuclear receptor subfamily 1 group I member 2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08278"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11261"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07528"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02369"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00196"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07894"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12154"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02801"
    },
    {
        "smiles": "NC(=O)[C@H]1C=[N+](C=CC1=O)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O",
        "id": "DB01753",
        "molecule": "4-oxo-nicotinamide-adenine dinucleotide phosphate",
        "iupac_name": "(3S)-1-[(2R,3R,4S,5R)-5-[({[({[(2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxy-4-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-4-oxo-3,4-dihydro-1lambda5-pyridin-1-ylium",
        "inchi": {
            "hash": "PIXSDSMVQQICPA-BYJCYCELSA-O",
            "id": "InChI=1S/C21H28N7O18P3/c22-17-12-19(25-6-24-17)28(7-26-12)21-16(45-47(34,35)36)14(31)11(44-21)5-42-49(39,40)46-48(37,38)41-4-10-13(30)15(32)20(43-10)27-2-1-9(29)8(3-27)18(23)33/h1-3,6-8,10-11,13-16,20-21,30-32H,4-5H2,(H7-,22,23,24,25,33,34,35,36,37,38,39,40)/p+1/t8-,10+,11+,13+,14+,15+,16+,20+,21+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 760.4123,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 760.078191695,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB01753",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UNADPH-ferredoxin reductase FprA"
            }
        ]
    },
    {
        "smiles": "CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC",
        "id": "DB09009",
        "molecule": "Articaine",
        "cas": "23964-58-1",
        "iupac_name": "methyl 4-methyl-3-[2-(propylamino)propanamido]thiophene-2-carboxylate",
        "background": "Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.\n",
        "inchi": {
            "hash": "QTGIAADRBBLJGA-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)"
        },
        "summary": "Articaine is a local anesthetic used for inducing local, infiltrative, or conductive anesthesia in both simple and complex dental procedures.",
        "weight": [
            {
                "type": "average",
                "weight": 284.374,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 284.119463206,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thiophene carboxylic acids and derivatives. These are compounds containing a thiophene ring which bears a carboxylic acid group (or a salt/ester thereof).",
        "link": "https://go.drugbank.com/drugs/DB09009",
        "type": "Small Molecule",
        "synonyms": [
            "Articana",
            "Articaine",
            "Articainum"
        ]
    },
    {
        "smiles": "OC[C@@H](O)C=O",
        "id": "DB02536",
        "molecule": "D-glyceraldehyde",
        "cas": "453-17-8",
        "iupac_name": "(2R)-2,3-dihydroxypropanal",
        "inchi": {
            "hash": "MNQZXJOMYWMBOU-VKHMYHEASA-N",
            "id": "InChI=1S/C3H6O3/c4-1-3(6)2-5/h1,3,5-6H,2H2/t3-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 90.0779,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 90.031694058,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monosaccharides. These are compounds containing one carbohydrate unit not glycosidically linked to another such unit, and no set of two or more glycosidically linked carbohydrate units. Monosaccharides have the general formula CnH2nOn.",
        "link": "https://go.drugbank.com/drugs/DB02536",
        "type": "Small Molecule",
        "synonyms": [
            "D-(+)-glyceraldehyde",
            "D-2,3-dihydroxypropanal",
            "D-2,3-dihydroxypropionaldehyde",
            "D-aldotriose",
            "D-glycerose",
            "Triose"
        ]
    },
    {
        "smiles": "N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O",
        "id": "DB00138",
        "molecule": "Cystine",
        "cas": "56-89-3",
        "iupac_name": "(2R)-2-amino-3-{[(2R)-2-amino-2-carboxyethyl]disulfanyl}propanoic acid",
        "background": "A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.\n",
        "inchi": {
            "hash": "LEVWYRKDKASIDU-IMJSIDKUSA-N",
            "id": "InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1"
        },
        "summary": "Cystine is an oxidated derivative of the amino acid cysteine found in various nutritional products, acne treatments, and creams to treat cervical injury or inflammation.",
        "weight": [
            {
                "type": "average",
                "weight": 240.3,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 240.023848262,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-cysteine-s-conjugates. These are compounds containing L-cysteine where the thio-group is conjugated.",
        "link": "https://go.drugbank.com/drugs/DB00138",
        "type": "Small Molecule",
        "synonyms": [
            "(R,R)-3,3'-dithiobis(2-aminopropanoic acid)",
            "Cistina",
            "Cystine",
            "L-alpha-Diamino-beta-dithiolactic acid",
            "L-Cystine",
            "L-Dicysteine",
            ",'-dithiodialanine"
        ],
        "indication": "It has been claimed that L-cysteine has anti-inflammatory properties, that it can protect against various toxins, and that it might be helpful in osteoarthritis and rheumatoid arthritis. More research will have to be done before L-cysteine can be indicated for any of these conditions. Research to date has mostly been in animal models.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "L-Cystine is a covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine. Cystine is a chemical substance which naturally occurs as a deposit in the urine, and can form a calculus (hard mineral formation) when deposited in the kidney. The compound produced when two cysteine molecules linked by a disulfide (S-S) bond. Cystine is required for proper vitamin B6 utilization and is also helpful in the healing of burns and wounds, breaking down mucus deposits in illnesses such as bronchitis as well as cystic fibrosis. Cysteine also assists in the supply of insulin to the pancreas, which is needed for the assimilation of sugars and starches. It increases the level of glutathione in the lungs, liver, kidneys and bone marrow, and this may have an anti-aging effect on the body by reducing age-spots etc.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCystine/glutamate transporter"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCystinosin"
            }
        ]
    },
    {
        "smiles": "CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O",
        "id": "DB11363",
        "molecule": "Alectinib",
        "cas": "1256580-46-7",
        "iupac_name": "9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H,6H,11H-benzo[b]carbazole-3-carbonitrile",
        "background": "Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. \nApproved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance.\n",
        "inchi": {
            "hash": "KDGFLJKFZUIJMX-UHFFFAOYSA-N",
            "id": "InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3"
        },
        "summary": "Alectinib is a kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer.",
        "weight": [
            {
                "type": "average",
                "weight": 482.6166,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 482.268176352,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB11363",
        "type": "Small Molecule",
        "synonyms": [
            "9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile",
            "Alectinib"
        ],
        "indication": "Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AALK tyrosine kinase receptor"
            }
        ]
    },
    {
        "smiles": "CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1",
        "id": "DB00905",
        "molecule": "Bimatoprost",
        "cas": "155206-00-1",
        "iupac_name": "(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide",
        "background": "Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma.13,14,15,20 Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth.16 It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.17\n",
        "inchi": {
            "hash": "AQOKCDNYWBIDND-FTOWTWDKSA-N",
            "id": "InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1"
        },
        "summary": "Bimatoprost is a prostaglandin analog used to treat hypotrichosis of the eyelashes and intraocular pressure in open angle glaucoma or ocular hypertension.",
        "weight": [
            {
                "type": "average",
                "weight": 415.5656,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 415.272258677,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.",
        "link": "https://go.drugbank.com/drugs/DB00905",
        "type": "Small Molecule",
        "synonyms": [
            "(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide",
            "Bimatoprost",
            "Bimatoprostum"
        ],
        "indication": "Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.\nThese patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.13\nBimatoprost is also indicated to treat eyelash hypotrichosis.16\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "High intraocular pressure is a major risk factor for glaucoma-related visual field loss. A linear relationship exists between intraocular pressure and the risk of damaging the optic nerve, which can lead to considerable visual impairment.13 Therefore, conditions such as ocular hypertension and glaucoma can cause dangerous elevations of intraocular pressure. Bimatoprost rapidly decreases intraocular pressure and reduces the risk for visual field loss from ocular hypertension due to various causes.13\nOther effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness.13 Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.13\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin F2-alpha receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP1 subtype"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP3 subtype"
            }
        ]
    },
    {
        "smiles": "NC1=CC2=C(C=C1)C1=CC=C(N)C=C1C(C1=CC=CC=C1)=[N+]2CCCCCCC1=CN=NN1CCNC1=C2CCCCC2=NC2=C1C=CC=C2",
        "id": "DB03005",
        "molecule": "3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium",
        "iupac_name": "3,8-diamino-6-phenyl-5-[6-(1-{2-[(1,2,3,4-tetrahydroacridin-9-yl)amino]ethyl}-1H-1,2,3-triazol-5-yl)hexyl]phenanthridin-5-ium",
        "inchi": {
            "hash": "ISUOMOOYAOQQPZ-UHFFFAOYSA-O",
            "id": "InChI=1S/C42H44N8/c43-30-19-21-33-34-22-20-31(44)27-40(34)49(42(37(33)26-30)29-12-4-3-5-13-29)24-11-2-1-6-14-32-28-46-48-50(32)25-23-45-41-35-15-7-9-17-38(35)47-39-18-10-8-16-36(39)41/h3-5,7,9,12-13,15,17,19-22,26-28,44H,1-2,6,8,10-11,14,16,18,23-25,43H2,(H,45,47)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 661.8603,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 661.37671848,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB03005",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAcetylcholinesterase"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(NC(=O)[C@H](CCCCN)NC(=O)C2=CC(NC(=O)[C@H](CCCCN)NC(=O)C3=CC(NC(=O)[C@H](CCCCN)NC(=O)C4=CC(NC(=O)[C@@H](N)CCCCN)=CC=C4OC)=CC=C3OC)=CC=C2OC)C=C1C(N)=O",
        "id": "DB12955",
        "molecule": "Delparantag",
        "cas": "872454-31-4",
        "iupac_name": "5-[(2S)-6-amino-2-({5-[(2S)-6-amino-2-({5-[(2S)-6-amino-2-({5-[(2S)-2,6-diaminohexanamido]-2-methoxyphenyl}formamido)hexanamido]-2-methoxyphenyl}formamido)hexanamido]-2-methoxyphenyl}formamido)hexanamido]-2-methoxybenzamide",
        "background": "Delparantag has been used in trials studying the treatment of Angioplasty, Coronary Artery Disease (CAD), and Percutaneous Coronary Intervention.\n",
        "inchi": {
            "hash": "PWFIFNGOPQUNIT-ITMZJIMRSA-N",
            "id": "InChI=1S/C56H79N13O12/c1-78-45-21-17-33(29-37(45)49(62)70)64-54(75)42(14-6-10-26-58)67-51(72)39-31-35(19-23-47(39)80-3)66-56(77)44(16-8-12-28-60)69-52(73)40-32-36(20-24-48(40)81-4)65-55(76)43(15-7-11-27-59)68-50(71)38-30-34(18-22-46(38)79-2)63-53(74)41(61)13-5-9-25-57/h17-24,29-32,41-44H,5-16,25-28,57-61H2,1-4H3,(H2,62,70)(H,63,74)(H,64,75)(H,65,76)(H,66,77)(H,67,72)(H,68,71)(H,69,73)/t41-,42-,43-,44-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1126.327,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1125.597115036,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.",
        "link": "https://go.drugbank.com/drugs/DB12955",
        "type": "Small Molecule",
        "synonyms": [
            "Delparantag"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1=NC(=C(O1)C(=O)NC(CC1=CC=CC=C1)C(=O)C(N)=O)C1=CC=CC=C1F",
        "id": "DB18301",
        "molecule": "Dazcapistat",
        "cas": "2221010-42-8",
        "inchi": {
            "hash": "XYQHCMDVGIJOTA-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H18FN3O4/c1-12-24-17(14-9-5-6-10-15(14)22)19(29-12)21(28)25-16(18(26)20(23)27)11-13-7-3-2-4-8-13/h2-10,16H,11H2,1H3,(H2,23,27)(H,25,28)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 395.39,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 395.128134235,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18301",
        "type": "Small Molecule",
        "synonyms": [
            "5-oxazolecarboxamide, n-(3-amino-2,3-dioxo-1-(phenylmethyl)propyl)-4-(2-fluorophenyl)-2-methyl-",
            "N-(3-amino-2,3-dioxo-1-(phenylmethyl)propyl)-4-(2-fluorophenyl)-2-methyl-5-oxazolecarboxamide",
            "N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyloxazole-5-carboxamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC[C@@H](O)[C@H](CO)OCN1C=CN=C1[N+]([O-])=O",
        "id": "DB17304",
        "molecule": "Doranidazole",
        "cas": "149838-23-3",
        "iupac_name": "(2R,3S)-3-[(2-nitro-1H-imidazol-1-yl)methoxy]butane-1,2,4-triol",
        "inchi": {
            "hash": "FIITXXIVUIXYMI-RQJHMYQMSA-N",
            "id": "InChI=1S/C8H13N3O6/c12-3-6(14)7(4-13)17-5-10-2-1-9-8(10)11(15)16/h1-2,6-7,12-14H,3-5H2/t6-,7+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 247.207,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 247.080435151,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17304",
        "type": "Small Molecule",
        "synonyms": [
            "(2rs,3sr)-3-((2-nitroimidazol-1-yl)methoxy)butane-1,2,4-triol",
            "1,2,4-butanetriol, 3-((2-nitro-1h-imidazol-1-yl)methoxy)-, (2r,3s)-rel-"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(C)CCC[C@@H]2[C@H](C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\\C)=C\\C1=CSC(C)=N1)N2CCOC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CN=C3N=C(N)NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O",
        "id": "DB12266",
        "molecule": "Epofolate",
        "cas": "958646-17-8",
        "iupac_name": "(2S)-2-[(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}phenyl)formamido]-4-{[(1S)-1-{[(1S)-4-carbamimidamido-1-{[(1S)-2-carboxy-1-{[(1R)-1-carboxy-2-({2-[({2-[(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-5,9-dioxo-4-oxa-17-azabicyclo[14.1.0]heptadecan-17-yl]ethoxy}carbonyl)oxy]ethyl}disulfanyl)ethyl]carbamoyl}ethyl]carbamoyl}butyl]carbamoyl}-2-carboxyethyl]carbamoyl}butanoic acid",
        "background": "Epofolate has been used in trials studying the treatment of Advanced Solid Tumors. Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells. In Phase I/IIa pharmacokinetic and safety studies epofolate was generally tolerable and toxicities known to be associated with epothilone class of anticancer agents were common, although peripheral neuropathy and neutropenia appear to have been less frequent and less severe as compared to epothilones. Antitumor activity was not demonstrated and further development of BMS-753493 has been discontinued.\n",
        "inchi": {
            "hash": "TURJYGRXEJIBGT-OCOMGVANSA-N",
            "id": "InChI=1S/C67H92N16O22S3/c1-32-9-7-11-45-46(26-47(33(2)23-38-30-106-35(4)74-38)105-52(90)27-48(84)67(5,6)55(92)34(3)54(32)91)83(45)19-20-103-66(102)104-21-22-107-108-31-44(63(100)101)80-60(96)43(25-51(88)89)79-58(94)40(10-8-18-71-64(68)69)77-59(95)42(24-50(86)87)76-49(85)17-16-41(62(98)99)78-57(93)36-12-14-37(15-13-36)72-28-39-29-73-56-53(75-39)61(97)82-65(70)81-56/h12-15,23,29-30,32,34,40-48,54,72,84,91H,7-11,16-22,24-28,31H2,1-6H3,(H,76,85)(H,77,95)(H,78,93)(H,79,94)(H,80,96)(H,86,87)(H,88,89)(H,98,99)(H,100,101)(H4,68,69,71)(H3,70,73,81,82,97)/b33-23+/t32-,34+,40-,41-,42-,43-,44-,45+,46-,47-,48-,54-,83?/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1569.74,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1568.573422188,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB12266",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "OC(=O)CCC(=O)C1=CC2=C(C=C1)C1=C3C2=CC=CC3=CC=C1",
        "id": "DB08975",
        "molecule": "Florantyrone",
        "cas": "519-95-9",
        "iupac_name": "4-(fluoranthen-8-yl)-4-oxobutanoic acid",
        "background": "Florantyrone is used in the treatment of biliary dyskinesia\n",
        "inchi": {
            "hash": "QOBAOSCOLAGPKI-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H14O3/c21-18(9-10-19(22)23)13-7-8-14-15-5-1-3-12-4-2-6-16(20(12)15)17(14)11-13/h1-8,11H,9-10H2,(H,22,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 302.329,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 302.094294311,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as butyrophenones. These are compounds containing 1-phenylbutan-1-one moiety.",
        "link": "https://go.drugbank.com/drugs/DB08975",
        "type": "Small Molecule",
        "synonyms": [
            "Florantyrone"
        ]
    },
    {
        "smiles": "[H][C@]12C[C@@H](O)[C@H](\\C=C\\[C@@H](O)C(C)CC#CC)[C@@]1([H])C1=C(O2)C(CCCC(O)=O)=CC=C1",
        "id": "DB05229",
        "molecule": "Beraprost",
        "cas": "88430-50-6",
        "iupac_name": "4-[(2S,3R,4R,6S)-4-hydroxy-3-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(8),9,11-trien-9-yl]butanoic acid",
        "background": "Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.\n",
        "inchi": {
            "hash": "CTPOHARTNNSRSR-APJZLKAGSA-N",
            "id": "InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 398.499,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 398.209324066,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB05229",
        "type": "Small Molecule",
        "synonyms": [
            "Beraprost",
            "Beraprostum"
        ],
        "indication": "For the treatment of pulmonary hypertension.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Beraprost is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost is generally well tolerated and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. Comparative data from a large randomised trial indicated that the drug appears as effective as ticlopidine in patients with these conditions. In patients with intermittent claudication, significant benefits of beraprost compared with placebo were reported in a randomised clinical trial; however, the use of beraprost in these patients is not supported by recent preliminary unpublished data from a large, phase III, placebo-controlled study. Limited data suggest some efficacy with long-term beraprost treatment of patients with PAH, where options are few and where oral administration of the drug could be a considerable advantage over intravenous prostacyclin (PGI2) therapy.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProstacyclin receptor"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)CN(CC2=CNC3=C2N=CN=C3N)C[C@]1([H])CSCC1=CC=CC=C1",
        "id": "DB07649",
        "molecule": "(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(benzylsulfanyl)methyl]pyrrolidin-3-ol",
        "iupac_name": "(3R,4S)-1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-4-[(benzylsulfanyl)methyl]pyrrolidin-3-ol",
        "inchi": {
            "hash": "DIGGNILBPCEZIV-CVEARBPZSA-N",
            "id": "InChI=1S/C19H23N5OS/c20-19-18-17(22-12-23-19)14(6-21-18)7-24-8-15(16(25)9-24)11-26-10-13-4-2-1-3-5-13/h1-6,12,15-16,21,25H,7-11H2,(H2,20,22,23)/t15-,16+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 369.484,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 369.162331073,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB07649",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli O157:H7",
                "target": "U5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase"
            }
        ]
    },
    {
        "smiles": "COC(=O)C1=CN=CN1[C@H](C)C1=CC=C(I)C=C1",
        "id": "DB13021",
        "molecule": "123I-iodometomidate",
        "cas": "813466-05-6",
        "iupac_name": "methyl 1-[(1R)-1-(4-iodophenyl)ethyl]-1H-imidazole-5-carboxylate",
        "background": "123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).\n",
        "inchi": {
            "hash": "KECBLXVYTIVCTG-SECBINFHSA-N",
            "id": "InChI=1S/C13H13IN2O2/c1-9(10-3-5-11(14)6-4-10)16-8-15-7-12(16)13(17)18-2/h3-9H,1-2H3/t9-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 356.163,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 356.00217,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carbonylimidazoles. These are substituted imidazoles in which the imidazole ring bears a carbonyl group.",
        "link": "https://go.drugbank.com/drugs/DB13021",
        "type": "Small Molecule",
        "synonyms": [
            "123 I Iodometomidate"
        ],
        "is_stub": true
    },
    {
        "smiles": "ClC1=CC=C(OS(=O)(=O)C2=CC=C(Cl)C=C2)C=C1",
        "id": "DB05377",
        "molecule": "Chlorfenson",
        "cas": "80-33-1",
        "iupac_name": "4-chlorophenyl 4-chlorobenzene-1-sulfonate",
        "background": "Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.\n",
        "inchi": {
            "hash": "RZXLPPRPEOUENN-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H8Cl2O3S/c13-9-1-5-11(6-2-9)17-18(15,16)12-7-3-10(14)4-8-12/h1-8H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 303.161,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 301.957120226,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonate esters. These are arenesulfonate esters that result from the formal condensation of the hydroxy group of an alcohol, enol, phenol or heteroarenol with benzenesulfonic acid.",
        "link": "https://go.drugbank.com/drugs/DB05377",
        "type": "Small Molecule",
        "synonyms": [
            "4-Chlorophenyl 4-chlorobenzenesulfonate",
            "Ester sulfonate"
        ],
        "indication": "Investigated for use/treatment in fungal infections.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "CC(C)O",
        "id": "DB02325",
        "molecule": "Isopropyl alcohol",
        "cas": "67-63-0",
        "iupac_name": "propan-2-ol",
        "background": "An isomer of 1-propanol. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.\n",
        "inchi": {
            "hash": "KFZMGEQAYNKOFK-UHFFFAOYSA-N",
            "id": "InChI=1S/C3H8O/c1-3(2)4/h3-4H,1-2H3"
        },
        "summary": "Isopropyl alcohol is an antiseptic and disinfectant used in a variety of clinical and domestic settings.",
        "weight": [
            {
                "type": "average",
                "weight": 60.095,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 60.057514878,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as secondary alcohols. These are compounds containing a secondary alcohol functional group, with the general structure HOC(R)(R') (R,R'=alkyl, aryl).",
        "link": "https://go.drugbank.com/drugs/DB02325",
        "type": "Small Molecule",
        "synonyms": [
            "2-Propanol",
            "Alcohol isoproplico",
            "Isopropanol",
            "Isopropyl alcohol"
        ]
    },
    {
        "smiles": "[H][C@](CC)(C(O)=O)[C@]([H])(NS(=O)(=O)C1=CC=C(C)C=C1)C(O)=O",
        "id": "DB06951",
        "molecule": "(3R)-3-ethyl-N-[(4-methylphenyl)sulfonyl]-L-aspartic acid",
        "iupac_name": "(2R,3S)-2-ethyl-3-(4-methylbenzenesulfonamido)butanedioic acid",
        "inchi": {
            "hash": "KPHLTCNXHCHMOW-MNOVXSKESA-N",
            "id": "InChI=1S/C13H17NO6S/c1-3-10(12(15)16)11(13(17)18)14-21(19,20)9-6-4-8(2)5-7-9/h4-7,10-11,14H,3H2,1-2H3,(H,15,16)(H,17,18)/t10-,11+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 315.342,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 315.077657971,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as p-toluenesulfonamides. These are aromatic heterocyclic compounds containing a toluene that is p-substituted with a sulfonamide group.",
        "link": "https://go.drugbank.com/drugs/DB06951",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UChymotrypsin-like elastase family member 1"
            }
        ]
    },
    {
        "smiles": "CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1",
        "id": "DB06311",
        "molecule": "Darapladib",
        "cas": "356057-34-6",
        "iupac_name": "N-[2-(diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]sulfanyl}-4-oxo-1H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-1-yl)-N-{[4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl]methyl}acetamide",
        "inchi": {
            "hash": "WDPFJWLDPVQCAJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 666.78,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 666.265160306,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.",
        "link": "https://go.drugbank.com/drugs/DB06311",
        "type": "Small Molecule",
        "synonyms": [
            "Darapladib"
        ],
        "indication": "Investigated for use/treatment in atherosclerosis.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytosolic phospholipase A2"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)C1=CC(C)=C(F)C=C1F",
        "id": "DB07652",
        "molecule": "1-[2-DEOXYRIBOFURANOSYL]-2,4-DIFLUORO-5-METHYL-BENZENE-5'MONOPHOSPHATE",
        "iupac_name": "{[(2R,3S,5R)-5-(2,4-difluoro-5-methylphenyl)-3-hydroxyoxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "NMMWBGNJJMNAIJ-QJPTWQEYSA-N",
            "id": "InChI=1S/C12H15F2O6P/c1-6-2-7(9(14)3-8(6)13)11-4-10(15)12(20-11)5-19-21(16,17)18/h2-3,10-12,15H,4-5H2,1H3,(H2,16,17,18)/t10-,11+,12+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 324.2145,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 324.057431134,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as c-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a C-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB07652",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA polymerase kappa"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125)",
                "target": "URibonuclease H"
            }
        ]
    },
    {
        "id": "DB16988",
        "molecule": "ASN120290",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16988",
        "type": "Small Molecule",
        "synonyms": [
            "ASN-561"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN(C)CCCN1C=C(C2=C1C=CC=C2)C1=C(C(=O)NC1=O)C1=CNC2=C1C=CC=C2",
        "id": "DB03777",
        "molecule": "Bisindolylmaleimide I",
        "cas": "133052-90-1",
        "iupac_name": "3-{1-[3-(dimethylamino)propyl]-1H-indol-3-yl}-4-(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione",
        "inchi": {
            "hash": "QMGUOJYZJKLOLH-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 412.4837,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 412.189926032,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB03777",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U3-phosphoinositide-dependent protein kinase 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein kinase C iota type"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein kinase pim-1"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CO)O[C@@]([H])(S[C@@]2([H])[C@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(OC3([H])C([H])(O)C([H])(CO)OC([H])(OC4=CC=C(C=C4)N(=O)=O)C3([H])O)[C@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O",
        "id": "DB03990",
        "molecule": "4'-nitrophenyl-3i-thiolaminaritrioside",
        "iupac_name": "(2S,3R,4S,5S,6R)-2-{[(2S,3S,4S,5R,6R)-2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxan-4-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]sulfanyl}-6-(hydroxymethyl)oxane-3,4,5-triol",
        "inchi": {
            "hash": "VWNONHZCCMYIGR-VGNFVTAUSA-N",
            "id": "InChI=1S/C24H35NO17S/c26-5-10-13(29)16(32)17(33)24(41-10)43-21-15(31)12(7-28)40-23(19(21)35)42-20-14(30)11(6-27)39-22(18(20)34)38-9-3-1-8(2-4-9)25(36)37/h1-4,10-24,26-35H,5-7H2/t10-,11?,12-,13-,14?,15-,16+,17-,18?,19-,20?,21+,22?,23+,24+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 641.596,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 641.162569389,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB03990",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(N)[C@]1([H])O",
        "id": "DB04102",
        "molecule": "2-Amino-Adenosine",
        "iupac_name": "(2R,3S,4R,5R)-4-amino-5-(6-amino-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol",
        "inchi": {
            "hash": "CQKMBZHLOYVGHW-QYYRPYCUSA-N",
            "id": "InChI=1S/C10H14N6O3/c11-5-7(18)4(1-17)19-10(5)16-3-15-6-8(12)13-2-14-9(6)16/h2-5,7,10,17-18H,1,11H2,(H2,12,13,14)/t4-,5-,7-,10-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 266.2566,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 266.112738344,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine 2'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB04102",
        "type": "Small Molecule"
    },
    {
        "smiles": "CC(C)[C@@H](NC(=O)NCC(C)(C)O)C(=O)N1CC[C@](O)(C2=CC=C(Cl)C=C2)C(C)(C)C1",
        "id": "DB14941",
        "molecule": "BMS-817399",
        "cas": "1202400-18-7",
        "iupac_name": "1-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-(2-hydroxy-2-methylpropyl)urea",
        "background": "BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).\n",
        "inchi": {
            "hash": "GTDPZONCGOCXOD-JPYJTQIMSA-N",
            "id": "InChI=1S/C23H36ClN3O4/c1-15(2)18(26-20(29)25-13-22(5,6)30)19(28)27-12-11-23(31,21(3,4)14-27)16-7-9-17(24)10-8-16/h7-10,15,18,30-31H,11-14H2,1-6H3,(H2,25,26,29)/t18-,23+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 454.01,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 453.2394344,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14941",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "OC(=O)C1=CC=C(O)C=C1",
        "id": "DB04242",
        "molecule": "4-hydroxybenzoic acid",
        "cas": "99-96-7",
        "iupac_name": "4-hydroxybenzoic acid",
        "inchi": {
            "hash": "FJKROLUGYXJWQN-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H6O3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8H,(H,9,10)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 138.122,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 138.031694053,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxybenzoic acid derivatives. These are compounds containing a hydroxybenzoic acid (or a derivative), which is a benzene ring bearing a carboxyl and a hydroxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB04242",
        "type": "Small Molecule",
        "synonyms": [
            "4-carboxyphenol",
            "p-Hydroxybenzoic acid",
            "p-salicylic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "Up-hydroxybenzoate hydroxylase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UChorismate--pyruvate lyase"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas fluorescens",
                "target": "Up-hydroxybenzoate hydroxylase"
            },
            {
                "action": "Not Available",
                "organism": "Arthrobacter sp.",
                "target": "U4-hydroxybenzoyl-CoA thioesterase"
            }
        ]
    },
    {
        "smiles": "NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12",
        "id": "DB00564",
        "molecule": "Carbamazepine",
        "cas": "298-46-4",
        "iupac_name": "2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide",
        "background": "Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965.3 Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.16 Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.6\n",
        "inchi": {
            "hash": "FFGPTBGBLSHEPO-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)"
        },
        "summary": "Carbamazepine is an anticonvulsant used to treat various types of seizures and pain resulting from trigeminal neuralgia.",
        "weight": [
            {
                "type": "average",
                "weight": 236.2686,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 236.094963016,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB00564",
        "type": "Small Molecule",
        "synonyms": [
            "5-Carbamoyl-5H-dibenz(b,f)azepine",
            "5-carbamoyl-5H-dibenz[b,f]azepine",
            "5-Carbamoyl-5H-dibenzo(b,f)azepine",
            "5-Carbamyl-5H-dibenzo(b,f)azepine",
            "5H-Dibenz(b,f)azepine-5-carboxamide",
            "Carbamazepen",
            "Carbamazepin",
            "Carbamazepina",
            "Carbamazpine",
            "Carbamazepine",
            "Carbamazepinum",
            "CBZ",
            "Molecusol-Carbamazepine"
        ],
        "indication": "Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.16 In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.3,16 Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.16 Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.9,10\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "General effects\nCarbamazepine treats seizures and the symptoms of trigeminal neuralgia by inhibiting sodium channels. In bipolar 1 disorder, carbamazepine has been found to decrease mania symptoms in a clinically significant manner according to the Young Mania Rating Scale (YMRS).16 Carbamazepine has a narrow therapeutic index.3\nA note on genetic variation and carbamazepine use\nIn studies of Han Chinese ancestry patients, a pronounced association between the HLA-B*1502 genotype and Steven Johnson syndrome and/or toxic epidermal necrolysis (SJS/TEN) resulting from carbamazepine use was observed.7\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AVoltage-gated sodium channel alpha subunit"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-4"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UNuclear receptor subfamily 1 group I member 2"
            }
        ]
    },
    {
        "smiles": "CC(C)=CCC\\C(C)=C\\CO[P@@](=O)(O)OP(=O)(O)O",
        "id": "DB02552",
        "molecule": "Geranyl Diphosphate",
        "iupac_name": "[({[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}(hydroxy)phosphoryl)oxy]phosphonic acid",
        "inchi": {
            "hash": "GVVPGTZRZFNKDS-JXMROGBWSA-N",
            "id": "InChI=1S/C10H20O7P2/c1-9(2)5-4-6-10(3)7-8-16-19(14,15)17-18(11,12)13/h5,7H,4,6,8H2,1-3H3,(H,14,15)(H2,11,12,13)/b10-7+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 314.2091,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 314.068426018,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as isoprenoid phosphates. These are prenol lipids containing a phosphate group linked to an isoprene (2-methylbuta-1,3-diene) unit.",
        "link": "https://go.drugbank.com/drugs/DB02552",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "U2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFarnesyl pyrophosphate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Streptomyces sp. (strain CL190)",
                "target": "UPrenyltransferase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGeranylgeranyl pyrophosphate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "U(2Z,6E)-farnesyl diphosphate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UDecaprenyl diphosphate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Shigella flexneri",
                "target": "U2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase"
            },
            {
                "action": "Not Available",
                "organism": "Campylobacter jejuni subsp. jejuni serotype O:2 (strain NCTC 11168)",
                "target": "UBifunctional enzyme IspD/IspF"
            }
        ]
    },
    {
        "smiles": "[Fe]",
        "id": "DB01592",
        "molecule": "Iron",
        "cas": "7439-89-6",
        "iupac_name": "iron",
        "background": "A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.\n",
        "inchi": {
            "hash": "XEEYBQQBJWHFJM-UHFFFAOYSA-N",
            "id": "InChI=1S/Fe"
        },
        "summary": "Iron is an essential element commonly used for the treatment of patients with documented iron deficiency.",
        "weight": [
            {
                "type": "average",
                "weight": 55.845,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 55.934942133,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.",
        "link": "https://go.drugbank.com/drugs/DB01592",
        "type": "Small Molecule",
        "synonyms": [
            "Carbonyl iron",
            "Eisen",
            "Electrolytic iron",
            "Fe",
            "fer",
            "Ferrum",
            "Ferrum metallicum",
            "Hierro",
            "Iron powder",
            "Iron, carbonyl",
            "Iron, electrolytic",
            "Iron, elemental",
            "Iron, reduced",
            "Reduced iron"
        ],
        "indication": "Used in preventing and treating iron-deficiency anemia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTransferrin receptor protein 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEgl nine homolog 1"
            },
            {
                "action": "cofactor",
                "organism": "Humans",
                "target": "UHistone deacetylase 8"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-hemoglobin-stabilizing protein"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHemoglobin subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFrataxin, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFerritin heavy chain"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFlap endonuclease 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEndonuclease 8-like 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEndonuclease 8-like 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA polymerase beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCeruloplasmin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerotransferrin"
            }
        ]
    },
    {
        "smiles": "[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CS(O)(=O)=O)C(=O)N([H])CC(O)=O)C(O)=O",
        "id": "DB03003",
        "molecule": "Glutathione sulfonic acid",
        "cas": "3773-07-7",
        "iupac_name": "(2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfoethyl]carbamoyl}butanoic acid",
        "inchi": {
            "hash": "QGWRMTHFAZVWAM-WDSKDSINSA-N",
            "id": "InChI=1S/C10H17N3O9S/c11-5(10(18)19)1-2-7(14)13-6(4-23(20,21)22)9(17)12-3-8(15)16/h5-6H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)(H,20,21,22)/t5-,6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 355.322,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 355.068549847,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB03003",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione S-transferase Mu 4"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione S-transferase A1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione S-transferase P"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UGlutathione S-transferase GstA"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04504"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12733"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04342"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01832"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12929"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08138"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08667"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05633"
    },
    {
        "smiles": "FC1=CC(=CC(=C1)C(=O)NC1=CC=C2NC=CC2=C1)N1CCOCC1",
        "id": "DB08092",
        "molecule": "3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide",
        "iupac_name": "3-fluoro-N-(1H-indol-5-yl)-5-(morpholin-4-yl)benzamide",
        "background": "3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide is a solid. This compound belongs to the phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond. This drug targets mitogen-activated protein kinase 14.\n",
        "inchi": {
            "hash": "VMLSXFMXUNVCSK-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H18FN3O2/c20-15-9-14(11-17(12-15)23-5-7-25-8-6-23)19(24)22-16-1-2-18-13(10-16)3-4-21-18/h1-4,9-12,21H,5-8H2,(H,22,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 339.3635,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 339.13830504,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.",
        "link": "https://go.drugbank.com/drugs/DB08092",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 14"
            }
        ]
    },
    {
        "smiles": "CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C",
        "id": "DB01436",
        "molecule": "Alfacalcidol",
        "cas": "41294-56-8",
        "iupac_name": "(1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol",
        "background": "Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of vitamin D.4 It plays an essential function in calcium homeostasis and bone metabolism. Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones. The pharmacological actions of alfacalcidol are prolonged than vitamin D because a negative feedback mechanism regulates the final activation step of vitamin D in the kidneys.1,2\nAlfacalcidol is available in oral and intravenous formulations. In Canada, it is marketed as ONE-ALPHA, which manages hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in adults with chronic renal failure.9 In approving European countries, alfacalcidol is also indicated for managing nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.11,12\n",
        "inchi": {
            "hash": "OFHCOWSQAMBJIW-AVJTYSNKSA-N",
            "id": "InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1"
        },
        "summary": "Alfacalcidol is a vitamin D analogue used for the management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure, as well as some types of rickets and osteomalacia.",
        "weight": [
            {
                "type": "average",
                "weight": 400.6371,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 400.334130652,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.",
        "link": "https://go.drugbank.com/drugs/DB01436",
        "type": "Small Molecule",
        "synonyms": [
            "(5Z,7E)-9,10-seco-5,7,10(19)-cholestatrien-1,3-diol",
            "1-hydroxycholecalciferol",
            "1alpha-hydroxycholecalciferol",
            "1-hydroxy-vitamin D3",
            "1-hydroxycholecalciferol",
            "1-hydroxyvitamin D3",
            "9,10-secocholesta-5,7,10(19)-triene-1,3-diol",
            "Alfacalcidol",
            "Alfacalcidolum"
        ],
        "indication": "Alfacalcidol is indicated in adult patients with chronic renal failure for the management of hypocalcemia, secondary hyperparathyroidism, or osteodystrophy.9\nAlfacalcidol is indicated in the management of nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.11,12\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Alfacalcidol works to increase serum levels of calcium by stimulating intestinal calcium absorption, reabsorption of calcium from bone, and possibly the renal reabsorption of calcium. It also modestly promotes intestinal phosphorus absorption.9 In patients with renal failure, alfacalcidol increased intestinal calcium and phosphorus absorption in a dose-related manner. This increase in calcium and phosphorus levels occurs within three days following drug administration: this effect was reversed within three days of drug discontinuation. In patients with chronic renal failure, serum calcium levels were elevated while parathyroid hormone and alkaline phosphatase levels returned to normal levels within five days following alfacalcidol administration.12 Since alfacalcidol suppresses parathyroid hormone, a reduction in parathyroid hormone levels is achieved more rapidly in patients on intermittent intravenous therapy, with significant reductions occurring within three months of therapy. In patients receiving daily oral therapy of alfacalcidol, the time it takes alfacalcidol to normalize plasma calcium levels may be up to several months, possibly reflecting calcium being utilized for bone mineralization.9 In patients with nutritional osteomalacia, alfacalcidol increased calcium absorption with six hours of oral administration and the effects peaked at 24 hours.12\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AVitamin D3 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URetinoic acid receptor RXR-alpha"
            }
        ]
    },
    {
        "smiles": "CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2",
        "id": "DB04209",
        "molecule": "Dequalinium",
        "cas": "6707-58-0",
        "iupac_name": "4-amino-1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium",
        "background": "Dequalinium is an antibacterial agent with multi-targeted actions. It also possesses antifungal, antiparasitic, antiviral, anticancer, and neuroprotective properties.9 It is a quaternary ammonium compound,10 as it consists of an amphipathic cation with two aminoquinaldinium rings at both ends of a long hydrophobic hydrocarbon chain. Due to its flexible structure, dequalinium was investigated to build drug and gene delivery systems.9\nFirst used as an antiseptic and disinfectant in the 1950s, dequalinium is still found in various OTC products to treat conditions of oral infections and inflammation.9 It is also used in vaginal tablets to treat bacterial vaginosis.10\n",
        "inchi": {
            "hash": "PCSWXVJAIHCTMO-UHFFFAOYSA-P",
            "id": "InChI=1S/C30H38N4/c1-23-21-27(31)25-15-9-11-17-29(25)33(23)19-13-7-5-3-4-6-8-14-20-34-24(2)22-28(32)26-16-10-12-18-30(26)34/h9-12,15-18,21-22,31-32H,3-8,13-14,19-20H2,1-2H3/p+2"
        },
        "summary": "Dequalinium is a quaternary ammonium cation antimicrobial agent used to treat common infections of the mouth and throat, as well as vaginal candidiasis.",
        "weight": [
            {
                "type": "average",
                "weight": 456.6654,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 456.3252973,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.",
        "link": "https://go.drugbank.com/drugs/DB04209",
        "type": "Small Molecule",
        "synonyms": [
            "1,1'-(1,10-Decanediyl)bis(4-amino-2-methylquinolinium) dichloride",
            "1,1'-Decamethylenebis(4-aminoquinaldinium chloride)",
            "Decamethylenebis(4-aminoquinaldinium chloride)"
        ],
        "indication": "Dequalinium is used in several OTC products to treat mouth infections and inflammation, such as tonsillitis, pharyngitis, and gingivitis.9 As vaginal tablets, dequalinium is indicated for the treatment of bacterial vaginosis in adult women under 55 years of age.10\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "In vitro, dequalinium possesses antimicrobial activity against gram-positive and gram-negative bacteria, yeasts, and protozoa.6 Dequalinium has a rapid bactericidal and fungicidal action.1 The antiparasitic and antiviral properties of dequalinium have also been noted. For example, dequalinium can bind to the membrane-proximal external region (MPER) of the spike envelope of the human immunodeficiency virus HIV-1.9\nAs with other quaternary ammonium compounds similar to dequalinium, gram-positive bacteria are more sensitive to dequalinium than gram-negative bacteria.6,10 The bactericidal and fungicidal effects of dequalinium can occur within 30 to 60 minutes.7 According to in vitro studies, the minimal inhibitory concentration (MIC) for dequalinium against relevant vaginal pathogens ranges from 0.2 to  1024 g/mL.10\nThere is evidence that dequalinium exhibits anticancer activity in human leukemia cells: dequalinium induces a cytotoxic effect by altering redox balance, downregulating Raf/MEK/ERK1/2 and PI3K/Akt signalling pathways, and promoting apoptosis of leukemic cells.3,4,5 Dequalinium was also shown to block small conductance Ca2+-activated K+ channels, called SK channels, which are often expressed in some cancer cells to play a role in cell proliferation and migration.9 One study showed that dequalinium reduced macrophage motility in mice, inhibiting macrophage infiltration of irradiated tumours and attenuating local metastasis.2\nInterestingly, dequalinium was shown to modulate and induce self-oligomerization of alpha-synuclein, a synaptic protein known to cause aggregates in several neurodegenerative disorders. This finding highlights the neuroprotective actions of dequalinium; however, further investigations are warranted as dequalinium is a neurotoxic agent.9\n",
        "moa": [
            {
                "action": "antagonistinhibitor",
                "organism": "Humans",
                "target": "AE3 ubiquitin-protein ligase XIAP"
            },
            {
                "action": "blocker",
                "organism": "Humans",
                "target": "UcGMP-gated cation channel alpha-1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCalcium-activated potassium channel subunit alpha-1"
            },
            {
                "action": "regulator",
                "organism": "Staphylococcus aureus",
                "target": "UHTH-type transcriptional regulator QacR"
            },
            {
                "action": "regulator",
                "organism": "Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145)",
                "target": "UResponse regulator RamR"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UCalmodulin"
            },
            {
                "action": "blocker",
                "organism": "Humans",
                "target": "USmall conductance calcium-activated potassium channel protein 3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProtein kinase C"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "UAlpha-synuclein"
            },
            {
                "action": "inhibitor",
                "organism": "Mycobacterium tuberculosis (strain ATCC 25177 / H37Ra)",
                "target": "UL-cysteine:1D-myo-inositol 2-amino-2-deoxy-alpha-D-glucopyranoside ligase"
            }
        ]
    },
    {
        "smiles": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2",
        "id": "DB00530",
        "molecule": "Erlotinib",
        "cas": "183321-74-6",
        "iupac_name": "N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine",
        "background": "Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.\n",
        "inchi": {
            "hash": "AAKJLRGGTJKAMG-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)"
        },
        "summary": "Erlotinib is an EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers.",
        "weight": [
            {
                "type": "average",
                "weight": 393.4357,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 393.168856239,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB00530",
        "type": "Small Molecule",
        "synonyms": [
            "[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",
            "Erlotinib"
        ],
        "indication": "Erlotinib is indicated for:\n\nThe treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations Label. \nIn combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer Label.\n\nThe safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy. Label\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ANuclear receptor subfamily 1 group I member 2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AEpidermal growth factor receptor"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC=C2OC(=O)C1=CC=CC=C1",
        "id": "DB15465",
        "molecule": "Benzhydrocodone",
        "cas": "1259440-61-3",
        "iupac_name": "(1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,14-tetraen-14-yl benzoate",
        "background": "Benzhydrocodone is a benzylic prodrug of hydrocodone.5 It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.4 Benzhydrocodone is indicated for use in the short-term management of pain. It was first approved by the FDA in February 2018 in combination with acetaminophen under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.6,7\n",
        "inchi": {
            "hash": "VPMRSLWWUXNYRY-NDOYXKHWSA-N",
            "id": "InChI=1S/C25H25NO4/c1-26-13-12-25-17-9-11-20(29-24(27)15-6-4-3-5-7-15)23(25)30-22-19(28-2)10-8-16(21(22)25)14-18(17)26/h3-8,10-11,17-18,23H,9,12-14H2,1-2H3/t17-,18-,23+,25+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 403.478,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 403.178358289,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15465",
        "type": "Small Molecule",
        "synonyms": [
            "Benzhydrocodone"
        ],
        "indication": "Benzyhydrocodone is indicated, in combination with acetaminophen, for the short-term management of acute pain requiring opioid therapy.5\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Benzhydrocodone is rapidly metabolized to hydrocodone which acts on the central nervous system to produce analgesia. The action of hydrocodone in the brain can also produce euphoria, leading to addiction.\n"
    },
    {
        "smiles": "NC1=CC=C2N=C3N(CC2=C1)C(=O)C1=CC=CC=C31",
        "id": "DB12804",
        "molecule": "Daniquidone",
        "cas": "67199-66-0",
        "iupac_name": "8-amino-10H,12H-isoindolo[1,2-b]quinazolin-12-one",
        "background": "Daniquidone has been used in trials studying the treatment of Neoplasms.\n",
        "inchi": {
            "hash": "SRIOCKJKFXAKHK-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H11N3O/c16-10-5-6-13-9(7-10)8-18-14(17-13)11-3-1-2-4-12(11)15(18)19/h1-7H,8,16H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 249.273,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 249.090211986,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indoloquinazolines. These are polycyclic aromatic compounds containing an indole fused to a quinazoline. Indole is a bicyclic compound consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring. Quinazoline is a heterocyclic compound consisting of two fused six-membered simple aromatic rings, a benzene ring and a pyrimidine ring.",
        "link": "https://go.drugbank.com/drugs/DB12804",
        "type": "Small Molecule",
        "synonyms": [
            "Batracylin",
            "Daniquidone"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=C(NC2=NC=C(C(OC3=CC=CC4=C3C(=O)N(C)C4)=N2)C(F)(F)F)C=C(F)C(=C1)C(=O)NC1CCN(C)CC1",
        "id": "DB17570",
        "molecule": "Ifebemtinib",
        "cas": "1227948-82-4",
        "iupac_name": "2-fluoro-5-methoxy-4-({4-[(2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)-N-(1-methylpiperidin-4-yl)benzamide",
        "inchi": {
            "hash": "ULMMVBPTWVRPSI-UHFFFAOYSA-N",
            "id": "InChI=1S/C28H28F4N6O4/c1-37-9-7-16(8-10-37)34-24(39)17-11-22(41-3)20(12-19(17)29)35-27-33-13-18(28(30,31)32)25(36-27)42-21-6-4-5-15-14-38(2)26(40)23(15)21/h4-6,11-13,16H,7-10,14H2,1-3H3,(H,34,39)(H,33,35,36)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 588.564,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 588.210816058,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17570",
        "type": "Small Molecule",
        "synonyms": [
            "Ifebemtinib"
        ]
    },
    {
        "smiles": "FC1=C(OC(F)(F)F)C=CC(CNC(=O)[C@H]2CN(CCN2S(=O)(=O)C2=CC=C(C=C2)C(F)(F)F)C2=NC3=C(S2)C=NC(=N3)C2CC2)=C1",
        "id": "DB13095",
        "molecule": "JTK-853",
        "cas": "954389-09-4",
        "iupac_name": "(2R)-4-{5-cyclopropyl-[1,3]thiazolo[4,5-d]pyrimidin-2-yl}-N-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-1-[4-(trifluoromethyl)benzenesulfonyl]piperazine-2-carboxamide",
        "background": "JTK-853 has been used in trials studying the treatment of Hepatitis C Virus Infection, Response to Therapy of.\n",
        "inchi": {
            "hash": "JQLOVYLALGSISI-HXUWFJFHSA-N",
            "id": "InChI=1S/C28H23F7N6O4S2/c29-19-11-15(1-8-21(19)45-28(33,34)35)12-37-25(42)20-14-40(26-39-24-22(46-26)13-36-23(38-24)16-2-3-16)9-10-41(20)47(43,44)18-6-4-17(5-7-18)27(30,31)32/h1,4-8,11,13,16,20H,2-3,9-10,12,14H2,(H,37,42)/t20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 704.639,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 704.111042069,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB13095",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "COC1=C(OC)C(OC)=C2C(CCC(NC(C)=O)C3=CC(=O)C(O)=CC=C23)=C1",
        "id": "DB15534",
        "molecule": "Colchiceine",
        "cas": "477-27-0",
        "iupac_name": "N-{14-hydroxy-3,4,5-trimethoxy-13-oxotricyclo[9.5.0.0^{2,7}]hexadeca-1(16),2,4,6,11,14-hexaen-10-yl}acetamide",
        "background": "Colchiceine is one of several metabolites of the anti-gout medication colchicine.1\n",
        "inchi": {
            "hash": "PRGILOMAMBLWNG-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H23NO6/c1-11(23)22-15-7-5-12-9-18(26-2)20(27-3)21(28-4)19(12)13-6-8-16(24)17(25)10-14(13)15/h6,8-10,15H,5,7H2,1-4H3,(H,22,23)(H,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 385.416,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 385.152537465,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15534",
        "type": "Small Molecule",
        "synonyms": [
            "10-O-demethylcolchicine",
            "O-Demethylcolchicine",
            "O10-Demethylcolchicine"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UTubulin beta chain"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UTubulin alpha-1A chain"
            }
        ]
    },
    {
        "smiles": "C[C@@H](OC1=NN=C(N1C)C1=CC=NC=C1)C1=NOC(=C1)C1=CC(Cl)=CC=C1",
        "id": "DB17078",
        "molecule": "AZD2066",
        "cas": "934282-55-0",
        "iupac_name": "4-{5-[(1R)-1-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl}pyridine",
        "inchi": {
            "hash": "SXWHYTICXCLKDG-GFCCVEGCSA-N",
            "id": "InChI=1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 381.82,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 381.0992525,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridyl-1,2,4-triazoles. These are organic compounds containing a pyridine ring attached to a 1,2,4-triazole ring.",
        "link": "https://go.drugbank.com/drugs/DB17078",
        "type": "Small Molecule",
        "synonyms": [
            "Pyridine, 4-(5-((1r)-1-(5-(3-chlorophenyl)-3-isoxazolyl)ethoxy)-4-methyl-4h-1,2,4-triazol-3-yl)-"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB02379",
        "molecule": "Beta-D-Glucose",
        "cas": "492-61-5",
        "iupac_name": "(2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol",
        "background": "A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.\n",
        "inchi": {
            "hash": "WQZGKKKJIJFFOK-VFUOTHLCSA-N",
            "id": "InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 180.1559,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 180.063388116,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB02379",
        "type": "Small Molecule",
        "synonyms": [
            "beta-D-glucopyranose",
            "Beta-D-glucose anhydrous",
            "Beta-D-glucose, anhydrous",
            "Glucoside",
            "-D-glucose"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA"
            },
            {
                "action": "Not Available",
                "organism": "Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / NCIB 9290)",
                "target": "UChondroitinase-B"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus agaradhaerens",
                "target": "UEndoglucanase 5A"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULactase-like protein"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, muscle form"
            },
            {
                "action": "Not Available",
                "organism": "Streptomyces olivochromogenes",
                "target": "UXylose isomerase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlucokinase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UFerrichrome-iron receptor"
            },
            {
                "action": "Not Available",
                "organism": "Thermoactinomyces vulgaris",
                "target": "UNeopullulanase 1"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus circulans",
                "target": "UCyclomaltodextrin glucanotransferase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMyoglobin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHexokinase-1"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UAlpha-amylase"
            },
            {
                "action": "Not Available",
                "organism": "Cellulomonas fimi",
                "target": "UExoglucanase/xylanase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus sp. (strain 1011)",
                "target": "UCyclomaltodextrin glucanotransferase"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium cellulolyticum (strain ATCC 35319 / DSM 5812 / JCM 6584 / H10)",
                "target": "UEndoglucanase G"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGalectin-7"
            },
            {
                "action": "Not Available",
                "organism": "Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)",
                "target": "UCholera enterotoxin subunit B"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides",
                "target": "UDimethyl sulfoxide/trimethylamine N-oxide reductase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-amylase 2B"
            },
            {
                "action": "Not Available",
                "organism": "Thermoactinomyces vulgaris",
                "target": "UNeopullulanase 2"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium botulinum",
                "target": "UBotulinum neurotoxin type B"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium tetani (strain Massachusetts / E88)",
                "target": "UTetanus toxin"
            },
            {
                "action": "Not Available",
                "organism": "Streptomyces rubiginosus",
                "target": "UXylose isomerase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus sp. (strain 707)",
                "target": "UGlucan 1,4-alpha-maltohexaosidase"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas stutzeri",
                "target": "UGlucan 1,4-alpha-maltotetraohydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium cellulolyticum (strain ATCC 35319 / DSM 5812 / JCM 6584 / H10)",
                "target": "UEndoglucanase F"
            },
            {
                "action": "Not Available",
                "organism": "Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)",
                "target": "UGlucose--fructose oxidoreductase"
            },
            {
                "action": "Not Available",
                "organism": "Enterobacteria phage P22",
                "target": "UBifunctional tail protein"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, liver form"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPulmonary surfactant-associated protein D"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UInterferon beta"
            },
            {
                "action": "Not Available",
                "organism": "Pseudoalteromonas haloplanktis",
                "target": "UAlpha-amylase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycosyltransferase 6 domain-containing protein 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlucosamine-6-phosphate isomerase 1"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus cereus",
                "target": "UBeta-amylase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UADP-ribose pyrophosphatase, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5"
            },
            {
                "action": "Not Available",
                "organism": "Thermoanaerobacter thermosulfurogenes",
                "target": "UCyclomaltodextrin glucanotransferase"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus",
                "target": "UEnterotoxin type B"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-amylase 1"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMaltodextrin phosphorylase"
            },
            {
                "action": "Not Available",
                "organism": "Bacteriophage H30",
                "target": "UShiga-like toxin 1 subunit B"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeurocan core protein"
            },
            {
                "action": "Not Available",
                "organism": "Paenibacillus macerans",
                "target": "UBeta-glucanase"
            },
            {
                "action": "Not Available",
                "organism": "Acinetobacter calcoaceticus",
                "target": "UQuinoprotein glucose dehydrogenase B"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus amyloliquefaciens",
                "target": "UAlpha-amylase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMaltose-binding periplasmic protein"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UEnoyl-[acyl-carrier-protein] reductase [NADH] FabI"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium thermocellum",
                "target": "UEndoglucanase A"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium thermocellum",
                "target": "UCellulose 1,4-beta-cellobiosidase (reducing end) CelS"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UD-galactose-binding periplasmic protein"
            },
            {
                "action": "Not Available",
                "organism": "Streptomyces lividans",
                "target": "UCellulase B"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAspartate ammonia-lyase"
            },
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UPossible cellulase CelA1 (Endoglucanase) (Endo-1,4-beta-glucanase) (FI-cmcase) (Carboxymethyl cellulase)"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UGlucokinase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus sp.",
                "target": "UAmylase"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UFucose-binding lectin PA-IIL"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125)",
                "target": "UBH0236 protein"
            },
            {
                "action": "Not Available",
                "organism": "Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)",
                "target": "ULaminarinase"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium stercorarium",
                "target": "UEndo-1,4-beta-xylanase A"
            },
            {
                "action": "Not Available",
                "organism": "Cellvibrio mixtus",
                "target": "UCellulase B"
            },
            {
                "action": "Not Available",
                "organism": "Cellulomonas fimi (strain ATCC 484 / DSM 20113 / JCM 1341 / NBRC 15513 / NCIMB 8980 / NCTC 7547)",
                "target": "UEndoglucanase C"
            },
            {
                "action": "Not Available",
                "organism": "Lactococcus lactis",
                "target": "UAldose 1-epimerase"
            },
            {
                "action": "Not Available",
                "organism": "Neisseria polysaccharea",
                "target": "UAmylosucrase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPancreatic alpha-amylase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UPutative monooxygenase MoxC"
            },
            {
                "action": "Not Available",
                "organism": "Acidothermus cellulolyticus (strain ATCC 43068 / 11B)",
                "target": "UEndoglucanase E1"
            },
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UD-galactose-binding periplasmic protein"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UEcotin"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UA/G-specific adenine glycosylase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UKeratin-associated protein 5-2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USialoadhesin"
            },
            {
                "action": "Not Available",
                "organism": "Geobacillus stearothermophilus",
                "target": "UNeopullulanase"
            },
            {
                "action": "Not Available",
                "organism": "Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)",
                "target": "UEndo-1,4-beta-xylanase A"
            },
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UMaltoporin"
            },
            {
                "action": "Not Available",
                "organism": "Blood fluke",
                "target": "UHexokinase"
            },
            {
                "action": "Not Available",
                "organism": "Geobacillus stearothermophilus",
                "target": "UEndo-1,4-beta-xylanase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMaltoporin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGalectin-2"
            },
            {
                "action": "Not Available",
                "organism": "Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)",
                "target": "UMalto-oligosyltrehalose trehalohydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Arthrobacter sp. (strain KM)",
                "target": "UInorganic polyphosphate/ATP-glucomannokinase"
            },
            {
                "action": "Not Available",
                "organism": "Klebsiella pneumoniae",
                "target": "UDiacetyl reductase [(S)-acetoin forming]"
            },
            {
                "action": "Not Available",
                "organism": "MPyV",
                "target": "UCapsid protein VP1"
            },
            {
                "action": "Not Available",
                "organism": "Streptomyces olivaceoviridis",
                "target": "UHydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UKeratin-associated protein 5-3"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium sp. (strain F1)",
                "target": "UEndoglucanase C307"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium cellulovorans",
                "target": "UEndo-1,4-beta glucanase EngF"
            },
            {
                "action": "Not Available",
                "organism": "Thermomonospora fusca",
                "target": "UEndoglucanase E-4"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UOrf protein"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1",
        "id": "DB12364",
        "molecule": "Betrixaban",
        "cas": "330942-05-7",
        "iupac_name": "N-(5-chloropyridin-2-yl)-2-[4-(N,N-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide",
        "background": "Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa 1. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity 3. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE 2. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients 4.\n",
        "inchi": {
            "hash": "XHOLNRLADUSQLD-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)"
        },
        "summary": "Betrixaban is a Factor Xa inhibitor used for prophylaxis of venous thromboembolism in hospitalized patients.",
        "weight": [
            {
                "type": "average",
                "weight": 451.91,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 451.1411173,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.",
        "link": "https://go.drugbank.com/drugs/DB12364",
        "type": "Small Molecule",
        "synonyms": [
            "Betrixaban",
            "N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide",
            "N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide"
        ],
        "indication": "Betrixaban is indicated for prophylaxis of venous thromboembolism (VTE) in conditions of moderate to severe restricted mobility or in patients that qualify as in risk of VTE. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Betrixaban is an oral anticoagulant that excerts its action by preventing thrombin generation without having a direct effect on platelet aggregation 5.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACoagulation factor X"
            }
        ]
    },
    {
        "smiles": "OC(=O)\\C=C\\C(O)=O",
        "id": "DB01677",
        "molecule": "Fumaric acid",
        "cas": "110-17-8",
        "iupac_name": "(2E)-but-2-enedioic acid",
        "inchi": {
            "hash": "VZCYOOQTPOCHFL-OWOJBTEDSA-N",
            "id": "InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 116.0722,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 116.010958616,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dicarboxylic acids and derivatives. These are organic compounds containing exactly two carboxylic acid groups.",
        "link": "https://go.drugbank.com/drugs/DB01677",
        "type": "Small Molecule",
        "synonyms": [
            "(2E)-2-butenedioic acid",
            "(E)-2-butenedioic acid",
            "Fumaric acid",
            "Fumaricum acidum",
            "Fumarsure",
            "trans-1,2-ethylenedicarboxylic acid",
            "trans-but-2-enedioic acid",
            "trans-Butenedioic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Chloroflexus aurantiacus (strain ATCC 29366 / DSM 635 / J-10-fl)",
                "target": "UMalate dehydrogenase"
            },
            {
                "action": "Not Available",
                "organism": "Shewanella oneidensis (strain MR-1)",
                "target": "UFumarate reductase flavoprotein subunit"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNAD-dependent malic enzyme, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFumarylacetoacetase"
            },
            {
                "action": "Not Available",
                "organism": "Shewanella frigidimarina",
                "target": "UFumarate reductase flavoprotein subunit"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1",
        "id": "DB08868",
        "molecule": "Fingolimod",
        "cas": "162359-55-9",
        "iupac_name": "2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol",
        "background": "Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.3 Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010.12 Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.13,14\n",
        "inchi": {
            "hash": "KKGQTZUTZRNORY-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3"
        },
        "summary": "Fingolimod is a sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19.",
        "weight": [
            {
                "type": "average",
                "weight": 307.4708,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 307.251129305,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.",
        "link": "https://go.drugbank.com/drugs/DB08868",
        "type": "Small Molecule",
        "synonyms": [
            "Fingolimod",
            "Fingolimodum"
        ],
        "indication": "Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.12,16\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "In multiple sclerosis, fingolimod binds to sphingosine receptors, reducing its associated neuroinflammation.12In COVID-19, it may reduce lung inflammation and improve the clinical outcomes of patients with this disease.13 \nFingolimod causes a transient reduction in heart rate and AV conduction during treatment initiation. It has the potential to prolong the QT interval.13\n",
        "moa": [
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "ASphingosine 1-phosphate receptor 5"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "ASphingosine 1-phosphate receptor 1"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "ASphingosine 1-phosphate receptor 3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UHistone deacetylase 1"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "USphingosine 1-phosphate receptor 4"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14096"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06841"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04220"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11279"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07155"
    },
    {
        "smiles": "[H][H]",
        "id": "DB15127",
        "molecule": "Hydrogen",
        "cas": "1333-74-0",
        "iupac_name": "dihydrogen",
        "background": "Hydrogen is under investigation in clinical trial NCT02830854 (Molecular Hydrogen for Cognitive Function and Performance in Elderly).\n",
        "inchi": {
            "hash": "UFHFLCQGNIYNRP-UHFFFAOYSA-N",
            "id": "InChI=1S/H2/h1H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 2.016,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 2.015650064,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15127",
        "type": "Small Molecule",
        "synonyms": [
            "Dihydrogen",
            "Molecular hydrogen",
            "Protium"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](N)(CCC1=CC=CC=C1)C(C)=O",
        "id": "DB07913",
        "molecule": "HOMOPHENYLALANINYLMETHANE",
        "iupac_name": "(3S)-3-amino-5-phenylpentan-2-one",
        "inchi": {
            "hash": "ZDTWNRLBYDWRII-NSHDSACASA-N",
            "id": "InChI=1S/C11H15NO/c1-9(13)11(12)8-7-10-5-3-2-4-6-10/h2-6,11H,7-8,12H2,1H3/t11-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 177.2429,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 177.115364107,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.",
        "link": "https://go.drugbank.com/drugs/DB07913",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCathepsin F"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02675"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13600"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14783"
    },
    {
        "smiles": "CCC1(CC)C(=O)NC(=O)NC1=O",
        "id": "DB01483",
        "molecule": "Barbital",
        "cas": "57-44-3",
        "iupac_name": "5,5-diethyl-1,3-diazinane-2,4,6-trione",
        "background": "A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.\n",
        "inchi": {
            "hash": "FTOAOBMCPZCFFF-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 184.1925,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 184.08479226,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.",
        "link": "https://go.drugbank.com/drugs/DB01483",
        "type": "Small Molecule",
        "synonyms": [
            "Barbital"
        ],
        "moa": [
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-1"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-2"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-3"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-4"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-5"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-6"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-7"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor 2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15031"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08999"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05179"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04071"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04436"
    },
    {
        "smiles": "NC1=C2C(SC=C2C2=CC=C(NC(=O)NC3=CC(F)=CC=C3)C=C2)=C(C=N1)C1=CN(CCO)N=C1",
        "id": "DB11694",
        "molecule": "Ilorasertib",
        "cas": "1227939-82-3",
        "iupac_name": "1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea",
        "background": "Ilorasertib has been used in trials studying the treatment of Myelodysplasia, Solid Neoplasm, Advanced Cancers, Advanced Solid Tumors, and Acute Myelogenous Leukemia, among others.\n",
        "inchi": {
            "hash": "WPHKIQPVPYJNAX-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 488.54,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 488.143073277,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrazolylpyridines. These are compounds containing a pyrazolylpyridine skeleton, which consists of a pyrazole linked (not fused) to a pyridine by a bond.",
        "link": "https://go.drugbank.com/drugs/DB11694",
        "type": "Small Molecule",
        "synonyms": [
            "1-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea",
            "1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)",
            "Ilorasertib",
            "Urea, N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno(3,2-c)pyridin-3-yl)phenyl)-N'-(3-fluorophenyl)-"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)CCC(=O)NC1=CC=C(Br)C=N1",
        "id": "DB08578",
        "molecule": "4-[(5-bromopyridin-2-yl)amino]-4-oxobutanoic acid",
        "iupac_name": "3-[(5-bromopyridin-2-yl)carbamoyl]propanoic acid",
        "inchi": {
            "hash": "XFYYQDHEDOXWGA-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H9BrN2O3/c10-6-1-2-7(11-5-6)12-8(13)3-4-9(14)15/h1-2,5H,3-4H2,(H,14,15)(H,11,12,13)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 273.083,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 271.979654811,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-arylamides. These are organic compounds that contain a carboxamide group that is N-linked to a aryl group. They have the generic structure RC(=O)N(R')H, R = organyl group and R'= aryl group.",
        "link": "https://go.drugbank.com/drugs/DB08578",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Hepatitis C virus genotype 1b (isolate BK)",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "smiles": "CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1",
        "id": "DB13443",
        "molecule": "Esatenolol",
        "cas": "93379-54-5",
        "iupac_name": "2-{4-[(2S)-2-hydroxy-3-[(propan-2-yl)amino]propoxy]phenyl}acetamide",
        "background": "Esatenolol is a beta blocker.\n",
        "inchi": {
            "hash": "METKIMKYRPQLGS-LBPRGKRZSA-N",
            "id": "InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)/t12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 266.341,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 266.163042576,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.",
        "link": "https://go.drugbank.com/drugs/DB13443",
        "type": "Small Molecule",
        "synonyms": [
            "(-)-Atenolol",
            "(S)-4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide",
            "2-(p-((2S)-2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide",
            "Esatenolol",
            "S-(-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide",
            "S-atenolol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1=C(C)C(OCCCC(O)=O)=CC=C1NC(=O)NC(=O)C1=CC=C(Cl)C=C1Cl",
        "id": "DB04644",
        "molecule": "4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID",
        "iupac_name": "4-(4-{[(2,4-dichlorobenzoyl)carbamoyl]amino}-2,3-dimethylphenoxy)butanoic acid",
        "inchi": {
            "hash": "FCEMCUPAYRPTLS-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H20Cl2N2O5/c1-11-12(2)17(29-9-3-4-18(25)26)8-7-16(11)23-20(28)24-19(27)14-6-5-13(21)10-15(14)22/h5-8,10H,3-4,9H2,1-2H3,(H,25,26)(H2,23,24,27,28)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 439.289,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 438.074927174,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-benzoyl-n'-phenylureas. These are n-acyl-phenylureas that have the acyl group substituted by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB04644",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, muscle form"
            }
        ]
    },
    {
        "smiles": "COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br",
        "id": "DB13795",
        "molecule": "Brodimoprim",
        "cas": "56518-41-3",
        "iupac_name": "5-[(4-bromo-3,5-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine",
        "inchi": {
            "hash": "BFCRRLMMHNLSCP-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H15BrN4O2/c1-19-9-4-7(5-10(20-2)11(9)14)3-8-6-17-13(16)18-12(8)15/h4-6H,3H2,1-2H3,(H4,15,16,17,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 339.193,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 338.037839,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.",
        "link": "https://go.drugbank.com/drugs/DB13795",
        "type": "Small Molecule",
        "synonyms": [
            "2,4-diamino-5-(4-bromo-3,5-dimethoxybenzyl)pyrimidine",
            "Brodimoprim",
            "Brodimoprima",
            "Brodimoprime",
            "Brodimoprimum"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C",
        "id": "DB00944",
        "molecule": "Demecarium",
        "cas": "16505-84-3",
        "iupac_name": "N,N,N-trimethyl-3-{[methyl({10-[methyl({[3-(trimethylazaniumyl)phenoxy]carbonyl})amino]decyl})carbamoyl]oxy}anilinium",
        "background": "Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle. The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.\n",
        "inchi": {
            "hash": "RWZVPVOZTJJMNU-UHFFFAOYSA-N",
            "id": "InChI=1S/C32H52N4O4/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8/h17-22,25-26H,9-16,23-24H2,1-8H3/q+2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 556.7797,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 556.398856172,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenoxy compounds. These are aromatic compounds contaning a phenoxy group.",
        "link": "https://go.drugbank.com/drugs/DB00944",
        "type": "Small Molecule",
        "synonyms": [
            "Demecarium",
            "Demecarium cation",
            "Demecarium ion"
        ],
        "indication": "For the topical treatment of chronic open-angle glaucoma.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Demecarium is a long-acting cholinesterase inhibitor and potent miotic. Because of its toxicity, it should be reserved for use in patients with open-angle glaucoma or other chronic glaucomas not satisfactorily controlled with the short-acting miotics and other agents. Application of demecarium to the eye produces intense miosis and ciliary muscle contraction due to inhibition of cholinesterase, allowing acetylcholine to accumulate at sites of cholinergic transmission. These effects are accompanied by increased capillary permeability of the ciliary body and iris, increased permeability of the blood-aqueous barrier, and vasodilation. Myopia may be induced or, if present, may be augmented by the increased refractive power of the lens that results from the accommodative effect of the drug.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AAcetylcholinesterase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCholinesterase"
            }
        ]
    },
    {
        "smiles": "[H][C@](O)(CO)CO[P@@]([O-])(=O)OC[C@@]([H])(COC(=O)CCCC)OC(=O)CCCCCCC",
        "id": "DB07349",
        "molecule": "(1S)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PENTANOYLOXY)METHYL]ETHYL OCTANOATE",
        "iupac_name": "(2R)-1-{[(2S)-2,3-dihydroxypropyl phosphonato]oxy}-3-(pentanoyloxy)propan-2-yl octanoate",
        "inchi": {
            "hash": "UQSXQYRZHMGKIE-DLBZAZTESA-M",
            "id": "InChI=1S/C19H37O10P/c1-3-5-7-8-9-11-19(23)29-17(14-26-18(22)10-6-4-2)15-28-30(24,25)27-13-16(21)12-20/h16-17,20-21H,3-15H2,1-2H3,(H,24,25)/p-1/t16-,17+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 455.4569,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 455.204608884,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phosphatidylglycerols. These are glycerophosphoglycerols in which two fatty acids are bonded to the 1-glycerol moiety through ester linkages. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions.",
        "link": "https://go.drugbank.com/drugs/DB07349",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "URespiratory nitrate reductase 1 alpha chain"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "URespiratory nitrate reductase 1 beta chain"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "URespiratory nitrate reductase 1 gamma chain"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAquaporin Z"
            }
        ]
    },
    {
        "smiles": "CCOC(=O)N1CCC(CC1)NC1=NC=CC(C)=C1",
        "id": "DB07388",
        "molecule": "ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE",
        "iupac_name": "ethyl 4-[(4-methylpyridin-2-yl)amino]piperidine-1-carboxylate",
        "inchi": {
            "hash": "LNRMJBWADUSJTA-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H21N3O2/c1-3-19-14(18)17-8-5-12(6-9-17)16-13-10-11(2)4-7-15-13/h4,7,10,12H,3,5-6,8-9H2,1-2H3,(H,15,16)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 263.3354,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 263.163376931,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as piperidinecarboxylic acids. These are compounds containing a piperidine ring which bears a carboxylic acid group.",
        "link": "https://go.drugbank.com/drugs/DB07388",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, inducible"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, endothelial"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01878"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07447"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06967"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04294"
    },
    {
        "id": "DB05196",
        "molecule": "ACR325",
        "background": "ACR325 is developed for the treatment of Parkinsons disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects. ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05196",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in affective disorders, bipolar disorders, and psychosis.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "O[C@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1OP(O)(O)=O",
        "id": "DB03956",
        "molecule": "Inositol 2,4,5-trisphosphate",
        "cas": "91840-07-2",
        "iupac_name": "{[(1R,2S,3S,4S,5S,6R)-2,3,5-trihydroxy-4,6-bis(phosphonooxy)cyclohexyl]oxy}phosphonic acid",
        "inchi": {
            "hash": "MMWCIQZXVOZEGG-LKPKBOIGSA-N",
            "id": "InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2-,3-,4-,5+,6+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 420.0956,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 419.962379346,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as inositol phosphates. These are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety.",
        "link": "https://go.drugbank.com/drugs/DB03956",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]",
        "id": "DB13857",
        "molecule": "Demegestone",
        "cas": "10116-22-0",
        "iupac_name": "(1S,3aS,3bS,11aS)-1-acetyl-1,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-7-one",
        "background": "Demegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.\n",
        "inchi": {
            "hash": "JWAHBTQSSMYISL-MHTWAQMVSA-N",
            "id": "InChI=1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 312.4458,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 312.20893014,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 20-oxosteroids. These are steroid derivatives carrying a C=O group at the 20-position of the steroid skeleton.",
        "link": "https://go.drugbank.com/drugs/DB13857",
        "type": "Small Molecule",
        "synonyms": [
            "Demegestone"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProgesterone receptor"
            }
        ]
    },
    {
        "smiles": "NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB06413",
        "molecule": "Armodafinil",
        "cas": "112111-43-0",
        "iupac_name": "2-[(R)-diphenylmethanesulfinyl]acetamide",
        "background": "Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the ()-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.\n",
        "inchi": {
            "hash": "YFGHCGITMMYXAQ-LJQANCHMSA-N",
            "id": "InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1"
        },
        "summary": "Armodafinil is a stimulant used to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy, or shift work disorder.",
        "weight": [
            {
                "type": "average",
                "weight": 273.35,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 273.082349901,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB06413",
        "type": "Small Molecule",
        "synonyms": [
            "()-2-[(R)-(diphenylmethyl)sulfinyl]acetamide",
            "()-(R)-modafinil",
            "()-modafinil",
            "(R)-()-modafinil",
            "(R)-modafinil",
            "Armodafinil",
            "Armodafinilo",
            "Armodafinilum",
            "R-modafinil"
        ],
        "indication": "Investigated for use/treatment in sleep disorders, obstructive sleep apnea, schizophrenia and schizoaffective disorders, depression, and bipolar disorders.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "antagonistinhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent dopamine transporter"
            }
        ]
    },
    {
        "smiles": "NC1=CC=C(C=N1)C#CC1=C2N=C(C=C(N2N=C1)C(F)(F)F)C1=CC=C(C=C1)C(F)(F)F",
        "id": "DB11923",
        "molecule": "Decoglurant",
        "cas": "911115-16-7",
        "iupac_name": "5-{2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl}pyridin-2-amine",
        "background": "Decoglurant has been used in trials studying the treatment of Major Depressive Disorder.\n",
        "inchi": {
            "hash": "DMJHZVARRXJSEG-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 447.344,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 447.091864352,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB11923",
        "type": "Small Molecule",
        "synonyms": [
            "Decoglurant"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=C(OC)C(=O)[C@H](C)[C@@H](C\\C=C(/C)CC\\C=C(/C)CCC=C(C)C)[C@H]1O",
        "id": "DB12326",
        "molecule": "Antroquinonol",
        "cas": "1010081-09-0",
        "iupac_name": "(4R,5R,6R)-4-hydroxy-2,3-dimethoxy-6-methyl-5-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]cyclohex-2-en-1-one",
        "background": "Antroquinonol has been used in trials studying the treatment of Hyperlipidemias, Non-small Cell Lung Cancer, and Non-small Cell Lung Cancer Stage IV.\n",
        "inchi": {
            "hash": "LJTSIMVOOOLKOL-FNRDIUJOSA-N",
            "id": "InChI=1S/C24H38O4/c1-16(2)10-8-11-17(3)12-9-13-18(4)14-15-20-19(5)21(25)23(27-6)24(28-7)22(20)26/h10,12,14,19-20,22,26H,8-9,11,13,15H2,1-7H3/b17-12+,18-14+/t19-,20-,22-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 390.564,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 390.277009704,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diterpenoids. These are terpene compounds formed by four isoprene units.",
        "link": "https://go.drugbank.com/drugs/DB12326",
        "type": "Small Molecule",
        "synonyms": [
            "HOCENA"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCC\\C=C\\CCCCCCCC(N)=O",
        "id": "DB03784",
        "molecule": "Elaidamide",
        "cas": "4303-70-2",
        "iupac_name": "(9E)-octadec-9-enamide",
        "inchi": {
            "hash": "FATBGEAMYMYZAF-MDZDMXLPSA-N",
            "id": "InChI=1S/C18H35NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H2,19,20)/b10-9+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 281.4766,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 281.271864747,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fatty amides. These are carboxylic acid amide derivatives of fatty acids, that are formed from a fatty acid and an amine.",
        "link": "https://go.drugbank.com/drugs/DB03784",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPhospholipase A2, membrane associated"
            }
        ]
    },
    {
        "smiles": "C[C@]12CC[C@H]3[C@@H](CCC4=C[C@@H](O)CC[C@H]34)[C@@H]1CC[C@@H]2O",
        "id": "DB01554",
        "molecule": "Bolandiol",
        "cas": "19793-20-5",
        "iupac_name": "(1S,2R,5S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,14-diol",
        "inchi": {
            "hash": "CMXKUJNZWYTFJN-XFUVECHXSA-N",
            "id": "InChI=1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,12-17,19-20H,2-9H2,1H3/t12-,13-,14+,15+,16-,17-,18-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 276.42,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 276.208930142,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.",
        "link": "https://go.drugbank.com/drugs/DB01554",
        "type": "Small Molecule",
        "synonyms": [
            "19-nor-4-androstenediol",
            "3beta,17beta-dihydroxyestr-4-ene",
            "4-norendiol",
            "Bolandiol"
        ]
    },
    {
        "smiles": "CC(=O)CCO",
        "id": "DB04094",
        "molecule": "4-hydroxybutan-2-one",
        "cas": "590-90-9",
        "iupac_name": "4-hydroxybutan-2-one",
        "inchi": {
            "hash": "LVSQXDHWDCMMRJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H8O2/c1-4(6)2-3-5/h5H,2-3H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 88.1051,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 88.0524295,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta-hydroxy ketones. These are ketones containing a hydroxyl group attached to the beta-carbon atom, relative to the C=O group.",
        "link": "https://go.drugbank.com/drugs/DB04094",
        "type": "Small Molecule",
        "synonyms": [
            "3-Oxo-1-butanol",
            "3-Oxobutanol",
            "4-Hydroxy-2-butanone",
            "Methylolacetone",
            "Monomethylolacetone"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPeptidyl-prolyl cis-trans isomerase FKBP1A"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)C(Br)=C(N1)C1=CC=CC=C1",
        "id": "DB04168",
        "molecule": "Bropirimine",
        "cas": "56741-95-8",
        "iupac_name": "2-amino-5-bromo-6-phenyl-1,4-dihydropyrimidin-4-one",
        "inchi": {
            "hash": "CIUUIPMOFZIWIZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 266.094,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 264.98507454,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB04168",
        "type": "Small Molecule",
        "synonyms": [
            "Bropirimina",
            "Bropirimine",
            "Bropiriminum"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus",
                "target": "UDihydroneopterin aldolase"
            }
        ]
    },
    {
        "smiles": "C[C@@H](O)[C@H](C)O",
        "id": "DB02418",
        "molecule": "(R,R)-2,3-Butanediol",
        "cas": "24347-58-8",
        "iupac_name": "(2R,3S)-butane-2,3-diol",
        "inchi": {
            "hash": "OWBTYPJTUOEWEK-ZXZARUISSA-N",
            "id": "InChI=1S/C4H10O2/c1-3(5)4(2)6/h3-6H,1-2H3/t3-,4+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 90.121,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 90.068079564,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2-diols. These are polyols containing an alcohol group at two adjacent positions.",
        "link": "https://go.drugbank.com/drugs/DB02418",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UUbiquitin-conjugating enzyme E2 D2"
            }
        ]
    },
    {
        "smiles": "[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@@]([H])(S)CCCCC)C(O)=O",
        "id": "DB02597",
        "molecule": "[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala",
        "iupac_name": "(2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic acid",
        "inchi": {
            "hash": "GOIYKVXXGCPHQU-BPUTZDHNSA-N",
            "id": "InChI=1S/C19H28N2O4S/c1-3-4-6-11-16(26)18(23)21-15(12-14-9-7-5-8-10-14)17(22)20-13(2)19(24)25/h5,7-10,13,15-16,26H,3-4,6,11-12H2,1-2H3,(H,20,22)(H,21,23)(H,24,25)/t13-,15-,16-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 380.502,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 380.176978084,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB02597",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus thermoproteolyticus",
                "target": "UThermolysin"
            },
            {
                "action": "Not Available",
                "organism": "Geobacillus stearothermophilus",
                "target": "UThermolysin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeprilysin"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02495"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05929"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06777"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06554"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04151"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09095"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06908"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00297"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13784"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01659"
    },
    {
        "smiles": "CC1(C)OB(O)C2=CC(NC(=O)C3=CC=C(F)C=C3C(F)(F)F)=CC=C12",
        "id": "DB13086",
        "molecule": "Acoziborole",
        "cas": "1266084-51-8",
        "iupac_name": "4-fluoro-N-(1-hydroxy-3,3-dimethyl-1,3-dihydro-2,1-benzoxaborol-6-yl)-2-(trifluoromethyl)benzamide",
        "background": "SCYX-7158 has been used in trials studying the treatment of Trypanosomiasis, Parasitic Diseases, Protozoan Infections, and Trypanosomiasis, African.\n",
        "inchi": {
            "hash": "PTYGDEXEGLDNAZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H14BF4NO3/c1-16(2)12-6-4-10(8-14(12)18(25)26-16)23-15(24)11-5-3-9(19)7-13(11)17(20,21)22/h3-8,25H,1-2H3,(H,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 367.11,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 367.100286,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.",
        "link": "https://go.drugbank.com/drugs/DB13086",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(=C(O)C=C1O)C(C)(C)C",
        "id": "DB11881",
        "molecule": "AUY922",
        "cas": "747412-64-2",
        "iupac_name": "5-(5-tert-butyl-2,4-dihydroxyphenyl)-N-ethyl-4-{4-[(morpholin-4-yl)methyl]phenyl}-1,2-oxazole-3-carboxamide",
        "background": "AUY922 has been used in trials studying the treatment of Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms, among others.\n",
        "inchi": {
            "hash": "WLYWTGDTMWWNNG-UHFFFAOYSA-N",
            "id": "InChI=1S/C27H33N3O5/c1-5-28-26(33)24-23(18-8-6-17(7-9-18)16-30-10-12-34-13-11-30)25(35-29-24)19-14-20(27(2,3)4)22(32)15-21(19)31/h6-9,14-15,31-32H,5,10-13,16H2,1-4H3,(H,28,33)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 479.577,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 479.242021175,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.",
        "link": "https://go.drugbank.com/drugs/DB11881",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "Cl[Fe](Cl)Cl",
        "id": "DB15536",
        "molecule": "Ferric chloride",
        "cas": "7705-08-0",
        "iupac_name": "trichloroiron",
        "inchi": {
            "hash": "RBTARNINKXHZNM-UHFFFAOYSA-K",
            "id": "InChI=1S/3ClH.Fe/h3*1H;/q;;;+3/p-3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 162.204,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 160.841500254,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as transition metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a transition metal.",
        "link": "https://go.drugbank.com/drugs/DB15536",
        "type": "Small Molecule",
        "synonyms": [
            "Ferric chloride, anhydrous",
            "Iron (III) chloride",
            "Iron chloride",
            "Iron perchloride"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=NC(=O)C2=C(N1)N([C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O)C(=O)S2",
        "id": "DB04860",
        "molecule": "Isatoribine",
        "cas": "122970-40-5",
        "iupac_name": "5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2H,3H,4H,7H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione",
        "background": "Isatoribine is a selective agonist of TLR7.\n",
        "inchi": {
            "hash": "TZYVRXZQAWPIAB-FCLHUMLKSA-N",
            "id": "InChI=1S/C10H12N4O6S/c11-9-12-6-5(7(18)13-9)21-10(19)14(6)8-4(17)3(16)2(1-15)20-8/h2-4,8,15-17H,1H2,(H3,11,12,13,18)/t2-,3-,4-,8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 316.29,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 316.047754826,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glycosylamines. These are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether).",
        "link": "https://go.drugbank.com/drugs/DB04860",
        "type": "Small Molecule",
        "synonyms": [
            "7-Deaza-7-thia-8-oxoguanosine",
            "7-Thia-8-oxoguanosine",
            "7-TOG",
            "Isatoribine"
        ],
        "indication": "For the treatment of Hepatitis C.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Isatoribine is a compound that elevates levels of interferon-alpha and provides antiviral and antimetastatic activity in a variety of murine systems. Isatoribine interacts with a specific receptor, Toll-like receptor 7, or TLR7, that is present on certain immune system cells. The compound also has a promising toxicity profile in multiple species. As of February 2007 this drug was no longer listed on Anadys development pipeline.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UToll-like receptor 7"
            }
        ]
    },
    {
        "smiles": "CC(=O)NC1=CC=C(C=C1NC(=O)C[NH3+])C(O)=O",
        "id": "DB02829",
        "molecule": "4-(Acetylamino)-3-[(Aminoacetyl)Amino]Benzoic Acid",
        "iupac_name": "[(5-carboxy-2-acetamidophenyl)carbamoyl]methanaminium",
        "inchi": {
            "hash": "FJGXEWVOOHZQDN-UHFFFAOYSA-O",
            "id": "InChI=1S/C11H13N3O4/c1-6(15)13-8-3-2-7(11(17)18)4-9(8)14-10(16)5-12/h2-4H,5,12H2,1H3,(H,13,15)(H,14,16)(H,17,18)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 252.2466,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 252.098430951,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.",
        "link": "https://go.drugbank.com/drugs/DB02829",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Influenza A virus (strain A/Tokyo/3/1967 H2N2)",
                "target": "UNeuraminidase"
            }
        ]
    },
    {
        "smiles": "[H][C@@](CCCCC)(CC(=O)NO)C(=O)N[C@@]([H])(C(C)C)C(=O)N1CCC[C@@]1([H])CO",
        "id": "DB04310",
        "molecule": "2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide",
        "cas": "13434-13-4",
        "iupac_name": "(2R)-N'-hydroxy-N-[(2S)-1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide",
        "inchi": {
            "hash": "XJLATMLVMSFZBN-VYDXJSESSA-N",
            "id": "InChI=1S/C19H35N3O5/c1-4-5-6-8-14(11-16(24)21-27)18(25)20-17(13(2)3)19(26)22-10-7-9-15(22)12-23/h13-15,17,23,27H,4-12H2,1-3H3,(H,20,25)(H,21,24)/t14-,15+,17+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 385.4983,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 385.257671245,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB04310",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus",
                "target": "UPeptide deformylase"
            },
            {
                "action": "Not Available",
                "organism": "Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601)",
                "target": "UPeptide deformylase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus cereus (strain ATCC 14579 / DSM 31)",
                "target": "UPeptide deformylase 1"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus cereus (strain ATCC 14579 / DSM 31)",
                "target": "UPeptide deformylase 2"
            },
            {
                "action": "Not Available",
                "organism": "Enterococcus faecalis (strain ATCC 700802 / V583)",
                "target": "UPeptide deformylase"
            },
            {
                "action": "Not Available",
                "organism": "Streptococcus pyogenes serotype M1",
                "target": "UPeptide deformylase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPeptide deformylase, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UPeptide deformylase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPeptide deformylase"
            },
            {
                "action": "Not Available",
                "organism": "Geobacillus stearothermophilus",
                "target": "UPeptide deformylase 2"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus (strain MW2)",
                "target": "UPeptide deformylase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB00741",
        "molecule": "Hydrocortisone",
        "cas": "50-23-7",
        "iupac_name": "(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one",
        "background": "Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex.7 Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.14,15,16,17,18,19 It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone.9\nHydrocortisone was granted FDA approval on 5 August 1952.20\n",
        "inchi": {
            "hash": "JYGXADMDTFJGBT-VWUMJDOOSA-N",
            "id": "InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1"
        },
        "summary": "Hydrocortisone is a glucocorticoid used to treat corticosteroid-responsive dermatoses, endocrine disorders, immune conditions, and allergic disorders.",
        "weight": [
            {
                "type": "average",
                "weight": 362.4599,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 362.20932407,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.",
        "link": "https://go.drugbank.com/drugs/DB00741",
        "type": "Small Molecule",
        "synonyms": [
            "(11)-11,17,21-trihydroxypregn-4-ene-3,20-dione",
            "11beta-hydrocortisone",
            "11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione",
            "11-hydrocortisone",
            "17-Hydroxycorticosterone",
            "4-pregnen-11,17,21-triol-3,20-dione",
            "Cortisol",
            "Hidrocortisona",
            "Hydrocortisone",
            "Hydrocortisonum",
            "Kendall's compound F",
            "Reichstein's substance M"
        ],
        "indication": "Otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammation.14,15 Hydrocortisone tablets are indicated for certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions.16 A hydrocortisone enema is indicated for ulcerative colitis,17 a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infections,18 and a topical cream with acyclovir is indicated to treat cold sores.19 Oral granules of hydrocortisone are used as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.21\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocortisone binds to the glucocorticoid receptor leading to downstream effects such as inhibition of phospholipase A2, NF-kappa B, other inflammatory transcription factors, and the promotion of anti-inflammatory genes.10 Hydrocortisone has a wide therapeutic index8 and a moderate duration of action.1,6 Patients should stop taking the medication if irritation or sensitization occurs.14,15,16,17,18,19\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AGlucocorticoid receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAnnexin A1"
            }
        ]
    },
    {
        "id": "DB16899",
        "molecule": "Hydromethylthionine mesylate",
        "cas": "1236208-20-0",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16899",
        "type": "Small Molecule",
        "synonyms": [
            "Hydromethylthionine mesylate",
            "Leuco-methylthioninium dimesylate",
            "Leucomethylene Blue bismesylate",
            "Leucomethylene Blue dimesylate",
            "LMTM",
            "TRX-0237",
            "TRX-0237 dimesylate",
            "TRX0237 dimesylate"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC[C@H](C)C(NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(N)=O",
        "id": "DB11879",
        "molecule": "Dusquetide",
        "cas": "931395-42-5",
        "iupac_name": "(3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-N-[(2S)-1-[(2S)-2-{[(1S)-1-carbamoylethyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-methylpentanamide",
        "background": "Dusquetide has been used in trials studying the treatment of Oral Mucositis.\n",
        "inchi": {
            "hash": "ZUJBBVJXXYRPFS-OUROWQTJSA-N",
            "id": "InChI=1S/C25H47N9O5/c1-6-14(4)19(33-21(36)16(26)9-7-11-30-25(28)29)23(38)32-18(13(2)3)24(39)34-12-8-10-17(34)22(37)31-15(5)20(27)35/h13-19H,6-12,26H2,1-5H3,(H2,27,35)(H,31,37)(H,32,38)(H,33,36)(H4,28,29,30)/t14-,15-,16-,17-,18-,19?/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 553.709,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 553.370015649,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11879",
        "type": "Small Molecule",
        "synonyms": [
            "ARG-ILE-VAL-PRO-ALA-NH2",
            "Dusquetide",
            "L-ALANINAMIDE, L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-PROLYL-",
            "L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-PROLYL-L-ALANINAMIDE",
            "L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC2=C(C(=O)N=C(N2)C2=CC(C)=C(OCCO)C(C)=C2)C(OC)=C1",
        "id": "DB12000",
        "molecule": "Apabetalone",
        "cas": "1044870-39-4",
        "iupac_name": "2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1,4-dihydroquinazolin-4-one",
        "background": "Apabetalone has been investigated for the treatment of Diabetes, Atherosclerosis, and Coronary Artery Disease.\n",
        "inchi": {
            "hash": "NETXMUIMUZJUTB-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H22N2O5/c1-11-7-13(8-12(2)18(11)27-6-5-23)19-21-15-9-14(25-3)10-16(26-4)17(15)20(24)22-19/h7-10,23H,5-6H2,1-4H3,(H,21,22,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 370.3991,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 370.152871824,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.",
        "link": "https://go.drugbank.com/drugs/DB12000",
        "type": "Small Molecule",
        "synonyms": [
            "Apabetalone"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOP(=O)(CC1=CC=C(C)C=C1)OCC",
        "id": "DB02138",
        "molecule": "Diethyl 4-Methylbenzylphosphonate",
        "cas": "3762-25-2",
        "iupac_name": "diethyl [(4-methylphenyl)methyl]phosphonate",
        "inchi": {
            "hash": "QKGBKPZAXXBLJE-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H19O3P/c1-4-14-16(13,15-5-2)10-12-8-6-11(3)7-9-12/h6-9H,4-5,10H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 242.2512,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 242.107180986,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as toluenes. These are compounds containing a benzene ring which bears a methane group.",
        "link": "https://go.drugbank.com/drugs/DB02138",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Brevundimonas diminuta",
                "target": "UParathion hydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Flavobacterium sp. (strain ATCC 27551)",
                "target": "UParathion hydrolase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00743"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08513"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15925"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16580"
    },
    {
        "smiles": "CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC\\C(C)=C\\CC\\C(C)=C\\CC\\C(C)=C\\CC\\C(C)=C\\CC\\C(C)=C\\CC1=CC=CC=C1O",
        "id": "DB03232",
        "molecule": "2-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-Octamethyldotriaconta-2,6,10,14,18,22,26,30-Octaenyl]Phenol",
        "iupac_name": "2-[(2E,6E,10E,14E,18E,22E,26E)-3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaen-1-yl]phenol",
        "inchi": {
            "hash": "VUNQJPPPTJIREN-CMAXTTDKSA-N",
            "id": "InChI=1S/C46H70O/c1-37(2)19-12-20-38(3)21-13-22-39(4)23-14-24-40(5)25-15-26-41(6)27-16-28-42(7)29-17-30-43(8)31-18-32-44(9)35-36-45-33-10-11-34-46(45)47/h10-11,19,21,23,25,27,29,31,33-35,47H,12-18,20,22,24,26,28,30,32,36H2,1-9H3/b38-21+,39-23+,40-25+,41-27+,42-29+,43-31+,44-35+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 639.0474,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 638.542666862,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as polyprenylphenols. These are compounds containing a polyisoprene chain attached to a phenol group.",
        "link": "https://go.drugbank.com/drugs/DB03232",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UProtein YceI"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(CNS(=O)(=O)C2=CC=CC3=CN=CC=C23)C[C@]([H])(CN1)OCC1=CC=C(Cl)C=C1",
        "id": "DB07583",
        "molecule": "(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE",
        "iupac_name": "N-{[(2S,4R)-4-[(4-chlorophenyl)methoxy]pyrrolidin-2-yl]methyl}isoquinoline-5-sulfonamide",
        "inchi": {
            "hash": "RLNNFNGBXLTQOB-RBUKOAKNSA-N",
            "id": "InChI=1S/C21H22ClN3O3S/c22-17-6-4-15(5-7-17)14-28-19-10-18(24-13-19)12-25-29(26,27)21-3-1-2-16-11-23-9-8-20(16)21/h1-9,11,18-19,24-25H,10,12-14H2/t18-,19+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 431.936,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 431.107039982,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as isoquinolines and derivatives. These are aromatic polycyclic compounds containing an isoquinoline moiety, which consists of a benzene ring fused to a pyridine ring and forming benzo[c]pyridine.",
        "link": "https://go.drugbank.com/drugs/DB07583",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase catalytic subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase inhibitor alpha"
            }
        ]
    },
    {
        "smiles": "CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1",
        "id": "DB09039",
        "molecule": "Eliglustat",
        "cas": "491833-29-5",
        "iupac_name": "N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]octanamide",
        "background": "Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.2,6 Gaucher disease is a rare genetic disorder characterized by the deficiency of acid -glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.6,4 By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide.6\nEliglustat is mainly metabolized by CYP2D6.6 Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.6,1 Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.6,1 Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease (imiglucerase, velaglucerase alfa, taliglucerase alfa); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.5,1\n",
        "inchi": {
            "hash": "FJZZPCZKBUKGGU-AUSIDOKSSA-N",
            "id": "InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1"
        },
        "summary": "Eliglustat is a glucosylceramide synthase used to treat type 1 Gaucher disease in patients who are CYP2D6 extensive, intermediate, or poor metabolizers.",
        "weight": [
            {
                "type": "average",
                "weight": 404.551,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 404.267507647,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzo-1,4-dioxanes. These are heterocyclic compounds containing a benzene ring fused to a 1,4-dioxane ring.",
        "link": "https://go.drugbank.com/drugs/DB09039",
        "type": "Small Molecule",
        "synonyms": [
            "Eliglustat",
            "liglustat",
            "Eliglustatum",
            "N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide"
        ],
        "indication": "Eliglustat is a glucosylceramide synthase inhibitor indicated for the long-term treatment of type 1 Gaucher disease in adult patients who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.6 CYP2D6 ultra-rapid metabolizers may not achieve adequate eliglustat concentrations to achieve a therapeutic effect. A specific dosage cannot be recommended for CYP2D6 indeterminate metabolizers.6\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Eliglustat is a specific inhibitor of glucosylceramide synthase (IC50 =10 ng/mL).6 In vitro studies suggest that eliglustat has minimal or no off-target activity against other glycosidases, such as -glucosidase I and II, and lysosomal and non-lysosomal glucosylceramidases.3 \nAt 8 times the recommended dose (800 mg) and a mean peak concentration of 237 ng/mL, eliglustat did not have a clinically significant effect on QTc prolongation. However, modelling of PK/PD data predicts that at a plasma concentration of 500 ng/mL, PR, QRS and QTcF intervals increase 22, 7, and 13 msec, respectively.6 Since high plasma concentrations of eliglustat may increase the risk of cardiac arrhythmias, there are warnings and precautions for patients taking CYP2D6 or CYP3A4 inhibitors, those with specific CYP2D6 metabolizer status and different degrees of hepatic impairment. Depending on each case, the use of this drug is contraindicated, to be avoided, or requires dosage adjustment.6 \nPatients with preexisting cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, or those taking Class IA or Class II antiarrhythmic drugs are advised to avoid eliglustat.6\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACeramide glucosyltransferase"
            }
        ]
    },
    {
        "smiles": "NC(N)=NCCN1CCCCCCC1",
        "id": "DB01170",
        "molecule": "Guanethidine",
        "cas": "55-65-2",
        "iupac_name": "N''-[2-(azocan-1-yl)ethyl]guanidine",
        "background": "An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem]\n",
        "inchi": {
            "hash": "ACGDKVXYNVEAGU-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)"
        },
        "summary": "Guanethidine is an antihypertensive agent used in the management of moderate and severe hypertension, either alone or as an adjunct, and for the management of renal hypertension.",
        "weight": [
            {
                "type": "average",
                "weight": 198.3085,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 198.184446724,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as guanidines. These are compounds containing a guanidine moiety, with the general structure (R1R2N)(R3R4N)C=N-R5.",
        "link": "https://go.drugbank.com/drugs/DB01170",
        "type": "Small Molecule",
        "synonyms": [
            "(2-(hexahydro-1(2h)-azocinyl)ethyl)guanidine",
            "(2-(Octahydro-1-azocinyl)ethyl)guanidine",
            "2-(1-N,N-Heptamethyleneimino)ethylguanidine",
            "2-(1'-Azacyclooctyl)ethylguanidine",
            "Azocine, 1-(2-guanidinoethyl)octahydro-",
            "guanthidine",
            "Guanethidine",
            "guanethidinum",
            "guanetidina",
            "Guanidine, (2-(hexahydro-1(2H)-azocinyl)ethyl)-",
            "Heptamethylenimine, 1-(2-guanidinoethyl)-",
            "N-(2-Perhydroazocin-1-ylethyl)guanidine"
        ],
        "indication": "For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "High blood pressure can cause the heart and arteries to not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled. Guanethidine works by decreasing the heart rate and relaxing the blood vessels so that blood can flow more easily through the body, thereby reducing these risks. It is a postganglionic sympathetic nerve terminal blocker that prevents the release of norepinephrine from nerve terminals.\n",
        "moa": [
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "ASodium-dependent noradrenaline transporter"
            }
        ]
    },
    {
        "smiles": "[H]\\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F",
        "id": "DB00875",
        "molecule": "Flupentixol",
        "cas": "2709-56-0",
        "iupac_name": "2-(4-{3-[(9Z)-2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol",
        "background": "Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)flupentixol with decanoic acid.1 Flupentixol is an antagonist of both D1 and D2 dopamine receptors.1\nAvailable as oral tablets or long-acting intramuscular injections, flupentixol is marketed under brand names such as Depixol and Fluanxol. It is approved for use in Canada and other countries around the world, but not in the US. It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity.11 It has been marketed to manage symptoms of depression in patients who may or may not exhibit signs of anxiety.14 In combination with melitracen, flupentixol is used to manage symptoms of anxiety, depression, and asthenia.13\n",
        "inchi": {
            "hash": "NJMYODHXAKYRHW-DVZOWYKESA-N",
            "id": "InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-"
        },
        "summary": "Flupentixol is a thioxanthene neuroleptic used to treat schizophrenia and depression.",
        "weight": [
            {
                "type": "average",
                "weight": 434.52,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 434.163969096,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.",
        "link": "https://go.drugbank.com/drugs/DB00875",
        "type": "Small Molecule",
        "synonyms": [
            "Flupenthixol",
            "Flupenthixole",
            "Flupentixol",
            "Flupentixolo",
            "Flupentixolum"
        ],
        "indication": "Flupentixol is indicated for maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation or hyperactivity.11\nIt is indicated for the management of depression in adult patients who may, or may not, also be showing signs of anxiety.14\nFlupentixol in combination with melitracen is indicated to manage symptoms of anxiety, depression, and asthenia in adults.13\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Flupentixol is an antipsychotic agent with anxiolytic and mild sedative actions. It exerts weak anticholinergic and adrenergic effects. It possesses antiemetic actions. As flupentixol works by antagonizing dopamine actions, it can cause extrapyramidal effects,11 mostly at doses greater than 10 mg. In clinical trials, flupentixol-induced extrapyramidal effects have been managed with anti-Parkinsonian drugs.3 Drug esterification in the intramuscular formulation of the drug results in slow release of the drug from the injection site and a prolonged duration of action.11 Flupentixol has been investigated for use in mild to moderate depression: compared to other antidepressant agents, flupentixol has a rapid onset of action, where antidepressive effects were observed within the first two to three days after administration.3\nAs with other antipsychotic agents, flupentixol can cause QTc prolongation and increase the risk of arrhythmias. In clinical trials, flupentixol was associated with the risk of cardiovascular disease, cerebrovascular adverse events, stroke, and venous thromboembolism. Flupentixol can elevate the levels of prolactin; however, the clinical significance of hyperprolactinemia caused by neuroleptic drugs is unclear. Long-term hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone mineral density in both female and male subjects.11\nInterestingly, recent studies show that flupentixol exhibits anti-tumour properties alone or synergistically with other anticancer drugs like gefitinib. One study demonstrated that in vitro, flupentixol docks to the ATP binding pocket of phosphatidylinositol 3-kinase (PI3K), a lipid kinase that activates signalling pathways that are often hyperactivated in some cancers. Flupentixol inhibited the PI3K/AKT pathway and survival of lung cancer cells in vitro and in vivo.5\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D1 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UAlpha-1A adrenergic receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UDopamine D3 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UDopamine D4 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2C"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M1"
            }
        ]
    },
    {
        "smiles": "CC(N(C)C)C(=O)N1C2=CC=CC=C2SC2=CC=CC=C12",
        "id": "DB13672",
        "molecule": "Dimethylaminopropionylphenothiazine",
        "cas": "63834-04-8",
        "iupac_name": "2-(dimethylamino)-1-(10H-phenothiazin-10-yl)propan-1-one",
        "inchi": {
            "hash": "POZJNEBUHLZROM-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H18N2OS/c1-12(18(2)3)17(20)19-13-8-4-6-10-15(13)21-16-11-7-5-9-14(16)19/h4-12H,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 298.4,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 298.113984382,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.",
        "link": "https://go.drugbank.com/drugs/DB13672",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCC\\C=C\\CCCCCCCC(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O",
        "id": "DB12564",
        "molecule": "Gemcitabine elaidate",
        "cas": "210829-30-4",
        "iupac_name": "[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (9E)-octadec-9-enoate",
        "background": "Gemcitabine elaidate has been used in trials studying the treatment of Solid Tumor, Lung Cancer, Non-small-cell Lung Cancer, and Metastatic Pancreatic Adenocarcinoma.\n",
        "inchi": {
            "hash": "HESSNRGIEVBPRB-QDDPNBLJSA-N",
            "id": "InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)/b10-9+/t21-,24-,25-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 527.654,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 527.317077823,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB12564",
        "type": "Small Molecule",
        "synonyms": [
            "2'-Deoxy-2',2'-difluorocytidine 5'-(9E)-octadec-9-enoate",
            "5'-O-(TRANS-9''-OCTADECENOYL)-1-.BETA.-D-2'DEOXY-2',2'-DIFLUOROCYTIDINE",
            "5'-O-(trans-9\"-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine",
            "Gemcitabine elaidate"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=[NH2+]",
        "id": "DB07005",
        "molecule": "D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide",
        "iupac_name": "{amino[4-({[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}methyl)phenyl]methylidene}azanium",
        "inchi": {
            "hash": "VZFTWWJAUZOJDH-MOPGFXCFSA-O",
            "id": "InChI=1S/C22H27N5O2/c23-18(13-15-5-2-1-3-6-15)22(29)27-12-4-7-19(27)21(28)26-14-16-8-10-17(11-9-16)20(24)25/h1-3,5-6,8-11,18-19H,4,7,12-14,23H2,(H3,24,25)(H,26,28)/p+1/t18-,19+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 394.49,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 394.224300165,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB07005",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "CC(C)=CCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB13364",
        "molecule": "Feprazone",
        "cas": "30748-29-9",
        "iupac_name": "4-(3-methylbut-2-en-1-yl)-1,2-diphenylpyrazolidine-3,5-dione",
        "inchi": {
            "hash": "RBBWCVQDXDFISW-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 320.392,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 320.152477892,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.",
        "link": "https://go.drugbank.com/drugs/DB13364",
        "type": "Small Molecule",
        "synonyms": [
            "Feprazone"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",
        "id": "DB00380",
        "molecule": "Dexrazoxane",
        "cas": "24584-09-6",
        "iupac_name": "4-[(2S)-1-(3,5-dioxopiperazin-1-yl)propan-2-yl]piperazine-2,6-dione",
        "background": "An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]\nThe Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.\n",
        "inchi": {
            "hash": "BMKDZUISNHGIBY-ZETCQYMHSA-N",
            "id": "InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1"
        },
        "summary": "Dexrazoxane is a cytoprotective drug used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer.",
        "weight": [
            {
                "type": "average",
                "weight": 268.2691,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 268.11715502,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB00380",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione",
            "(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane",
            "4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione",
            "Dexrazoxan",
            "Dexrazoxane",
            "Dexrazoxano",
            "Dexrazoxanum",
            "Dextrorazoxane"
        ],
        "indication": "For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. Patients receiving anthracycline-derivative antineoplastic agents may experience three types of cardiotoxicity: acute transient type; chronic, subacute type (related to cumulative dose and has a more indolent onset later on); and a late-onset type that manifests years after therapy, mainly in patients that have been exposed to the drug as a child. Although the exact mechanism of anthracycline-induced cardiotoxicity is not known, it has shown to exert a variety of actions that may result in the development of cardiotoxicity. In animals, anthracyclines cause a selective inhibition of cardiac muscle gene expression for -actin, troponin, myosin light-chain 2, and the M isoform of creatine kinase. This may lead to myofibrillar loss associated with anthracycline-induced cardiotoxicity. Anthracyclines may also cause myocyte damage via calcium overload, altered myocardial adrenergic function, release of vasoactive amines, and proinflammatory cytokines. Furthermore, it has been suggested that the main cause of anthracycline-induced cardiotoxicity is associated with free-radical damage to DNA. The drugs intercalate DNA, chelate metal ions to produce drug-metal complexes, and generate superoxide radicals via oxidation-reduction reactions. Anthracyclines also contain a quinone structure that can undergo reduction via NADPH-dependent reactions to produce a semiquinone free radical that initiates a cascade of superoxide and hydroxide radical generation. Chelation of metal ions, particularly iron, by anthracyclines results in an anthracycline-metal complex that catalyzes the generation of reactive oxygen free radicals. This complex is a powerful oxidant that can initiate lipid peroxidation in the absence of oxygen free radicals. The toxicity induced by antrhacyclines may be exacerbated in cardiac cells, as these cells do not possess sufficient amounts of certain enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) involved in detoxifying free radicals and protecting the cells from subsequent damage.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ADNA topoisomerase 2-alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA topoisomerase 2-beta"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(OC(=C[C@H](O)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO",
        "id": "DB03991",
        "molecule": "2-deoxy-2,3-dehydro-N-acetylneuraminic acid",
        "cas": "24967-27-9",
        "iupac_name": "(2R,3R,4S)-3-acetamido-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid",
        "inchi": {
            "hash": "JINJZWSZQKHCIP-UFGQHTETSA-N",
            "id": "InChI=1S/C11H17NO8/c1-4(14)12-8-5(15)2-7(11(18)19)20-10(8)9(17)6(16)3-13/h2,5-6,8-10,13,15-17H,3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,8+,9+,10+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 291.2546,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 291.095416525,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as secondary alcohols. These are compounds containing a secondary alcohol functional group, with the general structure HOC(R)(R') (R,R'=alkyl, aryl).",
        "link": "https://go.drugbank.com/drugs/DB03991",
        "type": "Small Molecule",
        "synonyms": [
            "Neu2en5Ac"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "HPIV-3",
                "target": "UHemagglutinin-neuraminidase"
            },
            {
                "action": "Not Available",
                "organism": "Micromonospora viridifaciens",
                "target": "USialidase"
            },
            {
                "action": "Not Available",
                "organism": "Influenza A virus (strain A/Tern/Australia/G70C/1975 H11N9)",
                "target": "UNeuraminidase"
            },
            {
                "action": "Not Available",
                "organism": "NDV",
                "target": "UHemagglutinin-neuraminidase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USialidase-2"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(CC(C)N)C=C1",
        "id": "DB01472",
        "molecule": "4-Methoxyamphetamine",
        "cas": "64-13-1",
        "iupac_name": "1-(4-methoxyphenyl)propan-2-amine",
        "inchi": {
            "hash": "NEGYEDYHPHMHGK-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 165.2322,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 165.115364107,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.",
        "link": "https://go.drugbank.com/drugs/DB01472",
        "type": "Small Molecule",
        "synonyms": [
            "(2RS)-1-(4-methoxyphenyl)propan-2-amine",
            "4-methoxyamfetamine",
            "D,L-p-methoxyamphetamine",
            "Formoterol fumarate related compound G",
            "P-methoxyamfetamine",
            "P-methoxyamphetamine",
            "Paramethoxyamphetamine"
        ],
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent dopamine transporter"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent serotonin transporter"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASynaptic vesicular amine transporter"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-1A adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-2A adrenergic receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UAmine oxidase [flavin-containing] A"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UAmine oxidase [flavin-containing] B"
            }
        ]
    },
    {
        "smiles": "[H][C@]12C[C@@H](O)[C@H](\\C=C\\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\\C(C2)=C\\CCCC(O)=O",
        "id": "DB01088",
        "molecule": "Iloprost",
        "cas": "78919-13-8",
        "iupac_name": "5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid",
        "background": "Iloprost is a synthetic analogue of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH).\n",
        "inchi": {
            "hash": "HIFJCPQKFCZDDL-ACWOEMLNSA-N",
            "id": "InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1"
        },
        "summary": "Iloprost is a synthetic prostacyclin analog indicated to treat pulmonary arterial hypertension (PAH).",
        "weight": [
            {
                "type": "average",
                "weight": 360.494,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 360.23005951,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.",
        "link": "https://go.drugbank.com/drugs/DB01088",
        "type": "Small Molecule",
        "synonyms": [
            "Iloprost"
        ],
        "indication": "Used for the treatment of pulmonary arterial hypertension.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Iloprost is a synthetic analogue of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds. It was shown to affect platelet aggregation, but whether this effect contributes to its vasodilatory action has not been elucidated. There are two diastereoisomers of iloprost and the 4S isomer is reported to exhibit a higher potency in dilating blood vessels compared to the 4R isomer.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstacyclin receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP1 subtype"
            },
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4A"
            },
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4B"
            },
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4C"
            },
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4D"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "UTissue-type plasminogen activator"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UProstaglandin D2 receptor 2"
            }
        ]
    },
    {
        "smiles": "CN1N(C(=O)C=C1C)C1=CC=CC=C1",
        "id": "DB01435",
        "molecule": "Antipyrine",
        "cas": "60-80-0",
        "iupac_name": "1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one",
        "background": "An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)\n",
        "inchi": {
            "hash": "VEQOALNAAJBPNY-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3"
        },
        "summary": "Antipyrine is an antipyretic agent used for the symptomatic treatment of acute otitis media, most commonly in combination with benzocaine.",
        "weight": [
            {
                "type": "average",
                "weight": 188.2258,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 188.094963016,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB01435",
        "type": "Small Molecule",
        "synonyms": [
            "1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one",
            "2,3-Dimethyl-1-phenyl-5-pyrazolone",
            "Analgesine",
            "Antipyrine",
            "Fenazon",
            "Fenazona",
            "Phenazon",
            "Phenazone"
        ],
        "indication": "Antipyrine is an analgesic often used to test effects of other drugs on liver enzymes.\nIn combination with benzocaine in otic solutions, antipyrine is indicated for the symptomatic relief of acute otitis media arising from various etiologies. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Antipyrine is an analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 1"
            }
        ]
    },
    {
        "smiles": "NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)C1=CC=CC=C1",
        "id": "DB11821",
        "molecule": "Danegaptide",
        "cas": "943134-39-2",
        "iupac_name": "(2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid",
        "background": "Danegaptide has been investigated for the treatment of Focus of Study is STEMI.\n",
        "inchi": {
            "hash": "BIZKIHUJGMSVFD-MNOVXSKESA-N",
            "id": "InChI=1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)/t10-,11+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 291.307,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 291.121906039,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB11821",
        "type": "Small Molecule",
        "synonyms": [
            "Danegaptide"
        ],
        "is_stub": true
    },
    {
        "smiles": "[Na+].[Na+].[Cu++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O",
        "id": "DB14599",
        "molecule": "Edetate copper disodium",
        "cas": "14025-15-1",
        "iupac_name": "copper(2+) disodium 2-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetate",
        "inchi": {
            "hash": "KCFCAUKZKOSSBI-UHFFFAOYSA-J",
            "id": "InChI=1S/C10H16N2O8.Cu.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;/q;+2;2*+1/p-4"
        },
        "weight": [
            {
                "type": "average",
                "weight": 397.738,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 396.968502,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB14599",
        "type": "Small Molecule",
        "synonyms": [
            "Copper disodium edetate",
            "Copper disodium ethylenediaminetetraacetate",
            "Copper versenate",
            "EDTA copper disodium salt"
        ],
        "is_stub": true
    },
    {
        "smiles": "OP(=O)(OC1=CC=C(C=C1)[N+]([O-])=O)OC1=CC=C(C=C1)[N+]([O-])=O",
        "id": "DB07418",
        "molecule": "bis(4-nitrophenyl) hydrogen phosphate",
        "iupac_name": "bis(4-nitrophenoxy)phosphinic acid",
        "inchi": {
            "hash": "MHSVUSZEHNVFKW-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H9N2O8P/c15-13(16)9-1-5-11(6-2-9)21-23(19,20)22-12-7-3-10(4-8-12)14(17)18/h1-8H,(H,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 340.1822,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 340.009651786,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aryl phosphodiesters. These are aryl phosphates in which the phosphate is esterified at exactly two positions.",
        "link": "https://go.drugbank.com/drugs/DB07418",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UUncharacterized protein PA1000"
            }
        ]
    },
    {
        "smiles": "NC(=N)C1=CC2=C(NC(=N2)C2=CC=CC(C3=CC=CC=C3)=C2O)C=C1",
        "id": "DB01725",
        "molecule": "2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide",
        "iupac_name": "2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide",
        "inchi": {
            "hash": "LMGQGPVCSYOMNS-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H16N4O/c21-19(22)13-9-10-16-17(11-13)24-20(23-16)15-8-4-7-14(18(15)25)12-5-2-1-3-6-12/h1-11,25H,(H3,21,22)(H,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 328.3672,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 328.132411154,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylbenzimidazoles. These are compounds containing a phenylbenzimidazole skeleton, which consists of a benzimidazole moiety where its imidazole ring is attached to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB01725",
        "type": "Small Molecule",
        "synonyms": [
            "2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
            "3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UUrokinase-type plasminogen activator"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "OP(O)(=O)OCCCC1=CNC2=C1C=CC=C2",
        "id": "DB03171",
        "molecule": "Indole-3-Propanol Phosphate",
        "iupac_name": "[3-(1H-indol-3-yl)propoxy]phosphonic acid",
        "inchi": {
            "hash": "NKEZSFZOUIIZFL-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H14NO4P/c13-17(14,15)16-7-3-4-9-8-12-11-6-2-1-5-10(9)11/h1-2,5-6,8,12H,3-4,7H2,(H2,13,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 255.2069,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 255.066044453,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.",
        "link": "https://go.drugbank.com/drugs/DB03171",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UTryptophan synthase alpha chain"
            },
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UTryptophan synthase beta chain"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)",
                "target": "UTryptophan synthase alpha chain"
            }
        ]
    },
    {
        "smiles": "OC1=CC(O)=C2C(CC(=O)CCC\\C=C\\CCOC2=O)=C1Cl",
        "id": "DB08293",
        "molecule": "(5E)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE",
        "iupac_name": "(5E)-12-chloro-13,15-dihydroxy-1,3,4,7,8,9,10,11-octahydro-2-benzoxacyclotridecine-1,10-dione",
        "inchi": {
            "hash": "AQKZYZQONWDDLS-HNQUOIGGSA-N",
            "id": "InChI=1S/C16H17ClO5/c17-15-11-8-10(18)6-4-2-1-3-5-7-22-16(21)14(11)12(19)9-13(15)20/h1,3,9,19-20H,2,4-8H2/b3-1+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 324.756,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 324.076451361,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxybenzoic acid derivatives. These are compounds containing a hydroxybenzoic acid (or a derivative), which is a benzene ring bearing a carboxyl and a hydroxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB08293",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHeat shock protein HSP 90-beta"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)N2CC12",
        "id": "DB05003",
        "molecule": "Imexon",
        "cas": "59643-91-3",
        "iupac_name": "4-amino-1,3-diazabicyclo[3.1.0]hex-3-en-2-one",
        "background": "Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon. Imexon is a cyanoaziridine derivative.\nImexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.\n",
        "inchi": {
            "hash": "BIXBBIPTYBJTRY-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H5N3O/c5-3-2-1-7(2)4(8)6-3/h2H,1H2,(H2,5,6,8)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 111.102,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 111.043261797,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB05003",
        "type": "Small Molecule",
        "synonyms": [
            "Imexon"
        ],
        "indication": "Investigated for use/treatment in melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, and solid tumors.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URibonucleoside-diphosphate reductase subunit M2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URibonucleoside-diphosphate reductase large subunit"
            }
        ]
    },
    {
        "smiles": "CC1=CC=C(O)C(O)=C1",
        "id": "DB04120",
        "molecule": "4-Methyl-1,2-Benzenediol",
        "cas": "452-86-8",
        "iupac_name": "4-methylbenzene-1,2-diol",
        "inchi": {
            "hash": "ZBCATMYQYDCTIZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H8O2/c1-5-2-3-6(8)7(9)4-5/h2-4,8-9H,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 124.1372,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 124.0524295,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as catechols. These are compounds containing a 1,2-benzenediol moiety.",
        "link": "https://go.drugbank.com/drugs/DB04120",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UNicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase"
            },
            {
                "action": "Not Available",
                "organism": "Acinetobacter sp. (strain ADP1)",
                "target": "UCatechol 1,2-dioxygenase"
            }
        ]
    },
    {
        "id": "DB05079",
        "molecule": "HY10275",
        "background": "HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to \"let you sleep\" rather than depress the entire brain to \"make you sleep.\" This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought to account for the compounds excellent efficacy and tolerability profile.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05079",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in insomnia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHistamine H1 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2A"
            }
        ]
    },
    {
        "smiles": "[O-][N+](=O)C1=CC2=C(NC3=C2CC(=O)NC2=C3C=CC=C2)C=C1",
        "id": "DB04014",
        "molecule": "Alsterpaullone",
        "iupac_name": "14-nitro-8,18-diazatetracyclo[9.7.0.0^{2,7}.0^{12,17}]octadeca-1(11),2(7),3,5,12(17),13,15-heptaen-9-one",
        "inchi": {
            "hash": "OLUKILHGKRVDCT-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H11N3O3/c20-15-8-12-11-7-9(19(21)22)5-6-14(11)18-16(12)10-3-1-2-4-13(10)17-15/h1-7,18H,8H2,(H,17,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 293.2768,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 293.080041233,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).",
        "link": "https://go.drugbank.com/drugs/DB04014",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen synthase kinase-3 beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 5"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 1"
            }
        ]
    },
    {
        "smiles": "CC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CCC(=O)NCCNC(=O)C1=C(O)C=CC=C1",
        "id": "DB15010",
        "molecule": "Edasalonexent",
        "cas": "1204317-86-1",
        "iupac_name": "(4Z,7Z,10Z,13Z,16Z,19Z)-N-{2-[(2-hydroxyphenyl)formamido]ethyl}docosa-4,7,10,13,16,19-hexaenamide",
        "background": "Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).\n",
        "inchi": {
            "hash": "JQLBBYLGWHUHRW-KUBAVDMBSA-N",
            "id": "InChI=1S/C31H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-30(35)32-26-27-33-31(36)28-23-21-22-24-29(28)34/h3-4,6-7,9-10,12-13,15-16,18-19,21-24,34H,2,5,8,11,14,17,20,25-27H2,1H3,(H,32,35)(H,33,36)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 490.688,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 490.31954322,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15010",
        "type": "Small Molecule",
        "synonyms": [
            "Edasalonexent"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=NC(=O)N(CN1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",
        "id": "DB17151",
        "molecule": "5,6-dihydro-5-azacytidine",
        "cas": "62488-57-7",
        "iupac_name": "4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,5,6-tetrahydro-1,3,5-triazin-2-one",
        "inchi": {
            "hash": "LJIRBXZDQGQUOO-KVTDHHQDSA-N",
            "id": "InChI=1S/C8H14N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h3-6,13-15H,1-2H2,(H3,9,10,11,16)/t3-,4-,5-,6-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 246.223,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 246.096419567,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17151",
        "type": "Small Molecule",
        "synonyms": [
            "1,3,5-triazin-2(1h)-one, 4-amino-5,6-dihydro-1-.beta.-d-ribofuranosyl-"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)CN(CCCN1CCN(CCCNC2=NC3=CC=CC=C3N2)CC1)CC(C)C",
        "id": "DB16954",
        "molecule": "Ezeprogind",
        "cas": "615539-20-3",
        "iupac_name": "N-[3-(4-{3-[bis(2-methylpropyl)amino]propyl}piperazin-1-yl)propyl]-1H-1,3-benzodiazol-2-amine",
        "inchi": {
            "hash": "KLKKWCPJBTXWOV-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H44N6/c1-21(2)19-31(20-22(3)4)14-8-13-30-17-15-29(16-18-30)12-7-11-26-25-27-23-9-5-6-10-24(23)28-25/h5-6,9-10,21-22H,7-8,11-20H2,1-4H3,(H2,26,27,28)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 428.669,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 428.362745441,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16954",
        "type": "Small Molecule",
        "synonyms": [
            "1,4-piperazinedipropanamine, n'-1h-benzimidazol-2-yl-n,n-bis(2-methylpropyl)-",
            "1,4-piperazinedipropanamine, n4-1h-benzimidazol-2-yl-n1,n1-bis(2-methylpropyl)-",
            "Azp-2006 free base",
            "Azp2006 free base",
            "N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo(d)imidazol-2-amine",
            "N4-1h-benzimidazol-2-yl-n1,n1-bis(2-methylpropyl)-1,4-piperazinedipropanamine"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCS(=O)(=O)N1CCN(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C3=CC(NC(=O)C4CC4)=CC=C3OC(F)(F)F)C=C2)CC1",
        "id": "DB12724",
        "molecule": "AZD-7295",
        "cas": "929890-64-2",
        "iupac_name": "5'-cyclopropaneamido-N-(4-{[4-(propane-1-sulfonyl)piperazin-1-yl]methyl}phenyl)-2'-(trifluoromethoxy)-[1,1'-biphenyl]-4-carboxamide",
        "background": "AZD7295 has been investigated for the treatment of Hepatitis C.\n",
        "inchi": {
            "hash": "MAQDQJWCSSCURR-UHFFFAOYSA-N",
            "id": "InChI=1S/C32H35F3N4O5S/c1-2-19-45(42,43)39-17-15-38(16-18-39)21-22-3-11-26(12-4-22)36-30(40)24-7-5-23(6-8-24)28-20-27(37-31(41)25-9-10-25)13-14-29(28)44-32(33,34)35/h3-8,11-14,20,25H,2,9-10,15-19,21H2,1H3,(H,36,40)(H,37,41)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 644.71,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 644.228025906,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.",
        "link": "https://go.drugbank.com/drugs/DB12724",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "C[C@@H]1C(=O)O[C@H]2C[C@]34[C@@H]5OC(=O)[C@]3(O[C@@H]3OC(=O)[C@H](O)[C@]43[C@@H]([C@H]5O)C(C)(C)C)[C@@]12O",
        "id": "DB06746",
        "molecule": "ginkgolide-J",
        "cas": "107438-79-9",
        "iupac_name": "(1R,3R,6R,7S,8S,9R,10S,11S,13S,16S,17R)-8-tert-butyl-6,9,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.0^{1,11}.0^{3,7}.0^{7,11}.0^{13,17}]nonadecane-5,15,18-trione",
        "inchi": {
            "hash": "LMEHVEUFNRJAAV-UKWFQYJJSA-N",
            "id": "InChI=1S/C20H24O10/c1-6-12(23)27-7-5-17-11-8(21)9(16(2,3)4)18(17)10(22)13(24)29-15(18)30-20(17,14(25)28-11)19(6,7)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11-,15+,17-,18+,19-,20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 424.3986,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 424.136946988,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as ginkgolides and bilobalides. These are diterpene lactones with a structure based either on the gingkolide or the bilobalide skeleton. The ginkgolide skeleton is a very rigid structure consisting of hexacyclic C20 trilactone. The cis-fused F/A/D/C ring junction forms an empty semi-ball hole, the D ring contains a cage form tetrahydrofuran ring which occupies the center of the empty hole, and the oxygen atoms of the D,C and F ring and 10-hydroxyl group consist of an analogous crown ether structure.",
        "link": "https://go.drugbank.com/drugs/DB06746",
        "type": "Small Molecule"
    },
    {
        "smiles": "[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)OC([H])(F)[C@@]1([H])F",
        "id": "DB02318",
        "molecule": "2-deoxy-2-fluoro-alpha-D-mannosyl fluoride",
        "iupac_name": "(2R,3S,4S,5S)-5,6-difluoro-2-(hydroxymethyl)oxane-3,4-diol",
        "inchi": {
            "hash": "YZRDPODBASCWCK-CBPJZXOFSA-N",
            "id": "InChI=1S/C6H10F2O4/c7-3-5(11)4(10)2(1-9)12-6(3)8/h2-6,9-11H,1H2/t2-,3+,4-,5-,6?/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 184.138,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 184.054715218,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB02318",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-mannosidase 2"
            }
        ]
    },
    {
        "smiles": "NC1=CC=C(C=C1[Hg])S(N)(=O)=O",
        "id": "DB04203",
        "molecule": "3-Mercuri-4-Aminobenzenesulfonamide",
        "iupac_name": "(2-amino-5-sulfamoylphenyl)mercury",
        "inchi": {
            "hash": "KGGLGSZFQPTPPT-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H7N2O2S.Hg/c7-5-1-3-6(4-2-5)11(8,9)10;/h1,3-4H,7H2,(H2,8,9,10);"
        },
        "weight": [
            {
                "type": "average",
                "weight": 371.79,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 372.993448772,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB04203",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNCC1=CC=C([123I])C=C1)C(O)=O)C(O)=O",
        "id": "DB12514",
        "molecule": "Iofolastat I-123",
        "cas": "949575-24-0",
        "iupac_name": "(2S)-2-({[(1S)-1-carboxy-5-({[4-(I)iodophenyl]methyl}amino)pentyl]carbamoyl}amino)pentanedioic acid",
        "background": "Iofolastat I-123 is under investigation in clinical trial NCT00992745 (A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer).\n",
        "inchi": {
            "hash": "OXUUJYOSVPMNKP-ZANJDRPYSA-N",
            "id": "InChI=1S/C19H26IN3O7/c20-13-6-4-12(5-7-13)11-21-10-2-1-3-14(17(26)27)22-19(30)23-15(18(28)29)8-9-16(24)25/h4-7,14-15,21H,1-3,8-11H2,(H,24,25)(H,26,27)(H,28,29)(H2,22,23,30)/t14-,15-/m0/s1/i20-4"
        },
        "weight": [
            {
                "type": "average",
                "weight": 531.337,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 531.082673133,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB12514",
        "type": "Small Molecule",
        "synonyms": [
            "Iofolastat (123 I)"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(=O)NC1=CC=C(OC(=O)C2=CC=CC=C2OC(C)=O)C=C1",
        "id": "DB13657",
        "molecule": "Benorilate",
        "cas": "5003-48-5",
        "iupac_name": "4-acetamidophenyl 2-(acetyloxy)benzoate",
        "inchi": {
            "hash": "FEJKLNWAOXSSNR-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H15NO5/c1-11(19)18-13-7-9-14(10-8-13)23-17(21)15-5-3-4-6-16(15)22-12(2)20/h3-10H,1-2H3,(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 313.309,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 313.095022587,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone).",
        "link": "https://go.drugbank.com/drugs/DB13657",
        "type": "Small Molecule",
        "synonyms": [
            "4-acetamidophenyl salicylate acetate",
            "Bnorilate",
            "Benorilate",
            "Benorilato",
            "Fenasprate"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN(C)CC1=C(OC2=CC=CC=C12)C(=O)NCCOC1=CC=C(C=C1)C(=O)NO",
        "id": "DB12565",
        "molecule": "Abexinostat",
        "cas": "783355-60-2",
        "iupac_name": "3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide",
        "background": "Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.\n",
        "inchi": {
            "hash": "MAUCONCHVWBMHK-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 397.431,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 397.163770853,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.",
        "link": "https://go.drugbank.com/drugs/DB12565",
        "type": "Small Molecule",
        "synonyms": [
            "Abexinostat"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHistone deacetylase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UHistone deacetylase"
            }
        ]
    },
    {
        "smiles": "N#CC(C1=NC2=C(S1)C=CC=C2)C1=CC=NC(OCC2=CC=C(CN3CCOCC3)C=C2)=N1",
        "id": "DB16851",
        "molecule": "Bentamapimod",
        "cas": "848344-36-5",
        "iupac_name": "2-(1,3-benzothiazol-2-yl)-2-[2-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)pyrimidin-4-yl]acetonitrile",
        "inchi": {
            "hash": "XCPPIJCBCWUBNT-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 457.55,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 457.157246175,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16851",
        "type": "Small Molecule",
        "synonyms": [
            "Bentamapimod"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
        "id": "DB14703",
        "molecule": "Dexamethasone metasulfobenzoate",
        "cas": "16978-57-7",
        "iupac_name": "3-({2-[(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}carbonyl)benzene-1-sulfonic acid",
        "inchi": {
            "hash": "TWQWRHIQRAZHPR-XNXCGYEVSA-N",
            "id": "InChI=1S/C29H33FO9S/c1-16-11-22-21-8-7-18-13-19(31)9-10-26(18,2)28(21,30)23(32)14-27(22,3)29(16,35)24(33)15-39-25(34)17-5-4-6-20(12-17)40(36,37)38/h4-6,9-10,12-13,16,21-23,32,35H,7-8,11,14-15H2,1-3H3,(H,36,37,38)/t16-,21+,22+,23+,26+,27+,28+,29+/m1/s1"
        },
        "summary": "Dexamethasone metasulfobenzoate is an ophthalmic and auricular corticosteroid used with antibiotics for the treatment of otitis externa, blepharitis, and other inflammatory eye conditions.",
        "weight": [
            {
                "type": "average",
                "weight": 576.63,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 576.18293198,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14703",
        "type": "Small Molecule",
        "synonyms": [
            "Dexamethasone m-sulfobenzoate",
            "Dexamethasone-21-sulfobenzoate"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]\\C1=C([H])\\C(=O)[C@@H](O)[C@@H](O)C[C@H]2O[C@@H]2C2=C(C(O)=CC(OC)=C2)C(=O)O[C@@H](C)C1",
        "id": "DB07905",
        "molecule": "Hypothemycin",
        "cas": "76958-67-3",
        "iupac_name": "(2R,4R,6S,7S,9Z,12S)-6,7,16-trihydroxy-18-methoxy-12-methyl-3,13-dioxatricyclo[13.4.0.0^{2,4}]nonadeca-1(15),9,16,18-tetraene-8,14-dione",
        "inchi": {
            "hash": "SSNQAUBBJYCSMY-KNTMUCJRSA-N",
            "id": "InChI=1S/C19H22O8/c1-9-4-3-5-12(20)17(23)14(22)8-15-18(27-15)11-6-10(25-2)7-13(21)16(11)19(24)26-9/h3,5-7,9,14-15,17-18,21-23H,4,8H2,1-2H3/b5-3-/t9-,14-,15+,17+,18+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 378.377,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 378.131467668,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB07905",
        "type": "Small Molecule",
        "synonyms": [
            "Aigialomycin A"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 1"
            }
        ]
    },
    {
        "smiles": "CC(C)N1CC(O)C2=C\\C(=N\\NC(N)=O)C(=O)C=C12",
        "id": "DB13541",
        "molecule": "Iprazochrome",
        "cas": "7248-21-7",
        "iupac_name": "{[(5Z)-3-hydroxy-6-oxo-1-(propan-2-yl)-2,3,5,6-tetrahydro-1H-indol-5-ylidene]amino}urea",
        "inchi": {
            "hash": "XZKVIDLLLOUTSS-ZSOIEALJSA-N",
            "id": "InChI=1S/C12H16N4O3/c1-6(2)16-5-11(18)7-3-8(14-15-12(13)19)10(17)4-9(7)16/h3-4,6,11,18H,5H2,1-2H3,(H3,13,15,19)/b14-8-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 264.285,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 264.122240391,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indoles and derivatives. These are organic compounds containing an indole, which is a bicyclic ring system made up of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring.",
        "link": "https://go.drugbank.com/drugs/DB13541",
        "type": "Small Molecule",
        "synonyms": [
            "Iprazochrome",
            "Iprazochromum",
            "Iprazocromo"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](CC)(C1=CC=CC=C1)C1=C(O)C2=C(CCCCCC2)OC1=O",
        "id": "DB08686",
        "molecule": "5,6,7,8,9,10-HEXAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOOCTA[B]PYRAN-2-ONE",
        "iupac_name": "4-hydroxy-3-[(1S)-1-phenylpropyl]-2H,5H,6H,7H,8H,9H,10H-cycloocta[b]pyran-2-one",
        "inchi": {
            "hash": "UXCLJNSXDNCIIT-HNNXBMFYSA-N",
            "id": "InChI=1S/C20H24O3/c1-2-15(14-10-6-5-7-11-14)18-19(21)16-12-8-3-4-9-13-17(16)23-20(18)22/h5-7,10-11,15,21H,2-4,8-9,12-13H2,1H3/t15-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 312.4028,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 312.172544634,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.",
        "link": "https://go.drugbank.com/drugs/DB08686",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "HIV-2",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "COC1=CC(=O)C2=C(C(COC3=CC=C(C=C3)[N+]([O-])=O)=C(C)N2C)C1=O",
        "id": "DB02400",
        "molecule": "ES-936",
        "cas": "192820-78-3",
        "iupac_name": "5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]-4,7-dihydro-1H-indole-4,7-dione",
        "inchi": {
            "hash": "IBLWSLZYYZHSRG-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H16N2O6/c1-10-13(9-26-12-6-4-11(5-7-12)20(23)24)16-17(19(10)2)14(21)8-15(25-3)18(16)22/h4-8H,9H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 356.3294,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 356.100836254,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitrophenyl ethers. These are aromatic compounds containing a nitrobenzene moiety that carries an ether group on the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB02400",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNAD(P)H dehydrogenase [quinone] 1"
            }
        ]
    },
    {
        "smiles": "O=C1CCCC(NC2=NN=NN2)=C1",
        "id": "DB07865",
        "molecule": "3-(1H-tetrazol-5-ylamino)cyclohex-2-en-1-one",
        "iupac_name": "3-[(1H-1,2,3,4-tetrazol-5-yl)amino]cyclohex-2-en-1-one",
        "inchi": {
            "hash": "REZXFQGPXQJVJG-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H9N5O/c13-6-3-1-2-5(4-6)8-7-9-11-12-10-7/h4H,1-3H2,(H2,8,9,10,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 179.1793,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 179.080709935,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as secondary alkylarylamines. These are secondary alkylarylamines with the general formula HN(R)R' (R = alkyl, R' = aryl).",
        "link": "https://go.drugbank.com/drugs/DB07865",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1N=CNC2=O",
        "id": "DB06185",
        "molecule": "Forodesine",
        "cas": "209799-67-7",
        "iupac_name": "7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one",
        "background": "Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic leukemia and cutaneous T-cell lymphoma. Additional preliminary findings support its use for the management of some B-cell malignancies.\n",
        "inchi": {
            "hash": "IWKXDMQDITUYRK-KUBHLMPHSA-N",
            "id": "InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 266.2533,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 266.101504956,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB06185",
        "type": "Small Molecule",
        "synonyms": [
            "(1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitol",
            "1,4-Dideoxy-4-aza-1-(S)-(9-deazahypoxanthin-9-yl)-D-ribitol",
            "Forodesine",
            "Immucillin H",
            "Immucillin-H"
        ],
        "indication": "Investigated for use/treatment in lymphoma (non-hodgkin's) and leukemia (lymphoid).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPurine nucleoside phosphorylase"
            }
        ]
    },
    {
        "smiles": "CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1",
        "id": "DB09019",
        "molecule": "Bromhexine",
        "cas": "3572-43-8",
        "iupac_name": "2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline",
        "background": "Bromhexine is mucolytic agent used for a variety of respiratory conditions associated with increased mucus secretion. It is derived from the Adhatoda vasica plant and aids in the clearance of excess mucus, improving breathing and reducing cough. It was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries.1 Recently, bromhexine and its metabolite ambroxol have garnered interest for the potential prevention and treatment of COVID-19 due to their interactions with cell receptors in the lungs.5,6\n",
        "inchi": {
            "hash": "OJGDCBLYJGHCIH-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3"
        },
        "summary": "Bromhexine is a mucolytic drug used to decrease the viscosity of mucus in the airway, enhancing mucus clearance.",
        "weight": [
            {
                "type": "average",
                "weight": 376.13,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 373.999323944,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.",
        "link": "https://go.drugbank.com/drugs/DB09019",
        "type": "Small Molecule",
        "synonyms": [
            "3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine",
            "Bromexina",
            "Bromhexina",
            "Bromhexine",
            "Bromhexinum",
            "N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine"
        ],
        "indication": "Bromohexine is used alone or with other ingredients such as diphenhydramine, dextromethorphan, and guaifenesin to reduce mucus viscosity and clear mucus in conditions associated with mucus hypersecretion, including the common cold, influenza, respiratory tract infections, or other conditions.16,15,13\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions.1,11,13\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTransmembrane protease serine 2"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UAngiotensin-converting enzyme 2"
            }
        ]
    },
    {
        "smiles": "COC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(OC2=CC3=C(C=C2Cl)[C@H](CCO3)C(O)=O)C=C1",
        "id": "DB16053",
        "molecule": "ARRY-502",
        "cas": "1202891-16-4",
        "iupac_name": "(4S)-6-chloro-7-(4-{[2-(4-chloro-2-methoxyphenyl)ethyl]carbamoyl}phenoxy)-3,4-dihydro-2H-1-benzopyran-4-carboxylic acid",
        "background": "ARRY-502 is under investigation in clinical trial NCT01561690 (A Study of ARRY-502 in Patients With Persistent Asthma).\n",
        "inchi": {
            "hash": "QIDYUNXQPQEJEC-IBGZPJMESA-N",
            "id": "InChI=1S/C26H23Cl2NO6/c1-33-22-12-17(27)5-2-15(22)8-10-29-25(30)16-3-6-18(7-4-16)35-24-14-23-20(13-21(24)28)19(26(31)32)9-11-34-23/h2-7,12-14,19H,8-11H2,1H3,(H,29,30)(H,31,32)/t19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 516.37,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 515.0902429,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16053",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "id": "DB11143",
        "molecule": "Cresol",
        "cas": "1319-77-3",
        "background": "Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers. Cresols are precursors or synthetic intermediates to various other compounds and materials, including plastics, pesticides, pharmaceuticals, disinfectants, and dyes. Ingestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal pain, and/or vomiting. At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.\n",
        "inchi": {},
        "summary": "Cresol is a dental disinfectant used to remove dental pulp.",
        "link": "https://go.drugbank.com/drugs/DB11143",
        "type": "Small Molecule",
        "synonyms": [
            "Cresol"
        ],
        "indication": "The primary medical indications for cresols in general include being used as bactericides, pesticides, and disinfectants 10. Certain isomers of cresol, like m-cresol, may be used as inactive ingredients for the purpose of serving as a preservative in some pharmaceuticals 10.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "All cresol isomers are absorbed across the respiratory and gastrointestinal tract and through the intact skin 9. Limited data indicate that cresols are widely distributed throughout the body after uptake 9. Cresols are mainly conjugated with glucuronic acid and inorganic sulfate and excreted as conjugates with the urine 9.\nAt physiological pH, the conjugated metabolites are ionized to a greater extent than the parent compound, which reduces renal reabsorption and increases elimination with the urine 9. In addition to urinary excretion, cresols are excreted in the bile, but the most part undergoes enterohepatic circulation 9. There are know species differences in the specific conjugation reactions of cresol isomers and the relative amounts of glucuronide and sulfate conjugates therefore differ between species and also vary with dose 9.\n"
    },
    {
        "smiles": "CCNC1=NC(=O)C(O1)C1=CC=CC=C1",
        "id": "DB13341",
        "molecule": "Fenozolone",
        "cas": "15302-16-6",
        "iupac_name": "2-(ethylamino)-5-phenyl-4,5-dihydro-1,3-oxazol-4-one",
        "inchi": {
            "hash": "RXOIEVSUURELPG-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H12N2O2/c1-2-12-11-13-10(14)9(15-11)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 204.229,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 204.089877634,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.",
        "link": "https://go.drugbank.com/drugs/DB13341",
        "type": "Small Molecule",
        "synonyms": [
            "Fenozolona",
            "Fenozolone",
            "Fenozolonum"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@H](OC1=CC=C(C=C1C(F)(F)F)C1=NC(=NO1)C1=CC=C2NC=NC2=C1)C(F)(F)F",
        "id": "DB11819",
        "molecule": "ASP-4058",
        "cas": "952565-91-2",
        "iupac_name": "5-{5-[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]-1,2,4-oxadiazol-3-yl}-1H-1,3-benzodiazole",
        "background": "ASP4058 has been used in trials studying Food Effect of ASP4058 and Pharmacokinetics of ASP4058.\n",
        "inchi": {
            "hash": "NJNXCJPSMWKXHO-VIFPVBQESA-N",
            "id": "InChI=1S/C19H12F6N4O2/c1-9(18(20,21)22)30-15-5-3-11(6-12(15)19(23,24)25)17-28-16(29-31-17)10-2-4-13-14(7-10)27-8-26-13/h2-9H,1H3,(H,26,27)/t9-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 442.321,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 442.08644462,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenyloxadiazoles. These are polycyclic aromatic compounds containing a benzene ring linked to a 1,2,4-oxadiazole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB11819",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[68Ga+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC(CN(CCN(CC([O-])=O)CC2=C(O)C=CC(CCC([O-])=O)=C2)CC([O-])=O)=C(O)C=C1)C(O)=O)C(O)=O",
        "id": "DB16019",
        "molecule": "Gallium Ga-68 gozetotideCommonly known or available as Ga 68 PSMA-11",
        "cas": "1906894-20-9",
        "iupac_name": "(68Ga)gallium(3+) 3-(3-{[(2-{[(5-{2-[(5-{[(5S)-5-carboxy-5-({[(1S)-1,3-dicarboxypropyl]carbamoyl}amino)pentyl]carbamoyl}pentyl)carbamoyl]ethyl}-2-hydroxyphenyl)methyl](carboxylatomethyl)amino}ethyl)(carboxylatomethyl)amino]methyl}-4-hydroxyphenyl)propanoate",
        "background": "Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET).7 Prostate cancer is one of the most commonly diagnosed cancers among men in Western countries and many patients treated with androgen-deprivation therapy relapse with castration-resistant prostate cancer.1 In nearly all prostate cancers, malignant cells express a transmembrane protein called prostate-specific membrane antigen (PSMA).1 Ga-68 PSMA-11 is an imaging agent that binds PSMA during positron emission tomography: it emits positrons to indicate the presence of PSMA-positive prostate cancer lesions in patients with suspected prostate cancer or in patients who may have recurrent prostate cancer.8 \nOn December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.8 It is administered intravenously. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Ga-68 gozetotide be granted marketing authorization for the diagnosis of prostate cancer.10 In December of the same year, the drug was fully authorized by the EMA.12 In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer.14\n",
        "inchi": {
            "hash": "AEBYHKKMCWUMKX-LNTZDJBBSA-K",
            "id": "InChI=1S/C44H62N6O17.Ga/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);/q;+3/p-3/t32-,33-;/m0./s1/i;1-2"
        },
        "summary": "Ga 68 PSMA-11 is a radiopharmaceutical agent used in the diagnosis of prostate-specific membrane antigen (PSMA) positive lesions in male patients during positron emission tomography.",
        "weight": [
            {
                "type": "average",
                "weight": 1011.909,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1011.321652961,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16019",
        "type": "Small Molecule",
        "synonyms": [
            "(68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC",
            "(68Ga)Hbed-psma",
            "(68Ga)Psma-hbed-CC",
            "68Ga-Psma-11",
            "68Ga-Psma-hbed-CC",
            "DKFZ-PSMA-11 Ga-68",
            "Ga-68 PSMA-11",
            "Ga-68-Labeled PSMA-11",
            "Ga-Psma-hbed-CC Ga-68",
            "Gallium (68Ga) gozetotide",
            "Gallium Ga 68 PSMA-11",
            "Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC",
            "PSMA-11 Ga 68",
            "PSMA-11 Ga-68",
            "Psma-hbed-CC Ga-68"
        ],
        "indication": "Gallium Ga-68 gozetotide, or Gallium Ga-68 PSMA-11, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer metastasis with:\n\nPrimary staging of patients with high-risk or suspected metastatic prostate cancer prior to primary curative therapy, such as initial surgical or radiation therapy.7,9,11\nSuspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.7,9,11\nIdentification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.13\n\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Ga-68 PSMA-11 works by binding to prostate-specific membrane antigen (PSMA) expressed on malignant prostate cancer cells. Gallium-68 (Ga-68) is a +-emitting radionuclide and Ga-68 PSMA-11 can be imaged by PET to indicate the presence of PSMA-positive prostate cancer lesions in the tissues of the body.7 Ga-68 PMSA-11 has a high affinity to PSMA and was shown to be effective in imaging of both local prostate cancer tumours and distant metastatic lesions in clinical trials.3,4 In a clinical trial comprising patients with relapsed prostate cancer, Ga-68 PSMA-11 PET detection rate was different depending on the clinical stage of biochemical recurrence.6\n",
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "AProstate-specific antigen"
            }
        ]
    },
    {
        "smiles": "CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12",
        "id": "DB01091",
        "molecule": "Butenafine",
        "cas": "101828-21-1",
        "iupac_name": "[(4-tert-butylphenyl)methyl](methyl)[(naphthalen-1-yl)methyl]amine",
        "background": "Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.\n",
        "inchi": {
            "hash": "ABJKWBDEJIDSJZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3"
        },
        "summary": "Butenafine is a topical antifungal used to treat tinea versicolor, tinea pedis, tinea cruris, and tinea corporis.",
        "weight": [
            {
                "type": "average",
                "weight": 317.4672,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 317.214349869,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB01091",
        "type": "Small Molecule",
        "synonyms": [
            "(4-tert-Butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine",
            "(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine",
            "4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine",
            "Butenafina",
            "Butenafine",
            "Butenafinum",
            "N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine"
        ],
        "indication": "For the topical treatment of the following dermatologic infections: tinea (pityriasis) versicolor due to M. furfur, interdigital tinea pedis (athletes foot), tinea corporis (ringworm) and tinea cruris (jock itch) due to E. floccosum, T. mentagrophytes, T. rubrum, and T. tonsurans.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Butenafine is a synthetic antifungal agent that is structurally and pharmacologically related to allylamine antifungals. The exact mechanism of action has not been established, but it is suggested that butenafine's antifungal activity is exerted through the alteration of cellular membranes, which results in increased membrane permeability, and growth inhibition. Butenafine is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is also active against Candida albicans and this activity is superior to that of terbinafine and naftifine. Butenafine also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASqualene monooxygenase"
            }
        ]
    },
    {
        "smiles": "[NH3+]C1(CC2=CC=C(Cl)C=C2)CCN(CC1)C1=C2C=CNC2=NC=N1",
        "id": "DB08150",
        "molecule": "4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium",
        "iupac_name": "4-[(4-chlorophenyl)methyl]-1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperidin-4-aminium",
        "inchi": {
            "hash": "RZIDZIGAXXNODG-UHFFFAOYSA-O",
            "id": "InChI=1S/C18H20ClN5/c19-14-3-1-13(2-4-14)11-18(20)6-9-24(10-7-18)17-15-5-8-21-16(15)22-12-23-17/h1-5,8,12H,6-7,9-11,20H2,(H,21,22,23)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 342.846,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 342.148548404,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4-benzylpiperidines. These are organic compounds containing a benzyl group attached to the 4-position of a piperidine.",
        "link": "https://go.drugbank.com/drugs/DB08150",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase catalytic subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase inhibitor alpha"
            }
        ]
    },
    {
        "smiles": "[H][C@](NC(=O)C1=CC=C(CCC2=CNC3=C2C(=O)NC(N)=N3)C=C1)(C(C)C)C(O)=O",
        "id": "DB08131",
        "molecule": "2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-3-METHYL-BUTYRIC ACID",
        "iupac_name": "(2S)-2-{[4-(2-{2-amino-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}-3-methylbutanoic acid",
        "inchi": {
            "hash": "MYENGRJSPURSQB-HNNXBMFYSA-N",
            "id": "InChI=1S/C20H23N5O4/c1-10(2)15(19(28)29)23-17(26)12-6-3-11(4-7-12)5-8-13-9-22-16-14(13)18(27)25-20(21)24-16/h3-4,6-7,9-10,15H,5,8H2,1-2H3,(H,23,26)(H,28,29)(H4,21,22,24,25,27)/t15-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 397.4277,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 397.175004249,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hippuric acids. These are compounds containing hippuric acid, which consists of a of a benzoyl group linked to the N-terminal of a glycine.",
        "link": "https://go.drugbank.com/drugs/DB08131",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UThymidylate synthase"
            }
        ]
    },
    {
        "smiles": "ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl",
        "id": "DB01238",
        "molecule": "Aripiprazole",
        "cas": "129722-12-9",
        "iupac_name": "7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one",
        "background": "Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's.8 It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.8 Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.8,1 Aripiprazole was given FDA approval on November 15, 2002.6\n",
        "inchi": {
            "hash": "CEUORZQYGODEFX-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)"
        },
        "summary": "Aripiprazole is an atypical antipsychotic used in the treatment of a wide variety of mood and psychotic disorders, such as schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's syndrome.",
        "weight": [
            {
                "type": "average",
                "weight": 448.385,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 447.148032537,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB01238",
        "type": "Small Molecule",
        "synonyms": [
            "Aripiprazol",
            "Aripiprazole",
            "Aripiprazolum"
        ],
        "indication": "Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder.8 It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania.8 Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.9\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1a and 5-HT2a receptors (Ki values of 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively), moderate affinity for dopamine D4, serotonin 5-HT2c and 5-HT7, alpha1-adrenergic and histamine H1 receptors (Ki values of 44 nM, 15 nM, 39 nM, 57 nM, and 61 nM, respectively), and moderate affinity for the serotonin reuptake site (Ki=98 nM). Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors (IC50\u003e1000 nM).8\n",
        "moa": [
            {
                "action": "antagonistpartial agonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "partial agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1A"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "NAlpha-1A adrenergic receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "NAlpha-1B adrenergic receptor"
            },
            {
                "action": "antagonistpartial agonist",
                "organism": "Humans",
                "target": "UDopamine D3 receptor"
            },
            {
                "action": "antagonistligand",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1D"
            },
            {
                "action": "antagonistpartial agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 7"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "NAlpha-2A adrenergic receptor"
            },
            {
                "action": "antagonistother/unknown",
                "organism": "Humans",
                "target": "NAlpha-2C adrenergic receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "NHistamine H1 receptor"
            },
            {
                "action": "antagonistligand",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1B"
            },
            {
                "action": "antagonistpartial agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2C"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 3A"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 6"
            },
            {
                "action": "antagonistpartial agonistligand",
                "organism": "Humans",
                "target": "UDopamine D1 receptor"
            },
            {
                "action": "antagonistpartial agonist",
                "organism": "Humans",
                "target": "UDopamine D4 receptor"
            },
            {
                "action": "antagonistligand",
                "organism": "Humans",
                "target": "NAlpha-2B adrenergic receptor"
            },
            {
                "action": "antagonistligand",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1E"
            },
            {
                "action": "antagonistpartial agonistligand",
                "organism": "Humans",
                "target": "UDopamine D5 receptor"
            },
            {
                "action": "inverse agonist",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2B"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 5A"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UBeta-1 adrenergic receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UBeta-2 adrenergic receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UHistamine H2 receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UHistamine H3 receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UHistamine H4 receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M1"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M2"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M3"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M4"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M5"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UKappa-type opioid receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UMu-type opioid receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UDelta-type opioid receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UGlutamate (NMDA) receptor"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "USodium-dependent dopamine transporter"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "USodium-dependent serotonin transporter"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12013"
    },
    {
        "id": "DB11361",
        "molecule": "Betula pendula tar oil",
        "cas": "8001-88-5",
        "background": "Betula pendula tar oil is an essential oil found in the buds of the plant with the same name. The origin plant, also known as the European white or silver birch, grows mainly in the northern hemisphere. This oil is usually obtained by using both hydrodistillation and micro-distillation1 and it is conformed mainly by Cresol and Guaiacol.2 The utilization of this product started during the second world war in the Sovietic Union.10 Betula pendula tar oil has been approved for its utilization in over-the-counter product combinations by Health Canada.4 By the FDA, it is considered under the substances approved to be added to the food.5 Under the EMA, betula pendula tar oil is approved under the category of herbal medicines for human use.7\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11361",
        "type": "Small Molecule",
        "synonyms": [
            "Betula alba oil",
            "Betula alba var. pendula tar oil",
            "Betula pendula resin oil",
            "Betula pendula tar volatile oil",
            "Betula verrucosa tar oil",
            "Birch tar oil",
            "Birch tar oil, rectified",
            "European white birch tar oil",
            "Rectified birch tar oil",
            "White birch oil"
        ],
        "indication": "Betula pendula tar oil is used in over-the-counter products for the treatment of wounds, ulcers, bedsores and shallow inflammatory processes such as thrombophlebitis and erysipelas. It is only used externally in over-the-counter dermatologic combinations with Castor oil.6 \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Betula pendula tar oil is thought to present antiseptic properties.8\n"
    },
    {
        "smiles": "C1C[C@@]23C[N@@]1CC[C@@H]2OC1=C(C3)N=CC=C1",
        "id": "DB12125",
        "molecule": "Dianicline",
        "cas": "292634-27-6",
        "iupac_name": "(1R,10S,13S)-9-oxa-4,13-diazatetracyclo[11.2.1.0^{1,10}.0^{3,8}]hexadeca-3(8),4,6-triene",
        "background": "Dianicline has been used in trials studying the treatment of Smoking, Smoking Cessation, and Tobacco Use Cessation.\n",
        "inchi": {
            "hash": "SUPRUPHAEXPGPF-QWHCGFSZSA-N",
            "id": "InChI=1S/C13H16N2O/c1-2-11-10(14-5-1)8-13-4-7-15(9-13)6-3-12(13)16-11/h1-2,5,12H,3-4,6-9H2/t12-,13+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 216.284,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 216.126263143,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyranopyridines. These are polycyclic aromatic compounds containing a pyran ring fused to a pyridine ring.",
        "link": "https://go.drugbank.com/drugs/DB12125",
        "type": "Small Molecule",
        "synonyms": [
            "Dianicline"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)C(=O)N1C2=C(C=C(C)C(C)=C2)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)[N+]2=CN=C3C2=NC=NC3=N)C2=C1C([O-])=NC(=O)N2",
        "id": "DB03531",
        "molecule": "Flavin-adenine dinucleotide-N5-isobutyl ketone",
        "iupac_name": "9-[(2R,3R,4S,5R)-5-[({[({[(2R,3S,4S)-5-[7,8-dimethyl-5-(2-methylpropanoyl)-4-oxido-2-oxo-1H,2H,5H,10H-benzo[g]pteridin-10-yl]-2,3,4-trihydroxypentyl]oxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-3,4-dihydroxyoxolan-2-yl]-6-imino-6H-9lambda5-purin-9-ylium",
        "inchi": {
            "hash": "NQOFHJRBABCNHU-UYOVOMPXSA-N",
            "id": "InChI=1S/C31H39N9O16P2/c1-12(2)29(47)40-16-6-14(4)13(3)5-15(16)38(27-21(40)28(46)37-31(48)36-27)7-17(41)22(43)18(42)8-53-57(49,50)56-58(51,52)54-9-19-23(44)24(45)30(55-19)39-11-35-20-25(32)33-10-34-26(20)39/h5-6,10-12,17-19,22-24,30,32,41-45H,7-9H2,1-4H3,(H3-,36,37,46,48,49,50,51,52)/t17-,18+,19+,22-,23+,24+,30+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 855.6396,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 855.198999269,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine ribonucleoside diphosphates. These are purine ribobucleotides with diphosphate group linked to the ribose moiety.",
        "link": "https://go.drugbank.com/drugs/DB03531",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UD-amino-acid oxidase"
            }
        ]
    },
    {
        "smiles": "[H][C@]12CC3=C(C=C(O)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C",
        "id": "DB14682",
        "molecule": "Dextrorphan",
        "cas": "125-73-5",
        "iupac_name": "(1S,9S,10S)-17-methyl-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-ol",
        "inchi": {
            "hash": "JAQUASYNZVUNQP-PVAVHDDUSA-N",
            "id": "InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 257.3706,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 257.177964363,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14682",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-dextrorphan",
            "(+)-N-methylmorphinan-3-ol",
            "d-3-hydroxy-N-methylmorphinan",
            "Dextro-dromoran",
            "Dextrorphan",
            "Dextrorphane",
            "Dextrorphanum",
            "Levorphanol D-form"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC(CC2=C[NH+]=C(N)N=C2N)=CC(OC)=C1OC",
        "id": "DB03125",
        "molecule": "2,4-Diamino-5-(3,4,5-Trimethoxy-Benzyl)-Pyrimidin-1-Ium",
        "iupac_name": "2,4-diamino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-1-ium",
        "inchi": {
            "hash": "IEDVJHCEMCRBQM-UHFFFAOYSA-O",
            "id": "InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 291.3257,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 291.145715494,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB03125",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydrofolate reductase"
            },
            {
                "action": "Not Available",
                "organism": "Lactobacillus casei",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "C[11C](O)=O",
        "id": "DB15111",
        "molecule": "Acetic acid C-11",
        "cas": "78887-71-5",
        "iupac_name": "(1-11C)acetic acid",
        "background": "Acetic acid C-11 is under investigation in clinical trial NCT01953965 (Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.).\n",
        "inchi": {
            "hash": "QTBSBXVTEAMEQO-JVVVGQRLSA-N",
            "id": "InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)/i2-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 59.052,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 59.032563187,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.",
        "link": "https://go.drugbank.com/drugs/DB15111",
        "type": "Small Molecule",
        "synonyms": [
            "[11C]Acetic Acid",
            "11C-ACETATE"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]12CCN(C[C@@]3([H])CC[C@]4([H])N[C@@]([H])(N)N[C@@]([H])(N)[C@]4([H])C3)[C@@]1([H])CCCC2",
        "id": "DB02559",
        "molecule": "6-(Octahydro-1h-Indol-1-Ylmethyl)Decahydroquinazoline-2,4-Diamine",
        "iupac_name": "(2R,4R,4aR,6S,8aS)-6-{[(3aR,7aS)-octahydro-1H-indol-1-yl]methyl}-decahydroquinazoline-2,4-diamine",
        "inchi": {
            "hash": "HDQIGGQUKAQTGU-SZTTVXCBSA-N",
            "id": "InChI=1S/C17H33N5/c18-16-13-9-11(5-6-14(13)20-17(19)21-16)10-22-8-7-12-3-1-2-4-15(12)22/h11-17,20-21H,1-10,18-19H2/t11-,12+,13+,14-,15-,16+,17+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 307.4774,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 307.273596081,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.",
        "link": "https://go.drugbank.com/drugs/DB02559",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydrofolate reductase"
            },
            {
                "action": "Not Available",
                "organism": "Pneumocystis carinii",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(C[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)CC)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])OC(=O)CC)OC(=O)CC",
        "id": "DB14641",
        "molecule": "Estriol tripropionate",
        "cas": "2236-31-9",
        "iupac_name": "(1R,2R,3aS,3bR,9bS,11aS)-11a-methyl-1,7-bis(propanoyloxy)-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-2-yl propanoate",
        "inchi": {
            "hash": "ONMZMZJEZHMWQL-REUUDLSRSA-N",
            "id": "InChI=1S/C27H36O6/c1-5-23(28)31-17-9-11-18-16(14-17)8-10-20-19(18)12-13-27(4)21(20)15-22(32-24(29)6-2)26(27)33-25(30)7-3/h9,11,14,19-22,26H,5-8,10,12-13,15H2,1-4H3/t19-,20-,21+,22-,26+,27+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 456.5711,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 456.251188884,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.",
        "link": "https://go.drugbank.com/drugs/DB14641",
        "type": "Small Molecule",
        "synonyms": [
            "Estriol propionate",
            "Estriol, tripropionate"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AEstrogen receptor alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USex hormone-binding globulin"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N",
        "id": "DB01209",
        "molecule": "Dezocine",
        "cas": "53648-55-8",
        "iupac_name": "(1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.0^{2,7}]pentadeca-2,4,6-trien-4-ol",
        "background": "Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.\n",
        "inchi": {
            "hash": "VTMVHDZWSFQSQP-VBNZEHGJSA-N",
            "id": "InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 245.3599,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 245.177964363,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.",
        "link": "https://go.drugbank.com/drugs/DB01209",
        "type": "Small Molecule",
        "synonyms": [
            "()-13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-5,11-methanobenzocyclodecen-3-ol",
            "Dezocina",
            "Dezocine",
            "Dezocinum"
        ],
        "indication": "Indicated in the treatment of moderate to severe pain.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dezocine is a parenteral narcotic analgesic possessing both agonist and antagonist activity. It is similar to morphine with respect to analgesic potency and onset and duration of action. The narcotic antagonist activity is greater than that of pentazocine.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AMu-type opioid receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AKappa-type opioid receptor"
            }
        ]
    },
    {
        "smiles": "[H]\\C(=C(\\[H])C(=O)OC)C(=O)OC",
        "id": "DB08908",
        "molecule": "Dimethyl fumarate",
        "cas": "624-49-7",
        "iupac_name": "1,4-dimethyl (2E)-but-2-enedioate",
        "background": "Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.3,4 The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress.4 Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following fingolimod and teriflunomide.2 Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.2\n",
        "inchi": {
            "hash": "LDCRTTXIJACKKU-ONEGZZNKSA-N",
            "id": "InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+"
        },
        "summary": "Dimethyl fumarate is a medication used to treat patients with the relapsing-remitting form of multiple sclerosis.",
        "weight": [
            {
                "type": "average",
                "weight": 144.1253,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 144.042258744,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fatty acid esters. These are carboxylic ester derivatives of a fatty acid.",
        "link": "https://go.drugbank.com/drugs/DB08908",
        "type": "Small Molecule",
        "synonyms": [
            "(E)-But-2-enedioic acid dimethyl ester",
            "1,2-bis(methoxycarbonyl)-trans-ethylene",
            "Dimethyl fumarate",
            "Dimethyl trans-ethylenedicarboxylate",
            "Dimethylfumarat",
            "Fumaric acid, dimethyl ester",
            "trans-1,2-Ethylenedicarboxylic acid dimethyl ester",
            "trans-Butenedioic acid dimethyl ester"
        ],
        "indication": "Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.4,7\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The physiological effects of dimethyl fumarate on the body are not well understood. It has anti-inflammatory and cytoprotective effects, likely involved in its actions in multiple sclerosis (MS) patients.3 Dimethyl fumarate does not cause clinically significant QT interval prolongation. However, cases of progressive multifocal leukoencephalopathy, serious opportunistic infections, lymphopenia and liver injury have been reported in MS patients treated with this drug. Dimethyl fumarate may also cause anaphylaxis and angioedema.4\n",
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "AKelch-like ECH-associated protein 1"
            },
            {
                "action": "inhibitorbinder",
                "organism": "Humans",
                "target": "UTranscription factor p65"
            }
        ]
    },
    {
        "smiles": "CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1C2=CC=CC=C2CCC2=C1C=CC=C2",
        "id": "DB13466",
        "molecule": "Deptropine",
        "cas": "604-51-3",
        "iupac_name": "(1R,3S,5S)-8-methyl-3-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-2-yloxy}-8-azabicyclo[3.2.1]octane",
        "inchi": {
            "hash": "ZWPODSUQWXAZNC-PMOLBWCYSA-N",
            "id": "InChI=1S/C23H27NO/c1-24-18-12-13-19(24)15-20(14-18)25-23-21-8-4-2-6-16(21)10-11-17-7-3-5-9-22(17)23/h2-9,18-20,23H,10-15H2,1H3/t18-,19+,20+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 333.475,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 333.209264493,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.",
        "link": "https://go.drugbank.com/drugs/DB13466",
        "type": "Small Molecule",
        "synonyms": [
            "deptropina",
            "Deptropine"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(OC2=C(C=C1)C(CC1=CN=C(N)N=C1N)=CC(OC)=C2OC)C1CC1",
        "id": "DB07938",
        "molecule": "(S)-iclaprim",
        "iupac_name": "5-{[(2S)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl}pyrimidine-2,4-diamine",
        "inchi": {
            "hash": "HWJPWWYTGBZDEG-CQSZACIVSA-N",
            "id": "InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)/t14-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 354.403,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 354.16919059,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-benzopyrans. These are organic aromatic compounds that 1-benzopyran, a bicyclic compound made up of a benzene ring fused to a pyran, so that the oxygen atom is at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB07938",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "OC(O)(C1=CC=C(S1)C(=O)N1CCN2C(C1)=NC=C2C1=CC=CC=C1)C(F)(F)F",
        "id": "DB08613",
        "molecule": "2,2,2-TRIFLUORO-1-{5-[(3-PHENYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)CARBONYL]THIOPHEN-2-YL}ETHANE-1,1-DIOL",
        "iupac_name": "2,2,2-trifluoro-1-(5-{3-phenyl-5H,6H,7H,8H-imidazo[1,2-a]pyrazine-7-carbonyl}thiophen-2-yl)ethane-1,1-diol",
        "inchi": {
            "hash": "OFBFUNBBOQCNFX-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H16F3N3O3S/c20-19(21,22)18(27,28)15-7-6-14(29-15)17(26)24-8-9-25-13(10-23-16(25)11-24)12-4-2-1-3-5-12/h1-7,10,27-28H,8-9,11H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 423.409,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 423.086446698,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB08613",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHistone deacetylase 4"
            }
        ]
    },
    {
        "smiles": "OP(O)(=O)C(F)(F)C1=CC2=CC(=CC=C2C=C1)C(F)(F)P(O)(O)=O",
        "id": "DB03154",
        "molecule": "{[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid",
        "iupac_name": "({7-[difluoro(phosphono)methyl]naphthalen-2-yl}difluoromethyl)phosphonic acid",
        "inchi": {
            "hash": "VHKBLEYUHBIBNR-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H10F4O6P2/c13-11(14,23(17,18)19)9-3-1-7-2-4-10(6-8(7)5-9)12(15,16)24(20,21)22/h1-6H,(H2,17,18,19)(H2,20,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 388.1453,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 387.988873896,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB03154",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein phosphatase non-receptor type 1"
            }
        ]
    },
    {
        "smiles": "[O-]C(=O)C\\C(=C\\C([O-])=O)C([O-])=O",
        "id": "DB04351",
        "molecule": "Aconitate Ion",
        "iupac_name": "(1Z)-prop-1-ene-1,2,3-tricarboxylate",
        "inchi": {
            "hash": "GTZCVFVGUGFEME-IWQZZHSRSA-K",
            "id": "InChI=1S/C6H6O6/c7-4(8)1-3(6(11)12)2-5(9)10/h1H,2H2,(H,7,8)(H,9,10)(H,11,12)/p-3/b3-1-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 171.0844,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 170.992962828,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB04351",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAconitate hydratase, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAconitate hydratase 2"
            }
        ]
    },
    {
        "smiles": "CC1(C)[C@H]2CC[C@]1(C)C(=O)C2",
        "id": "DB11345",
        "molecule": "(S)-camphor",
        "cas": "464-48-2",
        "iupac_name": "(1S,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one",
        "background": "(S)-camphor, or L(-)-Camphor, is a stereoisomer of Camphor, a bicyclic monoterpene known to potentiate both heat and cold sensations 2. (S)-camphor is not the naturally-occurring stereoisomer but displays similar TRPV channel affinity and current inhibition 1. Camphor is isolated from the wood of the camphor laurel tree, Cinnamomum camphora, and had a long history of medicinal use. It has been used as a nasal decongestant and cough suppressant, and has been topically applied due to its antipruritic, analgesic, and counterirritant properties 1. Camphor is a major active ingredient in over-the-counter balms and liniments supplied as topical analgesics by causing sensitization to heat and coolness to relieve minor muscle and joint pain 1.\n",
        "inchi": {
            "hash": "DSSYKIVIOFKYAU-OIBJUYFYSA-N",
            "id": "InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3/t7-,10+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 152.2334,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 152.120115134,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.",
        "link": "https://go.drugbank.com/drugs/DB11345",
        "type": "Small Molecule",
        "synonyms": [
            "()-bornan-2-one",
            "()-camphor",
            "(1S,4S)-camphor",
            "(1S)-()-camphor",
            "l-camphor"
        ],
        "indication": "Indicated for the temporary symptomatic relief of minor aches and pains of muscles and joints in topical analgesics. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Camphor exerts an analgesic action when applied topically by producing a warm sensation. It excites and desensitizes sensory nerves by activating heat-sensitive TRP vanilloid subtype 1 (TRPV1) and TRPV3 receptors. (S)-camphor is reported to exert a weaker action on TRPV1 channels, which is thought to be a result of tachyphylaxis, which is the reduction of the response to multiple stimulations 1. \n",
        "moa": [
            {
                "action": "agonistactivator",
                "organism": "Humans",
                "target": "ATransient receptor potential cation channel subfamily V member 1"
            },
            {
                "action": "agonistactivator",
                "organism": "Humans",
                "target": "ATransient receptor potential cation channel subfamily V member 3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ATransient receptor potential cation channel subfamily A member 1"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "ATransient receptor potential cation channel subfamily M member 8"
            }
        ]
    },
    {
        "smiles": "NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1",
        "id": "DB00880",
        "molecule": "Chlorothiazide",
        "cas": "58-94-6",
        "iupac_name": "6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide",
        "background": "A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)\n",
        "inchi": {
            "hash": "JBMKAUGHUNFTOL-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)"
        },
        "summary": "Chlorothiazide is a thiazide diuretic used to treat hypertension and edema in congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 295.723,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 294.948824782,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB00880",
        "type": "Small Molecule",
        "synonyms": [
            "6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide",
            "6-chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide",
            "Chlorothiazid",
            "Chlorothiazide",
            "Chlorothiazidum",
            "Chlorthiazide",
            "Clorotiazida"
        ],
        "indication": "Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASolute carrier family 12 member 3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACarbonic anhydrase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "COC1=CC=CC=C1OCC(O)CO",
        "id": "DB00874",
        "molecule": "Guaifenesin",
        "cas": "93-14-1",
        "iupac_name": "3-(2-methoxyphenoxy)propane-1,2-diol",
        "background": "Guaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and used as an expectorant 11. Since that time the agent has been a combination component of various prescription and non-prescription over-the-counter cough and cold products and is currently a widely available over-the-counter generic medication 11. Although it is principally believed that guaifenesin elicits an action to facilitate productive cough to manage chest congestion 4,7,9,10,11, it is not known whether the agent can reliably mitigate coughing.\nRegardless, on March 1, 2007, the FDA received a petition asking the FDA to notify the public that some antitussives, expectorants, decongestants, antihistamines, and cough/cold combinations are not known to be safe and effective in children under the age of 6 years 11. After the negotiation between FDA and major manufacturers, a voluntary transition of labels for not using guaifenesin in children under the age of 4 years was endorsed by FDA in 2008 11.\nFurthermore, there has also been contemporary research to suggest that guaifenesin possesses and is capable of demonstrating anticonvulsant and muscle relaxant effects to some degree possibly by acting as an NMDA receptor antagonist 3.\n",
        "inchi": {
            "hash": "HSRJKNPTNIJEKV-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3"
        },
        "summary": "Guaifenesin is an expectorant commonly found in OTC products for the symptomatic relief from congested chests and coughs associated with cold, bronchitis, and/or other breathing illnesses.",
        "weight": [
            {
                "type": "average",
                "weight": 198.2158,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 198.089208936,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB00874",
        "type": "Small Molecule",
        "synonyms": [
            "Glyceryl guaiacolate",
            "Guaifenesin",
            "Guaifenesina",
            "guaiphenesin"
        ],
        "indication": "Guaifenesin is an expectorant that is indicated for providing temporary symptomatic relief from congested chests and coughs which may be due to a cold, bronchitis, and/or other breathing illnesses Label,8,6.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Guaifenesin is categorized as an expectorant that acts by enhancing the output of phlegm (sputum) and bronchial secretions via decreasing the adhesiveness and surface tension of such material 9. Furthermore, guaifenesin elicits an increased flow of less viscous gastric secretions that subsequently promote ciliary action - all actions that ultimately change dry, unproductive coughing to coughs that are more productive and less frequent 9. Essentially, by decreasing the viscosity and adhesiveness of such secretions, guaifenesin enhances the efficacy of mucociliary activity in removing accumulated secretions from the upper and lower airway 9.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNMDA receptor"
            }
        ]
    },
    {
        "smiles": "CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C",
        "id": "DB00153",
        "molecule": "Ergocalciferol",
        "cas": "50-14-6",
        "iupac_name": "(1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol",
        "background": "Ergocalciferol is an inactivated vitamin D analog.1 It is synthesized by some plants in the presence of UVB light.6 The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932.7\nErgocalciferol is considered the first vitamin D analog and is differentiated from cholecalciferol by the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism.3\nThe first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941.10\n",
        "inchi": {
            "hash": "MECHNRXZTMCUDQ-RKHKHRCZSA-N",
            "id": "InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1"
        },
        "summary": "Ergocalciferol is a vitamin found in many supplement products.",
        "weight": [
            {
                "type": "average",
                "weight": 396.6484,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 396.33921603,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.",
        "link": "https://go.drugbank.com/drugs/DB00153",
        "type": "Small Molecule",
        "synonyms": [
            "(3,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol",
            "(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol",
            "(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol",
            "Activated ergosterol",
            "Ercalciol",
            "Ergocalciferol",
            "Ergocalcifrol",
            "Ergocalciferolum",
            "Oleovitamin D2",
            "Viosterol",
            "Vitamin D2",
            "Vitamina D2"
        ],
        "indication": "Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.Label\nHypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This condition produces decreased calcium and increased phosphorus levels.11\nRickets is a condition produced due to a deficiency in vitamin D, calcium or phosphorus. However, this condition can also be related to renal diseases. It is characterized to present weak or soft bones.4\nFamilial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin D metabolism in the kidneys. The presence of this condition can derive in the presence of osteomalacia, bone softening and rickets.12\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "After the activation of the vitamin D receptor, some of the biological changes produced by ergocalciferol include mobilization and accretion of calcium and phosphorus in the bone, absorption of calcium and phosphorus in the intestine, and reabsorption of calcium and phosphorus in the kidney.7 \nSome other effects known to be produced due to the presence of vitamin D are osteoblast formation, fetus development, induction of pancreatic function, induction of neural function, improvement of immune function, cellular growth and cellular differentiation.7\nWhen compared to its vitamin D counterpart cholecalciferol, ergocalciferol has been shown to present a reduced induction of calcidiol and hence, it is less potent.2\nErgocalciferol supplementation in patients with end-stage renal disease has been shown to generate a significant benefit in lab parameters of bone and mineral metabolism as well as improvement in glycemic control, serum albumin levels and reduced levels of inflammatory markers.1\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AVitamin D3 receptor"
            },
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "NVoltage-dependent calcium channel"
            }
        ]
    },
    {
        "smiles": "C\\C(\\C=C\\C=C(/C)\\C=C\\[C@H]1C(C)=CCCC1(C)C)=C/C=C/C=C(\\C)/C=C/C=C(\\C)/C=C/C1=C(C)CCCC1(C)C",
        "id": "DB15909",
        "molecule": "alpha-Carotene",
        "cas": "7488-99-5",
        "iupac_name": "(6R)-1,5,5-trimethyl-6-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohex-1-en-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]cyclohex-1-ene",
        "inchi": {
            "hash": "ANVAOWXLWRTKGA-NTXLUARGSA-N",
            "id": "InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-23,25-28,37H,15-16,24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+/t37-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 536.888,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 536.438201803,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15909",
        "type": "Small Molecule",
        "synonyms": [
            "(6'R)-beta,epsilon-Carotene",
            "(all-e)-1,3,3-trimethyl-2-(3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1,3,5,7,9,11,13,15,17-octadecanonaenyl)cyclohexene",
            "1,3,3-trimethyl-2-((1e,3e,5e,7e,9e,11e,13e,15e,17e)-3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1,3,5,7,9,11,13,15,17-octadecanonaen-1-yl)cyclohexene"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCC(CC)COC(=O)[C@@H]1C[C@H]2C[C@H](CC[C@H]2CN1)OC1=CC=CC(Cl)=C1C1=NN=NN1",
        "id": "DB12049",
        "molecule": "Dasolampanel etibutil",
        "cas": "503291-52-9",
        "iupac_name": "2-ethylbutyl (3S,4aS,6S,8aR)-6-[3-chloro-2-(1H-1,2,3,4-tetrazol-5-yl)phenoxy]-decahydroisoquinoline-3-carboxylate",
        "background": "Dasolampanel etibutil has been used in trials studying the treatment of Diabetic Neuropathy, Painful.\n",
        "inchi": {
            "hash": "HPBRMCFZIGUGTK-ZMMAXQRCSA-N",
            "id": "InChI=1S/C23H32ClN5O3/c1-3-14(4-2)13-31-23(30)19-11-16-10-17(9-8-15(16)12-25-19)32-20-7-5-6-18(24)21(20)22-26-28-29-27-22/h5-7,14-17,19,25H,3-4,8-13H2,1-2H3,(H,26,27,28,29)/t15-,16+,17-,19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 461.99,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 461.2193676,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB12049",
        "type": "Small Molecule",
        "synonyms": [
            "Dasolampanel etibutil"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](CCCCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O",
        "id": "DB07659",
        "molecule": "AC-(D)PHE-PRO-BOROHOMOLYS-OH",
        "iupac_name": "[(1R)-6-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}hexyl]boronic acid",
        "inchi": {
            "hash": "AILSWIBFGYYZTK-AABGKKOBSA-N",
            "id": "InChI=1S/C22H35BN4O5/c1-16(28)25-18(15-17-9-4-2-5-10-17)22(30)27-14-8-11-19(27)21(29)26-20(23(31)32)12-6-3-7-13-24/h2,4-5,9-10,18-20,31-32H,3,6-8,11-15,24H2,1H3,(H,25,28)(H,26,29)/t18-,19+,20+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 446.348,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 446.270050716,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB07659",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "OC(=O)CC1=CC(=O)NC(=O)N1",
        "id": "DB03048",
        "molecule": "6-Carboxymethyluracil",
        "iupac_name": "2-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetic acid",
        "inchi": {
            "hash": "NQAUNZZEYKWTHM-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H6N2O4/c9-4-1-3(2-5(10)11)7-6(12)8-4/h1H,2H2,(H,10,11)(H2,7,8,9,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 170.1228,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 170.03275669,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxypyrimidines. These are organic compounds containing a hydroxyl group attached to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB03048",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydropyrimidine dehydrogenase [NADP(+)]"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(N)CN2C(C[C@]1([H])C1=C(F)C=C(F)C(F)=C1)=NC1=CC(=CC=C21)S(C)(=O)=O",
        "id": "DB07193",
        "molecule": "(2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine",
        "iupac_name": "(11R,12R)-5-methanesulfonyl-11-(2,4,5-trifluorophenyl)-1,8-diazatricyclo[7.4.0.0^{2,7}]trideca-2,4,6,8-tetraen-12-amine",
        "inchi": {
            "hash": "HJJAYSSCWGUPKO-ABAIWWIYSA-N",
            "id": "InChI=1S/C18H16F3N3O2S/c1-27(25,26)9-2-3-17-16(4-9)23-18-6-11(15(22)8-24(17)18)10-5-13(20)14(21)7-12(10)19/h2-5,7,11,15H,6,8,22H2,1H3/t11-,15+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 395.399,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 395.091532076,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB07193",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDipeptidyl peptidase 4"
            }
        ]
    },
    {
        "smiles": "CCCCC(C)(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\\C=C\\C(=O)OC",
        "id": "DB08964",
        "molecule": "Gemeprost",
        "cas": "64318-79-2",
        "iupac_name": "methyl (2E)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3R)-3-hydroxy-4,4-dimethyloct-1-en-1-yl]-5-oxocyclopentyl]hept-2-enoate",
        "background": "Gemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy 1. It is not FDA-approved but available in Japan marketed as Preglandin.\n",
        "inchi": {
            "hash": "KYBOHGVERHWSSV-VNIVIJDLSA-N",
            "id": "InChI=1S/C23H38O5/c1-5-6-15-23(2,3)21(26)14-13-18-17(19(24)16-20(18)25)11-9-7-8-10-12-22(27)28-4/h10,12-14,17-18,20-21,25-26H,5-9,11,15-16H2,1-4H3/b12-10+,14-13+/t17-,18-,20-,21-/m1/s1"
        },
        "summary": "Gemeprost is a prostaglandin E1 analogue used for cervical dilation and, in combination with mifepristone, for pregnancy termination.",
        "weight": [
            {
                "type": "average",
                "weight": 394.552,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 394.271924324,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fatty alcohols. These are aliphatic alcohols consisting of a chain of a least six carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB08964",
        "type": "Small Molecule",
        "synonyms": [
            "16,16-Dimethyl-trans-delta-2-PGE1 methyl ester",
            "16,16-Dimethyl-trans-delta(sup 2)-prostaglandin E1 methyl ester",
            "Gemeprost",
            "SC-37681"
        ],
        "indication": "Indicated for the softening and dilatation of the cervix uteri prior to transcervical, intrauterine operative procedures in the first trimester of pregnancy or facilitating therapeutic termination of pregnancy in patients in the second trimester of gestation.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Gemeprost softens and dilates of the cervix prior to transcervical intrauterine operative procedures. It is a prostaglandin E1 analog that potently stimulates uterine contractions and causes cervical ripening and relaxation 1.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP3 subtype"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UProstaglandin E2 receptor EP2 subtype"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(O)CCN2C(=O)N(C(=O)[C@]12[H])C1=C(C)C(Cl)=C(C=C1)C#N",
        "id": "DB07286",
        "molecule": "BMS-564929",
        "cas": "627530-84-1",
        "iupac_name": "4-[(7R,7aS)-7-hydroxy-1,3-dioxo-hexahydro-1H-pyrrolo[1,2-c]imidazol-2-yl]-2-chloro-3-methylbenzonitrile",
        "background": "BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.\n",
        "inchi": {
            "hash": "KEJORAMIZFOODM-PWSUYJOCSA-N",
            "id": "InChI=1S/C14H12ClN3O3/c1-7-9(3-2-8(6-16)11(7)15)18-13(20)12-10(19)4-5-17(12)14(18)21/h2-3,10,12,19H,4-5H2,1H3/t10-,12+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 305.716,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 305.056718972,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07286",
        "type": "Small Molecule",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAndrogen receptor"
            }
        ]
    },
    {
        "smiles": "FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1",
        "id": "DB04908",
        "molecule": "Flibanserin",
        "cas": "167933-07-5",
        "iupac_name": "1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one",
        "background": "Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.\n",
        "inchi": {
            "hash": "PPRRDFIXUUSXRA-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)"
        },
        "summary": "Flibanserin is a 5-HT receptor modulator used for the treatment of selected premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).",
        "weight": [
            {
                "type": "average",
                "weight": 390.4021,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 390.166745929,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB04908",
        "type": "Small Molecule",
        "synonyms": [
            "Flibanserin"
        ],
        "indication": "For the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 1A"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "antagonistagonist",
                "organism": "Humans",
                "target": "ADopamine D4 receptor"
            }
        ]
    },
    {
        "smiles": "COC1=NC=C(F)C2=NC(=NN12)S(=O)(=O)NC1=C(F)C=CC=C1F",
        "id": "DB15316",
        "molecule": "Florasulam",
        "cas": "145701-23-1",
        "iupac_name": "N-(2,6-difluorophenyl)-8-fluoro-5-methoxy-[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide",
        "background": "Florasulam is under investigation in clinical trial NCT01193465 (Temperature and Humidity Among Different Anesthesia Work-station).\n",
        "inchi": {
            "hash": "QZXATCCPQKOEIH-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H8F3N5O3S/c1-23-12-16-5-8(15)10-17-11(18-20(10)12)24(21,22)19-9-6(13)3-2-4-7(9)14/h2-5,19H,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 359.28,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 359.029994801,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15316",
        "type": "Small Molecule",
        "synonyms": [
            "PRIMUS"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07461"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04454"
    },
    {
        "smiles": "CCOC(=O)OC(C)OC1=C(N(C)S(=O)(=O)C2=CC=CC=C12)C(=O)NC1=NC=CC=C1",
        "id": "DB16877",
        "molecule": "Ampiroxicam",
        "cas": "99464-64-9",
        "iupac_name": "ethyl 1-({2-methyl-1,1-dioxo-3-[(pyridin-2-yl)carbamoyl]-2H-1lambda6,2-benzothiazin-4-yl}oxy)ethyl carbonate",
        "inchi": {
            "hash": "LSNWBKACGXCGAJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 447.46,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 447.110021202,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16877",
        "type": "Small Molecule",
        "synonyms": [
            "Ampiroxicam"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCC[C@@H]1CCC2=C(C1)C=CC(=C2)[C@H]1CC[C@](N)(CO)C1",
        "id": "DB15214",
        "molecule": "BMS-986104",
        "cas": "1622180-31-7",
        "iupac_name": "[(1R,3S)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methanol",
        "background": "BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).\n",
        "inchi": {
            "hash": "BPMMYKAHRIEVDH-VOQZNFBZSA-N",
            "id": "InChI=1S/C22H35NO/c1-2-3-4-5-6-17-7-8-19-14-20(10-9-18(19)13-17)21-11-12-22(23,15-21)16-24/h9-10,14,17,21,24H,2-8,11-13,15-16,23H2,1H3/t17-,21+,22-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 329.528,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 329.271864751,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.",
        "link": "https://go.drugbank.com/drugs/DB15214",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCOCC",
        "id": "DB13598",
        "molecule": "Diethyl ether",
        "cas": "60-29-7",
        "iupac_name": "ethoxyethane",
        "inchi": {
            "hash": "RTZKZFJDLAIYFH-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H10O/c1-3-5-4-2/h3-4H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 74.1216,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 74.073164942,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dialkyl ethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are alkyl groups.",
        "link": "https://go.drugbank.com/drugs/DB13598",
        "type": "Small Molecule",
        "synonyms": [
            "Ether"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC(=N)NCCC[C@H](N1CCC1=O)C(O)=O",
        "id": "DB02475",
        "molecule": "Deoxyamidinoproclavaminic acid",
        "iupac_name": "(2S)-5-carbamimidamido-2-(2-oxoazetidin-1-yl)pentanoic acid",
        "inchi": {
            "hash": "UYADDEKIZFRINK-LURJTMIESA-N",
            "id": "InChI=1S/C9H16N4O3/c10-9(11)12-4-1-2-6(8(15)16)13-5-3-7(13)14/h6H,1-5H2,(H,15,16)(H4,10,11,12)/t6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 228.2483,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 228.122240398,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monobactams. These are compounds comprising beta-lactam ring is alone and not fused to another ring.",
        "link": "https://go.drugbank.com/drugs/DB02475",
        "type": "Small Molecule",
        "synonyms": [
            "Deoxyamidinoproclavaminate",
            "Deoxyguanidinoproclavaminate",
            "Deoxyguanidinoproclavaminic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces clavuligerus (strain ATCC 27064 / DSM 738 / JCM 4710 / NBRC 13307 / NCIMB 12785 / NRRL 3585 / VKM Ac-602)",
                "target": "UClavaminate synthase 1"
            }
        ]
    },
    {
        "smiles": "OC1=CC=C(C=C1)\\N=C1/C(=O)NC2=CC=CC=C12",
        "id": "DB03650",
        "molecule": "(3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One",
        "iupac_name": "(3Z)-3-[(4-hydroxyphenyl)imino]-2,3-dihydro-1H-indol-2-one",
        "inchi": {
            "hash": "ZJASRZFZRYISET-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H10N2O2/c17-10-7-5-9(6-8-10)15-13-11-3-1-2-4-12(11)16-14(13)18/h1-8,17H,(H,15,16,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 238.2414,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 238.074227574,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB03650",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerine/threonine-protein kinase pim-1"
            }
        ]
    },
    {
        "smiles": "[Cr+3].[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1",
        "id": "DB11255",
        "molecule": "Chromium picolinate",
        "cas": "14639-25-9",
        "iupac_name": "chromium(3+) tris(pyridine-2-carboxylate)",
        "background": "Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor 1.\n",
        "inchi": {
            "hash": "CBDQOLKNTOMMTL-UHFFFAOYSA-K",
            "id": "InChI=1S/3C6H5NO2.Cr/c3*8-6(9)5-3-1-2-4-7-5;/h3*1-4H,(H,8,9);/q;;;+3/p-3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 418.3005,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 418.013122035,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.",
        "link": "https://go.drugbank.com/drugs/DB11255",
        "type": "Small Molecule",
        "synonyms": [
            "Chromium(III) picolinate"
        ],
        "is_stub": true
    },
    {
        "smiles": "OCCOCCOC1=CC=C(C=C1)C(=C(\\CCCl)C1=CC=CC=C1)\\C1=CC=CC=C1",
        "id": "DB06640",
        "molecule": "Fispemifene",
        "cas": "341524-89-8",
        "iupac_name": "2-(2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethoxy)ethan-1-ol",
        "inchi": {
            "hash": "NKZTZAQIKKGTDB-QPLCGJKRSA-N",
            "id": "InChI=1S/C26H27ClO3/c27-16-15-25(21-7-3-1-4-8-21)26(22-9-5-2-6-10-22)23-11-13-24(14-12-23)30-20-19-29-18-17-28/h1-14,28H,15-20H2/b26-25-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 422.95,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 422.1648724,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.",
        "link": "https://go.drugbank.com/drugs/DB06640",
        "type": "Small Molecule",
        "synonyms": [
            "Fispemifene"
        ],
        "indication": "Investigated for use/treatment in male hormonal deficiencies/abnormalities.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "[H][C@]12[C@@H](CC[C@]1(CO)CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(C)=C",
        "id": "DB16890",
        "molecule": "Betulin",
        "cas": "473-98-3",
        "iupac_name": "(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-icosahydro-1H-cyclopenta[a]chrysen-9-ol",
        "inchi": {
            "hash": "FVWJYYTZTCVBKE-ROUWMTJPSA-N",
            "id": "InChI=1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3/t20-,21+,22-,23+,24-,25+,27-,28+,29+,30+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 442.728,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 442.38108085,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16890",
        "type": "Small Molecule",
        "synonyms": [
            "Betuline",
            "Betulinic alcohol",
            "Betulinol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1=C(Cl)C(=O)OC2=C1C=CC(OP(=O)(OCCCl)OCCCl)=C2",
        "id": "DB11419",
        "molecule": "Haloxon",
        "cas": "321-55-1",
        "iupac_name": "3-chloro-4-methyl-2-oxo-2H-chromen-7-yl bis(2-chloroethyl) phosphate",
        "inchi": {
            "hash": "KULDXINYXFTXMO-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H14Cl3O6P/c1-9-11-3-2-10(8-12(11)22-14(18)13(9)17)23-24(19,20-6-4-15)21-7-5-16/h2-3,8H,4-7H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 415.58,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 413.9593583,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one).",
        "link": "https://go.drugbank.com/drugs/DB11419",
        "type": "Small Molecule",
        "synonyms": [
            "Haloxon",
            "Haloxona",
            "Haloxone",
            "Haloxonum"
        ],
        "is_stub": true
    },
    {
        "smiles": "C\\C(=C/C1=CC=C(C=C1)C(O)=O)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C",
        "id": "DB02877",
        "molecule": "Arotinoid acid",
        "cas": "71441-28-6",
        "iupac_name": "4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl]benzoic acid",
        "background": "Arotinoid acid is a retinoic acid analog which acts as a selective RAR agonist.\n",
        "inchi": {
            "hash": "FOIVPCKZDPCJJY-JQIJEIRASA-N",
            "id": "InChI=1S/C24H28O2/c1-16(14-17-6-8-18(9-7-17)22(25)26)19-10-11-20-21(15-19)24(4,5)13-12-23(20,2)3/h6-11,14-15H,12-13H2,1-5H3,(H,25,26)/b16-14+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 348.4779,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 348.20893014,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.",
        "link": "https://go.drugbank.com/drugs/DB02877",
        "type": "Small Molecule",
        "synonyms": [
            "(E)-4-(2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propen-1-yl)benzoic acid",
            "Arotinoic acid",
            "Arotinoid acid",
            "TTNPB"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URetinoic acid receptor beta"
            }
        ]
    },
    {
        "smiles": "[H]N([C@H]1[C@H](O[C@@H]2[C@@H](CO)O[C@@H](OC3=CC4=C(C=C3)C(C)=CC(=O)O4)[C@H](N([H])C(C)=O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O)C(C)=O",
        "id": "DB02759",
        "molecule": "4-methyl-umbelliferyl-N-acetyl-chitobiose",
        "cas": "53643-12-2",
        "iupac_name": "N-[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4R,5R,6S)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-[(4-methyl-2-oxo-2H-chromen-7-yl)oxy]oxan-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide",
        "inchi": {
            "hash": "UPSFMJHZUCSEHU-JYGUBCOQSA-N",
            "id": "InChI=1S/C26H34N2O13/c1-10-6-18(33)38-15-7-13(4-5-14(10)15)37-25-20(28-12(3)32)23(36)24(17(9-30)40-25)41-26-19(27-11(2)31)22(35)21(34)16(8-29)39-26/h4-7,16-17,19-26,29-30,34-36H,8-9H2,1-3H3,(H,27,31)(H,28,32)/t16-,17-,19-,20-,21-,22-,23-,24-,25-,26+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 582.5538,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 582.206089184,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as coumarin glycosides. These are aromatic compounds containing a carbohydrate moiety glycosidically bound to a coumarin moiety.",
        "link": "https://go.drugbank.com/drugs/DB02759",
        "type": "Small Molecule",
        "synonyms": [
            "4-methylumbelliferyl-N,N-diacetylchitobioside",
            "4-Mudacb"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULysozyme C"
            }
        ]
    },
    {
        "smiles": "C[C@@H](OC1=CC=C(OC2=C(Cl)C=C(C=N2)C(F)(F)F)C=C1)C(O)=O",
        "id": "DB07870",
        "molecule": "Haloxyfop-P",
        "cas": "95977-29-0",
        "iupac_name": "(2R)-2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoic acid",
        "inchi": {
            "hash": "GOCUAJYOYBLQRH-MRVPVSSYSA-N",
            "id": "InChI=1S/C15H11ClF3NO4/c1-8(14(21)22)23-10-2-4-11(5-3-10)24-13-12(16)6-9(7-20-13)15(17,18)19/h2-8H,1H3,(H,21,22)/t8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 361.7,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 361.032870167,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aryloxyphenoxypropionic acids. These are aromatic compounds containing a phenoxypropionic acid that is para-substituted with an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB07870",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-haloxyfop",
            "(R)-haloxyfop",
            "(R)-haloxyfop-acid",
            "R-haloxyfop-acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAcetyl-CoA carboxylase 2"
            }
        ]
    },
    {
        "smiles": "ClC1=CC=C(S1)C(=O)NCCNC(=O)C1=CC=C(C=C1)N1C=CC=CC1=O",
        "id": "DB08173",
        "molecule": "5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE",
        "iupac_name": "N-{2-[(5-chlorothiophen-2-yl)formamido]ethyl}-4-(2-oxo-1,2-dihydropyridin-1-yl)benzamide",
        "inchi": {
            "hash": "UCKHUNHXYMAFQM-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H16ClN3O3S/c20-16-9-8-15(27-16)19(26)22-11-10-21-18(25)13-4-6-14(7-5-13)23-12-2-1-3-17(23)24/h1-9,12H,10-11H2,(H,21,25)(H,22,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 401.867,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 401.06008979,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzamides. These are organic compounds containing a carboxamido substituent attached to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08173",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "smiles": "OC(=O)CC1=CC(O)=CC=C1O",
        "id": "DB08327",
        "molecule": "Homogentisic acid",
        "cas": "451-13-8",
        "iupac_name": "2-(2,5-dihydroxyphenyl)acetic acid",
        "inchi": {
            "hash": "IGMNYECMUMZDDF-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H8O4/c9-6-1-2-7(10)5(3-6)4-8(11)12/h1-3,9-10H,4H2,(H,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 168.1467,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 168.042258744,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2(hydroxyphenyl)acetic acids. These are phenylacetic acids that carry a hydroxyl group at the 2-position.",
        "link": "https://go.drugbank.com/drugs/DB08327",
        "type": "Small Molecule",
        "synonyms": [
            "2,5-Dihydroxyphenylacetic acid",
            "Homogentisate acid",
            "Homogentisic acid",
            "Homogentisinic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UPenicillin G acylase"
            }
        ]
    },
    {
        "smiles": "CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1",
        "id": "DB01038",
        "molecule": "Carphenazine",
        "cas": "2622-30-2",
        "iupac_name": "1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one",
        "background": "Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.\n",
        "inchi": {
            "hash": "XZSMZRXAEFNJCU-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 425.59,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 425.213698424,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.",
        "link": "https://go.drugbank.com/drugs/DB01038",
        "type": "Small Molecule",
        "synonyms": [
            "Carfenazina",
            "Carfenazine",
            "Carfnazine",
            "Carfenazinum",
            "Carphenazine"
        ],
        "indication": "Used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Carphenazine is a phenothiazine antipsychotic agent with a piperazine side-chain.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D1 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D5 receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07581"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11987"
    },
    {
        "id": "DB18235",
        "molecule": "CKD-504",
        "background": "CKD-504 is a novel, selective histone deacetylase 6 inhibitor.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18235",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCCCCCCS([O-])(=O)=O",
        "id": "DB07681",
        "molecule": "DODECANESULFONATE ION",
        "iupac_name": "dodecane-1-sulfonate",
        "inchi": {
            "hash": "LDMOEFOXLIZJOW-UHFFFAOYSA-M",
            "id": "InChI=1S/C12H26O3S/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15/h2-12H2,1H3,(H,13,14,15)/p-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 249.39,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 249.152440356,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organosulfonic acids. These are compounds containing the sulfonic acid group, which has the general structure RS(=O)2OH (R is not a hydrogen atom).",
        "link": "https://go.drugbank.com/drugs/DB07681",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCholinesterase"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=CC=C(NC(=O)NC(=O)C2=CC(F)=C(F)C=C2Cl)C(OC(F)(F)F)=C1",
        "id": "DB07395",
        "molecule": "4-[3-(2-Chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid",
        "iupac_name": "4-{[(2-chloro-4,5-difluorobenzoyl)carbamoyl]amino}-3-(trifluoromethoxy)benzoic acid",
        "inchi": {
            "hash": "NWQGDIBCFLDHDO-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H8ClF5N2O5/c17-8-5-10(19)9(18)4-7(8)13(25)24-15(28)23-11-2-1-6(14(26)27)3-12(11)29-16(20,21)22/h1-5H,(H,26,27)(H2,23,24,25,28)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 438.69,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 438.004190108,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-benzoyl-n'-phenylureas. These are n-acyl-phenylureas that have the acyl group substituted by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07395",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, liver form"
            }
        ]
    },
    {
        "smiles": "CC\\C=C/C=C/C=C/CCCCCCCCCC(O)=O",
        "id": "DB04747",
        "molecule": "11-TRANS-13-TRANS-15-CIS-OCTADECATRIENOIC ACID",
        "iupac_name": "(11E,13E,15Z)-octadeca-11,13,15-trienoic acid",
        "inchi": {
            "hash": "ZSXWVPXJLXTOQQ-ZRGCPWHVSA-N",
            "id": "InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-8H,2,9-17H2,1H3,(H,19,20)/b4-3-,6-5+,8-7+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 278.4296,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 278.224580204,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as lineolic acids and derivatives. These are derivatives of lineolic acid. Lineolic acid is a polyunsaturated omega-6 18 carbon long fatty acid, with two CC double bonds at the 9- and 12-positions.",
        "link": "https://go.drugbank.com/drugs/DB04747",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Propionibacterium acnes",
                "target": "UPutative aminooxidase"
            }
        ]
    },
    {
        "smiles": "NC(=N)N1C=C2C=CC=C(C2=N1)[N+]([O-])=O",
        "id": "DB03065",
        "molecule": "7-Nitroindazole-2-Carboxamidine",
        "iupac_name": "7-nitro-2H-indazole-2-carboximidamide",
        "inchi": {
            "hash": "GFYAZUABYOOPCN-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H7N5O2/c9-8(10)12-4-5-2-1-3-6(13(14)15)7(5)11-12/h1-4H,(H3,9,10)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 205.1735,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 205.059974493,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.",
        "link": "https://go.drugbank.com/drugs/DB03065",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, endothelial"
            }
        ]
    },
    {
        "smiles": "CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1",
        "id": "DB06535",
        "molecule": "Etilevodopa",
        "cas": "37178-37-3",
        "iupac_name": "ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate",
        "inchi": {
            "hash": "NULMGOSOSZBEQL-QMMMGPOBSA-N",
            "id": "InChI=1S/C11H15NO4/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7/h3-4,6,8,13-14H,2,5,12H2,1H3/t8-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 225.244,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 225.100107967,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB06535",
        "type": "Small Molecule",
        "synonyms": [
            "Etilevodopa"
        ],
        "indication": "Investigated for use/treatment in parkinson's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O",
        "id": "DB01401",
        "molecule": "Choline magnesium trisalicylate",
        "cas": "64425-90-7",
        "iupac_name": "magnesium(2+) (2-hydroxyethyl)trimethylazanium tris(2-hydroxybenzoate)",
        "background": "Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% 1,2.\n",
        "inchi": {
            "hash": "FQCQGOZEWWPOKI-UHFFFAOYSA-K",
            "id": "InChI=1S/3C7H6O3.C5H14NO.Mg/c3*8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7;/h3*1-4,8H,(H,9,10);7H,4-5H2,1-3H3;/q;;;+1;+2/p-3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 539.814,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 539.164188051,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.",
        "link": "https://go.drugbank.com/drugs/DB01401",
        "type": "Small Molecule",
        "indication": "Choline magnesium trisalicylate is used to reduce pain and inflammation caused by conditions such as arthritis. This medication is also used to treat fever in adults.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Trisalicylate-choline is a non-steroidal anti-inflammatory drug (NSAID) that contains a combination of choline salicylate and magnesium salicylate. Does not affect platelet aggregation.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 2"
            }
        ]
    },
    {
        "smiles": "NCC1=CC(=CC=C1)N1N=C(C=C1C(=O)NC1=CC(=CC=C1F)[C@H](NCC1CC1)C1=CC=CC(=C1)C#N)C(F)(F)F",
        "id": "DB15982",
        "molecule": "Berotralstat",
        "cas": "1809010-50-1",
        "iupac_name": "1-[3-(aminomethyl)phenyl]-N-{5-[(R)-(3-cyanophenyl)[(cyclopropylmethyl)amino]methyl]-2-fluorophenyl}-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide",
        "background": "Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE).5 It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.3 Berotralstat is strictly used to prevent, but not treat, these attacks.4\nDeveloped by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules.1 Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older.5 Berotralstat was approved by the European Commission on April 30, 2021 7 and by Health Canada on June 06, 2022.6\n",
        "inchi": {
            "hash": "UXNXMBYCBRBRFD-MUUNZHRXSA-N",
            "id": "InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1"
        },
        "summary": "Berotralstat is an inhibitor of plasma kallikrein used for prophylaxis of angioedema attacks in patients with hereditary angioedema.",
        "weight": [
            {
                "type": "average",
                "weight": 562.573,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 562.210422133,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15982",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride",
            "(R)-1-(3-(aminomethyl) phenyl)-N-(5-((3- cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride",
            "2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide",
            "BCX7353",
            "Berotralstat"
        ],
        "indication": "Berotralstat is indicated for prophylaxis of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. It is not used for the treatment of acute HAE attacks.5,7,8\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Berotralstat prevents angioedema attacks by inhibiting plasma kallikrein, thereby regulating excess bradykinin generation in patients with hereditary angioedema (HAE). It had a fast onset of action, long duration of action, and acceptable tolerance in clinical trials.1 Berotralstat inhibits plasma kallikrein in a concentration-dependent.5 In clinical trials, berotralstat reduced HAE attack rates at 24 weeks, and its effects sustained through 48 weeks.4\nIn clinical trials, doses of berotralstat higher than 150 mg once daily led to QT Prolongation in a concentration-dependent manner.5\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "APlasma kallikrein"
            }
        ]
    },
    {
        "smiles": "CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1",
        "id": "DB00357",
        "molecule": "Aminoglutethimide",
        "cas": "125-84-8",
        "iupac_name": "3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione",
        "background": "An aromatase inhibitor that produces a state of \"medical\" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)\n",
        "inchi": {
            "hash": "ROBVIMPUHSLWNV-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)"
        },
        "summary": "Aminoglutethimide is an adrenocortical steroid synthesis inhibitor used in the treatment of Cushing's syndrome.",
        "weight": [
            {
                "type": "average",
                "weight": 232.2783,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 232.121177766,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB00357",
        "type": "Small Molecule",
        "synonyms": [
            "2-(p-Aminophenyl)-2-ethylglutarimide",
            "3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine",
            "Aminoglutethimid",
            "Aminoglutthimide",
            "Aminoglutethimide",
            "Aminoglutethimidum",
            "Aminoglutetimida",
            "Aminoglutetimide",
            "DL-Aminoglutethimide",
            "p-Aminoglutethimide",
            "-(p-Aminophenyl)--ethylglutarimide"
        ],
        "indication": "For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Aminoglutethimide inhibits the enzymatic conversion of cholesterol to D5-pregnenolone, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACholesterol side-chain cleavage enzyme, mitochondrial"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACytochrome P450 19A1"
            }
        ]
    },
    {
        "smiles": "[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C",
        "id": "DB00907",
        "molecule": "Cocaine",
        "cas": "50-36-2",
        "iupac_name": "methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",
        "background": "An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.\n",
        "inchi": {
            "hash": "ZPUCINDJVBIVPJ-LJISPDSOSA-N",
            "id": "InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1"
        },
        "summary": "Cocaine is an ester local anesthetic used during diagnostic procedures and surgeries in or through the nasal cavities.",
        "weight": [
            {
                "type": "average",
                "weight": 303.3529,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 303.147058165,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.",
        "link": "https://go.drugbank.com/drugs/DB00907",
        "type": "Small Molecule",
        "synonyms": [
            "(-)-Cocaine",
            "()-cocaine",
            "[1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester",
            "2-methyl-3-hydroxy-1H,5H-tropane-2-carboxylate benzoate (ester)",
            "Benzoylmethylecgonine",
            "beta-Cocain",
            "Cocain",
            "Cocaina",
            "Cocaine",
            "Cocainum",
            "Kokain",
            "L-Cocain",
            "L-Cocaine",
            "methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",
            "Methyl benzoylecgonine",
            "Neurocaine"
        ],
        "indication": "For the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cocaine is a local anesthetic indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent dopamine transporter"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent noradrenaline transporter"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium channel protein"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent serotonin transporter"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M2"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "USigma non-opioid intracellular receptor 1"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "ULiver carboxylesterase 1"
            }
        ]
    },
    {
        "smiles": "Cl",
        "id": "DB13366",
        "molecule": "Hydrochloric acid",
        "cas": "7647-01-0",
        "iupac_name": "hydrogen chloride",
        "inchi": {
            "hash": "VEXZGXHMUGYJMC-UHFFFAOYSA-N",
            "id": "InChI=1S/ClH/h1H"
        },
        "summary": "Hydrochloric acid is a strong acid used to adjust the pH of injections and ophthalmic solutions.",
        "weight": [
            {
                "type": "average",
                "weight": 36.461,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 35.976677739,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as halogen hydrides. These are inorganic compounds in which the heaviest atom bonded to a hydrogen atom is a halogen.",
        "link": "https://go.drugbank.com/drugs/DB13366",
        "type": "Small Molecule",
        "synonyms": [
            "Chlorowodor",
            "Chlorure d'hydrogne",
            "Chlorwasserstoff",
            "Cloruro de hidrgeno",
            "Hydrochloric acid",
            "Hydrogenchlorid",
            "Wasserstoffchlorid"
        ],
        "is_stub": true
    },
    {
        "smiles": "CNC1=C(F)C=C2C(NC(=O)N(C2=O)C2=CC=C(NC(=O)NS(=O)(=O)C3=CC=C(Cl)S3)C=C2)=C1",
        "id": "DB06350",
        "molecule": "Elinogrel",
        "cas": "936500-94-6",
        "iupac_name": "3-[(5-chlorothiophen-2-yl)sulfonyl]-1-{4-[6-fluoro-7-(methylamino)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl]phenyl}urea",
        "background": "A P2Y12 inhibitor and platelet aggregation inhibitor.\n",
        "inchi": {
            "hash": "LGSDFTPAICUONK-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 523.94,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 523.0187168,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB06350",
        "type": "Small Molecule",
        "synonyms": [
            "Elinogrel"
        ],
        "indication": "Investigated for use/treatment in cardiovascular disorders and myocardial infarction.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UP2Y purinoceptor 12"
            }
        ]
    },
    {
        "smiles": "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2",
        "id": "DB04529",
        "molecule": "Desvancosaminyl vancomycin",
        "cas": "101485-50-1",
        "iupac_name": "(1S,2R,18R,19R,22S,25R,28R,40S)-22-(carbamoylmethyl)-5,47-dichloro-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-48-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{14,17}.1^{8,12}.1^{29,33}.0^{10,25}.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid",
        "inchi": {
            "hash": "QCHYVJAUGVHJHX-PZIRYZLHSA-N",
            "id": "InChI=1S/C59H62Cl2N8O22/c1-20(2)10-30(63-3)52(80)68-44-46(75)22-5-8-34(28(60)12-22)88-36-14-24-15-37(51(36)91-59-50(79)49(78)48(77)38(19-70)90-59)89-35-9-6-23(13-29(35)61)47(76)45-57(85)67-43(58(86)87)27-16-25(71)17-33(73)40(27)26-11-21(4-7-32(26)72)41(54(82)69-45)66-55(83)42(24)65-53(81)31(18-39(62)74)64-56(44)84/h4-9,11-17,20,30-31,38,41-50,59,63,70-73,75-79H,10,18-19H2,1-3H3,(H2,62,74)(H,64,84)(H,65,81)(H,66,83)(H,67,85)(H,68,80)(H,69,82)(H,86,87)/t30-,31+,38-,41-,42-,43+,44-,45+,46-,47-,48-,49+,50-,59+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1306.08,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1304.3355711,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB04529",
        "type": "Small Molecule",
        "synonyms": [
            "Pseudovancomycin",
            "Vancomycin pseudoaglycone"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Amycolatopsis orientalis",
                "target": "UGlycosyltransferase GtfD"
            },
            {
                "action": "Not Available",
                "organism": "Amycolatopsis orientalis",
                "target": "UGlycosyltransferase GtfA"
            }
        ]
    },
    {
        "smiles": "O=C1CCCN1C1=CC=C(OC2=CC3=C(CCN(CC3)C3CCC3)C=C2)N=C1",
        "id": "DB15120",
        "molecule": "GSK-239512",
        "cas": "720691-69-0",
        "iupac_name": "1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]pyridin-3-yl}pyrrolidin-2-one",
        "background": "GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).\n",
        "inchi": {
            "hash": "YFRBKEVUUCQYOW-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 377.488,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 377.210327121,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15120",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC=C(OC4=CC=C(C)N=C4)C(C)=C3)C2=C1",
        "id": "DB12302",
        "molecule": "CP-724714",
        "cas": "537705-08-1",
        "iupac_name": "2-methoxy-N-[(2E)-3-[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-6-yl]prop-2-en-1-yl]acetamide",
        "background": "CP-724,714 has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasm Metastasis.\n",
        "inchi": {
            "hash": "LLVZBTWPGQVVLW-SNAWJCMRSA-N",
            "id": "InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 469.545,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 469.211389749,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB12302",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1",
        "id": "DB12100",
        "molecule": "Abediterol",
        "cas": "915133-65-2",
        "iupac_name": "5-[(1R)-2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one",
        "background": "Abediterol has been used in trials studying the treatment of Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Chronic Obstructive Pulmonary Disease (COPD) and Asthma.\n",
        "inchi": {
            "hash": "SFYAXIFVXBKRPK-QFIPXVFZSA-N",
            "id": "InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 460.522,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 460.21736378,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxyquinolones. These are compounds containing a quinoline moiety bearing a hydroxyl group and a ketone. Quinoline or benzo[b]pyridine is a bicyclic compound that consists of benzene fused to a pyridine.",
        "link": "https://go.drugbank.com/drugs/DB12100",
        "type": "Small Molecule",
        "synonyms": [
            "Abediterol"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC[C@H](O)[C@H](O)CO",
        "id": "DB04481",
        "molecule": "Erythritol",
        "cas": "149-32-6",
        "iupac_name": "(2R,3S)-butane-1,2,3,4-tetrol",
        "background": "Erythritol is a four-carbon sugar that is found in algae, fungi, and lichens. It is twice as sweet as sucrose and can be used as a coronary vasodilator.\n",
        "inchi": {
            "hash": "UNXHWFMMPAWVPI-ZXZARUISSA-N",
            "id": "InChI=1S/C4H10O4/c5-1-3(7)4(8)2-6/h3-8H,1-2H2/t3-,4+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 122.1198,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 122.057908808,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.",
        "link": "https://go.drugbank.com/drugs/DB04481",
        "type": "Small Molecule",
        "synonyms": [
            "(2R,3S)-butane-1,2,3,4-tetrol",
            "Erythrit",
            "Erythrite",
            "Erythritol",
            "Erythro-tetritol",
            "Erythrol",
            "L-erythritol",
            "Mesoerythritol",
            "Phycite",
            "Phycitol"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)",
                "target": "U5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](C)CC2=CC(=O)CC[C@]12C",
        "id": "DB01471",
        "molecule": "Bolasterone",
        "cas": "1605-89-6",
        "iupac_name": "(1S,3aS,3bR,4R,9aR,9bS,11aS)-1-hydroxy-1,4,9a,11a-tetramethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one",
        "inchi": {
            "hash": "IVFYLRMMHVYGJH-VLOLGRDOSA-N",
            "id": "InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16+,17+,18-,19+,20+,21+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 316.4776,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 316.240230268,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.",
        "link": "https://go.drugbank.com/drugs/DB01471",
        "type": "Small Molecule",
        "synonyms": [
            "Bolasterone"
        ]
    },
    {
        "smiles": "C[N+]1=CN([C@@H]2O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]2O)C2=C1C(=O)NC(N)=N2",
        "id": "DB03593",
        "molecule": "7-methyl-5'-guanylic acid",
        "iupac_name": "2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-7-methyl-6-oxo-6,9-dihydro-1H-purin-7-ium",
        "inchi": {
            "hash": "AOKQNZVJJXPUQA-KQYNXXCUSA-O",
            "id": "InChI=1S/C11H16N5O8P/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(24-10)2-23-25(20,21)22/h3-4,6-7,10,17-18H,2H2,1H3,(H4-,12,13,14,19,20,21,22)/p+1/t4-,6-,7-,10-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 378.2551,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 378.081474057,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine ribonucleoside monophosphates. These are nucleotides consisting of a purine base linked to a ribose to which one monophosphate group is attached.",
        "link": "https://go.drugbank.com/drugs/DB03593",
        "type": "Small Molecule",
        "synonyms": [
            "7-methylguanosine 5'-(dihydrogen phosphate)",
            "7-methylguanosine 5'-phosphate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "Um7GpppX diphosphatase"
            }
        ]
    },
    {
        "smiles": "CO[C@H]1C=CO[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\\C=N\\N4CCN(CC4)C4CCCC4)=C(NC(=O)\\C(C)=C/C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@@H]1C)C(O)=C2C(O)=C3C",
        "id": "DB15213",
        "molecule": "25-desacetylrifapentine",
        "cas": "79039-56-8",
        "iupac_name": "(7S,9E,11S,12S,13S,14R,15R,16R,17S,18S,19E,21E)-26-[(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl]-2,13,15,17,27,29-hexahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(29),2,4,9,19,21,25,27-octaene-6,23-dione",
        "background": "25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).\n",
        "inchi": {
            "hash": "LPUNEQQTZOWCNO-WEOUFWGLSA-N",
            "id": "InChI=1S/C45H62N4O11/c1-23-12-11-13-24(2)44(57)47-35-30(22-46-49-19-17-48(18-20-49)29-14-9-10-15-29)40(54)32-33(41(35)55)39(53)28(6)42-34(32)43(56)45(7,60-42)59-21-16-31(58-8)25(3)37(51)27(5)38(52)26(4)36(23)50/h11-13,16,21-23,25-27,29,31,36-38,50-55H,9-10,14-15,17-20H2,1-8H3,(H,47,57)/b12-11-,21-16-,24-13-,46-22+/t23-,25+,26+,27-,31-,36-,37+,38+,45-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 835.008,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 834.441508832,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15213",
        "type": "Small Molecule",
        "synonyms": [
            "25-DESACETYL RIFAPENTINE"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2",
        "id": "DB15394",
        "molecule": "gamma-Tocopherol",
        "cas": "54-28-4",
        "iupac_name": "(2R)-2,7,8-trimethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-ol",
        "background": "gamma-Tocopherol is under investigation in clinical trial NCT00836368 (In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics).\n",
        "inchi": {
            "hash": "QUEDXNHFTDJVIY-DQCZWYHMSA-N",
            "id": "InChI=1S/C28H48O2/c1-20(2)11-8-12-21(3)13-9-14-22(4)15-10-17-28(7)18-16-25-19-26(29)23(5)24(6)27(25)30-28/h19-22,29H,8-18H2,1-7H3/t21-,22-,28-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 416.6795,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 416.36543078,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15394",
        "type": "Small Molecule",
        "synonyms": [
            "D-gamma-Tocopherol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C=O",
        "id": "DB15251",
        "molecule": "Antipain",
        "cas": "37691-11-5",
        "iupac_name": "(2S)-2-({[(1S)-4-carbamimidamido-1-{[(1S)-1-{[(2S)-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl}-2-methylpropyl]carbamoyl}butyl]carbamoyl}amino)-3-phenylpropanoic acid",
        "background": "Antipain is a serine/cysteine protease inhibitor originally isolated from various strains of actinomycetes.1 Early studies investigated the potential for antipain to alter DNA damage and chromosomal aberrations in irradiated cells or those treated with chemical mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).2,3\nAntipain was used in 2010 to obtain a crystal structure of the Leishmania major oligopeptidase B (OPB), a serine protease that serves as a virulence factor in trypanosomatids.4 The binding of antipain to OPB has been used in molecular dynamic studies to identify other OPB inhibitors with more favourable pharmacodynamic and pharmacokinetic properties for potential development as anti-trypanosomatid drugs.5,6\n",
        "inchi": {
            "hash": "SDNYTAYICBFYFH-TUFLPTIASA-N",
            "id": "InChI=1S/C27H44N10O6/c1-16(2)21(23(40)34-18(15-38)10-6-12-32-25(28)29)37-22(39)19(11-7-13-33-26(30)31)35-27(43)36-20(24(41)42)14-17-8-4-3-5-9-17/h3-5,8-9,15-16,18-21H,6-7,10-14H2,1-2H3,(H,34,40)(H,37,39)(H,41,42)(H4,28,29,32)(H4,30,31,33)(H2,35,36,43)/t18-,19-,20-,21-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 604.713,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 604.344529177,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15251",
        "type": "Small Molecule"
    },
    {
        "id": "DB17253",
        "molecule": "Fimaporfin",
        "cas": "1443547-43-0",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17253",
        "type": "Small Molecule",
        "synonyms": [
            "4,4'-(15,20-diphenyl-7,8(or 12,13 or 17,18)-dihydro-21h,23h-porphine-5,10-diyl)bisbenzenesulfonic acid, mixture of three isomers a, b and c (25%, 50%, 25%)",
            "Amphinex",
            "Benzenesulfonic acid, 4,4'-(7,8(or 17,18)-dihydro-10,15(or 15,20)-diphenyl-21h,23h-porphine-5,20(or 5,10)-diyl)bis-"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@@H]1CN(C2=C(C=CC(=N2)N2C=CC(OCCC3(CC3)C(F)(F)F)=N2)C(=O)NS(=O)(=O)C2=CC=CC=C2)C(C)(C)C1",
        "id": "DB15177",
        "molecule": "Bamocaftor",
        "cas": "2204245-48-5",
        "iupac_name": "N-(benzenesulfonyl)-6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide",
        "background": "Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis).\n",
        "inchi": {
            "hash": "IGEOJNMYRZUKIK-IBGZPJMESA-N",
            "id": "InChI=1S/C28H32F3N5O4S/c1-19-17-26(2,3)35(18-19)24-21(25(37)34-41(38,39)20-7-5-4-6-8-20)9-10-22(32-24)36-15-11-23(33-36)40-16-14-27(12-13-27)28(29,30)31/h4-11,15,19H,12-14,16-18H2,1-3H3,(H,34,37)/t19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 591.65,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 591.212710193,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15177",
        "type": "Small Molecule",
        "synonyms": [
            "3-Pyridinecarboxamide, N-(phenylsulfonyl)-6-(3-(2-(1-(trifluoromethyl)cyclopropyl)ethoxy)-1H-pyrazol-1-yl)-2-((4S)-2,2,4-trimethyl-1-pyrrolidinyl)-",
            "N-(benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "C(NC1=CC(=NC2=C(C=NN12)C1CC1)C1=CC=CC=C1)C1=CN=CC=C1",
        "id": "DB08539",
        "molecule": "3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",
        "iupac_name": "3-cyclopropyl-5-phenyl-N-[(pyridin-3-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine",
        "inchi": {
            "hash": "CCDIUVLNHCGSMH-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H19N5/c1-2-6-17(7-3-1)19-11-20(23-13-15-5-4-10-22-12-15)26-21(25-19)18(14-24-26)16-8-9-16/h1-7,10-12,14,16,23H,8-9,13H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 341.4091,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 341.164045633,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB08539",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "[H][C@@](CC(C)C)(NC(=O)C1=CC=CO1)C(O)=O",
        "id": "DB02215",
        "molecule": "Furoyl-Leucine",
        "iupac_name": "(2S)-2-[(furan-2-yl)formamido]-4-methylpentanoic acid",
        "inchi": {
            "hash": "LXBURZIESWDWIV-QMMMGPOBSA-N",
            "id": "InChI=1S/C11H15NO4/c1-7(2)6-8(11(14)15)12-10(13)9-4-3-5-16-9/h3-5,7-8H,6H2,1-2H3,(H,12,13)(H,14,15)/t8-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 225.2411,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 225.100107973,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as leucine and derivatives. These are compounds containing leucine or a derivative thereof resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB02215",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDisintegrin and metalloproteinase domain-containing protein 28"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C",
        "id": "DB01524",
        "molecule": "Androstenediol",
        "cas": "521-17-5",
        "iupac_name": "(1S,3aS,3bR,7S,9aR,9bS,11aS)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-diol",
        "background": "Androstenediol is an intermediate in testosterone biosynthesis, found in the testis or the adrenal glands. Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group to a 3-keto group (3-hydroxysteroid dehydrogenases).\n",
        "inchi": {
            "hash": "QADHLRWLCPCEKT-LOVVWNRFSA-N",
            "id": "InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 290.4403,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 290.224580204,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.",
        "link": "https://go.drugbank.com/drugs/DB01524",
        "type": "Small Molecule",
        "synonyms": [
            "5-andendiol",
            "5-androstenediol",
            "androst-5-ene-3beta,17beta-diol",
            "androst-5-enediol",
            "Androstenediol",
            "hermaphrodiol"
        ]
    },
    {
        "smiles": "CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](NC2=NC=NC3=CC(=NN23)C(C)(C)C)C1=O)NC(C)(C)C",
        "id": "DB16240",
        "molecule": "BMS-813160",
        "cas": "1286279-29-5",
        "iupac_name": "N-[(1R,2S,5R)-5-(tert-butylamino)-2-[(3S)-3-({7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-yl}amino)-2-oxopyrrolidin-1-yl]cyclohexyl]acetamide",
        "background": "BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).\n",
        "inchi": {
            "hash": "CMVHFGNTABZQJU-HCXYKTFWSA-N",
            "id": "InChI=1S/C25H40N8O2/c1-15(34)28-18-12-16(30-25(5,6)7)8-9-19(18)32-11-10-17(22(32)35)29-23-27-14-26-21-13-20(24(2,3)4)31-33(21)23/h13-14,16-19,30H,8-12H2,1-7H3,(H,28,34)(H,26,27,29)/t16-,17+,18-,19+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 484.649,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 484.32742256,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16240",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "COC1=CC=C2SCCN(CC3=CC=C(C=C3)C(O)=O)CC2=C1",
        "id": "DB16944",
        "molecule": "ARM-210",
        "cas": "1467605-57-7",
        "iupac_name": "4-[(7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepin-4-yl)methyl]benzoic acid",
        "inchi": {
            "hash": "JIGDAUOKKYKRKO-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H19NO3S/c1-22-16-6-7-17-15(10-16)12-19(8-9-23-17)11-13-2-4-14(5-3-13)18(20)21/h2-7,10H,8-9,11-12H2,1H3,(H,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 329.41,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 329.10856465,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16944",
        "type": "Small Molecule",
        "synonyms": [
            "4-((7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5h)-yl)methyl)benzoic acid",
            "Benzoic acid, 4-((2,3-dihydro-7-methoxy-1,4-benzothiazepin-4(5h)-yl)methyl)-",
            "Rycal dmd"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1=NC(=CO1)C1=CC(C)=C(OCCCC2=CC(C)=NO2)C(C)=C1",
        "id": "DB08715",
        "molecule": "2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL",
        "iupac_name": "4-{3,5-dimethyl-4-[3-(3-methyl-1,2-oxazol-5-yl)propoxy]phenyl}-2-methyl-1,3-oxazole",
        "inchi": {
            "hash": "SLPKYEWAKMNCPT-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H22N2O3/c1-12-8-16(18-11-23-15(4)20-18)9-13(2)19(12)22-7-5-6-17-10-14(3)21-24-17/h8-11H,5-7H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 326.3896,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 326.16304258,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenyl-1,3-oxazoles. These are aromatic heterocyclic compounds containing a 1,3-oxazole substituted at one or more positions by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB08715",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "HRV-16",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "smiles": "CO[C@@H]1[C@H](O)O[C@@H](C)[C@@H](O)[C@H]1O",
        "id": "DB04515",
        "molecule": "2-O-methyl-alpha-L-fucopyranose",
        "cas": "1887228-22-9",
        "iupac_name": "(2R,3S,4R,5S,6S)-3-methoxy-6-methyloxane-2,4,5-triol",
        "inchi": {
            "hash": "YLAMTMNJXPWCQN-CXNFULCWSA-N",
            "id": "InChI=1S/C7H14O5/c1-3-4(8)5(9)6(11-2)7(10)12-3/h3-10H,1-2H3/t3-,4+,5+,6-,7+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 178.1831,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 178.084123558,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB04515",
        "type": "Small Molecule",
        "synonyms": [
            "6-deoxy-2-O-methyl-alpha-L-galactopyranose",
            "6-deoxy-2-O-methyl--L-galactopyranose"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / NCIB 9290)",
                "target": "UChondroitinase-B"
            }
        ]
    },
    {
        "smiles": "ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1",
        "id": "DB08142",
        "molecule": "AT-7519",
        "cas": "844442-38-2",
        "iupac_name": "4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide",
        "background": "AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.\n",
        "inchi": {
            "hash": "OVPNQJVDAFNBDN-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 382.244,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 381.075930227,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 2-position of the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08142",
        "type": "Small Molecule",
        "synonyms": [
            "4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide"
        ],
        "indication": "Investigated for use/treatment in leukemia (unspecified), lymphoma (unspecified), myelodysplastic syndrome, and solid tumors.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 1"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(C=C1)N1C=NC2=C1C=C(C=C2)C1=NNC(=S)O1",
        "id": "DB07058",
        "molecule": "5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione",
        "iupac_name": "5-[1-(4-methoxyphenyl)-1H-1,3-benzodiazol-6-yl]-2,3-dihydro-1,3,4-oxadiazole-2-thione",
        "inchi": {
            "hash": "QBVJMUOTMRYUKR-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H12N4O2S/c1-21-12-5-3-11(4-6-12)20-9-17-13-7-2-10(8-14(13)20)15-18-19-16(23)22-15/h2-9H,1H3,(H,19,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 324.357,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 324.068096338,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylbenzimidazoles. These are compounds containing a phenylbenzimidazole skeleton, which consists of a benzimidazole moiety where its imidazole ring is attached to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07058",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen synthase kinase-3 beta"
            }
        ]
    },
    {
        "smiles": "CCCCC1=C(NC2=NC=CN=C12)C1=CC=C(O)C=C1",
        "id": "DB07364",
        "molecule": "6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE",
        "iupac_name": "4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol",
        "inchi": {
            "hash": "PRIGRJPRGZCFAS-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H17N3O/c1-2-3-4-13-14(11-5-7-12(20)8-6-11)19-16-15(13)17-9-10-18-16/h5-10,20H,2-4H2,1H3,(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 267.3257,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 267.137162181,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB07364",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 5"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 5 activator 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@](N)(COC1=CN=CC(\\C=C\\C2=CC=NC=C2)=C1)CC1=CNC2=C1C=CC=C2",
        "id": "DB07107",
        "molecule": "(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE",
        "iupac_name": "(2S)-1-(1H-indol-3-yl)-3-({5-[(1E)-2-(pyridin-4-yl)ethenyl]pyridin-3-yl}oxy)propan-2-amine",
        "inchi": {
            "hash": "SGHXFHRRWFLILP-XJDXJNMNSA-N",
            "id": "InChI=1S/C23H22N4O/c24-20(12-19-14-27-23-4-2-1-3-22(19)23)16-28-21-11-18(13-26-15-21)6-5-17-7-9-25-10-8-17/h1-11,13-15,20,27H,12,16,24H2/b6-5+/t20-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 370.447,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 370.179361346,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.",
        "link": "https://go.drugbank.com/drugs/DB07107",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase catalytic subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase inhibitor alpha"
            }
        ]
    },
    {
        "smiles": "C[C@H](O)CBr",
        "id": "DB03335",
        "molecule": "(+)-1-bromo-2-propanol",
        "cas": "16088-60-1",
        "iupac_name": "(2S)-1-bromopropan-2-ol",
        "inchi": {
            "hash": "WEGOLYBUWCMMMY-VKHMYHEASA-N",
            "id": "InChI=1S/C3H7BrO/c1-3(5)2-4/h3,5H,2H2,1H3/t3-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 138.991,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 137.968027493,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bromohydrins. These are alcohols substituted by a bromine atom at a saturated carbon atom otherwise bearing only hydrogen or hydrocarbyl groups.",
        "link": "https://go.drugbank.com/drugs/DB03335",
        "type": "Small Molecule",
        "synonyms": [
            "(S)-(+)-1-Bromo-2-propanol"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas paucimobilis",
                "target": "UHaloalkane dehalogenase"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1",
        "id": "DB04924",
        "molecule": "Itopride",
        "cas": "122898-67-3",
        "iupac_name": "N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide",
        "background": "Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.\n",
        "inchi": {
            "hash": "QQQIECGTIMUVDS-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)"
        },
        "summary": "Itopride is an acetylcholine esterase inhibitor and dopamine D2 receptor antagonist used to treat symptoms of functional dyspepsia such as nausea and vomiting.",
        "weight": [
            {
                "type": "average",
                "weight": 358.4314,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 358.18925733,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-benzylbenzamides. These are compounds containing a benzamide moiety that is N-linked to a benzyl group.",
        "link": "https://go.drugbank.com/drugs/DB04924",
        "type": "Small Molecule",
        "synonyms": [
            "Itopride",
            "N-(p-(2-(Dimethylamino)ethoxy)benzyl)veratramide"
        ],
        "indication": "Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDopamine D2 receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UAcetylcholinesterase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C",
        "id": "DB09015",
        "molecule": "Canrenoic acid",
        "cas": "4138-96-9",
        "iupac_name": "3-[(1S,2R,10R,11S,14R,15S)-14-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-6,8-dien-14-yl]propanoic acid",
        "background": "Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.\n",
        "inchi": {
            "hash": "PBKZPPIHUVSDNM-WNHSNXHDSA-N",
            "id": "InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1"
        },
        "summary": "Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.",
        "weight": [
            {
                "type": "average",
                "weight": 358.478,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 358.214409446,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.",
        "link": "https://go.drugbank.com/drugs/DB09015",
        "type": "Small Molecule",
        "synonyms": [
            "cido canrenoico",
            "Canrenoate",
            "Canrenoic acid"
        ]
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](CO[P@](O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC",
        "id": "DB01966",
        "molecule": "Di-Stearoyl-3-Sn-Phosphatidylethanolamine",
        "iupac_name": "(2-aminoethoxy)[(2S)-2,3-bis(octadecanoyloxy)propoxy]phosphinic acid",
        "inchi": {
            "hash": "LVNGJLRDBYCPGB-KDXMTYKHSA-N",
            "id": "InChI=1S/C41H82NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42)50-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h39H,3-38,42H2,1-2H3,(H,45,46)/t39-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 748.0654,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 747.577805117,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phosphatidylethanolamines. These are glycerophosphoetahnolamines in which two fatty acids are bonded to the glycerol moiety through ester linkages.",
        "link": "https://go.drugbank.com/drugs/DB01966",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProactivator polypeptide"
            }
        ]
    },
    {
        "smiles": "[H][C@](CC1=CC=C(O)C=C1)(N1C(=O)C2=C(C=C(C=C2)C(O)=O)C1=O)C(O)=O",
        "id": "DB07663",
        "molecule": "2-[(1R)-1-CARBOXY-2-(4-HYDROXYPHENYL)ETHYL]-1,3-DIOXOISOINDOLINE-5-CARBOXYLIC ACID",
        "iupac_name": "2-[(1R)-1-carboxy-2-(4-hydroxyphenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid",
        "inchi": {
            "hash": "QISJEFYTLZTWIQ-CQSZACIVSA-N",
            "id": "InChI=1S/C18H13NO7/c20-11-4-1-9(2-5-11)7-14(18(25)26)19-15(21)12-6-3-10(17(23)24)8-13(12)16(19)22/h1-6,8,14,20H,7H2,(H,23,24)(H,25,26)/t14-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 355.2983,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 355.069201775,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB07663",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O",
        "id": "DB11979",
        "molecule": "Elagolix",
        "cas": "834153-87-6",
        "iupac_name": "4-{[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl]-1-phenylethyl]amino}butanoic acid",
        "background": "Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain 7.\nIt has been determined that endometriosis is one of the most common gynecologic disorders in the United States 4,5,6. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms 4,5,6. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis 4,5,6. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review 7, this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.\n",
        "inchi": {
            "hash": "HEAUOKZIVMZVQL-VWLOTQADSA-N",
            "id": "InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1"
        },
        "summary": "Elagolix is a gonadotropin releasing hormone receptor antagonist used to treat moderate to severe pain in endometriosis.",
        "weight": [
            {
                "type": "average",
                "weight": 631.6,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 631.210561893,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB11979",
        "type": "Small Molecule",
        "synonyms": [
            "Elagolix"
        ],
        "indication": "Elagolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis Label.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "During a three menstrual cycle study in healthy women, an elagolix 150 mg once daily regimen and a 200 mg twice daily regimen resulted in an ovulation rate of about 50% and 32%, respectively Label. In Phase 3 trials in women with endometriosis, elagolix caused a dose-dependent reduction in median estradiol concentrations to approximately 42 pg/mL for the 150 mg once daily regimen and 12 pg/mL for the 200 mg twice daily regimen Label.\nFurthermore, the effect of elagolix on the QTc interval was investigated in a randomized, placebo- and positive-controlled, open-label, single-dose, crossover thorough QTc study in 48 healthy adult premenopausal women Label. Elagolix concentrations in subjects administered a single dose of 1200 mg was seventeen times higher than the concentration in subjects given elagolix 200 mg twice daily. Nevertheless, there was no clinically relevant prolongation of the QTc interval Label. \n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGonadotropin-releasing hormone receptor"
            }
        ]
    },
    {
        "smiles": "[H][C@]12C[C@]34[C@H](O)C1[C@@]1([H])C[C@]([H])(N2[C@H](O)[C@H]1CC)[C@]3([H])N(C)C1=CC=CC=C41",
        "id": "DB01426",
        "molecule": "Ajmaline",
        "cas": "4360-12-7",
        "iupac_name": "(1R,9R,10S,12R,13S,14R,16S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.0^{1,9}.0^{2,7}.0^{10,15}.0^{12,17}]nonadeca-2,4,6-triene-14,18-diol",
        "background": "An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. Ajmaline produces potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the WolffParkinsonWhite syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation.\n",
        "inchi": {
            "hash": "CJDRUOGAGYHKKD-HEFSZTOGSA-N",
            "id": "InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16?,17-,18+,19+,20+/m0/s1"
        },
        "summary": "Ajmaline is an antiarrhythmic used to manage a variety of forms of tachycardias.",
        "weight": [
            {
                "type": "average",
                "weight": 326.4326,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 326.199428086,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as ajmaline-sarpagine alkaloids. These are organic compounds containing either of the ajmalan, sarpagan skeleton, or derivative thereof. The Sarpagine (Akuammidine) group, based on the sarpagan nucleus, arises from bond formation between C-16 and C-5 of the corynantheine precursor. Ajmaline alkaloids are based on a 17,19-secoyohimban skeleton (oxayohimban) which is invariably present as an ether.",
        "link": "https://go.drugbank.com/drugs/DB01426",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-Ajmaline",
            "(5aR,6S,8S,10S,11S,11aS,12aR,13R)-5-methyl-5a,6,8,9,10,11,11a,12-octahydro-5H-6,10:11,12a-dimethanoindolo[3,2-b]quinolizine-8,13-diol",
            "Ajmalin",
            "Ajmaline"
        ],
        "indication": "For use as an antiarrhythmic agent.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Ajmaline is a class 1A antiarrhythmic agent. By interfering with the sodium channels, this drug allows for improvement in abnormal rhythms of the heart\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium channel protein type 5 subunit alpha"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F",
        "id": "DB00441",
        "molecule": "Gemcitabine",
        "cas": "95058-81-4",
        "iupac_name": "4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one",
        "background": "Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers.1 Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose.3 As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells.6 The structure, metabolism, and mechanism of action of gemcitabine are similar to cytarabine, but gemcitabine has a wider spectrum of antitumour activity.2\nGemcitabine is marketed as Gemzar and it is available as intravenous injection. It is approved by the FDA to treat advanced ovarian cancer in combination with carboplatin, metastatic breast cancer in combination with paclitaxel, non-small cell lung cancer in combination with cisplatin, and pancreatic cancer as monotherapy.4 It is also being investigated in other cancer and tumour types.\n",
        "inchi": {
            "hash": "SDUQYLNIPVEERB-QPPQHZFASA-N",
            "id": "InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1"
        },
        "summary": "Gemcitabine is a nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.",
        "weight": [
            {
                "type": "average",
                "weight": 263.1981,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 263.071762265,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB00441",
        "type": "Small Molecule",
        "synonyms": [
            "2'-Deoxy-2',2'-difluorocytidine",
            "2',2'-Difluorodeoxycytidine",
            "4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one",
            "Gemcitabin",
            "Gemcitabina",
            "Gemcitabine",
            "Gemcitabinum"
        ],
        "indication": "Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents. \nIn combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.4\nGemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.4\nIn combination with cisplatin, gemcitabine is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).4 Dual therapy with cisplatin is also used to treat patients with Stage IV (locally advanced or metastatic) transitional cell carcinoma (TCC) of the bladder.5\nGemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with fluorouracil.4\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Gemcitabine is a nucleoside analog that mediates its antitumour effects by promoting apoptosis of malignant cells undergoing DNA synthesis. More specifically, it blocks the progression of cells through the G1/S-phase boundary.4 Gemcitabine demonstrated cytotoxic effects against a broad range of cancer cell lines in vitro. It displayed schedule-dependent antitumour activity in various animal models and xenografts from human non-small cell lung cancer (NSCLC) and pancreatic cancer.2 Therefore, the antineoplastic effects of gemcitabine are enhanced through prolonged infusion time rather than higher dosage.2 Gemcitabine inhibited the growth of human xenografts from carcinoma of the lung, pancreas, ovaries, head and neck, and breast. In mice, gemcitabine inhibited the growth of human tumour xenografts from the breast, colon, lung or pancreas by 69 to 99%. In clinical trials of advanced NSCLC, gemcitabine monotherapy produced objective response rates ranging from 18 to 26%, with a median duration of response ranging from 3.3 to 12.7 months. Overall median survival time was 6.2 to 12.3 months. The combined use of cisplatin and gemcitabine produced better objective response rates compared to monotherapy. In patients with advanced pancreatic cancer, objective response rates in patients ranged from 5.to 12%, with a median survival duration of 3.9 to 6.3 months.3 In Phase II trials involving patients with metastatic breast cancer, treatment with gemcitabine alone or with adjuvant chemotherapies resulted in response rate ranging from 13 to 42% and median survival duration ranging from 11.5 to 17.8 months. In metastatic bladder cancer, gemcitabine has a response rate 20 to 28%. In Phase II trials of advanced ovarian cancer, patients treated with gemcitabine had response rate of 57.1%, with progression free survival of 13.4 months and median survival of 24 months.2\nGemcitabine causes dose-limiting myelosuppression, such as anemia, leukopenia, neutropenia, and thrombocytopenia; however, events leading to discontinuation tend to occur less than 1% of the patients. Gemcitabine can elevate ALT, AST and alkaline phosphatase levels.3\n",
        "moa": [
            {
                "action": "cross-linking/alkylation",
                "organism": "Humans",
                "target": "ADNA"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ARibonucleoside-diphosphate reductase large subunit"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UThymidylate synthase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UUMP-CMP kinase"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)N(C=C1Cl)[C@H]1C[C@H](O)[C@@H](CO)O1",
        "id": "DB12383",
        "molecule": "Cytochlor",
        "cas": "32387-56-7",
        "iupac_name": "4-amino-5-chloro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one",
        "background": "Cytochlor has been used in trials studying the treatment of Head and Neck Cancer and Brain and Central Nervous System Tumors.\n",
        "inchi": {
            "hash": "NGGRGTWYSXYVDK-RRKCRQDMSA-N",
            "id": "InChI=1S/C9H12ClN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)/t5-,6+,7+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 261.66,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 261.0516336,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB12383",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H]\\C(CCCCCCCC)=C(/[H])CCCCCCCC(=O)OCC(O)CO",
        "id": "DB13171",
        "molecule": "Glyceryl 1-oleate",
        "cas": "111-03-5",
        "iupac_name": "2,3-dihydroxypropyl (9Z)-octadec-9-enoate",
        "inchi": {
            "hash": "RZRNAYUHWVFMIP-KTKRTIGZSA-N",
            "id": "InChI=1S/C21H40O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h9-10,20,22-23H,2-8,11-19H2,1H3/b10-9-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 356.5399,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 356.292659768,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-monoacylglycerols. These are monoacylglycerols containing a glycerol acylated at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB13171",
        "type": "Small Molecule",
        "synonyms": [
            "1-(9Z-octadecenoyl)-rac-glycerol",
            "1-(9Z)-octadecenoylglycerol",
            "1-Glyceryl oleate",
            "1-monoolein",
            "1-monooleoyl-rac-glycerol",
            "1-monooleoylglycerol",
            "1-oleoyl-rac-glycerol",
            "1-oleoylglycerol",
            "2,3-dihydroxypropyl oleate",
            "9-Octadecenoic acid, 2,3-dihydroxypropyl ester",
            "Glyceryl monooleate",
            "Glyceryl oleate",
            "MG (18:1/0:0/0:0)",
            "Monoolein"
        ]
    },
    {
        "smiles": "CC1=NC2=CC=C(NC(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=C2C(N)=C1",
        "id": "DB04452",
        "molecule": "Aminoquinuride",
        "cas": "3811-56-1",
        "iupac_name": "1,3-bis(4-amino-2-methylquinolin-6-yl)urea",
        "inchi": {
            "hash": "HOUSDILKOJMENG-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H20N6O/c1-11-7-17(22)15-9-13(3-5-19(15)24-11)26-21(28)27-14-4-6-20-16(10-14)18(23)8-12(2)25-20/h3-10H,1-2H3,(H2,22,24)(H2,23,25)(H2,26,27,28)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 372.4231,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 372.169859292,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.",
        "link": "https://go.drugbank.com/drugs/DB04452",
        "type": "Small Molecule",
        "synonyms": [
            "Aminoquinuride"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus anthracis",
                "target": "ULethal factor"
            }
        ]
    },
    {
        "smiles": "CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO",
        "id": "DB01637",
        "molecule": "3,7,11,15-tetramethyl-hexadecan-1-ol",
        "iupac_name": "(3S,7S,11S)-3,7,11,15-tetramethylhexadecan-1-ol",
        "inchi": {
            "hash": "AJAKLDUGVSKVDG-UFYCRDLUSA-N",
            "id": "InChI=1S/C20H42O/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-21/h17-21H,6-16H2,1-5H3/t18-,19-,20-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 298.5469,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 298.323565966,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acyclic diterpenoids. These are diterpenoids (compounds made of four consecutive isoprene units) that do not contain a cycle.",
        "link": "https://go.drugbank.com/drugs/DB01637",
        "type": "Small Molecule"
    },
    {
        "smiles": "CN(CC(O)CO)C(=O)C1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(NC(=O)C(CO)CO)=C1I",
        "id": "DB12407",
        "molecule": "Iobitridol",
        "cas": "136949-58-1",
        "iupac_name": "N1,N3-bis(2,3-dihydroxypropyl)-5-[3-hydroxy-2-(hydroxymethyl)propanamido]-2,4,6-triiodo-N1,N3-dimethylbenzene-1,3-dicarboxamide",
        "background": "Iobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.\n",
        "inchi": {
            "hash": "YLPBXIKWXNRACS-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H28I3N3O9/c1-25(3-10(31)7-29)19(34)12-14(21)13(20(35)26(2)4-11(32)8-30)16(23)17(15(12)22)24-18(33)9(5-27)6-28/h9-11,27-32H,3-8H2,1-2H3,(H,24,33)"
        },
        "summary": "Iobitridol is an iodine-based contrast agent used with X-ray or CT imaging.",
        "weight": [
            {
                "type": "average",
                "weight": 835.169,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 834.89596,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB12407",
        "type": "Small Molecule",
        "synonyms": [
            "Iobitridol"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=C2N=CN(CCOCP(O)(O)=O)C2=NC=N1",
        "id": "DB13868",
        "molecule": "Adefovir",
        "cas": "106941-25-7",
        "iupac_name": "{[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid",
        "inchi": {
            "hash": "SUPKOOSCJHTBAH-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 273.1857,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 273.062690409,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.",
        "link": "https://go.drugbank.com/drugs/DB13868",
        "type": "Small Molecule",
        "synonyms": [
            "9-(2-(phosphonomethoxy)ethyl)adenine",
            "9-(2-phosphonylmethoxyethyl)adenine",
            "Adfovir",
            "Adefovir",
            "Adefovirum"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "HBV-D",
                "target": "ADNA polymerase/reverse transcriptase"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](COP(O)(O)=O)O1",
        "id": "DB02883",
        "molecule": "2',3'-Dideoxycytidine-5'-Monophosphate",
        "iupac_name": "{[(2S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "RAJMXAZJKUGYGW-POYBYMJQSA-N",
            "id": "InChI=1S/C9H14N3O6P/c10-7-3-4-12(9(13)11-7)8-2-1-6(18-8)5-17-19(14,15)16/h3-4,6,8H,1-2,5H2,(H2,10,11,13)(H2,14,15,16)/t6-,8+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 291.1977,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 291.062021707,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB02883",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UCytidylate kinase"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(COP(O)([O-])=O)O[C@@]([H])(N2C=NC(C(N)=O)=C2[O-])[C@]([H])(O)[C@]1([H])O",
        "id": "DB01945",
        "molecule": "4-Carbamoyl-1-Beta-D-Ribofuranosyl-Imidazolium-5-Olate-5'-Phosphate",
        "iupac_name": "4-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1H-imidazol-5-olate",
        "inchi": {
            "hash": "KTKAFSMJDTUUAN-UUOKFMHZSA-L",
            "id": "InChI=1S/C9H14N3O9P/c10-7(15)4-8(16)12(2-11-4)9-6(14)5(13)3(21-9)1-20-22(17,18)19/h2-3,5-6,9,13-14,16H,1H2,(H2,10,15)(H2,17,18,19)/p-2/t3-,5-,6-,9-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 337.18,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 337.031115509,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-ribosyl-imidazolecarboxamides. These are organic compounds containing the imidazole ring linked to a ribose ring through a 1-2 bond.",
        "link": "https://go.drugbank.com/drugs/DB01945",
        "type": "Small Molecule"
    },
    {
        "smiles": "N[C@@H](C[S@@](O)=O)C(O)=O",
        "id": "DB02153",
        "molecule": "3-sulfino-L-alanine",
        "cas": "1115-65-7",
        "iupac_name": "(2R)-2-amino-3-[(R)-sulfino]propanoic acid",
        "inchi": {
            "hash": "ADVPTQAUNPRNPO-REOHCLBHSA-N",
            "id": "InChI=1S/C3H7NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)(H,7,8)/t2-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 153.157,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 153.009578407,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB02153",
        "type": "Small Molecule",
        "synonyms": [
            "(2R)-2-amino-3-sulfinopropanoic acid",
            "3-sulfinoalanine",
            "3-Sulphino-L-alanine",
            "L-Cysteinesulfinic acid",
            "S-Cysteinesulfinic acid",
            "S-Sulfinocysteine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPyridoxamine kinase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus cereus",
                "target": "UBeta-lactamase 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPoly(A) polymerase alpha"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UChorismate mutase AroH"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione reductase, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)",
                "target": "US-ribosylhomocysteine lyase"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas sp. (strain B13)",
                "target": "UCarboxymethylenebutenolidase"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides",
                "target": "UDimethyl sulfoxide/trimethylamine N-oxide reductase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPeroxiredoxin-2"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus (strain MW2)",
                "target": "UPeptide deformylase"
            },
            {
                "action": "Not Available",
                "organism": "Bradyrhizobium japonicum",
                "target": "UMalonamidase E2"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus aureus",
                "target": "UHMG-CoA synthase"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus",
                "target": "UOsmotically inducible protein C"
            }
        ]
    },
    {
        "smiles": "COC1=CC=CC(NC2=C(C=NC3=C(C)C=C(C=C23)S(=O)(=O)C2=CC(=CC=C2)C(=O)N(C)C)C(N)=O)=C1",
        "id": "DB12137",
        "molecule": "GSK-256066",
        "cas": "801312-28-7",
        "iupac_name": "6-[3-(dimethylcarbamoyl)benzenesulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide",
        "background": "Gsk256066 has been used in trials studying the treatment and diagnostic of SAR, Asthma, Mild Asthma, Allergic Rhinitis, and Seasonal Allergic Rhinitis, among others.\n",
        "inchi": {
            "hash": "JFHROPTYMMSOLG-UHFFFAOYSA-N",
            "id": "InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 518.584,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 518.162390652,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinoline-3-carboxamides. These are quinolines in which the quinoline ring system is substituted by one carboxamide group at the 3-position.",
        "link": "https://go.drugbank.com/drugs/DB12137",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@](N)(CC[C@@]1([H])C=CC([H])(N)C=C1)C(O)=O",
        "id": "DB02725",
        "molecule": "2-Amino-4-(4-Amino-Cyclohexa-2,5-Dienyl)-Butyric Acid",
        "iupac_name": "(2S)-2-amino-4-(4-aminocyclohexa-2,5-dien-1-yl)butanoic acid",
        "inchi": {
            "hash": "LAJWZJCOWPUSOA-SMOXQLQSSA-N",
            "id": "InChI=1S/C10H16N2O2/c11-8-4-1-7(2-5-8)3-6-9(12)10(13)14/h1-2,4-5,7-9H,3,6,11-12H2,(H,13,14)/t7-,8?,9-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 196.2462,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 196.121177766,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB02725",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAdenosylmethionine-8-amino-7-oxononanoate aminotransferase"
            }
        ]
    },
    {
        "smiles": "C[N+]1(C)CCCCC1COC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB13542",
        "molecule": "Bevonium",
        "cas": "33371-53-8",
        "iupac_name": "2-{[(2-hydroxy-2,2-diphenylacetyl)oxy]methyl}-1,1-dimethylpiperidin-1-ium",
        "inchi": {
            "hash": "UHUMRJKDOOEQIG-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H28NO3/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3/q+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 354.469,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 354.206370186,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB13542",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "O[S@@](=O)C1=CC=CC=C1",
        "id": "DB03848",
        "molecule": "Benzenesulfinic acid",
        "cas": "618-41-7",
        "iupac_name": "(R)-benzenesulfinic acid",
        "inchi": {
            "hash": "JEHKKBHWRAXMCH-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H6O2S/c7-9(8)6-4-2-1-3-5-6/h1-5H,(H,7,8)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 142.176,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 142.008850126,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.",
        "link": "https://go.drugbank.com/drugs/DB03848",
        "type": "Small Molecule",
        "synonyms": [
            "benzenesulphinic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UOxysterols receptor LXR-beta"
            }
        ]
    },
    {
        "smiles": "C[C@H](CO)CCO[P@](O)(=O)OP(O)(O)=O",
        "id": "DB01799",
        "molecule": "4-Hydroxy-3-Methyl Butyl Diphosphate",
        "iupac_name": "({hydroxy[(3S)-4-hydroxy-3-methylbutoxy]phosphoryl}oxy)phosphonic acid",
        "inchi": {
            "hash": "URURINNTPGGDIV-YFKPBYRVSA-N",
            "id": "InChI=1S/C5H14O8P2/c1-5(4-6)2-3-12-15(10,11)13-14(7,8)9/h5-6H,2-4H2,1H3,(H,10,11)(H2,7,8,9)/t5-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 264.1074,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 264.016390448,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organic pyrophosphates. These are organic compounds containing the pyrophosphate oxoanion, with the structure OP([O-])(=O)OP(O)([O-])=O.",
        "link": "https://go.drugbank.com/drugs/DB01799",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UIsopentenyl-diphosphate Delta-isomerase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07007"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11576"
    },
    {
        "smiles": "C[C@H]1CCCC[C@]1(N1CCCCC1)C1=CC=CS1",
        "id": "DB13096",
        "molecule": "Gacyclidine",
        "cas": "68134-81-6",
        "iupac_name": "1-[(1R,2S)-2-methyl-1-(thiophen-2-yl)cyclohexyl]piperidine",
        "background": "Gacyclidine has been used in trials studying the treatment of Tinnitus.\n",
        "inchi": {
            "hash": "DKFAAPPUYWQKKF-GOEBONIOSA-N",
            "id": "InChI=1S/C16H25NS/c1-14-8-3-4-10-16(14,15-9-7-13-18-15)17-11-5-2-6-12-17/h7,9,13-14H,2-6,8,10-12H2,1H3/t14-,16+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 263.44,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 263.170770983,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.",
        "link": "https://go.drugbank.com/drugs/DB13096",
        "type": "Small Molecule",
        "synonyms": [
            "Gacyclidine"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=C(OC)C2=C[N+]3=C(C=C2C=C1)C1=CC2=C(OCO2)C=C1CC3.[H][C@@]12CC[C@H]([C@H](C)CCC([O-])=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@]2([H])C[C@H](O)CC[C@]12C",
        "id": "DB18111",
        "molecule": "Berberine ursodeoxycholate",
        "cas": "1868138-66-2",
        "inchi": {
            "hash": "FHZVFXJRSFLYDY-FUXQPCDDSA-M",
            "id": "InChI=1S/C24H40O4.C20H18NO4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26;1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28);3-4,7-10H,5-6,11H2,1-2H3/q;+1/p-1/t14-,15-,16-,17-,18+,19-,20+,22-,23-,24-;/m1./s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 727.939,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 727.408417799,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18111",
        "type": "Small Molecule",
        "synonyms": [
            "9,10-dimethoxy-5,6-dihydro-2H,8H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-ylium 3,7-dihydroxy-5-cholan-24-oate",
            "Cholan-24-oic acid, 3,7-dihydroxy-, ion(1-), (3,5,7)-, 5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium (1:1)"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C",
        "id": "DB01485",
        "molecule": "4-Hydroxytestosterone",
        "cas": "2141-17-5",
        "iupac_name": "(1S,3aS,3bR,9aR,9bS,11aS)-1,6-dihydroxy-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one",
        "background": "4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.\nFormestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism. It is specifically the 17-hydroxylated analog to formestane. 1 Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in 1955 by G.D Searle \u0026 Company.\n",
        "inchi": {
            "hash": "BQOIJSIMMIDHMO-FBPKJDBXSA-N",
            "id": "InChI=1S/C19H28O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,16,21-22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 304.43,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 304.203844762,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.",
        "link": "https://go.drugbank.com/drugs/DB01485",
        "type": "Small Molecule",
        "synonyms": [
            "4-Androstene-7alpha-17beta-diol-3-one",
            "4,17beta-Dihydroxy-4-androstene-3-one",
            "7alpha-Hydroxytestosterone"
        ],
        "pharmacodynamics": "Aanabolic steroids have a similar effect to testosterone in the body. Effects include an increase in protein production within cells, (ie. skeletal muscle cells) and well as the development and maintenance of masculine characteristics. \n"
    },
    {
        "smiles": "CC[C@@H]1CN(C)CC[C@]1(OC(=O)CC)C1=CC=CC=C1",
        "id": "DB01552",
        "molecule": "Betameprodine",
        "cas": "468-50-8",
        "iupac_name": "(3R,4R)-3-ethyl-1-methyl-4-phenylpiperidin-4-yl propanoate",
        "background": "Betameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. The stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine. It exerts physiological effects characteristic of opioids, such as analgesia, euphoria and sedation, as well as itching, nausea, and respiratory depression.\n",
        "inchi": {
            "hash": "ODEGQXRCQDVXSJ-RHSMWYFYSA-N",
            "id": "InChI=1S/C17H25NO2/c1-4-14-13-18(3)12-11-17(14,20-16(19)5-2)15-9-7-6-8-10-15/h6-10,14H,4-5,11-13H2,1-3H3/t14-,17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 275.392,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 275.188529049,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB01552",
        "type": "Small Molecule",
        "synonyms": [
            "beta-1-Methyl-3-ethyl-4-phenyl-4-propionoxy-piperidin",
            "beta-3-Ethyl-1-methyl-4-phenyl-4-propionoxypiperidine",
            "beta-meprodine",
            "Betameprodina",
            "Betameprodine",
            "Betameprodinum"
        ]
    },
    {
        "smiles": "OC(=O)C1=CC=C(OCCN2C=CN=C2)C=C1",
        "id": "DB03052",
        "molecule": "Dazoxiben",
        "cas": "78218-09-4",
        "iupac_name": "4-[2-(1H-imidazol-1-yl)ethoxy]benzoic acid",
        "inchi": {
            "hash": "XQGZSYKGWHUSDH-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 232.2353,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 232.08479226,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acids. These are organic Compounds containing a benzene ring which bears at least one carboxyl group.",
        "link": "https://go.drugbank.com/drugs/DB03052",
        "type": "Small Molecule",
        "synonyms": [
            "Dazoxiben",
            "Dazoxibene",
            "Dazoxibenum"
        ],
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UThromboxane-A synthase"
            }
        ]
    },
    {
        "smiles": "CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O",
        "id": "DB04931",
        "molecule": "Afamelanotide",
        "cas": "75921-69-6",
        "iupac_name": "(4S)-4-{[(1S)-1-{[(1R)-1-{[(1S)-1-{[(1S)-1-[({[(2S)-6-amino-1-[(2S)-2-{[(1S)-1-carbamoyl-2-methylpropyl]carbamoyl}pyrrolidin-1-yl]-1-oxohexan-2-yl]carbamoyl}methyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-2-phenylethyl]carbamoyl}-2-(1H-imidazol-5-yl)ethyl]carbamoyl}-4-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-acetamido-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]hexanamido]butanoic acid",
        "background": "Afamelanotide is a first-in-class, synthetic, 13-amino acid peptide analogue of the endogenous alpha melanocyte-stimulating hormone (-MSH).4 It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer biological half-life.2,3 Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 20147 and subsequent FDA approval in October 2019.5 Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.8,9\n",
        "inchi": {
            "hash": "UAHFGYDRQSXQEB-LEBBXHLNSA-N",
            "id": "InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1"
        },
        "summary": "Afamelanotide is an injectable subcutaneous implant used to mitigate phototoxicity secondary to erythropoietic protoporphyria (EPP).",
        "weight": [
            {
                "type": "average",
                "weight": 1646.8452,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1645.836510475,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.",
        "link": "https://go.drugbank.com/drugs/DB04931",
        "type": "Small Molecule",
        "synonyms": [
            "Afamelanotide",
            "Melanotan 1",
            "Melanotan I",
            "Melanotan-1",
            "MT-I"
        ],
        "indication": "Afamelanotide is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).4\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Afamelanotide increases the production of eumelanin, an endogenous photoprotective agent, to attenuate UV-induced skin damage in patients with a condition that predisposes them to phototoxicity.4 It has a relatively long duration of therapeutic effect despite its short half-life due to its ability to increase melanosome density and therefore skin pigmentation.2 As afamelanotide may darken pre-existing skin pigmentary lesions, patients receiving afamelanotide should undergo a full body skin examination every 6 months to monitor for progression or worsening of any skin abnormalities.4 Standard sun safety measures should continue to be employed during afamelanotide therapy.4\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AMelanocyte-stimulating hormone receptor"
            }
        ]
    },
    {
        "smiles": "[H]N(C1=C([H])C([H])=C(\\C([H])=C(/[H])C2=C([H])N=C(OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])[18F])C([H])=C2[H])C([H])=C1[H])C([H])([H])[H]",
        "id": "DB09149",
        "molecule": "Florbetapir (18F)",
        "cas": "956103-76-7",
        "iupac_name": "4-[(E)-2-[6-(2-{2-[2-(F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl]-N-methylaniline",
        "background": "Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. Marketed as the product Amyvid, florbetapir 18F is indicated for positron emission tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. \nThe radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.\n",
        "inchi": {
            "hash": "YNDIAUKFXKEXSV-CRYLGTRXSA-N",
            "id": "InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1"
        },
        "summary": "Florbetapir (18F) is a radiopharmaceutical diagnostic agent used during Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients to diagnose the causes of cognitive impairment.",
        "weight": [
            {
                "type": "average",
                "weight": 359.432,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 359.18745534,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB09149",
        "type": "Small Molecule",
        "synonyms": [
            "[18F]Florbetapir",
            "4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline",
            "Florbetapir (18F)",
            "Florbetapir F-18",
            "Florbetapir F18",
            "florbetapir-fluorine-18"
        ],
        "indication": "Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Following intravenous injection, florbetapir F 18 diffuses across the human blood-brain barrier and produces a radioactivity signal detectable throughout the brain. Subsequently, cerebral perfusion decreases the brain florbetapir F 18 content, with differential retention of the drug in areas that contain -amyloid aggregates compared to areas that lack the aggregates.\n",
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "AAmyloid beta A4 protein"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(C=C1OC1CCCC1)C(\\C)=N\\OC(N)=O",
        "id": "DB02660",
        "molecule": "Filaminast",
        "cas": "141184-34-1",
        "iupac_name": "(E)-{1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethylidene}amino carbamate",
        "background": "Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).\n",
        "inchi": {
            "hash": "STTRYQAGHGJXJJ-LICLKQGHSA-N",
            "id": "InChI=1S/C15H20N2O4/c1-10(17-21-15(16)18)11-7-8-13(19-2)14(9-11)20-12-5-3-4-6-12/h7-9,12H,3-6H2,1-2H3,(H2,16,18)/b17-10+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 292.3303,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 292.142307138,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB02660",
        "type": "Small Molecule",
        "synonyms": [
            "Filaminast"
        ],
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UcAMP-specific 3',5'-cyclic phosphodiesterase 4B"
            }
        ]
    },
    {
        "smiles": "CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O",
        "id": "DB00241",
        "molecule": "Butalbital",
        "cas": "77-26-9",
        "iupac_name": "5-(2-methylpropyl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione",
        "background": "Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia.1 Butalbital has a low degree of selectivity and a narrow therapeutic index.1 Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines 1 thus it is not indicated for such condition. As with other barbiturates, butalbital carries a risk of abuse or misuse potential, intoxication, hangover, tolerance, dependence, and overdosage possibly leading to death.10 Butalbitalcontaining analgesics can also produce a druginduced headache in addition to tolerance and dependence. Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully monitored.1\n",
        "inchi": {
            "hash": "UZVHFVZFNXBMQJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)"
        },
        "summary": "Butalbital is a barbiturate drug used for symptomatic treatment of tension-type headache in various combinations with acetaminophen, aspirin, caffeine, and codeine.",
        "weight": [
            {
                "type": "average",
                "weight": 224.2563,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 224.116092388,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.",
        "link": "https://go.drugbank.com/drugs/DB00241",
        "type": "Small Molecule",
        "synonyms": [
            "5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",
            "5-allyl-5-(2-methylpropyl)barbituric acid",
            "5-allyl-5-(2'-methyl-n-propyl) barbituric acid",
            "5-allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione",
            "5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione",
            "5-allyl-5-isobutylbarbituric acid",
            "5-isobutyl-5-allylbarbituric acid",
            "Allylbarbital",
            "Allylbarbitone",
            "Allylbarbituric acid",
            "Butalbarbital",
            "Butalbital",
            "Butalbitalum",
            "iso-butylallylbarbituric acid",
            "Itobarbital",
            "Tetrallobarbital"
        ],
        "indication": "Indicated for the management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate, in various combinations with acetaminophen, aspirin, caffeine, and codeine .10\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Butalbital is a short to intermediate-acting barbiturate that reversibly depresses the activity of excitable tissues, including the central nervous system in a nonselective manner.1 Barbiturates exhibit muscle-relaxing and anti-anxiety properties 3 and they are capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma.11 The sedative dose of butalbital in nontolerant individuals is 5-100 mg and the hypnotic dose is 100-200 mg.8 Pain perception and reaction are relatively unimpaired until the moment of unconsciousness.1 In some cases, an unwanted paradoxical response of excitement may be observed instead of sedation with barbiturate treatment, which may be due to their depressant effects on inhibitory centers of the CNS.1 At sufficiently high therapeutic doses, barbiturates induce anesthesia; however, barbiturates are reported to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks.11 Barbiturates are habit-forming; they can produce tolerance and both dependence and addiction, which is partly explained by decreased drug concentration at the site of action due to enhanced drug metabolism by induced enzymes, or to cellular adaptive changes. In addition, butalbital may lead to analgesic overuse headache.1 \nWhile butalbital is expected to mediate similar actions as other members of the barbiturate drug class, the effects of butalbital in isolation are not well understood.3 It is suggested that butalbital is added in combination products to antagonize the unwanted central stimulating effect of stimulatory ingredients such as caffeine.3 Butalbital may decrease blood pressure and heart rate when administered at sedative and hypnotic doses.10\n",
        "moa": [
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-2"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-3"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-4"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-5"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-6"
            },
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-7"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor 2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 2"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C",
        "id": "DB03619",
        "molecule": "Deoxycholic acid",
        "cas": "83-44-3",
        "iupac_name": "(4R)-4-[(1R,3aS,3bR,5aR,7R,9aS,9bS,11S,11aR)-7,11-dihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid",
        "background": "Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures.\n",
        "inchi": {
            "hash": "KXGVEGMKQFWNSR-LLQZFEROSA-N",
            "id": "InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1"
        },
        "summary": "Deoxycholic acid is a cytolytic agent injected subcutaneously to improve the appearance submental fat.",
        "weight": [
            {
                "type": "average",
                "weight": 392.572,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 392.292659768,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dihydroxy bile acids, alcohols and derivatives. These are compounds containing or derived from a bile acid or alcohol, and which bears exactly two carboxylic acid groups.",
        "link": "https://go.drugbank.com/drugs/DB03619",
        "type": "Small Molecule",
        "synonyms": [
            "(3,5,12)-3,12-dihydroxycholan-24-oic acid",
            "3alpha,12alpha-Dihydroxy-5beta-cholanic acid",
            "7-deoxycholic acid",
            "Deoxycholate",
            "Deoxycholic acid",
            "Desoxycholic acid",
            "Desoxycholsure"
        ],
        "indication": "For improvement in appearance of moderate to severe fullness associated with submental fat in adults. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "USteroid Delta-isomerase"
            },
            {
                "action": "Not Available",
                "organism": "Geobacter sulfurreducens",
                "target": "UPpcA"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UElongation factor Tu GTP-binding domain-containing protein 1"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium perfringens (strain 13 / Type A)",
                "target": "UCholoylglycine hydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "ULactaldehyde dehydrogenase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAcriflavine resistance protein B"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides",
                "target": "UCytochrome c oxidase subunit 1"
            },
            {
                "action": "Not Available",
                "organism": "Rhodobacter sphaeroides",
                "target": "UCytochrome c oxidase subunit 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UBile acid receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione S-transferase P"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UG-protein coupled bile acid receptor 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UGlutathione S-transferases (Cytosolic)"
            }
        ]
    },
    {
        "smiles": "CCC1=C2C=C3N4C(=CC5=C(C)C(CCC(O)=O)=C6C=C7N8C(=CC(N2[Fe]48N56)=C1C)C(C)=C7CCC(O)=O)C(C=C)=C3C",
        "id": "DB02182",
        "molecule": "Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe)",
        "iupac_name": "3-[20-(2-carboxyethyl)-15-ethenyl-10-ethyl-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^{2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid",
        "inchi": {
            "hash": "BUYPFLNIJYEQJK-RGGAHWMASA-N",
            "id": "InChI=1S/C34H34N4O4.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h8,13-16H,2,7,9-12H2,1,3-6H3,(H,39,40)(H,41,42);/q-4;+4/b25-13-,26-13-,27-14-,28-15-,29-14-,30-15-,31-16-,32-16-;"
        },
        "weight": [
            {
                "type": "average",
                "weight": 618.503,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 618.192947729,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB02182",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "USoluble cytochrome b562"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13860"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11619"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13482"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06604"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08726"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07178"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07456"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02214"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01803"
    },
    {
        "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C",
        "id": "DB01513",
        "molecule": "17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane",
        "cas": "641-83-8",
        "iupac_name": "(1S,3aS,3bR,5aS,7S,9aS,9bS,11aS)-1,9a,11a-trimethyl-hexadecahydro-1H-cyclopenta[a]phenanthrene-1,7-diol",
        "inchi": {
            "hash": "QGKQXZFZOIQFBI-UYEYMFBJSA-N",
            "id": "InChI=1S/C20H34O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h13-17,21-22H,4-12H2,1-3H3/t13-,14-,15+,16-,17-,18-,19-,20-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 306.49,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 306.255880335,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.",
        "link": "https://go.drugbank.com/drugs/DB01513",
        "type": "Small Molecule"
    },
    {
        "smiles": "CC1=C(NC(=O)NC2=CC=C(Cl)C(=C2O)S(=O)(=O)[C@H]2CCCNC2)C=CC=C1F",
        "id": "DB11922",
        "molecule": "Danirixin",
        "cas": "954126-98-8",
        "iupac_name": "1-{4-chloro-2-hydroxy-3-[(3S)-piperidine-3-sulfonyl]phenyl}-3-(3-fluoro-2-methylphenyl)urea",
        "background": "Danirixin has been used in trials studying the treatment and basic science of Virus Diseases, Nutritional Status, Pulmonary Disease, Chronic Obstructive, and Infections, Respiratory Syncytial Virus.\n",
        "inchi": {
            "hash": "NGYNBSHYFOFVLS-LBPRGKRZSA-N",
            "id": "InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 441.9,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 441.0925332,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-phenylureas. These are compounds containing a N-phenylurea moiety, which is structurally characterized by a phenyl group linked to one nitrogen atom of a urea group.",
        "link": "https://go.drugbank.com/drugs/DB11922",
        "type": "Small Molecule",
        "synonyms": [
            "Danirixin"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOCCOC(=O)\\C=C\\C1=CC=C(OC)C=C1",
        "id": "DB15467",
        "molecule": "Cinoxate",
        "cas": "104-28-9",
        "iupac_name": "2-ethoxyethyl (2E)-3-(4-methoxyphenyl)prop-2-enoate",
        "inchi": {
            "hash": "CMDKPGRTAQVGFQ-RMKNXTFCSA-N",
            "id": "InChI=1S/C14H18O4/c1-3-17-10-11-18-14(15)9-6-12-4-7-13(16-2)8-5-12/h4-9H,3,10-11H2,1-2H3/b9-6+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 250.294,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 250.12050906,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15467",
        "type": "Small Molecule",
        "synonyms": [
            "2-Ethoxyethyl-p-methoxycinnamate",
            "Cinoxate",
            "Cinoxato",
            "Cinoxatum"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](CC1=CC=CC2=CC=CC=C12)(N1C(=O)C2=CC=C(C=C2C1=O)C(O)=O)C(O)=O",
        "id": "DB06922",
        "molecule": "2-[(1R)-1-carboxy-2-naphthalen-1-ylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid",
        "iupac_name": "2-[(1R)-1-carboxy-2-(naphthalen-1-yl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid",
        "inchi": {
            "hash": "CZNPWASYMRBJCX-GOSISDBHSA-N",
            "id": "InChI=1S/C22H15NO6/c24-19-16-9-8-14(21(26)27)10-17(16)20(25)23(19)18(22(28)29)11-13-6-3-5-12-4-1-2-7-15(12)13/h1-10,18H,11H2,(H,26,27)(H,28,29)/t18-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 389.3576,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 389.089937217,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phthalimides. These are aromatic heterocyclic compounds containing a 1,3-dioxoisoindoline moiety. They are imide derivatives of phthalic anhydrides.",
        "link": "https://go.drugbank.com/drugs/DB06922",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "[H][C@@](CC)(CCCC)COS(O)(=O)=O",
        "id": "DB07518",
        "molecule": "(2R)-2-ETHYL-1-HEXANESULFONIC ACID",
        "iupac_name": "{[(2R)-2-ethylhexyl]oxy}sulfonic acid",
        "inchi": {
            "hash": "MHGOKSLTIUHUBF-MRVPVSSYSA-N",
            "id": "InChI=1S/C8H18O4S/c1-3-5-6-8(4-2)7-12-13(9,10)11/h8H,3-7H2,1-2H3,(H,9,10,11)/t8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 210.291,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 210.092579754,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sulfuric acid monoesters. These are organic compounds containing the sulfuric acid monoester functional group, with the generic structure ROS(O)(=O)=O, (R=organyl group).",
        "link": "https://go.drugbank.com/drugs/DB07518",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "UPutative alkylsulfatase"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(N(C(C)=O)C2=CC=CC(O)=C2NC2=C1C(=O)CC(C)(C)C2)C1=C(Cl)C=C(Cl)C=C1",
        "id": "DB08747",
        "molecule": "(11R)-10-acetyl-11-(2,4-dichlorophenyl)-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one",
        "iupac_name": "(10R)-9-acetyl-10-(2,4-dichlorophenyl)-4-hydroxy-14,14-dimethyl-2,9-diazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7-tetraen-12-one",
        "inchi": {
            "hash": "JJTPPGUNMJMPLY-QFIPXVFZSA-N",
            "id": "InChI=1S/C23H22Cl2N2O3/c1-12(28)27-17-5-4-6-18(29)21(17)26-16-10-23(2,3)11-19(30)20(16)22(27)14-8-7-13(24)9-15(14)25/h4-9,22,26,29H,10-11H2,1-3H3/t22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 445.338,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 444.100747994,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).",
        "link": "https://go.drugbank.com/drugs/DB08747",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "smiles": "NS(=O)(=O)C1=CC2=C(NC(CC3CCCC3)NS2(=O)=O)C=C1Cl",
        "id": "DB13532",
        "molecule": "Cyclopenthiazide",
        "cas": "742-20-1",
        "iupac_name": "6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide",
        "background": "Cyclopenthiazide is a thiazide diuretic with antihypertensive properties. In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients 2. It is a positive allosteric modulator at AMPA-A receptors 3.\n",
        "inchi": {
            "hash": "BKYKPTRYDKTTJY-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 379.87,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 379.0427261,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB13532",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "C[C@H](O)CC(C)(C)O",
        "id": "DB03564",
        "molecule": "(4r)-2-Methylpentane-2,4-Diol",
        "iupac_name": "(4S)-2-methylpentane-2,4-diol",
        "inchi": {
            "hash": "SVTBMSDMJJWYQN-YFKPBYRVSA-N",
            "id": "InChI=1S/C6H14O2/c1-5(7)4-6(2,3)8/h5,7-8H,4H2,1-3H3/t5-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 118.1742,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 118.099379692,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tertiary alcohols. These are compounds in which a hydroxy group, -OH, is attached to a saturated carbon atom R3COH (R not H ).",
        "link": "https://go.drugbank.com/drugs/DB03564",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces rubiginosus",
                "target": "UXylose isomerase"
            },
            {
                "action": "Not Available",
                "organism": "Thermus thermophilus",
                "target": "U1-pyrroline-5-carboxylate dehydrogenase"
            }
        ]
    },
    {
        "smiles": "N[C@H](CCC(N)=O)C(O)=O",
        "id": "DB02174",
        "molecule": "D-Glutamine",
        "cas": "5959-95-5",
        "iupac_name": "(2R)-2-amino-4-carbamoylbutanoic acid",
        "background": "A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.\n",
        "inchi": {
            "hash": "ZDXPYRJPNDTMRX-GSVOUGTGSA-N",
            "id": "InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 146.1445,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 146.069142196,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as d-alpha-amino acids. These are alpha amino acids which have the D-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB02174",
        "type": "Small Molecule",
        "synonyms": [
            "(2R)-2-amino-4-carbamoylbutanoic acid",
            "(2R)-2,5-diamino-5-oxopentanoic acid",
            "(R)-2,5-diamino-5-oxopentanoic acid",
            "D-2-Aminoglutaramic acid",
            "D-Glutamin",
            "D-Glutaminsure-5-amid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Aquifex pyrophilus",
                "target": "UGlutamate racemase"
            }
        ]
    },
    {
        "smiles": "CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1",
        "id": "DB01156",
        "molecule": "Bupropion",
        "cas": "34911-55-2",
        "iupac_name": "2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one",
        "background": "Bupropion (also known as the brand name product Wellbutrin) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).8,12\nBupropion was originally classified as an \"atypical\" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,9,10 bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.8,16 Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.10,11\nWhen used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.15,1,14 A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as nicotine replacement therapy (NRT).13\nBupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response.7 Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD.28\nWhen used in combination with naltrexone in the marketed product Contrave for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways.24 Studies have shown that the combined activity of bupropion and naltrexone increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.24,20,22 The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo.21\n",
        "inchi": {
            "hash": "SNPPWIUOZRMYNY-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3"
        },
        "summary": "Bupropion is a norepinephrine and dopamine reuptake inhibitor used in the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.",
        "weight": [
            {
                "type": "average",
                "weight": 239.741,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 239.10769191,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB01156",
        "type": "Small Molecule",
        "synonyms": [
            "Amfebutamone",
            "Bupropion"
        ],
        "indication": "Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. \nWhen used in combination with naltrexone as the marketed product Contrave, bupropion is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m^2 or greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).\nBupropion is also used off-label as a first-line treatment in patients with ADHD and comorbid bipolar disorder when used as an adjunct to mood stabilizers.28\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bupropion is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitors, or other known antidepressant agents. Compared to classical tricyclic antidepressants, Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine. In addition, Bupropion does not inhibit monoamine oxidase. Bupropion has been found to be essentially inactive at the serotonin transporter (SERT)(IC50 \u003e10 000 nM),12 however both bupropion and its primary metabolite hydroxybupropion have been found to block the function of cation-selective serotonin type 3A receptors (5-HT3ARs). \nBupropion produces dose-related central nervous system (CNS) stimulant effects in animals, as evidenced by increased locomotor activity, increased rates of responding in various schedule-controlled operant behaviour tasks, and, at high doses, induction of mild stereotyped behaviour Label. Due to these stimulant effects and selective activity at dopamine and norepinephrine receptors, bupropion has been identified as having an abuse potential.Label,17 Bupropion has a similar structure to the controlled substance Cathinone, and has been identified as having mild amphetamine-like activity, particularly when inhaled or injected.17\nBupropion is also known to lower the seizure threshold, making any pre-existing seizure conditions a contraindication to its use. This risk is exacerbated when bupropion is combined with other drugs or substances that lower the seizure threshold, such as cocaine, or in clinical situations that would increase the risk of a seizure such as abrupt alcohol or benzodiazepine withdrawal.Label As norepinephrine has been shown to have anticonvulsant properties, bupropion's inhibitory effects on NET are thought to contribute to its pro-convulsant activity.17\nBupropion has been shown to increase blood pressure and pose a risk for exacerbation of unmanaged or pre-existing hypertension,18,Label however, clinical trials of bupropion in smokers with CVD have not identified an increased incidence of CV events including stroke or heart attack.19 In clinical trials, the mean increase in systolic blood pressure associated with the use of bupropion was found to be 1.3 mmHg.Label\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent dopamine transporter"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent noradrenaline transporter"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-3"
            },
            {
                "action": "negative modulator",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 3A"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01127"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03526"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07540"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08359"
    },
    {
        "id": "DB17340",
        "molecule": "ENB-003",
        "background": "ENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17340",
        "type": "Small Molecule",
        "synonyms": [
            "ENB 003",
            "ENB003",
            "sodium bispiperidine-carboxamido-dimethylpenatnamido-methoxycarbonyl-indol-propanamidohexanoate"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00808"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02603"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05013"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01419"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08692"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03763"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08140"
    },
    {
        "smiles": "OC[C@H]1O[C@H](OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB17678",
        "molecule": "Alpha-D-mannose 1-phosphate",
        "cas": "15978-07-1",
        "iupac_name": "{[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phosphonic acid",
        "inchi": {
            "hash": "HXXFSFRBOHSIMQ-RWOPYEJCSA-N",
            "id": "InChI=1S/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5+,6-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 260.135,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 260.029718997,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17678",
        "type": "Small Molecule",
        "synonyms": [
            ".alpha.-d-mannopyranose, 1-(dihydrogen phosphate)",
            ".alpha.-d-mannose 1-phosphate",
            "Mannopyranose, 1-(dihydrogen phosphate), .alpha.-d-",
            "Mannose 1-phosphate, .alpha.-d-"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC(=N)C1=CC=C(CC(=O)C(O)=O)C=C1",
        "id": "DB02018",
        "molecule": "Amido Phenyl Pyruvic Acid",
        "iupac_name": "3-(4-carbamimidoylphenyl)-2-oxopropanoic acid",
        "inchi": {
            "hash": "ZXBYWYQEQQBMBT-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H10N2O3/c11-9(12)7-3-1-6(2-4-7)5-8(13)10(14)15/h1-4H,5H2,(H3,11,12)(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 206.198,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 206.069142196,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyruvic acid derivatives. These are compounds containing a phenylpyruvic acid moiety, which consists of a phenyl group substituted at the second position by an pyruvic acid.",
        "link": "https://go.drugbank.com/drugs/DB02018",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTryptase beta-2"
            }
        ]
    },
    {
        "smiles": "CC1=C(CC(CO)CO)NC(=O)NC1=O",
        "id": "DB02500",
        "molecule": "6-(Dihydroxy-Isobutyl)-Thymine",
        "iupac_name": "6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione",
        "inchi": {
            "hash": "CLCPDSJUXHDRGX-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H14N2O4/c1-5-7(2-6(3-12)4-13)10-9(15)11-8(5)14/h6,12-13H,2-4H2,1H3,(H2,10,11,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 214.2185,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 214.095356946,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB02500",
        "type": "Small Molecule",
        "synonyms": [
            "6-(1,3-dihydroxyisobutyl)thymine",
            "6-(Dihydroxyisobutyl)-Thymine"
        ],
        "moa": [
            {
                "action": "substrate",
                "organism": "HHV-1",
                "target": "UThymidine kinase"
            }
        ]
    },
    {
        "smiles": "CC(C)NC1=CC(Cl)=NC2=C(C=NN12)C#N",
        "id": "DB08139",
        "molecule": "5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile",
        "iupac_name": "5-chloro-7-[(propan-2-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile",
        "inchi": {
            "hash": "HFTLYNKTSANXFA-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H10ClN5/c1-6(2)14-9-3-8(11)15-10-7(4-12)5-13-16(9)10/h3,5-6,14H,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 235.673,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 235.062473052,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrazolo[1,5-a]pyrimidines. These are aromatic heterocyclic compounds containing a pyrazolo[3,4-d]pyrimidine ring system, which consists of a pyrazole ring fused to and sharing exactly one nitrogen atom with a pyrimidine ring.",
        "link": "https://go.drugbank.com/drugs/DB08139",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "CCOC1=C(C(=O)NC2=CC=C(OC3=C(Cl)C(N)=NC=C3)C(F)=C2)C(=O)N(C=C1)C1=CC=C(F)C=C1",
        "id": "DB12064",
        "molecule": "BMS-777607",
        "cas": "1025720-94-8",
        "iupac_name": "N-{4-[(2-amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl}-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide",
        "background": "BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.\n",
        "inchi": {
            "hash": "VNBRGSXVFBYQNN-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 512.893,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 512.106289233,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.",
        "link": "https://go.drugbank.com/drugs/DB12064",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CN1C=NC(N)=C2N=CN=C12",
        "id": "DB04104",
        "molecule": "3-Methyladenine",
        "cas": "5142-23-4",
        "iupac_name": "3-methyl-3H-purin-6-amine",
        "inchi": {
            "hash": "FSASIHFSFGAIJM-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H7N5/c1-11-3-10-5(7)4-6(11)9-2-8-4/h2-3H,7H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 149.1533,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 149.070145249,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.",
        "link": "https://go.drugbank.com/drugs/DB04104",
        "type": "Small Molecule",
        "synonyms": [
            "3-methyl-3H-adenine",
            "3-methyladenine",
            "6-amino-3-methylpurine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UDNA-3-methyladenine glycosylase 1"
            }
        ]
    },
    {
        "smiles": "OCN1C(NC(=O)NCNC(=O)NC2N(CO)C(=O)NC2=O)C(=O)NC1=O",
        "id": "DB14075",
        "molecule": "Imidurea",
        "cas": "39236-46-9",
        "iupac_name": "3-[3-(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]-1-[({[3-(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]carbamoyl}amino)methyl]urea",
        "background": "Imidurea is an antimicrobial preservative used in cosmetics. It acts as a formaldehyde releaser.\n",
        "inchi": {
            "hash": "ZCTXEAQXZGPWFG-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H16N8O8/c20-2-18-4(6(22)16-10(18)26)14-8(24)12-1-13-9(25)15-5-7(23)17-11(27)19(5)3-21/h4-5,20-21H,1-3H2,(H2,12,14,24)(H2,13,15,25)(H,16,22,26)(H,17,23,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 388.297,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 388.109109507,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14075",
        "type": "Small Molecule",
        "synonyms": [
            "Imidazolidinyl urea"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC[C@H]1O[C@@H]2[C@@H](OC3=NC(=O)C=CN23)[C@@H]1O",
        "id": "DB04627",
        "molecule": "Cyclouridine",
        "cas": "3736-77-4",
        "iupac_name": "(2R,4R,5R,6S)-5-hydroxy-4-(hydroxymethyl)-3,7-dioxa-1,9-diazatricyclo[6.4.0.0^{2,6}]dodeca-8,11-dien-10-one",
        "inchi": {
            "hash": "UUGITDASWNOAGG-CCXZUQQUSA-N",
            "id": "InChI=1S/C9H10N2O5/c12-3-4-6(14)7-8(15-4)11-2-1-5(13)10-9(11)16-7/h1-2,4,6-8,12,14H,3H2/t4-,6-,7+,8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 226.1861,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 226.05897144,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB04627",
        "type": "Small Molecule",
        "synonyms": [
            "2,2'-Anhydrouridine",
            "2,2'-O-Cyclouridine",
            "O2,2'-Cyclouridine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UUridine phosphorylase"
            }
        ]
    },
    {
        "smiles": "OC(=O)[C@@H]1CC(=O)NC(=O)N1",
        "id": "DB02129",
        "molecule": "Dihydroorotic Acid",
        "cas": "155-54-4",
        "iupac_name": "(4S)-2,6-dioxo-1,3-diazinane-4-carboxylic acid",
        "inchi": {
            "hash": "UFIVEPVSAGBUSI-REOHCLBHSA-N",
            "id": "InChI=1S/C5H6N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h2H,1H2,(H,9,10)(H2,6,7,8,11)/t2-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 158.1121,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 158.03275669,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB02129",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UDihydroorotase"
            }
        ]
    },
    {
        "smiles": "[H]N=C(CC1=CC(O)=C(O)C=C1)C(O)=O",
        "id": "DB07979",
        "molecule": "(2E)-3-(3,4-DIHYDROXYPHENYL)-2-IMINOPROPANOIC ACID",
        "iupac_name": "3-(3,4-dihydroxyphenyl)-2-iminopropanoic acid",
        "inchi": {
            "hash": "VFINRVRRNHRWEQ-POHAHGRESA-N",
            "id": "InChI=1S/C9H9NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,10-12H,3H2,(H,13,14)/b10-6-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 195.1721,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 195.053157781,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB07979",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UD-amino-acid oxidase"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC",
        "id": "DB06669",
        "molecule": "Arverapamil",
        "cas": "123932-43-4",
        "iupac_name": "(2R)-2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(propan-2-yl)pentanenitrile",
        "inchi": {
            "hash": "UPKQNCPKPOLASS-AREMUKBSSA-N",
            "id": "InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 440.584,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 440.267507647,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.",
        "link": "https://go.drugbank.com/drugs/DB06669",
        "type": "Small Molecule",
        "synonyms": [
            "(R)-norverapamil"
        ],
        "indication": "Investigated for use/treatment in irritable bowel syndrome (IBS) and diarrhea.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=C(F)C=C(F)C=C1F",
        "id": "DB02221",
        "molecule": "4-(Aminosulfonyl)-N-[(2,4,6-Trifluorophenyl)Methyl]-Benzamide",
        "iupac_name": "4-sulfamoyl-N-[(2,4,6-trifluorophenyl)methyl]benzamide",
        "inchi": {
            "hash": "DVTYOTODFLDHRL-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H11F3N2O3S/c15-9-5-12(16)11(13(17)6-9)7-19-14(20)8-1-3-10(4-2-8)23(18,21)22/h1-6H,7H2,(H,19,20)(H2,18,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 344.309,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 344.044247533,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-benzylbenzamides. These are compounds containing a benzamide moiety that is N-linked to a benzyl group.",
        "link": "https://go.drugbank.com/drugs/DB02221",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "CCCCC(CC)COC1=CC(O)=C(C=C1)C1=NC(=NC(=N1)C1=CC=C(OC)C=C1)C1=C(O)C=C(OCC(CC)CCCC)C=C1",
        "id": "DB11206",
        "molecule": "Bemotrizinol",
        "cas": "187393-00-6",
        "iupac_name": "5-[(2-ethylhexyl)oxy]-2-(4-{4-[(2-ethylhexyl)oxy]-2-hydroxyphenyl}-6-(4-methoxyphenyl)-1,3,5-triazin-2-yl)phenol",
        "background": "Bemotrizinol, or bis-ethylhexyloxyphenol methoxyphenyl triazine, is an organic UV filter found in over-the-counter sunscreen products. It primarily absorbs UV-A rays. Compared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity 2. It is claimed to be photostable, which increases its onset of action and its efficiency in providing protection against UV-rays upon topical application 2,3. Bemotrizinol is commonly marketed as Tinosorb S and Escalol S.\n",
        "inchi": {
            "hash": "XVAMCHGMPYWHNL-UHFFFAOYSA-N",
            "id": "InChI=1S/C38H49N3O5/c1-6-10-12-26(8-3)24-45-30-18-20-32(34(42)22-30)37-39-36(28-14-16-29(44-5)17-15-28)40-38(41-37)33-21-19-31(23-35(33)43)46-25-27(9-4)13-11-7-2/h14-23,26-27,42-43H,6-13,24-25H2,1-5H3"
        },
        "summary": "Bemotrizinol is an ingredient used in sunscreen to block UVA and UVB radiation.",
        "weight": [
            {
                "type": "average",
                "weight": 627.826,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 627.36722169,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11206",
        "type": "Small Molecule",
        "synonyms": [
            "Bemotrizinol",
            "BEMT"
        ],
        "indication": "Indicated as an active sunscreen agent. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Findings from an immature rat uterotrophic competitive binding assay suggest that bemotrizinol does not display significant binding affinities towards estrogen and androgen receptors in vitro, thus lacking intrinsic estrogenic, antiestrogenic, androgenic and antiandrogenic activity 1. Bemotrizinol minimizes erythema and provides excellent anti-aging effects as well as protectant effects on the skin's antioxidant defense system 2. In a comparative study of individuals with a history of polymorphic light eruption (PLE) undergoing photoprovocation, treatment of bemotrinizol was effective in preventing the development of PLE 4.\n"
    },
    {
        "smiles": "[NH3+]CC1CCCCC1",
        "id": "DB02435",
        "molecule": "Aminomethylcyclohexane",
        "cas": "3218-02-8",
        "iupac_name": "cyclohexylmethanaminium",
        "inchi": {
            "hash": "AVKNGPAMCBSNSO-UHFFFAOYSA-O",
            "id": "InChI=1S/C7H15N/c8-6-7-4-2-1-3-5-7/h7H,1-6,8H2/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 114.2086,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 114.128274517,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monoalkylamines. These are organic compounds containing an primary aliphatic amine group.",
        "link": "https://go.drugbank.com/drugs/DB02435",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Enterobacter cloacae subsp. cloacae (strain ATCC 13047 / DSM 30054 / NBRC 13535 / NCDC 279-56)",
                "target": "UUDP-N-acetylglucosamine 1-carboxyvinyltransferase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(C(C)C)N(CC2=CC=CC=C2)C(=O)C(=C1O)C1=NS(=O)(=O)C2=C1C=CC=C2",
        "id": "DB07414",
        "molecule": "(5S)-1-benzyl-3-(1,1-dioxido-1,2-benzisothiazol-3-yl)-4-hydroxy-5-(1-methylethyl)-1,5-dihydro-2H-pyrrol-2-one",
        "iupac_name": "3-[(5S)-1-benzyl-4-hydroxy-2-oxo-5-(propan-2-yl)-2,5-dihydro-1H-pyrrol-3-yl]-1lambda6,2-benzothiazole-1,1-dione",
        "inchi": {
            "hash": "XKOAFAIRGVAHRA-IBGZPJMESA-N",
            "id": "InChI=1S/C21H20N2O4S/c1-13(2)19-20(24)17(21(25)23(19)12-14-8-4-3-5-9-14)18-15-10-6-7-11-16(15)28(26,27)22-18/h3-11,13,19,24H,12H2,1-2H3/t19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 396.459,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 396.114377828,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzothiazoles. These are organic compounds containing a benzene fused to a thiazole ring (a five-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).",
        "link": "https://go.drugbank.com/drugs/DB07414",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Hepatitis C virus genotype 1b (isolate BK)",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "smiles": "O=C1NC(=O)\\C(S1)=C\\C1=CC=C2N=CC=C(C3=CC=NC=C3)C2=C1",
        "id": "DB11962",
        "molecule": "GSK-1059615",
        "cas": "958852-01-2",
        "iupac_name": "(5Z)-5-{[4-(pyridin-4-yl)quinolin-6-yl]methylidene}-1,3-thiazolidine-2,4-dione",
        "background": "GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer.\n",
        "inchi": {
            "hash": "QDITZBLZQQZVEE-YBEGLDIGSA-N",
            "id": "InChI=1S/C18H11N3O2S/c22-17-16(24-18(23)21-17)10-11-1-2-15-14(9-11)13(5-8-20-15)12-3-6-19-7-4-12/h1-10H,(H,21,22,23)/b16-10-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 333.37,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 333.05719778,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.",
        "link": "https://go.drugbank.com/drugs/DB11962",
        "type": "Small Molecule",
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASerine/threonine-protein kinase mTOR"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "APhosphatidylinositol 3-kinase catalytic subunit type 3"
            }
        ]
    },
    {
        "smiles": "CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=CC(Cl)=CC=C2C(=O)N1CC1=CC=CC=C1",
        "id": "DB06188",
        "molecule": "Ispinesib",
        "cas": "336113-53-2",
        "iupac_name": "N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide",
        "inchi": {
            "hash": "QJZRFPJCWMNVAV-HHHXNRCGSA-N",
            "id": "InChI=1S/C30H33ClN4O2/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3/t27-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 517.07,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 516.229204,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n,n-dialkyl-p-toluamides. These are aromatic that contain a m-toluamide, where the carboxamide group is N- substituted with two alkyl chains.",
        "link": "https://go.drugbank.com/drugs/DB06188",
        "type": "Small Molecule",
        "synonyms": [
            "Ispinesib"
        ],
        "indication": "Investigated for use/treatment in breast cancer, lung cancer, solid tumors, renal cell carcinoma, pediatric indications, ovarian cancer, and head and neck cancer.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](CC1=CC=C2OCOC2=C1)(C(O)=O)[C@]([H])(CC1=CC=C2OCOC2=C1)C(O)=O",
        "id": "DB02154",
        "molecule": "2,3-Bis-Benzo[1,3]Dioxol-5-Ylmethyl-Succinic Acid",
        "iupac_name": "(2S,3S)-2,3-bis[(2H-1,3-benzodioxol-5-yl)methyl]butanedioic acid",
        "inchi": {
            "hash": "FFYBYVPVYLMLAR-KBPBESRZSA-N",
            "id": "InChI=1S/C20H18O8/c21-19(22)13(5-11-1-3-15-17(7-11)27-9-25-15)14(20(23)24)6-12-2-4-16-18(8-12)28-10-26-16/h1-4,7-8,13-14H,5-6,9-10H2,(H,21,22)(H,23,24)/t13-,14-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 386.3521,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 386.100167552,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dibenzylbutane lignans. These are lignan compounds containing a 2,3-dibenzylbutane moiety.",
        "link": "https://go.drugbank.com/drugs/DB02154",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa",
                "target": "UBeta-lactamase"
            },
            {
                "action": "Not Available",
                "organism": "Serratia marcescens",
                "target": "UBeta-lactamase IMP-1"
            }
        ]
    },
    {
        "smiles": "CC1(C)CC(CC(C)(C)N1)OC1=NN=C(C=C1)C1=C(O)C=C(C=C1)C1=CNN=C1",
        "id": "DB14918",
        "molecule": "Branaplam",
        "cas": "1562338-42-4",
        "iupac_name": "5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol",
        "background": "Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).\n",
        "inchi": {
            "hash": "STWTUEAWRAIWJG-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H27N5O2/c1-21(2)10-16(11-22(3,4)27-21)29-20-8-7-18(25-26-20)17-6-5-14(9-19(17)28)15-12-23-24-13-15/h5-9,12-13,16,27-28H,10-11H2,1-4H3,(H,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 393.491,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 393.216475129,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14918",
        "type": "Small Molecule",
        "synonyms": [
            "Branaplam"
        ],
        "is_stub": true
    },
    {
        "smiles": "COCCCC(=O)NCC1=CC=C(C=C1)C(F)(F)F",
        "id": "DB12928",
        "molecule": "GET-73",
        "cas": "202402-01-5",
        "iupac_name": "4-methoxy-N-{[4-(trifluoromethyl)phenyl]methyl}butanamide",
        "background": "Get 73 has been investigated for the treatment of Alcohol Dependence.\n",
        "inchi": {
            "hash": "QLZOWJNFLXSDSH-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H16F3NO2/c1-19-8-2-3-12(18)17-9-10-4-6-11(7-5-10)13(14,15)16/h4-7H,2-3,8-9H2,1H3,(H,17,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 275.271,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 275.113313248,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.",
        "link": "https://go.drugbank.com/drugs/DB12928",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](OCCCCCC3CCCCC3)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB04664",
        "molecule": "Cyclohexyl-pentyl-maltoside",
        "cas": "250692-65-0",
        "iupac_name": "(2R,3R,4S,5S,6R)-2-{[(2R,3S,4R,5R,6R)-6-[(5-cyclohexylpentyl)oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol",
        "inchi": {
            "hash": "RVTGFZGNOSKUDA-ZNGNCRBCSA-N",
            "id": "InChI=1S/C23H42O11/c24-11-14-16(26)17(27)19(29)23(32-14)34-21-15(12-25)33-22(20(30)18(21)28)31-10-6-2-5-9-13-7-3-1-4-8-13/h13-30H,1-12H2/t14-,15-,16-,17+,18-,19-,20-,21-,22-,23-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 494.573,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 494.272712186,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fatty acyl glycosides of mono- and disaccharides. These are compounds composed of a mono- or disaccharide moiety linked to one hydroxyl group of a fatty alcohol or of a phosphorylated alcohol (phosphoprenols), a hydroxy fatty acid or to one carboxyl group of a fatty acid (ester linkage) or to an amino alcohol.",
        "link": "https://go.drugbank.com/drugs/DB04664",
        "type": "Small Molecule",
        "synonyms": [
            "5-cyclohexyl-1-pentyl-beta-D-maltoside",
            "CYMAL-5",
            "CYMAL(R)-5"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome P450 2B6"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(O)CN(CCCC2=CC=CC=C2)C[C@]([H])(CO)[C@@]1([H])O",
        "id": "DB07807",
        "molecule": "(3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL",
        "iupac_name": "(3R,4R,5R)-5-(hydroxymethyl)-1-(3-phenylpropyl)piperidine-3,4-diol",
        "inchi": {
            "hash": "NKARZGURZMIRMA-RBSFLKMASA-N",
            "id": "InChI=1S/C15H23NO3/c17-11-13-9-16(10-14(18)15(13)19)8-4-7-12-5-2-1-3-6-12/h1-3,5-6,13-15,17-19H,4,7-11H2/t13-,14-,15-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 265.348,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 265.167793607,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.",
        "link": "https://go.drugbank.com/drugs/DB07807",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, muscle form"
            }
        ]
    },
    {
        "smiles": "N[C@@H](C(=O)N[C@@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1",
        "id": "DB04293",
        "molecule": "7-(2-Amino-2-Phenyl-Acetylamino)-3-Chloro-8-Oxo-1-Aza-Bicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid",
        "iupac_name": "(6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",
        "inchi": {
            "hash": "JAPHQRWPEGVNBT-IJLUTSLNSA-N",
            "id": "InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 349.769,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 349.082933722,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carbacephems. These are a new class of beta-lactam antibiotics similar in structure to the cephalosporins. They differ from cephalosporins, however, in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring.",
        "link": "https://go.drugbank.com/drugs/DB04293",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C",
        "id": "DB08842",
        "molecule": "Acetylcarnitine",
        "cas": "3040-38-8",
        "iupac_name": "(3R)-3-(acetyloxy)-4-(trimethylazaniumyl)butanoate",
        "background": "Acetylcarnitine is an investigational drug in the United states, Italy, United Kingdom, China, Israel, and Norway, and it is approved in Italy, Portugal, Argentina, Chile, Philippines, Australia, and India. Acetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans. In human plasma and tissues, acetylcarnitine is the most predominant acylated ester of carnitine, which is an amino acid derivative that is made in the kidney, liver, and brain from lysine and methionine. The main role of acetylcarnitine is to help transport fatty acids into the mitochondrial matrix where fatty acid metabolism occurs.\n",
        "inchi": {
            "hash": "RDHQFKQIGNGIED-MRVPVSSYSA-N",
            "id": "InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1"
        },
        "summary": "Acetylcarnitine is an acetylated form of the amino acid derivative L-carnitine that assists in mitochondrial fatty acid metabolism. It is under investigation as a treatment for numerous conditions, including neuropathy, depression, and dementia.",
        "weight": [
            {
                "type": "average",
                "weight": 203.238,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 203.115758031,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acyl carnitines. These are organic compounds containing a fatty acid with the carboxylic acid attached to carnitine through an ester bond.",
        "link": "https://go.drugbank.com/drugs/DB08842",
        "type": "Small Molecule",
        "synonyms": [
            "acetyl-L-carnitine",
            "O-acetyl-L-carnitine",
            "O-Acetylcarnitine"
        ],
        "indication": "Acetylcarnitine is not approved for any indication in the United states and Canada, but it is approved and indicated in Italy for cerebrovascular disorders, mental function disorders, peripheral nerve disorders, diabetic neuropathy, and nutritional supplementation; Portugal for mental function disorders; Argentina for cerebral vasculopathy, nutritional supplementation, and peripheral neuropathy; Chile for dementia; Philippines for cerebrovascular disorders and mental function disorders; Australia for nutritional supplementation; and India for nutritional supplementation to increase sperm count. Acetylcarnitine also has several potential therapeutic indications for which it is still being investigated: in Norway, acetylcarnitine is in a phase IV trial for prophylactic treatment of migraines; in Italy acetylcarnitine is in a phase II trial for use in patients with type 2 Diabetes Mellitus, a phase III trial for alleviating fatigue in patients with chronic hepatitis C, and for use in patients with Minimal Hepatic Encephalopathy; in the United States acetylcarnitine is in a phase II trial for the neurodegenerative disorder Progressive Supranuclear Palsy, a phase II and III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy, a phase I and II trial for treating patients in septic shock, a phase II trial for bipolar depression, a phase II trial to reduce oxidative stress in patients with Sickle Cell disease, a phase I and II trial for chronic fatigue syndrome, and a study for preventing nerve damage in HIV patients; in China acetylcarnitine is in a phase III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy; in the United Kingdom acetylcarnitine is being investigated for preventing nerve damage in HIV patients; and in Israel acetylcarnitine is being studied for the treatment of male infertility.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The complete physiological effects of acetycarnitine are still being studied. What has been discovered so far is that acetylcarinitine has positive effects on mental fatigue, neurodegenerative disorders, cognitive functions, peripheral neuropathy, and sperm motility. Specifically, in one study involving patients with HIV, patients on acetylcarnitine supplementation had increased CD4 cells, decreased lymphocyte apoptosis, improved polyneuropathy and cardiovascular damage, and decreased triglyceride and TNF alpha levels in the blood. Another study showed that acetylcarnitine increased glucose disposal in type 2 diabetic patients through possibly increasing the activity of glycogen synthase.\n"
    },
    {
        "smiles": "CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1C\\C=C/CCCC(O)=O",
        "id": "DB00917",
        "molecule": "Dinoprostone",
        "cas": "363-24-6",
        "iupac_name": "(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid",
        "background": "Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.\n",
        "inchi": {
            "hash": "XEYBRNLFEZDVAW-ARSRFYASSA-N",
            "id": "InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1"
        },
        "summary": "Dinoprostone is a prostaglandin used to induce labor or abortion as well as to treat nonmetastatic gestational trophoblastic disease.",
        "weight": [
            {
                "type": "average",
                "weight": 352.4651,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 352.224974134,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.",
        "link": "https://go.drugbank.com/drugs/DB00917",
        "type": "Small Molecule",
        "synonyms": [
            "(15S)-prostaglandin E2",
            "(5Z,11,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid",
            "(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate",
            "(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate",
            "(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid",
            "(Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid",
            "Dinoproston",
            "Dinoprostona",
            "Dinoprostone",
            "Dinoprostone Prostaglandin E2",
            "Dinoprostonum",
            "PGE2",
            "Prostaglandin E2"
        ],
        "indication": "For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical \"ripening\") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpartum hemorrhage.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dinoprostone is equivalent to prostaglandin E2 (PGE2). It stimulates labor and delivery by stimulating the uterine, and thus terminates pregnancy. Dinoprostone is also capable of stimulating the smooth muscle of the gastrointestinal tract of man. This activity may be responsible for the vomiting and/or diarrhea that is not uncommon when dinoprostone is used to terminate pregnancy.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP2 subtype"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP1 subtype"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP3 subtype"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AProstaglandin E2 receptor EP4 subtype"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UProstaglandin D2 receptor 2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17969"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16159"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03487"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03129"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16071"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01940"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01858"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02269"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12039"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04391"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02030"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04676"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13952"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08541"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01034"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15821"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13369"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13840"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05631"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05688"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03444"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13727"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07021"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15917"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08210"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02693"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13518"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03046"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03256"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06866"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13180"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03851"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15971"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02933"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03555"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18049"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16476"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18391"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00913"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05200"
    },
    {
        "smiles": "NC1=C(O)C=CC=C1C(O)=O",
        "id": "DB03644",
        "molecule": "3-hydroxyanthranilic acid",
        "cas": "548-93-6",
        "iupac_name": "2-amino-3-hydroxybenzoic acid",
        "background": "An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.\n",
        "inchi": {
            "hash": "WJXSWCUQABXPFS-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H7NO3/c8-6-4(7(10)11)2-1-3-5(6)9/h1-3,9H,8H2,(H,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 153.1354,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 153.042593095,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxybenzoic acid derivatives. These are compounds containing a hydroxybenzoic acid (or a derivative), which is a benzene ring bearing a carboxyl and a hydroxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB03644",
        "type": "Small Molecule",
        "synonyms": [
            "2-Amino-3-hydroxy-benzoic acid",
            "2-Amino-3-Hydroxybenzoic Acid",
            "3-Oxyanthranilic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas fluorescens",
                "target": "UTrans-2,3-dihydro-3-hydroxyanthranilate isomerase"
            }
        ]
    },
    {
        "smiles": "CNC1=CC=C(\\C=C\\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1",
        "id": "DB09148",
        "molecule": "Florbetaben F-18",
        "cas": "902143-01-5",
        "iupac_name": "4-[(E)-2-[4-(2-{2-[2-(F)fluoroethoxy]ethoxy}ethoxy)phenyl]ethenyl]-N-methylaniline",
        "background": "Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. It is used for the non-invasive detection of the density of -amyloid neuritic plaques in the brain of adult patients with cognitive impairment.\n",
        "inchi": {
            "hash": "NCWZOASIUQVOFA-FWZJPQCDSA-N",
            "id": "InChI=1S/C21H26FNO3/c1-23-20-8-4-18(5-9-20)2-3-19-6-10-21(11-7-19)26-17-16-25-15-14-24-13-12-22/h2-11,23H,12-17H2,1H3/b3-2+/i22-1"
        },
        "summary": "Florbetaben F-18 is a radiopharmaceutical diagnostic agent used during Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients to diagnose the causes of cognitive impairment.",
        "weight": [
            {
                "type": "average",
                "weight": 358.444,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 358.192206368,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.",
        "link": "https://go.drugbank.com/drugs/DB09148",
        "type": "Small Molecule",
        "synonyms": [
            "4-((1E)-2-(4-(2-(2-(2-((SUP 18(F))FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETH-1-EN-1-YL)-N-METHYLANILINE",
            "Florbetaben (18F)",
            "florbetaben (F)",
            "florbetaben F18",
            "FLORBETABEN(18F)"
        ],
        "indication": "Florbetaben is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimers Disease (AD) and other causes of cognitive decline.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Following intravenous administration, Neuraceq crosses the blood brain barrier and shows differential retention in brain regions that contain -amyloid deposits. Differences in signal intensity between brain regions showing specific and non-specific Neuraceq uptake form the basis for the image interpretation method.\n",
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "AAmyloid beta A4 protein"
            }
        ]
    },
    {
        "smiles": "CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1",
        "id": "DB00289",
        "molecule": "Atomoxetine",
        "cas": "83015-26-3",
        "iupac_name": "methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine",
        "background": "Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory.5 Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum.8 This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which is a limiting factor associated with the use of stimulant medications such as Methylphenidate, Dextroamphetamine, and Lisdexamfetamine.8 Use of non-stimulant medications such as atomoxetine is therefore thought to offer a clinical advantage over the use of traditional medications for the management of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT),9 and blocks the N-methyl-d-aspartate (NMDA) receptor,10 indicating a role for the glutamatergic system in the pathophysiology of ADHD. \nLong-acting formulations of psychostimulants (such as Methylphenidate, Dextroamphetamine, and Lisdexamfetamine) are typically considered the most effective and first-line treatment for ADHD in adults and children as recommended by CADDRA (Canadian ADHD Resource Alliance).16 However, these stimulant medications are limited by dose-related side effects and concerns of abuse. Many contain a blackbox warning stating that CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. In particular, increased dopamine in key areas caused by these stimulant medications is associated with their reinforcing and addictive properties, and even amplifies the potency and reinforcing effects of other drugs of abuse such as amphetamines, making ADHD sufferers more susceptible to their addictive effects.6 Concerns about abuse potential have spurred research into medications with fewer effects on DA and the use of non-stimulant ADHD medications including atomoxetine, Modafinil and Guanfacine. The non-stimulant norepinephrine/dopamine reuptake inhibitor Bupropion (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of ADHD.7\n",
        "inchi": {
            "hash": "VHGCDTVCOLNTBX-QGZVFWFLSA-N",
            "id": "InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1"
        },
        "summary": "Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) used in the management of Attention Deficit Hyperactivity Disorder (ADHD).",
        "weight": [
            {
                "type": "average",
                "weight": 255.3547,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 255.162314299,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB00289",
        "type": "Small Molecule",
        "synonyms": [
            "(-)-Tomoxetine",
            "Atomoxetina",
            "Atomoxetine",
            "Tomoxetina",
            "Tomoxetine",
            "Tomoxetinum"
        ],
        "indication": "Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine has been shown to specifically increase norepinephrine and dopamine within the prefrontal cortex, which results in improved ADHD symptoms.8,8,18\nDue to atomoxetine's noradrenergic activity, it also has effects on the cardiovascular system such as increased blood pressure and tachycardia.11 Sudden deaths, stroke, and myocardial infarction have been reported in patients taking atomoxetine at usual doses for ADHD. Atomoxetine should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. It should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate. Although the role of atomoxetine in these cases is unknown, consideration should be given to not treating patients with clinically significant cardiac abnormalities. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation.18\nIn general, particular care should be taken in treating ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in patients at risk for bipolar disorder. Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by atomoxetine at usual doses. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine, and discontinuation of treatment should be considered.18\nAtomoxetine capsules increased the risk of suicidal ideation in short-term studies in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). All pediatric patients being treated with atomoxetine should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.18\nPostmarketing reports indicate that atomoxetine can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6000 patients, there have been rare cases of clinically significant liver injury that were considered probably or possibly related to atomoxetine use in postmarketing experience. Rare cases of liver failure have also been reported, including a case that resulted in a liver transplant. Atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted. Laboratory testing to determine liver enzyme levels should be done upon the first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained flu like symptoms).18\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent noradrenaline transporter"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "USodium-dependent serotonin transporter"
            },
            {
                "action": "blocker",
                "organism": "Humans",
                "target": "UNMDA receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UG protein-activated inward rectifier potassium channel 1"
            },
            {
                "action": "partial agonist",
                "organism": "Humans",
                "target": "UKappa-type opioid receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12160"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07017"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06258"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07234"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00255"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02329"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02023"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16041"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06898"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05043"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11200"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09537"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07298"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11744"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07887"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03822"
    },
    {
        "smiles": "CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC2=CC=CC=C2)CC1)C(=O)OC",
        "id": "DB01535",
        "molecule": "Carfentanil",
        "cas": "59708-52-0",
        "iupac_name": "methyl 1-(2-phenylethyl)-4-(N-phenylpropanamido)piperidine-4-carboxylate",
        "background": "Carfentanil or carfentanyl (Wildnil) is an analogue of the popular synthetic opioid analgesic fentanyl, and is one of the most potent opioids known (also the most potent opioid used commercially). Carfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen. It has a quantitative potency approximately 10,000 times that of morphine and 100 times that of fentanyl, with activity in humans starting at about 1 microgram. It is marketed under the trade name Wildnil as a general anaesthetic agent for large animals. Carfentanil is intended for large-animal use only as its extreme potency makes it inappropriate for use in humans. Currently sufentanil, approximately 1020 times less potent (500 to 1000 times the efficacy of morphine per weight) than carfentanil, is the maximum strength fentanyl analog for use in humans.\n",
        "inchi": {
            "hash": "YDSDEBIZUNNPOB-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H30N2O3/c1-3-22(27)26(21-12-8-5-9-13-21)24(23(28)29-2)15-18-25(19-16-24)17-14-20-10-6-4-7-11-20/h4-13H,3,14-19H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 394.5066,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 394.225642836,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fentanyls. These are compounds containing the fentanyl moiety or a derivative, which is based on a N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide skeleton.",
        "link": "https://go.drugbank.com/drugs/DB01535",
        "type": "Small Molecule",
        "synonyms": [
            "Carfentanil",
            "carfentanila",
            "Carfentanyl"
        ],
        "indication": "Carfentanil is similar (but more potent) to the opioid analgesic fentanyl. It is used as a tranquilizer for large animals.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Carfentanil acts primarily on the mu (some kappa and delta) opioid receptors as an agonist. It will induce similar effects of analgesia as other opioids, however, due to its potency, it will also induce strong side effects such as sedation. Consequently, that is why it is used as a tranquilizer for large animals.\nCarfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the brain, spinal cord, and other tissues. It exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Carfentanil also depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AMu-type opioid receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ADelta-type opioid receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UKappa-type opioid receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07654"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03834"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18034"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07051"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05382"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08487"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07001"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08390"
    },
    {
        "id": "DB05027",
        "molecule": "DG041",
        "background": "DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.\nDG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular diseases. It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05027",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in peripheral vascular disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC=C1",
        "id": "DB07143",
        "molecule": "D-phenylalanyl-N-benzyl-L-prolinamide",
        "iupac_name": "(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-benzylpyrrolidine-2-carboxamide",
        "inchi": {
            "hash": "MEPJWLFTTFHOQO-MOPGFXCFSA-N",
            "id": "InChI=1S/C21H25N3O2/c22-18(14-16-8-3-1-4-9-16)21(26)24-13-7-12-19(24)20(25)23-15-17-10-5-2-6-11-17/h1-6,8-11,18-19H,7,12-15,22H2,(H,23,25)/t18-,19+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 351.4421,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 351.194677059,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB07143",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(C=N1)C1=NC(N2CCOCC2)=C2SC(CN(C)C3=NC=C(C=N3)C(=O)NO)=CC2=N1",
        "id": "DB11891",
        "molecule": "Fimepinostat",
        "cas": "1339928-25-4",
        "iupac_name": "N-hydroxy-2-({[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}(methyl)amino)pyrimidine-5-carboxamide",
        "background": "Fimepinostat (CUDC-907) has been used in trials studying the treatment of lymphoma, solid tumors, breast cancer, multiple myeloma, and NUT midline carcinoma, among others.\n",
        "inchi": {
            "hash": "JOWXJLIFIIOYMS-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 508.56,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 508.164122459,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.",
        "link": "https://go.drugbank.com/drugs/DB11891",
        "type": "Small Molecule",
        "synonyms": [
            "5-pyrimidinecarboxamide, N-hydroxy-2-[[[2-(6-methoxy-3-pyridinyl)-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl]methylamino]-",
            "N-hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide",
            "PI3K/HDAC inhibitor CUDC-907"
        ],
        "is_stub": true
    },
    {
        "smiles": "FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=C(F)C=C(OC2=C(Cl)C=C(C=C2)C(F)(F)F)C=C1",
        "id": "DB15006",
        "molecule": "Flufenoxuron",
        "cas": "101463-69-8",
        "iupac_name": "1-{4-[2-chloro-4-(trifluoromethyl)phenoxy]-2-fluorophenyl}-3-(2,6-difluorobenzoyl)urea",
        "background": "Flufenoxuron is under investigation in clinical trial NCT00922870 (Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock).\n",
        "inchi": {
            "hash": "RYLHNOVXKPXDIP-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H11ClF6N2O3/c22-12-8-10(21(26,27)28)4-7-17(12)33-11-5-6-16(15(25)9-11)29-20(32)30-19(31)18-13(23)2-1-3-14(18)24/h1-9H,(H2,29,30,31,32)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 488.77,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 488.0362389,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-benzoyl-n'-phenylureas. These are n-acyl-phenylureas that have the acyl group substituted by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB15006",
        "type": "Small Molecule",
        "synonyms": [
            "CASCADE"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]N1C=C(C[N+]2([H])C[C@H](O)[C@@H](CO)C2)C2N=CN([H])C(=O)C12",
        "id": "DB03551",
        "molecule": "(3R,4R)-3-Hydroxy-4-(hydroxymethyl)-1-[(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]pyrrolidinium",
        "iupac_name": "(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-({4-oxo-3H,4H,4aH,5H,7aH-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)pyrrolidin-1-ium",
        "inchi": {
            "hash": "WFVGWLHAOKEIOJ-MFQSTILNSA-O",
            "id": "InChI=1S/C12H18N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-11,13,17-18H,2-5H2,(H,14,15,19)/p+1/t8-,9+,10?,11?/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 267.3043,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 267.145715494,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB03551",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPurine nucleoside phosphorylase"
            },
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UPurine nucleoside phosphorylase"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)N(C=C1I)[C@H]1C[C@H](O)[C@@H](CO)O1",
        "id": "DB13776",
        "molecule": "Ibacitabine",
        "cas": "611-53-0",
        "iupac_name": "4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2-dihydropyrimidin-2-one",
        "inchi": {
            "hash": "WEVJJMPVVFNAHZ-RRKCRQDMSA-N",
            "id": "InChI=1S/C9H12IN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)/t5-,6+,7+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 353.116,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 352.98725,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB13776",
        "type": "Small Molecule",
        "synonyms": [
            "Ibacitabine"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]N(O)C(=O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O",
        "id": "DB02093",
        "molecule": "5-phospho-D-arabinohydroxamic acid",
        "iupac_name": "[(2R,3R,4S)-2,3,4-trihydroxy-4-(hydroxycarbamoyl)butoxy]phosphonic acid",
        "inchi": {
            "hash": "OHQFMJPEBPCIEQ-JJYYJPOSSA-N",
            "id": "InChI=1S/C5H12NO9P/c7-2(1-15-16(12,13)14)3(8)4(9)5(10)6-11/h2-4,7-9,11H,1H2,(H,6,10)(H2,12,13,14)/t2-,3-,4+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 261.1238,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 261.024967499,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.",
        "link": "https://go.drugbank.com/drugs/DB02093",
        "type": "Small Molecule",
        "synonyms": [
            "(2R,3R,4S)-2,3,4-Trihydroxy-5-(hydroxyamino)-5-oxopentyl dihydrogen phosphate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlucose-6-phosphate isomerase"
            }
        ]
    },
    {
        "smiles": "CNC1CC(C2=CC=CC=C2)C2=CC=CC=C2C1",
        "id": "DB09193",
        "molecule": "CP-39,332",
        "cas": "61764-60-1",
        "iupac_name": "N-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine",
        "background": "CP-39,332 is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency. However, none of the members of this stereoisomers has been marketed.\n",
        "inchi": {
            "hash": "HLOCJJORRHQDKS-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H19N/c1-18-15-11-14-9-5-6-10-16(14)17(12-15)13-7-3-2-4-8-13/h2-10,15,17-18H,11-12H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 237.346,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 237.151749616,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.",
        "link": "https://go.drugbank.com/drugs/DB09193",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1",
        "id": "DB08954",
        "molecule": "Ifenprodil",
        "cas": "23210-56-2",
        "iupac_name": "4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol",
        "background": "N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.1,2 NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding domain (LBD), a transmembrane domain, and a C-terminal cytoplasmic domain. Binding at the LBD of the agonists glycine (or D-serine) to the GluN1 subunits and of glutamate to the GluN2 subunits is a regulatory mechanism for channel activation. In addition, allosteric modulators are known to bind at the NTDs and form another layer of regulation.1,2 One such allosteric regulator is ifenprodil, which was first shown to bind the NMDARs in the 1990s, and specifically to those NMDARs containing the GluN2B subunit.3 Further studies elucidated that ifenprodil binds strongly at the inter-subunit interface of adjacent GluN1 and GluN2B NTDs, where it acts as a non-competitive antagonist.1,2\nAlthough ifenprodil has received considerable interest in its potential neuromodulatory activities in psychiatric conditions, including dependency4 and depression,5 it has also been shown to have an immunomodulatory effect.5,6 In an unbiased screen for compounds capable of reducing cell death induced by infection with the influenza strain H5N1, ifenprodil was found to have a protective effect against H5N1-induced lung damage, in part through its ability to alleviate the H5N1-induced cytokine storm and reduce pulmonary infiltration of neutrophils, natural killer cells, and T cells.6 Ifenprodil is being investigated for its potential utility in treating COVID-19 in an ongoing phase 2b/3 clinical trial (NCT04382924).7\n",
        "inchi": {
            "hash": "UYNVMODNBIQBMV-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 325.4446,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 325.204179113,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4-benzylpiperidines. These are organic compounds containing a benzyl group attached to the 4-position of a piperidine.",
        "link": "https://go.drugbank.com/drugs/DB08954",
        "type": "Small Molecule",
        "synonyms": [
            "Ifenprodil",
            "Ifenprodilum"
        ],
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AGlutamate receptor ionotropic, NMDA 2B"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AGlutamate receptor ionotropic, NMDA 1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UG protein-activated inward rectifier potassium channel 1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UG protein-activated inward rectifier potassium channel 2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UG protein-activated inward rectifier potassium channel 4"
            }
        ]
    },
    {
        "smiles": "[H]N(C(C)=O)C1=CC=C(CP([O-])(=O)O[C@@H](C)C2=CC=CC=C2)C=C1",
        "id": "DB08545",
        "molecule": "(1S)-1-Phenylethyl (4-acetamidobenzyl)phosphonate",
        "iupac_name": "(1S)-1-phenylethyl [(4-acetamidophenyl)methyl]phosphonate",
        "inchi": {
            "hash": "YPTMOJMDCPUCJT-ZDUSSCGKSA-M",
            "id": "InChI=1S/C17H20NO4P/c1-13(16-6-4-3-5-7-16)22-23(20,21)12-15-8-10-17(11-9-15)18-14(2)19/h3-11,13H,12H2,1-2H3,(H,18,19)(H,20,21)/p-1/t13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 332.3108,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 332.105169613,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acetanilides. These are organic compounds containing an acetamide group conjugated to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB08545",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHepatitis B virus receptor binding protein"
            }
        ]
    },
    {
        "smiles": "[H][C@](N)(CCSC[C@@]([H])(O)[C@@]([H])(O)C(=O)CO)C(O)=O",
        "id": "DB04182",
        "molecule": "(S)-2-Amino-4-[(2s,3r)-2,3,5-Trihydroxy-4-Oxo-Pentyl]Mercapto-Butyric Acid",
        "iupac_name": "(2S)-2-amino-4-{[(2S,3R)-2,3,5-trihydroxy-4-oxopentyl]sulfanyl}butanoic acid",
        "inchi": {
            "hash": "QFXXRJSDEMCBPH-ARDNSNSESA-N",
            "id": "InChI=1S/C9H17NO6S/c10-5(9(15)16)1-2-17-4-7(13)8(14)6(12)3-11/h5,7-8,11,13-14H,1-4,10H2,(H,15,16)/t5-,7+,8-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 267.299,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 267.077657971,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB04182",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "US-ribosylhomocysteine lyase"
            }
        ]
    },
    {
        "smiles": "CC(C)N(C(=O)CN1C2=CC=CC=C2N(C2=CC=CC=C2)C(=O)[C@@H](NC(=O)NC2=CC=CC(=C2)C(O)=O)C1=O)C1=CC=CC=C1",
        "id": "DB12309",
        "molecule": "GI-181771X",
        "cas": "305366-98-7",
        "iupac_name": "3-({[(3S)-2,4-dioxo-1-phenyl-5-{[phenyl(propan-2-yl)carbamoyl]methyl}-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl]carbamoyl}amino)benzoic acid",
        "background": "Gski181771 X is under investigation in clinical trial NCT00600743 (Effect of a CCK-1R Agonist on Food Intake in Humans).\n",
        "inchi": {
            "hash": "CABBMMXFOOZVMS-PMERELPUSA-N",
            "id": "InChI=1S/C34H31N5O6/c1-22(2)38(25-14-5-3-6-15-25)29(40)21-37-27-18-9-10-19-28(27)39(26-16-7-4-8-17-26)32(42)30(31(37)41)36-34(45)35-24-13-11-12-23(20-24)33(43)44/h3-20,22,30H,21H2,1-2H3,(H,43,44)(H2,35,36,45)/t30-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 605.651,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 605.227433738,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).",
        "link": "https://go.drugbank.com/drugs/DB12309",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](CC)(C=O)[C@@]([H])(CNS(=O)(=O)C1=CC=C(C=C1)[N+]([O-])=O)C(O)=O",
        "id": "DB08641",
        "molecule": "(2S,3S)-3-FORMYL-2-({[(4-NITROPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID",
        "iupac_name": "(2S,3S)-3-formyl-2-[(4-nitrobenzenesulfonamido)methyl]pentanoic acid",
        "inchi": {
            "hash": "JPQYVEFTAZEPOD-BXKDBHETSA-N",
            "id": "InChI=1S/C13H16N2O7S/c1-2-9(8-16)12(13(17)18)7-14-23(21,22)11-5-3-10(4-6-11)15(19)20/h3-6,8-9,12,14H,2,7H2,1H3,(H,17,18)/t9-,12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 344.34,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 344.067821566,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB08641",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UChymotrypsin-like elastase family member 1"
            }
        ]
    },
    {
        "smiles": "[H][C@]12O[C@]([H])(C(C(=O)OC)=C1C(=O)OC)C(=C2C1=CC=C(O)C=C1)C1=CC=C(O)C=C1",
        "id": "DB07932",
        "molecule": "dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate",
        "iupac_name": "2,3-dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate",
        "inchi": {
            "hash": "CRLQCBACIMUGDZ-BGYRXZFFSA-N",
            "id": "InChI=1S/C22H18O7/c1-27-21(25)17-18(22(26)28-2)20-16(12-5-9-14(24)10-6-12)15(19(17)29-20)11-3-7-13(23)8-4-11/h3-10,19-20,23-24H,1-2H3/t19-,20+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 394.3741,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 394.10525293,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.",
        "link": "https://go.drugbank.com/drugs/DB07932",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor coactivator 2"
            }
        ]
    },
    {
        "smiles": "[67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O",
        "id": "DB06784",
        "molecule": "Gallium citrate Ga-67",
        "cas": "41183-64-6",
        "iupac_name": "(67Ga)gallium(3+) 2-hydroxypropane-1,2,3-tricarboxylate",
        "background": "Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization. Ga-67 scintigraphy (GS) cannot differentiate between tumor and acute inflammation. [NCI Thesaurus]\n",
        "inchi": {
            "hash": "YEEGWNXDUZONAA-RYDPDVNUSA-K",
            "id": "InChI=1S/C6H8O7.Ga/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3/i;1-3"
        },
        "summary": "Gallium citrate Ga-67 is a radiopharmaceutical agent used in the detection of the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma, as well as some acute inflammatory lesions.",
        "weight": [
            {
                "type": "average",
                "weight": 256.0279,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 255.931732429,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB06784",
        "type": "Small Molecule",
        "synonyms": [
            "Gallium (67 Ga) citrate",
            "Gallium citrate Ga 67",
            "Gallium citrate Ga-67",
            "Gallium-67 Citrate"
        ],
        "indication": "Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "It has been reported in the scientific literature that following intravenous injection, the highest tissue concentration of gallium Ga-67 - other than tumors and sites of infection - is the renal cortex. After the first day, the maximum concentration shifts to bone and lymph nodes and after the first week, to liver and spleen. Gallium Ga-67 is excreted relatively slowly from the body. The average whole body retention is 65 percent after seven days, with 26 percent having been excreted in the urine and 9 percent in the stools.\n"
    },
    {
        "smiles": "CCN(CC)C(=O)C1CN2CCC3=CC(OC)=C(OC)C=C3C2CC1OC(C)=O",
        "id": "DB00767",
        "molecule": "Benzquinamide",
        "cas": "63-12-7",
        "iupac_name": "3-(diethylcarbamoyl)-9,10-dimethoxy-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-yl acetate",
        "background": "Benzquinamide is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors. \n",
        "inchi": {
            "hash": "JSZILQVIPPROJI-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H32N2O5/c1-6-23(7-2)22(26)17-13-24-9-8-15-10-20(27-4)21(28-5)11-16(15)18(24)12-19(17)29-14(3)25/h10-11,17-19H,6-9,12-13H2,1-5H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 404.4999,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 404.231122144,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.",
        "link": "https://go.drugbank.com/drugs/DB00767",
        "type": "Small Molecule",
        "synonyms": [
            "benzquinamida",
            "Benzquinamide",
            "BZQ"
        ],
        "indication": "Used to prevent and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or intravenously.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Benzquinamide is an antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AHistamine H1 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M5"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M3"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB14539",
        "molecule": "Hydrocortisone acetate",
        "cas": "50-03-3",
        "iupac_name": "2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate",
        "inchi": {
            "hash": "ALEXXDVDDISNDU-JZYPGELDSA-N",
            "id": "InChI=1S/C23H32O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-18,20,26,28H,4-9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1"
        },
        "summary": "Hydrocortisone acetate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses and ulcerative colitis.",
        "weight": [
            {
                "type": "average",
                "weight": 404.4966,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 404.219888756,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB14539",
        "type": "Small Molecule",
        "synonyms": [
            "21-O-acetylcortisol",
            "Cortisol 21-acetate",
            "Hydrocortisone 21-acetate",
            "Hydrocortisone acetate"
        ],
        "indication": "For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AAnnexin A1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AGlucocorticoid receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U3 beta-hydroxysteroid dehydrogenase/Delta 5--\u003e4-isomerase type 1"
            }
        ]
    },
    {
        "smiles": "CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O",
        "id": "DB08818",
        "molecule": "Hyaluronic acid",
        "cas": "9004-61-9",
        "iupac_name": "(2S,3S,4R,5R,6R)-3-{[(2S,3R,5S,6R)-4-{[(2R,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-{[(2R,3R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid",
        "background": "Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. Karl Meyer and John Palmer obtained glycosaminoglycan (GAG) from the bovine eye, giving it the name hyaluronic acid. HA is involved in many important physiological processes, including but not limited to wound healing, tissue regeneration, and joint lubrication. It demonstrates unique viscoelasticity, moisturizing, anti-inflammatory qualities, and other important properties that prove beneficial in various clinical applications.2 \nHA is used in drug delivery systems for the treatment of cancer, ophthalmological conditions, joint conditions, and aesthetic imperfections.3 Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms. A popular use of hyaluronic acid in recent years is cosmetic injection due to its ability to minimize the appearance of wrinkles and aging-related skin imperfections.17\n",
        "inchi": {
            "hash": "KIUKXJAPPMFGSW-MNSSHETKSA-N",
            "id": "InChI=1S/C28H44N2O23/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45)/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18?,19?,20+,21+,22+,25-,26+,27-,28-/m1/s1"
        },
        "summary": "Hyaluronic acid is a glycosaminoglycan used for the relief of joint pain, wound healing, ophthalmologic treatment, cosmetic treatment, and various other applications.",
        "weight": [
            {
                "type": "average",
                "weight": 776.6486,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 776.233485724,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group.",
        "link": "https://go.drugbank.com/drugs/DB08818",
        "type": "Small Molecule",
        "synonyms": [
            "Hyaluronan",
            "Hyaluronate"
        ],
        "indication": "The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis.23 Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body.20,22 It is frequently an ingredient in topical applications for wound healing and symptomatic treatment of skin irritation from various causes.18 Hyaluronic acid may also be indicated in ophthalmological preparations or oral capsules to treat discomfort caused by dry eyes or conjunctivitis and for its protective qualities during and before eye surgery.2,21 Finally, hyaluronic acid can be used off-label to coat the bladder for relief of interstitial cystitis symptoms.6\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "HA has long-acting lubricant, shock absorbing, joint stabilizing, and water balancing properties.2,17 It is similar to the naturally occurring glycosaminoglycan (GAG) in joints. Hyaluronic acid works by acting as a lubricant and shock absorber, facilitating joint mobility and thereby reducing osteoarthritic pain. Hyaluronic acid has antioxidative, anti-inflammatory, and analgesic effects.2 The water-balancing properties and viscoelasticity of hyaluronic acid are beneficial in cosmetic injections, imparting volume and reducing the appearance of imperfections and wrinkles.17 Due to the abovementioned properties, HA has a protective effect on the eyes and cornea.3\n",
        "moa": [
            {
                "action": "binder",
                "organism": "Humans",
                "target": "ACD44 antigen"
            },
            {
                "action": "inhibitorbinder",
                "organism": "Humans",
                "target": "AIntercellular adhesion molecule 1"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "AHyaluronan mediated motility receptor"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UNeurocan core protein"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UVersican core protein"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UComplement component 1 Q subcomponent-binding protein, mitochondrial"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UHyaluronan and proteoglycan link protein 1"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UHyaluronan and proteoglycan link protein 3"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UHyaluronan-binding protein 2"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "ULayilin"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UStabilin-2"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UTumor necrosis factor-inducible gene 6 protein"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UInterphotoreceptor matrix proteoglycan 2"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UIntracellular hyaluronan-binding protein 4"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULymphatic vessel endothelial hyaluronic acid receptor 1"
            }
        ]
    },
    {
        "smiles": "FC1=CNC(=O)NC1=O",
        "id": "DB00544",
        "molecule": "Fluorouracil",
        "cas": "51-21-8",
        "iupac_name": "5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione",
        "background": "A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.\n",
        "inchi": {
            "hash": "GHASVSINZRGABV-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)"
        },
        "summary": "Fluorouracil is a pyrimidine analog used to treat basal cell carcinomas, and as an injection in palliative cancer treatment.",
        "weight": [
            {
                "type": "average",
                "weight": 130.0772,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 130.017855555,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB00544",
        "type": "Small Molecule",
        "synonyms": [
            "5-Fluoracil",
            "5-Fluoropyrimidine-2,4-dione",
            "5-Fluorouracil",
            "5-Fluracil",
            "5-FU",
            "Fluoro Uracil",
            "Fluorouracil",
            "Fluorouracilo",
            "Fluorouracilum",
            "Fluouracil"
        ],
        "indication": "For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the \"S\" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.\n",
        "moa": [
            {
                "action": "incorporation into and destabilization",
                "organism": "Humans",
                "target": "ADNA"
            },
            {
                "action": "incorporation into and destabilization",
                "organism": "Humans",
                "target": "ARNA"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "AThymidylate synthase"
            }
        ]
    },
    {
        "smiles": "CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CC5=C(NN=C5)N=C4)=C(C)C=C3)C=C2)C(F)(F)F)CC1",
        "id": "DB16185",
        "molecule": "HQP1351",
        "cas": "1257628-77-5",
        "iupac_name": "4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide",
        "background": "HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).\n",
        "inchi": {
            "hash": "TZKBVRDEOITLRB-UHFFFAOYSA-N",
            "id": "InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 532.571,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 532.219844002,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16185",
        "type": "Small Molecule",
        "synonyms": [
            "Hqp-1351 free base",
            "Hqp1351 free base",
            "Olverembatinib"
        ],
        "is_stub": true
    },
    {
        "smiles": "CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O",
        "id": "DB13034",
        "molecule": "Foxy-5",
        "cas": "881188-51-8",
        "iupac_name": "(2S)-2-[(2S)-4-carboxy-2-[(2R)-2-{2-[(2S)-3-carboxy-2-[(2S)-2-formamido-4-(methylsulfanyl)butanamido]propanamido]acetamido}-3-sulfanylpropanamido]butanamido]-4-methylpentanoic acid",
        "background": "Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer.\n",
        "inchi": {
            "hash": "WFZPJYYCTSHDJI-ATIWLJMLSA-N",
            "id": "InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 694.77,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 694.230213164,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB13034",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(CC2=CC=C(C=C2)C(N)=N)CCCC[C@@]([H])(CC2=CC=C(C=C2)C(N)=N)C1=O",
        "id": "DB02081",
        "molecule": "Bis-Benzamidine",
        "iupac_name": "4-{[(1S,3S)-3-[(4-carbamimidoylphenyl)methyl]-2-oxocycloheptyl]methyl}benzene-1-carboximidamide",
        "inchi": {
            "hash": "BXYGSMRTHHSAHZ-PMACEKPBSA-N",
            "id": "InChI=1S/C23H28N4O/c24-22(25)17-9-5-15(6-10-17)13-19-3-1-2-4-20(21(19)28)14-16-7-11-18(12-8-16)23(26)27/h5-12,19-20H,1-4,13-14H2,(H3,24,25)(H3,26,27)/t19-,20-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 376.4946,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 376.226311538,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.",
        "link": "https://go.drugbank.com/drugs/DB02081",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "id": "DB11118",
        "molecule": "Ammonia",
        "cas": "7664-41-7",
        "background": "Ammonia is a naturally-occurring compound with a chemical formula NH3 and structure of trigonal pyramidal geometry. It is a colorless gas with a pungent smell, and become NH4, or ammonium ion, when in water. Although ammonia is used as a food additive in the anhydrous form and serves as a starting material in pharmaceutical and commercial products, it is caustic and hazardous when concentrated. Ammonia gas has been used in the clinical setting as a respiratory stimulant to prevent fainting. The radiolabelled form of ammonia, ammonia N 13, is intravenously administered as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the myocardium to evaluate myocardial perfusion. Ammonia is a natural byproduct of biological and chemical reactions, including decomposition of organic matter, including plants, animals, and animal wastes. It is present in normally present in all tissues constituting a metabolic pool, where it is mostly taken up by glutamic acid and take part in transamination and other reactions, including the synthesis of protein by the Krebs-Hanseleit cycle in the liver 5. It is proposed that human adults produce about 1000 mmol of ammonia daily, most of which undergoes excretion in the urine.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11118",
        "type": "Small Molecule",
        "indication": "\nIndicated for use as a smelling salt to treat or prevent fainting. \n(when radiolabelled) Indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease Label.\n\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "As a gas, ammonia is a natural byproduct and respiratory stimulant. Its renal metabolism plays a role in whole body acid-base balance.\n"
    },
    {
        "smiles": "[O-][N+](=O)C1=CC=C(O1)\\C=N\\N1CCOC1=O",
        "id": "DB00614",
        "molecule": "Furazolidone",
        "cas": "67-45-8",
        "iupac_name": "3-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one",
        "background": "A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)\n",
        "inchi": {
            "hash": "PLHJDBGFXBMTGZ-WEVVVXLNSA-N",
            "id": "InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+"
        },
        "summary": "Furazolidone is a drug for the treatment of infectious diarrhea.",
        "weight": [
            {
                "type": "average",
                "weight": 225.16,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 225.038570337,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB00614",
        "type": "Small Molecule",
        "synonyms": [
            "3-(5'-Nitrofurfuralamino)-2-oxazolidone",
            "3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone",
            "3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone",
            "3-[(5-Nitrofurylidene)amino]-2-oxazolidone",
            "3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone",
            "5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine",
            "Furazolidona",
            "Furazolidone",
            "Furazolidonum",
            "FZL",
            "N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone",
            "N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one",
            "Nitrofurazolidone",
            "Nitrofurazolidonum"
        ],
        "indication": "For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Furoxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms.\n",
        "moa": [
            {
                "action": "cross-linking/alkylation",
                "organism": "Humans",
                "target": "ADNA"
            }
        ]
    },
    {
        "smiles": "COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O",
        "id": "DB09081",
        "molecule": "Idebenone",
        "cas": "58186-27-9",
        "iupac_name": "2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione",
        "background": "Idebenone is a synthetic analogue of ubiquinone (also known as Coenzyme Q10), a vital cell antioxidant and essential component of the Electron Transport Chain (ETC). It has been proposed that by interacting with the ETC, idebenone increases ATP production required for mitochondrial function, reduces free radicals, inhibits lipid peroxidation, and consequently protects the lipid membrane and mitochondria from oxidative damage 2. More specifically, idebenone is thought to transfer electrons directly to complex III of the mitochondrial ETC, thereby circumventing complex I and restoring cellular energy (ATP) generation 4. \nDue to its ability to reduce oxidative damage and improve ATP production, idebenone was originally investigated for its potential use in Alzheimer's Disease and other cognitivie disorders 3. Lack of improvement in cognitive function halted its production for these conditions, however it continues to be investigated for use in other conditions associated with mitochondrial damage. \nIdebenone is currently only indicated for use by the European Medicines Agency (EMA) for the treatment of visual impairment in adolescent and adult patients with\nLebers Hereditary Optic Neuropathy (LHON). LHON is a mitochondrially inherited degeneration of retinal ganglion cells, resulting in acute central vision loss. Due to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients 4. It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.\n",
        "inchi": {
            "hash": "JGPMMRGNQUBGND-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3"
        },
        "summary": "Idebenone is an analogue of ubiquinone used for the treatment of visual impairment in adolescent and adult patients with Lebers Hereditary Optic Neuropathy (LHON).",
        "weight": [
            {
                "type": "average",
                "weight": 338.444,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 338.209324066,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as ubiquinones. These are coenzyme Q derivatives containing a 5, 6-dimethoxy-3-methyl(1,4-benzoquinone) moiety to which an isoprenyl group is attached at ring position 2(or 6).",
        "link": "https://go.drugbank.com/drugs/DB09081",
        "type": "Small Molecule",
        "synonyms": [
            "2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone",
            "2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone",
            "2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione",
            "2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone",
            "6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone",
            "6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-p-benzoquinone",
            "idebenona",
            "idbnone",
            "Idebenone"
        ],
        "indication": "Idebenone is indicated for use by the European Medicines Agency (EMA) for the treatment of visual impairment in adolescent and adult patients with\nLebers Hereditary Optic Neuropathy (LHON). It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada 4.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[H][C@]1(CCCCN1C(C)=O)C(O)=O",
        "id": "DB07384",
        "molecule": "1-ACETYL-2-CARBOXYPIPERIDINE",
        "iupac_name": "(2S)-1-acetylpiperidine-2-carboxylic acid",
        "inchi": {
            "hash": "JACZWLDAHFCGCC-ZETCQYMHSA-N",
            "id": "InChI=1S/C8H13NO3/c1-6(10)9-5-3-2-4-7(9)8(11)12/h7H,2-5H2,1H3,(H,11,12)/t7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 171.1937,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 171.089543287,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-l-alpha-amino acids. These are n-acylated alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB07384",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UATP synthase subunit alpha, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UATP synthase subunit beta, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UATP synthase subunit gamma, mitochondrial"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC(=C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
        "id": "DB08970",
        "molecule": "Fluprednidene",
        "cas": "2193-87-5",
        "iupac_name": "(1R,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-2-methylidene-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one",
        "background": "Fluprednidene is a corticosteroid.\n",
        "inchi": {
            "hash": "YVHXHNGGPURVOS-SBTDHBFYSA-N",
            "id": "InChI=1S/C22H27FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,15-17,24,26,28H,1,4-5,8,10-11H2,2-3H3/t15-,16-,17-,19-,20-,21-,22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 390.4452,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 390.184252179,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.",
        "link": "https://go.drugbank.com/drugs/DB08970",
        "type": "Small Molecule",
        "synonyms": [
            "Fluprednidene"
        ]
    },
    {
        "smiles": "CCC[C@H](C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1OC[C@H](O1)N1C=CC(N)=NC1=O)OC1=CC=C(Br)C=C1",
        "id": "DB18090",
        "molecule": "Fostroxacitabine bralpamide",
        "cas": "2129993-56-0",
        "inchi": {
            "hash": "JBYKMODFCUCTGY-LLSQRQBFSA-N",
            "id": "InChI=1S/C22H30BrN4O8P/c1-4-5-14(2)33-21(28)15(3)26-36(30,35-17-8-6-16(23)7-9-17)32-13-20-31-12-19(34-20)27-11-10-18(24)25-22(27)29/h6-11,14-15,19-20H,4-5,12-13H2,1-3H3,(H,26,30)(H2,24,25,29)/t14-,15-,19-,20-,36+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 589.38,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 588.098464,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18090",
        "type": "Small Molecule",
        "synonyms": [
            "Troxacitabine nucleotide prodrug miv-818"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@H](NC1=C2N=CNC2=NC=N1)C1=C(C(=O)N2C(C)=CSC2=N1)C1=CC=CC(F)=C1",
        "id": "DB16137",
        "molecule": "Dezapelisib",
        "cas": "1262440-25-4",
        "iupac_name": "6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one",
        "background": "Dezapelisib is under investigation in clinical trial NCT02456675 (INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/refractory Hodgkin Lymphoma).\n",
        "inchi": {
            "hash": "RSIWALKZYXPAGW-NSHDSACASA-N",
            "id": "InChI=1S/C20H16FN7OS/c1-10-7-30-20-27-15(11(2)26-18-16-17(23-8-22-16)24-9-25-18)14(19(29)28(10)20)12-4-3-5-13(21)6-12/h3-9,11H,1-2H3,(H2,22,23,24,25,26)/t11-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 421.45,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 421.1121075,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16137",
        "type": "Small Molecule",
        "synonyms": [
            "6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-(7H-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one",
            "Dezapelisib"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN(CC1=CC=CC=C1)C(=O)[C@@H](NC(=O)C1=CC2=C(C=CC(NC(=O)C3=CC=CC=C3C3=CC=C(C=C3)C(F)(F)F)=C2)N1C)C1=CC=CC=C1",
        "id": "DB11399",
        "molecule": "Dirlotapide",
        "cas": "481658-94-0",
        "iupac_name": "N-[(S)-[benzyl(methyl)carbamoyl](phenyl)methyl]-1-methyl-5-[4'-(trifluoromethyl)-[1,1'-biphenyl]-2-amido]-1H-indole-2-carboximidic acid",
        "background": "Dirlotapide is a drug employed in the treatment of obesity in dogs. It is marketed by Pfizer and Zoetis under the brand name, Slentrol, and is not intended for human use.\n",
        "inchi": {
            "hash": "TUOSYWCFRFNJBS-BHVANESWSA-N",
            "id": "InChI=1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 674.724,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 674.250475428,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB11399",
        "type": "Small Molecule",
        "synonyms": [
            "Dirlotapide"
        ],
        "is_stub": true
    },
    {
        "smiles": "C\\C=C\\C(O)=O",
        "id": "DB02074",
        "molecule": "Butenoic Acid",
        "cas": "107-93-7",
        "iupac_name": "(2E)-but-2-enoic acid",
        "inchi": {
            "hash": "LDHQCZJRKDOVOX-NSCUHMNNSA-N",
            "id": "InChI=1S/C4H6O2/c1-2-3-4(5)6/h2-3H,1H3,(H,5,6)/b3-2+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 86.0892,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 86.036779436,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as straight chain fatty acids. These are fatty acids with a straight aliphatic chain.",
        "link": "https://go.drugbank.com/drugs/DB02074",
        "type": "Small Molecule"
    },
    {
        "smiles": "OC(=O)C1=CC=C(O1)C1=CC=CC=C1Cl",
        "id": "DB02909",
        "molecule": "5-(2-Chlorophenyl)Furan-2-Carboxylic Acid",
        "iupac_name": "5-(2-chlorophenyl)furan-2-carboxylic acid",
        "inchi": {
            "hash": "PJGGWIHXGHQXMM-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H7ClO3/c12-8-4-2-1-3-7(8)9-5-6-10(15-9)11(13)14/h1-6H,(H,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 222.624,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 222.008371797,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as furoic acids. These are organic compounds containing a furoic acid moiety, with a structure characterized by a furan ring bearing a carboxylic acid group at the C2 or C3 carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB02909",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UMethionine aminopeptidase 2"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMethionine aminopeptidase"
            }
        ]
    },
    {
        "smiles": "OOOC1=C(Cl)C=C(NC2=CC=CC=C2C(O)=O)C=C1Cl",
        "id": "DB04756",
        "molecule": "2-[(3,5-Dichloro-4-trioxidanylphenyl)amino]benzoic acid",
        "iupac_name": "2-{[3,5-dichloro-4-(hydroxyperoxy)phenyl]amino}benzoic acid",
        "inchi": {
            "hash": "SNAMTVTZDPUVRA-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H9Cl2NO5/c14-9-5-7(6-10(15)12(9)20-21-19)16-11-4-2-1-3-8(11)13(17)18/h1-6,16,19H,(H,17,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 330.12,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 328.985777817,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB04756",
        "type": "Small Molecule"
    },
    {
        "smiles": "CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=C(C1)C=CC=C2",
        "id": "DB13312",
        "molecule": "Delapril",
        "cas": "83435-66-9",
        "iupac_name": "2-[(2S)-N-(2,3-dihydro-1H-inden-2-yl)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanamido]acetic acid",
        "inchi": {
            "hash": "WOUOLAUOZXOLJQ-MBSDFSHPSA-N",
            "id": "InChI=1S/C26H32N2O5/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30)/t18-,23-/m0/s1"
        },
        "summary": "Delapril is an ACE inhibitor indicated in the treatment of essential hypertension.",
        "weight": [
            {
                "type": "average",
                "weight": 452.551,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 452.231122138,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as peptoid-peptide hybrids. These are compounds containing a peptoid-peptide backbone, which consists alternating amino acid and n-substituted amino acids linked to each other by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB13312",
        "type": "Small Molecule",
        "synonyms": [
            "Delapril"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]\\C(CN1CCCC1)=C(\\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\\[H])=C(/[H])C(O)=O",
        "id": "DB09488",
        "molecule": "Acrivastine",
        "cas": "87848-99-5",
        "iupac_name": "(2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid",
        "background": "Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. \nAcrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.\n",
        "inchi": {
            "hash": "PWACSDKDOHSSQD-IUTFFREVSA-N",
            "id": "InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+"
        },
        "summary": "Acrivastine is an antihistamine agent used for the symptomatic relief of seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.",
        "weight": [
            {
                "type": "average",
                "weight": 348.4382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 348.183778022,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB09488",
        "type": "Small Molecule",
        "synonyms": [
            "(2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}acrylic acid",
            "acrivastina",
            "Acrivastine"
        ],
        "indication": "For the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AHistamine H1 receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07095"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03880"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12395"
    },
    {
        "smiles": "C[C@H](O)[C@@H](CCC1=C2C=CC=CC2=CC=C1)N1C=NC(=C1)C(N)=O",
        "id": "DB03220",
        "molecule": "FR-234938",
        "cas": "256461-79-7",
        "iupac_name": "1-[(3R,4S)-4-hydroxy-1-(naphthalen-1-yl)pentan-3-yl]-1H-imidazole-4-carboxamide",
        "inchi": {
            "hash": "OODDZQQDDOVCFD-SCLBCKFNSA-N",
            "id": "InChI=1S/C19H21N3O2/c1-13(23)18(22-11-17(19(20)24)21-12-22)10-9-15-7-4-6-14-5-2-3-8-16(14)15/h2-8,11-13,18,23H,9-10H2,1H3,(H2,20,24)/t13-,18+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 323.3889,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 323.163376931,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB03220",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenosine deaminase"
            }
        ]
    },
    {
        "smiles": "O=C(OCC1=CC=CC=C1)C1=CN2C(S1)=CC(=O)N(CC1=CC=CC=C1)C2=O",
        "id": "DB08561",
        "molecule": "BENZYL 6-BENZYL-5,7-DIOXO-6,7-DIHYDRO-5H-[1,3]THIAZOLO[3,2-C]PYRIMIDINE-2-CARBOXYLATE",
        "iupac_name": "benzyl 6-benzyl-5,7-dioxo-5H,6H,7H-[1,3]thiazolo[3,2-c]pyrimidine-2-carboxylate",
        "inchi": {
            "hash": "PLBINCOCFGQAJM-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H16N2O4S/c24-18-11-19-23(21(26)22(18)12-15-7-3-1-4-8-15)13-17(28-19)20(25)27-14-16-9-5-2-6-10-16/h1-11,13H,12,14H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 392.428,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 392.0830777,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzyloxycarbonyls. These are organic compounds containing a carbonyl group substituted with a benzyloxyl group.",
        "link": "https://go.drugbank.com/drugs/DB08561",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCollagenase 3"
            }
        ]
    },
    {
        "smiles": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O",
        "id": "DB04690",
        "molecule": "Camptothecin",
        "cas": "7689-03-4",
        "iupac_name": "(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione",
        "background": "Camptothecin is an alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.\n",
        "inchi": {
            "hash": "VSJKWCGYPAHWDS-FQEVSTJZSA-N",
            "id": "InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 348.352,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 348.11100701,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).",
        "link": "https://go.drugbank.com/drugs/DB04690",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-camptothecin",
            "(+)-camptothecine",
            "(S)-(+)-camptothecin",
            "20(S)-camptothecine",
            "21,22-Secocamptothecin-21-oic acid lactone",
            "Camptothecine",
            "D-camptothecin"
        ],
        "indication": "Investigated for the treatment of cancer.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Camptothecin demonstrated strong anticancer activity in preliminary clinical trials but also low solubility and adverse drug reaction. Camptothecin is believed to be a potent topoisomerase inhibitor that interferes with the essential function of topoisomerase in DNA replication.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UDNA topoisomerase 1"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1",
        "id": "DB12236",
        "molecule": "Bexagliflozin",
        "cas": "1118567-05-7",
        "iupac_name": "(2S,3R,4R,5S,6R)-2-(4-chloro-3-{[4-(2-cyclopropoxyethoxy)phenyl]methyl}phenyl)-6-(hydroxymethyl)oxane-3,4,5-triol",
        "background": "Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor.1,2,6 Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge.2 SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney.1 By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, which reduces blood glucose levels independently of insulin sensitivity.4,6 In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. Its use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.6\n",
        "inchi": {
            "hash": "BTCRKOKVYTVOLU-SJSRKZJXSA-N",
            "id": "InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1"
        },
        "summary": "Bexagliflozin is a sodium-glucose co-transporter 2 inhibitor used to improve glycemic control in patients with type 2 diabetes mellitus.",
        "weight": [
            {
                "type": "average",
                "weight": 464.94,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 464.160181,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.",
        "link": "https://go.drugbank.com/drugs/DB12236",
        "type": "Small Molecule",
        "synonyms": [
            "(2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol",
            "Bexagliflozin",
            "D-glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1s)-"
        ],
        "indication": "Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.6\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Healthy subjects and adults with type 2 diabetes mellitus given single or multiple doses of bexagliflozin had dose-dependent increases in urinary glucose excretion (UGE) accompanied by increases in urine volume. A 20 mg bexagliflozin dose can provide near-maximal UGE, and elevated UGE values are maintained with multiple-dose administration. Bexagliflozin does not cause clinically significant QTc interval prolongation at 5 times the recommended dose.6\nThe use of bexagliflozin may cause ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum and genital mycotic infections. There is also an increased incidence of lower limb amputation in patients treated with bexagliflozin compared to those receiving a placebo. In addition, the use of bexagliflozin in patients treated with insulin and insulin secretagogues may increase the risk of hypoglycemia.6\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium/glucose cotransporter 2"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O",
        "id": "DB00254",
        "molecule": "Doxycycline",
        "cas": "564-25-0",
        "iupac_name": "(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide",
        "background": "Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.13 It is a second-generation tetracycline that was first discovered in 1967.6 Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines.5 Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.8\n",
        "inchi": {
            "hash": "JBIWCJUYHHGXTC-AKNGSSGZSA-N",
            "id": "InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1"
        },
        "summary": "Doxycycline is a tetracycline antibiotic used to treat a wide variety of bacterial infections.",
        "weight": [
            {
                "type": "average",
                "weight": 444.4346,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 444.153265754,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.",
        "link": "https://go.drugbank.com/drugs/DB00254",
        "type": "Small Molecule",
        "synonyms": [
            "5-hydroxy--6-deoxytetracycline",
            "6-alpha-deoxy-5-oxytetracycline",
            "6alpha-deoxy-5-oxytetracycline",
            "6-deoxy-5-oxytetracycline",
            "Anhydrous doxycycline",
            "Doxiciclina",
            "Doxycyclin",
            "Doxycycline",
            "Doxycycline (anhydrous)",
            "Doxycycline anhydrous",
            "Doxycyclinum"
        ],
        "indication": "Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:\n\nEarly Lyme disease (as evidenced by erythema migraines) due to Borrelia burgdorferi in adults and pediatric patients 8 years of age and older weighing 45 kg and above 12\nRickettsial infections,11 such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers 13\nSexually transmitted infections 11\nRespiratory tract infections 11 caused by Mycoplasma pneumoniae and Haemophilus influenzae 13\nSpecific bacterial infections 11 after indicative bacteriologic testing. These include infections caused by Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, and Klebsiella species 13\nOphthalmic infections,11 such as inclusion conjunctivitis caused by Chlamydia trachomatis 13\nAnthrax, including inhalational anthrax (post-exposure) 11\nAlternative treatment for selected infections when penicillin is contraindicated 11\nAdjunctive therapy in acute intestinal amebiasis and severe acne 11,13\nLymphogranuloma venereum caused by Chlamydia trachomatis 13\nPsittacosis (ornithosis) caused by Chlamydophila psittaci 13\nTrachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence 13\nUncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis 13\nNongonococcal urethritis caused by Ureaplasma urealyticum 13\nRelapsing fever due to Borrelia recurrentis 13\nProphylaxis of malaria due to Plasmodium falciparum in short-term travelers (\u003c4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains 11,13\n\nIt is also used to treat infections caused by the following gram-negative microorganisms:\n\nChancroid caused by Haemophilus ducreyi 13\nPlague due to Yersinia pestis 13\nTularemia due to Francisella tularensis 13\nCholera caused by Vibrio cholerae 13\nCampylobacter fetus infections caused by Campylobacter fetus 13\nBrucellosis due to Brucella species (in conjunction with streptomycin) 13\nBartonellosis due to Bartonella bacilliformis 13\nGranuloma inguinale caused by Klebsiella granulomatis 13\n\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Doxycycline and other tetracyclines are mainly bacteriostatic and are thought to exert antimicrobial effects by the inhibition of protein synthesis. They suppress the growth of bacteria or keep them in the stationary phase of growth.3 Tetracyclines have antimicrobial spectrum of activity against a variety of gram-positive and gram-negative microorganisms.11 Cross-resistance of these microorganisms to tetracyclines is a common occurrence.11 \nAs it is a highly lipophilic drug, doxycycline crosses multiple membranes of target molecules.8 Doxycycline shows favorable intra-cellular penetration, with bacteriostatic activity against a wide range of bacteria.9 Doxycycline also exhibits antiparasitic properties 1,2,3 and anti-inflammatory actions.4,8 Its anti-inflammatory effects were investigated in various inflammatory skin conditions, such as bullous dermatoses 8 and rosacea.4,8\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "",
                "target": "A30S ribosomal protein"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)C2=C(N1)N(COCCO)C=N2",
        "id": "DB00787",
        "molecule": "Acyclovir",
        "cas": "59277-89-3",
        "iupac_name": "2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one",
        "background": "Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis10,11,12,13,14,15. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.13\nAcyclovir was granted FDA approval on 29 March 1982.12\n",
        "inchi": {
            "hash": "MKUXAQIIEYXACX-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)"
        },
        "summary": "Acyclovir is a guanosine analog used to treat herpes simplex, varicella zoster, herpes zoster.",
        "weight": [
            {
                "type": "average",
                "weight": 225.2046,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 225.086189243,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.",
        "link": "https://go.drugbank.com/drugs/DB00787",
        "type": "Small Molecule",
        "synonyms": [
            "Aciclovir",
            "Aciclovirum",
            "Acycloguanosine",
            "Acyclovir"
        ],
        "indication": "An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older.10 Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox.11 An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients.12 An acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis, and shortening lesion healing time in patients 6 years and older.13 An acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialis.14 An acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitis.15\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Acyclovir is a nucleoside analog that inhibits the action of viral DNA polymerase and DNA replication of different herpesvirus.10,11,12,13,14,15 Acyclovir has a wide therapeutic window as overdose is rare in otherwise healthy patients.11\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "HHV-1",
                "target": "ADNA polymerase catalytic subunit"
            },
            {
                "action": "inhibitor",
                "organism": "HHV-3",
                "target": "ADNA polymerase catalytic subunit"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02509"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17226"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01241"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18443"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05157"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03376"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07508"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00718"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03493"
    },
    {
        "smiles": "CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I",
        "id": "DB09135",
        "molecule": "Ioxilan",
        "cas": "107793-72-6",
        "iupac_name": "N1-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-N3-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide",
        "background": "Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs.\n",
        "inchi": {
            "hash": "UUMLTINZBQPNGF-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)"
        },
        "summary": "Ioxilan is a diagnostic contrast agent used in various medical imaging procedures, such as angiography, urography, and computed tomographic scans.",
        "weight": [
            {
                "type": "average",
                "weight": 791.116,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 790.86975,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.",
        "link": "https://go.drugbank.com/drugs/DB09135",
        "type": "Small Molecule",
        "synonyms": [
            "Ioxilan",
            "Ioxilane",
            "Ioxilanum",
            "N-(2,3-dihydroxypropyl)-N-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide"
        ],
        "indication": "When administered intra-arterially, Ioxilan is indicated for the following diagnostic tests: cerebral arteriography (300 mgI/mL), coronary arteriography and left ventriculography (350 mgI/mL), visceral angiography(350 mgI/mL), aortography(350 mgI/mL), and peripheral arteriography(350 mgI/mL).\nWhen administered intravenously, Ioxilan is indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300 and 350 mgI/mL).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "As with other iodinated contrast agents the degree of contrast enhancement is directly related to the iodine content in the administered dose.\n"
    },
    {
        "smiles": "FC1=CC=C(NC(=O)C2(CC2)C(=O)NC2=C(F)C=C(OC3=CC=NC(NC(=O)C4CC4)=C3)C(F)=C2)C=C1",
        "id": "DB17191",
        "molecule": "Altiratinib",
        "cas": "1345847-93-9",
        "iupac_name": "N1-{4-[(2-cyclopropaneamidopyridin-4-yl)oxy]-2,5-difluorophenyl}-N'1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide",
        "inchi": {
            "hash": "GNNDEPIMDAZHRQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 510.473,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 510.151489661,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17191",
        "type": "Small Molecule",
        "synonyms": [
            "1,1-cyclopropanedicarboxamide, n-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)-",
            "N-(4-((2-((cyclopropylcarbonyl)amino)pyridin-4-yl)oxy)-2,5-difluorophenyi)-n-(4- fluorophenyl)cyclopropane-1,1-dicarboxamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1",
        "id": "DB13270",
        "molecule": "Dibekacin",
        "cas": "34493-98-6",
        "iupac_name": "(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol",
        "background": "Dibekacin is an aminoglycoside antibiotic marketed in Japan 1.\n",
        "inchi": {
            "hash": "JJCQSGDBDPYCEO-XVZSLQNASA-N",
            "id": "InChI=1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 451.521,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 451.264213171,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4,6-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C6-positions.",
        "link": "https://go.drugbank.com/drugs/DB13270",
        "type": "Small Molecule",
        "synonyms": [
            "Dibekacin",
            "Dibekacina",
            "Dibekacine",
            "Dibekacinum"
        ],
        "is_stub": true
    },
    {
        "smiles": "N1C=NC2=CC=CC=C12",
        "id": "DB02962",
        "molecule": "Benzimidazole",
        "cas": "51-17-2",
        "iupac_name": "1H-1,3-benzodiazole",
        "inchi": {
            "hash": "HYZJCKYKOHLVJF-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H6N2/c1-2-4-7-6(3-1)8-5-9-7/h1-5H,(H,8,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 118.1359,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 118.053098202,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB02962",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UNicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase"
            }
        ]
    },
    {
        "smiles": "N[C@@H]([C@@H](O)C(O)=O)C(O)=O",
        "id": "DB03640",
        "molecule": "Beta-Hydroxyaspartic Acid",
        "iupac_name": "(2S,3R)-2-amino-3-hydroxybutanedioic acid",
        "inchi": {
            "hash": "YYLQUHNPNCGKJQ-NHYDCYSISA-N",
            "id": "InChI=1S/C4H7NO5/c5-1(3(7)8)2(6)4(9)10/h1-2,6H,5H2,(H,7,8)(H,9,10)/t1-,2+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 149.1021,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 149.032422339,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aspartic acid and derivatives. These are compounds containing an aspartic acid or a derivative thereof resulting from reaction of aspartic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB03640",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhi",
                "target": "UBeta-lactamase TEM"
            }
        ]
    },
    {
        "smiles": "CC(C)(COP([O-])(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@H](O)C[N+](C)(C)C",
        "id": "DB02516",
        "molecule": "(R)-carnitinyl-CoA betaine",
        "iupac_name": "[(2R)-4-[(2-{3-[(2R)-4-[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)oxy]-2-hydroxy-3,3-dimethylbutanamido]propanamido}ethyl)sulfanyl]-2-hydroxy-4-oxobutyl]trimethylazanium",
        "inchi": {
            "hash": "BBRISSLDTUHWKG-PVMHLSDZSA-N",
            "id": "InChI=1S/C28H49N8O18P3S/c1-28(2,23(41)26(42)31-7-6-18(38)30-8-9-58-19(39)10-16(37)11-36(3,4)5)13-51-57(48,49)54-56(46,47)50-12-17-22(53-55(43,44)45)21(40)27(52-17)35-15-34-20-24(29)32-14-33-25(20)35/h14-17,21-23,27,37,40-41H,6-13H2,1-5H3,(H7-,29,30,31,32,33,38,42,43,44,45,46,47,48,49)/t16-,17-,21-,22-,23+,27-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 910.718,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 910.20983703,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as (s)-3-hydroxyacyl coas. These are organic compounds containing a (S)-3-hydroxyl acylated coenzyme A derivative.",
        "link": "https://go.drugbank.com/drugs/DB02516",
        "type": "Small Molecule",
        "synonyms": [
            "(R)-carnitinyl-CoA ine",
            "L-carnitinyl-CoA betaine",
            "R-carnitinyl-CoA inner salt"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UCrotonobetainyl-CoA:carnitine CoA-transferase"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O",
        "id": "DB02061",
        "molecule": "Cellobiose",
        "cas": "528-50-7",
        "iupac_name": "(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-{[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxane-3,4,5-triol",
        "background": "A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. Obtained from the partial hydrolysis of cellulose. [PubChem]\n",
        "inchi": {
            "hash": "GUBGYTABKSRVRQ-CUHNMECISA-N",
            "id": "InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8-,9-,10-,11?,12+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 342.297,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 342.116211528,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB02061",
        "type": "Small Molecule",
        "synonyms": [
            "1-beta-D-Glucopyranosyl-4-D-glucopyranose",
            "4-beta-d-glucopyranosyl-d-glucopyranose",
            "4-o-beta-d-glucopyranosyl-d-glucose",
            "4-O--D-glucopyranosyl-D-glucopyranose",
            "4--D-glucopyranosyl-D-glucopyranose",
            "Cellose",
            "D-(+)-cellobiose",
            "D-cellobiose",
            "D-glucosyl--(1-4)-D-glucose"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Clostridium cellulolyticum (strain ATCC 35319 / DSM 5812 / JCM 6584 / H10)",
                "target": "UEndoglucanase G"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus agaradhaerens",
                "target": "UEndoglucanase 5A"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus sp. (strain KSM-635)",
                "target": "UEndoglucanase"
            }
        ]
    },
    {
        "smiles": "OP(O)(=O)CCC(=C)C=O",
        "id": "DB03211",
        "molecule": "(3-Formyl-but-3-Enyl)-Phosphonic Acid",
        "iupac_name": "(3-methylidene-4-oxobutyl)phosphonic acid",
        "inchi": {
            "hash": "UBLMBCUBDKMVMQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C5H9O4P/c1-5(4-6)2-3-10(7,8)9/h4H,1-3H2,(H2,7,8,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 164.0963,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 164.023845288,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organic phosphonic acids. These are organic compounds containing phosphonic acid.",
        "link": "https://go.drugbank.com/drugs/DB03211",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Trypanosoma cruzi",
                "target": "UGlyceraldehyde-3-phosphate dehydrogenase, glycosomal"
            }
        ]
    },
    {
        "smiles": "CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1",
        "id": "DB01205",
        "molecule": "Flumazenil",
        "cas": "78755-81-4",
        "iupac_name": "ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate",
        "background": "Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system.\n",
        "inchi": {
            "hash": "OFBIFZUFASYYRE-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3"
        },
        "summary": "Flumazenil is a benzodiazepine antagonist that is used for the complete or partial reversal of the sedative effects caused by benzodiazepines in various clinical settings, such as induced general anesthesia for diagnostic and therapeutic procedures.",
        "weight": [
            {
                "type": "average",
                "weight": 303.2884,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 303.101919534,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as imidazo[1,5-a][1,4]benzodiazepines. These are compounds containing an imidazole ring and a 1,4-benzodiazepine ring system, both sharing one nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB01205",
        "type": "Small Molecule",
        "synonyms": [
            "Flumazenil",
            "Flumazenilo",
            "Flumazenilum",
            "Flumazepil"
        ],
        "indication": "For the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Flumazenil antagonizes the CNS effects produced by benzodiazepines, but does not antagonize the central nervous system effects of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (including ethanol, barbiturates, or general anesthetics) and does not reverse the effects of opioids.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit gamma-2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-5"
            },
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-1"
            }
        ]
    },
    {
        "smiles": "N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O",
        "id": "DB06262",
        "molecule": "Droxidopa",
        "cas": "23651-95-8",
        "iupac_name": "(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid",
        "background": "Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease.\nThough L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout Europe. Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011. Additionally, phase II clinical trials for intradialytic hypotension are also underway. Chelsea Therapeutics obtained orphan drug status (ODS) for L-DOPS in the U.S. for NOH, and that of which associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the pharmaceutical company developing it in that country.\n",
        "inchi": {
            "hash": "QXWYKJLNLSIPIN-JGVFFNPUSA-N",
            "id": "InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1"
        },
        "summary": "Droxidopa is a medication used to treat symptomatic neurogenic orthostatic hypotension (nOH) caused by dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy and primary autonomic failure caused by conditions such as Parkinson's disease.",
        "weight": [
            {
                "type": "average",
                "weight": 213.189,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 213.063722458,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB06262",
        "type": "Small Molecule",
        "synonyms": [
            "DOPS",
            "Droxidopa",
            "L-Dihydroxyphenylserine",
            "L-DOPS",
            "L-threo-dihydroxyphenylserine"
        ],
        "indication": "For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-1A adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-1B adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-1D adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-2A adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-2B adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAlpha-2C adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ABeta-1 adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ABeta-2 adrenergic receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ABeta-3 adrenergic receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NPhenylalanine-4-hydroxylase"
            }
        ]
    },
    {
        "id": "DB17471",
        "molecule": "AL-034",
        "background": "AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17471",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H]N1C=C[C@H](O)N([H])C1=O",
        "id": "DB03939",
        "molecule": "(4S)-4-hydroxy-3,4-dihydro-2(1H)-pyrimidinone",
        "iupac_name": "(4S)-4-hydroxy-1,2,3,4-tetrahydropyrimidin-2-one",
        "inchi": {
            "hash": "DEAAWXYGBWCVJW-VKHMYHEASA-N",
            "id": "InChI=1S/C4H6N2O2/c7-3-1-2-5-4(8)6-3/h1-3,7H,(H2,5,6,8)/t3-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 114.1026,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 114.042927446,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB03939",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UCytosine deaminase"
            }
        ]
    },
    {
        "smiles": "CC1(C)OC[C@H](COP(O)(=O)CCCCC=C)O1",
        "id": "DB08548",
        "molecule": "[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl hydrogen hex-5-enylphosphonate",
        "iupac_name": "{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}(hex-5-en-1-yl)phosphinic acid",
        "inchi": {
            "hash": "BUTLRPVAJSANIT-LLVKDONJSA-N",
            "id": "InChI=1S/C12H23O5P/c1-4-5-6-7-8-18(13,14)16-10-11-9-15-12(2,3)17-11/h4,11H,1,5-10H2,2-3H3,(H,13,14)/t11-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 278.2818,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 278.128310358,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB08548",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "ULipase EstA"
            }
        ]
    },
    {
        "smiles": "[H][C@](OCC[As+](C)(C)C)(C1=CC=CC=C1[N+](O)=O)C(F)(F)F",
        "id": "DB07555",
        "molecule": "Hydroxy(oxo)(2-{(1S)-2,2,2-trifluoro-1-[2-(trimethylarsonio)ethoxy]ethyl}phenyl)ammonium",
        "iupac_name": "trimethyl({2-[(1S)-2,2,2-trifluoro-1-{2-[hydroxy(oxo)azaniumyl]phenyl}ethoxy]ethyl})arsanium",
        "inchi": {
            "hash": "LUSVMAVUPPIHKA-LBPRGKRZSA-N",
            "id": "InChI=1S/C13H19AsF3NO3/c1-14(2,3)8-9-21-12(13(15,16)17)10-6-4-5-7-11(10)18(19)20/h4-7,12H,8-9H2,1-3H3,(H,19,20)/q+2/t12-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 369.2117,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 369.053299511,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitrobenzenes. These are compounds containing a nitrobenzene moiety, which consists of a benzene ring with a carbon bearing a nitro group.",
        "link": "https://go.drugbank.com/drugs/DB07555",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAcetylcholinesterase"
            }
        ]
    },
    {
        "smiles": "NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O",
        "id": "DB00562",
        "molecule": "Benzthiazide",
        "cas": "91-33-8",
        "iupac_name": "3-[(benzylsulfanyl)methyl]-6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide",
        "background": "Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.\n",
        "inchi": {
            "hash": "NDTSRXAMMQDVSW-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 431.937,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 430.983495728,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB00562",
        "type": "Small Molecule",
        "synonyms": [
            "3-((benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide",
            "3-benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide",
            "3-benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide",
            "6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide",
            "6-chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide",
            "Benzothiazide",
            "Benzotiazida",
            "Benzthiazid",
            "Benzthiazide",
            "Benzthiazidum",
            "Benztiazide"
        ],
        "indication": "For the treatment of high blood pressure and management of edema.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASolute carrier family 12 member 3"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACarbonic anhydrase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 4"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 9"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 12"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15943"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04460"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07840"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17273"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02818"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02858"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08369"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07864"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01215"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12934"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05765"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11804"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00292"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18044"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09101"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16767"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14600"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07454"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07033"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05161"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02075"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05024"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02726"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18081"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04288"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07392"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03008"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12831"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14477"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00802"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16963"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07329"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11918"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01816"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12052"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00567"
    },
    {
        "id": "DB06063",
        "molecule": "CAM-2029",
        "background": "CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the target one-month therapeutic period.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06063",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in acromegaly and cancer/tumors (unspecified).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "CN1C=C[NH+]=C1C",
        "id": "DB03789",
        "molecule": "2,3-Dimethylimidazolium Ion",
        "iupac_name": "1,2-dimethyl-1H-imidazol-3-ium",
        "inchi": {
            "hash": "GIWQSPITLQVMSG-UHFFFAOYSA-O",
            "id": "InChI=1S/C5H8N2/c1-5-6-3-4-7(5)2/h3-4H,1-2H3/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 97.1384,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 97.076573298,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-substituted imidazoles. These are heterocyclic compounds containing an imidazole ring substituted at position 1.",
        "link": "https://go.drugbank.com/drugs/DB03789",
        "type": "Small Molecule"
    },
    {
        "smiles": "COC1=C(OC)C=C(C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C)C(O)=C1",
        "id": "DB12482",
        "molecule": "Acotiamide",
        "cas": "185106-16-5",
        "iupac_name": "N-{2-[bis(propan-2-yl)amino]ethyl}-2-(2-hydroxy-4,5-dimethoxybenzamido)-1,3-thiazole-4-carboxamide",
        "background": "Acotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.\n",
        "inchi": {
            "hash": "TWHZNAUBXFZMCA-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 450.55,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 450.193691256,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.",
        "link": "https://go.drugbank.com/drugs/DB12482",
        "type": "Small Molecule",
        "synonyms": [
            "Acotiamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "NCC1=CC=CC(=C1)C1CCN(CC1)C(=O)C1=CC(CCC2=CC=CC=C2)=CN=C1",
        "id": "DB04764",
        "molecule": "[4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE",
        "iupac_name": "1-(3-{1-[5-(2-phenylethyl)pyridine-3-carbonyl]piperidin-4-yl}phenyl)methanamine",
        "inchi": {
            "hash": "CCLHROFBSWWOQO-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H29N3O/c27-17-21-7-4-8-24(15-21)23-11-13-29(14-12-23)26(30)25-16-22(18-28-19-25)10-9-20-5-2-1-3-6-20/h1-8,15-16,18-19,23H,9-14,17,27H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 399.528,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 399.231062565,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB04764",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTryptase beta-2"
            }
        ]
    },
    {
        "smiles": "CS(=O)(=O)C1=CC=C(C=C1)C(N)=N",
        "id": "DB07368",
        "molecule": "4-(METHYLSULFONYL)BENZENECARBOXIMIDAMIDE",
        "iupac_name": "4-methanesulfonylbenzene-1-carboximidamide",
        "inchi": {
            "hash": "ANPBNAUKOUYEGJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H10N2O2S/c1-13(11,12)7-4-2-6(3-5-7)8(9)10/h2-5H,1H3,(H3,9,10)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 198.242,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 198.046298264,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.",
        "link": "https://go.drugbank.com/drugs/DB07368",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "NC1(CCCC1)C(O)=O",
        "id": "DB04620",
        "molecule": "Cycloleucine",
        "cas": "52-52-8",
        "iupac_name": "1-aminocyclopentane-1-carboxylic acid",
        "background": "Cycloleucine is non-metabolisable amino acid formed by cyclization of leucine. It is also a specific and reversible inhibitor of nucleic acid methylation and widely used in biochemical experiments.\n",
        "inchi": {
            "hash": "NILQLFBWTXNUOE-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H11NO2/c7-6(5(8)9)3-1-2-4-6/h1-4,7H2,(H,8,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 129.157,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 129.078978601,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB04620",
        "type": "Small Molecule",
        "synonyms": [
            "1-amino-1-cyclopentanecarboxylic acid",
            "1-aminocyclopentane-1-carboxylic acid",
            "1-aminocyclopentanecarboxylic acid",
            "Cyclo-leucine",
            "Cycloleucin"
        ],
        "pharmacodynamics": "Cycloleucine has cytostatic, immunosuppressive and antineoplastic activities.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, NMDA 1"
            }
        ]
    },
    {
        "smiles": "NC1=NC2=C(N=NN2)C(=O)N1",
        "id": "DB01667",
        "molecule": "8-azaguanine",
        "cas": "134-58-7",
        "iupac_name": "5-amino-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one",
        "background": "8-azaguanine is one of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.\n",
        "inchi": {
            "hash": "LPXQRXLUHJKZIE-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H4N6O/c5-4-6-2-1(3(11)7-4)8-10-9-2/h(H4,5,6,7,8,9,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 152.1142,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 152.04465878,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as triazolopyrimidines. These are polycyclic aromatic compounds containing triazole ring fused to a pyrimidine ring. Triazole is a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB01667",
        "type": "Small Molecule",
        "synonyms": [
            "3-amino-2,4,7,8,9-pentazabicyclo[4.3.0]nona-1,3,6-trien-5-one",
            "8 AG",
            "Azaguanine",
            "Azaguanine-8",
            "Guanazol",
            "Pathocidin",
            "Pathocidine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPurine nucleoside phosphorylase"
            }
        ]
    },
    {
        "smiles": "OC1=CC=C(C=C1)C1=C(Br)C2=C(C=C(O)C=C2)C1=O",
        "id": "DB07230",
        "molecule": "3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE",
        "iupac_name": "3-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1H-inden-1-one",
        "inchi": {
            "hash": "DHPCBFMFERFZLR-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H9BrO3/c16-14-11-6-5-10(18)7-12(11)15(19)13(14)8-1-3-9(17)4-2-8/h1-7,17-18H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 317.134,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 315.973506801,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indenes and isoindenes. These are compounds containing an indene moiety(which consists of a cyclopentadiene fused to a benzene ring), or a isoindene moiety (which consists of a cyclopentadiene fused to cyclohexadiene ring).",
        "link": "https://go.drugbank.com/drugs/DB07230",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor coactivator 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC",
        "id": "DB00542",
        "molecule": "Benazepril",
        "cas": "86541-75-5",
        "iupac_name": "2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid",
        "background": "Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure3,2. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor1.\n",
        "inchi": {
            "hash": "XPCFTKFZXHTYIP-PMACEKPBSA-N",
            "id": "InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1"
        },
        "summary": "Benazepril is an ACE inhibitor prodrug used to treat hypertension.",
        "weight": [
            {
                "type": "average",
                "weight": 424.4895,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 424.199822016,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB00542",
        "type": "Small Molecule",
        "synonyms": [
            "Bnazpril",
            "Benazepril",
            "Benazeprilum"
        ],
        "indication": "Benazepril is indicated for the treatment of hypertension5. It may be used alone or in combination with thiazide diureticsLabel.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by esterases to its active Benazeprilat1, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients5,3,2. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals5,1. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin IILabel. Angiotensin II also stimulates aldosterone secretion by the adrenal cortexLabel.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AAngiotensin-converting enzyme"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17624"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18009"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00257"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09006"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04052"
    },
    {
        "id": "DB05841",
        "molecule": "AI-128",
        "background": "AI-128 is the first human demonstration of sustained release drug administration in the lung. AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05841",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in asthma.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1",
        "id": "DB01274",
        "molecule": "Arformoterol",
        "cas": "67346-49-0",
        "iupac_name": "N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide",
        "background": "Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long-acting beta agonists for the treatment of asthma.\n",
        "inchi": {
            "hash": "BPZSYCZIITTYBL-YJYMSZOUSA-N",
            "id": "InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1"
        },
        "summary": "Arformoterol is a beta-2 adrenergic agonist and bronchodilator used for long-term, symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
        "weight": [
            {
                "type": "average",
                "weight": 344.4049,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 344.173607266,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.",
        "link": "https://go.drugbank.com/drugs/DB01274",
        "type": "Small Molecule",
        "synonyms": [
            "(-)-formoterol",
            "(R,R)-formoterol",
            "Arformoterol"
        ],
        "indication": "Arformoterol is indicated in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.8\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Arformoterol, the active (R,R)-enantiomer of formoterol, is a selective long-acting 2-adrenergic receptor agonist (beta2-agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent as a 2-agonist than the (R,R)-enantiomer. Arformoterol seems to have little or no effect on 1-adrenergic receptors.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ABeta-2 adrenergic receptor"
            }
        ]
    },
    {
        "smiles": "CO\\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1",
        "id": "DB01413",
        "molecule": "Cefepime",
        "cas": "88040-23-7",
        "iupac_name": "1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium",
        "background": "Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics.1,4 Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia.4 The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases.4 In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.4,5,6\n",
        "inchi": {
            "hash": "HVFLCNVBZFFHBT-ZKDACBOMSA-N",
            "id": "InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1"
        },
        "summary": "Cefepime is a fourth-generation cephalosporin antibiotic used in the treatment of infections caused by susceptible bacteria, such as pneumonia, urinary tract infections, and skin infections.",
        "weight": [
            {
                "type": "average",
                "weight": 480.561,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 480.124959288,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 3'-quaternary ammonium cephalosporins. These are cephalosporins that are substituted at the 3'-position by a quaternary ammonium group.",
        "link": "https://go.drugbank.com/drugs/DB01413",
        "type": "Small Molecule",
        "synonyms": [
            "(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate",
            "Cefepima",
            "Cefepime",
            "Cefepimum"
        ],
        "indication": "Cefepime is indicated for the treatment of pneumonia caused by susceptible bacteria, and for empiric therapy for febrile neutropenic patients. Cefepime is also indicated for the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and complicated intra-abdominal infections (used in combination with metronidazole) in adults caused by susceptible bacteria.5,6\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cefepime is a fourth-generation cephalosporin antibiotic.5,6 It is active against Gram-negative bacteria such as Enterobacter spp., Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa, and Gram-positive bacteria such as Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pneumoniae, Streptococcus pyogenes and Viridans group streptococci.5,6 Compared to third-generation cephalosporins, cefepime has an extended Gram-negative coverage. Whereas other cephalosporins are degraded by plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and not significantly hydrolyzed by these enzymes.1,4 Cefepime is also a poor inducer of type 1 beta-lactamases and, therefore, a good alternative against bacteria resistant to third-generation cephalosporins.1 \nIn animal models of infection, the time that the unbound plasma concentration of cefepime exceeds the minimum inhibitory concentration (MIC) of infecting organisms has been shown to correlate with treatment efficacy.5,6 It has been suggested that cefepime can cross the inflamed blood-brain barrier.5,6 This, along with its ability to inhibit -aminobutyric acid (GABA), could lead to the neurotoxic effects observed in some of the patients treated with cefepime.3,4\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Escherichia coli (strain K12)",
                "target": "APenicillin-binding protein 1A"
            },
            {
                "action": "inhibitor",
                "organism": "Escherichia coli (strain K12)",
                "target": "APenicillin-binding protein 1B"
            },
            {
                "action": "inhibitor",
                "organism": "Escherichia coli (strain K12)",
                "target": "APenicillin-binding protein 2"
            },
            {
                "action": "inhibitor",
                "organism": "Escherichia coli (strain K12)",
                "target": "APeptidoglycan synthase FtsI"
            },
            {
                "action": "inhibitor",
                "organism": "Pseudomonas aeruginosa",
                "target": "APenicillin-binding protein 1B"
            },
            {
                "action": "inhibitor",
                "organism": "Pseudomonas aeruginosa",
                "target": "APenicillin-binding protein 3"
            },
            {
                "action": "inhibitor",
                "organism": "Pseudomonas aeruginosa",
                "target": "UPenicillin-binding protein 2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11785"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05056"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14149"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00824"
    },
    {
        "smiles": "C[C@]12C[C@H](Cl)[C@@]3(Cl)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",
        "id": "DB13856",
        "molecule": "Fluclorolone",
        "cas": "3693-38-7",
        "iupac_name": "(1R,2S,8S,10S,11S,13R,14S,15S,17S)-1,17-dichloro-8-fluoro-13,14-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one",
        "inchi": {
            "hash": "VTWKPILBIUBMDS-OTJLYDAYSA-N",
            "id": "InChI=1S/C21H25Cl2FO5/c1-18-4-3-10(26)5-13(18)14(24)6-12-11-7-16(27)21(29,17(28)9-25)19(11,2)8-15(22)20(12,18)23/h3-5,11-12,14-16,25,27,29H,6-9H2,1-2H3/t11-,12-,14-,15-,16+,18-,19-,20-,21-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 447.32,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 446.1063075,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.",
        "link": "https://go.drugbank.com/drugs/DB13856",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC1=CC2=C(C=C1C)N=CN2",
        "id": "DB02591",
        "molecule": "5,6-Dimethylbenzimidazole",
        "cas": "582-60-5",
        "iupac_name": "5,6-dimethyl-1H-1,3-benzodiazole",
        "inchi": {
            "hash": "LJUQGASMPRMWIW-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H10N2/c1-6-3-8-9(4-7(6)2)11-5-10-8/h3-5H,1-2H3,(H,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 146.1891,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 146.08439833,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB02591",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UNicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase"
            }
        ]
    },
    {
        "smiles": "OC(=O)CC1=CC=C(C=C1)C1=CC=CC=C1",
        "id": "DB07477",
        "molecule": "Felbinac",
        "cas": "5728-52-9",
        "iupac_name": "2-{[1,1'-biphenyl]-4-yl}acetic acid",
        "inchi": {
            "hash": "QRZAKQDHEVVFRX-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 212.2439,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 212.083729628,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.",
        "link": "https://go.drugbank.com/drugs/DB07477",
        "type": "Small Molecule",
        "synonyms": [
            "Felbinac"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCathepsin L1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05120"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04204"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16935"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13611"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08161"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11886"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04555"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05169"
    },
    {
        "smiles": "COC1=CC=C(C=C1OC)C1=CC(=O)C2=C(O)C(OC)=C(O)C=C2O1",
        "id": "DB16885",
        "molecule": "Eupatilin",
        "cas": "22368-21-4",
        "iupac_name": "2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-methoxy-4H-chromen-4-one",
        "inchi": {
            "hash": "DRRWBCNQOKKKOL-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H16O7/c1-22-12-5-4-9(6-14(12)23-2)13-7-10(19)16-15(25-13)8-11(20)18(24-3)17(16)21/h4-8,20-21H,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 344.319,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 344.089602855,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16885",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08968"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00640"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03118"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07671"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01166"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01025"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08557"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15775"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13228"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01732"
    },
    {
        "smiles": "C[C@H](CCC(=O)N[C@@H](CCCCNC(=S)NC1=CC=C(C2C3=CC=C(O)C=C3OC3=C2C=CC(O)=C3)C(=C1)C(O)=O)C(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C",
        "id": "DB12030",
        "molecule": "Fluorescein lisicol",
        "cas": "140616-46-2",
        "iupac_name": "5-({[(5S)-5-carboxy-5-[(4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]pentyl]carbamothioyl}amino)-2-(3,6-dihydroxy-9H-xanthen-9-yl)benzoic acid",
        "background": "Fluorescein lisicol has been used in trials studying the diagnostic of Pharmacokinetics, Hepatic Cirrhosis, Hepatitis, Viral, Human, Nonalcoholic Steatohepatitis, and Non-Alcoholic Fatty Liver Disease.\n",
        "inchi": {
            "hash": "PVZRIVQDZVBHOW-TZCNZRNCSA-N",
            "id": "InChI=1S/C51H65N3O11S/c1-26(36-14-15-37-46-38(25-43(59)51(36,37)3)50(2)18-17-31(57)20-27(50)21-40(46)58)7-16-44(60)54-39(48(63)64)6-4-5-19-52-49(66)53-28-8-11-32(35(22-28)47(61)62)45-33-12-9-29(55)23-41(33)65-42-24-30(56)10-13-34(42)45/h8-13,22-24,26-27,31,36-40,43,45-46,55-59H,4-7,14-21,25H2,1-3H3,(H,54,60)(H,61,62)(H,63,64)(H2,52,53,66)/t26-,27+,31-,36-,37+,38+,39+,40-,43+,46+,50+,51-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 928.15,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 927.433981099,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glycinated bile acids and derivatives. These are compounds with a structure characterized by the presence of a glycine linked to a bile acid skeleton.",
        "link": "https://go.drugbank.com/drugs/DB12030",
        "type": "Small Molecule",
        "synonyms": [
            "Fluorescein lisicol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-]",
        "id": "DB12283",
        "molecule": "Balapiravir",
        "cas": "690270-29-2",
        "iupac_name": "[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-azido-3,4-bis[(2-methylpropanoyl)oxy]oxolan-2-yl]methyl 2-methylpropanoate",
        "background": "Balapiravir has been used in trials studying the treatment of Dengue and Hepatitis C, Chronic.\n",
        "inchi": {
            "hash": "VKXWOLCNTHXCLF-DXEZIKHYSA-N",
            "id": "InChI=1S/C21H30N6O8/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31)/t14-,15+,16-,21-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 494.505,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 494.21251195,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glycosylamines. These are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether).",
        "link": "https://go.drugbank.com/drugs/DB12283",
        "type": "Small Molecule",
        "synonyms": [
            "Balapiravir"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H]C([H])(C=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CO",
        "id": "DB08831",
        "molecule": "2-deoxyglucose",
        "cas": "154-17-6",
        "iupac_name": "(3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal",
        "background": "2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel). By using positron emission tomography (PET), radiolabelled 2-deoxyglucose can determine glucose metabolism, which is altered in diseases such as cardiovascular disease, tumors, and Alzheimer's disease. Therapeutically, 2-deoxyglucose is an investigational drug that is being studied as an anticancer and antiviral agent. Concerning the former, 2- deoxyglucose was used as an adjunct to chemotherapy and radiotherapy in the treatment of solid tumors (lung, breast, pancreas, head, neck, and gastric tumors). The exact mechanisms of action of 2-deoxyglucose is still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor that prevents ATP production and, ultimately, cell survival. With respect to antiviral therapy, 2-deoxyglucose was shown to be effective against herpes simplex virus by affecting the virus' ability to penetrate cells. As an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. In this condition, 2-deoxyglucose represses the expression of certain proteins that are at high levels after a seizure. Although there are several possible therapeutic indications for 2-deoxyglucose, presently there is no approved indication for 2-deoxyglucose as a therapeutic agent.\n",
        "inchi": {
            "hash": "VRYALKFFQXWPIH-PBXRRBTRSA-N",
            "id": "InChI=1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 164.1565,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 164.068473494,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fatty alcohols. These are aliphatic alcohols consisting of a chain of a least six carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB08831",
        "type": "Small Molecule",
        "synonyms": [
            "2-Deoxy-D-arabino-hexose",
            "2-deoxy-D-glucose",
            "2-DG",
            "D-arabino-2-desoxyhexose"
        ],
        "indication": "As of July 2013, there is no approved therapeutic indication for 2-deoxyglucose. 2-deoxyglucose may have several potential indications as an adjunct to chemotherapy and radiotherapy in the treatment of solid tumors, as an antiviral treatment in herpes simplex patients, and as an antiepileptic in temporal lobe epilepsy patients.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Physiologically 2-deoxyglucose is an inhibitor of glycolysis, certain viruses, and seizures. \n"
    },
    {
        "smiles": "CC(C)N(C(=O)C1=C(Cl)C=C(Cl)C=C1)C1=C(SC(=C1)C1=CC=CC=C1)C(O)=O",
        "id": "DB03388",
        "molecule": "3-[(2,4-Dichlorobenzoyl)(Isopropyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid",
        "iupac_name": "5-phenyl-3-[N-(propan-2-yl)2,4-dichlorobenzamido]thiophene-2-carboxylic acid",
        "inchi": {
            "hash": "UKNZREOUDLFUFF-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H17Cl2NO3S/c1-12(2)24(20(25)15-9-8-14(22)10-16(15)23)17-11-18(28-19(17)21(26)27)13-6-4-3-5-7-13/h3-12H,1-2H3,(H,26,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 434.336,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 433.030619519,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB03388",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGenome polyprotein"
            }
        ]
    },
    {
        "smiles": "[H]\\C(C)=C(\\[H])/C(/[H])=C(\\[H])C1OC(O)(C(CC)C(O)=NC\\C([H])=C(/[H])\\C(\\[H])=C(/C)C(OC)C(C)C2OC(\\C([H])=C(/[H])\\C(\\[H])=C(/[H])C([H])=C(C)C(\\O)=C3\\C(=O)C=CN(C)C3=O)C(O)C2O)C(O)C(OC2OC(C)C(OC3OC(C)C(OC)C(O)C3OC)C(OC)C2O)C1(C)C",
        "id": "DB11401",
        "molecule": "Efrotomycin",
        "iupac_name": "2-[2,3-dihydroxy-4-({3-hydroxy-5-[(4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-5,5-dimethyl-6-[(1E,3E)-penta-1,3-dien-1-yl]oxan-2-yl]-N-[(2E,4E)-7-{3,4-dihydroxy-5-[(1E,3E,5E)-7-hydroxy-6-methyl-7-[(3Z)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyridin-3-ylidene]hepta-1,3,5-trien-1-yl]oxolan-2-yl}-6-methoxy-5-methylocta-2,4-dien-1-yl]butanimidic acid",
        "inchi": {
            "hash": "ZLECMEJICSWJLT-LIWMBINXSA-N",
            "id": "InChI=1S/C59H88N2O20/c1-15-17-19-27-39-58(8,9)53(80-56-45(67)50(74-13)49(35(7)76-56)79-57-51(75-14)44(66)48(73-12)34(6)77-57)52(68)59(71,81-39)36(16-2)54(69)60-29-23-22-25-32(4)46(72-11)33(5)47-43(65)42(64)38(78-47)26-21-18-20-24-31(3)41(63)40-37(62)28-30-61(10)55(40)70/h15,17-28,30,33-36,38-39,42-53,56-57,63-68,71H,16,29H2,1-14H3,(H,60,69)/b17-15+,20-18+,23-22+,26-21+,27-19+,31-24+,32-25+,41-40+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1145.347,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1144.593043242,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB11401",
        "type": "Small Molecule",
        "synonyms": [
            "Efrotomycin"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O",
        "id": "DB01842",
        "molecule": "3'-Phosphate-Adenosine-5'-Diphosphate",
        "iupac_name": "[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]phosphonic acid",
        "inchi": {
            "hash": "GBBWIZKLHXYJOA-KQYNXXCUSA-N",
            "id": "InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7(27-29(17,18)19)4(26-10)1-25-31(23,24)28-30(20,21)22/h2-4,6-7,10,16H,1H2,(H,23,24)(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 507.181,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 506.995745159,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB01842",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URibonuclease pancreatic"
            },
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UAminoglycoside 2'-N-acetyltransferase"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(C)CN=C(N)C2=C(O1)C=CS2",
        "id": "DB07003",
        "molecule": "(2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine",
        "iupac_name": "(2S)-2-methyl-2H,3H-thieno[2,3-f][1,4]oxazepin-5-amine",
        "inchi": {
            "hash": "TUOXPJFCQDMQOX-YFKPBYRVSA-N",
            "id": "InChI=1S/C8H10N2OS/c1-5-4-10-8(9)7-6(11-5)2-3-12-7/h2-3,5H,4H2,1H3,(H2,9,10)/t5-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 182.243,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 182.051383642,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl aryl ethers. These are organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB07003",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNitric oxide synthase, inducible"
            }
        ]
    },
    {
        "smiles": "[H]N1C=C(C2=CC=CC=C12)C1=C(C(=O)N([H])C1=O)C1=CN(CC[C@@H]2CCCN2C)C2=CC=CC=C12",
        "id": "DB07458",
        "molecule": "3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione",
        "iupac_name": "5-hydroxy-4-(1H-indol-3-yl)-3-(1-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1H-indol-3-yl)-2H-pyrrol-2-one",
        "inchi": {
            "hash": "LBFDERUQORUFIN-KRWDZBQOSA-N",
            "id": "InChI=1S/C27H26N4O2/c1-30-13-6-7-17(30)12-14-31-16-21(19-9-3-5-11-23(19)31)25-24(26(32)29-27(25)33)20-15-28-22-10-4-2-8-18(20)22/h2-5,8-11,15-17,28H,6-7,12-14H2,1H3,(H,29,32,33)/t17-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 438.5209,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 438.205576096,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB07458",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UcAMP-dependent protein kinase catalytic subunit alpha"
            }
        ]
    },
    {
        "smiles": "[NH3+]CCCCCCCCNC1=C2CCCCC2=[NH+]C2=CC=CC=C12",
        "id": "DB04617",
        "molecule": "(9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM",
        "iupac_name": "9-[(8-azaniumyloctyl)amino]-1,2,3,4-tetrahydroacridin-10-ium",
        "inchi": {
            "hash": "LFBAUYQQFKFFCF-UHFFFAOYSA-P",
            "id": "InChI=1S/C21H31N3/c22-15-9-3-1-2-4-10-16-23-21-17-11-5-7-13-19(17)24-20-14-8-6-12-18(20)21/h5,7,11,13H,1-4,6,8-10,12,14-16,22H2,(H,23,24)/p+2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 327.5068,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 327.267448071,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring.",
        "link": "https://go.drugbank.com/drugs/DB04617",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAcetylcholinesterase"
            }
        ]
    },
    {
        "smiles": "[Fe+3].CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1",
        "id": "DB15598",
        "molecule": "Ferric maltol",
        "cas": "33725-54-1",
        "iupac_name": "iron(3+) tris(2-methyl-4-oxo-4H-pyran-3-olate)",
        "background": "Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate.1 Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.2\nFerric maltol was granted FDA Approval on 25 July 2019.7\n",
        "inchi": {
            "hash": "AHPWLYJHTFAWKI-UHFFFAOYSA-K",
            "id": "InChI=1S/3C6H6O3.Fe/c3*1-4-6(8)5(7)2-3-9-4;/h3*2-3,8H,1H3;/q;;;+3/p-3"
        },
        "summary": "Ferric maltol is a complexed iron supplement used to treat iron deficiency in adults.",
        "weight": [
            {
                "type": "average",
                "weight": 431.154,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 431.006543,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15598",
        "type": "Small Molecule",
        "synonyms": [
            "Ferric maltol",
            "Iron (III) maltol"
        ],
        "indication": "Ferric maltol is indicated to treat iron deficiency in adults.7\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Ferric maltol is used to provide supplemental iron to patients with an iron deficiency.7 It has a wide therapeutic index as patients generally take 30mg twice daily, while concentrations of 20mg/kg may produce toxicity.7 Patients should be counselled regarding the risk of inflammatory bowel disease flares, iron overload, and accidental ingestion in children.7\n",
        "moa": [
            {
                "action": "substrate",
                "organism": "Humans",
                "target": "UIntegrin beta-3"
            },
            {
                "action": "substrate",
                "organism": "Humans",
                "target": "UNatural resistance-associated macrophage protein 2"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CC1=CNC=N1)C(O)=O",
        "id": "DB00117",
        "molecule": "Histidine",
        "cas": "71-00-1",
        "iupac_name": "(2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid",
        "background": "An essential amino acid that is required for the production of histamine.\n",
        "inchi": {
            "hash": "HNDVDQJCIGZPNO-YFKPBYRVSA-N",
            "id": "InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1"
        },
        "summary": "Histidine is an amino acid commonly found as a component of total parenteral nutrition.",
        "weight": [
            {
                "type": "average",
                "weight": 155.1546,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 155.069476547,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as histidine and derivatives. These are compounds containing cysteine or a derivative thereof resulting from reaction of cysteine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB00117",
        "type": "Small Molecule",
        "synonyms": [
            "(S)-4-(2-Amino-2-carboxyethyl)imidazole",
            "(S)-a-Amino-1H-imidazole-4-propanoic acid",
            "(S)-alpha-amino-1H-Imidazole-4-propanoic acid",
            "(S)-alpha-Amino-1H-imidazole-4-propionic acid",
            "(S)--amino-1H-Imidazole-4-propanoic acid",
            "HIS",
            "Histidina",
            "Histidine",
            "L-()-histidine",
            "L-Histidin",
            "L-Histidine"
        ],
        "indication": "The actions of supplemental L-histidine are entirely unclear. It may have some immunomodulatory as well as antioxidant activity. L-histidine may be indicated for use in some with rheumatoid arthritis. It is not indicated for treatment of anemia or uremia or for lowering serum cholesterol.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHistidine decarboxylase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHistidine--tRNA ligase, cytoplasmic"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USodium-coupled neutral amino acid transporter 3"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHistidine ammonia-lyase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4",
        "id": "DB06697",
        "molecule": "Artemether",
        "cas": "71963-77-4",
        "iupac_name": "(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane",
        "background": "Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.\n",
        "inchi": {
            "hash": "SXYIRMFQILZOAM-HVNFFKDJSA-N",
            "id": "InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1"
        },
        "summary": "Artemether is an antimalarial agent used in combination with lumefantrine for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum.",
        "weight": [
            {
                "type": "average",
                "weight": 298.3746,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 298.178023942,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as artemisinins. These are sesquiterpenoids originally isolated from the herb Artemisia annua. Their structure is based on artemisinin, a tetracyclic compound that contains a 1,2-dioxepane fused to an octahydrobenzopyran moiety. The internal peroxide bridge is believed to be a key to the mode of action of artemisinins.",
        "link": "https://go.drugbank.com/drugs/DB06697",
        "type": "Small Molecule",
        "synonyms": [
            "(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane",
            "10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane",
            "Artemetero",
            "Artemether",
            "Artemetherum",
            "Artemisininelactol methyl ether",
            "Dihydroartemisinin methyl ether",
            "Dihydroqinghaosu methyl ether",
            "methyl-dihydroartemisinine",
            "-artemether",
            "-dihydroartemisinin methyl ether"
        ],
        "indication": "Artemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "In the body, artemether is metabolized into the active metabolite metabolite dihydroartemisinin. The drug works against the erythrocytic stages of P. falciparum by inhibiting nucleic acid and protein synthesis. Artemether is administered in combination with lumefantrine for improved efficacy. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thought that artemether provides rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites. \n"
    },
    {
        "smiles": "CC(=O)OC1=CC=CC(C(O)=O)=C1OC(C)=O",
        "id": "DB13839",
        "molecule": "Dipyrocetyl",
        "cas": "486-79-3",
        "iupac_name": "2,3-bis(acetyloxy)benzoic acid",
        "inchi": {
            "hash": "NYIZXMGNIUSNKL-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H10O6/c1-6(12)16-9-5-3-4-8(11(14)15)10(9)17-7(2)13/h3-5H,1-2H3,(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 238.195,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 238.047738042,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylsalicylic acids. These are o-acylated derivatives of salicylic acid.",
        "link": "https://go.drugbank.com/drugs/DB13839",
        "type": "Small Molecule",
        "synonyms": [
            "Dipyrocetyl"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC1=CC=CC(Cl)=C1",
        "id": "DB01957",
        "molecule": "3-Chlorophenol",
        "cas": "108-43-0",
        "iupac_name": "3-chlorophenol",
        "inchi": {
            "hash": "HORNXRXVQWOLPJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H5ClO/c7-5-2-1-3-6(8)4-5/h1-4,8H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 128.556,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 128.002892489,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as m-chlorophenols. These are chlorophenols carrying a iodine at the C3 position of the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB01957",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Enterobacteria phage T4",
                "target": "ULysozyme"
            }
        ]
    },
    {
        "smiles": "OC(CNCCNC(=O)CC1=CC=C(O)C=C1)COC1=CC=CC=C1C#N",
        "id": "DB13757",
        "molecule": "Epanolol",
        "cas": "86880-51-5",
        "iupac_name": "N-(2-{[3-(2-cyanophenoxy)-2-hydroxypropyl]amino}ethyl)-2-(4-hydroxyphenyl)acetamide",
        "background": "Epanolol is an beta blocker.\n",
        "inchi": {
            "hash": "YARKMNAWFIMDKV-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H23N3O4/c21-12-16-3-1-2-4-19(16)27-14-18(25)13-22-9-10-23-20(26)11-15-5-7-17(24)8-6-15/h1-8,18,22,24-25H,9-11,13-14H2,(H,23,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 369.421,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 369.168856233,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB13757",
        "type": "Small Molecule",
        "synonyms": [
            "Epanolol"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]2([H])F)[C@]([H])(O)[C@@]1([H])O",
        "id": "DB04155",
        "molecule": "2-Fluoro-2-Deoxy-Beta-D-Galactopyranosyl-Beta-D-Glucopyranose",
        "iupac_name": "(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-3-fluoro-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol",
        "inchi": {
            "hash": "KWMZPXRIEZDXAQ-QRZGKKJRSA-N",
            "id": "InChI=1S/C12H21FO10/c13-5-7(17)6(16)3(1-14)22-12(5)23-10-4(2-15)21-11(20)9(19)8(10)18/h3-12,14-20H,1-2H2/t3-,4-,5-,6+,7-,8-,9-,10-,11-,12+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 344.2875,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 344.111875097,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB04155",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-galactosidase"
            }
        ]
    },
    {
        "smiles": "C[C@H](O)C[NH3+]",
        "id": "DB02576",
        "molecule": "F-Loop of Vitamin B12",
        "cas": "78-96-6",
        "iupac_name": "(2S)-2-hydroxypropan-1-aminium",
        "inchi": {
            "hash": "HXKKHQJGJAFBHI-VKHMYHEASA-O",
            "id": "InChI=1S/C3H9NO/c1-3(5)2-4/h3,5H,2,4H2,1H3/p+1/t3-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 76.1176,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 76.076238947,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.",
        "link": "https://go.drugbank.com/drugs/DB02576",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Clostridium tetanomorphum",
                "target": "UMethylaspartate mutase S chain"
            }
        ]
    },
    {
        "smiles": "NC1=NC(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)=NC(=C1)N1CCN(CCP(O)(O)=O)CC1",
        "id": "DB11970",
        "molecule": "Burixafor",
        "cas": "1191448-17-5",
        "iupac_name": "(2-{4-[6-amino-2-({[(1r,4r)-4-({[3-(cyclohexylamino)propyl]amino}methyl)cyclohexyl]methyl}amino)pyrimidin-4-yl]piperazin-1-yl}ethyl)phosphonic acid",
        "background": "Burixafor has been used in trials studying the treatment of Multiple Myeloma, Hodgkin's Disease, and Non-hodgkin's Lymphoma.\n",
        "inchi": {
            "hash": "QLVSJMZJSABWRX-YHBQERECSA-N",
            "id": "InChI=1S/C27H51N8O3P/c28-25-19-26(35-15-13-34(14-16-35)17-18-39(36,37)38)33-27(32-25)31-21-23-9-7-22(8-10-23)20-29-11-4-12-30-24-5-2-1-3-6-24/h19,22-24,29-30H,1-18,20-21H2,(H2,36,37,38)(H3,28,31,32,33)/t22-,23-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 566.732,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 566.382174532,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB11970",
        "type": "Small Molecule",
        "synonyms": [
            "Burixafor"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCC\\C=C/CCCCCCCC(=O)OCC(COC(=O)CCCCCCC\\C=C/CCCCCCCC)OC(=O)CCCCCCC\\C=C/CCCCCCCC",
        "id": "DB13038",
        "molecule": "Glyceryl Trioleate",
        "cas": "122-32-7",
        "iupac_name": "1,3-bis[(9Z)-octadec-9-enoyloxy]propan-2-yl (9Z)-octadec-9-enoate",
        "background": "Glyceryl Trioleate has been investigated for the treatment of Adrenoleukodystrophy.\n",
        "inchi": {
            "hash": "PHYFQTYBJUILEZ-IUPFWZBJSA-N",
            "id": "InChI=1S/C57H104O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-55(58)61-52-54(63-57(60)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)53-62-56(59)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h25-30,54H,4-24,31-53H2,1-3H3/b28-25-,29-26-,30-27-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 885.4321,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 884.78329106,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as triacylglycerols. These are glycerides consisting of three fatty acid chains covalently bonded to a glycerol molecule through ester linkages.",
        "link": "https://go.drugbank.com/drugs/DB13038",
        "type": "Small Molecule",
        "synonyms": [
            "Triolein"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=C2N(C)C(=O)C=C(C)C2=C(OC)C=C1",
        "id": "DB08228",
        "molecule": "5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one",
        "iupac_name": "5,8-dimethoxy-1,4-dimethyl-1,2-dihydroquinolin-2-one",
        "inchi": {
            "hash": "FTGZPMFPUDKJBX-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H15NO3/c1-8-7-11(15)14(2)13-10(17-4)6-5-9(16-3)12(8)13/h5-7H,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 233.2631,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 233.105193351,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroquinolones. These are compounds containing a hydrogenated quinoline bearing a ketone group.",
        "link": "https://go.drugbank.com/drugs/DB08228",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URibosyldihydronicotinamide dehydrogenase [quinone]"
            }
        ]
    },
    {
        "smiles": "[O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1",
        "id": "DB11989",
        "molecule": "Benznidazole",
        "cas": "22994-85-0",
        "iupac_name": "N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide",
        "background": "Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.9 It is the first treatment made available in the United States for Chagas disease.\n",
        "inchi": {
            "hash": "CULUWZNBISUWAS-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)"
        },
        "summary": "Benznidazole is a trypanocidal agent used to treat Chagas disease.",
        "weight": [
            {
                "type": "average",
                "weight": 260.253,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 260.090940262,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitroaromatic compounds. These are c-nitro compounds where the nitro group is C-substituted with an aromatic group.",
        "link": "https://go.drugbank.com/drugs/DB11989",
        "type": "Small Molecule",
        "synonyms": [
            "Benznidazol",
            "Benznidazole",
            "Benznidazolum"
        ],
        "indication": "For use in the treatment of Chagas disease in children 2-12 years of age 9.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Benznidazole is a trypanocidal agent which kills the causative organism in Chagas disease, Trypanosoma cruzi 1.\n"
    },
    {
        "smiles": "BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1",
        "id": "DB01558",
        "molecule": "Bromazepam",
        "cas": "1812-30-2",
        "iupac_name": "7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one",
        "background": "One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.\n",
        "inchi": {
            "hash": "VMIYHDSEFNYJSL-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)"
        },
        "summary": "Bromazepam is a short-acting benzodiazepine with intermediate onset commonly used to treat panic disorders and severe anxiety.",
        "weight": [
            {
                "type": "average",
                "weight": 316.153,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 315.000724604,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.",
        "link": "https://go.drugbank.com/drugs/DB01558",
        "type": "Small Molecule",
        "synonyms": [
            "Bromacepam",
            "Bromazepam",
            "Bromazepamum"
        ],
        "indication": "For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.\n",
        "moa": [
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "AGABA(A) Receptor Benzodiazepine Binding Site"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07516"
    },
    {
        "smiles": "CCNCCCCNCCCCNCCCCNCC",
        "id": "DB13011",
        "molecule": "Diethylhomospermine",
        "cas": "119422-08-1",
        "iupac_name": "3,8,13,18-tetraazaicosane",
        "background": "Diethylhomospermine has been used in trials studying the treatment of Diarrhea and HIV Infections.\n",
        "inchi": {
            "hash": "QXOCYGPVDXDFLC-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H38N4/c1-3-17-11-5-7-13-19-15-9-10-16-20-14-8-6-12-18-4-2/h17-20H,3-16H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 286.508,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 286.30964724,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dialkylamines. These are organic compounds containing a dialkylamine group, characterized by two alkyl groups bonded to the amino nitrogen.",
        "link": "https://go.drugbank.com/drugs/DB13011",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12",
        "id": "DB09084",
        "molecule": "Benzydamine",
        "cas": "642-72-8",
        "iupac_name": "{3-[(1-benzyl-1H-indazol-3-yl)oxy]propyl}dimethylamine",
        "background": "Benzydamine (also known as Tantum Verde or Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties. It is used topically for pain relief and anti-inflammatory treatment of the mouth, throat, or muscoskeletal system.\nAlthough the indazole analogue benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but facilitate benzydamine's mechanism of action as an effective locally-acting NSAID with local anaesthetic and analgesic properties. Moreover, unlike aspirin-like NSAIDs which are acids or metabolised to acids, benzydamine is in fact a weak base.\n",
        "inchi": {
            "hash": "CNBGNNVCVSKAQZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3"
        },
        "summary": "Benzydamine is a locally-acting NSAID indicated for the symptomatic relief of pain in acute sore throat and for the symptomatic relief of oropharyngeal mucositis caused by radiation therapy.",
        "weight": [
            {
                "type": "average",
                "weight": 309.413,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 309.184112373,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.",
        "link": "https://go.drugbank.com/drugs/DB09084",
        "type": "Small Molecule",
        "synonyms": [
            "Bencidamina",
            "Benzydamine",
            "Benzydaminum"
        ],
        "indication": "Available predominantly as a liquid mouthwash, oromucosal spray, or topical cream, benzydamine is most frequently employed as a locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions. \nWhen formulated as a mouthwash or spray, benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a naso-gastric tube, inflammatory conditions like pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy, dentistry operations and procedures, or more general conditions like sore throat, sore tongue, sore gums, mouth ulcers, or discomfort caused by dentures. 6 \nWhen used as a topical cream, benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscolo-skeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains, strains, bruises, sore muscles, stiff joints, or even the after-effects of fractures. 7\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) designed to elicit local anesthetic and analgesic effects mainly for the mouth and throat. It specifically acts on the local mechanisms of inflammation such as pain, oedema, or granuloma. Typically applied topically, the drug demonstrates anti-inflammatory activity reducing oedema as well as exudate and granuloma formation. Moreover, benzydamine exhibits analgesic properties and local anaesthetic activity if pain is caused by an inflammatory condition. Benzydamine can be absorbed into the oral mucosa and intact skin. Once absorbed in the local area of pain or inflammation, benzydamine binds selectively to local inflamed tissues, usually allowing it to act with few adverse systemic effects. On average a period of 2 to 4 hours is necessary for the substance to reach peak plasma concentration. 5\nBenzydamine can be synthesized with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give N-nitoso derivative. This is next reduced by sodium thiosulfate to give transient hydrazine. This hydrazine can then undergo spontaneous internal hydrazide formation. Treating this resultant enolate with 3-chloro-1-dimethylamkino propane ultimately yields benzydamine.\n"
    },
    {
        "smiles": "NC(=O)C[C@@H]1NC(=O)C2(CCCCC2)NC(=O)C[C@H](\\C=C\\C[C@H](CNC1=O)CC1=CC=CC2=CC=CC=C12)C1=CC=C(C=C1)CP(O)(O)=O",
        "id": "DB03276",
        "molecule": "4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid",
        "iupac_name": "({4-[(10R,11E,14S,18S)-18-(carbamoylmethyl)-14-[(naphthalen-1-yl)methyl]-8,17,20-trioxo-7,16,19-triazaspiro[5.14]icos-11-en-10-yl]phenyl}methyl)phosphonic acid",
        "inchi": {
            "hash": "RHYFMOCFCFUTNH-GZNVFMSSSA-N",
            "id": "InChI=1S/C37H45N4O7P/c38-33(42)22-32-35(44)39-23-26(20-30-12-7-10-28-9-2-3-13-31(28)30)8-6-11-29(27-16-14-25(15-17-27)24-49(46,47)48)21-34(43)41-37(36(45)40-32)18-4-1-5-19-37/h2-3,6-7,9-17,26,29,32H,1,4-5,8,18-24H2,(H2,38,42)(H,39,44)(H,40,45)(H,41,43)(H2,46,47,48)/b11-6+/t26-,29-,32-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 688.7496,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 688.302586326,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.",
        "link": "https://go.drugbank.com/drugs/DB03276",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGrowth factor receptor-bound protein 2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00538"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11217"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08731"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15778"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15972"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01164"
    },
    {
        "smiles": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB01185",
        "molecule": "Fluoxymesterone",
        "cas": "76-43-7",
        "iupac_name": "(1S,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-1,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one",
        "background": "An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.\n",
        "inchi": {
            "hash": "YLRFCQOZQXIBAB-RBZZARIASA-N",
            "id": "InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1"
        },
        "summary": "Fluoxymesterone is a synthetic androgenic anabolic steroid that used in the treatment of hypogonadism and delayed puberty in males, as well as breast neoplasms in women.",
        "weight": [
            {
                "type": "average",
                "weight": 336.4409,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 336.210072999,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.",
        "link": "https://go.drugbank.com/drugs/DB01185",
        "type": "Small Molecule",
        "synonyms": [
            "11,17-Dihydroxy-9-fluoro-17-methyl-4-androster-3-one",
            "17-Methyl-9-fluoro-11-hydroxytesterone",
            "9-Fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one",
            "9-Fluoro-11-hydroxy-17-methyltestosterone",
            "Fluoximesterona",
            "Fluoxymesterone",
            "Fluoxymestrone",
            "Fluoxymesteronum"
        ],
        "indication": "In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fluoxymesterone is a synthetic androgen, or male hormone, similar to testosterone. Fluoxymesterone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AAndrogen receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AEstrogen receptor alpha"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlucocorticoid receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 2"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O",
        "id": "DB00956",
        "molecule": "Hydrocodone",
        "cas": "125-29-1",
        "iupac_name": "(1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one",
        "background": "Hydrocodone is a synthetic opioid derivative of codeine.14 It is commonly used in combination with acetaminophen to control moderate to severe pain. Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by dextromethorphan in current cough and cold formulations. Hydrocodone's more potent metabolite, hydromorphone has also found wide use as an analgesic and is frequently used in cases of severe pain. The FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.17\n",
        "inchi": {
            "hash": "LLPOLZWFYMWNKH-CMKMFDCUSA-N",
            "id": "InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1"
        },
        "summary": "Hydrocodone is an opioid agonist used as an analgesic and antitussive agent.",
        "weight": [
            {
                "type": "average",
                "weight": 299.3642,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 299.152143543,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.",
        "link": "https://go.drugbank.com/drugs/DB00956",
        "type": "Small Molecule",
        "synonyms": [
            "(-)-Dihydrocodeinone",
            "4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one",
            "Dihydrocodeinone",
            "Hidrocodona",
            "Hydrocodon",
            "Hydrocodone",
            "Hydrocodonum",
            "Hydrocone",
            "Hydroconum",
            "Idrocodone"
        ],
        "indication": "Hydrocodone is indicated for the management of acute pain, sometimes in combination with acetaminophen or ibuprofen, as well as the symptomatic treatment of the common cold and allergic rhinitis in combination with decongestants, antihistamines, and expectorants.Label,16\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocodone inhibits pain signaling in both the spinal cord and brain 12. Its actions in the brain also produce euphoria, respiratory depression, and sedation.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AMu-type opioid receptor"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ADelta-type opioid receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "USigma non-opioid intracellular receptor 1"
            }
        ]
    },
    {
        "smiles": "OC(=O)CCCCCCCC(O)=O",
        "id": "DB00548",
        "molecule": "Azelaic acid",
        "cas": "123-99-9",
        "iupac_name": "nonanedioic acid",
        "background": "Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is also produced by Malassezia furfur, also known as Pityrosporum ovale, which is a species of fungus that is normally found on human skin. Azelaic acid is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%. It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear. Azelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis.\n",
        "inchi": {
            "hash": "BDJRBEYXGGNYIS-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)"
        },
        "summary": "Azelaic acid is a saturated dicarboxylic acid used to treat mild to moderate acne vulgaris.",
        "weight": [
            {
                "type": "average",
                "weight": 188.2209,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 188.104859,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB00548",
        "type": "Small Molecule",
        "synonyms": [
            "1,7-dicarboxyheptane",
            "1,7-Heptanedicarboxylic acid",
            "1,9-nonanedioic acid",
            "Acide azlaque",
            "cido azelaico",
            "Acidum acelaicum",
            "Acidum azelaicum",
            "Anchoic acid",
            "Azelaic acid",
            "Azelainsure",
            "Lepargylic acid",
            "n-nonanedioic acid",
            "Nonandisure",
            "Nonanedioic acid"
        ],
        "indication": "For the topical treatment of mild-to-moderate inflammatory acne vulgaris.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is a natural substance that is produced by Malassezia furfur (also known as Pityrosporum ovale), a yeast that lives on normal skin. It is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%. It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear. Azelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Staphylococcus aureus (strain Mu50 / ATCC 700699)",
                "target": "AThioredoxin reductase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "A3-oxo-5-beta-steroid 4-dehydrogenase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "A3-oxo-5-alpha-steroid 4-dehydrogenase 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ATyrosinase"
            },
            {
                "action": "inhibitor",
                "organism": "Escherichia coli (strain K12)",
                "target": "ADNA polymerase I"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04009"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17121"
    },
    {
        "smiles": "[H][C@](CCCCC(N)=N)(C(O)=O)[C@@]1([H])C2=C(C[C@]1([H])O)C=CC(=C2)C1=CC=C(O)C=C1",
        "id": "DB06865",
        "molecule": "6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID",
        "iupac_name": "(2R)-6-carbamimidoyl-2-[(1S,2S)-2-hydroxy-6-(4-hydroxyphenyl)-2,3-dihydro-1H-inden-1-yl]hexanoic acid",
        "inchi": {
            "hash": "ZSRRBAKATXAISL-LMNJBCLMSA-N",
            "id": "InChI=1S/C22H26N2O4/c23-20(24)4-2-1-3-17(22(27)28)21-18-11-14(5-6-15(18)12-19(21)26)13-7-9-16(25)10-8-13/h5-11,17,19,21,25-26H,1-4,12H2,(H3,23,24)(H,27,28)/t17-,19+,21+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 382.4528,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 382.18925733,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB06865",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "OC(=O)CCCCCCCCCCCBr",
        "id": "DB02405",
        "molecule": "12-Bromododecanoic Acid",
        "cas": "73367-80-3",
        "iupac_name": "12-bromododecanoic acid",
        "inchi": {
            "hash": "YYKBWYBUCFHYPR-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H23BrO2/c13-11-9-7-5-3-1-2-4-6-8-10-12(14)15/h1-11H2,(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 279.214,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 278.088142627,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB02405",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycodelin"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12[C@@H](O)[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H]",
        "id": "DB12235",
        "molecule": "Estetrol",
        "cas": "15183-37-6",
        "iupac_name": "(1R,2R,3R,3aS,3bR,9bS,11aS)-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,2,3,7-tetrol",
        "background": "Naturally or synthetically produced steroid estrogens have a wide range of pharmaceutical uses ranging from hormonal contraception to the treatment of menopausal symptoms.15 Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception.14 It is more potent and is safer than the synthetic estrogen ethinylestradiol (EE2) found in 97% of oral contraceptive pills, reducing the environmental accumulation of unwanted endocrine disrupting chemicals (EDCs) that often lead to harmful epigenetic effects.15 \nOn April 15 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals were granted FDA approval for the oral contraceptive Estelle/Nextstellis, a combination of drospirenone and estetrol. Estetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. The combination of drospirenone and estetrol offers a new choice with a favourable safety profile for women seeking contraceptive therapy.14 In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.18\n",
        "inchi": {
            "hash": "AJIPIJNNOJSSQC-NYLIRDPKSA-N",
            "id": "InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1"
        },
        "summary": "Estetrol is an estrogen used in combination with drospirenone for oral contraception.",
        "weight": [
            {
                "type": "average",
                "weight": 304.3808,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 304.167459256,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.",
        "link": "https://go.drugbank.com/drugs/DB12235",
        "type": "Small Molecule",
        "synonyms": [
            "15-hydroxyestriol",
            "Estetrol",
            "Esttrol",
            "Estetrolum",
            "Oestetrol"
        ],
        "indication": "Estetrol is indicated in combination with drospirenone for the prevention of pregnancy.13\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Estetrol prevents pregnancy by suppressing ovulation.9,13 \n",
        "moa": [
            {
                "action": "agonistmodulatorregulator",
                "organism": "Humans",
                "target": "UEstrogen receptor alpha"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UEstrogen receptor beta"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04890"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02602"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16756"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14965"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15596"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08125"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03727"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06111"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02550"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11919"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03742"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03274"
    },
    {
        "smiles": "CCOC(=O)CO\\N=C(\\C1=CC=CC=N1)C1(CC1)C1=CC=C2N(C)C(CNC3=CC=C(C=C3)C(N)=N)=NC2=C1",
        "id": "DB04107",
        "molecule": "[(1-{2[(4-Carbamimidoyl-Phenylamino)-Methyl]-1-Methyl-1h-Benzoimidazol-5-Yl}-Cyclopropyl)-Pyridin-2-Yl-Methyleneaminooxy]-Acetic Acid Ethyl Ester",
        "iupac_name": "ethyl 2-{[(E)-{[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)cyclopropyl](pyridin-2-yl)methylidene}amino]oxy}acetate",
        "inchi": {
            "hash": "RNOYCNIZOAIUSV-LSWMGQQCSA-N",
            "id": "InChI=1S/C29H31N7O3/c1-3-38-26(37)18-39-35-27(22-6-4-5-15-32-22)29(13-14-29)20-9-12-24-23(16-20)34-25(36(24)2)17-33-21-10-7-19(8-11-21)28(30)31/h4-12,15-16,33H,3,13-14,17-18H2,1-2H3,(H3,30,31)/b35-27-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 525.6015,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 525.248837893,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).",
        "link": "https://go.drugbank.com/drugs/DB04107",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03522"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03927"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02527"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01321"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08075"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12156"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02842"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06634"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03213"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04599"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15777"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08555"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11149"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12752"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00527"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02377"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04289"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12370"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05352"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03797"
    },
    {
        "smiles": "CNC(=O)C1=C(OC2=C1C(F)=C(C=C2)C1=C(C)C=CC(=C1)C(=O)NC1(CC1)C1=NC=CC=N1)C1=CC=C(F)C=C1",
        "id": "DB14950",
        "molecule": "BMS-929075",
        "cas": "1217338-97-0",
        "iupac_name": "4-fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-{[1-(pyrimidin-2-yl)cyclopropyl]carbamoyl}phenyl)-1-benzofuran-3-carboxamide",
        "background": "BMS-929075 is under investigation in clinical trial NCT01525212 (Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients).\n",
        "inchi": {
            "hash": "LZAUGCMVNLZVJV-UHFFFAOYSA-N",
            "id": "InChI=1S/C31H24F2N4O3/c1-17-4-5-19(28(38)37-31(12-13-31)30-35-14-3-15-36-30)16-22(17)21-10-11-23-24(26(21)33)25(29(39)34-2)27(40-23)18-6-8-20(32)9-7-18/h3-11,14-16H,12-13H2,1-2H3,(H,34,39)(H,37,38)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 538.555,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 538.181646975,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14950",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(OB(O[C@]1([H])[C@H](O)CO)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)[C@H](O)CO",
        "id": "DB16741",
        "molecule": "Bortezomib D-mannitol",
        "cas": "444576-08-3",
        "iupac_name": "(2S)-N-[(1R)-1-[(4R,5R)-4,5-bis[(1R)-1,2-dihydroxyethyl]-1,3,2-dioxaborolan-2-yl]-3-methylbutyl]-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamide",
        "inchi": {
            "hash": "QDMRNLRJDHCHLB-DNNBANOASA-N",
            "id": "InChI=1S/C25H35BN4O8/c1-15(2)10-21(26-37-22(19(33)13-31)23(38-26)20(34)14-32)30-24(35)17(11-16-6-4-3-5-7-16)29-25(36)18-12-27-8-9-28-18/h3-9,12,15,17,19-23,31-34H,10-11,13-14H2,1-2H3,(H,29,36)(H,30,35)/t17-,19+,20+,21-,22+,23+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 530.39,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 530.254794,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16741",
        "type": "Small Molecule",
        "synonyms": [
            "Bortezomib D-mannitol ester",
            "Bortezomib D-mannitol symmetrical ester",
            "Bortezomib mannitol boronic ester"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](NC1=C(C=O)C=C2C=CC=CN12)(C(O)=O)[C@](C)(COC(=O)CC1=CC(O)=C(O)C=C1)[S@](O)=O",
        "id": "DB08116",
        "molecule": "(3R)-4-{[(3,4-dihydroxyphenyl)acetyl]oxy}-N-(2-formylindolizin-3-yl)-3-sulfino-D-valine",
        "iupac_name": "(2S,3R)-4-{[2-(3,4-dihydroxyphenyl)acetyl]oxy}-2-[(2-formylindolizin-3-yl)amino]-3-methyl-3-[(S)-sulfino]butanoic acid",
        "inchi": {
            "hash": "DEOZLEGRVHDNKC-UGKGYDQZSA-N",
            "id": "InChI=1S/C22H22N2O9S/c1-22(34(31)32,12-33-18(28)9-13-5-6-16(26)17(27)8-13)19(21(29)30)23-20-14(11-25)10-15-4-2-3-7-24(15)20/h2-8,10-11,19,23,26-27H,9,12H2,1H3,(H,29,30)(H,31,32)/t19-,22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 490.483,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 490.104601002,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as d-alpha-amino acids. These are alpha amino acids which have the D-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB08116",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Klebsiella pneumoniae",
                "target": "UBeta-lactamase SHV-1"
            }
        ]
    },
    {
        "smiles": "CCN(CC)CCOC1=CC=C(C=C1)C(=C(\\Cl)C1=CC=CC=C1)\\C1=CC=CC=C1",
        "id": "DB06735",
        "molecule": "Enclomiphene",
        "cas": "15690-57-0",
        "iupac_name": "(2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}ethyl)diethylamine",
        "inchi": {
            "hash": "GKIRPKYJQBWNGO-OCEACIFDSA-N",
            "id": "InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 405.97,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 405.1859422,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.",
        "link": "https://go.drugbank.com/drugs/DB06735",
        "type": "Small Molecule",
        "synonyms": [
            "Enclomifene",
            "Enclomifeno",
            "Enclomifenum",
            "Enclomiphene",
            "trans-Clomifene",
            "trans-Clomiphene"
        ],
        "is_stub": true
    },
    {
        "smiles": "NS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(O1)\\C=C1/SC(=O)NC1=O",
        "id": "DB07531",
        "molecule": "4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE",
        "iupac_name": "4-(5-{[(5Z)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}furan-2-yl)benzene-1-sulfonamide",
        "inchi": {
            "hash": "JNPRTUHVCHGFHJ-GHXNOFRVSA-N",
            "id": "InChI=1S/C14H10N2O5S2/c15-23(19,20)10-4-1-8(2-5-10)11-6-3-9(21-11)7-12-13(17)16-14(18)22-12/h1-7H,(H2,15,19,20)(H,16,17,18)/b12-7-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 350.37,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 350.00311282,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB07531",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "[H]N1C(=O)C(CC2=CC=C(C=C2)N2CCN(CC2)C=O)C2=CC=CC=C12",
        "id": "DB02058",
        "molecule": "3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone",
        "iupac_name": "4-{4-[(2-oxo-2,3-dihydro-1H-indol-3-yl)methyl]phenyl}piperazine-1-carbaldehyde",
        "inchi": {
            "hash": "AZGZGRJOCKSSHA-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H21N3O2/c24-14-22-9-11-23(12-10-22)16-7-5-15(6-8-16)13-18-17-3-1-2-4-19(17)21-20(18)25/h1-8,14,18H,9-13H2,(H,21,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 335.3996,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 335.163376931,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB02058",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFibroblast growth factor receptor 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFibroblast growth factor receptor 2"
            }
        ]
    },
    {
        "smiles": "O=C(CC1=CC=CS1)N1CCC(CC1)C1=NC(=NO1)C1=CC=CS1",
        "id": "DB08471",
        "molecule": "1-(thiophen-2-ylacetyl)-4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine",
        "iupac_name": "2-(thiophen-2-yl)-1-{4-[3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}ethan-1-one",
        "inchi": {
            "hash": "SJEVDMFUHCVNPM-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H17N3O2S2/c21-15(11-13-3-1-9-23-13)20-7-5-12(6-8-20)17-18-16(19-22-17)14-4-2-10-24-14/h1-4,9-10,12H,5-8,11H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 359.466,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 359.076218183,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acylpiperidines. These are compounds containing an N-acyethanolamine moiety, which is characterized by an acyl group is linked to the nitrogen atom of a piperidine.",
        "link": "https://go.drugbank.com/drugs/DB08471",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "UHTH-type transcriptional regulator EthR"
            }
        ]
    },
    {
        "smiles": "NNC(=O)C1=CN2C=CC3=C(C=CC=C3)C2=N1",
        "id": "DB08758",
        "molecule": "IMIDAZO[2,1-A]ISOQUINOLINE-2-CARBOHYDRAZIDE",
        "iupac_name": "imidazo[2,1-a]isoquinoline-2-carbohydrazide",
        "inchi": {
            "hash": "WSNWYZBDIKCPIG-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H10N4O/c13-15-12(17)10-7-16-6-5-8-3-1-2-4-9(8)11(16)14-10/h1-7H,13H2,(H,15,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 226.234,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 226.085460962,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as isoquinolines and derivatives. These are aromatic polycyclic compounds containing an isoquinoline moiety, which consists of a benzene ring fused to a pyridine ring and forming benzo[c]pyridine.",
        "link": "https://go.drugbank.com/drugs/DB08758",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMethionine aminopeptidase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB06789",
        "molecule": "Hydroxyprogesterone caproate",
        "cas": "630-56-8",
        "iupac_name": "(1R,3aS,3bR,9aR,9bS,11aS)-1-acetyl-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl hexanoate",
        "background": "Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999.6 The U.S. FDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy.\nIn April 2023, the FDA withdrew its approval of Makena and its generics given an unfavorable risk-to-benefit assessment.5\n",
        "inchi": {
            "hash": "DOMWKUIIPQCAJU-LJHIYBGHSA-N",
            "id": "InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1"
        },
        "summary": "Hydroxyprogesterone caproate is a synthetic progestin used for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth.",
        "weight": [
            {
                "type": "average",
                "weight": 428.6041,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 428.292659768,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB06789",
        "type": "Small Molecule",
        "synonyms": [
            "17-alpha-hydroxy-progesterone caproate",
            "17alpha-Caproyloxypregn-4-ene-3,20-dione",
            "17alpha-Hydroxyprogesterone hexanoate",
            "Caproate d'hydroxyprogesterone",
            "Caproato de hidroxiprogesterona",
            "Hydroxyprogesterone caproate",
            "Hydroxyprogesterone hexanoate"
        ],
        "indication": "Hydroxyprogesterone caproate was previously indicated in the US for the prevention of spontaneous preterm births in singleton pregnancies in women with a history of spontaneous preterm birth. This indication was revoked by the FDA in April 2023.5\nHydroxyprogesterone caproate remains indicated in other jurisdictions for the management of primary and secondary amenorrhea, corpus luteum insufficiency, and for the prevention of preterm birth.7\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "No specific pharmacodynamic studies have been performed to assess hydroxyprogesterone caproate injections. However, the mechanism of action is likely related to increased interaction between progesterone and progesterone receptors.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UProgesterone receptor"
            }
        ]
    },
    {
        "smiles": "FC(F)OC(Cl)C(F)(F)F",
        "id": "DB00753",
        "molecule": "Isoflurane",
        "cas": "26675-46-7",
        "iupac_name": "2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane",
        "background": "A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.\n",
        "inchi": {
            "hash": "PIWKPBJCKXDKJR-UHFFFAOYSA-N",
            "id": "InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H"
        },
        "summary": "Isoflurane is an inhaled general anesthetic used in surgery.",
        "weight": [
            {
                "type": "average",
                "weight": 184.492,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 183.971433418,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.",
        "link": "https://go.drugbank.com/drugs/DB00753",
        "type": "Small Molecule",
        "synonyms": [
            "1-chloro-2,2,2-trifluoroethyl difluoromethyl ether",
            "Isoflurane",
            "Isoflurano",
            "Isofluranum"
        ],
        "indication": "For induction and maintenance of general anesthesia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Isoflurane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit alpha-1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACalcium-transporting ATPase type 2C member 1"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "AGlycine receptor subunit alpha-1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AGlutamate receptor 1"
            },
            {
                "action": "inducer",
                "organism": "Humans",
                "target": "APotassium voltage-gated channel subfamily A member 1"
            },
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "unknown",
                "organism": "Humans",
                "target": "UATP synthase subunit delta, mitochondrial"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "UCalmodulin"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit beta-2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13539"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11396"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13040"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07542"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16888"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08099"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13995"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02523"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08346"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00559"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09132"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07398"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11751"
    },
    {
        "smiles": "CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@H](CC(=O)O3)OC(C)=O)[C@@H]12",
        "id": "DB14648",
        "molecule": "Acetyl simvastatin",
        "cas": "145576-25-6",
        "iupac_name": "(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-(acetyloxy)-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate",
        "inchi": {
            "hash": "OHVWRJDVJRNCPE-BIKFJBPRSA-N",
            "id": "InChI=1S/C27H40O6/c1-7-27(5,6)26(30)33-23-13-16(2)12-19-9-8-17(3)22(25(19)23)11-10-20-14-21(31-18(4)28)15-24(29)32-20/h8-9,12,16-17,20-23,25H,7,10-11,13-15H2,1-6H3/t16-,17-,20+,21+,22-,23-,25-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 460.611,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 460.282489008,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB14648",
        "type": "Small Molecule",
        "synonyms": [
            "4'-acetylsimvastatin",
            "Simvastatin acetate",
            "Simvastatin acetate ester"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(SC=C(NC=C1C=O)C(O)=O)C1=CN(C)N=N1",
        "id": "DB02816",
        "molecule": "7-(1-Methyl-1,2,3-Triazol-4-Yl)-6-Formyl-2,7-Dihydro-[1,4]Thiazepine-3-Carboxylic Acid, Brl42715, C6-(N1-Methyl-1,2,3-Triazolylmethylene)Penem",
        "iupac_name": "(7S)-6-formyl-7-(1-methyl-1H-1,2,3-triazol-4-yl)-4,7-dihydro-1,4-thiazepine-3-carboxylic acid",
        "inchi": {
            "hash": "BCPHJDLBOJMWOD-VIFPVBQESA-N",
            "id": "InChI=1S/C10H10N4O3S/c1-14-3-7(12-13-14)9-6(4-15)2-11-8(5-18-9)10(16)17/h2-5,9,11H,1H3,(H,16,17)/t9-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 266.276,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 266.047360896,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).",
        "link": "https://go.drugbank.com/drugs/DB02816",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Enterobacter cloacae",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "C[C@@](O)(CBr)CCOP(O)(=O)OP(O)(O)=O",
        "id": "DB02480",
        "molecule": "(S)-4-bromo-3-hydroxy-3-methylbutyl diphosphate",
        "iupac_name": "({[(3S)-4-bromo-3-hydroxy-3-methylbutoxy](hydroxy)phosphoryl}oxy)phosphonic acid",
        "inchi": {
            "hash": "YKAYCWPQDPILSA-YFKPBYRVSA-N",
            "id": "InChI=1S/C5H13BrO8P2/c1-5(7,4-6)2-3-13-16(11,12)14-15(8,9)10/h7H,2-4H2,1H3,(H,11,12)(H2,8,9,10)/t5-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 343.003,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 341.926903063,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as organic pyrophosphates. These are organic compounds containing the pyrophosphate oxoanion, with the structure OP([O-])(=O)OP(O)([O-])=O.",
        "link": "https://go.drugbank.com/drugs/DB02480",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UIsopentenyl-diphosphate Delta-isomerase"
            }
        ]
    },
    {
        "smiles": "CC(C)=CC1C(C(=O)OC2CC(=O)C(CC=C)=C2C)C1(C)C",
        "id": "DB13746",
        "molecule": "Bioallethrin",
        "cas": "584-79-2",
        "iupac_name": "2-methyl-4-oxo-3-(prop-2-en-1-yl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxylate",
        "background": "Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1, where both isomers are active ingredients. A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. A mixture containing only S-forms of allethrin is referred to as esbioallethrin or S-bioallethrin. Bioallethrin is a synthetic pyrethroid used as a pesticide against household pest insects such as mosquitoes, houseflies and cockroaches. It is claimed to have low mammalian toxicity.\n",
        "inchi": {
            "hash": "ZCVAOQKBXKSDMS-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H26O3/c1-7-8-13-12(4)16(10-15(13)20)22-18(21)17-14(9-11(2)3)19(17,5)6/h7,9,14,16-17H,1,8,10H2,2-6H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 302.414,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 302.188194697,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB13746",
        "type": "Small Molecule",
        "synonyms": [
            "Depallthrine"
        ],
        "indication": "Bioallethrin was used for lice and scabies infestation. Other pyrethroids are now used in place of bioallethrin.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bioallethrin causes respiratory paralysis in lice and scabies parasites resulting in death 1.\n",
        "moa": [
            {
                "action": "modulator",
                "organism": "Pediculus humanus",
                "target": "ASodium channel protein"
            },
            {
                "action": "modulator",
                "organism": "Humans",
                "target": "UVoltage-gated sodium channel alpha subunit"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UVoltage-dependent calcium channel"
            },
            {
                "action": "blocker",
                "organism": "Humans",
                "target": "UVoltage-dependent T-type calcium channel"
            },
            {
                "action": "blocker",
                "organism": "Humans",
                "target": "UVoltage-dependent P/Q-type calcium channel"
            },
            {
                "action": "blocker",
                "organism": "Humans",
                "target": "UVoltage-dependent L-type calcium channel"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O",
        "id": "DB12151",
        "molecule": "Brincidofovir",
        "cas": "444805-28-1",
        "iupac_name": "({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)[3-(hexadecyloxy)propoxy]phosphinic acid",
        "background": "Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir7,3 - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity typically associated with cidofovir therapy.3,4 Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,5,3 allowing for oral administration rather than intravenous. Cidofovir itself has broad antiviral activity against several DNA viruses,3 resulting in brincidofovir being investigated for the prevention and treatment of cytomegalovirus (CMV), BK Virus (BKV), adenoviruses (AdV), and Epstein-Barr virus (EBV), amongst others.\nBrincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021.8 As smallpox has been eradicated, the efficacy of Tembexa was assessed in animals infected with viruses closely related to variola. The approval was granted under the agencys Animal Rule,9 which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible.\n",
        "inchi": {
            "hash": "WXJFKKQWPMNTIM-VWLOTQADSA-N",
            "id": "InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1"
        },
        "summary": "Brincidofovir is an oral lipid prodrug of cidofovir used in the treatment of human smallpox disease.",
        "weight": [
            {
                "type": "average",
                "weight": 561.701,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 561.354288024,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB12151",
        "type": "Small Molecule",
        "synonyms": [
            "Brincidofovir",
            "Cidofovir hexadecyloxypropyl ester"
        ],
        "indication": "Brincidofovir is indicated for the treatment of human smallpox disease in adult and pediatric patients.7\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The pharmacologically active agent resulting from brincidofovir metabolism, cidofovir diphosphate, has an exceedingly long duration of action that allows for it to be dosed once weekly. The entirety of a brincidofovir smallpox treatment consists of only two doses, on days 1 and 8, which seemingly reduces the risk of adverse reactions. Regimens involving a longer duration of administration (i.e. more than a single dose on days 1 and 8) have been shown to increase mortality compared to placebo and should therefore be avoided.7 Brincidofovir is considered a potential human carcinogen and has demonstrated the potential to cause infertility7 - as such, its use should be restricted to situations in which it is absolutely necessary.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Variola virus",
                "target": "ADNA polymerase"
            },
            {
                "action": "incorporation into and destabilization",
                "organism": "Variola virus",
                "target": "AVariola virus DNA"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07246"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00611"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06236"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07530"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06924"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03638"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06843"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07667"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07687"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08802"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15990"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11246"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12446"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07691"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13088"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05744"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04131"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00403"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01665"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08500"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00838"
    },
    {
        "smiles": "[H][C@@](N)(C[C@]([H])(CC1=CC2=CC=CC=C2C=C1)C(O)=O)C(O)=O",
        "id": "DB08272",
        "molecule": "(4S)-4-(2-NAPHTHYLMETHYL)-D-GLUTAMIC ACID",
        "iupac_name": "(2R,4S)-2-amino-4-[(naphthalen-2-yl)methyl]pentanedioic acid",
        "inchi": {
            "hash": "YDWIUFASTTZKNI-UONOGXRCSA-N",
            "id": "InChI=1S/C16H17NO4/c17-14(16(20)21)9-13(15(18)19)8-10-5-6-11-3-1-2-4-12(11)7-10/h1-7,13-14H,8-9,17H2,(H,18,19)(H,20,21)/t13-,14+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 287.3105,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 287.115758037,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB08272",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptococcus pyogenes serotype M1",
                "target": "UGlutamate racemase"
            }
        ]
    },
    {
        "smiles": "CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",
        "id": "DB06750",
        "molecule": "Ginsenoside Rg1",
        "cas": "22427-39-0",
        "iupac_name": "(2S,3R,4S,5S,6R)-2-{[(2S)-2-[(1R,2R,5S,7R,8S,10R,11R,14S,15R,16R)-5,16-dihydroxy-2,6,6,10,11-pentamethyl-8-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[8.7.0.0,.0,]heptadecan-14-yl]-6-methylhept-5-en-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol",
        "background": "Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant genus Panax (ginseng). Ginsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy. Because ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.\n",
        "inchi": {
            "hash": "YURJSTAIMNSZAE-HHNZYBFYSA-N",
            "id": "InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,56-37-34(52)32(50)30(48)25(19-44)55-37)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23-,24+,25+,26+,27-,28-,29+,30+,31-,32-,33+,34+,35-,36+,37-,39+,40+,41+,42-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 801.024,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 800.492206998,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as triterpene saponins. These are glycosylated derivatives of triterpene sapogenins. The sapogenin moiety backbone is usually based on the oleanane, ursane, taraxastane, bauerane, lanostane, lupeol, lupane, dammarane, cycloartane, friedelane, hopane, 9b,19-cyclo-lanostane, cycloartane, or cycloartanol skeleton.",
        "link": "https://go.drugbank.com/drugs/DB06750",
        "type": "Small Molecule",
        "synonyms": [
            "Ginsenoside A2",
            "Panaxoside A",
            "Sanchinoside C1"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USolute carrier organic anion transporter family member 1B3"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14154"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09462"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04790"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08974"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08960"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01948"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00171"
    },
    {
        "smiles": "CNC1=NC(C)=C(S1)C1=CC=NC(NC2=CC=C(O)C=C2)=N1",
        "id": "DB04407",
        "molecule": "4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol",
        "iupac_name": "4-({4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl}amino)phenol",
        "inchi": {
            "hash": "OTMLAWRVLMYMDF-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H15N5OS/c1-9-13(22-15(16-2)18-9)12-7-8-17-14(20-12)19-10-3-5-11(21)6-4-10/h3-8,21H,1-2H3,(H,16,18)(H,17,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 313.378,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 313.099730817,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2,4,5-trisubstituted thiazoles. These are compounds containing a thiazole ring substituted at positions 2, 4 and 5 only.",
        "link": "https://go.drugbank.com/drugs/DB04407",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "C[C@](N)(C1=CC=C(F)C=C1)C1=CN=C(N=C1)N1CCN(CC1)C1=NC=NN2C=C(C=C12)C1=CN(CCO)N=C1",
        "id": "DB18489",
        "molecule": "Elenestinib",
        "cas": "2505078-08-8",
        "background": "Elenestinib is a selective KIT inhibitor.\n",
        "inchi": {
            "hash": "IPMARPMXSFFZFG-MHZLTWQESA-N",
            "id": "InChI=1S/C27H29FN10O/c1-27(29,21-2-4-23(28)5-3-21)22-14-30-26(31-15-22)36-8-6-35(7-9-36)25-24-12-19(17-38(24)34-18-32-25)20-13-33-37(16-20)10-11-39/h2-5,12-18,39H,6-11,29H2,1H3/t27-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 528.596,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 528.250983757,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18489",
        "type": "Small Molecule",
        "synonyms": [
            "(S)-2-(4-(4-(4-(5-(1-amino-1-(4-fluorophenyl)ethyl)pyrimidin-2-yl)piperazin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)-1H-pyrazol-1-yl)ethan-1-ol",
            "1H-Pyrazole-1-ethanol, 4-[4-[4-[5-[(1S)-1-amino-1-(4-fluorophenyl)ethyl]-2-pyrimidinyl]-1-piperazinyl]pyrrolo[2,1-f][1,2,4]triazin-6-yl]-",
            "2-{4-[4-(4-{5-[(1S)-1-amino-1-(4- fluorophenyl)ethyl]pyrimidin-2-yl}piperazin-1- yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]-1H-pyrazol-1- yl}ethan-1-ol",
            "4-[4-[4-[5-[(1S)-1-Amino-1-(4-fluorophenyl)ethyl]-2-pyrimidinyl]-1-piperazinyl]pyrrolo[2,1-f][1,2,4]triazin-6-yl]-1H-pyrazole-1-ethanol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CO[C@@H]1[C@@H](O)O[C@@H](C)[C@@H](O)[C@H]1O",
        "id": "DB03863",
        "molecule": "2-O-Methyl-beta-L-fucopyranose",
        "cas": "108266-96-2",
        "iupac_name": "(2S,3S,4R,5S,6S)-3-methoxy-6-methyloxane-2,4,5-triol",
        "inchi": {
            "hash": "YLAMTMNJXPWCQN-XUVCUMPTSA-N",
            "id": "InChI=1S/C7H14O5/c1-3-4(8)5(9)6(11-2)7(10)12-3/h3-10H,1-2H3/t3-,4+,5+,6-,7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 178.1831,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 178.084123558,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB03863",
        "type": "Small Molecule",
        "synonyms": [
            "6-Deoxy-2-O-methyl-beta-L-galactopyranose",
            "6-Deoxy-2-O-methyl--L-galactopyranose"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / NCIB 9290)",
                "target": "UChondroitinase-AC"
            },
            {
                "action": "Not Available",
                "organism": "Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / NCIB 9290)",
                "target": "UChondroitinase-B"
            }
        ]
    },
    {
        "smiles": "CC1=NC2=C(C=C1)C(Cl)=CC(Cl)=C2O",
        "id": "DB13306",
        "molecule": "Chlorquinaldol",
        "cas": "72-80-0",
        "iupac_name": "5,7-dichloro-2-methylquinolin-8-ol",
        "background": "Chlorquinaldol was used historically as a topical antiseptic under the trade name Sterosan.5 It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.6\n",
        "inchi": {
            "hash": "GPTXWRGISTZRIO-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H7Cl2NO/c1-5-2-3-6-7(11)4-8(12)10(14)9(6)13-5/h2-4,14H,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 228.07,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 226.9904692,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as chloroquinolines. These are compounds containing a quinoline moiety, which carries one or more chlorine atoms.",
        "link": "https://go.drugbank.com/drugs/DB13306",
        "type": "Small Molecule",
        "synonyms": [
            "2-methyl-5,7-dichloro-8-hydroxyquinoline",
            "5,7-dichloro-2-methyl-8-hydroxyquinoline",
            "5,7-dichloro-2-methyl-8-quinolinol",
            "5,7-dichloro-8-hydroxy-2-methylquinoline",
            "5,7-dichloro-8-hydroxyquinaldine",
            "5,7-dichloro-8-quinaldinol",
            "Chlorchinaldol",
            "Chlorquinaldol",
            "Chlorquinaldolum",
            "Clorquinaldol"
        ],
        "indication": "Chlorquinaldol was used historically as a topical antiseptic agent for skin infections.5 It maintains use in European countries as a combination vaginal tablet with promestriene for use in the treatment of vaginal infections.6\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Chlorquinaldol is bacteriocidal in both gram positive and gram negative bacteria. It is more effective in targeting gram positive bacteria, particularly staphylococci.1\n"
    },
    {
        "smiles": "C1C2CC3CC1CC(C2)C3",
        "id": "DB03627",
        "molecule": "Adamantane",
        "iupac_name": "adamantane",
        "background": "A tricyclo bridged hydrocarbon. [PubChem]\n",
        "inchi": {
            "hash": "ORILYTVJVMAKLC-YNFQOJQRSA-N",
            "id": "InChI=1S/C10H16/c1-7-2-9-4-8(1)5-10(3-7)6-9/h7-10H,1-6H2/t7-,8+,9-,10+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 136.234,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 136.125200512,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as polycyclic hydrocarbons. These are polycyclic organic compounds made up only of carbon and hydrogen atoms.",
        "link": "https://go.drugbank.com/drugs/DB03627",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "UCamphor 5-monooxygenase"
            }
        ]
    },
    {
        "smiles": "CC[C@@H](CO)NCCN[C@@H](CC)CO",
        "id": "DB00330",
        "molecule": "Ethambutol",
        "cas": "74-55-5",
        "iupac_name": "(2S)-2-[(2-{[(2S)-1-hydroxybutan-2-yl]amino}ethyl)amino]butan-1-ol",
        "background": "Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis.13 Ethambutol was first described in the literature in 1961.11 It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.11\nEthambutol was granted FDA approval on 6 November 1967.12\n",
        "inchi": {
            "hash": "AEUTYOVWOVBAKS-UWVGGRQHSA-N",
            "id": "InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1"
        },
        "summary": "Ethambutol is an antituberculosis agent used in the prophylaxis and treatment of tuberculosis (TB).",
        "weight": [
            {
                "type": "average",
                "weight": 204.3098,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 204.183778022,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.",
        "link": "https://go.drugbank.com/drugs/DB00330",
        "type": "Small Molecule",
        "synonyms": [
            "(+)-2,2'-(ethylenediimino)di-1-butanol",
            "(+)-ethambutol",
            "(+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine",
            "(+)-S,S-ethambutol",
            "(2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol",
            "(S,S)-ethambutol",
            "EMB",
            "Etambutol",
            "Etambutolo",
            "Ethambutol",
            "Ethambutolum",
            "S,S-Ethambutol"
        ],
        "indication": "Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis.12 Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.13\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis.12 It has a long duration of action as it is administered daily, and a moderate therapeutic window.12 Patients should be counselled regarding the risk of optic neuritis and hepatic toxicity.12\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Mycobacterium tuberculosis",
                "target": "AProbable arabinosyltransferase C"
            },
            {
                "action": "inhibitor",
                "organism": "Mycobacterium tuberculosis",
                "target": "AProbable arabinosyltransferase B"
            },
            {
                "action": "inhibitor",
                "organism": "Mycobacterium tuberculosis",
                "target": "AProbable arabinosyltransferase A"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05616"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07144"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06775"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04663"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06845"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05625"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04329"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08580"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17740"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11226"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07792"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00484"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08445"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07620"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02615"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08267"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06736"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07248"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00736"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01020"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11115"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01728"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06420"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06982"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07783"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02732"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14586"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00006"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00687"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04456"
    },
    {
        "smiles": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C",
        "id": "DB00990",
        "molecule": "Exemestane",
        "cas": "107868-30-4",
        "iupac_name": "(3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-5-methylidene-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione",
        "background": "Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.\n",
        "inchi": {
            "hash": "BFYIZQONLCFLEV-DAELLWKTSA-N",
            "id": "InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1"
        },
        "summary": "Exemestane is an aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen.",
        "weight": [
            {
                "type": "average",
                "weight": 296.4034,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 296.177630012,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.",
        "link": "https://go.drugbank.com/drugs/DB00990",
        "type": "Small Molecule",
        "synonyms": [
            "6-methyleneandrosta-1,4-diene-3,17-dione",
            "Exemestane",
            "Exemestano",
            "Exemestanum"
        ],
        "indication": "For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Aromatase is an enzyme that converts hormones to estrogen in the body's adrenal glands. The aromatase inhibitors (AIs) are drugs that reduce estrogen levels by blocking the action of aromatase in the adrenal glands. The selective AIs (SAIs) selectively reduce levels of estrogen without interfering with levels of other steroid hormones that are produced by the adrenal gland. Drugs in this class include anastrozole (Arimidex ), letrozole (Femara ) and exemestane (Aromasin ).\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ACytochrome P450 19A1"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1",
        "id": "DB00973",
        "molecule": "Ezetimibe",
        "cas": "163222-33-1",
        "iupac_name": "(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one",
        "background": "Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating the effect of ezetimibe on intestinal cholesterol absorption.3 Ezetimibe is used as an adjunctive therapy to a healthy diet to lower cholesterol levels in primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia (phytosterolemia).5\nUnlike other classes of cholesterol-reducing compounds including statins and bile acid sequestrants, ezetimibe has a distinct mechanism of action involving the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1), and is unique in that it does not affect the absorption of fat-soluble nutrients such as fat-soluble vitamins, triglycerides, or bile acids.4 In genetically NPC1L1-deficient mice, a 70% reduction in intestinal cholesterol absorption was seen, and these mice were insensitive to ezetimibe treatment - it was determined based on these findings that NPC1L1 plays an essential role in promoting intestinal cholesterol uptake via an ezetimibe-sensitive pathway.3 By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces the delivery of intestinal cholesterol to the liver.5\n",
        "inchi": {
            "hash": "OLNTVTPDXPETLC-XPWALMASSA-N",
            "id": "InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1"
        },
        "summary": "Ezetimibe is a cholesterol absorption inhibitor used to lower total cholesterol, LDL-C, Apo-B, and non-HDL-C in primary hyperlipidemia and familial cholesterolemia.",
        "weight": [
            {
                "type": "average",
                "weight": 409.4252,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 409.148949953,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monobactams. These are compounds comprising beta-lactam ring is alone and not fused to another ring.",
        "link": "https://go.drugbank.com/drugs/DB00973",
        "type": "Small Molecule",
        "synonyms": [
            "Ezetimiba",
            "ztimibe",
            "Ezetimibe",
            "Ezetimibum"
        ],
        "indication": "Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin).5,6,7 It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin.5 Ezetimibe may also be used to reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia).5\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Ezetimibe was shown to reduce the levels of total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apoprotein B (Apo B), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides (TG), and increase high-density lipoprotein cholesterol (HDL-C) in patients with hyperlipidemia.5 This therapeutic effect was more profound when ezetimibe was co-administered with a statin or fenofibrate compared to either treatment alone.5 In clinical trials involving patients with homozygous and heterozygous familial hypercholesterolemia and in those with sitosterolemia, a recommended therapeutic dose of ezetimibe was effective in reducing the LDL levels by 15-20% while increasing HDL-C by 2.5-5%.4\nThe effects of increased exposure to ezetimibe secondary to moderate-severe hepatic impairment have not been assessed - patients meeting these criteria should avoid the use of ezetimibe.5 Post-marketing reports indicate the potential for myopathy and rhabdomyolysis in patients taking ezetimibe, and this risk appears to be exacerbated in patients concurrently receiving, or having recently received, statin therapy.5 \n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ANiemann-Pick C1-like protein 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASterol O-acyltransferase 1"
            },
            {
                "action": "other",
                "organism": "Humans",
                "target": "UAminopeptidase N"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04518"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11734"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13584"
    },
    {
        "smiles": "OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1",
        "id": "DB00502",
        "molecule": "Haloperidol",
        "cas": "52-86-8",
        "iupac_name": "4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one",
        "background": "Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide.7 While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain,10 it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states.16 It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is theorized to be caused by a hyperdopaminergic state within the limbic system of the brain.9\nUse of the first-generation antipsychotics (including haloperidol) is considered highly effective for the management of the \"positive\" symptoms of schizophrenia including hallucinations, hearing voices, aggression/hostility, disorganized speech, and psychomotor agitation. However, this class of drugs is also limited by the development of movement disorders induced by dopamine-blockade such as drug-induced parkinsonism, akathisia, dystonia, tardive dyskinesia, as well as other side effects including sedation, weight gain, and prolactin changes. While there are limited high-quality studies comparing haloperidol to lower-potency first-generation antipsychotics such as Chlorpromazine, Zuclopenthixol, Fluphenazine, and Methotrimeprazine, haloperidol typically demonstrates the least amount of side effects within this class, but demonstrates a stronger disposition for causing extrapyramidal symptoms (EPS).6,7,8 These other lowpotency antipsychotics are limited by their lower affinity for dopamine receptors, which requires a higher dose to effectively treat symptoms of schizophrenia. In addition, they block many receptors other than the primary target (dopamine receptors), such as cholinergic or histaminergic receptors, resulting in a higher incidence of side effects such as sedation, weight gain, and hypotension.\nInterestingly, in vivo pharmacogenetic studies have demonstrated that the metabolism of haloperidol may be modulated by genetically determined polymorphic CYP2D6 activity. However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo. Inter-ethnic and pharmacogenetic differences in haloperidol metabolism may possibly explain these observations.3\nFirst-generation antipsychotic drugs have largely been replaced with second- and third-generation (atypical) antipsychotics such as Risperidone, Olanzapine, Clozapine, Quetiapine, Aripiprazole, and Ziprasidone. However, haloperidol use remains widespread and is considered the benchmark for comparison in trials of the newer generation antipsychotics.8\nThe efficacy of haloperidol was first established in controlled trials in the 1960s.5\n",
        "inchi": {
            "hash": "LNEPOXFFQSENCJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2"
        },
        "summary": "Haloperidol is an antipsychotic agent used to treat schizophrenia and other psychoses, as well as symptoms of agitation, irritability, and delirium.",
        "weight": [
            {
                "type": "average",
                "weight": 375.864,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 375.140134897,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB00502",
        "type": "Small Molecule",
        "synonyms": [
            "1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine",
            "4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone",
            "4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one",
            "4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone",
            "4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone",
            "Haloperidol",
            "Haloperidolum",
            "-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone"
        ],
        "indication": "Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourettes Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also indicated in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics.16\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Use of the first-generation antipsychotics (including haloperidol) is considered highly effective for the management of the \"positive\" symptoms of schizophrenia including hallucinations, hearing voices, aggression/hostility, disorganized speech, and psychomotor agitation. However, this class is limited by the development of movement disorders such as drug-induced parkinsonism, akathisia, dystonia, and tardive dyskinesia, and other side effects including sedation, weight gain, and prolactin changes. Compared to the lower-potency first-generation antipsychotics such as Chlorpromazine, Zuclopenthixol, Fluphenazine, and Methotrimeprazine, haloperidol typically demonstrates the least amount of side effects within class, but demonstrates a stronger disposition for causing extrapyramidal symptoms (EPS).6,7,8 Lowpotency medications have a lower affinity for dopamine receptors so that a higher dose is required to effectively treat symptoms of schizophrenia. In addition, they block many receptors other than the primary target (dopamine receptors), such as cholinergic or histaminergic receptors, resulting in a higher incidence of side effects such as sedation, weight gain, and hypotension.\nThe balance between the wanted drug effects on psychotic symptoms and unwanted side effects are largely at play within dopaminergic brain pathways affected by haloperidol. Cortical dopamine-D2-pathways play an important role in regulating these effects and include the nigrostriatal pathway, which is responsible for causing extrapyramidal symptoms (EPS), the mesolimbic and mesocortical pathways, which are responsible for the improvement in positive schizophrenic symptoms, and the tuberoinfundibular dopamine pathway, which is responsible for hyperprolactinemia. \nA syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.16\nCases of sudden death, QT-prolongation, and Torsades de Pointes have been reported in patients receiving haloperidol. Higher than recommended doses of any formulation and intravenous administration of haloperidol appear to be associated with a higher risk of QT-prolongation and Torsades de Pointes. Although cases have been reported even in the absence of predisposing factors, particular caution is advised in treating patients with other QT-prolonging conditions (including electrolyte imbalance [particularly hypokalemia and hypomagnesemia], drugs known to prolong QT, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome).16\nA potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.16\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 2C"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 2A"
            },
            {
                "action": "inverse agonist",
                "organism": "Humans",
                "target": "UDopamine D3 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMelanin-concentrating hormone receptor 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USynaptic vesicular amine transporter"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USigma non-opioid intracellular receptor 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHistamine H1 receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M3"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-1A adrenergic receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-2A adrenergic receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-2B adrenergic receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-2C adrenergic receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 1A"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 6"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U5-hydroxytryptamine receptor 7"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, NMDA 2B"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UDopamine D1 receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14152"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15269"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03260"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02398"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18043"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00921"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08795"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06972"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16881"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01505"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11108"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08638"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04686"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13225"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18214"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08606"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00965"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14750"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03238"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01452"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09361"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03304"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18578"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00267"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03094"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13053"
    },
    {
        "smiles": "CCCCCCC(O)(P(O)(O)=O)P(O)(O)=O",
        "id": "DB06830",
        "molecule": "(1-HYDROXYHEPTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",
        "iupac_name": "(1-hydroxy-1-phosphonoheptyl)phosphonic acid",
        "inchi": {
            "hash": "IJEGNOYPWRBKAE-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H18O7P2/c1-2-3-4-5-6-7(8,15(9,10)11)16(12,13)14/h8H,2-6H2,1H3,(H2,9,10,11)(H2,12,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 276.1611,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 276.052775954,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB06830",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGeranylgeranyl pyrophosphate synthase"
            }
        ]
    },
    {
        "smiles": "O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1",
        "id": "DB08909",
        "molecule": "Glycerol phenylbutyrate",
        "cas": "611168-24-2",
        "iupac_name": "1,3-bis[(4-phenylbutanoyl)oxy]propan-2-yl 4-phenylbutanoate",
        "background": "Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.\n",
        "inchi": {
            "hash": "ZSDBFLMJVAGKOU-UHFFFAOYSA-N",
            "id": "InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2"
        },
        "summary": "Glycerol phenylbutyrate is a nitrogen-binding agent used to manage patients with urea cycle disorders who cannot be sufficiently managed amino acid supplementation and/or dietary restrictions.",
        "weight": [
            {
                "type": "average",
                "weight": 530.6512,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 530.266838948,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as triacylglycerols. These are glycerides consisting of three fatty acid chains covalently bonded to a glycerol molecule through ester linkages.",
        "link": "https://go.drugbank.com/drugs/DB08909",
        "type": "Small Molecule",
        "synonyms": [
            "Glycerol phenylbutyrate",
            "Glyceryl Tri-4-Phenylbutyrate",
            "GPB",
            "GT4P"
        ],
        "indication": "Glycerol phenylbutyrate is a nitrogen-binding agent for the chronic management of adult and pediatric patients 2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Glycerol phenylbutyrate prolongs the QTc interval. \n"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11116"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08118"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08227"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06403"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04401"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15498"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03787"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04712"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16095"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04856"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11369"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07533"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07092"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17388"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13487"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16870"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03501"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11588"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07320"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18203"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13217"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03452"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15055"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11956"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16138"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03025"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16407"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14186"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12273"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01211"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04103"
    },
    {
        "smiles": "CC(C)C1=CC=CC([C@H](C)C2CC2)=C1O",
        "id": "DB16295",
        "molecule": "HSK-3486",
        "cas": "1637741-58-2",
        "iupac_name": "2-[(1R)-1-cyclopropylethyl]-6-(propan-2-yl)phenol",
        "background": "HSK-3486 is under investigation in clinical trial NCT04620031 (A Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation).\n",
        "inchi": {
            "hash": "BMEARIQHWSVDBS-SNVBAGLBSA-N",
            "id": "InChI=1S/C14H20O/c1-9(2)12-5-4-6-13(14(12)15)10(3)11-7-8-11/h4-6,9-11,15H,7-8H2,1-3H3/t10-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 204.313,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 204.151415264,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16295",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)C2=CC3=CC=C(Cl)C=C3C=C2)C1=O)C(=O)N1CCOCC1",
        "id": "DB07847",
        "molecule": "6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-(4-MORPHOLINYL)-2-OXO ETHYL]-2-OXO-3-PYRROLIDINYL}-2-NAPHTHALENESULFONAMIDE",
        "iupac_name": "6-chloro-N-[(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide",
        "inchi": {
            "hash": "ICLOZQFWTRAYPX-LIRRHRJNSA-N",
            "id": "InChI=1S/C21H24ClN3O5S/c1-14(20(26)24-8-10-30-11-9-24)25-7-6-19(21(25)27)23-31(28,29)18-5-3-15-12-17(22)4-2-16(15)13-18/h2-5,12-14,19,23H,6-11H2,1H3/t14-,19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 465.95,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 465.11251929,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB07847",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "smiles": "OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1",
        "id": "DB12401",
        "molecule": "Bromperidol",
        "cas": "10457-90-6",
        "iupac_name": "4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one",
        "background": "Bromperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.\n",
        "inchi": {
            "hash": "RKLNONIVDFXQRX-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2"
        },
        "summary": "Bromperidol is a first-generation butyrophenone antipsychotic used in the treatment of schizophrenia and other psychotic manifestations.",
        "weight": [
            {
                "type": "average",
                "weight": 420.322,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 419.08962,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB12401",
        "type": "Small Molecule",
        "synonyms": [
            "Bromperidol"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C(Cl)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",
        "id": "DB13728",
        "molecule": "Halometasone",
        "cas": "50629-82-8",
        "iupac_name": "(1R,2S,8S,10S,11S,13R,14R,15S,17S)-4-chloro-1,8-difluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one",
        "inchi": {
            "hash": "GGXMRPUKBWXVHE-MIHLVHIWSA-N",
            "id": "InChI=1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1"
        },
        "summary": "Halometasone is a corticosteroid indicated in the treatment of corticosteroid responsive dermatoses.",
        "weight": [
            {
                "type": "average",
                "weight": 444.9,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 444.151508,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.",
        "link": "https://go.drugbank.com/drugs/DB13728",
        "type": "Small Molecule",
        "synonyms": [
            "Halometasone"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15405"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04364"
    },
    {
        "smiles": "[H][C@]1(CCC(C)=C[C@@]1([H])C1=C(O)C=C(CCCCC)C(CC(O)=O)=C1O)C(C)=C",
        "id": "DB17825",
        "molecule": "Cannabidiolic acid methyl ester",
        "iupac_name": "2-{2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-6-pentylphenyl}acetic acid",
        "inchi": {
            "hash": "BOYRUNMTTPSTKZ-PKOBYXMFSA-N",
            "id": "InChI=1S/C23H32O4/c1-5-6-7-8-16-12-20(24)22(23(27)18(16)13-21(25)26)19-11-15(4)9-10-17(19)14(2)3/h11-12,17,19,24,27H,2,5-10,13H2,1,3-4H3,(H,25,26)/t17-,19+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 372.505,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 372.23005951,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17825",
        "type": "Small Molecule",
        "synonyms": [
            "2-{2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-6-pentylphenyl}acetic acid",
            "CBDA-ME"
        ],
        "is_stub": true
    },
    {
        "id": "DB11578",
        "molecule": "Hard fat",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11578",
        "type": "Small Molecule",
        "synonyms": [
            "Adeps Solidus",
            "Fat, hard",
            "Sus scrofa subcutaneous fat"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)CCCCCCCCC(=O)N(C)[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@H]1C2=CC(=C(O)C=C2)C2=CC(C[C@H](NC(=O)[C@H](C)NC1=O)C(O)=O)=CC=C2O",
        "id": "DB01934",
        "molecule": "Arylomycin A2",
        "iupac_name": "(8S,11S,14S)-14-{2-[(2R)-2-[(2R)-2-(N,10-dimethylundecanamido)-3-hydroxypropanamido]propanamido]-N-methylacetamido}-3,18-dihydroxy-11-methyl-10,13-dioxo-9,12-diazatricyclo[13.3.1.1^{2,6}]icosa-1(18),2(20),3,5,15(19),16-hexaene-8-carboxylic acid",
        "inchi": {
            "hash": "YFSXYWAZCKMYJN-JBBOGOJTSA-N",
            "id": "InChI=1S/C42H60N6O11/c1-24(2)13-11-9-7-8-10-12-14-35(52)47(5)32(23-49)40(56)44-25(3)38(54)43-22-36(53)48(6)37-28-16-18-34(51)30(21-28)29-19-27(15-17-33(29)50)20-31(42(58)59)46-39(55)26(4)45-41(37)57/h15-19,21,24-26,31-32,37,49-51H,7-14,20,22-23H2,1-6H3,(H,43,54)(H,44,56)(H,45,57)(H,46,55)(H,58,59)/t25-,26+,31+,32-,37+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 824.973,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 824.432006776,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB01934",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "USignal peptidase I"
            }
        ]
    },
    {
        "smiles": "CC1=CN=C(CNCC2(F)CCN(CC2)C(=O)C2=CC=C(F)C(Cl)=C2)N=C1",
        "id": "DB16936",
        "molecule": "F-15599",
        "cas": "635323-95-4",
        "iupac_name": "{[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl]methyl}[(5-methylpyrimidin-2-yl)methyl]amine",
        "inchi": {
            "hash": "WAAXKNFGOFTGLP-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H21ClF2N4O/c1-13-9-24-17(25-10-13)11-23-12-19(22)4-6-26(7-5-19)18(27)14-2-3-16(21)15(20)8-14/h2-3,8-10,23H,4-7,11-12H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 394.85,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 394.1371953,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16936",
        "type": "Small Molecule",
        "synonyms": [
            "(3-chloro-4-fluorophenyl)-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1-yl)methanone",
            "3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1yl)methanone",
            "3-Chloro-4-Fluorophenyl-[4-Fluoro-4-[[(5-Methylpyrimidin-2-ylmethyl)Amino]Methyl]Piperidin-1yl]Methanone",
            "4-piperidinemethanamine, 1-(3-chloro-4-fluorobenzoyl)-4-fluoro-n-((5-methyl-2-pyrimidinyl)methyl)-",
            "F15599",
            "Methanone, (3-chloro-4-fluorophenyl)(4-fluoro-4-((((5-methyl-2-pyrimidinyl)methyl)amino)methyl)-1-piperidinyl)-",
            "NLX-101",
            "NLX101"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC",
        "id": "DB11349",
        "molecule": "Cetyl ethylhexanoate",
        "cas": "59130-69-7",
        "iupac_name": "hexadecyl 2-ethylhexanoate",
        "background": "Cetyl ethylhexanoate is an ester of cetyl alcohol and 2-ethylhexanoic acid. It is present in cosmetic products as a skin conditioning agent and emollient.\n",
        "inchi": {
            "hash": "XJNUECKWDBNFJV-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H48O2/c1-4-7-9-10-11-12-13-14-15-16-17-18-19-20-22-26-24(25)23(6-3)21-8-5-2/h23H,4-22H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 368.646,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 368.365430786,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as fatty alcohol esters. These are ester derivatives of a fatty alcohol.",
        "link": "https://go.drugbank.com/drugs/DB11349",
        "type": "Small Molecule",
        "synonyms": [
            "Cetyl 2-ethylhexanoate",
            "Hexadecyl 2-ethylhexanoate",
            "Perceline oil"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)C2=CC3=C(S2)C=CC(Cl)=C3)C1=O)C(=O)N1CCOCC1",
        "id": "DB07843",
        "molecule": "5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE",
        "iupac_name": "5-chloro-N-[(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]-1-benzothiophene-2-sulfonamide",
        "inchi": {
            "hash": "LTJNKFUIOOJXNJ-WFASDCNBSA-N",
            "id": "InChI=1S/C19H22ClN3O5S2/c1-12(18(24)22-6-8-28-9-7-22)23-5-4-15(19(23)25)21-30(26,27)17-11-13-10-14(20)2-3-16(13)29-17/h2-3,10-12,15,21H,4-9H2,1H3/t12-,15-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 471.978,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 471.068939916,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB07843",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "smiles": "Cl.Cl.CC1=NC=CN1CC1=CC(=CN=N1)C1=CC=C(F)C(=C1)C(F)F",
        "id": "DB05956",
        "molecule": "EVT-101",
        "cas": "1189088-41-2",
        "iupac_name": "5-[3-(difluoromethyl)-4-fluorophenyl]-3-[(2-methyl-1H-imidazol-1-yl)methyl]pyridazine dihydrochloride",
        "inchi": {
            "hash": "OJBLXSPBJMGZDN-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H13F3N4.2ClH/c1-10-20-4-5-23(10)9-13-6-12(8-21-22-13)11-2-3-15(17)14(7-11)16(18)19;;/h2-8,16H,9H2,1H3;2*1H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 391.22,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 390.0625864,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyridazines. These are organic compounds containing a pyridazine ring substituted by a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB05956",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in alzheimer's disease, neurologic disorders, pain (acute or chronic), and parkinson's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URetinoic acid receptor RXR-alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, NMDA 2B"
            }
        ]
    },
    {
        "smiles": "O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1",
        "id": "DB00490",
        "molecule": "Buspirone",
        "cas": "36505-84-7",
        "iupac_name": "8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione",
        "background": "Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class,2 buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs.13 Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'.1 First synthesized in 1968 then patented in 1975,10 it is commonly marketed under the brand name Buspar. Buspirone was first approved in 1986 by the FDA 4 and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety. It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate.10 The potential use of buspirone in combination with melatonin in depression and cognitive impairment via promoting neurogenesis has also been investigated.4\n",
        "inchi": {
            "hash": "QWCRAEMEVRGPNT-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2"
        },
        "summary": "Buspirone is an anxiolytic agent used for short-term treatment of generalized anxiety and second-line treatment of depression.",
        "weight": [
            {
                "type": "average",
                "weight": 385.5031,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 385.247775261,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB00490",
        "type": "Small Molecule",
        "synonyms": [
            "8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione",
            "Buspiron",
            "Buspirona",
            "Buspirone",
            "Buspironum"
        ],
        "indication": "Indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.13\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The clinical effect of buspirone in alleviating the symptoms of generalized anxiety disorders typically takes 2 to 4 weeks to achieve.10 The delayed onset of action of buspirone suggests that the therapeutic effectiveness in generalized anxiety may involved more than its molecular mechanism of action at the 5-HT1A receptors,9 or buspirone may induce adaptations of 5-HT1A receptors.10 Buspirone was not shown to alter the psychomotor or cognitive function in healthy volunteers, and the risk of developing sedation is relatively low compared to other anxiolytics, such as benzodiazepines.1 Unlike benzodiazepines and barbiturates used in anxiety disorders, buspirone is not associated with a risk for developing physical dependence or withdrawal, or any significant interaction with central nervous system depressants such as ethanol. This is due to the lack of effects on GABA receptors.1,10 Buspirone also does not exhibit any anticonvulsant or muscle-relaxing properties,5 but may interfere with arousal reactions due to its inhibitory action on the aactivity of noradrenergic locus coerulus neurons.9\nDespite its clinical effectiveness in generalized anxiety, buspirone demonstrated limited clinical effectiveness on panic disorders, severe anxiety, phobias, and obsessive compulsive disorders.4,9 The clinical effectiveness of the long-term use of buspirone, for more than 3 to 4 weeks, has not demonstrated in controlled trials but there were no observable significant adverse events in patients receiving buspirone for a year in a study of long-term use.13\n",
        "moa": [
            {
                "action": "partial agonist",
                "organism": "Humans",
                "target": "A5-hydroxytryptamine receptor 1A"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UDopamine D3 receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UDopamine D4 receptor"
            },
            {
                "action": "partial agonist",
                "organism": "Humans",
                "target": "UAlpha-1 adrenergic receptors"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09172"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08220"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00663"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12007"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13953"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08203"
    },
    {
        "smiles": "CN(C)CC1=NC(=NO1)C1=C2CN(C)C(=O)C3=C(C=CC=C3Cl)N2C=N1",
        "id": "DB05721",
        "molecule": "EVT 201",
        "cas": "308239-86-3",
        "iupac_name": "11-chloro-5-{5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}-8-methyl-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,11,13-pentaen-9-one",
        "background": "EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.\n",
        "inchi": {
            "hash": "JCYLWUVDHLVGER-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 372.81,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 372.1101515,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB05721",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in insomnia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "pharmacodynamics": "In two Phase I/II studies using the traffic noise model of insomnia in healthy male volunteers, EVT 201 significantly reduced \"wake after sleep onset\" (WASO) while significantly increasing \"total sleep time\" (TST) and quality of sleep with no subjective residual effects. The compound was well tolerated without significant adverse events.\n"
    },
    {
        "smiles": "CCCCCCCCCCCCCCCCO",
        "id": "DB09494",
        "molecule": "Cetyl alcohol",
        "cas": "36653-82-4",
        "iupac_name": "hexadecan-1-ol",
        "background": "Cetyl alcohol, also known as 1-hexadecanol or n-hexadecyl alcohol, is a 16-C fatty alcohol with the chemical formula CH3(CH2)15OH. It can be produced from the reduction of palmitic acid. Cetyl alcohol is present in a waxy white powder or flake form at room temperature, and is insoluble in water and soluble in alcohols and oils 1. Discovered by Chevrenl in 1913, cetyl alcohol is one of the oldest known long-chain alcohol 1. It may be contained in cosmetic and personal care products such as shampoos, creams and lotions. Mainly it is used as an opacifier, emulsifier, and thickening agent that alter the thickness of the liquid, and increase and stabilize the foaming capacity. Due to its water-binding property, cetyl alcohol is commonly used as an emollient that prevents drying and chapping of the skin 1. According to the FDA Code of Federal Regulations, cetyl alcohol is a safe synthetic fatty acid in food and in the synthesis of food components under the condition that it contain not less than 98 percent of total alcohols and not less than 94 percent of straight chain alcohols 3. Cetyl alcohol is also listed in the OTC ingredient list as a skin protectant for skin irritations caused by poison ivy, oak, sumac, and insect bites or stings 4. Cetyl alcohol is reported to be a mild skin or eye irritant.\n",
        "inchi": {
            "hash": "BXWNKGSJHAJOGX-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H34O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h17H,2-16H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 242.4406,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 242.26096571,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as long-chain fatty alcohols. These are fatty alcohols that have an aliphatic tail of 13 to 21 carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB09494",
        "type": "Small Molecule",
        "synonyms": [
            "hexadecan-1-ol",
            "palmityl alcohol"
        ],
        "indication": "No therapeutic indications in medicinal products. Indicated to be used as an indirect additive in food contact substances, or an ingredient in commercial or cosmetic products. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cetyl alcohol exhibits skin protect properties against skin irritations caused by bites, rashes and stings. The inhibitory action of cetyl alcohol against the growth of Mycoplasma gallisepticum and Mycopiasma pneumoniae has been reported 1.\n"
    },
    {
        "smiles": "CCC(C)C1(CC)C(=O)NC(=O)NC1=O",
        "id": "DB00237",
        "molecule": "Butabarbital",
        "cas": "125-40-6",
        "iupac_name": "5-(butan-2-yl)-5-ethyl-1,3-diazinane-2,4,6-trione",
        "background": "Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.1,12 This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.1,12 Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines.3 Its short duration of action gives butabarbital a high abuse potential, comparable to secobarbital.1,2\nButabarbital was granted FDA approval on 5 June 1939.12\n",
        "inchi": {
            "hash": "ZRIHAIZYIMGOAB-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)"
        },
        "summary": "Butabarbital is a barbiturate drug used as a sedative and hypnotic.",
        "weight": [
            {
                "type": "average",
                "weight": 212.2456,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 212.116092388,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.",
        "link": "https://go.drugbank.com/drugs/DB00237",
        "type": "Small Molecule",
        "synonyms": [
            "5-ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione",
            "5-ethyl-5-(1-methylpropyl)barbituric acid",
            "5-sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione",
            "5-sec-butyl-5-ethylbarbituric acid",
            "5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione",
            "Butabarbital",
            "Secbutabarbital",
            "Secbutabarbitale",
            "Secbutabarbitalum"
        ],
        "indication": "Butabarbital is indicated for use as a sedative or hypnotic.12 Butabarbital should not be used to treat insomnia for longer than 2 weeks.12\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Butabarbital potentiates GABAergic neurons while inhibiting neuronal acetylcholine and glutamate receptors to produce sedation.8,10 Butabarbital is an intermediate acting barbiturate with a duration of action of approximately 6-8 hours.12 The therapeutic index is quite wide as doses vary considerably from patient to patient.12 Patients should be counselled regarding the risk of worsening insomnia, drowsiness, falls, and complex behaviour while not fully awake.12\n",
        "moa": [
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UNeuronal Acetylcholine (nACh) Receptor Subunits"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor 1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor 2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor 3"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor 4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 3"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, kainate 5"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07755"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01004"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04715"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13367"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14061"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12855"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02596"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06771"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08969"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01396"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15059"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13347"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06994"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13762"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00402"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06336"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06064"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03854"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07337"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05416"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00923"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06740"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08605"
    },
    {
        "smiles": "CCCCCCCC\\C(=C/CCCCCCCC(O)=O)[N+]([O-])=O",
        "id": "DB15026",
        "molecule": "CXA-10",
        "cas": "875685-46-4",
        "iupac_name": "(9E)-10-nitrooctadec-9-enoic acid",
        "background": "CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).\n",
        "inchi": {
            "hash": "WRADPCFZZWXOTI-BMRADRMJSA-N",
            "id": "InChI=1S/C18H33NO4/c1-2-3-4-5-8-11-14-17(19(22)23)15-12-9-6-7-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 327.465,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 327.240958547,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15026",
        "type": "Small Molecule",
        "synonyms": [
            "10-nitro-9(E)-octadec-9-enoic acid"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC[C@@]1(O)CCC2=CC=C(N=C12)N1N(CC=C)C(=O)C2=CN=C(NC3=CC=C(C=C3)N3CCN(C)CC3)N=C12",
        "id": "DB18028",
        "molecule": "Azenosertib",
        "cas": "2376146-48-2",
        "inchi": {
            "hash": "OXTSYWDBUVRXFF-GDLZYMKVSA-N",
            "id": "InChI=1S/C29H34N8O2/c1-4-14-36-27(38)23-19-30-28(31-21-7-9-22(10-8-21)35-17-15-34(3)16-18-35)33-26(23)37(36)24-11-6-20-12-13-29(39,5-2)25(20)32-24/h4,6-11,19,39H,1,5,12-18H2,2-3H3,(H,30,31,33)/t29-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 526.645,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 526.280472367,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18028",
        "type": "Small Molecule",
        "synonyms": [
            "3h-pyrazolo(3,4-d)pyrimidin-3-one, 1-((7r)-7-ethyl-6,7-dihydro-7-hydroxy-5h-cyclopenta(b)pyridin-2-yl)-1,2-dihydro-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-2-(2-propen-1-yl)-"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOC1=C(F)C(CCNC(=S)NC2=CC=C(C)C=N2)=NC=C1",
        "id": "DB08372",
        "molecule": "1-[2-(4-ETHOXY-3-FLUOROPYRIDIN-2-YL)ETHYL]-3-(5-METHYLPYRIDIN-2-YL)THIOUREA",
        "iupac_name": "1-[2-(4-ethoxy-3-fluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)thiourea",
        "inchi": {
            "hash": "QOVMZMFNTIUFLU-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H19FN4OS/c1-3-22-13-7-9-18-12(15(13)17)6-8-19-16(23)21-14-5-4-11(2)10-20-14/h4-5,7,9-10H,3,6,8H2,1-2H3,(H2,19,20,21,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 334.412,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 334.126360145,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl aryl ethers. These are organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB08372",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            },
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02146"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07503"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05288"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16833"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15594"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16302"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01975"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16650"
    },
    {
        "smiles": "[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1",
        "id": "DB00725",
        "molecule": "Homatropine methylbromide",
        "cas": "80-49-9",
        "iupac_name": "3-[(2-hydroxy-2-phenylacetyl)oxy]-8,8-dimethyl-8-azabicyclo[3.2.1]octan-8-ium bromide",
        "background": "Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.\n",
        "inchi": {
            "hash": "FUFVKLQESJNNAN-UHFFFAOYSA-M",
            "id": "InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1"
        },
        "summary": "Homatropine methylbromide is a muscarinic receptor antagonist used to treat peptic ulcers, gastric ulcers, and duodenal ulcers.",
        "weight": [
            {
                "type": "average",
                "weight": 370.281,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 369.093956286,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tropane alkaloids. These are organic compounds containing the nitrogenous bicyclic alkaloid parent N-Methyl-8-azabicyclo[3.2.1]Octane.",
        "link": "https://go.drugbank.com/drugs/DB00725",
        "type": "Small Molecule",
        "synonyms": [
            "3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate",
            "8-Methylhomatropinium bromide",
            "Homatropine methylbromide",
            "Homatropini methylbromidum",
            "Mthylbromure d'homatropine",
            "Methylhomatropine",
            "Methylhomatropine bromide",
            "Methylhomatropinum bromatum",
            "Metilbromuro de homatropina",
            "Omatropina metilbromuro",
            "Tropinium methobromide mandelate"
        ],
        "indication": "Used in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Homatropine methylbromide belongs to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M4"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M5"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M3"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00118"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08302"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06913"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07408"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12486"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08948"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02904"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01885"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03513"
    },
    {
        "smiles": "CCCCCC[C@](O)(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl",
        "id": "DB02617",
        "molecule": "1-(N-Imidazolyl)-2-Hydroxy-2-(2,3-Dichlorophenyl)Octane",
        "iupac_name": "(2R)-2-(2,4-dichlorophenyl)-1-(1H-imidazol-1-yl)octan-2-ol",
        "inchi": {
            "hash": "WJBNLGBHMWNHRZ-KRWDZBQOSA-N",
            "id": "InChI=1S/C17H22Cl2N2O/c1-2-3-4-5-8-17(22,12-21-10-9-20-13-21)15-7-6-14(18)11-16(15)19/h6-7,9-11,13,22H,2-5,8,12H2,1H3/t17-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 341.275,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 340.11091875,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.",
        "link": "https://go.drugbank.com/drugs/DB02617",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "UCamphor 5-monooxygenase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(O)O[C@@]([H])(C(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O",
        "id": "DB02945",
        "molecule": "alpha-L-iduronic acid",
        "cas": "71031-08-8",
        "iupac_name": "(2R,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid",
        "inchi": {
            "hash": "AEMOLEFTQBMNLQ-VCSGLWQLSA-N",
            "id": "InChI=1S/C6H10O7/c7-1-2(8)4(5(10)11)13-6(12)3(1)9/h1-4,6-9,12H,(H,10,11)/t1-,2-,3+,4+,6+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 194.1394,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 194.042652674,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glucuronic acid derivatives. These are compounds containing a glucuronic acid moiety (or a derivative), which consists of a glucose moiety with the C6 carbon oxidized to a carboxylic acid.",
        "link": "https://go.drugbank.com/drugs/DB02945",
        "type": "Small Molecule",
        "synonyms": [
            "L-iduronic acid",
            "-L-iduronic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / NCIB 9290)",
                "target": "UChondroitinase-AC"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(O)O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@]1([H])O",
        "id": "DB04127",
        "molecule": "beta-D-arabinofuranose 5-phosphate",
        "iupac_name": "{[(2R,3S,4S,5R)-3,4,5-trihydroxyoxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "KTVPXOYAKDPRHY-SQOUGZDYSA-N",
            "id": "InChI=1S/C5H11O8P/c6-3-2(1-12-14(9,10)11)13-5(8)4(3)7/h2-8H,1H2,(H2,9,10,11)/t2-,3-,4+,5-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 230.1098,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 230.01915384,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.",
        "link": "https://go.drugbank.com/drugs/DB04127",
        "type": "Small Molecule",
        "synonyms": [
            "5-O-phosphono--D-arabinofuranose",
            "-D-arabinofuranose 5-phosphate"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Shigella flexneri",
                "target": "URibose-5-phosphate isomerase A"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03466"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02642"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07082"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01594"
    },
    {
        "smiles": "O=C1NC2=CC=CC=C2C(=O)O1",
        "id": "DB11593",
        "molecule": "Isatoic anhydride",
        "cas": "118-48-9",
        "iupac_name": "2,4-dihydro-1H-3,1-benzoxazine-2,4-dione",
        "inchi": {
            "hash": "TXJUTRJFNRYTHH-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H5NO3/c10-7-5-3-1-2-4-6(5)9-8(11)12-7/h1-4H,(H,9,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 163.132,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 163.026943025,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).",
        "link": "https://go.drugbank.com/drugs/DB11593",
        "type": "Small Molecule",
        "synonyms": [
            "1,2-dihydro-3,1-benzoxazine-2,4-dione",
            "1h-benz(d)(1,3)oxazine-2,4-dione",
            "2,4-dioxo-1,2-dihydro-4h-3,1-benzoxazine",
            "2h-3,1-benzoxazine-2,4(1h)-dione",
            "3,1-benzoxazine-2,4(1h)-dione",
            "Isatoic acid anhydride",
            "N-carboxyanthranilic anhydride"
        ]
    },
    {
        "smiles": "NC(=O)C[C@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N1CCC[C@H]1C(=O)N[C@H](CC1=CC=C(O)C=C1)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(N)=O",
        "id": "DB18527",
        "molecule": "JAK4D",
        "cas": "882400-49-9",
        "background": "JAK4D is a first-in-class thyrotropin-releasing hormone (TRH)-based compound.\n",
        "inchi": {
            "hash": "SZQSOKVXBMULDL-VQHLWIOESA-N",
            "id": "InChI=1S/C34H40N8O8/c35-28(44)16-26(41-31(47)23-11-12-29(45)38-23)34(50)42-13-3-6-27(42)33(49)40-25(14-18-7-9-20(43)10-8-18)32(48)39-24(30(36)46)15-19-17-37-22-5-2-1-4-21(19)22/h1-2,4-5,7-10,17,23-27,37,43H,3,6,11-16H2,(H2,35,44)(H2,36,46)(H,38,45)(H,39,48)(H,40,49)(H,41,47)/t23-,24+,25+,26-,27+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 688.742,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 688.29691028,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18527",
        "type": "Small Molecule",
        "synonyms": [
            "5-oxo-l-prolyl-l-asparaginyl-l-prolyl-d-tyrosyl-d-tryptophanamide",
            "L-pyroglutamyl-l-asparaginyl-l-prolyl-d-tyrosyl-d-tryptophan amide"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)[N+]4=CC=CC(=C4)C(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1",
        "id": "DB04099",
        "molecule": "Deamido-Nad+",
        "iupac_name": "1-[(2R,3R,4S,5R)-5-[({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-3,4-dihydroxyoxolan-2-yl]-3-carboxy-1lambda5-pyridin-1-ylium",
        "inchi": {
            "hash": "SENPVEZBRZQVST-HISDBWNOSA-O",
            "id": "InChI=1S/C21H26N6O15P2/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(31)14(29)11(41-20)6-39-44(36,37)42-43(34,35)38-5-10-13(28)15(30)19(40-10)26-3-1-2-9(4-26)21(32)33/h1-4,7-8,10-11,13-16,19-20,28-31H,5-6H2,(H4-,22,23,24,32,33,34,35,36,37)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 665.4178,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 665.100962248,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as (5'-\u003e5')-dinucleotides. These are dinucleotides where the two bases are connected via a (5'-\u003e5')-phosphodiester linkage.",
        "link": "https://go.drugbank.com/drugs/DB04099",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UNH(3)-dependent NAD(+) synthetase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UNH(3)-dependent NAD(+) synthetase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNicotinamide mononucleotide adenylyltransferase 1"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UNicotinate-nucleotide adenylyltransferase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNicotinamide mononucleotide adenylyltransferase 3"
            },
            {
                "action": "Not Available",
                "organism": "Helicobacter pylori (strain ATCC 700392 / 26695)",
                "target": "UNH(3)-dependent NAD(+) synthetase"
            }
        ]
    },
    {
        "smiles": "OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O",
        "id": "DB00974",
        "molecule": "Edetic acid",
        "cas": "60-00-4",
        "iupac_name": "2-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid",
        "background": "A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.\n",
        "inchi": {
            "hash": "KCXVZYZYPLLWCC-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)"
        },
        "summary": "Edetic acid is a chelating agent used to treat mercury and lead toxicity and some blood transfusion dependent anemias.",
        "weight": [
            {
                "type": "average",
                "weight": 292.2426,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 292.090665498,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB00974",
        "type": "Small Molecule",
        "synonyms": [
            "(ethylenedinitrilo)tetraacetic acid, ion(4)",
            "{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid",
            "2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate",
            "Acide edetique",
            "Acide ethylenediaminetetracetique",
            "Acido edetico",
            "Acidum edeticum",
            "Edetic acid",
            "EDTA",
            "EDTA, ion(4-)",
            "Ethylenediaminetetraacetate",
            "Ethylenediaminetetraacetic acid",
            "N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)"
        ],
        "indication": "For the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Edetate calcium is a heavy metal chelating agent. The calcium in edetate calcium can be displaced by divalent or trivalent metals to form a stable water soluble complex that can be excreted in the urine. In theory, 1 g of edetate calcium can theoretically bind 620 mg of lead, but in reality only about 5 mg per gram is actually excreted into the urine in lead poisoned patients. In addition to chelating lead, edetate calcium also chelates and eliminates zinc from the body. Edetate calcium also binds cadmium, copper, iron and manganese, but to a much lesser extent than either lead or zinc. Edetate calcium is relatively ineffective for use in treating mercury, gold or arsenic poisoning.\n",
        "moa": [
            {
                "action": "chelator",
                "organism": "Humans",
                "target": "ALead"
            },
            {
                "action": "chelator",
                "organism": "Humans",
                "target": "UIron"
            },
            {
                "action": "chelator",
                "organism": "Humans",
                "target": "UManganese cation"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09167"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08942"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17865"
    },
    {
        "smiles": "CN1C(=O)COC2=C(C=C(Cl)C=C12)C(=O)NC1CN2CCC1CC2",
        "id": "DB16837",
        "molecule": "Azasetron",
        "cas": "123040-69-7",
        "iupac_name": "N-{1-azabicyclo[2.2.2]octan-3-yl}-6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide",
        "inchi": {
            "hash": "WUKZPHOXUVCQOR-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H20ClN3O3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 349.82,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 349.1193192,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16837",
        "type": "Small Molecule",
        "synonyms": [
            "Azasetron"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC1=CC(=CC=C1)C1=CC(=O)NS1(=O)=O",
        "id": "DB07730",
        "molecule": "5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE",
        "iupac_name": "5-(3-hydroxyphenyl)-2,3-dihydro-1lambda6,2-thiazole-1,1,3-trione",
        "inchi": {
            "hash": "FJABEDRGNJSWCC-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H7NO4S/c11-7-3-1-2-6(4-7)8-5-9(12)10-15(8,13)14/h1-5,11H,(H,10,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 225.221,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 225.009578407,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.",
        "link": "https://go.drugbank.com/drugs/DB07730",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein phosphatase non-receptor type 1"
            }
        ]
    },
    {
        "smiles": "COC1=CC=CC(CC2=CNC3=C2C=CC=N3)=C1",
        "id": "DB07525",
        "molecule": "3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine",
        "iupac_name": "3-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridine",
        "inchi": {
            "hash": "GHQCCHWTDLTMJT-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H14N2O/c1-18-13-5-2-4-11(9-13)8-12-10-17-15-14(12)6-3-7-16-15/h2-7,9-10H,8H2,1H3,(H,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 238.2845,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 238.11061308,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolopyridines. These are compounds containing a pyrrolopyridine moiety, which consists of a pyrrole ring fused to a pyridine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.",
        "link": "https://go.drugbank.com/drugs/DB07525",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFibroblast growth factor receptor 1"
            }
        ]
    },
    {
        "smiles": "[O--].[O--].[O--].[O--].[Fe++].[Fe+3].[Fe+3]",
        "id": "DB06215",
        "molecule": "Ferumoxytol",
        "cas": "722492-56-0",
        "iupac_name": "diiron(3+) lambda2-iron(2+) tetraoxidandiide",
        "background": "Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) 4.\nIt is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively high dose by rapid intravenous injection 8.\n",
        "inchi": {
            "hash": "WTFXARWRTYJXII-UHFFFAOYSA-N",
            "id": "InChI=1S/3Fe.4O/q+2;2*+3;4*-2"
        },
        "summary": "Ferumoxytol is an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD), or in patients who are unable to tolerate or who have not responded adequately to oral iron supplementation.",
        "weight": [
            {
                "type": "average",
                "weight": 231.531,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 231.784466,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06215",
        "type": "Small Molecule",
        "synonyms": [
            "Ferumoxytol",
            "Ferumoxytol non-stoichiometric magnetite"
        ],
        "indication": "This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or\nwho have chronic kidney disease (CKD) Label.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The pharmacodynamic effect of ferumoxytol on hematologic indexes such as Hgb (hemoglobin), serum ferritin, and TSAT (transferrin saturation) were studied and measured as primary and secondary endpoints in clinical efficacy studies 14. \nFeraheme (ferumoxytol) reached the primary endpoint with statistical significance (p\u003c0.001) in all three trials versus oral iron 14.\nFerumoxytol has been examined as a contrast agent for magnetic resonance imaging (MRI) studies. Because ferumoxytol is a very small superparamagnetic iron oxide (USPIO) with a polysaccharide coating, it may be administered via the intravenous bolus route without mast cell degranulation, which is an attributable property for magnetic resonance angiography and perfusion imaging. Unlike gadolinium, ferumoxytol crosses the blood-brain barrier at a slow pace and is considered a 'blood pool' agent. Ferumoxytol stays in the intravascular space and offers a longer time period for data acquisition during an MRI study so that data can be repeatedly obtained over a period of several minutes to hours with only small losses of intravascular signal intensity and minimal soft tissue enhancement 17.\nIron-containing proteins and enzymes are important in oxidation-reduction reactions, particularly those in the mitochondria. Iron is a part of myoglobin and several heme-enzymes, including the cytochromes, catalase, and peroxidase. Iron is an essential component of the metalloflavoprotein enzymes and the mitochondrial enzyme alpha-glycerophosphate oxidase. In addition, iron is a cofactor for enzymes such as aconitase and tryptophan pyrrolase. Iron deficiency cause anemia and decreased oxygen delivery. This also reduces the metabolism of muscle and decreases mitochondrial activity. Iron deficiency may also cause defects in both learning or thermoregulation. Therefore, iron is important to several metabolic functions in addition to erythropoiesis 17.\n"
    },
    {
        "smiles": "[H][C@]1(O)CN(CC2=CNC3=C2N=CN=C3N)C[C@]1([H])CSCCCC",
        "id": "DB07463",
        "molecule": "(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(butylsulfanyl)methyl]pyrrolidin-3-ol",
        "iupac_name": "(3R,4S)-1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-4-[(butylsulfanyl)methyl]pyrrolidin-3-ol",
        "inchi": {
            "hash": "LTSUEVPGSXUJHT-OLZOCXBDSA-N",
            "id": "InChI=1S/C16H25N5OS/c1-2-3-4-23-9-12-7-21(8-13(12)22)6-11-5-18-15-14(11)19-10-20-16(15)17/h5,10,12-13,18,22H,2-4,6-9H2,1H3,(H2,17,19,20)/t12-,13+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 335.468,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 335.177981137,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB07463",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)",
                "target": "U5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase"
            }
        ]
    },
    {
        "smiles": "OCC(O)COC1=CC=C(Cl)C=C1",
        "id": "DB00856",
        "molecule": "Chlorphenesin",
        "cas": "104-29-0",
        "iupac_name": "3-(4-chlorophenoxy)propane-1,2-diol",
        "inchi": {
            "hash": "MXOAEAUPQDYUQM-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H11ClO3/c10-7-1-3-9(4-2-7)13-6-8(12)5-11/h1-4,8,11-12H,5-6H2"
        },
        "summary": "Chlorphenesin is a phenol ether used to treat painful muscular conditions.",
        "weight": [
            {
                "type": "average",
                "weight": 202.635,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 202.039671925,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB00856",
        "type": "Small Molecule",
        "synonyms": [
            "3-(4-chlorophenoxy)-1,2-propanediol",
            "3-(p-chlorophenoxy)-1,2-propanediol",
            "3-(p-chlorophenoxy)propane-1,2-diol",
            "Chlorphenesin",
            "Chlorphnsine",
            "Chlorphenesinum",
            "Clorfenesina",
            "glycerol -p-chlorophenyl ether",
            "p-chlorophenyl--glyceryl ether"
        ],
        "indication": "Used, along with rest and physical therapy, to treat injuries and other painful muscular conditions. Investigated for use in trigeminal neuralgia (tic douloureux), a neuropathic disorder characterized by severe facial pain. Was investigated as a modulator of histamine release.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Chlorphenesin is a muscle relaxant. It blocks nerve impulses (or pain sensations) that are sent to the brain. \n"
    },
    {
        "smiles": "CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1",
        "id": "DB06441",
        "molecule": "Cangrelor",
        "cas": "163706-06-7",
        "iupac_name": "[dichloro({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-{[2-(methylsulfanyl)ethyl]amino}-2-[(3,3,3-trifluoropropyl)sulfanyl]-9H-purin-9-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl})methyl]phosphonic acid",
        "background": "Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.\n",
        "inchi": {
            "hash": "PAEBIVWUMLRPSK-IDTAVKCVSA-N",
            "id": "InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1"
        },
        "summary": "Cangrelor is a P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST).",
        "weight": [
            {
                "type": "average",
                "weight": 776.35,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 774.9483145,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine ribonucleoside monophosphates. These are nucleotides consisting of a purine base linked to a ribose to which one monophosphate group is attached.",
        "link": "https://go.drugbank.com/drugs/DB06441",
        "type": "Small Molecule",
        "synonyms": [
            "[dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid",
            "Cangrelor"
        ],
        "indication": "For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AP2Y purinoceptor 12"
            }
        ]
    },
    {
        "smiles": "CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O",
        "id": "DB13873",
        "molecule": "Fenofibric acid",
        "cas": "42017-89-0",
        "iupac_name": "2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid",
        "background": "Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.1,5 Due to its high hydrophilicity and poor absorption profile,1 prodrug ,fenofibrate, and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration.1,3\n",
        "inchi": {
            "hash": "MQOBSOSZFYZQOK-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)"
        },
        "summary": "Fenofibric acid is a fibrate used to treat severe hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia.",
        "weight": [
            {
                "type": "average",
                "weight": 318.75,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 318.0658867,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB13873",
        "type": "Small Molecule",
        "indication": "For use as an adjunctive therapy to diet to: (a) reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and (b) reduce elevated total cholesterol, low-density-lipoprotein (LDL-C), triglycerides, and apolipoprotein B, and to increase high-density-lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Label\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Various clinical studies have shown that elevated levels of total cholesterol, low-desnsity-lipoprotein (LDL-C), and apolipoprotein B (apo B) - an LDL membrane complex - are associated with human atherosclerosis Label. Concurrently, decreased levels of high-density-lioprotein (HDL-C) and its transport complex, apolipoproteins apo AI and apo AII, are associated with the development of atherosclerosis Label. Furthermore, epidemiological investigations demonstrate that cardiovascular morbidity and mortality vary directly with the levels of total cholesterol, LDL-C, and triglycerides, and inversely with the level of HDL-C Label.\nFenofibric acid, the active metabolite of fenofibrate, subsequently produces reductions in total cholesterol, LDL-C, apo B, total triglycerides, and triglyceride rich lipoprotein (VLDL) in treated patients Label. Moreover, such treatment with fenofibrate also results in increases in HDL-C and apo AI and apo AII Label. \n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "APeroxisome proliferator-activated receptor alpha"
            },
            {
                "action": "unknown",
                "organism": "Humans",
                "target": "UMatrix metalloproteinase-25"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPeroxisome proliferator-activated receptor gamma"
            },
            {
                "action": "unknown",
                "organism": "Humans",
                "target": "UPeroxisome proliferator-activated receptor delta"
            },
            {
                "action": "partial agonist",
                "organism": "Humans",
                "target": "UNuclear receptor subfamily 1 group I member 2"
            }
        ]
    },
    {
        "smiles": "[H][C@](C)(O)[C@]([H])(N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(CO)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(C)N=C(O)[C@]1([H])CCCN1C(=O)[C@@]([H])(N=C(O)[C@@]([H])(N=C(O)[C@]([H])(CCCNC(N)=N)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(C)N=C(O)[C@@]([H])(N=C(O)CN=C(O)CN=C(O)CN=C(O)[C@]([H])(CC(C)C)N=C(O)[C@@]([H])(N)C(C)C)C(C)C)C(C)C)[C@@]([H])(C)CC)C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(O)=O)C(O)=O",
        "id": "DB06651",
        "molecule": "DiaPep 277",
        "cas": "179822-83-4",
        "iupac_name": "(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-({[(2S)-1-[(2S,3R)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-({[(2S)-1-[(2S,3S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[2-({2-[(2-{[(2S)-2-{[(2S)-2-amino-1-hydroxy-3-methylbutylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-methylbutylidene]amino}-1-hydroxypropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-5-carbamimidamido-1-hydroxypentylidene]amino}-1-hydroxy-3-methylbutylidene]amino}-3-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxypropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-3-carboxy-1-hydroxypropylidene]amino}-1,3-dihydroxypropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-3-hydroxybutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxypropylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-4-carboxy-1-hydroxybutylidene]amino}butanedioic acid",
        "background": "DiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).\n",
        "inchi": {
            "hash": "VGGRNGOEDNBLPH-YJHCMWSWSA-N",
            "id": "InChI=1S/C106H180N28O34/c1-23-55(18)83(131-102(164)82(54(16)17)130-90(152)60(27-24-32-111-106(109)110)118-91(153)65(38-50(8)9)123-92(154)63(36-48(4)5)121-87(149)58(21)117-101(163)81(53(14)15)129-76(140)45-113-74(138)43-112-75(139)44-114-88(150)62(35-47(2)3)126-100(162)80(108)52(12)13)103(165)133-33-25-28-71(133)98(160)115-56(19)85(147)120-64(37-49(6)7)93(155)125-68(41-78(143)144)95(157)128-70(46-135)97(159)124-66(39-51(10)11)96(158)132-84(59(22)136)104(166)134-34-26-29-72(134)99(161)116-57(20)86(148)122-67(40-73(107)137)94(156)119-61(30-31-77(141)142)89(151)127-69(105(167)168)42-79(145)146/h47-72,80-84,135-136H,23-46,108H2,1-22H3,(H2,107,137)(H,112,139)(H,113,138)(H,114,150)(H,115,160)(H,116,161)(H,117,163)(H,118,153)(H,119,156)(H,120,147)(H,121,149)(H,122,148)(H,123,154)(H,124,159)(H,125,155)(H,126,162)(H,127,151)(H,128,157)(H,129,140)(H,130,152)(H,131,164)(H,132,158)(H,141,142)(H,143,144)(H,145,146)(H,167,168)(H4,109,110,111)/t55-,56-,57-,58-,59+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,80-,81-,82-,83-,84-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 2390.768,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 2389.321674988,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06651",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in diabetes mellitus type 1, autoimmune diseases, and diabetes mellitus type 2.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O",
        "id": "DB04483",
        "molecule": "2-deoxy-2-fluoro--D-mannose",
        "cas": "55449-80-4",
        "iupac_name": "(2R,3S,4S,5S,6R)-3-fluoro-6-(hydroxymethyl)oxane-2,4,5-triol",
        "inchi": {
            "hash": "ZCXUVYAZINUVJD-AIECOIEWSA-N",
            "id": "InChI=1S/C6H11FO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1H2/t2-,3+,4-,5-,6-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 182.1469,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 182.059051667,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB04483",
        "type": "Small Molecule",
        "synonyms": [
            "2-deoxy-2-fluoro-beta-D-mannose"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Cellvibrio japonicus (strain Ueda107)",
                "target": "UMannan endo-1,4-beta-mannosidase"
            }
        ]
    },
    {
        "smiles": "NC(=O)CC(O)=O",
        "id": "DB02649",
        "molecule": "3-Amino-3-Oxopropanoic Acid",
        "cas": "2345-56-4",
        "iupac_name": "2-carbamoylacetic acid",
        "inchi": {
            "hash": "CGJMROBVSBIBKP-UHFFFAOYSA-N",
            "id": "InChI=1S/C3H5NO3/c4-2(5)1-3(6)7/h1H2,(H2,4,5)(H,6,7)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 103.0767,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 103.026943031,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.",
        "link": "https://go.drugbank.com/drugs/DB02649",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bradyrhizobium japonicum",
                "target": "UMalonamidase E2"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(C)CNC2=C(SC3=C2C2=C(C=C3)N=C(C=C2)C2=CN=C(C)C=C2)C(=O)N1",
        "id": "DB07430",
        "molecule": "(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one",
        "iupac_name": "(15R)-15-methyl-5-(6-methylpyridin-3-yl)-11-thia-6,14,17-triazatetracyclo[8.8.0.0^{2,7}.0^{12,18}]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one",
        "inchi": {
            "hash": "CMWRPDHVGMHLSZ-GFCCVEGCSA-N",
            "id": "InChI=1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 374.459,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 374.120131908,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.",
        "link": "https://go.drugbank.com/drugs/DB07430",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMAP kinase-activated protein kinase 2"
            }
        ]
    },
    {
        "smiles": "CN(C)CCCN1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12",
        "id": "DB08996",
        "molecule": "Dimetacrine",
        "cas": "4757-55-5",
        "iupac_name": "[3-(9,9-dimethyl-9,10-dihydroacridin-10-yl)propyl]dimethylamine",
        "background": "Dimetacrine is also known as dimethacrine or acripamine. It is marketed under the names Istonil, Istonyl, Linostil, and Miroistonil. Dimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan.\n",
        "inchi": {
            "hash": "RYQOGSFEJBUZBX-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H26N2/c1-20(2)16-10-5-7-12-18(16)22(15-9-14-21(3)4)19-13-8-6-11-17(19)20/h5-8,10-13H,9,14-15H2,1-4H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 294.4338,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 294.209598842,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring.",
        "link": "https://go.drugbank.com/drugs/DB08996",
        "type": "Small Molecule",
        "synonyms": [
            "3-(9,9-dimethylacridin-10-yl)-N,N-dimethyl-propan-1-amine",
            "Dimetacrine",
            "Istonil",
            "Istonyl",
            "Linostil",
            "Miroistonil"
        ],
        "pharmacodynamics": "Little is known about the pharmacology of dimetacrine. \n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AAcetylcholinesterase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB14681",
        "molecule": "Cortisone",
        "cas": "53-06-5",
        "iupac_name": "(1R,3aS,3bS,9aR,9bS,11aS)-1-hydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-7,10-dione",
        "background": "A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite hydrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)\n",
        "inchi": {
            "hash": "MFYSYFVPBJMHGN-ZPOLXVRWSA-N",
            "id": "InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 360.444,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 360.193674006,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14681",
        "type": "Small Molecule",
        "synonyms": [
            "11-dehydro-17-hydroxycorticosterone",
            "17alpha,21-Dihydroxy-4-pregnene-3,11,20-trione",
            "17,21-dihydroxy-4-pregnene-3,11,20-trione",
            "4-pregnene-17,21-diol-3,11,20-trione",
            "Cortisona",
            "Cortisone",
            "Cortisonum",
            "Kendall's compound E",
            "Kortison",
            "pregn-4-en-17,21-diol-3,11,20-trione",
            "Reichstein's substance Fa",
            "Wintersteiner's compound F"
        ],
        "is_stub": true
    },
    {
        "smiles": "CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12",
        "id": "DB11679",
        "molecule": "Fruquintinib",
        "cas": "1194506-26-7",
        "iupac_name": "6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide",
        "background": "Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.\n",
        "inchi": {
            "hash": "BALLNEJQLSTPIO-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 393.399,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 393.132470724,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.",
        "link": "https://go.drugbank.com/drugs/DB11679",
        "type": "Small Molecule",
        "synonyms": [
            "Fruquintinib"
        ],
        "indication": "Fruquintinib is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.1 \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "pharmacodynamics": "In vitro studies showed fruquintinib inhibited VEGF-mediated endothelial cell proliferation and tubular formation, while in vivo studies demonstrated fruquintinib-mediated tumor growth inhibition in a tumor xenograft mouse model of colon cancer. Inhibition of VEGF-induced VEGFR-2 phosphorylation was illustrated in both in vitro and in vivo studies.1\nFruquintinib exposure-response relationships and the time course of pharmacodynamic response are unknown. A mean increase in QTc interval \u003e20 milliseconds (ms) was not observed at the approved recommended dosage.1 \n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AVascular endothelial growth factor receptor 1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AVascular endothelial growth factor receptor 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AVascular endothelial growth factor receptor 3"
            }
        ]
    },
    {
        "smiles": "[OH-].[Cl-].[99Tc+5].[O-]C(=O)CNCCNCC([O-])=O.C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C2=CN=C(NN)C=C2)C(=O)N[C@@H](CC2=CC=C([O-])C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1",
        "id": "DB17161",
        "molecule": "99mTc-HYNIC (Tyr3)-octreotide",
        "cas": "913556-61-3",
        "iupac_name": "(99Tc)technetium(5+) 2-({2-[(carboxylatomethyl)amino]ethyl}amino)acetate 4-{[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-{[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}-19-[(2R)-2-[(6-hydrazinylpyridin-3-yl)formamido]-3-phenylpropanamido]-7-[(1R)-1-hydroxyethyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-16-yl]methyl}benzen-1-olate chloride hydroxide",
        "inchi": {
            "hash": "LGXRRVXXRJRTHK-HWLOXKIFSA-I",
            "id": "InChI=1S/C55H71N13O12S2.C6H12N2O4.ClH.H2O.Tc/c1-30(70)43(27-69)64-54(79)45-29-82-81-28-44(65-51(76)40(22-32-10-4-3-5-11-32)61-48(73)34-17-20-46(68-57)59-25-34)53(78)62-41(23-33-15-18-36(72)19-16-33)50(75)63-42(24-35-26-58-38-13-7-6-12-37(35)38)52(77)60-39(14-8-9-21-56)49(74)67-47(31(2)71)55(80)66-45;9-5(10)3-7-1-2-8-4-6(11)12;;;/h3-7,10-13,15-20,25-26,30-31,39-45,47,58,69-72H,8-9,14,21-24,27-29,56-57H2,1-2H3,(H,59,68)(H,60,77)(H,61,73)(H,62,78)(H,63,75)(H,64,79)(H,65,76)(H,66,80)(H,67,74);7-8H,1-4H2,(H,9,10)(H,11,12);1H;1H2;/q;;;;+5/p-5/t30-,31-,39+,40-,41?,42-,43-,44+,45?,47?;;;;/m1..../s1/i;;;;1+2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1494.88,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1493.4127358,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17161",
        "type": "Small Molecule",
        "synonyms": [
            "99mtc-ethylenediamine n,n'-diacetic acid/hydrazinonicotinamide-tyr3-octreotide",
            "99mTc-HYNIC-[D-Phe1,Tyr3-Octreotide]",
            "99mTc-Hynic-TOC",
            "99mTcEDDA/HYNIC-TOC",
            "Hynic (tyr3)-octreotide technetium tc-99m"
        ],
        "is_stub": true
    },
    {
        "smiles": "[Al+3]",
        "id": "DB14519",
        "molecule": "Aluminum cation",
        "cas": "22537-23-1",
        "iupac_name": "aluminium(3+) ion",
        "inchi": {
            "hash": "REDXJYDRNCIFBQ-UHFFFAOYSA-N",
            "id": "InChI=1S/Al/q+3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 26.9815,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 26.981538441,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous post-transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a post-transition metal atom.",
        "link": "https://go.drugbank.com/drugs/DB14519",
        "type": "Small Molecule",
        "synonyms": [
            "Aluminium, ion (Al3+)",
            "Aluminum(3+)",
            "Aluminum(III)",
            "Aluminum(III) ion",
            "Alumunum ion"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(O)O[C@]([H])(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])OC(C)=O",
        "id": "DB03478",
        "molecule": "2'-O-Acetyl Adenosine-5-Diphosphoribose",
        "iupac_name": "[({[(2R,3R,4R,5S)-4-(acetyloxy)-3,5-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid",
        "inchi": {
            "hash": "BFNOPXRXIQJDHO-DLFWLGJNSA-N",
            "id": "InChI=1S/C17H25N5O15P2/c1-6(23)34-13-11(25)8(36-17(13)27)3-33-39(30,31)37-38(28,29)32-2-7-10(24)12(26)16(35-7)22-5-21-9-14(18)19-4-20-15(9)22/h4-5,7-8,10-13,16-17,24-27H,2-3H2,1H3,(H,28,29)(H,30,31)(H2,18,19,20)/t7-,8-,10-,11-,12-,13-,16-,17+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 601.3524,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 601.082238179,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleotide sugars. These are purine nucleotides bound to a saccharide derivative through the terminal phosphate group.",
        "link": "https://go.drugbank.com/drugs/DB03478",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNAD-dependent protein deacylase sirtuin-5, mitochondrial"
            }
        ]
    },
    {
        "smiles": "COC(=O)CCC=C=CC[C@H]1[C@H](\\C=C\\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O",
        "id": "DB13824",
        "molecule": "Enprostil",
        "cas": "73121-56-9",
        "iupac_name": "methyl 7-[(1S,2S,3S)-3-hydroxy-2-[(1E,3S)-3-hydroxy-4-phenoxybut-1-en-1-yl]-5-oxocyclopentyl]hepta-4,5-dienoate",
        "inchi": {
            "hash": "PTOJVMZPWPAXER-FPXSIRDUSA-N",
            "id": "InChI=1S/C23H28O6/c1-28-23(27)12-8-3-2-7-11-19-20(22(26)15-21(19)25)14-13-17(24)16-29-18-9-5-4-6-10-18/h3-7,9-10,13-14,17,19-20,22,24,26H,8,11-12,15-16H2,1H3/b14-13+/t2?,17-,19-,20-,22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 400.471,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 400.188588622,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB13824",
        "type": "Small Molecule",
        "synonyms": [
            "Enprostil"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](NC(=O)CC1=CC=CS1)(B(O)O)C1=CC=CC=C1",
        "id": "DB08552",
        "molecule": "(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid",
        "iupac_name": "[(R)-phenyl[2-(thiophen-2-yl)acetamido]methyl]boronic acid",
        "background": "(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid is a solid. This compound belongs to the benzenes and substituted derivatives. These are aromatic compounds containing at least one benzene ring. This medication targets the protein beta-lactamase.\n",
        "inchi": {
            "hash": "LGJCDEZMANATFA-ZDUSSCGKSA-N",
            "id": "InChI=1S/C13H14BNO3S/c16-12(9-11-7-4-8-19-11)15-13(14(17)18)10-5-2-1-3-6-10/h1-8,13,17-18H,9H2,(H,15,16)/t13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 275.131,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 275.078744475,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.",
        "link": "https://go.drugbank.com/drugs/DB08552",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=CC=C(O)C(O)=C1",
        "id": "DB03946",
        "molecule": "3,4-Dihydroxybenzoic Acid",
        "cas": "99-50-3",
        "iupac_name": "3,4-dihydroxybenzoic acid",
        "inchi": {
            "hash": "YQUVCSBJEUQKSH-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H6O4/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,8-9H,(H,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 154.1201,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 154.02660868,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxybenzoic acid derivatives. These are compounds containing a hydroxybenzoic acid (or a derivative), which is a benzene ring bearing a carboxyl and a hydroxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB03946",
        "type": "Small Molecule"
    },
    {
        "id": "DB11082",
        "molecule": "Coal tar",
        "cas": "8007-45-2",
        "background": "Coal tar is a brown or black liquid of extremely high viscosity. Coal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas. Coal tars are complex and variable mixtures of phenols, polycyclic aromatic hydrocarbons (PAHs), and heterocyclic compounds.\nIt has been indicated for local relief of itching, dryness, and irritation caused by psoriasis, seborrhea and eczema.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11082",
        "type": "Small Molecule",
        "synonyms": [
            "Coal tar",
            "Coal tars",
            "Tar, coal"
        ],
        "indication": "Relieving itching, irritation, redness, dryness, scaling, and flaking of the skin caused by psoriasis, seborrhea, or eczema. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Decrease bacterial growth. \n"
    },
    {
        "smiles": "O\\N=C1/C(=O)N(CC2=C3OCOCC3=CC(F)=C2)C2=CC=CC(\\C=C\\C3=CC=CC=C3)=C12",
        "id": "DB08010",
        "molecule": "(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime",
        "iupac_name": "(3Z)-1-[(6-fluoro-2,4-dihydro-1,3-benzodioxin-8-yl)methyl]-3-(hydroxyimino)-4-[(1E)-2-phenylethenyl]-2,3-dihydro-1H-indol-2-one",
        "inchi": {
            "hash": "DDHASJXGNUWZTM-ZLEWNXFRSA-N",
            "id": "InChI=1S/C25H19FN2O4/c26-20-11-18(24-19(12-20)14-31-15-32-24)13-28-21-8-4-7-17(22(21)23(27-30)25(28)29)10-9-16-5-2-1-3-6-16/h1-12,30H,13-15H2/b10-9+,27-23-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 430.4278,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 430.132885311,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.",
        "link": "https://go.drugbank.com/drugs/DB08010",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 10"
            }
        ]
    },
    {
        "smiles": "[H][C@@](N)(CC1=CC=C(I)C=C1)C(O)=O",
        "id": "DB04713",
        "molecule": "4-Iodo-D-phenylalanine",
        "cas": "62561-75-5",
        "iupac_name": "(2R)-2-amino-3-(4-iodophenyl)propanoic acid",
        "inchi": {
            "hash": "PZNQZSRPDOEBMS-MRVPVSSYSA-N",
            "id": "InChI=1S/C9H10INO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 291.0857,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 290.975621989,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB04713",
        "type": "Small Molecule",
        "synonyms": [
            "D-p-Iodophenylalanine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces griseus",
                "target": "UAminopeptidase S"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O[C@]([H])([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]1N",
        "id": "DB04263",
        "molecule": "Geneticin",
        "cas": "49863-47-0",
        "iupac_name": "(2R,3S,4R,5R,6S)-5-amino-6-{[(1R,2S,3S,4R,6S)-4,6-diamino-3-{[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-2-[(1R)-1-hydroxyethyl]oxane-3,4-diol",
        "background": "Geneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea. Geneticin blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells and is commonly used in laboratory research to select genetically engineered cells. Resistance to Geneticin is conferred by the neo gene from Tn5 encoding an aminoglycoside 3-phosphotransferase, APH 3 II.\n",
        "inchi": {
            "hash": "BRZYSWJRSDMWLG-DJWUNRQOSA-N",
            "id": "InChI=1S/C20H40N4O10/c1-6(25)14-11(27)10(26)9(23)18(32-14)33-15-7(21)4-8(22)16(12(15)28)34-19-13(29)17(24-3)20(2,30)5-31-19/h6-19,24-30H,4-5,21-23H2,1-3H3/t6-,7+,8-,9-,10-,11+,12+,13-,14-,15-,16+,17-,18-,19-,20+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 496.5524,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 496.27444352,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.",
        "link": "https://go.drugbank.com/drugs/DB04263",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UOrnithine decarboxylase"
            }
        ]
    },
    {
        "smiles": "CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O",
        "id": "DB11994",
        "molecule": "Diacerein",
        "cas": "13739-02-1",
        "iupac_name": "4,5-bis(acetyloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid",
        "background": "Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea 6. Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and Diabetes-Related Complications.\n",
        "inchi": {
            "hash": "TYNLGDBUJLVSMA-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)"
        },
        "summary": "Diacerein is an slow-onset anthraquinone IL-1 inhibitor used in the treatment of degenerative joint diseases like osteoarthritis.",
        "weight": [
            {
                "type": "average",
                "weight": 368.297,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 368.053217346,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as anthracenecarboxylic acids. These are organic compounds containing a carboxylic acid group attached to an anthracene ring system.",
        "link": "https://go.drugbank.com/drugs/DB11994",
        "type": "Small Molecule",
        "synonyms": [
            "Diacerein",
            "Diacerena"
        ],
        "indication": "For the treatment of osteoarthritis affecting the hip or knee 6.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Decreases inflammation and cartilage destruction and also corrects altered osteoblast acitivity 3 4 5.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UOxysterols receptor LXR-alpha"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UOxysterols receptor LXR-beta"
            },
            {
                "action": "inhibitor",
                "organism": "Helicobacter pylori",
                "target": "UArylamine N-acetyltransferase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UArachidonate 5-lipoxygenase"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 1A2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 3A Subfamily"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 2E1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 2C9"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UCytochrome P450 2D6"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
        "id": "DB14540",
        "molecule": "Hydrocortisone butyrate",
        "cas": "13609-67-1",
        "iupac_name": "(1R,3aS,3bS,9aR,9bS,10S,11aS)-10-hydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl butanoate",
        "inchi": {
            "hash": "BMCQMVFGOVHVNG-TUFAYURCSA-N",
            "id": "InChI=1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h12,17-19,22,26,28H,4-11,13-14H2,1-3H3/t17-,18-,19-,22+,23-,24-,25-/m0/s1"
        },
        "summary": "Hydrocortisone butyrate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.",
        "weight": [
            {
                "type": "average",
                "weight": 432.557,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 432.251188879,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.",
        "link": "https://go.drugbank.com/drugs/DB14540",
        "type": "Small Molecule",
        "synonyms": [
            "11,21-dihydroxy-17-butyryloxy-4-pregnene-3,20-dione",
            "17-O-butyrylcortisol",
            "Cortisol 17-butyrate",
            "H-17-B",
            "Hydrocortisone butyrate",
            "Hydrocortisone-17alpha-butyrate"
        ],
        "indication": "For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AAnnexin A1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AGlucocorticoid receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "U3 beta-hydroxysteroid dehydrogenase/Delta 5--\u003e4-isomerase type 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@](CC(O)=O)(N(C)C(=O)C1=C(NS(=O)(=O)C2=CC3=CC=CC=C3C=C2)C=CC(OS(=O)(=O)C2=CC3=CC=CC=C3C=C2)=C1)C(O)=O",
        "id": "DB01879",
        "molecule": "(S)-2-{Methyl-[2-(Naphthalene-2-Sulfonylamino)-5-(Naphthalene-2-Sulfonyloxy)-Benzoyl]-Amino}-Succinicacid",
        "iupac_name": "(2S)-2-{N-methyl-1-[2-(naphthalene-2-sulfonamido)-5-[(naphthalene-2-sulfonyl)oxy]phenyl]formamido}butanedioic acid",
        "inchi": {
            "hash": "JOAALZBSMWLOPQ-LJAQVGFWSA-N",
            "id": "InChI=1S/C32H26N2O10S2/c1-34(29(32(38)39)19-30(35)36)31(37)27-18-24(44-46(42,43)26-14-11-21-7-3-5-9-23(21)17-26)12-15-28(27)33-45(40,41)25-13-10-20-6-2-4-8-22(20)16-25/h2-18,29,33H,19H2,1H3,(H,35,36)(H,38,39)/t29-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 662.686,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 662.102886442,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aspartic acid and derivatives. These are compounds containing an aspartic acid or a derivative thereof resulting from reaction of aspartic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB01879",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Enterobacter cloacae subsp. cloacae (strain ATCC 13047 / DSM 30054 / NBRC 13535 / NCDC 279-56)",
                "target": "UUDP-N-acetylglucosamine 1-carboxyvinyltransferase"
            }
        ]
    },
    {
        "smiles": "[Gd]",
        "id": "DB12091",
        "molecule": "Gadolinium",
        "cas": "7440-54-2",
        "iupac_name": "gadolinium",
        "background": "Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.\n",
        "inchi": {
            "hash": "UIWYJDYFSGRHKR-UHFFFAOYSA-N",
            "id": "InChI=1S/Gd"
        },
        "weight": [
            {
                "type": "average",
                "weight": 157.25,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 157.924100533,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous lanthanide compounds. These are inorganic compounds containing only metal atoms, with the largest atom being a lanthanide atom.",
        "link": "https://go.drugbank.com/drugs/DB12091",
        "type": "Small Molecule",
        "synonyms": [
            "gadolinio"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C(=O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4",
        "id": "DB13132",
        "molecule": "Artemisinin",
        "cas": "63968-64-9",
        "iupac_name": "(1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0,.0,]hexadecan-10-one",
        "background": "Artemisinin has been used in trials studying the treatment of Schizophrenia, Malaria, Falciparum, and Plasmodium Falciparum.\n",
        "inchi": {
            "hash": "BLUAFEHZUWYNDE-NNWCWBAJSA-N",
            "id": "InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1"
        },
        "summary": "Artemisinin is a medication indicated in the treatment of malaria.",
        "weight": [
            {
                "type": "average",
                "weight": 282.336,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 282.146723808,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as terpene lactones. These are prenol lipids containing a lactone ring.",
        "link": "https://go.drugbank.com/drugs/DB13132",
        "type": "Small Molecule",
        "synonyms": [
            "Artemisinin",
            "artemisinina"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=CC=CC=C1O",
        "id": "DB01726",
        "molecule": "2-Aminophenol",
        "cas": "95-55-6",
        "iupac_name": "2-aminophenol",
        "inchi": {
            "hash": "CDAWCLOXVUBKRW-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H7NO/c7-5-3-1-2-4-6(5)8/h1-4,8H,7H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 109.1259,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 109.052763851,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB01726",
        "type": "Small Molecule",
        "synonyms": [
            "2-Aminophenol"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)",
                "target": "UNicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase"
            }
        ]
    },
    {
        "smiles": "NC1=NC2=CC=CC=C2C(=O)N1",
        "id": "DB03780",
        "molecule": "2-Aminoquinazolin-4(3h)-One",
        "iupac_name": "2-amino-3,4-dihydroquinazolin-4-one",
        "inchi": {
            "hash": "SDTFBAXSPXZDKC-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H7N3O/c9-8-10-6-4-2-1-3-5(6)7(12)11-8/h1-4H,(H3,9,10,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 161.1607,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 161.058911861,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB03780",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)",
                "target": "UQueuine tRNA-ribosyltransferase"
            }
        ]
    },
    {
        "smiles": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",
        "id": "DB00987",
        "molecule": "Cytarabine",
        "cas": "147-94-4",
        "iupac_name": "4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one",
        "background": "A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)\n",
        "inchi": {
            "hash": "UHDGCWIWMRVCDJ-CCXZUQQUSA-N",
            "id": "InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1"
        },
        "summary": "Cytarabine is a pyrimidine nucleoside analogue used to treat acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia.",
        "weight": [
            {
                "type": "average",
                "weight": 243.2166,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 243.085520541,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine nucleosides. These are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB00987",
        "type": "Small Molecule",
        "synonyms": [
            "1-beta-D-Arabinofuranosylcytosine",
            "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone",
            "Citarabina",
            "Cytarabine",
            "Cytarabine liposome",
            "Cytarabinum",
            "Cytosine arabinoside",
            "Cytosine-1-beta-D-arabinofuranoside",
            "cytosine--D-arabinofuranoside"
        ],
        "indication": "For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.\nCytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.2\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the \"S\" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ADNA polymerase beta"
            },
            {
                "action": "cross-linking/alkylation",
                "organism": "Humans",
                "target": "ADNA"
            }
        ]
    },
    {
        "smiles": "CC1=C[C@@H]2C[N@]([C@@H]1C(N)=O)C(=O)N2OS(O)(=O)=O",
        "id": "DB16704",
        "molecule": "Durlobactam",
        "cas": "1467829-71-5",
        "iupac_name": "[(1R,2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl]oxidanesulfonic acid",
        "background": "Durlobactam is under investigation in clinical trial NCT03894046 (Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex).\n",
        "inchi": {
            "hash": "BISPBXFUKNXOQY-RITPCOANSA-N",
            "id": "InChI=1S/C8H11N3O6S/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16)/t5-,6+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 277.25,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 277.03685626,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16704",
        "type": "Small Molecule",
        "synonyms": [
            "Durlobactam"
        ],
        "indication": "Durlobactam is co-packaged with sulbactam as a single combination product, and is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.2\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "pharmacodynamics": "For durlobactam, the ratio of the 24-hour unbound plasma durlobactam AUC to the sulbactam-durlobactam MIC (fAUC024/MIC) best predicts the activity in in vivo and in vitro models of infection.2 At a dose 4 times the maximum recommended single dose, durlobactam does not prolong the QTc interval to any clinically relevant extent.2\nDurlobactam has an extended spectrum of activity compared to other -lactamase inhibitors with a displayed potent inhibition against against class A, C, and D serine -lactamases. Particularly, inhibition of class D -lactamases is the key feature differentiating diazabicyclooctane like durlobactam from other inhibitors. Although it is not effective against class B metallo--lactamases, recent surveillance studies have demonstrated that this enzyme class is rarely observed in Acinetobacter clinical isolates.1\n"
    },
    {
        "smiles": "OC1=C(Br)C=C(OC2=CC=CC=C2)C=C1Br",
        "id": "DB08103",
        "molecule": "2,6-dibromo-4-phenoxyphenol",
        "iupac_name": "2,6-dibromo-4-phenoxyphenol",
        "inchi": {
            "hash": "CRSZEDOZGJPOHP-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H8Br2O2/c13-10-6-9(7-11(14)12(10)15)16-8-4-2-1-3-5-8/h1-7,15H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 343.999,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 341.889104794,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bromodiphenyl ethers. These are compounds that contain two benzene groups linked to each other via an ether bond, and where at least one ring is substituted with a bromo group.",
        "link": "https://go.drugbank.com/drugs/DB08103",
        "type": "Small Molecule"
    },
    {
        "smiles": "[Fe++].N[C@@H](CC([O-])=O)C([O-])=O",
        "id": "DB13220",
        "molecule": "Ferrous aspartate",
        "cas": "75802-64-1",
        "iupac_name": "lambda2-iron(2+) ion (2S)-2-aminobutanedioate",
        "background": "The use of ferrous acetate over ferrous sulfate is currently undergoing an investigation by a clinical trial 1. It is also used for dying of fabric or leather and as a wood preservative.\n",
        "inchi": {
            "hash": "KKPUODLFBBWJPH-DKWTVANSSA-L",
            "id": "InChI=1S/C4H7NO4.Fe/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H,6,7)(H,8,9);/q;+2/p-2/t2-;/m0./s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 186.932,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 186.956794,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aspartic acid and derivatives. These are compounds containing an aspartic acid or a derivative thereof resulting from reaction of aspartic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB13220",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCNCC(O)C1=CC=CC(O)=C1",
        "id": "DB08985",
        "molecule": "Etilefrine",
        "cas": "709-55-7",
        "iupac_name": "3-[2-(ethylamino)-1-hydroxyethyl]phenol",
        "background": "Etilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.\n",
        "inchi": {
            "hash": "SQVIAVUSQAWMKL-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3"
        },
        "summary": "Etilefrine is an adrenergic agonist primarily of 1 and 1 receptors used as an anti-hypotensive.",
        "weight": [
            {
                "type": "average",
                "weight": 181.2316,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 181.110278729,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.",
        "link": "https://go.drugbank.com/drugs/DB08985",
        "type": "Small Molecule",
        "synonyms": [
            "Etilefrina",
            "Etilefrine",
            "Etilefrinum"
        ]
    },
    {
        "smiles": "O[C@@]12CCN(C1=NC1=C(C=CC=C1)C2=O)C1=CC=CC=C1",
        "id": "DB07470",
        "molecule": "(3aS)-3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one",
        "iupac_name": "(3aS)-3a-hydroxy-1-phenyl-1H,2H,3H,3aH,4H-pyrrolo[2,3-b]quinolin-4-one",
        "inchi": {
            "hash": "DOMYOVZXZIZTRD-QGZVFWFLSA-N",
            "id": "InChI=1S/C17H14N2O2/c20-15-13-8-4-5-9-14(13)18-16-17(15,21)10-11-19(16)12-6-2-1-3-7-12/h1-9,21H,10-11H2/t17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 278.3053,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 278.105527702,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrroloquinolines. These are compounds containing a pyrroloquinoline moiety, which consists of a pyrrole ring fused to a quinoline.",
        "link": "https://go.drugbank.com/drugs/DB07470",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMyosin-14"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08198"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02839"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13592"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04240"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13512"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07280"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04781"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07767"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00248"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01496"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11868"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08285"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14055"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01189"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15334"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15063"
    },
    {
        "smiles": "O[C@H]1CCCN[C@@H]1CCCN1C=NC2=C(Cl)C(Cl)=CC=C12",
        "id": "DB18017",
        "molecule": "Bersiporocin",
        "cas": "2241808-52-4",
        "inchi": {
            "hash": "VXCNMWNXDDMFSX-YPMHNXCESA-N",
            "id": "InChI=1S/C15H19Cl2N3O/c16-10-5-6-12-15(14(10)17)19-9-20(12)8-2-3-11-13(21)4-1-7-18-11/h5-6,9,11,13,18,21H,1-4,7-8H2/t11-,13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 328.24,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 327.0905176,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18017",
        "type": "Small Molecule",
        "synonyms": [
            "(2r,3s)-2-(3-(4,5-dichloro-1h-benzo(d)imidazol-1-yl)propyl)piperidin-3-ol",
            "3-piperidinol, 2-(3-(4,5-dichloro-1h-benzimidazol-1-yl)propyl)-, (2r,3s)"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01884"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02170"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08997"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17554"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03399"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06525"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13032"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01328"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06225"
    },
    {
        "id": "DB05778",
        "molecule": "Col-118",
        "background": "COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders. It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05778",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in skin infections/disorders.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2",
        "id": "DB00732",
        "molecule": "Atracurium besylate",
        "cas": "64228-81-5",
        "iupac_name": "1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium dibenzenesulfonate",
        "background": "A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.\n",
        "inchi": {
            "hash": "XXZSQOVSEBAPGS-UHFFFAOYSA-L",
            "id": "InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2"
        },
        "summary": "Atracurium besylate is a non-depolarizing neuromuscular blocker used to facilitate endotracheal intubation and relax skeletal muscles during surgery.",
        "weight": [
            {
                "type": "average",
                "weight": 1243.49,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1242.500406156,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.",
        "link": "https://go.drugbank.com/drugs/DB00732",
        "type": "Small Molecule",
        "synonyms": [
            "Atracurium besilate",
            "Atracurium besylate",
            "Atracurium dibesylate",
            "Besilate d'atracurium",
            "Besilato de atracurio"
        ],
        "indication": "For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ANeuronal acetylcholine receptor subunit alpha-2"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CF)N1C=NC2=C1N=CN=C2N",
        "id": "DB07170",
        "molecule": "5'-FLUORO-2',5'-DIDEOXYADENOSINE",
        "iupac_name": "(2S,3S,5R)-5-(6-amino-9H-purin-9-yl)-2-(fluoromethyl)oxolan-3-ol",
        "inchi": {
            "hash": "QKUCDAPGYBWICH-RRKCRQDMSA-N",
            "id": "InChI=1S/C10H12FN5O2/c11-2-6-5(17)1-7(18-6)16-4-15-8-9(12)13-3-14-10(8)16/h3-7,17H,1-2H2,(H2,12,13,14)/t5-,6+,7+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 253.233,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 253.097502858,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2',5'-dideoxyribonucleosides. These are nucleosides characterized by a purine or pyrimidine base, which is N-linked to a 2',5'-dideoxyribose moiety.",
        "link": "https://go.drugbank.com/drugs/DB07170",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces cattleya",
                "target": "U5'-fluoro-5'-deoxy-adenosine synthase"
            }
        ]
    },
    {
        "smiles": "[H][C@](C)(O)[C@@]1([H])O[C@@]([H])(N2C=NC3=C(C)N=CN=C23)[C@]([H])(O)[C@]1([H])O",
        "id": "DB03952",
        "molecule": "9-(6-deoxy-beta-D-allofuranosyl)-6-methylpurine",
        "iupac_name": "(2R,3S,4R,5R)-2-[(1R)-1-hydroxyethyl]-5-(6-methyl-9H-purin-9-yl)oxolane-3,4-diol",
        "inchi": {
            "hash": "XJZDIUOABWMPLZ-FHQKJXBVSA-N",
            "id": "InChI=1S/C12H16N4O4/c1-5-7-11(14-3-13-5)16(4-15-7)12-9(19)8(18)10(20-12)6(2)17/h3-4,6,8-10,12,17-19H,1-2H3/t6-,8+,9-,10-,12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 280.2798,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 280.11715502,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.",
        "link": "https://go.drugbank.com/drugs/DB03952",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPurine nucleoside phosphorylase DeoD-type"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(N)CCCC[C@@]1([H])NC1=NC(NC2=CC=CC(C)=C2)=C(C=N1)C(N)=O",
        "id": "DB08361",
        "molecule": "2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide",
        "iupac_name": "2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide",
        "inchi": {
            "hash": "NZNTWOVDIXCHHS-LSDHHAIUSA-N",
            "id": "InChI=1S/C18H24N6O/c1-11-5-4-6-12(9-11)22-17-13(16(20)25)10-21-18(24-17)23-15-8-3-2-7-14(15)19/h4-6,9-10,14-15H,2-3,7-8,19H2,1H3,(H2,20,25)(H2,21,22,23,24)/t14-,15+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 340.4228,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 340.20115942,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidinecarboxamides. These are compounds containing a pyrimidine ring which bears a carboxamide.",
        "link": "https://go.drugbank.com/drugs/DB08361",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein kinase SYK"
            }
        ]
    },
    {
        "smiles": "CC1=CC=NC2=C3N=CC=C(C)C3=CC=C12",
        "id": "DB02586",
        "molecule": "4,7-Dimethyl-[1,10]Phenanthroline",
        "cas": "3248-05-3",
        "iupac_name": "4,7-dimethyl-1,10-phenanthroline",
        "inchi": {
            "hash": "JIVLDFFWTQYGSR-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H12N2/c1-9-5-7-15-13-11(9)3-4-12-10(2)6-8-16-14(12)13/h3-8H,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 208.2585,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 208.100048394,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenanthrolines. These are aromatic polycyclic compounds containing the phenanthroline skeleton, which is a derivative of phenanthrene, and consists of two pyridine rings non-linearly joined by a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB02586",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UAzurin"
            }
        ]
    },
    {
        "smiles": "[Cr]",
        "id": "DB11136",
        "molecule": "Chromium",
        "cas": "7440-47-3",
        "iupac_name": "chromium",
        "background": "Chromium is a transition element with the chemical symbol Cr and atomic number 24 that belongs to Group 6 of the periodic table. It is used in various chemical, industrial and manufacturing applications such as wood preservation and metallurgy. The uses of chromium compounds depend on the valency of chromium, where trivalent Cr (III) compounds are used for dietary Cr supplementation and hexavalent Cr (VI) compounds are used as corrosion inhibitors in commercial settings and are known to be human carcinogens 5. Humans can be exposed to chromium via ingestion, inhalation, and dermal or ocular exposure 6. Trivalent chromium (Cr(III)) ion is considered to be an essential dietary trace element as it is involved in metabolism of blood glucose, regulation of insulin resistance and metabolism of lipids. Clinical trials and other studies suggest the evidence of chromium intake improving glucose tolerance in patients with Type I and II diabetes, however its clinical application in the standard management of type II diabetes mellitus is not established. Chromium deficiency has been associated with a diabetic-like state, impaired growth, decreased fertility and increased risk of cardiovascular diseases 1,2,5.\nAccording to the National Institute of Health, the daily dietary reference intake (DRI) of chromium for adult male and non-pregnant female are 35 g and 25 g, respectively 7. Chromium picolinate capsules may be used as nutritional adjuvant in patients with or at risk of type 2 diabetes mellitus (T2DM) to improve blood sugar metabolism and stabilize the levels of serum cholesterol. Chromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) Label.\n",
        "inchi": {
            "hash": "VYZAMTAEIAYCRO-UHFFFAOYSA-N",
            "id": "InChI=1S/Cr"
        },
        "summary": "Chromium is an ingredient found in a variety of supplements and vitamins.",
        "weight": [
            {
                "type": "average",
                "weight": 51.9961,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 51.940511904,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.",
        "link": "https://go.drugbank.com/drugs/DB11136",
        "type": "Small Molecule",
        "synonyms": [
            "Biochrome",
            "Chrom",
            "Chromium, elemental",
            "Cromo",
            "Dinakrome"
        ],
        "indication": "Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN), to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms Label.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Trivalent chromium is part of glucose tolerance factor, an essential activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function. Chromium increases insulin binding to cells, increases insulin receptor density and activates insulin receptor kinase leading to enhanced insulin sensitivity 2. In chromium deficiency, intravenous administration of chromium resulted in normalization of the glucose tolerance curve from the diabetic-like curve typical of chromium deficiency Label. \n",
        "moa": [
            {
                "action": "substrate",
                "organism": "Humans",
                "target": "UCytochrome b5"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00724"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12031"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07565"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07915"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15968"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02688"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03058"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06497"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08467"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03317"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15379"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07598"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01228"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02446"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13213"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13667"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03912"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17537"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03958"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08634"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02185"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14082"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14517"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01951"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03177"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02455"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02731"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07761"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04172"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02128"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02802"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04771"
    },
    {
        "smiles": "CN(C)CCCOC1(CC2=CC=CC=C2)CCCCCC1",
        "id": "DB13488",
        "molecule": "Bencyclane",
        "cas": "2179-37-5",
        "iupac_name": "{3-[(1-benzylcycloheptyl)oxy]propyl}dimethylamine",
        "background": "A vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects. Its mechanism may involve block of calcium channels.\n",
        "inchi": {
            "hash": "FYJJXENSONZJRG-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H31NO/c1-20(2)15-10-16-21-19(13-8-3-4-9-14-19)17-18-11-6-5-7-12-18/h5-7,11-12H,3-4,8-10,13-17H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 289.463,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 289.240564622,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.",
        "link": "https://go.drugbank.com/drugs/DB13488",
        "type": "Small Molecule",
        "synonyms": [
            "3-((1-Benzylcycloheptyl)oxy)-N,N-dimethylpropylamin",
            "Benciclano",
            "Bencyclane",
            "Bencyclanum"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01888"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02049"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17283"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01424"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02633"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06910"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03970"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00126"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05353"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18516"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12850"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08300"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07632"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04561"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13452"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13849"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02625"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12040"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08144"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01612"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18000"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01526"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02136"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08156"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04587"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13955"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02391"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04619"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12497"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15962"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01545"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08873"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01946"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09555"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12011"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00272"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12499"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07621"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04166"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06579"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03765"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11281"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15333"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00711"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07921"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01797"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13662"
    },
    {
        "smiles": "[Ca++].[H][C@](O)(C([O-])=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)C([O-])=O",
        "id": "DB13962",
        "molecule": "Calcium saccharate",
        "cas": "5793-88-4",
        "iupac_name": "calcium (2R,3S,4S,5S)-2,3,4,5-tetrahydroxyhexanedioate",
        "background": "Pharmaceutic Aid (Stabilizer)\n",
        "inchi": {
            "hash": "UGZVNIRNPPEDHM-SBBOJQDXSA-L",
            "id": "InChI=1S/C6H10O8.Ca/c7-1(3(9)5(11)12)2(8)4(10)6(13)14;/h1-4,7-10H,(H,11,12)(H,13,14);/q;+2/p-2/t1-,2-,3-,4+;/m0./s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 248.2,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 247.9845081,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB13962",
        "type": "Small Molecule",
        "synonyms": [
            "Calcii saccharas",
            "Calcium D-glucarate",
            "Calcium D-saccharate",
            "Calcium glucarate",
            "Calcium saccharate",
            "Sacarato calcico",
            "Saccharate de calcium",
            "Saccharated lime"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1",
        "id": "DB00522",
        "molecule": "Bentiromide",
        "cas": "37106-97-1",
        "iupac_name": "4-[(2S)-3-(4-hydroxyphenyl)-2-(phenylformamido)propanamido]benzoic acid",
        "background": "Bentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy. It is typically administered orally. Cases of headache and gastrointestinal disturbances have been reported with the use of bentiromide. Bentiromide is currently not available in the U.S. or Canada.\n",
        "inchi": {
            "hash": "SPPTWHFVYKCNNK-FQEVSTJZSA-N",
            "id": "InChI=1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)/t20-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 404.4153,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 404.13722176,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB00522",
        "type": "Small Molecule",
        "synonyms": [
            "Bentiromide",
            "Bentiromido",
            "Bentiromidum",
            "BTPABA",
            "PFT"
        ],
        "indication": "Indicated as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. The amount of p-aminobenzoic acid and its metabolites excreted in the urine is the quantitative measure of the chymotrypsin-secreting activity of the pancreas. \n",
        "moa": [
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "ASerine protease hepsin"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06630"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02685"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18105"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07604"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07711"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08320"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04233"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04972"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13051"
    },
    {
        "smiles": "[H][C@](CC=C)(C=O)[C@@]1([H])CCC[C@]1([H])O",
        "id": "DB06901",
        "molecule": "2-(2-HYDROXY-CYCLOPENTYL)-PENT-4-ENAL",
        "iupac_name": "(2R)-2-[(1R,2S)-2-hydroxycyclopentyl]pent-4-enal",
        "inchi": {
            "hash": "NEWBFDLFXDTFGD-AEJSXWLSSA-N",
            "id": "InChI=1S/C10H16O2/c1-2-4-8(7-11)9-5-3-6-10(9)12/h2,7-10,12H,1,3-6H2/t8-,9+,10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 168.2328,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 168.115029756,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cyclopentanols. These are compounds containing a cyclopentane ring that carries an alcohol group.",
        "link": "https://go.drugbank.com/drugs/DB06901",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UChymotrypsin-like elastase family member 2A"
            }
        ]
    },
    {
        "smiles": "CSC1=CC=C(OCC2=NC=C(N2C)[N+]([O-])=O)C=C1",
        "id": "DB12265",
        "molecule": "Fexinidazole",
        "cas": "59729-37-2",
        "iupac_name": "1-methyl-2-{[4-(methylsulfanyl)phenoxy]methyl}-5-nitro-1H-imidazole",
        "background": "Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (\u003e1/10,000 inhabitants per year in endemic areas) despite focussed control efforts. Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively worsening neurological symptoms and eventually die if left untreated.1 Historical treatment options for meningoencephalitic HAT include melarsoprol, eflornithine, and nifurtimox/eflornithine combination therapy (NECT), though melarsoprol is highly toxic and each treatment requires lengthy infusions that are difficult to administer in resource-limited settings.1,3 Fexinidazole, which was originally developed in the 1970s/80s by Hoechst AG and subsequently rediscovered through the Drugs for Neglected Diseases Initiative (DNDi) in 2005, is the first all-oral treatment for first and second stage HAT caused by T. brucei gambiense.2,3\nFexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021.2,8 It is currently marketed by Sanofi-Aventis.8\n",
        "inchi": {
            "hash": "MIWWSGDADVMLTG-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H13N3O3S/c1-14-11(13-7-12(14)15(16)17)8-18-9-3-5-10(19-2)6-4-9/h3-7H,8H2,1-2H3"
        },
        "summary": "Fexinidazole is an orally bioavailable 2-substituted 5-nitroimidazole used to treat early- and late-stage human African trypanosomiasis caused by Trypanosoma brucei gambiense.",
        "weight": [
            {
                "type": "average",
                "weight": 279.31,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 279.067762465,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitroimidazoles. These are compounds containing an imidazole ring which bears a nitro group.",
        "link": "https://go.drugbank.com/drugs/DB12265",
        "type": "Small Molecule",
        "synonyms": [
            "Fexinidazole"
        ],
        "indication": "Fexinidazole is a nitroimidazole indicated for the treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in patients 6 years of age and older weighing at least 20 kg.8\nDue to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) \u003e100 cells/L), fexinidazole should only be used in these patients if there are no other available treatment options.8\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fexinidazole is a 2-substituted 5-nitroimidazole that is likely activated by parasitic nitroreductases to highly reactive species, leading to DNA and protein damage and eventual parasite death.2,3,8 The dosing schedule is designed to ensure a high enough concentration of fexinidazole and its reactive metabolites for at least 48 hours, which from in vitro studies was shown to be the minimum exposure time that was effectively trypanocidal.4,5 Although fexinidazole is effective in late-stage T. brucei gambiense HAT, it is less effective than NECT therapy in patients with severe (cerebrospinal fluid white blood cell count (CSF-WBC) \u003e100 cells/L at baseline) disease. It should only be used in these patients if there are no other available treatment options. Fexinidazole has been shown to prolong the QT interval in a dose-dependent manner and was also associated with a higher incidence of insomnia, headache, tremors, psychiatric disorders, and suicidal ideation in clinical trials; patients with pre-existing conditions or concomitant medications that could aggravate any of these effects should be treated with caution. In addition, fexinidazole has been associated with neutropenia and elevations in liver transaminases, which should be monitored. Nitroimidazoles like fexinidazole have been associated with a disulfiram-like reaction when used concomitantly with alcohol and psychotic reactions when taken with disulfiram itself; patients should avoid alcohol and disulfiram when taking fexinidazole.8\n"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00473"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03369"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11832"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02734"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08246"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18409"
    },
    {
        "smiles": "O=C1CCCCC2=C3N=C(NC4=CC(N1)=CC=C4)N=C(NC1CC1)N3N=C2",
        "id": "DB08338",
        "molecule": "19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one",
        "iupac_name": "18-(cyclopropylamino)-2,8,16,17,19,20-hexaazatetracyclo[12.5.2.1^{3,7}.0^{17,21}]docosa-1(20),3(22),4,6,14(21),15,18-heptaen-9-one",
        "inchi": {
            "hash": "HIJNSOUPEZHEMC-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H21N7O/c27-16-7-2-1-4-12-11-20-26-17(12)24-18(25-19(26)23-13-8-9-13)22-15-6-3-5-14(10-15)21-16/h3,5-6,10-11,13H,1-2,4,7-9H2,(H,21,27)(H2,22,23,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 363.4163,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 363.180758329,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides.",
        "link": "https://go.drugbank.com/drugs/DB08338",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCasein kinase II subunit alpha"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16824"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11742"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06738"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03183"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11676"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16911"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14774"
    },
    {
        "smiles": "NC(N)=NC1=CC=C(CC(NC(=O)CSC2=CC=C(Cl)C=C2)C(N)=O)C=C1",
        "id": "DB07105",
        "molecule": "2-[2-(4-Chloro-Phenylsulfanyl)-Acetylamino]-3-(4-Guanidino-Phenyl)-Propionamide",
        "iupac_name": "2-{2-[(4-chlorophenyl)sulfanyl]acetamido}-3-{4-[(diaminomethylidene)amino]phenyl}propanamide",
        "inchi": {
            "hash": "IEEYGOJDTRVYGR-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H20ClN5O2S/c19-12-3-7-14(8-4-12)27-10-16(25)24-15(17(20)26)9-11-1-5-13(6-2-11)23-18(21)22/h1-8,15H,9-10H2,(H2,20,26)(H,24,25)(H4,21,22,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 405.9,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 405.1026238,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB07105",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "NC1=NC2=C(C(=CN2)C#N)C(=O)N1",
        "id": "DB03074",
        "molecule": "7-cyano-7-deazaguanine",
        "iupac_name": "4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile",
        "inchi": {
            "hash": "FMKSMYDYKXQYRV-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H5N5O/c8-1-3-2-10-5-4(3)6(13)12-7(9)11-5/h2H,(H4,9,10,11,12,13)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 175.1475,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 175.049409807,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolo[2,3-d]pyrimidines. These are aromatic heteropolycyclic compounds containing a pyrrolo[2,3-d]pyrimidine ring system, which is an pyrrolopyrimidine isomers having the 3 ring nitrogen atoms at the 1-, 5-, and 7-positions.",
        "link": "https://go.drugbank.com/drugs/DB03074",
        "type": "Small Molecule",
        "synonyms": [
            "7-CN-7-deazaG",
            "7-Cyano-7-carbaguanine"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)",
                "target": "UQueuine tRNA-ribosyltransferase"
            }
        ]
    },
    {
        "smiles": "S=C(NCC1=CC=C2OCOC2=C1)N1CCN(CC1)C1=NC=NC2=C1OC1=C2C=CC=C1",
        "id": "DB12742",
        "molecule": "Amuvatinib",
        "cas": "850879-09-3",
        "iupac_name": "N-[(2H-1,3-benzodioxol-5-yl)methyl]-4-{8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl}piperazine-1-carbothioamide",
        "background": "Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.\n",
        "inchi": {
            "hash": "FOFDIMHVKGYHRU-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 447.51,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 447.13651073,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB12742",
        "type": "Small Molecule",
        "synonyms": [
            "1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-d)pyrimidin-4-yl-",
            "4-[1]Benzofuro[3,2-D]Pyrimidin-4-Yl-N-(1,3-Benzodioxol-5-Ylmethyl)Piperazine-1-Carbothioamide",
            "Amuvatinib",
            "N-(1,3-Benzodioxol-5-ylmethyl)-4-(benzofuro(3,2-d)pyrimidin-4-yl)piperazine-1- carbothioamide"
        ],
        "indication": "Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMast/stem cell growth factor receptor Kit"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHepatocyte growth factor receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProto-oncogene tyrosine-protein kinase receptor Ret"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPlatelet-derived growth factor receptor alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UReceptor-type tyrosine-protein kinase FLT3"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA repair protein RAD51 homolog 1"
            }
        ]
    },
    {
        "smiles": "CC(=O)N1CC(F)(F)C2=C(SC3=NC=C(N=C3N)N3CCC4(COC[C@H]4N)CC3)C=CC=C12",
        "id": "DB17131",
        "molecule": "JAB-3068",
        "iupac_name": "1-[4-({3-amino-5-[(4S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl}sulfanyl)-3,3-difluoro-2,3-dihydro-1H-indol-1-yl]ethan-1-one",
        "inchi": {
            "hash": "HGYTYZKWKUXRKA-MRXNPFEDSA-N",
            "id": "InChI=1S/C22H26F2N6O2S/c1-13(31)30-11-22(23,24)18-14(30)3-2-4-15(18)33-20-19(26)28-17(9-27-20)29-7-5-21(6-8-29)12-32-10-16(21)25/h2-4,9,16H,5-8,10-12,25H2,1H3,(H2,26,28)/t16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 476.55,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 476.180601601,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17131",
        "type": "Small Molecule",
        "synonyms": [
            "JAB3068"
        ]
    },
    {
        "id": "DB04893",
        "molecule": "AZD3409",
        "background": "AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04893",
        "type": "Small Molecule",
        "indication": "For the treatment of solid tumors.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "AZD3409 is a novel, oral, antitumor agent that acts as a prenyl transferase inhibitor. It has potentially broad antitumor activity both as monotherapy and in combination with other anticancer treatments. AZD3409 is a double pro-drug; its metabolism involves conversion to a thiol-ester intermediate, then, intracellularly, to a thiol-acid active species. Phase I trials were initiated January 2003, and were ongoing as of February 2004. Recent studies have shown that AZD3409 is a potent inhibitor of both prostate epithelial cell proliferation and cellular invasion, without an associated bone marrow cellular toxicity.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein farnesyltransferase subunit beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha"
            }
        ]
    },
    {
        "smiles": "C[C@H](NC(=O)C(=O)NC1=C(F)C=CC=C1F)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F",
        "id": "DB18073",
        "molecule": "IDN-7314",
        "cas": "254750-11-3",
        "inchi": {
            "hash": "VMPUKWSLCRUGSR-SDBXPKJASA-N",
            "id": "InChI=1S/C22H17F6N3O7/c1-8(29-21(36)22(37)31-18-9(23)3-2-4-10(18)24)20(35)30-13(6-15(33)34)14(32)7-38-19-16(27)11(25)5-12(26)17(19)28/h2-5,8,13H,6-7H2,1H3,(H,29,36)(H,30,35)(H,31,37)(H,33,34)/t8-,13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 549.382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 549.097068877,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18073",
        "type": "Small Molecule",
        "synonyms": [
            "(s)-3-((s)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid",
            "L-alaninamide, n-(2,6-difluorophenyl)-2-oxoglycyl-n-((1s)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl)-",
            "N-(2,6-difluorophenyl)-2-oxoglycyl-n-((1s)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl)-l-alaninamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=CC=C(C=C1)[As](O)(O)=O",
        "id": "DB03006",
        "molecule": "Arsanilic acid",
        "cas": "98-50-0",
        "iupac_name": "(4-aminophenyl)arsonic acid",
        "background": "An arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]\n",
        "inchi": {
            "hash": "XKNKHVGWJDPIRJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H8AsNO3/c8-6-3-1-5(2-4-6)7(9,10)11/h1-4H,8H2,(H2,9,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 217.0542,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 216.972014544,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB03006",
        "type": "Small Molecule",
        "synonyms": [
            "(p-aminophenyl)arsonic acid",
            "4-aminobenzenearsonic acid",
            "4-Aminophenylarsonic acid",
            "4-Aminophenylarsonsure",
            "4-arsanilic acid",
            "Arsanilic acid",
            "Arsanilsure",
            "atoxylic acid",
            "p-arsanilic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULysozyme C"
            }
        ]
    },
    {
        "smiles": "CC1=C2N(C=C1NC(=O)OC[C@@H]1COCCN1)N=CN=C2NC1=CC=C2N(CC3=CC=CC(F)=C3)N=CC2=C1",
        "id": "DB12318",
        "molecule": "BMS-599626",
        "cas": "714971-09-2",
        "iupac_name": "[(3S)-morpholin-3-yl]methyl N-[4-({1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl}amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate",
        "background": "BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.\n",
        "inchi": {
            "hash": "LUJZZYWHBDHDQX-QFIPXVFZSA-N",
            "id": "InChI=1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)/t22-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 530.564,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 530.219014924,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.",
        "link": "https://go.drugbank.com/drugs/DB12318",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "FC1=C(C=C(C=N1)C1CC2CCC1N2)C1=CC=C(C=C1)C#N",
        "id": "DB14029",
        "molecule": "Furafylline",
        "cas": "80288-49-9",
        "iupac_name": "4-(5-{7-azabicyclo[2.2.1]heptan-2-yl}-2-fluoropyridin-3-yl)benzonitrile",
        "background": "Furafylline is a derivative of methylxanthine derivative. It was developed on the context of asthma as a long-acting alternative for theophylline.\n",
        "inchi": {
            "hash": "HMZQULPVMKITSP-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H16FN3/c19-18-16(12-3-1-11(9-20)2-4-12)7-13(10-21-18)15-8-14-5-6-17(15)22-14/h1-4,7,10,14-15,17,22H,5-6,8H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 293.345,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 293.13282569,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14029",
        "type": "Small Molecule",
        "synonyms": [
            "Furafilina",
            "Furafylline",
            "Furafyllinum"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OC2CC(OC2CO)N2C=CC(N)=NC2=O)O1",
        "id": "DB03326",
        "molecule": "Deoxycytidylyl-3',5'-guanosine",
        "cas": "52474-59-6",
        "iupac_name": "{[5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy}({[(2R,3S,5R)-5-(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy})phosphinic acid",
        "inchi": {
            "hash": "OBCJQWSXSLYWHI-GVKYBDNRSA-N",
            "id": "InChI=1S/C19H25N8O10P/c20-12-1-2-26(19(31)23-12)14-4-9(10(5-28)35-14)37-38(32,33)34-6-11-8(29)3-13(36-11)27-7-22-15-16(27)24-18(21)25-17(15)30/h1-2,7-11,13-14,28-29H,3-6H2,(H,32,33)(H2,20,23,31)(H3,21,24,25,30)/t8-,9?,10?,11+,13+,14?/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 556.4232,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 556.143125572,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as (3'-\u003e5')-dinucleotides. These are dinucleotides where the two bases are connected via a (3'-\u003e5')-phosphodiester linkage.",
        "link": "https://go.drugbank.com/drugs/DB03326",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "URibonuclease pancreatic"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15576"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09226"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04709"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00606"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11342"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08657"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13371"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15578"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01114"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11811"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15969"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00223"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03831"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00997"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07242"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15911"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01820"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02080"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00151"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02717"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07934"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04156"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00266"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02921"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02305"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07451"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18518"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06157"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04630"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07390"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14157"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13681"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12736"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17815"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13576"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08087"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02940"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00626"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02793"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06931"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02466"
    },
    {
        "smiles": "CO[C@H]1[C@H](OC(=O)C2=CC=C(C)N2)[C@H](O)[C@@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=C(C)C(=CN2)C(=O)NC2=C(O)C4=C(OC2=O)C(C)=C(O[C@H]2OC(C)(C)[C@@H](OC)[C@H](OC(=O)C5=CC=C(C)N5)[C@@H]2O)C=C4)C(=O)O3)OC1(C)C",
        "id": "DB13912",
        "molecule": "Coumermycin A1",
        "cas": "4434-05-3",
        "iupac_name": "(3S,4R,5S,6S)-5-hydroxy-6-[(4-hydroxy-3-{5-[(4-hydroxy-7-{[(2S,3S,4R,5S)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1H-pyrrole-2-carbonyloxy)oxan-2-yl]oxy}-8-methyl-2-oxo-2H-chromen-3-yl)carbamoyl]-4-methyl-1H-pyrrole-3-amido}-8-methyl-2-oxo-2H-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyloxan-4-yl 5-methyl-1H-pyrrole-2-carboxylate",
        "inchi": {
            "hash": "WTIJXIZOODAMJT-IYKSDEDASA-N",
            "id": "InChI=1S/C55H59N5O20/c1-21-12-16-29(57-21)48(67)77-42-38(63)52(79-54(6,7)44(42)71-10)73-31-18-14-26-36(61)34(50(69)75-40(26)24(31)4)59-46(65)28-20-56-33(23(28)3)47(66)60-35-37(62)27-15-19-32(25(5)41(27)76-51(35)70)74-53-39(64)43(45(72-11)55(8,9)80-53)78-49(68)30-17-13-22(2)58-30/h12-20,38-39,42-45,52-53,56-58,61-64H,1-11H3,(H,59,65)(H,60,66)/t38-,39-,42+,43+,44-,45-,52-,53-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 1110.092,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1109.37533932,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as coumarin glycosides. These are aromatic compounds containing a carbohydrate moiety glycosidically bound to a coumarin moiety.",
        "link": "https://go.drugbank.com/drugs/DB13912",
        "type": "Small Molecule",
        "synonyms": [
            "Coumamycin",
            "Coumermycin",
            "Notomycin A1"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](CC1=CC=CC=C1)(NC(C)=O)C(=O)C(F)(F)F",
        "id": "DB07380",
        "molecule": "1,1,1-TRIFLUORO-3-ACETAMIDO-4-PHENYL BUTAN-2-ONE(N-ACETYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",
        "iupac_name": "N-[(2S)-4,4,4-trifluoro-3-oxo-1-phenylbutan-2-yl]acetamide",
        "inchi": {
            "hash": "JTIIYPHJIDENCW-JTQLQIEISA-N",
            "id": "InChI=1S/C12H12F3NO2/c1-8(17)16-10(11(18)12(13,14)15)7-9-5-3-2-4-6-9/h2-6,10H,7H2,1H3,(H,16,17)/t10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 259.2244,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 259.082013248,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.",
        "link": "https://go.drugbank.com/drugs/DB07380",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UChymotrypsinogen B"
            }
        ]
    },
    {
        "smiles": "OC[C@H]1O[C@H]([C@@H](F)[C@@H]1O)N1C=C(I)C(=O)NC1=O",
        "id": "DB15427",
        "molecule": "Fialuridine",
        "cas": "69123-98-4",
        "iupac_name": "1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione",
        "background": "Fialuridine is under investigation in clinical trial NCT01337466 (Biodistribution and Dosimetry Evaluation of [124I]FIAU).\n",
        "inchi": {
            "hash": "IPVFGAYTKQKGBM-BYPJNBLXSA-N",
            "id": "InChI=1S/C9H10FIN2O5/c10-5-6(15)4(2-14)18-8(5)13-1-3(11)7(16)12-9(13)17/h1,4-6,8,14-15H,2H2,(H,12,16,17)/t4-,5+,6-,8-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 372.091,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 371.96184,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15427",
        "type": "Small Molecule",
        "synonyms": [
            "Fialuridine"
        ],
        "is_stub": true
    },
    {
        "smiles": "NNC(=O)C1=CC=C(O1)C1=CC=CC=C1Cl",
        "id": "DB08757",
        "molecule": "5-(2-chlorophenyl)furan-2-carbohydrazide",
        "iupac_name": "5-(2-chlorophenyl)furan-2-carbohydrazide",
        "inchi": {
            "hash": "XQMRHWSGTVEDFG-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H9ClN2O2/c12-8-4-2-1-3-7(8)9-5-6-10(16-9)11(15)14-13/h1-6H,13H2,(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 236.654,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 236.035255249,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as furoic acid and derivatives. These are aromatic heterocyclic compounds containing a furan ring, which carries a carboxyl group or a derivative thereof.",
        "link": "https://go.drugbank.com/drugs/DB08757",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMethionine aminopeptidase"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=CC=C(O1)C1=CC=CC=C1C(F)(F)F",
        "id": "DB07759",
        "molecule": "5-[2-(TRIFLUOROMETHYL)PHENYL]-2-FUROIC ACID",
        "iupac_name": "5-[2-(trifluoromethyl)phenyl]furan-2-carboxylic acid",
        "inchi": {
            "hash": "IJPNRBZMRINMMR-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H7F3O3/c13-12(14,15)8-4-2-1-3-7(8)9-5-6-10(18-9)11(16)17/h1-6H,(H,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 256.1774,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 256.034728705,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.",
        "link": "https://go.drugbank.com/drugs/DB07759",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UMethionine aminopeptidase"
            }
        ]
    },
    {
        "smiles": "C[C@H](\\C=C\\C=C(/C)[C@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N2CCN(C)CC2)\\C=C\\[C@@H]1C)C1=CC=CC=N1",
        "id": "DB14017",
        "molecule": "H3B-8800",
        "cas": "1825302-42-8",
        "iupac_name": "(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-[(4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]-1-oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate",
        "background": "H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine 4. It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting 1. H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia 4.\n",
        "inchi": {
            "hash": "YOIQWBAHJZGRFW-WVRLKXNASA-N",
            "id": "InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 555.716,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 555.330836181,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14017",
        "type": "Small Molecule",
        "synonyms": [
            "(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate",
            "(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-Dimethyl-12-Oxo-2-[(2E,4E,6R)-6-(Pyridin-2-Yl)Hepta-2,4-Dien-2-Yl]Oxacyclododec-4-En-6-Yl 4-Methylpiperazine-1-Carboxylate",
            "1-PIPERAZINECARBOXYLIC ACID, 4-METHYL-, (2S,3S,4E,6S,7R,10R)-7,10-DIHYDROXY-3,7-DIMETHYL-2-((1E,3E,5R)-1-METHYL-5-(2-PYRIDINYL)-1,3-HEXADIEN-1-YL)-12-OXOOXACYCLODODEC-4-EN-6-YL ESTER"
        ],
        "is_stub": true,
        "pharmacodynamics": "H3B-8800 preferentially targets cells with spliceosome complexes containing mutant splicing factor 3B1 (SF3B1) protein, modulating intron splicing leading to increased death in cancer cells while having little effect on the viability cells with wild-type SF3B1 1,2. Both normal and aberrant mature mRNA are suppressed in mutant and wild-type cells, the selectivity of the lethal effect is thought to be due to the presence of mutant SF3B1 and its implications rather than a change in mechanism or potency of effect on the mutant protein over the wild-type 1,3.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASplicing factor 3B subunit 1"
            }
        ]
    },
    {
        "smiles": "C[S@@](=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1",
        "id": "DB08521",
        "molecule": "4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine",
        "cas": "652162-77-1",
        "iupac_name": "4-[4-(4-fluorophenyl)-2-{4-[(R)-methanesulfinyl]phenyl}-1H-imidazol-5-yl]pyridine",
        "inchi": {
            "hash": "CDMGBJANTYXAIV-HHHXNRCGSA-N",
            "id": "InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)/t27-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 377.435,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 377.099811044,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB08521",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 14"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 1"
            }
        ]
    },
    {
        "smiles": "CS(=O)(=O)C1=CC=C(OC2=CC(=CC(F)=C2)C#N)C2=C1[C@H](O)[C@H](F)[C@@H]2F",
        "id": "DB15463",
        "molecule": "Belzutifan",
        "cas": "1672668-24-4",
        "iupac_name": "3-{[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1H-inden-4-yl]oxy}-5-fluorobenzonitrile",
        "background": "Belzutifan is an inhibitor of hypoxia-inducible factor 2 (HIF-2) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers.1 The HIF-2 protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers.4 Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2 molecule which allowed for compounds to bind and inhibit these proteins. This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired by Merck in 2019).4\nBelzutifan inhibits the complexation of HIF-2 with another transcription factor, HIF-1, a necessary step in its activation - by preventing the formation of this complex, belzutifan can slow or stop the growth of VHL-associated tumors. Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021.2\n",
        "inchi": {
            "hash": "LOMMPXLFBTZENJ-ZACQAIPSSA-N",
            "id": "InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1"
        },
        "summary": "Belzutifan is an inhibitor of hypoxia-inducible factor 2 used as an antineoplastic in the treatment of certain cancers associated with von Hippel-Lindau (VHL) disease.",
        "weight": [
            {
                "type": "average",
                "weight": 383.34,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 383.043913533,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15463",
        "type": "Small Molecule",
        "synonyms": [
            "Belzutifan"
        ],
        "indication": "Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.1\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Belzutifan exerts its therapeutic effects by inhibiting a transcription factor necessary for the growth of solid tumors associated with VHL disease.1 It is taken once daily at approximately the same time each day, with or without food. Both severe anemia and hypoxia have been observed following therapy with belzutifan, and patients should be monitored closely before and during therapy to ensure patients can be managed as clinically indicated. There are no data regarding the use of erythropoiesis-stimulating agents for the treatment of belzutifan-induced anemia, and as such these therapies should be avoided.1\nBelzutifan may cause embryo-fetal toxicity when administered to pregnant women. Female patients and male patients with female partners of reproductive potential should ensure that an effective form of contraception is used throughout therapy and for one week after the last dose - as belzutifan appears to decrease the efficacy of systemic hormonal contraceptives, patients should be advised to use an additional method of contraception (e.g. condoms) to eliminate the possibility of pregnancy during therapy.1\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AEndothelial PAS domain-containing protein 1"
            }
        ]
    },
    {
        "smiles": "O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O",
        "id": "DB03389",
        "molecule": "alpha-D-Xylopyranose",
        "iupac_name": "(2S,3R,4S,5R)-oxane-2,3,4,5-tetrol",
        "inchi": {
            "hash": "SRBFZHDQGSBBOR-LECHCGJUSA-N",
            "id": "InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3+,4-,5+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 150.1299,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 150.05282343,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pentoses. These are monosaccharides in which the carbohydrate moiety contains five carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB03389",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / NCIB 9290)",
                "target": "UChondroitinase-B"
            },
            {
                "action": "Not Available",
                "organism": "Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / NCIB 9290)",
                "target": "UChondroitinase-AC"
            },
            {
                "action": "Not Available",
                "organism": "Cellulomonas fimi",
                "target": "UExoglucanase/xylanase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus cereus",
                "target": "UBeta-amylase"
            },
            {
                "action": "Not Available",
                "organism": "Lactococcus lactis",
                "target": "UAldose 1-epimerase"
            },
            {
                "action": "Not Available",
                "organism": "Cellvibrio japonicus",
                "target": "UEndo-beta-1,4-xylanase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125)",
                "target": "UReducing end xylose-releasing exo-oligoxylanase"
            },
            {
                "action": "Not Available",
                "organism": "Geobacillus stearothermophilus",
                "target": "UEndo-1,4-beta-xylanase"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus agaradhaerens",
                "target": "UEndo-1,4-beta-xylanase"
            },
            {
                "action": "Not Available",
                "organism": "Clostridium stercorarium",
                "target": "UEndo-1,4-beta-xylanase A"
            },
            {
                "action": "Not Available",
                "organism": "Streptomyces lividans",
                "target": "UEndo-1,4-beta-xylanase A"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus circulans",
                "target": "UEndo-1,4-beta-xylanase"
            },
            {
                "action": "Not Available",
                "organism": "Streptomyces olivaceoviridis",
                "target": "UHydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Pseudoalteromonas haloplanktis",
                "target": "UEndo-1,4-beta-xylanase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ULactase-phlorizin hydrolase"
            },
            {
                "action": "Not Available",
                "organism": "Cellvibrio mixtus",
                "target": "UEndoxylanase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02002"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15231"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18074"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03533"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08475"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13858"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08750"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13595"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01295"
    },
    {
        "smiles": "NC1=C2CCCC2=NC2=C1CCCC2",
        "id": "DB13668",
        "molecule": "Ipidacrine",
        "cas": "62732-44-9",
        "iupac_name": "1H,2H,3H,5H,6H,7H,8H-cyclopenta[b]quinolin-9-amine",
        "inchi": {
            "hash": "YLUSMKAJIQOXPV-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H16N2/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12/h1-7H2,(H2,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 188.274,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 188.131348523,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminoquinolines and derivatives. These are organic compounds containing an amino group attached to a quinoline ring system.",
        "link": "https://go.drugbank.com/drugs/DB13668",
        "type": "Small Molecule",
        "synonyms": [
            "Ipidacrine"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC1=CC=C(C=C1)N1N=C2C=CC(O)=CC2=C1Cl",
        "id": "DB07708",
        "molecule": "3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL",
        "iupac_name": "3-chloro-2-(4-hydroxyphenyl)-2H-indazol-5-ol",
        "inchi": {
            "hash": "ZNHQDSBJVFFIAK-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H9ClN2O2/c14-13-11-7-10(18)5-6-12(11)15-16(13)8-1-3-9(17)4-2-8/h1-7,17-18H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 260.676,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 260.035255249,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07708",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor coactivator 2"
            }
        ]
    },
    {
        "smiles": "[H][C@](N)(O)CC1=CNC2=CC=CC=C12",
        "id": "DB08649",
        "molecule": "(1S)-1-AMINO-2-(1H-INDOL-3-YL)ETHANOL",
        "iupac_name": "(1S)-1-amino-2-(1H-indol-3-yl)ethan-1-ol",
        "inchi": {
            "hash": "WNWJSYYPDDQIQV-JTQLQIEISA-N",
            "id": "InChI=1S/C10H12N2O/c11-10(13)5-7-6-12-9-4-2-1-3-8(7)9/h1-4,6,10,12-13H,5,11H2/t10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 176.2151,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 176.094963016,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.",
        "link": "https://go.drugbank.com/drugs/DB08649",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Alcaligenes faecalis",
                "target": "UAralkylamine dehydrogenase light chain"
            },
            {
                "action": "Not Available",
                "organism": "Alcaligenes faecalis",
                "target": "UAralkylamine dehydrogenase heavy chain"
            }
        ]
    },
    {
        "smiles": "OS(=O)(=O)C1=CC2=CC=CC=C2C=C1",
        "id": "DB08254",
        "molecule": "2-Naphthalenesulfonic acid",
        "cas": "120-18-3",
        "iupac_name": "naphthalene-2-sulfonic acid",
        "inchi": {
            "hash": "KVBGVZZKJNLNJU-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H8O3S/c11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h1-7H,(H,11,12,13)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 208.234,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 208.019414812,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-naphthalene sulfonates. These are organic aromatic compounds that contain a naphthalene moiety that carries a sulfonic acid group at the 2-position. Naphthalene is a bicyclic compound that is made up of two fused benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08254",
        "type": "Small Molecule",
        "synonyms": [
            "beta-Naphthalenesulfonic acid",
            "beta-Naphthylsulfonic acid",
            "Naphthalene-2-sulfonic acid",
            "-naphthalenesulfonic acid",
            "-naphthylsulfonic acid"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTrypsin-1"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(C)O[C@@]([H])(N2C=C(I)C3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O",
        "id": "DB07173",
        "molecule": "7-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE",
        "iupac_name": "(2R,3R,4S,5R)-2-{4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-5-methyloxolane-3,4-diol",
        "inchi": {
            "hash": "NTXUAWGNGBSCRS-TZQXKBMNSA-N",
            "id": "InChI=1S/C11H13IN4O3/c1-4-7(17)8(18)11(19-4)16-2-5(12)6-9(13)14-3-15-10(6)16/h2-4,7-8,11,17-18H,1H3,(H2,13,14,15)/t4-,7-,8-,11-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 376.1504,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 376.003233722,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glycosylamines. These are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether).",
        "link": "https://go.drugbank.com/drugs/DB07173",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAdenosine kinase"
            }
        ]
    },
    {
        "smiles": "CC1=C(CCCOC2=CC(=CC=C2F)C(O)=O)C(C)=NN1",
        "id": "DB17999",
        "molecule": "Acoramidis",
        "cas": "1446711-81-4",
        "iupac_name": "3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid",
        "inchi": {
            "hash": "WBFUHHBPNXWNCC-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H17FN2O3/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 292.31,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 292.122320578,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17999",
        "type": "Small Molecule",
        "synonyms": [
            "3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid",
            "Acoramidis"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)(C)C1=CC(O)=C(C=C1O)C(C)(C)C",
        "id": "DB04638",
        "molecule": "2,5-di-tert-butylhydroquinone",
        "cas": "88-58-4",
        "iupac_name": "2,5-di-tert-butylbenzene-1,4-diol",
        "inchi": {
            "hash": "JZODKRWQWUWGCD-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H22O2/c1-13(2,3)9-7-12(16)10(8-11(9)15)14(4,5)6/h7-8,15-16H,1-6H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 222.3233,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 222.161979948,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.",
        "link": "https://go.drugbank.com/drugs/DB04638",
        "type": "Small Molecule",
        "synonyms": [
            "2,5-di-tert-butylbenzene-1,4-diol"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USarcoplasmic/endoplasmic reticulum calcium ATPase 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@](CC1=CC=CC=C1)(NC(=O)C1=CC2=C(N1)C=CC(Cl)=C2)C(=O)N1CC(C1)C(O)=O",
        "id": "DB03744",
        "molecule": "Cp403700, (S)-1-{2-[(5-Chloro-1h-Indole-2-Carbonyl)-Amino]-3-Phenyl-Propionyl}-Azetidine-3-Carboxylate",
        "iupac_name": "1-[(2S)-2-[(5-chloro-1H-indol-2-yl)formamido]-3-phenylpropanoyl]azetidine-3-carboxylic acid",
        "inchi": {
            "hash": "RONLONYAIBUEKT-IBGZPJMESA-N",
            "id": "InChI=1S/C22H20ClN3O4/c23-16-6-7-17-14(9-16)10-18(24-17)20(27)25-19(8-13-4-2-1-3-5-13)21(28)26-11-15(12-26)22(29)30/h1-7,9-10,15,19,24H,8,11-12H2,(H,25,27)(H,29,30)/t19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 425.865,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 425.11423385,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB03744",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, liver form"
            }
        ]
    },
    {
        "smiles": "ClC1=CC(Cl)=CC(Cl)=C1",
        "id": "DB03836",
        "molecule": "1,3,5-trichlorobenzene",
        "cas": "108-70-3",
        "iupac_name": "1,3,5-trichlorobenzene",
        "inchi": {
            "hash": "XKEFYDZQGKAQCN-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H3Cl3/c7-4-1-5(8)3-6(9)2-4/h1-3H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 181.447,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 179.930033217,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB03836",
        "type": "Small Molecule",
        "synonyms": [
            "1,3,5-trichloro-benzene",
            "s-trichlorobenzene",
            "sym-trichlorobenzene"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "UCamphor 5-monooxygenase"
            }
        ]
    },
    {
        "smiles": "CC(C)C(CCCN(C)CCC1=CC=CC=C1)(C#N)C1=CC=CC=C1",
        "id": "DB14064",
        "molecule": "Emopamil",
        "cas": "78370-13-5",
        "iupac_name": "5-[methyl(2-phenylethyl)amino]-2-phenyl-2-(propan-2-yl)pentanenitrile",
        "background": "Prevents renal injury after warm \u0026 cold ischemia.\n",
        "inchi": {
            "hash": "DWAWDSVKAUWFHC-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H30N2/c1-20(2)23(19-24,22-13-8-5-9-14-22)16-10-17-25(3)18-15-21-11-6-4-7-12-21/h4-9,11-14,20H,10,15-18H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 334.4977,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 334.24089897,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14064",
        "type": "Small Molecule",
        "synonyms": [
            "Emopamil",
            "Emopamilo",
            "Emopamilum"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AP-glycoprotein 1"
            }
        ]
    },
    {
        "smiles": "NC1=CC2=C(C=C1)C1=CC=C(N)C=C1C(C1=CC=CC=C1)=[N+]2CCCCCCC1=CN(CCNC2=C3CCCCC3=NC3=C2C=CC=C3)N=N1",
        "id": "DB02226",
        "molecule": "3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium",
        "iupac_name": "3,8-diamino-6-phenyl-5-[6-(1-{2-[(1,2,3,4-tetrahydroacridin-9-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)hexyl]phenanthridin-5-ium",
        "inchi": {
            "hash": "NAARZDJZGYBXKL-UHFFFAOYSA-O",
            "id": "InChI=1S/C42H44N8/c43-30-19-21-33-34-22-20-31(44)27-40(34)50(42(37(33)26-30)29-12-4-3-5-13-29)24-11-2-1-6-14-32-28-49(48-47-32)25-23-45-41-35-15-7-9-17-38(35)46-39-18-10-8-16-36(39)41/h3-5,7,9,12-13,15,17,19-22,26-28,44H,1-2,6,8,10-11,14,16,18,23-25,43H2,(H,45,46)/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 661.8603,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 661.37671848,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB02226",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAcetylcholinesterase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02885"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04852"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01977"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04323"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08512"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01523"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06862"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03202"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03337"
    },
    {
        "smiles": "CCN(CCO)C1=CC=C(\\N=N\\C2=NC=C(S2)N(=O)=O)C(C)=C1",
        "id": "DB14203",
        "molecule": "Disperse Blue 106",
        "cas": "68516-81-4",
        "iupac_name": "2-[ethyl({3-methyl-4-[(E)-2-(5-nitro-1,3-thiazol-2-yl)diazen-1-yl]phenyl})amino]ethan-1-ol",
        "background": "Disperse Blue 106 is used in allergenic testing.\n",
        "inchi": {
            "hash": "UIHYHADQHHUIOF-WUKNDPDISA-N",
            "id": "InChI=1S/C14H17N5O3S/c1-3-18(6-7-20)11-4-5-12(10(2)8-11)16-17-14-15-9-13(23-14)19(21)22/h4-5,8-9,20H,3,6-7H2,1-2H3/b17-16+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 335.38,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 335.105210601,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14203",
        "type": "Small Molecule",
        "synonyms": [
            "5-Nitro-2-(2-methyl-4-(N-ethyl-N-(2-hydroxyethyl)amino)phenylazo)thiazole",
            "C.I. Disperse Blue 106",
            "C.I. Disperse Blue 357",
            "Disperse Blue 357"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOC1=C(C=CC=C1)C(N)=O",
        "id": "DB13544",
        "molecule": "Ethenzamide",
        "cas": "938-73-8",
        "iupac_name": "2-ethoxybenzamide",
        "inchi": {
            "hash": "SBNKFTQSBPKMBZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H11NO2/c1-2-12-8-6-4-3-5-7(8)9(10)11/h3-6H,2H2,1H3,(H2,10,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 165.192,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 165.078978598,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzamides. These are organic compounds containing a carboxamido substituent attached to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB13544",
        "type": "Small Molecule",
        "synonyms": [
            "Etenzamida",
            "Etenzamide",
            "Ethbenzamide",
            "thenzamide",
            "Ethenzamide",
            "Ethenzamidum",
            "o-Ethoxybenzamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC(=O)[C@@H](CCC(F)(F)F)N(CC1=CC=C(C=C1F)C1=NOC=N1)S(=O)(=O)C1=CC=C(Cl)C=C1",
        "id": "DB11893",
        "molecule": "Avagacestat",
        "cas": "1146699-66-2",
        "iupac_name": "(2R)-5,5,5-trifluoro-2-(N-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl}4-chlorobenzenesulfonamido)pentanamide",
        "background": "Avagacestat has been investigated for the basic science and treatment of Alzheimer Disease.\n",
        "inchi": {
            "hash": "XEAOPVUAMONVLA-QGZVFWFLSA-N",
            "id": "InChI=1S/C20H17ClF4N4O4S/c21-14-3-5-15(6-4-14)34(31,32)29(17(18(26)30)7-8-20(23,24)25)10-13-2-1-12(9-16(13)22)19-27-11-33-28-19/h1-6,9,11,17H,7-8,10H2,(H2,26,30)/t17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 520.88,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 520.0595166,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenyloxadiazoles. These are polycyclic aromatic compounds containing a benzene ring linked to a 1,2,4-oxadiazole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB11893",
        "type": "Small Molecule",
        "synonyms": [
            "Avagacestat"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOC(=O)C1(CCN(CCOCC2CCCO2)CC1)C1=CC=CC=C1",
        "id": "DB01464",
        "molecule": "Furethidine",
        "cas": "2385-81-1",
        "iupac_name": "ethyl 1-{2-[(oxolan-2-yl)methoxy]ethyl}-4-phenylpiperidine-4-carboxylate",
        "inchi": {
            "hash": "NNCOZXNZFLUYGG-UHFFFAOYSA-N",
            "id": "InChI=1S/C21H31NO4/c1-2-25-20(23)21(18-7-4-3-5-8-18)10-12-22(13-11-21)14-16-24-17-19-9-6-15-26-19/h3-5,7-8,19H,2,6,9-17H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 361.4751,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 361.225308485,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB01464",
        "type": "Small Molecule",
        "synonyms": [
            "Furethidine"
        ]
    },
    {
        "smiles": "ONC(=O)C1=CC(O)=C(O)C=C1",
        "id": "DB12948",
        "molecule": "Didox",
        "cas": "69839-83-4",
        "iupac_name": "N,3,4-trihydroxybenzamide",
        "background": "Didox has been used in trials studying the supportive care of Gastric Cancer.\n",
        "inchi": {
            "hash": "QJMCKEPOKRERLN-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H7NO4/c9-5-2-1-4(3-6(5)10)7(11)8-12/h1-3,9-10,12H,(H,8,11)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 169.136,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 169.037507709,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acids and derivatives. These are organic compounds containing a carboxylic acid substituent attached to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB12948",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "NNC(=O)C1=C(C2=C(N1)C=CC(=C2)S(N)(=O)=O)C1=CC=CC=C1",
        "id": "DB08659",
        "molecule": "2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide",
        "iupac_name": "2-(hydrazinecarbonyl)-3-phenyl-1H-indole-5-sulfonamide",
        "inchi": {
            "hash": "PPDLAUCFAOODER-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H14N4O3S/c16-19-15(20)14-13(9-4-2-1-3-5-9)11-8-10(23(17,21)22)6-7-12(11)18-14/h1-8,18H,16H2,(H,19,20)(H2,17,21,22)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 330.362,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 330.078661024,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.",
        "link": "https://go.drugbank.com/drugs/DB08659",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCarbonic anhydrase 2"
            }
        ]
    },
    {
        "smiles": "CC1=C(C=C)C2=CC3=[N+]4C(=CC5=C(C)C(CCC(O)=O)=C6N5[Fe]44N2C1=CC1=[N+]4C(C(CCC(O)=O)=C1C)=C6C1=CC=CC=C1)C(C=C)=C3C",
        "id": "DB03906",
        "molecule": "2-Phenylheme",
        "iupac_name": "5,9-bis(2-carboxyethyl)-14,19-diethenyl-4,10,15,20-tetramethyl-7-phenyl-2lambda5,22,23lambda5,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^{2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-2,4,6,8,10,12,14,16(23),17,19,21(24)-undecaene-2,23-bis(ylium)",
        "inchi": {
            "hash": "RHCCVTLDOSIQDM-NULOGZTHSA-L",
            "id": "InChI=1S/C40H38N4O4.Fe/c1-7-26-21(3)30-18-32-23(5)28(14-16-36(45)46)39(43-32)38(25-12-10-9-11-13-25)40-29(15-17-37(47)48)24(6)33(44-40)20-35-27(8-2)22(4)31(42-35)19-34(26)41-30;/h7-13,18-20H,1-2,14-17H2,3-6H3,(H4,41,42,43,44,45,46,47,48);/q;+4/p-2/b30-18-,31-19-,32-18-,33-20-,34-19-,35-20-,39-38-,40-38-;"
        },
        "weight": [
            {
                "type": "average",
                "weight": 692.583,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 692.208597793,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB03906",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHeme oxygenase 1"
            }
        ]
    },
    {
        "smiles": "NC(=O)N1C2=C(C[C@H](O)C3=C1C=CC=C3)C=CC=C2",
        "id": "DB14575",
        "molecule": "Eslicarbazepine",
        "cas": "104746-04-5",
        "iupac_name": "(9S)-9-hydroxy-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene-2-carboxamide",
        "background": "Eslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.\n",
        "inchi": {
            "hash": "BMPDWHIDQYTSHX-AWEZNQCLSA-N",
            "id": "InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1"
        },
        "summary": "Eslicarbazepine is an antiepileptic indicated as a monotherapy or adjunct therapy in the treatment of epilepsy.",
        "weight": [
            {
                "type": "average",
                "weight": 254.2839,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 254.105527702,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB14575",
        "type": "Small Molecule",
        "synonyms": [
            "Eslicarbazepina",
            "Eslicarbazepine",
            "S(+)-Liscarbazepine"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "AP2X purinoceptor 4"
            }
        ]
    },
    {
        "smiles": "CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",
        "id": "DB01101",
        "molecule": "Capecitabine",
        "cas": "154361-50-9",
        "iupac_name": "pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate",
        "background": "Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.\n",
        "inchi": {
            "hash": "GAGWJHPBXLXJQN-UORFTKCHSA-N",
            "id": "InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1"
        },
        "summary": "Capecitabine is a nucleoside metabolic inhibitor indicated to treat different gastrointestinal, including pancreatic cancer, and breast cancer.",
        "weight": [
            {
                "type": "average",
                "weight": 359.3501,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 359.149263656,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives.",
        "link": "https://go.drugbank.com/drugs/DB01101",
        "type": "Small Molecule",
        "synonyms": [
            "(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester",
            "Capecitabin",
            "Capecitabina",
            "Capcitabine",
            "Capecitabine",
            "Capecitabinum",
            "Pentyl [1-(5-deoxy--D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate",
            "pentyl 1-(5-deoxy--D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate"
        ],
        "indication": "Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer.42 For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy.42 For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease.42 Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.42\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Capecitabine is a fluoropyrimidine carbamate belonging to a group of antineoplastic agents called antimetabolites, which kill cancerous cells by interfering with DNA synthesis.39,26 It is an orally administered systemic prodrug that has little pharmacologic activity until it is converted to 5-fluorouracil (5-FU) by enzymes that are expressed in higher concentrations in many tumors.40 Capecitabine was designed specifically to overcome the disadvantages of 5-FU and to mimic the infusional pharmacokinetics of 5-FU without the associated complexity and complications of central venous access and infusion pumps.39 Particularly, since the enzymes converting 5-FU into active metabolites exist in the gastrointestinal tract, infusion of 5-FU can have gastrointestinal toxicity while also losing efficacy.41 Since capecitabine can be transported intact across the intestinal mucosa, it can be selectively delivered 5-FU to tumor tissues through enzymatic conversion preferentially inside tumor cells.41\n5-FU exerts its pharmacological action through the inhibition and interference of 3 main targets: thymidylate synthase, DNA, and RNA, leading through protein synthesis disruption and apoptosis.26,20 Population-based exposure-effect analyses demonstrated a positive association between AUC of 5-FU and grade 3-4 hyperbilirubinemia.42\n",
        "moa": [
            {
                "action": "incorporation into and destabilizationinhibition of synthesis",
                "organism": "Humans",
                "target": "ADNA"
            },
            {
                "action": "incorporation into and destabilization",
                "organism": "Humans",
                "target": "ARNA"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AThymidylate synthase"
            }
        ]
    },
    {
        "id": "DB05840",
        "molecule": "AGI-1096",
        "background": "AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05840",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in transplant (rejection).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[H][C@]1(CCC[C@]1([H])NC(=O)C1=CC=C(C=C1)N1C=CC=CC1=O)NC(=O)C1=CC=C(Cl)S1",
        "id": "DB08174",
        "molecule": "5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL)THIOPHENE-2-CARBOXAMIDE",
        "iupac_name": "5-chloro-N-[(1R,2S)-2-[4-(2-oxo-1,2-dihydropyridin-1-yl)benzamido]cyclopentyl]thiophene-2-carboxamide",
        "inchi": {
            "hash": "QCPYHSAHOYXXQK-DLBZAZTESA-N",
            "id": "InChI=1S/C22H20ClN3O3S/c23-19-12-11-18(30-19)22(29)25-17-5-3-4-16(17)24-21(28)14-7-9-15(10-8-14)26-13-2-1-6-20(26)27/h1-2,6-13,16-17H,3-5H2,(H,24,28)(H,25,29)/t16-,17+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 441.931,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 441.091389918,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzamides. These are organic compounds containing a carboxamido substituent attached to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08174",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor X"
            }
        ]
    },
    {
        "smiles": "CCCCS(=N)(=O)CCC(N)C(O)=O",
        "id": "DB12870",
        "molecule": "Buthionine sulfoximine",
        "cas": "5072-26-4",
        "iupac_name": "2-amino-4-[butyl(imino)oxo-lambda6-sulfanyl]butanoic acid",
        "background": "Buthionine sulfoximine has been used in trials studying the treatment of Neuroblastoma and Melanoma (Skin).\n",
        "inchi": {
            "hash": "KJQFBVYMGADDTQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 222.3,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 222.103813622,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).",
        "link": "https://go.drugbank.com/drugs/DB12870",
        "type": "Small Molecule",
        "synonyms": [
            "Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-",
            "Buthionine sulfoxamine",
            "DL-buthionine-(S,R)-sulfoximine"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(COP(O)(O)=O)O[C@@]([H])(C2=C3N=CN=C(N)C3=NN2)[C@]([H])(O)[C@]1([H])O",
        "id": "DB03464",
        "molecule": "Formycin-5'-Monophosphate",
        "iupac_name": "{[(2R,3S,4R,5S)-5-{7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl}-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid",
        "inchi": {
            "hash": "PBAHXXBYQACZMA-KSYZLYKTSA-N",
            "id": "InChI=1S/C10H14N5O7P/c11-10-6-4(12-2-13-10)5(14-15-6)9-8(17)7(16)3(22-9)1-21-23(18,19)20/h2-3,7-9,16-17H,1H2,(H,14,15)(H2,11,12,13)(H2,18,19,20)/t3-,7-,8-,9+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 347.2212,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 347.063084339,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.",
        "link": "https://go.drugbank.com/drugs/DB03464",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UAMP nucleosidase"
            }
        ]
    },
    {
        "smiles": "[H][C@@](NC(=O)CC1=CC=CS1)(C(O)=O)C1=N[C@]([H])(C(O)=O)C(=C)CS1",
        "id": "DB08623",
        "molecule": "2-[CARBOXY-(2-THIOPHEN-2-YL-ACETYLAMINO)-METHYL]-5-METHYLENE-5,6-DIHYDRO-2H-[1,3]THIAZINE-4-CARBOXYLIC ACID",
        "iupac_name": "(4S)-2-[(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl]-5-methylidene-5,6-dihydro-4H-1,3-thiazine-4-carboxylic acid",
        "inchi": {
            "hash": "VBBNCGUNWSPHOY-QWRGUYRKSA-N",
            "id": "InChI=1S/C14H14N2O5S2/c1-7-6-23-12(16-10(7)13(18)19)11(14(20)21)15-9(17)5-8-3-2-4-22-8/h2-4,10-11H,1,5-6H2,(H,15,17)(H,18,19)(H,20,21)/t10-,11-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 354.401,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 354.034412948,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-l-alpha-amino acids. These are n-acylated alpha amino acids which have the L-configuration of the alpha-carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB08623",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I",
        "id": "DB08947",
        "molecule": "Iopamidol",
        "cas": "60166-93-0",
        "iupac_name": "N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide",
        "background": "Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.\n",
        "inchi": {
            "hash": "XQZXYNRDCRIARQ-LURJTMIESA-N",
            "id": "InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1"
        },
        "summary": "Iopamidol is a diagnostic imaging agent used for angiography throughout the cardiovascular system.",
        "weight": [
            {
                "type": "average",
                "weight": 777.0853,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 776.854094955,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as iodobenzenes. These are aromatic compounds containing one or more iodine atoms attached to a benzene.",
        "link": "https://go.drugbank.com/drugs/DB08947",
        "type": "Small Molecule",
        "synonyms": [
            "Iopamidol",
            "Iopamidolum"
        ]
    },
    {
        "smiles": "C(CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1)CC1=NN=NN1",
        "id": "DB07917",
        "molecule": "4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE",
        "iupac_name": "4-(diphenylmethoxy)-1-[3-(1H-1,2,3,4-tetrazol-5-yl)propyl]piperidine",
        "inchi": {
            "hash": "TZQGXAHOROZEKN-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H27N5O/c1-3-8-18(9-4-1)22(19-10-5-2-6-11-19)28-20-13-16-27(17-14-20)15-7-12-21-23-25-26-24-21/h1-6,8-11,20,22H,7,12-17H2,(H,23,24,25,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 377.4827,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 377.221560511,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB07917",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHematopoietic prostaglandin D synthase"
            }
        ]
    },
    {
        "smiles": "C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O",
        "id": "DB14006",
        "molecule": "Choline salicylate",
        "cas": "2016-36-6",
        "iupac_name": "(2-hydroxyethyl)trimethylazanium 2-hydroxybenzoate",
        "background": "Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever 9.\nCholine Salicylate is the choline salt of salicylic acid, used as an analgesic, antipyretic and antirheumatic. It relieves mild to moderate pain and reduce fever and inflammation or swelling. Choline salicylate is effective in the treatment of gout, rheumatic fever, rheumatoid arthritis and muscle injuries 4.\nThis drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population 13. The UK government has regulated its use, due to toxicity in those under 16 years of age. Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers 13.\n",
        "inchi": {
            "hash": "UDKCHVLMFQVBAA-UHFFFAOYSA-M",
            "id": "InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 241.287,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 241.131408096,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.",
        "link": "https://go.drugbank.com/drugs/DB14006",
        "type": "Small Molecule",
        "synonyms": [
            "Choline salicylate"
        ],
        "indication": "The oral gel is indicated for the relief of pain and discomfort of common mouth ulcers, cold sores, denture sore spots, infant teething and mouth ulcers, and sore spots due to orthodontic devices in children 14.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "This is an anti-inflammatory and antipyretic medication 11, 12.\nIf is often used in oral gel form for the relief of pain, discomfort, and inflammation caused by common mouth ulcers, cold sores, denture and sore spots, as well as mouth ulcers, and sore spots because of orthodontic devices 17.\n",
        "moa": [
            {
                "action": "product of",
                "organism": "Humans",
                "target": "UCholine-phosphate cytidylyltransferase B"
            },
            {
                "action": "product of",
                "organism": "Humans",
                "target": "UAcetylcholinesterase"
            },
            {
                "action": "product of",
                "organism": "Humans",
                "target": "UCholine-phosphate cytidylyltransferase A"
            },
            {
                "action": "product of",
                "organism": "Humans",
                "target": "UPhospholipase D2"
            },
            {
                "action": "product of",
                "organism": "Humans",
                "target": "UCholinesterase"
            },
            {
                "action": "product of",
                "organism": "Humans",
                "target": "UPhospholipase D1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeuronal acetylcholine receptor subunit alpha-7"
            }
        ]
    },
    {
        "id": "DB17068",
        "molecule": "JZP-386 free base",
        "background": "JZP-386 is a deuterium-containing analog of sodium oxybate. Its safety, pharmacokinetics and pharmacodynamics were evaluated in clinical trial NCT02215499.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17068",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1",
        "id": "DB08981",
        "molecule": "Fenbufen",
        "cas": "36330-85-5",
        "iupac_name": "4-{[1,1'-biphenyl]-4-yl}-4-oxobutanoic acid",
        "background": "Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.\n",
        "inchi": {
            "hash": "ZPAKPRAICRBAOD-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 254.2806,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 254.094294314,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB08981",
        "type": "Small Molecule",
        "synonyms": [
            "3-(4-Biphenylylcarbonyl)propionic acid",
            "3-(4-Phenylbenzoyl)propionic acid",
            "4-(4-Biphenylyl)-4-oxobutyric acid",
            "Fenbufen",
            "Fenbufn",
            "Fenbufne",
            "Fenbufenum",
            "gamma-oxo(1,1'-biphenyl)-4-butanoic acid"
        ]
    },
    {
        "smiles": "[H][C@]12CS[C@@]([H])(CCCC(O)=O)[C@@]1([H])NC(=O)N2",
        "id": "DB02674",
        "molecule": "4-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Butyricacid",
        "iupac_name": "4-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl]butanoic acid",
        "inchi": {
            "hash": "AINAXQHKYSZESH-HAFWLYHUSA-N",
            "id": "InChI=1S/C9H14N2O3S/c12-7(13)3-1-2-6-8-5(4-15-6)10-9(14)11-8/h5-6,8H,1-4H2,(H,12,13)(H2,10,11,14)/t5-,6-,8-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 230.284,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 230.072513014,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thienoimidazolidines. These are heterocyclic compounds containing a thiophene ring fused to an imidazolidine ring. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Imidazolidine is 5-membered saturated ring of three carbon atoms, and two nitrogen centers at the 1- and 3-positions.",
        "link": "https://go.drugbank.com/drugs/DB02674",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces avidinii",
                "target": "UStreptavidin"
            }
        ]
    },
    {
        "smiles": "C(OC1=C2NC=NC2=NC(NC2=CC=CC=C2)=N1)C1CCCCC1",
        "id": "DB06948",
        "molecule": "2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE",
        "iupac_name": "6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine",
        "inchi": {
            "hash": "XWWRLKIBRPJQJX-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H21N5O/c1-3-7-13(8-4-1)11-24-17-15-16(20-12-19-15)22-18(23-17)21-14-9-5-2-6-10-14/h2,5-6,9-10,12-13H,1,3-4,7-8,11H2,(H2,19,20,21,22,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 323.3922,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 323.174610319,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.",
        "link": "https://go.drugbank.com/drugs/DB06948",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-A2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "CN1CCC(CC1)N(CC1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB13489",
        "molecule": "Bamipine",
        "cas": "4945-47-5",
        "iupac_name": "N-benzyl-1-methyl-N-phenylpiperidin-4-amine",
        "inchi": {
            "hash": "VZSXTYKGYWISGQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H24N2/c1-20-14-12-19(13-15-20)21(18-10-6-3-7-11-18)16-17-8-4-2-5-9-17/h2-11,19H,12-16H2,1H3"
        },
        "summary": "Bamipine is an H1 antihistamine used topically to relieve mild to moderate symptoms associated with insect bites.",
        "weight": [
            {
                "type": "average",
                "weight": 280.415,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 280.193948781,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.",
        "link": "https://go.drugbank.com/drugs/DB13489",
        "type": "Small Molecule",
        "synonyms": [
            "Bamipine"
        ],
        "is_stub": true
    },
    {
        "smiles": "COCC1=C(N=CC2=C1C1=C(N2)C=CC=C1OC1=CC=C(Cl)C=C1)C(=O)OC(C)C",
        "id": "DB13534",
        "molecule": "Gedocarnil",
        "cas": "109623-97-4",
        "iupac_name": "propan-2-yl 5-(4-chlorophenoxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylate",
        "inchi": {
            "hash": "SLYDYLLJUXFULK-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H21ClN2O4/c1-13(2)29-23(27)22-16(12-28-3)20-18(11-25-22)26-17-5-4-6-19(21(17)20)30-15-9-7-14(24)8-10-15/h4-11,13,26H,12H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 424.88,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 424.1189849,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as beta carbolines. These are compounds containing a 9H-pyrido[3,4-b]indole moiety.",
        "link": "https://go.drugbank.com/drugs/DB13534",
        "type": "Small Molecule",
        "synonyms": [
            "Gedocarnil"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(N)OC2=CC=CC=C2[C@]([H])(O)S1",
        "id": "DB03972",
        "molecule": "2-Amino-4h-1,3-Benzoxathiin-4-Ol",
        "iupac_name": "(2S,4R)-2-amino-2,4-dihydro-1,3-benzoxathiin-4-ol",
        "inchi": {
            "hash": "DVFUKUONLVBBEH-SFYZADRCSA-N",
            "id": "InChI=1S/C8H9NO2S/c9-8-11-6-4-2-1-3-5(6)7(10)12-8/h1-4,7-8,10H,9H2/t7-,8+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 183.228,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 183.035399227,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB03972",
        "type": "Small Molecule"
    },
    {
        "id": "DB09258",
        "molecule": "Bemiparin",
        "cas": "91449-79-5",
        "background": "Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). Like semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class 1. These heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting factor. Interestingly, current research is underway for the potential benefit of bemiparin in the treatment of tumors and diabetic foot ulcers 12,1.\n",
        "inchi": {},
        "summary": "Bemiparin is an ultra-low molecular weight heparin (ultra-LMWH) used to prevent thromboembolism following surgery and extracorporeal clotting during dialysis.",
        "link": "https://go.drugbank.com/drugs/DB09258",
        "type": "Small Molecule",
        "indication": "Bemiparin is indicated in the following cases: To prevent blood clots in the veins after general abdominal surgery in patients with a moderate risk of venous thromboembolism; in the prevention of the thromboembolic disease in non-surgical patients; prevention of clotting in the extracorporeal circuit during hemodialysis; to prevent blood clots in the veins after a major orthopedic surgery in patients with high risk of venous thromboembolism; secondary prevention of venous thromboembolism; recurrence in patients with deep vein thrombosis; transient prevention and treatment of deep vein thrombosis (DVT) 8.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Bemiparin is an anticoagulant classified under the broad category of low molecular weight heparins.\nIn humans, bemiparin has been proven to possess antithrombotic activity and, at therapeutic doses, does not significantly prolong global clotting laboratory tests 9.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ACoagulation factor X"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UAntithrombin-III"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UHeparin cofactor 2"
            }
        ]
    },
    {
        "smiles": "C[C@@H](OC1=NN=C(N1C)C1=CC=NC=C1)C1=NOC(=C1)C1=CC=CC(Cl)=C1",
        "id": "DB12644",
        "molecule": "AZD-2066",
        "cas": "934282-55-0",
        "iupac_name": "4-{5-[(1R)-1-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl}pyridine",
        "background": "AZD2066 has been used in trials studying the treatment and basic science of Pain, Chronic Pain, Reflux Episodes, Neuropathic Pain, and Diabetic Neuropathy, among others.\n",
        "inchi": {
            "hash": "SXWHYTICXCLKDG-GFCCVEGCSA-N",
            "id": "InChI=1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 381.82,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 381.0992525,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridyl-1,2,4-triazoles. These are organic compounds containing a pyridine ring attached to a 1,2,4-triazole ring.",
        "link": "https://go.drugbank.com/drugs/DB12644",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CCC(C)C(=O)C(O)=O",
        "id": "DB15831",
        "molecule": "alpha-Keto-beta-methylvaleric acid",
        "cas": "1460-34-0",
        "iupac_name": "3-methyl-2-oxopentanoic acid",
        "inchi": {
            "hash": "JVQYSWDUAOAHFM-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H10O3/c1-3-4(2)5(7)6(8)9/h4H,3H2,1-2H3,(H,8,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 130.143,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 130.062994182,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15831",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@](CC(=O)NC(CC)CC)(C(N)=O)C(C)(C)C",
        "id": "DB08474",
        "molecule": "3-(CARBOXYAMIDE(2-CARBOXYAMIDE-2-TERTBUTYLETHYL))PENTAN",
        "iupac_name": "(2R)-2-tert-butyl-N'-(pentan-3-yl)butanediamide",
        "inchi": {
            "hash": "UVHRROJQACYJNP-JTQLQIEISA-N",
            "id": "InChI=1S/C13H26N2O2/c1-6-9(7-2)15-11(16)8-10(12(14)17)13(3,4)5/h9-10H,6-8H2,1-5H3,(H2,14,17)(H,15,16)/t10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 242.3577,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 242.199428086,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl amines. These are compounds containing a fatty acid moiety linked to an amine group through an ester linkage.",
        "link": "https://go.drugbank.com/drugs/DB08474",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "HIV-2",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "NC(=O)C1=NN(C2=C1C=CC1=C2C=NN1)C1=CC=C(C=C1)S(N)(=O)=O",
        "id": "DB08527",
        "molecule": "1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE",
        "iupac_name": "1-(4-sulfamoylphenyl)-1H,6H-pyrazolo[3,4-g]indazole-3-carboxamide",
        "inchi": {
            "hash": "HGAKLLFPOGATII-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H12N6O3S/c16-15(22)13-10-5-6-12-11(7-18-19-12)14(10)21(20-13)8-1-3-9(4-2-8)25(17,23)24/h1-7H,(H2,16,22)(H,18,19)(H2,17,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 356.359,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 356.06915897,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indazole-3-carboxamides. These are aromatic compounds containing an indazole ring system that is substituted at the 3-position with a carboxamide group.",
        "link": "https://go.drugbank.com/drugs/DB08527",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-A2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2",
        "id": "DB00518",
        "molecule": "Albendazole",
        "cas": "54965-21-8",
        "iupac_name": "methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate",
        "background": "A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)\n",
        "inchi": {
            "hash": "HXHWSAZORRCQMX-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)"
        },
        "summary": "Albendazole is a benzimidazole anthelmintic used to treat parenchymal neurocysticercosis and other helminth infections.",
        "weight": [
            {
                "type": "average",
                "weight": 265.331,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 265.088497429,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-benzimidazolylcarbamic acid esters. These are aromatic heteropolycyclic compounds that contain a carbamic acid ester group, which is N-linked to the C2-atom of a benzimidazole moiety.",
        "link": "https://go.drugbank.com/drugs/DB00518",
        "type": "Small Molecule",
        "synonyms": [
            "(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester",
            "5-(propylthio)-2-carbomethoxyaminobenzimidazole",
            "Albendazol",
            "Albendazole",
            "Albendazolum",
            "Eskazole",
            "O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate",
            "Proftril"
        ],
        "indication": "For the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Albendazole is a broad-spectrum anthelmintic. The principal mode of action for albendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Pig roundworm",
                "target": "ATubulin beta-2 chain"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NTubulin alpha-1A chain"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "NTubulin beta-4B chain"
            },
            {
                "action": "inhibitor",
                "organism": "Shewanella oneidensis (strain MR-1)",
                "target": "UFumarate reductase flavoprotein subunit"
            }
        ]
    },
    {
        "smiles": "NCC1=CC=CC=C1O",
        "id": "DB14855",
        "molecule": "2-(aminomethyl)phenol",
        "cas": "932-30-9",
        "iupac_name": "2-(aminomethyl)phenol",
        "background": "2-(aminomethyl)phenol is under investigation in clinical trial NCT03556319 (2-HOBA: Multiple Dosing Study in Older Adults).\n",
        "inchi": {
            "hash": "KPRZOPQOBJRYSW-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H9NO/c8-5-6-3-1-2-4-7(6)9/h1-4,9H,5,8H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 123.155,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 123.068413914,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14855",
        "type": "Small Molecule",
        "synonyms": [
            "2-HOBA"
        ],
        "is_stub": true
    },
    {
        "smiles": "O[S@@](=O)C1=CC=CC=C1C1=CC=CC=C1",
        "id": "DB07483",
        "molecule": "1,1'-BIPHENYL-2-SULFINIC ACID",
        "iupac_name": "(R)-[1,1'-biphenyl]-2-sulfinic acid",
        "inchi": {
            "hash": "LZCLZDCSBDVAOV-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H10O2S/c13-15(14)12-9-5-4-8-11(12)10-6-2-1-3-7-10/h1-9H,(H,13,14)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 218.272,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 218.040150254,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.",
        "link": "https://go.drugbank.com/drugs/DB07483",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Rhodococcus sp. (strain IGTS8)",
                "target": "U2'-hydroxybiphenyl-2-sulfinate desulfinase"
            }
        ]
    },
    {
        "smiles": "CS(=O)(=O)NC1=CC2=C(C=C1OC1=CC=CC=C1)C(=O)C(NC=O)=CO2",
        "id": "DB12233",
        "molecule": "Iguratimod",
        "cas": "123663-49-0",
        "iupac_name": "N-(7-methanesulfonamido-4-oxo-6-phenoxy-4H-chromen-3-yl)formamide",
        "background": "Iguratimod is under investigation in Rheumatoid Arthritis.\n",
        "inchi": {
            "hash": "ANMATWQYLIFGOK-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 374.37,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 374.057257353,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as chromones. These are compounds containing a benzopyran-4-one moiety.",
        "link": "https://go.drugbank.com/drugs/DB12233",
        "type": "Small Molecule",
        "synonyms": [
            "Iguratimod"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCS(=O)(=O)N1CCN(CC1)C1=CC=C(NC2=NC=C(C(N)=O)C(NC3CC3)=N2)C=C1",
        "id": "DB15499",
        "molecule": "Cerdulatinib",
        "cas": "1198300-79-6",
        "iupac_name": "4-(cyclopropylamino)-2-({4-[4-(ethanesulfonyl)piperazin-1-yl]phenyl}amino)pyrimidine-5-carboxamide",
        "background": "Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).\n",
        "inchi": {
            "hash": "BGLPECHZZQDNCD-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 445.54,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 445.189608931,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15499",
        "type": "Small Molecule",
        "synonyms": [
            "4-(cyclopropylamino)-2-((4-(4-(ethanesulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide",
            "5-pyrimidinecarboxamide, 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)-1-piperazinyl)phenyl)amino)-",
            "Cerdulatinib"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCCCCOC1=CC=C(CCC(N)(CO)CO)C=C1C(F)(F)F",
        "id": "DB17074",
        "molecule": "Amiselimod",
        "cas": "942399-20-4",
        "iupac_name": "2-amino-2-{2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl}propane-1,3-diol",
        "inchi": {
            "hash": "JVCPIJKPAKAIIP-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H30F3NO3/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 377.448,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 377.217778319,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17074",
        "type": "Small Molecule",
        "synonyms": [
            "1,3-propanediol, 2-amino-2-(2-(4-(heptyloxy)-3-(trifluoromethyl)phenyl)ethyl)-",
            "2-amino-2-(2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl)propane-1,3-diol",
            "Amiselimod"
        ]
    },
    {
        "smiles": "OC1=CC(O)=C2C(CC(=O)CCC\\C=C/CCOC2=O)=C1Cl",
        "id": "DB08292",
        "molecule": "(5Z)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE",
        "iupac_name": "(5Z)-12-chloro-13,15-dihydroxy-1,3,4,7,8,9,10,11-octahydro-2-benzoxacyclotridecine-1,10-dione",
        "inchi": {
            "hash": "AQKZYZQONWDDLS-IWQZZHSRSA-N",
            "id": "InChI=1S/C16H17ClO5/c17-15-11-8-10(18)6-4-2-1-3-5-7-22-16(21)14(11)12(19)9-13(15)20/h1,3,9,19-20H,2,4-8H2/b3-1-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 324.756,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 324.076451361,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hydroxybenzoic acid derivatives. These are compounds containing a hydroxybenzoic acid (or a derivative), which is a benzene ring bearing a carboxyl and a hydroxyl groups.",
        "link": "https://go.drugbank.com/drugs/DB08292",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHeat shock protein HSP 90-beta"
            }
        ]
    },
    {
        "smiles": "O=C1NC(=S)NC(CC2=CC=CC=C2)=C1",
        "id": "DB13804",
        "molecule": "Benzylthiouracil",
        "cas": "6336-50-1",
        "iupac_name": "6-benzyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one",
        "inchi": {
            "hash": "PNXBXCRWXNESOV-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H10N2OS/c14-10-7-9(12-11(15)13-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H2,12,13,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 218.27,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 218.051384124,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB13804",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "id": "DB05839",
        "molecule": "BG-777",
        "background": "BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05839",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in cytomegalovirus (CMV) retinitis, HIV infection, influenza, and pneumonia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "CCOC1=CC2=C(C=C1)C(=NN(CC(=O)N(C)C1=CC3=C(C=C1)N=C(C)O3)C2=O)C1=CC=CC(F)=C1",
        "id": "DB16878",
        "molecule": "FDL169",
        "cas": "1628416-28-3",
        "iupac_name": "2-[7-ethoxy-4-(3-fluorophenyl)-1-oxo-1,2-dihydrophthalazin-2-yl]-N-methyl-N-(2-methyl-1,3-benzoxazol-6-yl)acetamide",
        "inchi": {
            "hash": "XRPSUWYWZUQALB-UHFFFAOYSA-N",
            "id": "InChI=1S/C27H23FN4O4/c1-4-35-20-9-10-21-22(14-20)27(34)32(30-26(21)17-6-5-7-18(28)12-17)15-25(33)31(3)19-8-11-23-24(13-19)36-16(2)29-23/h5-14H,4,15H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 486.503,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 486.1703334,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16878",
        "type": "Small Molecule",
        "synonyms": [
            "2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo(D)oxazol-6-yl)acetamide",
            "2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[D]oxazol-6-yl)acetamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "O[C@@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@H]1OP(O)(O)=O",
        "id": "DB01729",
        "molecule": "1D-myo-inositol 1,3,4-trisphosphate",
        "iupac_name": "{[(1S,2R,3R,4S,5S,6S)-2,3,5-trihydroxy-4,6-bis(phosphonooxy)cyclohexyl]oxy}phosphonic acid",
        "inchi": {
            "hash": "MMWCIQZXVOZEGG-MLQGYMEPSA-N",
            "id": "InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2-,3+,4+,5+,6+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 420.0956,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 419.962379346,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as inositol phosphates. These are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety.",
        "link": "https://go.drugbank.com/drugs/DB01729",
        "type": "Small Molecule",
        "synonyms": [
            "(1S,3S,4S)-1,3,4-triphospho-myo-inositol",
            "1D-myo-inositol 1,3,4-trisphosphate",
            "D-myo-Inositol 1,3,4-trisphosphate",
            "Inositol 1,3,4-trisphosphate"
        ]
    },
    {
        "smiles": "CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O",
        "id": "DB04729",
        "molecule": "Gentamicin C1a",
        "cas": "26098-04-4",
        "iupac_name": "(2R,3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol",
        "inchi": {
            "hash": "VEGXETMJINRLTH-BOZYPMBZSA-N",
            "id": "InChI=1S/C19H39N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h8-18,24-27H,3-7,20-23H2,1-2H3/t8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 449.5423,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 449.284948627,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.",
        "link": "https://go.drugbank.com/drugs/DB04729",
        "type": "Small Molecule",
        "synonyms": [
            "Gentamycin C12"
        ],
        "moa": [
            {
                "action": "adduct",
                "organism": "Escherichia coli (strain K12)",
                "target": "A30S ribosomal protein S12"
            },
            {
                "action": "adduct",
                "organism": "Enteric bacteria and other eubacteria",
                "target": "A16S ribosomal RNA"
            }
        ]
    },
    {
        "smiles": "CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC",
        "id": "DB09018",
        "molecule": "Bromopride",
        "cas": "4093-35-0",
        "iupac_name": "4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide",
        "background": "Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.\n",
        "inchi": {
            "hash": "GIYAQDDTCWHPPL-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)"
        },
        "summary": "Bromopride is a substituted benzamide, closely related to metoclopramide, used as an antiemetic.",
        "weight": [
            {
                "type": "average",
                "weight": 344.247,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 343.08953961,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB09018",
        "type": "Small Molecule",
        "synonyms": [
            "4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide",
            "Bromoprid",
            "Bromoprida",
            "Bromopride",
            "Bromopridum"
        ],
        "indication": "Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ADopamine D2 receptor"
            }
        ]
    },
    {
        "smiles": "[H]C(C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@@]([H])(C)CCOC[C@@]([H])(COP(O)(=O)OC[C@]([H])(O)COP([O-])([O-])=O)OCC[C@]([H])(C)CCC[C@]([H])(C)CCCC([H])(C)CCCC(C)C",
        "id": "DB02293",
        "molecule": "(2S)-2,3-bis{[(3R,7R)-3,7,11,15-tetramethylhexadecyl]oxy}propyl (2R)-2-hydroxy-3-[(hydroxyphosphinato)oxy]propyl phosphate",
        "iupac_name": "(3R,7R)-1-{[(2S)-1-({hydroxy[(2R)-2-hydroxy-3-(phosphonooxy)propoxy]phosphoryl}oxy)-3-{[(3R,7R)-3,7,11,15-tetramethylhexadecyl]oxy}propan-2-yl]oxy}-3,7,11,15-tetramethylhexadecane",
        "inchi": {
            "hash": "TZXJQSKPTCRGCA-VZSPAKCESA-L",
            "id": "InChI=1S/C46H96O11P2/c1-37(2)17-11-19-39(5)21-13-23-41(7)25-15-27-43(9)29-31-53-35-46(36-57-59(51,52)56-34-45(47)33-55-58(48,49)50)54-32-30-44(10)28-16-26-42(8)24-14-22-40(6)20-12-18-38(3)4/h37-47H,11-36H2,1-10H3,(H,51,52)(H2,48,49,50)/p-2/t39?,40?,41-,42-,43-,44-,45-,46+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 885.1795,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 884.627136874,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB02293",
        "type": "Small Molecule"
    },
    {
        "smiles": "COC1=CC(O)=C(C=C1CC=C(C)C)C(=O)\\C=C\\C1=CC=C(O)C=C1",
        "id": "DB07500",
        "molecule": "(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one",
        "iupac_name": "(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one",
        "inchi": {
            "hash": "ZUGCRBMNFSAUOC-YRNVUSSQSA-N",
            "id": "InChI=1S/C21H22O4/c1-14(2)4-8-16-12-18(20(24)13-21(16)25-3)19(23)11-7-15-5-9-17(22)10-6-15/h4-7,9-13,22,24H,8H2,1-3H3/b11-7+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 338.397,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 338.151809192,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 3-prenylated chalcones. These are chalcones featuring a C5-isoprenoid unit at the 3-position.",
        "link": "https://go.drugbank.com/drugs/DB07500",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGroup IIE secretory phospholipase A2"
            }
        ]
    },
    {
        "smiles": "ClC1=C(N2CCN(CC#C)CC2)C(NC(=O)C2=CC=C(Br)O2)=CC=C1",
        "id": "DB08021",
        "molecule": "5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide",
        "iupac_name": "5-bromo-N-{3-chloro-2-[4-(prop-2-yn-1-yl)piperazin-1-yl]phenyl}furan-2-carboxamide",
        "inchi": {
            "hash": "MEFJFXHHHNDHEN-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H17BrClN3O2/c1-2-8-22-9-11-23(12-10-22)17-13(20)4-3-5-14(17)21-18(24)15-6-7-16(19)25-15/h1,3-7H,8-12H2,(H,21,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 422.703,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 421.019267157,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-furanilides. These are aromatic heterocyclic compounds contaning a furan ring that is substituted at the 2-position with an anilide.",
        "link": "https://go.drugbank.com/drugs/DB08021",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMitogen-activated protein kinase 10"
            }
        ]
    },
    {
        "smiles": "[Na+].[Na+].[Na+].O=S1(=O)O[Au]2(OS(=O)(=O)S2)S1",
        "id": "DB15974",
        "molecule": "Gold sodium thiosulfate",
        "cas": "15283-45-1",
        "iupac_name": "trisodium 1,5-dioxa-2lambda6,3,6lambda6,7-tetrathia-4-auraspiro[3.3]heptane-2,2,6,6-tetrone",
        "inchi": {
            "hash": "OVUZJYJOLVHTIZ-UHFFFAOYSA-J",
            "id": "InChI=1S/Au.3Na.2H2O3S2/c;;;;2*1-5(2,3)4/h;;;;2*(H2,1,2,3,4)/q+4;3*+1;;/p-4"
        },
        "weight": [
            {
                "type": "average",
                "weight": 490.17,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 489.792004,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15974",
        "type": "Small Molecule",
        "synonyms": [
            "Gold sodium thiosulfate anhydrous",
            "Sodium aurothiosulfate",
            "Sodium aurothiosulfate anhydrous"
        ],
        "is_stub": true
    },
    {
        "id": "DB00702",
        "molecule": "Icodextrin",
        "cas": "337376-15-5",
        "background": "Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.\n",
        "inchi": {},
        "summary": "Icodextrin is an iso-osmotic solution used for continuous peritoneal dialysis or automated peritoneal dialysis.",
        "link": "https://go.drugbank.com/drugs/DB00702",
        "type": "Small Molecule",
        "synonyms": [
            "Icodextrin",
            "Icodextrina",
            "Icodextrine",
            "Icodextrinum"
        ],
        "indication": "Used for continuous ambulatory peritoneal dialysis (CAPD) of diabetic patients or automated peritoneal dialysis (APD) for the management of end-stage renal disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.\n"
    },
    {
        "smiles": "[H]C1(CCC(CC1)=C1C(O)=C(O)C2=CC=CC=C2C1=O)C1=CC=C(Cl)C=C1",
        "id": "DB04281",
        "molecule": "2-[4-(4-Chlorophenyl)Cyclohexylidene]-3,4-Dihydroxy-1(2h)-Naphthalenone",
        "iupac_name": "2-[4-(4-chlorophenyl)cyclohexylidene]-3,4-dihydroxy-1,2-dihydronaphthalen-1-one",
        "inchi": {
            "hash": "HKIDMHSZRQSXJE-XEMYWUMJSA-N",
            "id": "InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,25-26H,5-8H2/b19-15-/t13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 366.837,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 366.102272181,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB04281",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydroorotate dehydrogenase (quinone), mitochondrial"
            }
        ]
    },
    {
        "smiles": "CC(C(O)=O)C1=CC=C(C=C1)N1CC2=CC=CC=C2C1=O",
        "id": "DB08951",
        "molecule": "Indoprofen",
        "cas": "31842-01-0",
        "iupac_name": "2-[4-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)phenyl]propanoic acid",
        "background": "A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.\n",
        "inchi": {
            "hash": "RJMIEHBSYVWVIN-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H15NO3/c1-11(17(20)21)12-6-8-14(9-7-12)18-10-13-4-2-3-5-15(13)16(18)19/h2-9,11H,10H2,1H3,(H,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 281.3059,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 281.105193351,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.",
        "link": "https://go.drugbank.com/drugs/DB08951",
        "type": "Small Molecule",
        "synonyms": [
            "Indoprofen",
            "indoprofeno"
        ],
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UPyruvate kinase PKM"
            }
        ]
    },
    {
        "smiles": "CSC1=CC(\\N=C(/N)N(C)C2=CC(SC)=CC=C2)=C(Cl)C=C1",
        "id": "DB05824",
        "molecule": "CNS-5161",
        "iupac_name": "(E)-N''-[2-chloro-5-(methylsulfanyl)phenyl]-N-methyl-N-[3-(methylsulfanyl)phenyl]guanidine",
        "background": "CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.\n",
        "inchi": {
            "hash": "JHVHEDNLONERHY-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H18ClN3S2/c1-20(11-5-4-6-12(9-11)21-2)16(18)19-15-10-13(22-3)7-8-14(15)17/h4-10H,1-3H3,(H2,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 351.917,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 351.063066678,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aryl thioethers. These are organosulfur compounds containing a thioether group that is substituted by an aryl group.",
        "link": "https://go.drugbank.com/drugs/DB05824",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in migraine and cluster headaches, neuropathy (diabetic), and pain (acute or chronic).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutamate receptor ionotropic, NMDA 1"
            }
        ]
    },
    {
        "id": "DB05820",
        "molecule": "DP-b99",
        "background": "DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05820",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in strokes and traumatic brain injuries.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "NS(=O)(=O)C1=CC(NC2=NC(NC3=C(Cl)C=CC4=C3OCO4)=CC=N2)=CC=C1",
        "id": "DB07252",
        "molecule": "3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",
        "iupac_name": "3-({4-[(5-chloro-2H-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzene-1-sulfonamide",
        "inchi": {
            "hash": "TZHCXOMEOHEZDX-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H14ClN5O4S/c18-12-4-5-13-16(27-9-26-13)15(12)22-14-6-7-20-17(23-14)21-10-2-1-3-11(8-10)28(19,24)25/h1-8H,9H2,(H2,19,24,25)(H2,20,21,22,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 419.842,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 419.045502358,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB07252",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEphrin type-B receptor 4"
            }
        ]
    },
    {
        "smiles": "CCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C(N)N=CN=C12",
        "id": "DB03264",
        "molecule": "Dodecyl-Coa",
        "iupac_name": "{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-({[({[(3R)-3-[(2-{[2-(dodecanoylsulfanyl)ethyl]carbamoyl}ethyl)carbamoyl]-3-hydroxy-2,2-dimethylpropoxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}methyl)-4-hydroxyoxolan-3-yl]oxy}phosphonic acid",
        "inchi": {
            "hash": "YMCXGHLSVALICC-GMHMEAMDSA-N",
            "id": "InChI=1S/C33H58N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-24(42)61-17-16-35-23(41)14-15-36-31(45)28(44)33(2,3)19-54-60(51,52)57-59(49,50)53-18-22-27(56-58(46,47)48)26(43)32(55-22)40-21-39-25-29(34)37-20-38-30(25)40/h20-22,26-28,32,43-44H,4-19H2,1-3H3,(H,35,41)(H,36,45)(H,49,50)(H,51,52)(H2,34,37,38)(H2,46,47,48)/t22-,26-,27-,28+,32-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 949.837,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 949.282273691,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2,3,4-saturated fatty acyl coas. These are acyl-CoAs carrying a 2,3,4-saturated fatty acyl chain.",
        "link": "https://go.drugbank.com/drugs/DB03264",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Mycobacterium tuberculosis",
                "target": "U3-oxoacyl-[acyl-carrier-protein] synthase 3"
            },
            {
                "action": "Not Available",
                "organism": "Bacillus subtilis (strain 168)",
                "target": "UFatty acid metabolism regulator protein"
            }
        ]
    },
    {
        "smiles": "CCC1=C2C=C3N4C(=CC5=C(C)C(CCC(O)=O)=C6C=C7N8C(=CC(N2[Fe]48N56)=C1C)C(C)=C7CCC(O)=O)C(=O)C3(C)CC",
        "id": "DB04384",
        "molecule": "Fe-Mesopone",
        "iupac_name": "3-[20-(2-carboxyethyl)-10,14-diethyl-5,10,15,19-tetramethyl-9-oxo-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^{2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3,5,7,11,13,15,17,19,21(24)-nonaen-4-yl]propanoic acid",
        "inchi": {
            "hash": "RPYIPNWUMWMZRW-UHFFFAOYSA-K",
            "id": "InChI=1S/C34H39N4O5.Fe/c1-7-20-17(3)23-13-24-18(4)21(9-11-31(39)40)26(35-24)15-27-22(10-12-32(41)42)19(5)25(36-27)14-29-33(43)34(6,8-2)30(38-29)16-28(20)37-23;/h13-16H,7-12H2,1-6H3,(H5-,35,36,37,38,39,40,41,42,43);/q-1;+4/p-3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 636.53,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 636.203506,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as chlorins. These are large heterocyclic aromatic ring systems consisting, at the core, of three pyrroles and one pyrroline coupled through four methine linkages.",
        "link": "https://go.drugbank.com/drugs/DB04384",
        "type": "Small Molecule"
    },
    {
        "smiles": "C[C@H](N)[C@H](N)CCCCCC(O)=O",
        "id": "DB01715",
        "molecule": "7,8-Diamino-Nonanoic Acid",
        "iupac_name": "(7R,8S)-7,8-diaminononanoic acid",
        "inchi": {
            "hash": "KCEGBPIYGIWCDH-JGVFFNPUSA-N",
            "id": "InChI=1S/C9H20N2O2/c1-7(10)8(11)5-3-2-4-6-9(12)13/h7-8H,2-6,10-11H2,1H3,(H,12,13)/t7-,8+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 188.2673,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 188.152477894,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB01715",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UATP-dependent dethiobiotin synthetase BioD 1"
            }
        ]
    },
    {
        "smiles": "OC1=CC=C(C=C1)C1=CC2=C(O1)C(CC#N)=CC(O)=C2",
        "id": "DB06927",
        "molecule": "[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE",
        "iupac_name": "2-[5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]acetonitrile",
        "inchi": {
            "hash": "ZKJVCUXZMYKTLT-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H11NO3/c17-6-5-11-7-14(19)8-12-9-15(20-16(11)12)10-1-3-13(18)4-2-10/h1-4,7-9,18-19H,5H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 265.2634,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 265.073893223,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-arylbenzofuran flavonoids. These are phenylpropanoids containing the 2-phenylbenzofuran moiety.",
        "link": "https://go.drugbank.com/drugs/DB06927",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor coactivator 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor alpha"
            }
        ]
    },
    {
        "smiles": "CC(C)(N)CO.CN1C2=C(N=CN2)C(=O)N(C)C1=O",
        "id": "DB13812",
        "molecule": "Bufylline",
        "cas": "5634-34-4",
        "iupac_name": "1,3-dimethyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione; 2-amino-2-methylpropan-1-ol",
        "inchi": {
            "hash": "SEIRRUDMPNNSCY-UHFFFAOYSA-N",
            "id": "InChI=1S/C7H8N4O2.C4H11NO/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;1-4(2,5)3-6/h3H,1-2H3,(H,8,9);6H,3,5H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 269.305,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 269.148789492,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.",
        "link": "https://go.drugbank.com/drugs/DB13812",
        "type": "Small Molecule",
        "synonyms": [
            "Ambuphylline"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=C4C=CC=N2)C(=O)N1CC(F)(F)F)C1=C(F)C(F)=CC=C1F",
        "id": "DB16098",
        "molecule": "Atogepant",
        "cas": "1374248-81-3",
        "iupac_name": "(6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide",
        "background": "Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.7 While its approval was predated by two other members of the same drug family, namely ubrogepant and rimegepant, these agents are indicated only for abortive migraine therapy - atogepant is novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine.7 In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults.8 It also received approval for preventive treatment of adult migraine by the EMA in August 2023.12\nIn patients requiring preventative migraine therapy, current practice guidelines recommend the use of certain anti-epileptic medications (e.g. valproic acid or topiramate) or beta-blockers (e.g. propranolol), all of which can be associated with significant adverse effects.5 The \"gepants\" family of drugs, including atogepant, are comparatively well-tolerated1,6 and may provide a desirable treatment option for patients struggling with adverse reactions to other preventative therapies.\n",
        "inchi": {
            "hash": "QIVUCLWGARAQIO-OLIXTKCUSA-N",
            "id": "InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1"
        },
        "summary": "Atogepant is an oral CGRP antagonist used for the preventative therapy of episodic migraine headaches.",
        "weight": [
            {
                "type": "average",
                "weight": 603.525,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 603.170508599,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16098",
        "type": "Small Molecule",
        "synonyms": [
            "Atogepant"
        ],
        "indication": "Atogepant is indicated for the preventive treatment of migraine in adults by the FDA, EMA, and Health Canada.9,10,11\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Atogepant helps to prevent migraine headaches by antagonizing the activity of a pronociceptive molecule (CGRP) which has been implicated in migraine pathophysiology.6 Intended for preventative use, rather than abortive migraine therapy, atogepant is administered once daily.6\nWhile no dose adjustments are required for patients with mild or moderate hepatic impairment, atogepant should be avoided in patients with severe hepatic impairment. Similarly, no dose adjustments are required for patients with mild or moderate renal impairment, but patients with severe renal impairment should be limited to a maximum daily dose of 10mg.6\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "ACalcitonin gene-related peptide type 1 receptor"
            }
        ]
    },
    {
        "smiles": "[NH4+].CC(O)C([O-])=O",
        "id": "DB06768",
        "molecule": "Ammonium lactate",
        "cas": "515-98-0",
        "iupac_name": "ammonium 2-hydroxypropanoate",
        "background": "Ammonium lactate is the ammonium salt of lactic acid.\n",
        "inchi": {
            "hash": "RZOBLYBZQXQGFY-UHFFFAOYSA-N",
            "id": "InChI=1S/C3H6O3.H3N/c1-2(4)3(5)6;/h2,4H,1H3,(H,5,6);1H3"
        },
        "summary": "Ammonium lactate is an inorganic compound used for the symptomatic treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.",
        "weight": [
            {
                "type": "average",
                "weight": 107.1085,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 107.058243159,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carboxylic acid salts. These are ionic derivatives of carboxylic acid.",
        "link": "https://go.drugbank.com/drugs/DB06768",
        "type": "Small Molecule",
        "synonyms": [
            "Ammonium (+-)-lactate",
            "Ammonium lactate",
            "Lactic acid ammonium salt"
        ],
        "indication": "For the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Lactic acid is an alpha-hydroxy acid. It is a normal constituent of tissues and blood. The alpha-hydroxy acids (and their salts) may act as humectants when applied to the skin. This property may influence hydration of the stratum corneum. In addition, lactic acid, when applied to the skin, may act to decrease corneocyte cohesion.\n"
    },
    {
        "smiles": "[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)C[C@@]([H])(O)P(O)(O)=O",
        "id": "DB07895",
        "molecule": "ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID",
        "iupac_name": "[(1S,3R,7R)-1-hydroxy-3,7,11-trimethyldodecyl]phosphonic acid",
        "inchi": {
            "hash": "IJNCEETVCWDDQB-KFWWJZLASA-N",
            "id": "InChI=1S/C15H33O4P/c1-12(2)7-5-8-13(3)9-6-10-14(4)11-15(16)20(17,18)19/h12-16H,5-11H2,1-4H3,(H2,17,18,19)/t13-,14-,15+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 308.3939,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 308.211646056,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units.",
        "link": "https://go.drugbank.com/drugs/DB07895",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein farnesyltransferase subunit beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04343"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08124"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03973"
    },
    {
        "smiles": "[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2",
        "id": "DB12329",
        "molecule": "Eravacycline",
        "cas": "1207283-85-9",
        "iupac_name": "(4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide",
        "background": "Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, -lactam/-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens 1. It was first approved by the FDA on August 27, 2018 4. Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections 3.\n",
        "inchi": {
            "hash": "HLFSMUUOKPBTSM-ISIOAQNYSA-N",
            "id": "InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34,36-37,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1"
        },
        "summary": "Eravacycline is a tetracycline antibiotic used to treat complicated intra-abdominal infections.",
        "weight": [
            {
                "type": "average",
                "weight": 558.563,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 558.212592137,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.",
        "link": "https://go.drugbank.com/drugs/DB12329",
        "type": "Small Molecule",
        "synonyms": [
            "Eravacyclina",
            "Eravacycline",
            "Eravacyclinum"
        ],
        "indication": "Eravacycline is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older Label.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Eravacycline is an antibiotic that disrupts bacterial protein synthesis, treating complicated intraabdominal infections Label.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Escherichia coli (strain K12)",
                "target": "A30S ribosomal protein S4"
            }
        ]
    },
    {
        "smiles": "OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB01320",
        "molecule": "Fosphenytoin",
        "cas": "93390-81-9",
        "iupac_name": "[(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methoxy]phosphonic acid",
        "background": "Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.\n",
        "inchi": {
            "hash": "XWLUWCNOOVRFPX-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)"
        },
        "summary": "Fosphenytoin is an antiepileptic agent used for the management of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery.",
        "weight": [
            {
                "type": "average",
                "weight": 362.2739,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 362.066772734,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB01320",
        "type": "Small Molecule",
        "synonyms": [
            "(3-Phosphoryloxymethyl)phenytoin",
            "Fosfenitoina",
            "Fosphenytoin",
            "Fosphenytoine",
            "Fosphenytoinum"
        ],
        "indication": "Fosphenytoin is indicated for the treatment of generalized tonic-clonic status epilepticus and for the prevention and treatment of seizures occurring during neurosurgery in adult patients. It can also be substituted, short-term, for oral phenytoin in patients aged two years and older when oral phenytoin administration is not possible.6\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fosphenytoin is a water-soluble phenytoin prodrug used for the treatment of epileptic seizures. Following parenteral administration of fosphenytoin, fosphenytoin is converted to the anticonvulsant phenytoin by endogenous phosphatases. Each 1.5 mg of fosphenytoin sodium is equivalent to 1.0mg of phenytoin sodium (PE equivalents); care should be taken to calculate the dose required in PE equivalents properly. Serious adverse effects such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), and hematopoietic complications may occur and indicate an alternate antiepileptic should be used. Withdrawal of fosphenytoin sodium may precipitate seizures and should be done gradually.6\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium channel protein type 5 subunit alpha"
            }
        ]
    },
    {
        "id": "DB05230",
        "molecule": "AC3056",
        "background": "AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05230",
        "type": "Small Molecule",
        "indication": "For the treatment of atherosclerosis and other conditions related to the obstruction of blood vessels.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Oral administration of AC3056 results in dose-dependent antioxidant activity and was well tolerated. In 2002, positive results were reported from a phase I trial. In the double-blind, placebo-controlled, crossover trial, 14 healthy subjects received an oral formulation of AC3056 in a dose-escalating manner. Results demonstrated dose-dependent increases in blood levels of AC3056, as well as dose-dependent increases in serum antioxidant activity. The drug was well tolerated with no safety concerns.\n"
    },
    {
        "smiles": "[H][C@@]1(CC[C@@]2([H])[C@]3([H])C(=O)C[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC(=O)[C@]12C)[C@H](C)CCC(O)=O",
        "id": "DB11622",
        "molecule": "Dehydrocholic acid",
        "cas": "81-23-2",
        "iupac_name": "(4R)-4-[(1R,3aS,3bR,5aS,9aS,9bS,11aR)-9a,11a-dimethyl-4,7,11-trioxo-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid",
        "background": "Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid 1. It has been used for stimulation of biliary lipid secretion. The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.\n",
        "inchi": {
            "hash": "OHXPGWPVLFPUSM-KLRNGDHRSA-N",
            "id": "InChI=1S/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)/t13-,14+,16-,17+,18+,22+,23+,24-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 402.531,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 402.240624195,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bile acids, alcohols and derivatives. These are organic compounds containing an alcohol or acid derivative of cholic acid.",
        "link": "https://go.drugbank.com/drugs/DB11622",
        "type": "Small Molecule",
        "synonyms": [
            "3,7,12-Triketo-5beta-cholanoic acid",
            "3,7,12-triketocholanic acid",
            "3,7,12-trioxo-5beta-cholanic acid",
            "3,7,12-trioxo-5-cholanic acid",
            "3,7,12-trioxocholanic acid",
            "Decholin",
            "Dehydrocholate",
            "Dehydrocholic acid"
        ],
        "indication": "No approved therapeutic indications. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Following infusion of dehydrocholic acid (DHCA) in rats, the secretions of all the endogenous biliary bile acids were decreased within 30-60 minutes of infusion 2,4. Phospholipid secretion as well as cholesterol levels were also declined. The bile flow was increased after administration of dehydrocholic acid 1. \n"
    },
    {
        "smiles": "[H][C@]1(CC2=CC=C(OC[C@@]3(C)CCC4=C(C)C(O)=C(C)C(C)=C4O3)C=C2)SC(=O)NC1=O",
        "id": "DB08607",
        "molecule": "(5R)-5-(4-{[(2R)-6-HYDROXY-2,5,7,8-TETRAMETHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL]METHOXY}BENZYL)-1,3-THIAZOLIDINE-2,4-DIONE",
        "iupac_name": "(5R)-5-[(4-{[(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl]methoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione",
        "inchi": {
            "hash": "GXPHKUHSUJUWKP-NTKDMRAZSA-N",
            "id": "InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)/t19-,24-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 441.54,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 441.160993669,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-benzopyrans. These are organic aromatic compounds that 1-benzopyran, a bicyclic compound made up of a benzene ring fused to a pyran, so that the oxygen atom is at the 1-position.",
        "link": "https://go.drugbank.com/drugs/DB08607",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome P450 2C8"
            }
        ]
    },
    {
        "smiles": "OC(=O)CNC(=O)C1=C(O)C2=CC=CC=C2C(Cl)=N1",
        "id": "DB08687",
        "molecule": "FG-2216",
        "cas": "223387-75-5",
        "iupac_name": "2-[(1-chloro-4-hydroxyisoquinolin-3-yl)formamido]acetic acid",
        "background": "A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability. 1\n",
        "inchi": {
            "hash": "OUQVKRKGTAUJQA-UHFFFAOYSA-N",
            "id": "InChI=1S/C12H9ClN2O4/c13-11-7-4-2-1-3-6(7)10(18)9(15-11)12(19)14-5-8(16)17/h1-4,18H,5H2,(H,14,19)(H,16,17)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 280.664,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 280.025084493,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB08687",
        "type": "Small Molecule",
        "synonyms": [
            "(((1-Chloro-4-hydroxyisoquinolin-3-yl)carbonyl)amino)acetic acid",
            "1-Chloro-N- (hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide",
            "1-Chloro-N-(hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide"
        ],
        "indication": "Investigated for use/treatment in anemia and kidney disease.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEgl nine homolog 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHypoxia-inducible factor 1-alpha"
            }
        ]
    },
    {
        "smiles": "CC1=NC2=C(C(N)=CC=C2)C(=O)N1C1CCC(=O)NC1=O",
        "id": "DB14857",
        "molecule": "Avadomide",
        "cas": "1015474-32-4",
        "iupac_name": "3-(5-amino-2-methyl-4-oxo-3,4-dihydroquinazolin-3-yl)piperidine-2,6-dione",
        "background": "Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).\n",
        "inchi": {
            "hash": "RSNPAKAFCAAMBH-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 286.291,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 286.106590327,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14857",
        "type": "Small Molecule",
        "synonyms": [
            "3-(5-Amino-2-methyl-4-oxo-4H-quinazolin-3-yl)piperidine-2,6-dione",
            "Avadomide"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(O)C=C(O[C@@]([H])(OCC(C)C)[C@]1([H])NC(C)=O)C(O)=O",
        "id": "DB07960",
        "molecule": "5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID",
        "iupac_name": "(2R,3R,4S)-3-acetamido-4-hydroxy-2-(2-methylpropoxy)-3,4-dihydro-2H-pyran-6-carboxylic acid",
        "inchi": {
            "hash": "QDVFOADQCFRSSP-MKPLZMMCSA-N",
            "id": "InChI=1S/C12H19NO6/c1-6(2)5-18-12-10(13-7(3)14)8(15)4-9(19-12)11(16)17/h4,6,8,10,12,15H,5H2,1-3H3,(H,13,14)(H,16,17)/t8-,10+,12+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 273.2824,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 273.121237345,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acetamides. These are organic compounds with the general formula RNHC(=O)CH3, where R= organyl group.",
        "link": "https://go.drugbank.com/drugs/DB07960",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USialidase-2"
            }
        ]
    },
    {
        "smiles": "[H]N(CCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)C(=O)C1=CC(=CC(CN=[N+]=[N-])=C1)C(=O)N([H])CCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O",
        "id": "DB03634",
        "molecule": "1,3-DI(N-Propyloxy-A-mannopyranosyl)-carbomyl 5-methyazido-benzene",
        "iupac_name": "5-(azidomethyl)-N1,N3-bis(3-{[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propyl)benzene-1,3-dicarboxamide",
        "inchi": {
            "hash": "GKRIMQPDERYOML-LHMXEDMUSA-N",
            "id": "InChI=1S/C27H41N5O14/c28-32-31-10-13-7-14(24(41)29-3-1-5-43-26-22(39)20(37)18(35)16(11-33)45-26)9-15(8-13)25(42)30-4-2-6-44-27-23(40)21(38)19(36)17(12-34)46-27/h7-9,16-23,26-27,33-40H,1-6,10-12H2,(H,29,41)(H,30,42)/t16-,17-,18-,19-,20+,21+,22+,23+,26+,27+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 659.6395,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 659.265001045,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.",
        "link": "https://go.drugbank.com/drugs/DB03634",
        "type": "Small Molecule"
    },
    {
        "smiles": "[Fe++].[H][C@](O)(CO)[C@@]1([H])OC(=O)C(O)=C1O.[H][C@](O)(CO)[C@@]1([H])OC(=O)C([O-])=C1[O-]",
        "id": "DB14490",
        "molecule": "Ferrous ascorbate",
        "cas": "24808-52-4",
        "iupac_name": "lambda2-iron(2+) (2R)-2-[(1S)-1,2-dihydroxyethyl]-5-oxo-2,5-dihydrofuran-3,4-bis(olate) (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one",
        "inchi": {
            "hash": "RFBYLSCVRUTUSB-ZZMNMWMASA-L",
            "id": "InChI=1S/2C6H8O6.Fe/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1"
        },
        "summary": "Ferrous ascorbate is a medication used to treat iron-deficiency anemia.",
        "weight": [
            {
                "type": "average",
                "weight": 406.077,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 405.983462,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14490",
        "type": "Small Molecule",
        "synonyms": [
            "Ferrous cevitamate",
            "Iron(2+) L-ascorbate",
            "L-Ascorbic acid, iron complex"
        ],
        "indication": "Used in preventing and treating iron-deficiency anemia.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.\n",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTransferrin receptor protein 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEgl nine homolog 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHistone deacetylase 8"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAlpha-hemoglobin-stabilizing protein"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHemoglobin subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFrataxin, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFerritin heavy chain"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UFlap endonuclease 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEndonuclease 8-like 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEndonuclease 8-like 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA polymerase beta"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCeruloplasmin"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USerotransferrin"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08466"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08176"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04007"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07108"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13265"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13525"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09063"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05266"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06460"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07700"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08054"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15426"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07122"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03636"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09272"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02115"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16032"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04430"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02249"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16205"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08704"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05752"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01163"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02502"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06292"
    },
    {
        "smiles": "O=C(OCCN1CCCCC1)C1(CCCCC1)C1CCCCC1",
        "id": "DB13678",
        "molecule": "Dihexyverine",
        "cas": "561-77-3",
        "iupac_name": "2-(piperidin-1-yl)ethyl [1,1'-bi(cyclohexane)]-1-carboxylate",
        "inchi": {
            "hash": "MNSQDVCVWNXBFQ-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H35NO2/c22-19(23-17-16-21-14-8-3-9-15-21)20(12-6-2-7-13-20)18-10-4-1-5-11-18/h18H,1-17H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 321.505,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 321.266779371,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as piperidines. These are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB13678",
        "type": "Small Molecule",
        "synonyms": [
            "Dihexyverine"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](C)(N)C(=O)C1=NN=C(O1)C(C)(C)C",
        "id": "DB07391",
        "molecule": "(2S)-2-AMINO-1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)PROPAN-1-ONE",
        "iupac_name": "(2S)-2-amino-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)propan-1-one",
        "inchi": {
            "hash": "PVDZDTVFUVTTDU-YFKPBYRVSA-N",
            "id": "InChI=1S/C9H15N3O2/c1-5(10)6(13)7-11-12-8(14-7)9(2,3)4/h5H,10H2,1-4H3/t5-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 197.2343,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 197.116426739,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aryl alkyl ketones. These are ketones have the generic structure RC(=O)R', where R = aryl group and R'=alkyl group.",
        "link": "https://go.drugbank.com/drugs/DB07391",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Serratia marcescens",
                "target": "UProline iminopeptidase"
            }
        ]
    },
    {
        "smiles": "C[C@H](NP(=O)(OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O)OC1=C2C=CC=CC2=CC=C1)C(=O)OCC1=CC=CC=C1",
        "id": "DB14859",
        "molecule": "Fosifloxuridine nafalbenamide",
        "cas": "1332837-31-6",
        "iupac_name": "benzyl (2S)-2-[({[(2R,3S,5R)-5-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy}(naphthalen-1-yloxy)phosphoryl)amino]propanoate",
        "background": "Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).\n",
        "inchi": {
            "hash": "BIOWRMNRHMERIO-ZVAHOJSLSA-N",
            "id": "InChI=1S/C29H29FN3O9P/c1-18(28(36)39-16-19-8-3-2-4-9-19)32-43(38,42-24-13-7-11-20-10-5-6-12-21(20)24)40-17-25-23(34)14-26(41-25)33-15-22(30)27(35)31-29(33)37/h2-13,15,18,23,25-26,34H,14,16-17H2,1H3,(H,32,38)(H,31,35,37)/t18-,23-,25+,26+,43?/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 613.535,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 613.162544687,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14859",
        "type": "Small Molecule",
        "synonyms": [
            "Fosifloxuridine nafalbenamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC(=O)C1=C(C=CS1)S(=O)(=O)NC1=CC=C(Cl)C=C1",
        "id": "DB08573",
        "molecule": "3-[(4-CHLOROANILINO)SULFONYL]THIOPHENE-2-CARBOXYLIC ACID",
        "iupac_name": "3-[(4-chlorophenyl)sulfamoyl]thiophene-2-carboxylic acid",
        "inchi": {
            "hash": "YRWKEEDITQJPCZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H8ClNO4S2/c12-7-1-3-8(4-2-7)13-19(16,17)9-5-6-18-10(9)11(14)15/h1-6,13H,(H,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 317.769,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 316.958326836,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.",
        "link": "https://go.drugbank.com/drugs/DB08573",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "NC1=CC(=C(C=N1)C1=NC(=NC(=C1)N1CCOCC1)N1CCOCC1)C(F)(F)F",
        "id": "DB11666",
        "molecule": "Buparlisib",
        "cas": "944396-07-0",
        "iupac_name": "5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine",
        "background": "Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.\n",
        "inchi": {
            "hash": "CWHUFRVAEUJCEF-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 410.3935,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 410.167808561,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.",
        "link": "https://go.drugbank.com/drugs/DB11666",
        "type": "Small Molecule",
        "synonyms": [
            "Buparlisib",
            "Buparlisibum"
        ],
        "is_stub": true
    },
    {
        "smiles": "OC1=CC2=C(C=C1)C(=NO2)C1=CC(Br)=C(O)C=C1O",
        "id": "DB07502",
        "molecule": "4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol",
        "iupac_name": "4-bromo-6-(6-hydroxy-1,2-benzoxazol-3-yl)benzene-1,3-diol",
        "inchi": {
            "hash": "LZACPHWPRDKUPK-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H8BrNO4/c14-9-4-8(10(17)5-11(9)18)13-7-2-1-6(16)3-12(7)19-15-13/h1-5,16-18H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 322.111,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 320.963670396,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzisoxazoles. These are aromatic compounds containing a benzene ring fused to an isoxazole ring. Isoxazole is five-membered ring with three carbon atoms, and an oxygen atom next to a nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB07502",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHeat shock protein HSP 90-alpha"
            }
        ]
    },
    {
        "smiles": "COC1=CC=C(\\C=C\\C(=O)OCCC(C)C)C=C1",
        "id": "DB11207",
        "molecule": "Amiloxate",
        "cas": "71617-10-2",
        "iupac_name": "3-methylbutyl (2E)-3-(4-methoxyphenyl)prop-2-enoate",
        "background": "Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m 3. It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity 1.\n",
        "inchi": {
            "hash": "UBNYRXMKIIGMKK-RMKNXTFCSA-N",
            "id": "InChI=1S/C15H20O3/c1-12(2)10-11-18-15(16)9-6-13-4-7-14(17-3)8-5-13/h4-9,12H,10-11H2,1-3H3/b9-6+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 248.322,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 248.141244504,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cinnamic acid esters. These are compound containing an ester derivative of cinnamic acid.",
        "link": "https://go.drugbank.com/drugs/DB11207",
        "type": "Small Molecule",
        "synonyms": [
            "3-(4-Methoxyphenyl)-2-propenoic acid, 3-methylbutyl ester",
            "Amiloxate",
            "Isoamyl p-methoxycinnamate",
            "Isoamyl-p-methoxycinnamate"
        ],
        "indication": "Indicated as an active sunscreen agent. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "In a mouse study, amiloxate exerted a dose-dependent anti-inflammatory action and inhibited edema by about 70% even at a low dose 1. Due to structural similarities, amiloxate may also display antioxidant and antimicrobial properties of cinnamic acid 2.\n"
    },
    {
        "smiles": "C[C@]1(CCCN1C1=NN2C=CC=C2C(NC2=NNC(=C2)C2CC2)=N1)C(=O)NC1=CN=C(F)C=C1",
        "id": "DB15399",
        "molecule": "BMS-754807",
        "cas": "1001350-96-4",
        "iupac_name": "(2S)-1-{4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide",
        "background": "BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux in Subjects With Advanced or Metastatic Solid Tumors).\n",
        "inchi": {
            "hash": "LQVXSNNAFNGRAH-QHCPKHFHSA-N",
            "id": "InChI=1S/C23H24FN9O/c1-23(21(34)26-15-7-8-18(24)25-13-15)9-3-10-32(23)22-28-20(17-4-2-11-33(17)31-22)27-19-12-16(29-30-19)14-5-6-14/h2,4,7-8,11-14H,3,5-6,9-10H2,1H3,(H,26,34)(H2,27,28,29,30,31)/t23-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 461.4948,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 461.20878464,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15399",
        "type": "Small Molecule",
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UInsulin-like growth factor 1 receptor"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UInsulin receptor"
            }
        ]
    },
    {
        "smiles": "[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)N(C)CC1=COC2=NC(N)=NC(N)=C12)C(O)=O",
        "id": "DB02026",
        "molecule": "Furo[2,3d]Pyrimidine Antifolate",
        "iupac_name": "(2S)-2-({4-[({2,4-diaminofuro[2,3-d]pyrimidin-5-yl}methyl)(methyl)amino]phenyl}formamido)pentanedioic acid",
        "inchi": {
            "hash": "WXINNGCGSCFUCR-ZDUSSCGKSA-N",
            "id": "InChI=1S/C20H22N6O6/c1-26(8-11-9-32-18-15(11)16(21)24-20(22)25-18)12-4-2-10(3-5-12)17(29)23-13(19(30)31)6-7-14(27)28/h2-5,9,13H,6-8H2,1H3,(H,23,29)(H,27,28)(H,30,31)(H4,21,22,24,25)/t13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 442.4253,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 442.160082466,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB02026",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pneumocystis carinii",
                "target": "UDihydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "ClC1=CC2=C(NC(=C2)C(=O)NCCOCCOCCNC(=O)C2=CC3=C(N2)C=CC(Cl)=C3)C=C1",
        "id": "DB02089",
        "molecule": "CP-526423",
        "iupac_name": "5-chloro-N-[2-(2-{2-[(5-chloro-1H-indol-2-yl)formamido]ethoxy}ethoxy)ethyl]-1H-indole-2-carboxamide",
        "inchi": {
            "hash": "MWWXABBBAPKJDX-UHFFFAOYSA-N",
            "id": "InChI=1S/C24H24Cl2N4O4/c25-17-1-3-19-15(11-17)13-21(29-19)23(31)27-5-7-33-9-10-34-8-6-28-24(32)22-14-16-12-18(26)2-4-20(16)30-22/h1-4,11-14,29-30H,5-10H2,(H,27,31)(H,28,32)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 503.378,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 502.11746069,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.",
        "link": "https://go.drugbank.com/drugs/DB02089",
        "type": "Small Molecule",
        "synonyms": [
            "1,2-bis(2-(5-chloroindole-2-carbonylamino)ethoxy)ethane",
            "bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol",
            "N,N'-[1,2-Ethanediylbis(oxy-2,1-ethanediyl)]bis(5-chloro-1H-indole-2-carboxamide)"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlycogen phosphorylase, liver form"
            }
        ]
    },
    {
        "smiles": "NC(=O)O[C@@H](CN1N=CN=N1)C1=C(Cl)C=CC=C1",
        "id": "DB06119",
        "molecule": "Cenobamate",
        "cas": "913088-80-9",
        "iupac_name": "(1R)-1-(2-chlorophenyl)-2-(2H-1,2,3,4-tetrazol-2-yl)ethyl carbamate",
        "background": "Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.1,3 The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels.3\nCenobamate was granted FDA approval on 21 November 2019.3\n",
        "inchi": {
            "hash": "GFHAXPJGXSQLPT-VIFPVBQESA-N",
            "id": "InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1"
        },
        "summary": "Cenobamate is a small molecule drug indicated to treat partial onset seizures in adults.",
        "weight": [
            {
                "type": "average",
                "weight": 267.67,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 267.0523023,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06119",
        "type": "Small Molecule",
        "synonyms": [
            "Cenobamate",
            "Cnobamate",
            "Cenobamato",
            "Cenobamatum"
        ],
        "indication": "Cenobamate is indicated for the treatment of partial onset seizures in adults.3\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "The mechanism of cenobamate is unknown, however it modulates GABAA and inhibit voltage gated sodium channels.3 Cenobamate is given once daily and so it has a long duration of action.3 The therapeutic window is wide as doses of 750mg can be well tolerated.2 Patients should be counselled regarding the risk of DRESS syndrome, QT interval shortening, suicidal behavior, and neurological adverse effects.3\n"
    },
    {
        "smiles": "CC(CCCCC[18F])(C(O)=O)C(O)=O",
        "id": "DB16029",
        "molecule": "2-(5-fluoro-pentyl)-2-methyl-malonic-acid",
        "cas": "1236354-10-1",
        "iupac_name": "2-[5-(F)fluoropentyl]-2-methylpropanedioic acid",
        "background": "2-(5-fluoro-pentyl)-2-methyl-malonic-acid is under investigation in clinical trial NCT00696943 (18F ML-10 for Early Detection of Response of Brain Metastases to SRS).\n",
        "inchi": {
            "hash": "BOYGOAXVKOOCKN-LMANFOLPSA-N",
            "id": "InChI=1S/C9H15FO4/c1-9(7(11)12,8(13)14)5-3-2-4-6-10/h2-6H2,1H3,(H,11,12)(H,13,14)/i10-1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 205.216,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 205.09797163,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16029",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@](N)(C1CCCCC1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=C(OCC(=O)NCC)C=CC(Cl)=C1",
        "id": "DB06869",
        "molecule": "1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE",
        "iupac_name": "(2S)-1-[(2R)-2-amino-2-cyclohexylacetyl]-N-({5-chloro-2-[(ethylcarbamoyl)methoxy]phenyl}methyl)pyrrolidine-2-carboxamide",
        "inchi": {
            "hash": "BMHVHOJXEQTIEA-SIKLNZKXSA-N",
            "id": "InChI=1S/C24H35ClN4O4/c1-2-27-21(30)15-33-20-11-10-18(25)13-17(20)14-28-23(31)19-9-6-12-29(19)24(32)22(26)16-7-4-3-5-8-16/h10-11,13,16,19,22H,2-9,12,14-15,26H2,1H3,(H,27,30)(H,28,31)/t19-,22+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 479.012,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 478.234683335,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB06869",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProthrombin"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(N)C=C(CO)C[C@]([H])(O)[C@@]1([H])O",
        "id": "DB01789",
        "molecule": "1-Amino-2,3-Dihydroxy-5-Hydroxymethyl Cyclohex-5-Ene",
        "iupac_name": "(1S,2S,3S)-3-amino-5-(hydroxymethyl)cyclohex-4-ene-1,2-diol",
        "inchi": {
            "hash": "BMZJPVSGERKRHP-ACZMJKKPSA-N",
            "id": "InChI=1S/C7H13NO3/c8-5-1-4(3-9)2-6(10)7(5)11/h1,5-7,9-11H,2-3,8H2/t5-,6-,7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 159.183,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 159.089543287,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB01789",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacillus circulans",
                "target": "UCyclomaltodextrin glucanotransferase"
            }
        ]
    },
    {
        "smiles": "[H][C@@](CCC)(C(O)=O)C1=CNC2=CC=CC=C12",
        "id": "DB06981",
        "molecule": "(2S)-2-(1H-indol-3-yl)pentanoic acid",
        "iupac_name": "(2S)-2-(1H-indol-3-yl)pentanoic acid",
        "inchi": {
            "hash": "QRCBLBWFQJDFJQ-JTQLQIEISA-N",
            "id": "InChI=1S/C13H15NO2/c1-2-5-10(13(15)16)11-8-14-12-7-4-3-6-9(11)12/h3-4,6-8,10,14H,2,5H2,1H3,(H,15,16)/t10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 217.2637,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 217.110278729,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as indole-3-acetic acid derivatives. These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole.",
        "link": "https://go.drugbank.com/drugs/DB06981",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "US-phase kinase-associated protein 1"
            }
        ]
    },
    {
        "smiles": "CC(C)C1=CC=C(N)C=C1",
        "id": "DB02114",
        "molecule": "Cumidine",
        "cas": "99-88-7",
        "iupac_name": "4-(propan-2-yl)aniline",
        "inchi": {
            "hash": "LRTFPLFDLJYEKT-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H13N/c1-7(2)8-3-5-9(10)6-4-8/h3-7H,10H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 135.2062,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 135.104799421,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB02114",
        "type": "Small Molecule",
        "synonyms": [
            "4-(1-methylethyl)aniline",
            "4-Amino-1-isopropylbenzene",
            "4-Aminocumene",
            "4-Isopropylaniline",
            "p-Cumidine",
            "p-Isopropylaniline",
            "para-isopropylaniline"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UChymotrypsin-like elastase family member 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(O)C[C@@]([H])(O)[C@]([H])(OCCCCCC)O[C@]1([H])CO",
        "id": "DB03772",
        "molecule": "2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,5-Diol",
        "iupac_name": "(2R,3R,5R,6R)-2-(hexyloxy)-6-(hydroxymethyl)oxane-3,5-diol",
        "inchi": {
            "hash": "TXGXIVBQPNUSRY-DDHJBXDOSA-N",
            "id": "InChI=1S/C12H24O5/c1-2-3-4-5-6-16-12-10(15)7-9(14)11(8-13)17-12/h9-15H,2-8H2,1H3/t9-,10-,11-,12-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 248.316,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 248.162373878,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.",
        "link": "https://go.drugbank.com/drugs/DB03772",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHisto-blood group ABO system transferase"
            }
        ]
    },
    {
        "smiles": "C[C@@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O",
        "id": "DB03034",
        "molecule": "D-Levofloxacin",
        "cas": "100986-86-5",
        "iupac_name": "(2R)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5,7,9(13),11-tetraene-11-carboxylic acid",
        "background": "A synthetic fluoroquinolone (FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.\n",
        "inchi": {
            "hash": "GSDSWSVVBLHKDQ-SNVBAGLBSA-N",
            "id": "InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 361.3675,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 361.143784348,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.",
        "link": "https://go.drugbank.com/drugs/DB03034",
        "type": "Small Molecule",
        "synonyms": [
            "D-Ofloxacin",
            "R-Ofloxacin"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)",
                "target": "UAutolysin"
            }
        ]
    },
    {
        "smiles": "CC(=O)CCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB08940",
        "molecule": "Kebuzone",
        "cas": "853-34-9",
        "iupac_name": "4-(3-oxobutyl)-1,2-diphenylpyrazolidine-3,5-dione",
        "background": "Kebuzone (also known as ketophenylbutazone ) is a non-steroidal anti-inflammatory drug.\n",
        "inchi": {
            "hash": "LGYTZKPVOAIUKX-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H18N2O3/c1-14(22)12-13-17-18(23)20(15-8-4-2-5-9-15)21(19(17)24)16-10-6-3-7-11-16/h2-11,17H,12-13H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 322.3578,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 322.131742452,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.",
        "link": "https://go.drugbank.com/drugs/DB08940",
        "type": "Small Molecule",
        "synonyms": [
            "Kebuzone",
            "ketophenylbutazone",
            "quebuzona"
        ]
    },
    {
        "smiles": "C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O",
        "id": "DB04618",
        "molecule": "4,6-DIDEOXY-4-{[4-[(4-O-HEXOPYRANOSYLHEXOPYRANOSYL)OXY]-5,6-DIHYDROXY-3-(HYDROXYMETHYL)CYCLOHEX-2-EN-1-YL]AMINO}HEXOPYRANOSYL-(1-\u003e4)HEXOPYRANOSYL-(1-\u003e4)HEXOPYRANOSE",
        "iupac_name": "(2S,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-5-{[(1S,4R,5R,6S)-4-{[(2S,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-5,6-dihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol",
        "inchi": {
            "hash": "HAWINQMQXQMONI-OBPZNAFQSA-N",
            "id": "InChI=1S/C37H63NO28/c1-8-15(18(46)25(53)34(58-8)64-31-13(6-42)62-37(28(56)23(31)51)65-30-12(5-41)59-33(57)24(52)21(30)49)38-10-2-9(3-39)29(20(48)16(10)44)63-36-27(55)22(50)32(14(7-43)61-36)66-35-26(54)19(47)17(45)11(4-40)60-35/h2,8,10-57H,3-7H2,1H3/t8-,10+,11-,12-,13-,14-,15-,16+,17-,18+,19+,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33+,34-,35-,36-,37-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 969.886,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 969.353660437,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.",
        "link": "https://go.drugbank.com/drugs/DB04618",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPancreatic alpha-amylase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC",
        "id": "DB01590",
        "molecule": "Everolimus",
        "cas": "159351-69-6",
        "iupac_name": "(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0,]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone",
        "background": "Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.\n",
        "inchi": {
            "hash": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
            "id": "InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1"
        },
        "summary": "Everolimus is a mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies.",
        "weight": [
            {
                "type": "average",
                "weight": 958.24,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 957.581356357,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.",
        "link": "https://go.drugbank.com/drugs/DB01590",
        "type": "Small Molecule",
        "synonyms": [
            "40-O-(2-hydroxyethyl)-rapamycin",
            "42-O-(2-Hydroxyethyl)rapamycin",
            "Everolimus",
            "vrolimus"
        ],
        "indication": "Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.\nIndicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.\nIndicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.\nIndicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.\nIndicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASerine/threonine-protein kinase mTOR"
            }
        ]
    },
    {
        "smiles": "CC1=C(COCCN)C2=CC3=C(OC(=O)C=C3C)C(C)=C2O1",
        "id": "DB17693",
        "molecule": "Amotosalen",
        "cas": "161262-29-9",
        "iupac_name": "3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one",
        "inchi": {
            "hash": "FERWCFYKULABCE-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H19NO4/c1-9-6-15(19)22-16-10(2)17-13(7-12(9)16)14(11(3)21-17)8-20-5-4-18/h6-7H,4-5,8,18H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 301.342,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 301.131408096,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17693",
        "type": "Small Molecule",
        "synonyms": [
            "3-((2-aminoethoxy)methyl)-2,5,9-trimethyl-7h-furo(3,2-g)chromen-7-one",
            "7h-furo(3,2-g)(1)benzopyran-7-one, 3-((2-aminoethoxy)methyl)-2,5,9-trimethyl-",
            "Amotosalen"
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08428"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04386"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09213"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07267"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07498"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16895"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02651"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00588"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01196"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09075"
    },
    {
        "smiles": "[18F-]",
        "id": "DB09398",
        "molecule": "Fluoride ion F-18",
        "cas": "67862-54-8",
        "iupac_name": "(18F)fluoride",
        "background": "Sodium Fluoride F 18 Injection is a positron emitting radiopharmaceutical, no-carrier added. It contains radioactive fluoride F 18 that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging and is administered by intravenous injection. Its primary indication is for bone imaging. Increased deposition around joints can occur in arthritis and following trauma and increased deposition in bone has been noted around fracture sites, in osteomyelitis, fibrous dysplasia, spondylitis tuberculosa, and Paget's disease. No adverse reactions have been reported.\n",
        "inchi": {
            "hash": "KRHYYFGTRYWZRS-BJUDXGSMSA-M",
            "id": "InChI=1S/FH/h1H/p-1/i1-1"
        },
        "summary": "Fluoride ion F-18 is a diagnostic radiopharmaceutical agent used as a bone imaging agent to delineate areas of altered osteogenesis.",
        "weight": [
            {
                "type": "average",
                "weight": 18.0015,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 18.001486247,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of inorganic compounds known as homogeneous halogens. These are inorganic non-metallic compounds in which the largest atom is a nobel gas.",
        "link": "https://go.drugbank.com/drugs/DB09398",
        "type": "Small Molecule",
        "synonyms": [
            "(18F)-Fluoride",
            "18F-Fluoride",
            "Fluoride-18 anion"
        ],
        "indication": "18F is used as a bone imaging agent to define areas of altered osteogenic activity. It has been indicated for back pain and otherwise unexplained bone pain, child abuse, abnormal radiographic or laboratory findings, osteomyelitis, trauma, inflammatory and degenerative arthritis, avascular necrosis. Osteonecrosis of the mandible, condylar hyperplasia, and metabolic bone disease are also among the indications for fluoride imaging. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Deposition of 18F fluoride in bone appears to be primarily a function of blood flow to the bone and the efficiency of the bone in extracting the 18F from the blood perfusing the bone. Increased fluorine F 18 ion deposition around joints can occur in arthritis or following trauma; increased deposition has also been documented in bone around fracture sites, in osteomyelities, fibrous dysplasia, spondylitis tuberculosa, Paget's disease, hyperstosis frontalis interna, myositis, ossificans, and in rapidly growing epiphyses. The tendency for fluorine F 18 ions to accumulate in the vicinity of primary and metastatic malignancy in bone has proven clinically useful in detection of such lesions\n"
    },
    {
        "smiles": "[H][C@@](N)(CO)CC1=CNC2=CC=CC=C12",
        "id": "DB04236",
        "molecule": "2-Amino-3-(1h-Indol-3-Yl)-Propan-1-Ol",
        "iupac_name": "(2S)-2-amino-3-(1H-indol-3-yl)propan-1-ol",
        "inchi": {
            "hash": "UDQCRUSSQAXPJY-VIFPVBQESA-N",
            "id": "InChI=1S/C11H14N2O/c12-9(7-14)5-8-6-13-11-4-2-1-3-10(8)11/h1-4,6,9,13-14H,5,7,12H2/t9-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 190.2417,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 190.11061308,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.",
        "link": "https://go.drugbank.com/drugs/DB04236",
        "type": "Small Molecule"
    },
    {
        "smiles": "N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O",
        "id": "DB03310",
        "molecule": "Glutathione disulfide",
        "cas": "27025-41-8",
        "iupac_name": "(2S)-2-amino-4-{[(1R)-2-{[(2R)-2-[(4S)-4-amino-4-carboxybutanamido]-2-[(carboxymethyl)carbamoyl]ethyl]disulfanyl}-1-[(carboxymethyl)carbamoyl]ethyl]carbamoyl}butanoic acid",
        "background": "A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.\n",
        "inchi": {
            "hash": "YPZRWBKMTBYPTK-BJDJZHNGSA-N",
            "id": "InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1"
        },
        "summary": "Glutathione disulfide is an ingredient of ophthalmic irrigation solutions used during ophthalmological procedures.",
        "weight": [
            {
                "type": "average",
                "weight": 612.631,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 612.151961898,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.",
        "link": "https://go.drugbank.com/drugs/DB03310",
        "type": "Small Molecule",
        "synonyms": [
            "Glutathione disulphide",
            "GSSG",
            "Oxidized glutathione",
            "Oxiglutatione"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGlutathione peroxidase"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UMicrosomal glutathione S-transferase 1"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UGlutathione S-transferases (Cytosolic)"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UGlutathione S-transferase Mu 2"
            },
            {
                "action": "substrate",
                "organism": "Humans",
                "target": "UGlutathione reductase, mitochondrial"
            }
        ]
    },
    {
        "smiles": "COCCCC\\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F",
        "id": "DB00176",
        "molecule": "Fluvoxamine",
        "cas": "54739-18-3",
        "iupac_name": "(E)-(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine",
        "background": "Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.\nFluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.\n",
        "inchi": {
            "hash": "CJOFXWAVKWHTFT-XSFVSMFZSA-N",
            "id": "InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+"
        },
        "summary": "Fluvoxamine is a selective serotonin-reuptake inhibitor used to treat obsessive-compulsive disorder.",
        "weight": [
            {
                "type": "average",
                "weight": 318.34,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 318.155512413,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB00176",
        "type": "Small Molecule",
        "synonyms": [
            "Fluvoxamina",
            "Fluvoxamine",
            "Fluvoxaminum"
        ],
        "indication": "Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) Label. Has also been used in the management of bulimia nervosa 2.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fluvoxamine, an aralkylketone-derivative agent Label, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs 1. It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety 1. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin Label,1,2. In vitro studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake 2. Moreover, apart from binding to 1 receptors 2, fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs 1. Furthermore, some studies have demonstrated that the chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors (as has been observed with other drugs effective in the treatment of major depressive disorder), while others suggest the opposite 3.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-dependent serotonin transporter"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPotassium voltage-gated channel subfamily H member 2"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08098"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05252"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11698"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02700"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07676"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08261"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08528"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18120"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07501"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12470"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04857"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08193"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14983"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01864"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02724"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01000"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02865"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06897"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11574"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07891"
    },
    {
        "smiles": "CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\\C=C/CCCCCCCC",
        "id": "DB11331",
        "molecule": "1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))",
        "cas": "185435-28-3",
        "iupac_name": "(2,3-dihydroxypropoxy)[(2R)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propoxy]phosphinic acid",
        "background": "Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label]. The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.\n",
        "inchi": {
            "hash": "PAZGBAOHGQRCBP-DDDNOICHSA-N",
            "id": "InChI=1S/C40H77O10P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-40(44)50-38(36-49-51(45,46)48-34-37(42)33-41)35-47-39(43)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,37-38,41-42H,3-16,19-36H2,1-2H3,(H,45,46)/b18-17-/t37?,38-/m1/s1"
        },
        "summary": "1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) is a synthetic lung surfactant used to treat infant respiratory distress syndrome.",
        "weight": [
            {
                "type": "average",
                "weight": 749.02,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 748.525435677,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11331",
        "type": "Small Molecule",
        "synonyms": [
            "1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))",
            "1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol",
            "1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol",
            "l-Alpha-1-palmitoyl-2-oleoylglycerophosphoglycerol",
            "Palmitoyloleoyl-phosphatidylglycerol",
            "PG(16:0/18:1(9Z))",
            "PG(16:0/18:1)",
            "POPG"
        ],
        "indication": "Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin which was indicated for the prevention of respiratory distress syndrome in premature infants.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Palmitoyloleoyl-phosphatidylglycerol is a replacement surfactant which prevents alveolar collapse when administered intratracheally.\n"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08771"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00866"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01772"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03075"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08151"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07678"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01342"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05390"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17255"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02042"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13068"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07512"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02525"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02841"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03344"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09502"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13268"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07410"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12192"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03812"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12314"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08498"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02982"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16842"
    },
    {
        "smiles": "NC(=O)C(=C\\N1C=NC(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)\\C1=CN=CN=C1",
        "id": "DB16153",
        "molecule": "Eltanexor",
        "cas": "1642300-52-4",
        "iupac_name": "(2E)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-2-(pyrimidin-5-yl)prop-2-enamide",
        "background": "Eltanexor is under investigation in clinical trial NCT02649790 (Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/refractory Cancer Indications).\n",
        "inchi": {
            "hash": "JFBAVWVBLRIWHM-AWNIVKPZSA-N",
            "id": "InChI=1S/C17H10F6N6O/c18-16(19,20)11-1-9(2-12(3-11)17(21,22)23)15-27-8-29(28-15)6-13(14(24)30)10-4-25-7-26-5-10/h1-8H,(H2,24,30)/b13-6+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 428.298,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 428.082027944,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16153",
        "type": "Small Molecule",
        "synonyms": [
            "Eltanexor"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1=C(C(C)=NO1)C1=CC(=C2N=C(NC2=C1)C1CC1)C(O)(C1=CC=CC=N1)C1=NC=CC=C1",
        "id": "DB14970",
        "molecule": "Alobresib",
        "cas": "1637771-14-2",
        "iupac_name": "[2-cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-1,3-benzodiazol-4-yl]bis(pyridin-2-yl)methanol",
        "background": "Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer).\n",
        "inchi": {
            "hash": "CMSUJGUHYXQSOK-UHFFFAOYSA-N",
            "id": "InChI=1S/C26H23N5O2/c1-15-23(16(2)33-31-15)18-13-19(24-20(14-18)29-25(30-24)17-9-10-17)26(32,21-7-3-5-11-27-21)22-8-4-6-12-28-22/h3-8,11-14,17,32H,9-10H2,1-2H3,(H,29,30)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 437.503,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 437.185175001,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB14970",
        "type": "Small Molecule",
        "synonyms": [
            "Alobresib"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC(C)N1C(C)=NC=C1C1=NC(NC2=CC=C(C=C2)N2CCN(CC2)C(=O)CO)=NC=C1",
        "id": "DB07982",
        "molecule": "2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol",
        "iupac_name": "2-hydroxy-1-{4-[4-({4-[2-methyl-1-(propan-2-yl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}ethan-1-one",
        "inchi": {
            "hash": "PVTKDXZNSUHUMO-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H29N7O2/c1-16(2)30-17(3)25-14-21(30)20-8-9-24-23(27-20)26-18-4-6-19(7-5-18)28-10-12-29(13-11-28)22(32)15-31/h4-9,14,16,31H,10-13,15H2,1-3H3,(H,24,26,27)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 435.5221,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 435.238273207,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07982",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(O[C@@H]2[C@@H](CC)\\C=C(C)\\[C@@H](O)C\\C=C\\C=C(CO[C@@H]3O[C@H](C)[C@@H](OC(=O)C4=C(CC)C(Cl)=C(O)C(Cl)=C4O)[C@H](O)[C@@H]3OC)\\C(=O)O[C@@H](C\\C=C(/C)\\C=C2/C)[C@@H](C)O)OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O",
        "id": "DB08874",
        "molecule": "Fidaxomicin",
        "cas": "873857-62-6",
        "iupac_name": "(2R,3S,4S,5S,6R)-6-{[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-{[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-[(2-methylpropanoyl)oxy]oxan-2-yl]oxy}-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy}-4-hydroxy-5-methoxy-2-methyloxan-3-yl 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate",
        "background": "Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months.10 Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation.8 Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.6 The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent.6 Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile,4 and it displays a narrow spectrum of activity against gram-positive anaerobes.2 It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription.4 The minimum inhibitory concentration (MIC90) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin.6 Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.7\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18.6 Later that year in December, the drug was also approved by the European Medicine Agency.6 In June 2012, fidaxomicin was also granted approval by Health Canada.4 The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.10\n",
        "inchi": {
            "hash": "ZVGNESXIJDCBKN-UUEYKCAUSA-N",
            "id": "InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1"
        },
        "summary": "Fidaxomicin is a macrolide antibiotic used to treat diarrhea associated with Clostridium difficile infection.",
        "weight": [
            {
                "type": "average",
                "weight": 1058.05,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1056.4252209,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB08874",
        "type": "Small Molecule",
        "synonyms": [
            "Difimicin",
            "Fidaxomicin",
            "Fidaxomicina",
            "Lipiarmicin",
            "Lipiarmycin",
            "Lipiarrmycin",
            "Tiacumicin B"
        ],
        "indication": "Fidaxomicin is indicated for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea in adult and pediatric patients 6 months of age and older.10\nFidaxomicin should only be used in patients with proven or strongly suspected C. difficile infection to reduce the risk of development of drug-resistant bacteria and maximize the therapeutic effectiveness of fidaxomicin and other antimicrobial agents.10\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fidaxomicin has a narrow-spectrum antibacterial profile, with potent bactericidal activity specifically against C. difficile.5 The minimum inhibitory concentration for 90% of organisms for fidaxomicin against C. difficile ranged from 0.0078 to 2 g/mL in vitro.2 The bactericidal activity of fidaxomicin is time-dependent.6 Other than C. difficile, fidaxomicin has moderate inhibitory activity against Gram-positive bacteria (S. aureus and Enterococcus spp.) 5 and poor activity against normal colonic flora, including anaerobes and enteric Gram-negative bacilli.4 Isolates of C. difficile that are resistant to rifamycins or other antimicrobial classes (such as cephalosporins, fluoroquinolones, clindamycin) were not shown to be cross-resistant to fidaxomicin.4\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Clostridium difficile (strain 630)",
                "target": "ARNA polymerase sigma factor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05742"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04953"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02884"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07655"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01779"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04397"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15694"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03165"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09300"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02416"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00557"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01016"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09335"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02485"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08274"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03077"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04506"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01536"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13300"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05722"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05874"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13876"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04063"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16167"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04043"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06893"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00443"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08207"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15027"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00754"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02614"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18117"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07931"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07358"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07400"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07245"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14932"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03381"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12105"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08192"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03698"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11282"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01840"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01288"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17487"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06073"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07623"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07029"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04112"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02954"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06724"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12559"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03207"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07338"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00195"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07675"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17733"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11995"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16084"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00080"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17297"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01880"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03495"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02408"
    },
    {
        "id": "DB05320",
        "molecule": "ATG-Fresenius S",
        "background": "ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05320",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in immunosuppressive and transplant (rejection).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03019"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03319"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11373"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04038"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03301"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13688"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11485"
    },
    {
        "smiles": "CCS(=O)(=O)C1=CC=C2OC(=NC2=C1)C1=CC=C2C=CC=CC2=C1",
        "id": "DB12888",
        "molecule": "Ezutromid",
        "cas": "945531-77-1",
        "iupac_name": "5-(ethanesulfonyl)-2-(naphthalen-2-yl)-1,3-benzoxazole",
        "background": "Ezutromid has been investigated for the treatment of Muscular Dystrophy, Duchenne.\n",
        "inchi": {
            "hash": "KSGCNXAZROJSNW-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 337.39,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 337.077264521,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.",
        "link": "https://go.drugbank.com/drugs/DB12888",
        "type": "Small Molecule",
        "synonyms": [
            "5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo(d)oxazole",
            "Benzoxazole, 5-(ethylsulfonyl)-2-(2-naphthalenyl)-",
            "Ezutromid"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C1=CC=CC=C1",
        "id": "DB16731",
        "molecule": "Dextilidine",
        "cas": "32447-90-8",
        "iupac_name": "ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate",
        "inchi": {
            "hash": "WDEFBBTXULIOBB-WBVHZDCISA-N",
            "id": "InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 273.376,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 273.172878985,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.",
        "link": "https://go.drugbank.com/drugs/DB16731",
        "type": "Small Molecule",
        "synonyms": [
            "Dextilidina",
            "Dextilidine",
            "Dextilidinum"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02384"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05295"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11863"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08239"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02159"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03479"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04881"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07729"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11794"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05225"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01784"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13330"
    },
    {
        "id": "DB05114",
        "molecule": "EHC18",
        "background": "EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05114",
        "type": "Small Molecule",
        "indication": "Investigated for use/treatment in hepatitis (viral, C) and hepatocellular carcinoma.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "[H][C@@]12CCC3=C(C=C(O)C(O)=C3)[C@@]1([H])C1=C(CN2)C=CC=C1",
        "id": "DB16139",
        "molecule": "DAR-0100A",
        "cas": "174691-84-0",
        "iupac_name": "(6aR,12bS)-5H,6H,6aH,7H,8H,12bH-benzo[a]phenanthridine-10,11-diol",
        "background": "DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).\n",
        "inchi": {
            "hash": "BGOQGUHWXBGXJW-RHSMWYFYSA-N",
            "id": "InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2/t14-,17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 267.328,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 267.125928791,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16139",
        "type": "Small Molecule",
        "synonyms": [
            "Dihydrexidine, (+)-"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=C(C(=O)N1C1=CC=CC=C1)C(=CC=C2)C#CC1=CN(C)N=C1",
        "id": "DB16296",
        "molecule": "IPI-549",
        "cas": "1693758-51-8",
        "iupac_name": "2-amino-N-[(1S)-1-{8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl}ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide",
        "background": "IPI-549 is under investigation in clinical trial NCT03795610 (Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma).\n",
        "inchi": {
            "hash": "XUMALORDVCFWKV-IBGZPJMESA-N",
            "id": "InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 528.576,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 528.202222045,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16296",
        "type": "Small Molecule",
        "synonyms": [
            "Pi3k-gamma inhibitor ipi-549"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](CO)(NC(=O)C(Cl)Cl)[C@]([H])(O)C1=CC=C(N)C=C1",
        "id": "DB04411",
        "molecule": "Alpha-N-Dichloroacetyl-P-Aminophenylserinol",
        "iupac_name": "N-[(1R,2R)-1-(4-aminophenyl)-1,3-dihydroxypropan-2-yl]-2,2-dichloroacetamide",
        "inchi": {
            "hash": "BFLNGKUCFYKCFZ-RKDXNWHRSA-N",
            "id": "InChI=1S/C11H14Cl2N2O3/c12-10(13)11(18)15-8(5-16)9(17)6-1-3-7(14)4-2-6/h1-4,8-10,16-17H,5,14H2,(H,15,18)/t8-,9-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 293.146,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 292.038147738,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB04411",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Streptomyces venezuelae (strain ATCC 10712 / CBS 650.69 / DSM 40230 / JCM 4526 / NBRC 13096 / PD 04745)",
                "target": "UChloramphenicol 3-O phosphotransferase"
            }
        ]
    },
    {
        "smiles": "CC1=NN=C(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CN2C=C(Cl)C(=O)C(Cl)=C2)C3=O)C(O)=O)S1",
        "id": "DB13778",
        "molecule": "Cefazedone",
        "cas": "56187-47-4",
        "iupac_name": "(6R,7R)-7-[2-(3,5-dichloro-4-oxo-1,4-dihydropyridin-1-yl)acetamido]-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",
        "inchi": {
            "hash": "VTLCNEGVSVJLDN-MLGOLLRUSA-N",
            "id": "InChI=1S/C18H15Cl2N5O5S3/c1-7-22-23-18(33-7)32-6-8-5-31-16-12(15(28)25(16)13(8)17(29)30)21-11(26)4-24-2-9(19)14(27)10(20)3-24/h2-3,12,16H,4-6H2,1H3,(H,21,26)(H,29,30)/t12-,16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 548.43,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 546.9612375,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB13778",
        "type": "Small Molecule",
        "synonyms": [
            "cefazedona",
            "Cefazedone"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@](O)(CCCCCC)C(O)=O",
        "id": "DB07907",
        "molecule": "(2S)-2-HYDROXYOCTANOIC ACID",
        "iupac_name": "(2S)-2-hydroxyoctanoic acid",
        "inchi": {
            "hash": "JKRDADVRIYVCCY-ZETCQYMHSA-N",
            "id": "InChI=1S/C8H16O3/c1-2-3-4-5-6-7(9)8(10)11/h7,9H,2-6H2,1H3,(H,10,11)/t7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 160.2108,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 160.109944378,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB07907",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHydroxyacid oxidase 1"
            },
            {
                "action": "Not Available",
                "organism": "Pseudomonas putida",
                "target": "U(S)-mandelate dehydrogenase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14938"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02414"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11405"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13664"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02017"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04578"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07350"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18029"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08717"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04846"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02803"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13141"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01393"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16938"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13119"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01147"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07362"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05443"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14525"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17576"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07474"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11323"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07415"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04695"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17822"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03583"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11264"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09004"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06288"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17248"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03502"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00993"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13262"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08436"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08196"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11393"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15970"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07749"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13404"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08366"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05592"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04521"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06446"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07977"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02915"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06988"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14906"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00288"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15444"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08848"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03340"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15062"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03503"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00982"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07627"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02931"
    },
    {
        "smiles": "CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1",
        "id": "DB00821",
        "molecule": "Carprofen",
        "cas": "53716-49-7",
        "iupac_name": "2-(6-chloro-9H-carbazol-2-yl)propanoic acid",
        "background": "Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory drugs. It is no longer marketed for human usage, after being withdrawn on commercial grounds.\n",
        "inchi": {
            "hash": "PUXBGTOOZJQSKH-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 273.714,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 273.05565634,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB00821",
        "type": "Small Molecule",
        "synonyms": [
            "(+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid",
            "()-6-chloro--methylcarbazole-2-acetic acid",
            "2-(6-Chloro-9H-carbazol-2-yl)-propionic acid",
            "6-chloro--methyl-9H-carbazole-2-acetic acid",
            "Carprofen",
            "Carprofne",
            "Carprofeno",
            "Carprofenum"
        ],
        "indication": "For use as a pain reliever in the treatment of joint pain and post-surgical pain.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Carprofen is a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class that includes ibuprofen, naproxen, and ketoprofen. It is no longer used in the clinical setting, but is approved for use in dogs. Carprofen is non-narcotic and has characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AProstaglandin G/H synthase 2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UProstaglandin G/H synthase 1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08325"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14549"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17749"
    },
    {
        "smiles": "[H][C@]1(CC[C@@H](N)[C@@]([H])(O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1)[C@@H](C)N",
        "id": "DB17884",
        "molecule": "Gentamicin C2",
        "cas": "25876-11-3",
        "iupac_name": "(2R,3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol",
        "inchi": {
            "hash": "XUFIWSHGXVLULG-IDLVJFIQSA-N",
            "id": "InChI=1S/C20H41N5O7/c1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19/h8-19,25-28H,4-7,21-24H2,1-3H3/t8-,9-,10+,11-,12+,13-,14+,15-,16+,17-,18+,19+,20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 463.576,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 463.30059868,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17884",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(C)CN(CC2(CC2)C(N)=O)CCN1S(=O)(=O)C1=CC=C(C=C1)[C@](C)(O)C(F)(F)F",
        "id": "DB07624",
        "molecule": "1-{[(3R)-3-methyl-4-({4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]phenyl}sulfonyl)piperazin-1-yl]methyl}cyclopropanecarboxamide",
        "iupac_name": "1-{[(3R)-3-methyl-4-{4-[(2S)-1,1,1-trifluoro-2-hydroxypropan-2-yl]benzenesulfonyl}piperazin-1-yl]methyl}cyclopropane-1-carboxamide",
        "inchi": {
            "hash": "YJFULAYRAKPBCY-DYVFJYSZSA-N",
            "id": "InChI=1S/C19H26F3N3O4S/c1-13-11-24(12-18(7-8-18)16(23)26)9-10-25(13)30(28,29)15-5-3-14(4-6-15)17(2,27)19(20,21)22/h3-6,13,27H,7-12H2,1-2H3,(H2,23,26)/t13-,17+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 449.488,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 449.15961164,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB07624",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCorticosteroid 11-beta-dehydrogenase isozyme 1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C",
        "id": "DB12221",
        "molecule": "Canrenone",
        "cas": "976-71-6",
        "iupac_name": "(1R,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-2,3,3a,3b,7,8,9,9a,9b,10,11,11a-dodecahydrospiro[cyclopenta[a]phenanthrene-1,2'-oxolane]-5',7-dione",
        "background": "Canrenone has been used in trials studying the diagnostic of Heart Failure.\n",
        "inchi": {
            "hash": "UJVLDDZCTMKXJK-WNHSNXHDSA-N",
            "id": "InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1"
        },
        "summary": "Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).",
        "weight": [
            {
                "type": "average",
                "weight": 340.4559,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 340.203844762,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as steroid lactones. These are sterol lipids containing a lactone moiety linked to the steroid skeleton.",
        "link": "https://go.drugbank.com/drugs/DB12221",
        "type": "Small Molecule",
        "synonyms": [
            "Canrenone"
        ],
        "is_stub": true
    },
    {
        "smiles": "O=C1CCCC(=O)N1CCC1=CN=CN1",
        "id": "DB16016",
        "molecule": "Histamine glutarimide",
        "cas": "1464897-15-1",
        "iupac_name": "1-[2-(1H-imidazol-5-yl)ethyl]piperidine-2,6-dione",
        "background": "Histamine glutarimide is under investigation in clinical trial NCT03450434 (XC8 in the Treatment of Patients With Bronchial Asthma).\n",
        "inchi": {
            "hash": "DYKZYSKWOHKZMF-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H13N3O2/c14-9-2-1-3-10(15)13(9)5-4-8-6-11-7-12-8/h6-7H,1-5H2,(H,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 207.233,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 207.100776671,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16016",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CN(CC=C)C\\C=C\\COC1=CC2=C(C=C1F)C(=NN2C)C1=CC=C(Br)C=C1",
        "id": "DB02139",
        "molecule": "(2e)-N-Allyl-4-{[3-(4-Bromophenyl)-5-Fluoro-1-Methyl-1h-Indazol-6-Yl]Oxy}-N-Methyl-2-Buten-1-Amine",
        "iupac_name": "[(2E)-4-{[3-(4-bromophenyl)-5-fluoro-1-methyl-1H-indazol-6-yl]oxy}but-2-en-1-yl](methyl)(prop-2-en-1-yl)amine",
        "inchi": {
            "hash": "YDWPQZUWZDRRSE-AATRIKPKSA-N",
            "id": "InChI=1S/C22H23BrFN3O/c1-4-11-26(2)12-5-6-13-28-21-15-20-18(14-19(21)24)22(25-27(20)3)16-7-9-17(23)10-8-16/h4-10,14-15H,1,11-13H2,2-3H3/b6-5+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 444.34,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 443.100853225,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB02139",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Alicyclobacillus acidocaldarius subsp. acidocaldarius (strain ATCC 27009 / DSM 446 / 104-1A)",
                "target": "USqualene--hopene cyclase"
            }
        ]
    },
    {
        "smiles": "NC1=NC2=C(C=N1)C=C(C1=CC=CC=C1)C(=N2)N1CC=CC1",
        "id": "DB08146",
        "molecule": "7-(2,5-dihydropyrrol-1-yl)-6-phenyl-pyrido[6,5-d]pyrimidin-2-amine",
        "iupac_name": "7-(2,5-dihydro-1H-pyrrol-1-yl)-6-phenylpyrido[2,3-d]pyrimidin-2-amine",
        "inchi": {
            "hash": "QFWNOFXQNCLFBC-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H15N5/c18-17-19-11-13-10-14(12-6-2-1-3-7-12)16(20-15(13)21-17)22-8-4-5-9-22/h1-7,10-11H,8-9H2,(H2,18,19,20,21)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 289.3345,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 289.132745505,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB08146",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBiotin carboxylase"
            }
        ]
    },
    {
        "smiles": "C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1",
        "id": "DB06787",
        "molecule": "Hexocyclium",
        "cas": "6004-98-4",
        "iupac_name": "4-(2-cyclohexyl-2-hydroxy-2-phenylethyl)-1,1-dimethylpiperazin-1-ium",
        "background": "Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like Omeprazole and opiate anti-diarrheal agents like Loperamide have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more favorable side effect profiles.\n",
        "inchi": {
            "hash": "ZRYHPQCHHOKSMD-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H33N2O/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3/q+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 317.496,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 317.258740111,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.",
        "link": "https://go.drugbank.com/drugs/DB06787",
        "type": "Small Molecule",
        "indication": "The World Health Organization classifies hexocyclium as a drug for functional gastrointestinal disorders 5. Like other anti-muscarinic agents, hexocyclium was likely used to treat peptic ulcers or diarrhea.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Hexocyclium reduces gastrointesitinal motility and gastric acid secretion 2,3.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AMuscarinic acetylcholine receptor M3"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M1"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M2"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UMuscarinic acetylcholine receptor M4"
            }
        ]
    },
    {
        "smiles": "[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(OC)[C@@]([H])(O)C=O",
        "id": "DB16765",
        "molecule": "3-O-Methyl-d-glucose",
        "cas": "146-72-5",
        "iupac_name": "(2R,3S,4R,5R)-2,4,5,6-tetrahydroxy-3-methoxyhexanal",
        "inchi": {
            "hash": "RMTFNDVZYPHUEF-XZBKPIIZSA-N",
            "id": "InChI=1S/C7H14O6/c1-13-7(5(11)3-9)6(12)4(10)2-8/h3-8,10-12H,2H2,1H3/t4-,5+,6-,7-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 194.183,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 194.079038171,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16765",
        "type": "Small Molecule",
        "synonyms": [
            "3-Methyl-D-glucose",
            "3-Methylglucose",
            "3-O-Methylglucose",
            "Methylglucose",
            "O(3)-methyl-D-glucose"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCCCN1C(CC2=CC=C(OC)C=C2)=NC2=C(N)N=CN=C12",
        "id": "DB03899",
        "molecule": "9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine",
        "iupac_name": "9-butyl-8-[(4-methoxyphenyl)methyl]-9H-purin-6-amine",
        "inchi": {
            "hash": "NVYATAJRTRFKSW-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H21N5O/c1-3-4-9-22-14(10-12-5-7-13(23-2)8-6-12)21-15-16(18)19-11-20-17(15)22/h5-8,11H,3-4,9-10H2,1-2H3,(H2,18,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 311.3815,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 311.174610319,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.",
        "link": "https://go.drugbank.com/drugs/DB03899",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHeat shock protein HSP 90-alpha"
            }
        ]
    },
    {
        "smiles": "C1CC1",
        "id": "DB13984",
        "molecule": "Cyclopropane",
        "cas": "75-19-4",
        "iupac_name": "cyclopropane",
        "background": "Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene. Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining stable hemodynamics. Its use was ultimately limited because it was highly explosive.\n",
        "inchi": {
            "hash": "LVZWSLJZHVFIQJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C3H6/c1-2-3-1/h1-3H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 42.081,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 42.046950193,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB13984",
        "type": "Small Molecule",
        "synonyms": [
            "Ciclopropano",
            "Cyclopropan",
            "Cyclopropane",
            "Cyclopropanum",
            "Trimethylene",
            "Zyklopropan"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07549"
    },
    {
        "smiles": "FC1=C2[C@H](CN3CCC(CC3)NCC3=NN=C4OCCOC4=C3)CN3C2=C(C=C1)C=CC3=O",
        "id": "DB15345",
        "molecule": "GSK-945237",
        "cas": "944406-54-6",
        "iupac_name": "(3R)-3-({4-[({6H,7H-[1,4]dioxino[2,3-c]pyridazin-3-yl}methyl)amino]piperidin-1-yl}methyl)-5-fluoro-1-azatricyclo[6.3.1.0^{4,12}]dodeca-4,6,8(12),9-tetraen-11-one",
        "background": "GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.).\n",
        "inchi": {
            "hash": "SRICOHRDRMZREQ-MRXNPFEDSA-N",
            "id": "InChI=1S/C24H26FN5O3/c25-19-3-1-15-2-4-21(31)30-14-16(22(19)23(15)30)13-29-7-5-17(6-8-29)26-12-18-11-20-24(28-27-18)33-10-9-32-20/h1-4,11,16-17,26H,5-10,12-14H2/t16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 451.502,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 451.20196788,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15345",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC1=NC2=C(C=C(C=C2N1CC1=C(C)C(=CC=C1)C(F)(F)F)N1CCOCC1)C(O)=O",
        "id": "DB11795",
        "molecule": "GSK-2636771",
        "cas": "1372540-25-4",
        "iupac_name": "2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid",
        "background": "GSK2636771 has been used in trials studying the treatment of CANCER, LYMPHOMA, Solid Neoplasm, Recurrent Solid Neoplasm, and Advanced Malignant Neoplasm, among others.\n",
        "inchi": {
            "hash": "XTKLTGBKIDQGQL-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 433.431,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 433.161326069,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.",
        "link": "https://go.drugbank.com/drugs/DB11795",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "OC[C@H]1O[C@H](C[C@@H]1O)N1C=CC(=O)NC1=O",
        "id": "DB02256",
        "molecule": "2'-Deoxyuridine",
        "cas": "951-78-0",
        "iupac_name": "1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione",
        "background": "2'-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies. [PubChem]\n",
        "inchi": {
            "hash": "MXHRCPNRJAMMIM-SHYZEUOFSA-N",
            "id": "InChI=1S/C9H12N2O5/c12-4-6-5(13)3-8(16-6)11-2-1-7(14)10-9(11)15/h1-2,5-6,8,12-13H,3-4H2,(H,10,14,15)/t5-,6+,8+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 228.202,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 228.074621504,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.",
        "link": "https://go.drugbank.com/drugs/DB02256",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UUridine phosphorylase"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UThymidylate synthase"
            }
        ]
    },
    {
        "smiles": "ClC1=C2SC(=CC2=CC=C1)C(=O)N[C@H]1CN2CCC1CC2",
        "id": "DB11726",
        "molecule": "Encenicline",
        "cas": "550999-75-2",
        "iupac_name": "N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide",
        "background": "Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.\n",
        "inchi": {
            "hash": "SSRDSYXGYPJKRR-ZDUSSCGKSA-N",
            "id": "InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 320.84,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 320.075012,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1-benzothiophenes. These are aromatic heterocyclic compound containing the Benzo[b]thiophene ring system.",
        "link": "https://go.drugbank.com/drugs/DB11726",
        "type": "Small Molecule",
        "synonyms": [
            "Encenicline"
        ],
        "is_stub": true,
        "moa": [
            {
                "action": "partial agonist",
                "organism": "Humans",
                "target": "ANeuronal acetylcholine receptor subunit alpha-7"
            }
        ]
    },
    {
        "smiles": "CN1C2=CC=CC=C2C(C#N)(C(=O)NCCC(O)=O)C2=C1C=CC=C2",
        "id": "DB07441",
        "molecule": "3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID",
        "iupac_name": "3-[(9-cyano-10-methyl-9,10-dihydroacridin-9-yl)formamido]propanoic acid",
        "inchi": {
            "hash": "FRBAOMHMZCGBOJ-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H17N3O3/c1-22-15-8-4-2-6-13(15)19(12-20,14-7-3-5-9-16(14)22)18(25)21-11-10-17(23)24/h2-9H,10-11H2,1H3,(H,21,25)(H,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 335.3566,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 335.126991425,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring.",
        "link": "https://go.drugbank.com/drugs/DB07441",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIg gamma-1 chain C region"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIg kappa chain C region"
            }
        ]
    },
    {
        "smiles": "NC1=CC=CC(SC2=CC=C(\\C=C\\C(=O)N3CCOCC3)C(=C2C(F)(F)F)C(F)(F)F)=C1",
        "id": "DB07486",
        "molecule": "3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline",
        "iupac_name": "(2E)-3-{4-[(3-aminophenyl)sulfanyl]-2,3-bis(trifluoromethyl)phenyl}-1-(morpholin-4-yl)prop-2-en-1-one",
        "inchi": {
            "hash": "KLSZVPNVFKKIRD-FNORWQNLSA-N",
            "id": "InChI=1S/C21H18F6N2O2S/c22-20(23,24)18-13(5-7-17(30)29-8-10-31-11-9-29)4-6-16(19(18)21(25,26)27)32-15-3-1-2-14(28)12-15/h1-7,12H,8-11,28H2/b7-5+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 476.435,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 476.09931775,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cinnamic acids and derivatives. These are organic aromatic compounds containing a benzene and a carboxylic acid group (or a derivative thereof) forming 3-phenylprop-2-enoic acid.",
        "link": "https://go.drugbank.com/drugs/DB07486",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIntegrin alpha-L"
            }
        ]
    },
    {
        "smiles": "COC1=CC(=CC=C1)C1=CC(CC[C@]2(C)CC(=O)N(C)C(N)=N2)=CC=C1",
        "id": "DB07519",
        "molecule": "(6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one",
        "iupac_name": "(6R)-2-amino-6-(2-{3'-methoxy-[1,1'-biphenyl]-3-yl}ethyl)-3,6-dimethyl-3,4,5,6-tetrahydropyrimidin-4-one",
        "inchi": {
            "hash": "VDFBMQAUECXNKR-OAQYLSRUSA-N",
            "id": "InChI=1S/C21H25N3O2/c1-21(14-19(25)24(2)20(22)23-21)11-10-15-6-4-7-16(12-15)17-8-5-9-18(13-17)26-3/h4-9,12-13H,10-11,14H2,1-3H3,(H2,22,23)/t21-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 351.4421,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 351.194677059,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.",
        "link": "https://go.drugbank.com/drugs/DB07519",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UBeta-secretase 1"
            }
        ]
    },
    {
        "smiles": "C[C@]1(OC(=O)N(NC2=CC=CC=C2)C1=O)C1=CC=C(F)C=C1F",
        "id": "DB07763",
        "molecule": "(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",
        "iupac_name": "(5S)-5-(2,4-difluorophenyl)-5-methyl-3-(phenylamino)-1,3-oxazolidine-2,4-dione",
        "inchi": {
            "hash": "OZZFJGCAYWBVBI-INIZCTEOSA-N",
            "id": "InChI=1S/C16H12F2N2O3/c1-16(12-8-7-10(17)9-13(12)18)14(21)20(15(22)23-16)19-11-5-3-2-4-6-11/h2-9,19H,1H3/t16-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 318.2749,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 318.08159867,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylhydrazines. These are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent attached to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB07763",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome c1, heme protein, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 1, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 2, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 6, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 8"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit Rieske, mitochondrial"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 10"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 7"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome b-c1 complex subunit 9"
            }
        ]
    },
    {
        "smiles": "OC(=O)C1=CC=NC=C1",
        "id": "DB16884",
        "molecule": "Isonicotinic acid",
        "cas": "55-22-1",
        "iupac_name": "pyridine-4-carboxylic acid",
        "inchi": {
            "hash": "TWBYWOBDOCUKOW-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H5NO2/c8-6(9)5-1-3-7-4-2-5/h1-4H,(H,8,9)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 123.111,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 123.032028405,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16884",
        "type": "Small Molecule",
        "synonyms": [
            "4-Pyridinecarboxylic acid"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC=C(SC2=C3N=CN(CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F)C3=NC(N)=N2)C=C1",
        "id": "DB06368",
        "molecule": "Alamifovir",
        "cas": "193681-12-8",
        "iupac_name": "bis(2,2,2-trifluoroethyl) [(2-{2-amino-6-[(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}ethoxy)methyl]phosphonate",
        "background": "Alamifovir is an antiviral agent specific for HBV.\n",
        "inchi": {
            "hash": "VDBGPMJFHCJMOL-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H20F6N5O5PS/c1-32-12-2-4-13(5-3-12)37-16-14-15(28-17(26)29-16)30(10-27-14)6-7-33-11-36(31,34-8-18(20,21)22)35-9-19(23,24)25/h2-5,10H,6-9,11H2,1H3,(H2,26,28,29)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 575.42,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 575.082695914,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB06368",
        "type": "Small Molecule",
        "synonyms": [
            "Alamifovir"
        ],
        "indication": "Investigated for use/treatment in hepatitis (viral, B).\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "is_stub": true
    },
    {
        "smiles": "C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)C(O)=O",
        "id": "DB13223",
        "molecule": "Fluocortin",
        "cas": "33124-50-4",
        "iupac_name": "2-[(1S,2R,8S,10S,11S,13R,14S,15S,17S)-8-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl]-2-oxoacetic acid",
        "background": "Fluocortin has been studied as a corticosteroid for treatment of dermatitis and eczema Spain 1.\n",
        "inchi": {
            "hash": "PUWHHWCHAVXSIG-NCLPIGKXSA-N",
            "id": "InChI=1S/C22H27FO5/c1-10-6-13-12-8-15(23)14-7-11(24)4-5-21(14,2)18(12)16(25)9-22(13,3)17(10)19(26)20(27)28/h4-5,7,10,12-13,15-18,25H,6,8-9H2,1-3H3,(H,27,28)/t10-,12+,13+,15+,16+,17-,18-,21+,22+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 390.451,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 390.184252132,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB13223",
        "type": "Small Molecule",
        "synonyms": [
            "Fluocortin",
            "Fluocortina"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=C(OC)C=C(C=C1)C1=NN(C2CCC2)C2=NC=NC(N)=C12",
        "id": "DB08053",
        "molecule": "1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",
        "iupac_name": "1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",
        "inchi": {
            "hash": "ITOYZJGFTNTKKR-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H19N5O2/c1-23-12-7-6-10(8-13(12)24-2)15-14-16(18)19-9-20-17(14)22(21-15)11-4-3-5-11/h6-9,11H,3-5H2,1-2H3,(H2,18,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 325.3651,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 325.153874877,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.",
        "link": "https://go.drugbank.com/drugs/DB08053",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProto-oncogene tyrosine-protein kinase Src"
            }
        ]
    },
    {
        "smiles": "C=CCSS(=O)CC=C",
        "id": "DB11780",
        "molecule": "Allicin",
        "cas": "539-86-6",
        "iupac_name": "3-[(prop-2-ene-1-sulfinyl)sulfanyl]prop-1-ene",
        "background": "Allicin has been used in trials studying the treatment of Follicular Lymphoma.\n",
        "inchi": {
            "hash": "JDLKFOPOAOFWQN-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 162.273,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 162.017306322,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thiosulfinic acid esters. These are organic compounds containing an ester of thiosulfinic acid with the general structure RS(=S)OR' (R, R'=alkyl, aryl).",
        "link": "https://go.drugbank.com/drugs/DB11780",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "NC(=O)C1=CC(NC2=NC(NC3=C(Cl)C=CC4=C3OCO4)=CC=N2)=CC=C1",
        "id": "DB07256",
        "molecule": "3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE",
        "iupac_name": "3-({4-[(5-chloro-2H-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzamide",
        "inchi": {
            "hash": "ZVQZIVCQLFGXFZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H14ClN5O3/c19-12-4-5-13-16(27-9-26-13)15(12)23-14-6-7-21-18(24-14)22-11-3-1-2-10(8-11)17(20)25/h1-8H,9H2,(H2,20,25)(H2,21,22,23,24)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 383.788,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 383.078517046,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as aminobenzoic acids and derivatives. These are benzoic acids (or derivative thereof) containing an amine group attached to the benzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB07256",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEphrin type-B receptor 4"
            }
        ]
    },
    {
        "smiles": "NCC1=C(C=CC=C1)C1=CC=CC=C1",
        "id": "DB07412",
        "molecule": "1-biphenyl-2-ylmethanamine",
        "iupac_name": "1-{[1,1'-biphenyl]-2-yl}methanamine",
        "inchi": {
            "hash": "YHXKXVFQHWJYOD-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H13N/c14-10-12-8-4-5-9-13(12)11-6-2-1-3-7-11/h1-9H,10,14H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 183.249,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 183.104799421,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.",
        "link": "https://go.drugbank.com/drugs/DB07412",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDipeptidyl peptidase 4"
            }
        ]
    },
    {
        "smiles": "[H]N1C=C(F)[C@H](O)N([H])C1=O",
        "id": "DB04135",
        "molecule": "(4S)-5-Fluoro-4-hydroxy-3,4-dihydro-2(1H)-pyrimidinone",
        "iupac_name": "(4S)-5-fluoro-4-hydroxy-1,2,3,4-tetrahydropyrimidin-2-one",
        "inchi": {
            "hash": "PRVUBDAKZJCBTI-VKHMYHEASA-N",
            "id": "InChI=1S/C4H5FN2O2/c5-2-1-6-4(9)7-3(2)8/h1,3,8H,(H2,6,7,9)/t3-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 132.0931,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 132.033505619,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB04135",
        "type": "Small Molecule",
        "synonyms": [
            "(4S)-5-Fluoro-4-hydroxy-3,4-dihydropyrimidin-2(1H)-one"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UCytosine deaminase"
            }
        ]
    },
    {
        "smiles": "C[N+](C)(C)[C@@H](CC1=CNC(=S)N1)C([O-])=O",
        "id": "DB17614",
        "molecule": "Ergothioneine",
        "cas": "497-30-3",
        "iupac_name": "(2S)-3-(2-sulfanylidene-2,3-dihydro-1H-imidazol-4-yl)-2-(trimethylazaniumyl)propanoate",
        "inchi": {
            "hash": "SSISHJJTAXXQAX-ZETCQYMHSA-N",
            "id": "InChI=1S/C9H15N3O2S/c1-12(2,3)7(8(13)14)4-6-5-10-9(15)11-6/h5,7H,4H2,1-3H3,(H2-,10,11,13,14,15)/t7-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 229.3,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 229.088497909,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17614",
        "type": "Small Molecule",
        "synonyms": [
            "L-(+)-ergothioneine",
            "L-ergothioneine",
            "L(+)-ergothioneine",
            "Sympectothion",
            "Thiasine",
            "Thioneine"
        ],
        "is_stub": true
    },
    {
        "smiles": "[Ca++].[Ca++].[Ca++].[Ca++].[Mn++].CC1=NC=C(COP(O)([O-])=O)C(CN(CCN(CC(O)=O)CC2=C(COP(O)([O-])=O)C=NC(C)=C2O)CC(O)=O)=C1O.CC1=NC=C(COP(O)([O-])=O)C(CN(CCN(CC(O)=O)CC2=C(COP(O)([O-])=O)C=NC(C)=C2O)CC(O)=O)=C1O.CC1=NC=C(COP(O)([O-])=O)C(CN(CCN(CC(O)=O)CC2=C(COP(O)([O-])=O)C=NC(C)=C2O)CC(O)=O)=C1O.CC1=NC=C(COP(O)([O-])=O)C(CN(CCN(CC(O)=O)CC2=C(COP(O)([O-])=O)C=NC(C)=C2O)CC(O)=O)=C1O.CC1=NC=C(COP(O)([O-])=O)C(CN(CCN(CC(O)=O)CC2=C(COP(O)([O-])=O)C=NC(C)=C2O)CC(O)=O)=C1O",
        "id": "DB18398",
        "molecule": "Calmangafodipir",
        "cas": "1401243-67-1",
        "inchi": {
            "hash": "QAOJLUYEMFXJGX-UHFFFAOYSA-D",
            "id": "InChI=1S/5C22H32N4O14P2.4Ca.Mn/c5*1-13-21(31)17(15(5-23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-18-16(12-40-42(36,37)38)6-24-14(2)22(18)32;;;;;/h5*5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H2,33,34,35)(H2,36,37,38);;;;;/q;;;;;5*+2/p-10"
        },
        "weight": [
            {
                "type": "average",
                "weight": 3397.468,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 3395.405286,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB18398",
        "type": "Small Molecule",
        "synonyms": [
            "Calcium,n,n'-1,2-ethanediylbis(n-((3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinyl)methyl)glycine) manganese complexes trisodium trihydrogen manganate",
            "Calmangafodipir (ca4mn(dpdp)5)",
            "Pledox",
            "Tetracalcium monomanganese penta(dipyridoxyl diphosphate)"
        ],
        "is_stub": true
    },
    {
        "smiles": "CC1(C)C2CC1C(=C)CC2",
        "id": "DB15574",
        "molecule": "beta-Pinene",
        "cas": "127-91-3",
        "iupac_name": "6,6-dimethyl-2-methylidenebicyclo[3.1.1]heptane",
        "inchi": {
            "hash": "WTARULDDTDQWMU-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H16/c1-7-4-5-8-6-9(7)10(8,2)3/h8-9H,1,4-6H2,2-3H3"
        },
        "summary": "beta-Pinene is a mono-terpene indicated in combination with other plant-derived compounds for the treatment of bladder, kidney, and urinary stones.",
        "weight": [
            {
                "type": "average",
                "weight": 136.238,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 136.125200515,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15574",
        "type": "Small Molecule",
        "synonyms": [
            "2(10)-pinene",
            "nopinene",
            "pseudopinene",
            "-pinene"
        ],
        "is_stub": true
    },
    {
        "smiles": "O=C(NC1=NC=CS1)NC1=CC(=CC=C1)S(=O)(=O)N1CCN(CC1)C1=CC=CC=N1",
        "id": "DB07817",
        "molecule": "1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea",
        "iupac_name": "1-(3-{[4-(pyridin-2-yl)piperazin-1-yl]sulfonyl}phenyl)-3-(1,3-thiazol-2-yl)urea",
        "inchi": {
            "hash": "NJPVZSIGDRLLTD-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H20N6O3S2/c26-18(23-19-21-8-13-29-19)22-15-4-3-5-16(14-15)30(27,28)25-11-9-24(10-12-25)17-6-1-2-7-20-17/h1-8,13-14H,9-12H2,(H2,21,22,23,26)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 444.531,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 444.103829916,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.",
        "link": "https://go.drugbank.com/drugs/DB07817",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Staphylococcus haemolyticus (strain JCSC1435)",
                "target": "UPhenylalanine--tRNA ligase alpha subunit"
            },
            {
                "action": "Not Available",
                "organism": "Staphylococcus haemolyticus (strain JCSC1435)",
                "target": "UPhenylalanine--tRNA ligase beta subunit"
            }
        ]
    },
    {
        "smiles": "NC(C(O)=O)C1=CC=C(O)C=C1",
        "id": "DB02601",
        "molecule": "4-Hydroxyphenylglycine",
        "cas": "37784-25-1",
        "iupac_name": "2-amino-2-(4-hydroxyphenyl)acetic acid",
        "inchi": {
            "hash": "LJCWONGJFPCTTL-UHFFFAOYSA-N",
            "id": "InChI=1S/C8H9NO3/c9-7(8(11)12)5-1-3-6(10)4-2-5/h1-4,7,10H,9H2,(H,11,12)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 167.164,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 167.058243154,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).",
        "link": "https://go.drugbank.com/drugs/DB02601",
        "type": "Small Molecule",
        "synonyms": [
            "(+/-)-alpha-amino-4-hydroxybenzeneacetic acid",
            "(RS)-2-(4-hydroxyphenyl)glycine",
            "dl-p-hydroxyphenylglycine",
            "p-hydroxyphenylglycine"
        ]
    },
    {
        "smiles": "COC1=CC=C(C=C1)S(=O)(=O)NC1=C(NC2=CC=C(O)C=C2)N=CC=C1",
        "id": "DB12254",
        "molecule": "ABT-751",
        "cas": "141430-65-1",
        "iupac_name": "N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzene-1-sulfonamide",
        "background": "ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.\n",
        "inchi": {
            "hash": "URCVCIZFVQDVPM-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 371.41,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 371.093976737,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB12254",
        "type": "Small Molecule",
        "synonyms": [
            "N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamide",
            "N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide",
            "N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@]1(CCC[C@@]1([H])N(C)C)NC1=NC(NC2=CC=C(C=C2)S(=O)(=O)NC)=NC=C1C(F)(F)F",
        "id": "DB08341",
        "molecule": "4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide",
        "iupac_name": "4-[(4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl)amino]-N-methylbenzene-1-sulfonamide",
        "inchi": {
            "hash": "CAUFYHKGKDJMQG-HZPDHXFCSA-N",
            "id": "InChI=1S/C19H25F3N6O2S/c1-23-31(29,30)13-9-7-12(8-10-13)25-18-24-11-14(19(20,21)22)17(27-18)26-15-5-4-6-16(15)28(2)3/h7-11,15-16,23H,4-6H2,1-3H3,(H2,24,25,26,27)/t15-,16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 458.501,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 458.171179379,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB08341",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein-tyrosine kinase 2-beta"
            }
        ]
    },
    {
        "smiles": "CC1=CC(=CC=C1)[C@]12SCCN1C(=O)C1=CC=CC=C21",
        "id": "DB07472",
        "molecule": "(R)-(+)9B-(3-METHYL)PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-5(9BH)-ONE",
        "iupac_name": "(9bR)-9b-(3-methylphenyl)-2H,3H,5H,9bH-[1,3]thiazolo[2,3-a]isoindol-5-one",
        "inchi": {
            "hash": "FQVDJZWFSZSGGA-QGZVFWFLSA-N",
            "id": "InChI=1S/C17H15NOS/c1-12-5-4-6-13(11-12)17-15-8-3-2-7-14(15)16(19)18(17)9-10-20-17/h2-8,11H,9-10H2,1H3/t17-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 281.372,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 281.087434797,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.",
        "link": "https://go.drugbank.com/drugs/DB07472",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "",
                "target": "UGag-Pol polyprotein"
            }
        ]
    },
    {
        "smiles": "NC(N)=NCCC1=CC=C(C=C1)B1OC[C@@H](CO)O1",
        "id": "DB07071",
        "molecule": "(R)-1-(4-(4-(Hydroxymethyl)-1,3,2-dioxaborolan-2-YL)phenethyl)guanidine",
        "iupac_name": "N''-(2-{4-[(4R)-4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl]phenyl}ethyl)guanidine",
        "inchi": {
            "hash": "ZYCNKSJMJFKCBX-LLVKDONJSA-N",
            "id": "InChI=1S/C12H18BN3O3/c14-12(15)16-6-5-9-1-3-10(4-2-9)13-18-8-11(7-17)19-13/h1-4,11,17H,5-8H2,(H4,14,15,16)/t11-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 263.101,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 263.144121923,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.",
        "link": "https://go.drugbank.com/drugs/DB07071",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor XI"
            }
        ]
    },
    {
        "smiles": "OC(=O)CCCN1C2=C(C(=O)C3=CC=CC=C23)C2=CC=CC=C2C1=O",
        "id": "DB08159",
        "molecule": "4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE",
        "iupac_name": "4-{5,11-dioxo-5H,6H,11H-indeno[1,2-c]isoquinolin-6-yl}butanoic acid",
        "inchi": {
            "hash": "AHIJTWCJGCWHMT-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H15NO4/c22-16(23)10-5-11-21-18-13-7-2-3-8-14(13)19(24)17(18)12-6-1-4-9-15(12)20(21)25/h1-4,6-9H,5,10-11H2,(H,22,23)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 333.3374,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 333.100107973,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as isoquinolones and derivatives. These are aromatic polycyclic compounds containing a ketone bearing isoquinoline moiety.",
        "link": "https://go.drugbank.com/drugs/DB08159",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDNA topoisomerase 1"
            }
        ]
    },
    {
        "smiles": "[H][C@]1(C2CCN(CC2)S(C)(=O)=O)C2=C(C=C(Cl)C=C2)C(=CC2=C1N=CC=C2)N1CCNCC1",
        "id": "DB07216",
        "molecule": "(11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE",
        "iupac_name": "(2S)-13-chloro-2-(1-methanesulfonylpiperidin-4-yl)-10-(piperazin-1-yl)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene",
        "inchi": {
            "hash": "ZMGCFGGMTCMSDP-QHCPKHFHSA-N",
            "id": "InChI=1S/C24H29ClN4O2S/c1-32(30,31)29-11-6-17(7-12-29)23-20-5-4-19(25)16-21(20)22(28-13-9-26-10-14-28)15-18-3-2-8-27-24(18)23/h2-5,8,15-17,23,26H,6-7,9-14H2,1H3/t23-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 473.031,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 472.169974589,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzocycloheptapyridines. These are aromatic compounds containing a benzene ring and a pyridine ring fused to a seven membered carbocycle.",
        "link": "https://go.drugbank.com/drugs/DB07216",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProtein farnesyltransferase subunit beta"
            }
        ]
    },
    {
        "smiles": "CC(=O)NC1=CC=C(C=C1)C(O)=O",
        "id": "DB04500",
        "molecule": "Acedoben",
        "cas": "556-08-1",
        "iupac_name": "4-acetamidobenzoic acid",
        "inchi": {
            "hash": "QCXJEYYXVJIFCE-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H9NO3/c1-6(11)10-8-4-2-7(3-5-8)9(12)13/h2-5H,1H3,(H,10,11)(H,12,13)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 179.1727,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 179.058243159,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acids. These are organic Compounds containing a benzene ring which bears at least one carboxyl group.",
        "link": "https://go.drugbank.com/drugs/DB04500",
        "type": "Small Molecule",
        "synonyms": [
            "4-(Acetylamino)benzoic acid",
            "4-acetamidobenzoic acid",
            "4-Acetylaminobenzoic acid",
            "4-Carboxyacetanilide",
            "Acedoben",
            "Acedobene",
            "Acedobenum",
            "N-Acetyl-p-aminobenzoic acid",
            "N-Acetyl-PABA",
            "p-Acetamidobenzoic acid",
            "p-Acetoaminobenzoic acid",
            "p-Acetylaminobenzoic acid",
            "PAAB",
            "Para acetamido benzoic acid"
        ]
    },
    {
        "smiles": "NCC1(CC(O)=O)CCCCC1",
        "id": "DB00996",
        "molecule": "Gabapentin",
        "cas": "60142-96-3",
        "iupac_name": "2-[1-(aminomethyl)cyclohexyl]acetic acid",
        "background": "Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993.16 It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures14,5 - today it is also widely used to treat neuropathic pain.8,10 Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.5,3,16. It is structurally and functionally related to another GABA derivative, pregabalin.\n",
        "inchi": {
            "hash": "UGJMXCAKCUNAIE-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)"
        },
        "summary": "Gabapentin is an anticonvulsant medication used in the management of peripheral neuropathic pains, postherpetic neuralgia, and partial-onset seizures.",
        "weight": [
            {
                "type": "average",
                "weight": 171.2368,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 171.125928793,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.",
        "link": "https://go.drugbank.com/drugs/DB00996",
        "type": "Small Molecule",
        "synonyms": [
            "1-(Aminomethyl)cyclohexaneacetic acid",
            "Gabapentin",
            "Gabapentina",
            "Gabapentine",
            "Gabapentino",
            "Gabapentinum"
        ],
        "indication": "In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older.16 In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.19\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Gabapentin is an anti-convulsant medication that inhibits the release of excitatory neurotransmitters, allowing for its use against pathologic neurotransmission such as that seen in neuropathic pain and seizure disorders.16,19 It has a wide therapeutic index, with doses in excess of 8000 mg/kg failing to cause a fatal reaction in rats.21\nGabapentin is ineffective in absence seizures and should be used in caution in patients with mixed seizure disorders involving absence seizures. Gabapentin has been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), otherwise known as multi-organ hypersensitivity. This reaction can prove fatal and early symptoms such as fever, lymphadenopathy, and rash should be promptly investigated.16,17,19\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AVoltage-dependent calcium channel subunit alpha-2/delta-1"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UVoltage-dependent calcium channel subunit alpha-2/delta-2"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UVoltage-dependent N-type calcium channel"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UAdenosine receptor A1"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UPotassium voltage-gated channel subfamily KQT member 3"
            },
            {
                "action": "activator",
                "organism": "Humans",
                "target": "UPotassium voltage-gated channel subfamily KQT member 5"
            }
        ]
    },
    {
        "smiles": "C=C1\\C(=C/C=C2\\CCC[C@]3(C)[C@]([H])(CC[C@@]23[H])C#CC#CC(C)(O)C)C[C@](O)([H])C[C@@]1(O)[H]",
        "id": "DB08742",
        "molecule": "1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)",
        "iupac_name": "(1R,3S,5Z)-5-{2-[(1S,3aS,4E,7aS)-1-(5-hydroxy-5-methylhexa-1,3-diyn-1-yl)-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol",
        "inchi": {
            "hash": "CEEUUHVULXTFGS-BQXVGYHGSA-N",
            "id": "InChI=1S/C26H34O3/c1-18-20(16-22(27)17-24(18)28)11-10-19-8-7-15-26(4)21(12-13-23(19)26)9-5-6-14-25(2,3)29/h10-11,21-24,27-29H,1,7-8,12-13,15-17H2,2-4H3/b19-10+,20-11-/t21-,22+,23-,24-,26+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 394.5464,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 394.250794954,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as steroids and steroid derivatives. These are compounds based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred.",
        "link": "https://go.drugbank.com/drugs/DB08742",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNuclear receptor coactivator 1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UVitamin D3 receptor"
            }
        ]
    },
    {
        "id": "DB09344",
        "molecule": "Invert sugar",
        "cas": "8013-17-0",
        "background": "Invert sugar is obtained from sugar cane when this is treated with dilute acid or with the invertase enzyme. It is formed by an equal amount of glucose and fructose. It differentiates from sugar cane in the rotation of the polarized light, which in the case of invert sugar it is to the left (levorotatory).1 Invert sugar is FDA approved since 1988 as a safe substance (GRAS).\n",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09344",
        "type": "Small Molecule",
        "indication": "Invert sugar presents a large variety of uses. It can be used therapeutically for parenteral hyperalimentation6 or to be used as an excipient with a known effect.10 Invert sugar is also approved for its use in food products as a humectant, crystallization modifier, and liquid and nutritive sweetener.7\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Intravenous administration of invert sugar has been proven to be favorable. These reports indicate a temporary rise, within physiological levels, of lactate, pyruvate, and insulin in the blood plasma whereas the level of free fatty acids was declined.5\n"
    },
    {
        "smiles": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O",
        "id": "DB00485",
        "molecule": "Dicloxacillin",
        "cas": "3116-76-5",
        "iupac_name": "(2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",
        "background": "One of the penicillins which is resistant to penicillinase.\n",
        "inchi": {
            "hash": "YFAGHNZHGGCZAX-JKIFEVAISA-N",
            "id": "InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1"
        },
        "summary": "Dicloxacillin is a penicillin used to treat penicillinase-producing bacterial infections that are susceptible to the drug.",
        "weight": [
            {
                "type": "average",
                "weight": 470.326,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 469.026596773,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.",
        "link": "https://go.drugbank.com/drugs/DB00485",
        "type": "Small Molecule",
        "synonyms": [
            "(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",
            "Dicloxacilina",
            "Dicloxacillin",
            "Dicloxacillina",
            "Dicloxacilline",
            "Dicloxacillinum"
        ],
        "indication": "Used to treat infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Dicloxacillin is a beta-lactamase resistant penicillin similar to oxacillin. Dicloxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of dicloxacillin results from the inhibition of cell wall synthesis and is mediated through dicloxacillin binding to penicillin binding proteins (PBPs). Dicloxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Listeria monocytogenes serotype 4b str. LL195",
                "target": "APenicillin-binding protein 3"
            },
            {
                "action": "inhibitor",
                "organism": "Streptococcus pneumoniae (strain ATCC BAA-255 / R6)",
                "target": "APenicillin-binding protein 1b"
            },
            {
                "action": "inhibitor",
                "organism": "Streptococcus pneumoniae (strain ATCC BAA-255 / R6)",
                "target": "APenicillin-binding protein 2a"
            },
            {
                "action": "inhibitor",
                "organism": "Streptococcus pneumoniae",
                "target": "APenicillin-binding protein 3"
            },
            {
                "action": "inhibitor",
                "organism": "Streptococcus pneumoniae (strain ATCC BAA-255 / R6)",
                "target": "APenicillin-binding protein 1A"
            },
            {
                "action": "inhibitor",
                "organism": "Streptococcus pneumoniae (strain ATCC BAA-255 / R6)",
                "target": "APenicillin-binding protein 2B"
            }
        ]
    },
    {
        "smiles": "C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\\C(C)=C1/N=C(/C=C3\\N=C(\\C(\\C)=C4\\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2",
        "id": "DB00115",
        "molecule": "CyanocobalaminCommonly known or available as Vitamin B12",
        "cas": "68-19-9",
        "iupac_name": "cyano[(1R,2R,3R,4R,6Z,8S,11Z,13S,14S,16Z,18S,19S)-8,13,18-tris(2-carbamoylethyl)-3,14,19-tris(carbamoylmethyl)-4-(2-{[(2R)-2-{[(2R,3S,4R,5S)-5-(5,6-dimethyl-1H-1,3-benzodiazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl phosphonato]oxy}propyl]carbamoyl}ethyl)-1,4,6,9,9,14,16,19-octamethyl-20,21,22,23-tetraazapentacyclo[15.2.1.1^{2,5}.1^{7,10}.1^{12,15}]tricosa-5(23),6,10(22),11,15(21),16-hexaen-20-yl]cobaltylium",
        "background": "Cyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt. This vitamin is produced naturally by bacteria 16, and is necessary for DNA synthesis and cellular energy production. Vitamin B12 has many forms, including the cyano-, methyl-, deoxyadenosyl- and hydroxy-cobalamin forms. The cyano form, is the most widely used form in supplements and prescription drugs 10, Label. Several pharmaceutical forms of cyanocobalamin have been developed, including the tablet, injection, and nasal spray forms Label, 19, 20. This drug was initially approved by the FDA in 1942 Label.\n",
        "inchi": {
            "hash": "RMRCNWBMXRMIRW-WZHZPDAFSA-L",
            "id": "InChI=1S/C62H90N13O14P.CN.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;/q;;+2/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1"
        },
        "summary": "Vitamin B12 is a vitamin available in many formulations to correct vitamin B12 deficiency.",
        "weight": [
            {
                "type": "average",
                "weight": 1355.3652,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1354.5674053,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cobalamin derivatives. These are organic compounds containing a corrin ring, a cobalt atom, an a nucleotide moiety. Cobalamin Derivatives are actually derived from vitamin B12.",
        "link": "https://go.drugbank.com/drugs/DB00115",
        "type": "Small Molecule",
        "synonyms": [
            "Cianocobalamina",
            "Cyanocob(III)alamin",
            "Cyanocobalamin",
            "Cyanocobalamine",
            "Cyanocobalaminum",
            "Vitamin B12",
            "Vitamin B12 complex",
            "Vitamin B12 NOS"
        ],
        "indication": "Nasal spray\nThe cyanocobalamin nasal spray is indicated for the maintenance of vitamin B12 concentrations after normalization with intramuscular vitamin B12 therapy in patients with deficiency of this vitamin who have no nervous system involvement Label.\nNote: CaloMist Label, the nasal spray form, has not been evaluated for the treatment of newly diagnosed vitamin B12 deficiency.\nInjection forms (subcutaneous, intramuscular)\nThese forms are indicated for vitamin B12 deficiencies due to various causes, with or without neurologic manifestations 26. Vitamin B12 deficiency is frequently caused by malabsorption, which is often associated with the following conditions 20:\nAddisonian (pernicious) anemia\nGastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy\nFish tapeworm infestation\nMalignancy of the pancreas or bowel\nFolic acid deficiency\nOral forms\nVitamin B12 supplements are widely available and indicated in patients who require supplementation for various reasons. Dose requirements for vitamin B12 which are higher than normal (caused by pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be achieved with oral supplementation 20. Oral products of vitamin B12 are not recommended in patients with malabsorption, as these forms are primarily absorbed in the gastrointestinal tract 27. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "General effects\nCyanocobalamin corrects vitamin B12 deficiency and improves the symptoms and laboratory abnormalities associated with pernicious anemia (megaloblastic indices, gastrointestinal lesions, and neurologic damage). This drug aids in growth, cell reproduction, hematopoiesis, nucleoprotein, and myelin synthesis. It also plays an important role in fat metabolism, carbohydrate metabolism, as well as protein synthesis. Cells that undergo rapid division (for example, epithelial cells, bone marrow, and myeloid cells) have a high demand for vitamin B12 10. \nParenteral cyanocobalamin effects\nThe parenteral administration of vitamin B12 rapidly and completely reverses the megaloblastic anemia and gastrointestinal symptoms of vitamin B12 deficiency. Rapid parenteral administration of vitamin B12 in deficiency related neurological damage prevents the progression of this condition 20. \nNasal spray effects\nIn 24 vitamin B12 deficient patients who were already stabilized on intramuscular (IM) vitamin B12 therapy, single daily doses of intranasal cyanocobalamin for 8 weeks lead to serum vitamin B12 concentrations that were within the target therapeutic range (\u003e200 ng/L) Label.\n",
        "moa": [
            {
                "action": "cofactor",
                "organism": "Humans",
                "target": "AMethionine synthase"
            },
            {
                "action": "cofactor",
                "organism": "Humans",
                "target": "AMethylmalonyl-CoA mutase, mitochondrial"
            },
            {
                "action": "cofactor",
                "organism": "Humans",
                "target": "UMethionine synthase reductase"
            },
            {
                "action": "binder",
                "organism": "Humans",
                "target": "UMethylmalonic aciduria type A protein, mitochondrial"
            },
            {
                "action": "cofactor",
                "organism": "Humans",
                "target": "UMethylmalonic aciduria and homocystinuria type C protein"
            },
            {
                "action": "cofactor",
                "organism": "Humans",
                "target": "UMethylenetetrahydrofolate reductase"
            }
        ]
    },
    {
        "smiles": "CN\\C(NCCSCC1=C(C)NC=N1)=N\\C#N",
        "id": "DB00501",
        "molecule": "Cimetidine",
        "cas": "51481-61-9",
        "iupac_name": "(Z)-N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine",
        "background": "A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.\n",
        "inchi": {
            "hash": "AQIXAKUUQRKLND-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)"
        },
        "summary": "Cimetidine is a histamine H2 receptor antagonist used to manage GERD, peptic ulcer disease, and indigestion.",
        "weight": [
            {
                "type": "average",
                "weight": 252.339,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 252.115715232,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as imidazoles. These are compounds containing an imidazole ring, which is an aromatic five-member ring with two nitrogen atoms at positions 1 and 3, and three carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB00501",
        "type": "Small Molecule",
        "synonyms": [
            "1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine",
            "2-cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine",
            "Cimetidin",
            "Cimetidina",
            "Cimtidine",
            "Cimetidine",
            "Cimetidinum",
            "N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine",
            "N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine"
        ],
        "indication": "Cimetidine is indicated to reduce gastric acid secretion and to treat the following disease states: duodenal ulcers, non-malignant gastric ulcers, gastroesophageal reflux disease, and pathological hypersecretion associated with Zollinger-Ellison Syndrome, systemic mastocytosis, and multiple endocrine adenomas.7 It is indicated for prophylaxis of recurrent gastric or duodenal ulcers, as adjunctive therapy in the management of cystic fibrosis in children, and to treat NSAID induced lesions and gastrointestinal symptoms.7\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Cimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.\n",
        "moa": [
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "AHistamine H2 receptor"
            }
        ]
    },
    {
        "smiles": "[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C",
        "id": "DB14662",
        "molecule": "Flunisolide acetate",
        "cas": "4533-89-5",
        "iupac_name": "2-[(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-8-yl]-2-oxoethyl acetate",
        "inchi": {
            "hash": "WEGNFRKBIKYVLC-XTLNBZDDSA-N",
            "id": "InChI=1S/C26H33FO7/c1-13(28)32-12-20(31)26-21(33-23(2,3)34-26)10-16-15-9-18(27)17-8-14(29)6-7-24(17,4)22(15)19(30)11-25(16,26)5/h6-8,15-16,18-19,21-22,30H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,22+,24-,25-,26+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 476.541,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 476.221031566,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.",
        "link": "https://go.drugbank.com/drugs/DB14662",
        "type": "Small Molecule",
        "synonyms": [
            "Flunisolide 21-acetate",
            "Flunisolide acetate"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOC(=O)NC",
        "id": "DB02856",
        "molecule": "Ethyl N-methylcarbamate",
        "cas": "105-40-8",
        "iupac_name": "ethyl N-methylcarbamate",
        "inchi": {
            "hash": "SURZCVYFPAXNGN-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H9NO2/c1-3-7-4(6)5-2/h3H2,1-2H3,(H,5,6)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 103.1198,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 103.063328537,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.",
        "link": "https://go.drugbank.com/drugs/DB02856",
        "type": "Small Molecule",
        "synonyms": [
            "Ethyl methylcarbamate",
            "Ethyl N-methylcarbamate",
            "Ethyl-N-methylcarbamate",
            "N-Methyl urethan",
            "N-Methylurethan",
            "N-Methylurethane"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Bacteriophage H30",
                "target": "UShiga-like toxin 1 subunit B"
            }
        ]
    },
    {
        "smiles": "CCOC1=CC(=CC=C1)C1=CC=C(NC(=O)C(\\C#N)=C(\\C)O)C=C1",
        "id": "DB07561",
        "molecule": "(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide",
        "iupac_name": "(2Z)-2-cyano-N-{3'-ethoxy-[1,1'-biphenyl]-4-yl}-3-hydroxybut-2-enamide",
        "inchi": {
            "hash": "RPILZQUCBKIPAZ-AQTBWJFISA-N",
            "id": "InChI=1S/C19H18N2O3/c1-3-24-17-6-4-5-15(11-17)14-7-9-16(10-8-14)21-19(23)18(12-20)13(2)22/h4-11,22H,3H2,1-2H3,(H,21,23)/b18-13-"
        },
        "weight": [
            {
                "type": "average",
                "weight": 322.3578,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 322.131742452,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.",
        "link": "https://go.drugbank.com/drugs/DB07561",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UDihydroorotate dehydrogenase (quinone), mitochondrial"
            }
        ]
    },
    {
        "smiles": "OCC(=O)CO",
        "id": "DB01775",
        "molecule": "Dihydroxyacetone",
        "cas": "96-26-4",
        "iupac_name": "1,3-dihydroxypropan-2-one",
        "background": "A ketotriose compound. Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate levels during storage. It is readily phosphorylated to dihydroxyacetone phosphate by triokinase in erythrocytes. In combination with naphthoquinones it acts as a sunscreening agent. [PubChem]\n",
        "inchi": {
            "hash": "RXKJFZQQPQGTFL-UHFFFAOYSA-N",
            "id": "InChI=1S/C3H6O3/c4-1-3(6)2-5/h4-5H,1-2H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 90.0779,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 90.031694058,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as monosaccharides. These are compounds containing one carbohydrate unit not glycosidically linked to another such unit, and no set of two or more glycosidically linked carbohydrate units. Monosaccharides have the general formula CnH2nOn.",
        "link": "https://go.drugbank.com/drugs/DB01775",
        "type": "Small Molecule",
        "synonyms": [
            "Dihydroxyacetone"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Citrobacter freundii",
                "target": "UDihydroxyacetone kinase"
            }
        ]
    },
    {
        "id": "DB09507",
        "molecule": "Ferumoxsil",
        "cas": "171544-35-7",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09507",
        "type": "Small Molecule",
        "synonyms": [
            "Ferumoxsil",
            "Siloxane-coated superparamagnetic iron oxide"
        ],
        "is_stub": true
    },
    {
        "smiles": "CNC(=O)C1=C(OC[C@@H](O)CN2CCC3(CC4=CC(Cl)=CC=C4O3)CC2)C=C(OC(C)(C)C(O)=O)C(Cl)=C1",
        "id": "DB12002",
        "molecule": "AZD-4818",
        "cas": "1003566-93-5",
        "iupac_name": "2-{2-chloro-5-[(2S)-3-{5-chloro-3H-spiro[1-benzofuran-2,4'-piperidine]-1'-yl}-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy}-2-methylpropanoic acid",
        "background": "AZD4818 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease (COPD).\n",
        "inchi": {
            "hash": "HVTUHSABWJPWNK-SFHVURJKSA-N",
            "id": "InChI=1S/C27H32Cl2N2O7/c1-26(2,25(34)35)37-23-12-22(19(11-20(23)29)24(33)30-3)36-15-18(32)14-31-8-6-27(7-9-31)13-16-10-17(28)4-5-21(16)38-27/h4-5,10-12,18,32H,6-9,13-15H2,1-3H3,(H,30,33)(H,34,35)/t18-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 567.46,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 566.1586568,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.",
        "link": "https://go.drugbank.com/drugs/DB12002",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC1(C)C2CCC1(C)C(O)C2",
        "id": "DB11288",
        "molecule": "Borneol",
        "cas": "507-70-0",
        "iupac_name": "1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol",
        "inchi": {
            "hash": "DTGKSKDOIYIVQL-UHFFFAOYSA-N",
            "id": "InChI=1S/C10H18O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7-8,11H,4-6H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 154.2493,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 154.135765198,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB11288",
        "type": "Small Molecule",
        "synonyms": [
            "Borneo camphor",
            "Bornyl alcohol",
            "endo-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol",
            "endo-2-bornanol",
            "endo-2-camphanol",
            "endo-2-hydroxycamphane",
            "Sumatra camphor"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOC(C(=O)OCCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB01461",
        "molecule": "Dimenoxadol",
        "cas": "509-78-4",
        "iupac_name": "2-(dimethylamino)ethyl 2-ethoxy-2,2-diphenylacetate",
        "background": "Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative. In the United States it is classified as a Schedule I controlled drug.\n",
        "inchi": {
            "hash": "RHUWRJWFHUKVED-UHFFFAOYSA-N",
            "id": "InChI=1S/C20H25NO3/c1-4-24-20(17-11-7-5-8-12-17,18-13-9-6-10-14-18)19(22)23-16-15-21(2)3/h5-14H,4,15-16H2,1-3H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 327.4174,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 327.183443671,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB01461",
        "type": "Small Molecule",
        "synonyms": [
            "Dimenossadolo",
            "Dimenoxadol",
            "Dimenoxadole",
            "Dimenoxadolum"
        ]
    },
    {
        "smiles": "[H][C@]12C(=O)N(C(=O)[C@@]1([H])[C@@]1(CC[C@@]2([H])CC1)NC(=O)OCC(O)=O)C1=CC=C(NC(C)=O)C=C1",
        "id": "DB07784",
        "molecule": "[4-(4-ACETYLAMINO-PHENYL)-3,5-DIOXO-4-AZA-TRICYCLO[5.2.2.0 2,6]UNDEC-1-YLCARBAMOYLOXY]-ACETIC ACID",
        "iupac_name": "2-({[(1S,2R,6R,7R)-4-(4-acetamidophenyl)-3,5-dioxo-4-azatricyclo[5.2.2.0^{2,6}]undecan-1-yl]carbamoyl}oxy)acetic acid",
        "inchi": {
            "hash": "WBCOLMYVEBTZOA-OKRSVSQCSA-N",
            "id": "InChI=1S/C21H23N3O7/c1-11(25)22-13-2-4-14(5-3-13)24-18(28)16-12-6-8-21(9-7-12,17(16)19(24)29)23-20(30)31-10-15(26)27/h2-5,12,16-17H,6-10H2,1H3,(H,22,25)(H,23,30)(H,26,27)/t12-,16-,17+,21-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 429.4232,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 429.153600105,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB07784",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UIg kappa chain C region"
            }
        ]
    },
    {
        "smiles": "CN(C)C1=NC(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C(F)(F)F)C=C2)=NC(N(C)C)=C1CC(O)=O",
        "id": "DB12524",
        "molecule": "BI-671800",
        "cas": "1093108-50-9",
        "iupac_name": "2-[4,6-bis(dimethylamino)-2-({4-[4-(trifluoromethyl)benzamido]phenyl}methyl)pyrimidin-5-yl]acetic acid",
        "background": "Bi 671800 has been used in trials studying the treatment of Asthma and Rhinitis, Allergic, Perennial.\n",
        "inchi": {
            "hash": "XEOSTBFUCNZKGS-UHFFFAOYSA-N",
            "id": "InChI=1S/C25H26F3N5O3/c1-32(2)22-19(14-21(34)35)23(33(3)4)31-20(30-22)13-15-5-11-18(12-6-15)29-24(36)16-7-9-17(10-8-16)25(26,27)28/h5-12H,13-14H2,1-4H3,(H,29,36)(H,34,35)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 501.51,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 501.198774206,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.",
        "link": "https://go.drugbank.com/drugs/DB12524",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC1=CC=C(CN2C=NC(=C2)C2=CC=CS2)C=C1",
        "id": "DB03030",
        "molecule": "4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole",
        "iupac_name": "1-[(4-methylphenyl)methyl]-4-(thiophen-2-yl)-1H-imidazole",
        "inchi": {
            "hash": "UMOFOLLUKPBVQG-UHFFFAOYSA-N",
            "id": "InChI=1S/C15H14N2S/c1-12-4-6-13(7-5-12)9-17-10-14(16-11-17)15-3-2-8-18-15/h2-8,10-11H,9H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 254.35,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 254.087769148,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as toluenes. These are compounds containing a benzene ring which bears a methane group.",
        "link": "https://go.drugbank.com/drugs/DB03030",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UEnoyl-[acyl-carrier-protein] reductase [NADH] FabI"
            }
        ]
    },
    {
        "smiles": "COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1CC1",
        "id": "DB13465",
        "molecule": "Ciclobendazole",
        "cas": "31431-43-3",
        "iupac_name": "methyl N-(5-cyclopropanecarbonyl-1H-1,3-benzodiazol-2-yl)carbamate",
        "inchi": {
            "hash": "OXLKOMYHDYVIDM-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H13N3O3/c1-19-13(18)16-12-14-9-5-4-8(6-10(9)15-12)11(17)7-2-3-7/h4-7H,2-3H2,1H3,(H2,14,15,16,18)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 259.265,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 259.095691291,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-benzimidazolylcarbamic acid esters. These are aromatic heteropolycyclic compounds that contain a carbamic acid ester group, which is N-linked to the C2-atom of a benzimidazole moiety.",
        "link": "https://go.drugbank.com/drugs/DB13465",
        "type": "Small Molecule",
        "synonyms": [
            "Ciclobendazol",
            "Ciclobendazole",
            "Ciclobendazolum",
            "Cyclobendazole"
        ],
        "is_stub": true
    },
    {
        "smiles": "NC1=NC=C(O1)C(=O)N(CC1=CC=CC=C1)CC1=CC=CC=C1",
        "id": "DB08315",
        "molecule": "2-AMINO-N,N-BIS(PHENYLMETHYL)-1,3-OXAZOLE-5-CARBOXAMIDE",
        "iupac_name": "2-amino-N,N-dibenzyl-1,3-oxazole-5-carboxamide",
        "inchi": {
            "hash": "KIJXWOGFYAWTNC-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H17N3O2/c19-18-20-11-16(23-18)17(22)21(12-14-7-3-1-4-8-14)13-15-9-5-2-6-10-15/h1-11H,12-13H2,(H2,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 307.3465,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 307.132076803,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2-heteroaryl carboxamides. These are compounds containing a heteroaromatic ring that carries a carboxamide group.",
        "link": "https://go.drugbank.com/drugs/DB08315",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UBiotin carboxylase"
            }
        ]
    },
    {
        "smiles": "OP(O)(=O)C(NC1=CC=C(Cl)C=N1)P(O)(O)=O",
        "id": "DB03649",
        "molecule": "[{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate",
        "iupac_name": "{[(5-chloropyridin-2-yl)amino](phosphono)methyl}phosphonic acid",
        "inchi": {
            "hash": "BNMYZGAZFGNKTH-UHFFFAOYSA-N",
            "id": "InChI=1S/C6H9ClN2O6P2/c7-4-1-2-5(8-3-4)9-6(16(10,11)12)17(13,14)15/h1-3,6H,(H,8,9)(H2,10,11,12)(H2,13,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 302.546,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 301.962436761,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB03649",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "U1-deoxy-D-xylulose 5-phosphate reductoisomerase"
            }
        ]
    },
    {
        "smiles": "NCC1=CC2=C(OCC22CCN(CC2)C(=O)\\C=C\\C2=CC=CC=C2)C=C1",
        "id": "DB06849",
        "molecule": "1-[1'-(3-phenylacryloyl)spiro[1-benzofuran-3,4'-piperidin]-5-yl]methanamine",
        "iupac_name": "(2E)-1-[5-(aminomethyl)-2H-spiro[1-benzofuran-3,4'-piperidin]-1'-yl]-3-phenylprop-2-en-1-one",
        "inchi": {
            "hash": "RQWYWHUKHYFIPB-VQHVLOKHSA-N",
            "id": "InChI=1S/C22H24N2O2/c23-15-18-6-8-20-19(14-18)22(16-26-20)10-12-24(13-11-22)21(25)9-7-17-4-2-1-3-5-17/h1-9,14H,10-13,15-16,23H2/b9-7+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 348.4382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 348.183778022,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cinnamic acids and derivatives. These are organic aromatic compounds containing a benzene and a carboxylic acid group (or a derivative thereof) forming 3-phenylprop-2-enoic acid.",
        "link": "https://go.drugbank.com/drugs/DB06849",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTryptase alpha/beta-1"
            }
        ]
    },
    {
        "smiles": "OCCCCO",
        "id": "DB01955",
        "molecule": "1,4-Butanediol",
        "cas": "110-63-4",
        "iupac_name": "butane-1,4-diol",
        "inchi": {
            "hash": "WERYXYBDKMZEQL-UHFFFAOYSA-N",
            "id": "InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 90.121,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 90.068079564,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as primary alcohols. These are compounds comprising the primary alcohol functional group, with the general structure RCOH (R=alkyl, aryl).",
        "link": "https://go.drugbank.com/drugs/DB01955",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEndoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPhospholipase A2, membrane associated"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGroup IIE secretory phospholipase A2"
            },
            {
                "action": "Not Available",
                "organism": "Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)",
                "target": "URibosomal small subunit pseudouridine synthase A"
            },
            {
                "action": "Not Available",
                "organism": "Escherichia coli (strain K12)",
                "target": "UPenicillin-insensitive murein endopeptidase"
            }
        ]
    },
    {
        "smiles": "O=C1C=C(OC2=C1C1=CC=CC=C1C=C2)C1=CC=CC=C1",
        "id": "DB06732",
        "molecule": "beta-Naphthoflavone",
        "cas": "6051-87-2",
        "iupac_name": "3-phenyl-1H-benzo[f]chromen-1-one",
        "background": "-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs). It may be a chemopreventive agent.\n",
        "inchi": {
            "hash": "OUGIDAPQYNCXRA-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H12O2/c20-16-12-18(14-7-2-1-3-8-14)21-17-11-10-13-6-4-5-9-15(13)19(16)17/h1-12H"
        },
        "weight": [
            {
                "type": "average",
                "weight": 272.2974,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 272.083729628,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as flavones. These are flavonoids with a structure based on the backbone of 2-phenylchromen-4-one (2-phenyl-1-benzopyran-4-one).",
        "link": "https://go.drugbank.com/drugs/DB06732",
        "type": "Small Molecule",
        "synonyms": [
            "3-phenyl-1H-naphtho(2,1-b)pyran-1-one",
            "5,6-benzoflavone",
            "beta-NF",
            "-NF"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UEstrogen receptor alpha"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "USteroid hormone receptor ERR1"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCOUP transcription factor 1"
            },
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "UAryl hydrocarbon receptor"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCytochrome P450 1B1"
            }
        ]
    },
    {
        "smiles": "CC(C)(N1CCN(CC1)C1=NC=C(C=C1)C(F)(F)F)C(=O)N[C@H]1C2CC3CC1C[C@@](C3)(C2)C(N)=O",
        "id": "DB12501",
        "molecule": "ABT-384",
        "cas": "868623-40-9",
        "iupac_name": "(1s,4r)-4-(2-methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}propanamido)adamantane-1-carboxamide",
        "background": "ABT-384 has been used in trials studying the treatment of Alzheimer's Disease.\n",
        "inchi": {
            "hash": "CLHMYBJIOZXCEX-MALZWFGSSA-N",
            "id": "InChI=1S/C25H34F3N5O2/c1-23(2,33-7-5-32(6-8-33)19-4-3-18(14-30-19)25(26,27)28)22(35)31-20-16-9-15-10-17(20)13-24(11-15,12-16)21(29)34/h3-4,14-17,20H,5-13H2,1-2H3,(H2,29,34)(H,31,35)/t15?,16?,17?,20-,24+"
        },
        "weight": [
            {
                "type": "average",
                "weight": 493.575,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 493.266459844,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.",
        "link": "https://go.drugbank.com/drugs/DB12501",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "O=C1N(CCC2=NN=NN2)C(=O)C2=CC=CC=C12",
        "id": "DB07055",
        "molecule": "2-[2-(1H-tetrazol-5-yl)ethyl]-1H-isoindole-1,3(2H)-dione",
        "iupac_name": "2-[2-(1H-1,2,3,4-tetrazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione",
        "inchi": {
            "hash": "DEOJDUHRJBKATO-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H9N5O2/c17-10-7-3-1-2-4-8(7)11(18)16(10)6-5-9-12-14-15-13-9/h1-4H,5-6H2,(H,12,13,14,15)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 243.2215,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 243.075624557,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phthalimides. These are aromatic heterocyclic compounds containing a 1,3-dioxoisoindoline moiety. They are imide derivatives of phthalic anhydrides.",
        "link": "https://go.drugbank.com/drugs/DB07055",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Escherichia coli",
                "target": "UBeta-lactamase"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(CN)CNC2=C(SC3=C2C=C(OC)C=C3)C(=O)N1",
        "id": "DB07431",
        "molecule": "(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one",
        "iupac_name": "(12R)-12-(aminomethyl)-4-methoxy-8-thia-11,14-diazatricyclo[7.5.0.0^{2,7}]tetradeca-1(9),2(7),3,5-tetraen-10-one",
        "inchi": {
            "hash": "TXYKBKYDFZQOCB-SSDOTTSWSA-N",
            "id": "InChI=1S/C13H15N3O2S/c1-18-8-2-3-10-9(4-8)11-12(19-10)13(17)16-7(5-14)6-15-11/h2-4,7,15H,5-6,14H2,1H3,(H,16,17)/t7-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 277.342,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 277.088497429,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as thienodiazepines. These are heteropolycyclic containing a thiophene ring fused to a diazepine ring. Thiophene is 5-membered ring consisting of four carbon and one sulfur atoms. Diazepine is a 7-membered ring consisting of five carbon and two nitrogen atoms.",
        "link": "https://go.drugbank.com/drugs/DB07431",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UMAP kinase-activated protein kinase 2"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCyclin-dependent kinase 2"
            }
        ]
    },
    {
        "smiles": "[H][C@](N)(CCC(=O)N[C@@]([H])(CS[C@]1([H])C2=CC=CC=C2C2=CC=CC=C2[C@@]1([H])O)C(=O)NCC(O)=O)C(O)=O",
        "id": "DB01834",
        "molecule": "(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene",
        "iupac_name": "(2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-{[(9R,10R)-10-hydroxy-9,10-dihydrophenanthren-9-yl]sulfanyl}ethyl]carbamoyl}butanoic acid",
        "inchi": {
            "hash": "JNNIZILNBMPOAC-MOXQZVSFSA-N",
            "id": "InChI=1S/C24H27N3O7S/c25-17(24(33)34)9-10-19(28)27-18(23(32)26-11-20(29)30)12-35-22-16-8-4-2-6-14(16)13-5-1-3-7-15(13)21(22)31/h1-8,17-18,21-22,31H,9-12,25H2,(H,26,32)(H,27,28)(H,29,30)(H,33,34)/t17-,18-,21+,22+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 501.552,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 501.156970923,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB01834",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione S-transferase P"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UGlutathione S-transferase Mu 1"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13851"
    },
    {
        "smiles": "CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC",
        "id": "DB13716",
        "molecule": "Dibutylphthalate",
        "cas": "84-74-2",
        "iupac_name": "1,2-dibutyl benzene-1,2-dicarboxylate",
        "inchi": {
            "hash": "DOIRQSBPFJWKBE-UHFFFAOYSA-N",
            "id": "InChI=1S/C16H22O4/c1-3-5-11-19-15(17)13-9-7-8-10-14(13)16(18)20-12-6-4-2/h7-10H,3-6,11-12H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 278.3435,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 278.151809192,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.",
        "link": "https://go.drugbank.com/drugs/DB13716",
        "type": "Small Molecule",
        "synonyms": [
            "Dibutyl phthalate"
        ],
        "is_stub": true
    },
    {
        "smiles": "[H][C@@]1(CCCN1C(=O)C1=C(O)C=C(O)C=C1)C1=CC=CC=C1C",
        "id": "DB08442",
        "molecule": "4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol",
        "iupac_name": "4-[(2R)-2-(2-methylphenyl)pyrrolidine-1-carbonyl]benzene-1,3-diol",
        "inchi": {
            "hash": "TWODFUZHWYZBHZ-MRXNPFEDSA-N",
            "id": "InChI=1S/C18H19NO3/c1-12-5-2-3-6-14(12)16-7-4-10-19(16)18(22)15-9-8-13(20)11-17(15)21/h2-3,5-6,8-9,11,16,20-21H,4,7,10H2,1H3/t16-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 297.3484,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 297.136493479,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.",
        "link": "https://go.drugbank.com/drugs/DB08442",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHeat shock protein HSP 90-alpha"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07478"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17087"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12308"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06177"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04255"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12739"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00453"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11963"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06745"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15107"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08734"
    },
    {
        "id": "DB11321",
        "molecule": "Cod liver oil",
        "cas": "8001-69-2",
        "background": "Cod liver oil is extracted from the liver of cod fish and mainly consists of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Also being a rich source of vitamin A and D, cod liver oil can be taken orally as daily supplements. It is used as an adjunct treatment and preventative therapy of rickets, osteomalacia and osteoporosis while meeting the consumption criteria.\n",
        "inchi": {},
        "summary": "Cod liver oil is an ingredient found in a variety of nutritional products.",
        "link": "https://go.drugbank.com/drugs/DB11321",
        "type": "Small Molecule",
        "synonyms": [
            "Cod liver oil",
            "Cod-liver oil",
            "Gadus morhua liver oil",
            "Oils, cod liver",
            "Oleum morrhuae"
        ],
        "indication": "Cod liver oil is predominantly manufactured, marketed, and used by the population at large as a general nutraceutical dietary supplement 1,2,7.\nHistorically, cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin D deficiency and condition of rickets associated with it 2. Over time, this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful all-purpose dietary supplement.\nHowever, since cod liver oil is a composite of several other nutritional compounds including the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as vitamin A and vitamin D 2,7,6, the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiency.\nRegardless, because it does contain a combination of a number of important and healthy nutritional compounds, cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds, such as the potential use of cod liver oil supplements in post-heart attack patients for secondary prophylaxis associated with the use of omega-3 fatty acids 5.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "As cod liver oil is a composite of several other nutritional compounds including the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as vitamin A and vitamin D 2,7,6, the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiency.\nFor example, one tablespoon of cod liver oil contains approximately 4,080 ug of retinol (vitamin A) and 34 ug (1,360 IU) of vitamin D 6. Since the general dietary reference intake of vitamin A is only 900 ug per day for adult men, 700 ug per day for women, and 3000 ug per day as the tolerable upper intake level, the regular intake of cod liver oil as a regular supplement can result in harmful levels of vitamin A accumulating in the liver and sufficient to cause hypervitaminosis A 3, which is associated with various symptoms such as blurred vision, changes in consciousness, skin and hair changes, liver damage, among many others.\nMoreover, while cod liver oil only contains a certain percentage of the omega-3 fatty acids EPA and DHA per amount of the oil 6, separate fish oils supplement products that exclusively consist of only EPA and DHA are available in a great variety of different percentage content formulations, even including prescription strength formulations should certain patients need such a level of therapy. Furthermore, such exclusive omega-3 fatty acid supplement products do not contain any vitamin A or D either, which allows patients to use the supplements without any concern about affecting their vitamin A or D levels or exposing themselves to the unnecessary excess intake of vitamins.\nSubsequently, although cod liver oil contains a combination of healthy dietary supplements like EPA, DHA, vitamin A, and vitamin D, the presence in varying amounts of all of these compounds all at once makes it difficult to effectively titrate for appropriate amounts of intake for all the compounds involved when using cod liver oil as a general supplement, often resulting in either an excess or insufficient amount of one or more the aforementioned compounds.\nNevertheless, because cod liver oil does consist of the component compounds of EPA, DHA, vitamin A, and vitamin D, further information about the pharmacodynamics of these cod liver oil components can be found by searching for fish oil, vitamin A, and vitamin D on DrugBank.\n"
    },
    {
        "smiles": "CC1=C(O)C(C)=C2CCC(C)(C)OC2=C1C",
        "id": "DB13111",
        "molecule": "Chromanol",
        "cas": "950-99-2",
        "iupac_name": "2,2,5,7,8-pentamethyl-3,4-dihydro-2H-1-benzopyran-6-ol",
        "background": "Chromanol has been used in trials studying the treatment of Prostate Cancer.\n",
        "inchi": {
            "hash": "SEBPXHSZHLFWRL-UHFFFAOYSA-N",
            "id": "InChI=1S/C14H20O2/c1-8-9(2)13-11(10(3)12(8)15)6-7-14(4,5)16-13/h15H,6-7H2,1-5H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 220.3074,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 220.146329884,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 2,2-dimethyl-1-benzopyrans. These are organic compounds containing a 1-benzopyran moiety that carries two methyl groups at the 2-position.",
        "link": "https://go.drugbank.com/drugs/DB13111",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O",
        "id": "DB06716",
        "molecule": "Fospropofol",
        "cas": "258516-89-1",
        "iupac_name": "{[2,6-bis(propan-2-yl)phenoxy]methoxy}phosphonic acid",
        "background": "Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent. Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008.\nFospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act.\n",
        "inchi": {
            "hash": "QVNNONOFASOXQV-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16)"
        },
        "summary": "Fospropofol is a sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.",
        "weight": [
            {
                "type": "average",
                "weight": 288.2766,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 288.112660294,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.",
        "link": "https://go.drugbank.com/drugs/DB06716",
        "type": "Small Molecule",
        "synonyms": [
            "Fospropofol"
        ],
        "indication": "For monitored anaesthesia care sedation in patients undergoing diagnostic procedures like bronchoscopy and colonscopy or minor surgical procedures like arthroscopy and bunionectomy. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Fospropofol is a prodrug of propofol, a sedative hypnotic drug. Unlike propofol, fospropofol is water soluble and can be administered in an aqueous solution. 1.86 mg of fospropofol is the molar equivalent for 1mg of propofol. \n",
        "moa": [
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit beta-2"
            },
            {
                "action": "potentiator",
                "organism": "Humans",
                "target": "AGamma-aminobutyric acid receptor subunit beta-3"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03668"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07028"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11939"
    },
    {
        "smiles": "CC(C)CC1NC2=C(C=C(C(Cl)=C2)S(N)(=O)=O)S(=O)(=O)N1",
        "id": "DB15861",
        "molecule": "Buthiazide",
        "cas": "2043-38-1",
        "iupac_name": "6-chloro-3-(2-methylpropyl)-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide",
        "inchi": {
            "hash": "HGBFRHCDYZJRAO-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H16ClN3O4S2/c1-6(2)3-11-14-8-4-7(12)9(20(13,16)17)5-10(8)21(18,19)15-11/h4-6,11,14-15H,3H2,1-2H3,(H2,13,16,17)"
        },
        "summary": "Buthiazide is a diuretic indicated in the treatment of edema caused by congestive heart failure, as well as hepatic and renal diseases.",
        "weight": [
            {
                "type": "average",
                "weight": 353.84,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 353.0270761,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB15861",
        "type": "Small Molecule",
        "synonyms": [
            "Buthiazide",
            "Butizida",
            "Butizide",
            "Butizidum",
            "Isobutylhydrochlorothiazide"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)N=O",
        "id": "DB04106",
        "molecule": "Fotemustine",
        "cas": "92118-27-9",
        "iupac_name": "diethyl [(1S)-1-{[N-(2-chloroethyl)-N'-oxohydrazinecarbonyl]amino}ethyl]phosphonate",
        "inchi": {
            "hash": "YAKWPXVTIGTRJH-QMMMGPOBSA-N",
            "id": "InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)/t8-/m0/s1"
        },
        "summary": "Fotemustine is an alkylating agent used in the treatment of metastatic melanoma.",
        "weight": [
            {
                "type": "average",
                "weight": 315.691,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 315.075084952,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dialkyl alkylphosphonates. These are compounds containing a phosphonic acid that is diesterified with alkyl groups, and the phosphorus atom is also directly attached to an alkyl group.",
        "link": "https://go.drugbank.com/drugs/DB04106",
        "type": "Small Molecule",
        "synonyms": [
            "(+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate",
            "Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate",
            "Fotemustina",
            "Fotemustine",
            "Fotemustinum",
            "Mustoforan"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UThioredoxin reductase 1, cytoplasmic"
            }
        ]
    },
    {
        "smiles": "CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1",
        "id": "DB13550",
        "molecule": "Bifemelane",
        "cas": "90293-01-9",
        "iupac_name": "[4-(2-benzylphenoxy)butyl](methyl)amine",
        "inchi": {
            "hash": "QSQQPMHPCBLLGX-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H23NO/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16/h2-6,9-12,19H,7-8,13-15H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 269.388,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 269.177964365,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB13550",
        "type": "Small Molecule",
        "synonyms": [
            "Bifemelane",
            "Bifemelano",
            "Bifemelanum"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC=CC=C1C1=CNC2=C1C=C(C=N2)C1=CC(=CN=C1)C(=O)N(C)C",
        "id": "DB08350",
        "molecule": "5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE",
        "iupac_name": "5-[3-(2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylpyridine-3-carboxamide",
        "inchi": {
            "hash": "GYQRHHQPEMOLKH-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H20N4O2/c1-26(2)22(27)16-8-14(10-23-11-16)15-9-18-19(13-25-21(18)24-12-15)17-6-4-5-7-20(17)28-3/h4-13H,1-3H3,(H,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 372.4198,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 372.158625904,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.",
        "link": "https://go.drugbank.com/drugs/DB08350",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UTyrosine-protein kinase ABL1"
            }
        ]
    },
    {
        "smiles": "[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O",
        "id": "DB00314",
        "molecule": "Capreomycin",
        "cas": "11003-38-6",
        "iupac_name": "(3S)-3,6-diamino-N-{[(2S,5S,8E,11S,15S)-15-amino-11-[(4R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-5-yl]methyl}hexanamide; (3S)-3,6-diamino-N-{[(2S,5S,8E,11S,15S)-15-amino-11-[(4R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-5-yl]methyl}hexanamide",
        "background": "Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.\n",
        "inchi": {
            "hash": "VCOPTHOUUNAYKQ-WBTCAYNUSA-N",
            "id": "InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1"
        },
        "summary": "Capreomycin is an aminoglycoside antibiotic used as an adjunct drug in tuberculosis.",
        "weight": [
            {
                "type": "average",
                "weight": 1321.4123,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 1320.698394286,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB00314",
        "type": "Small Molecule",
        "synonyms": [
            "Capreomicina",
            "Capreomycin"
        ],
        "indication": "Used in the treatment of tuberculosis in combination with other drugs.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Capreomycin is a member of the aminoglycoside family of antibiotics. These antibiotics have the ability to kill a wide variety of bacteria, including bacteria responsible for causing tuberculosis (TB).\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)",
                "target": "A16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA"
            }
        ]
    },
    {
        "id": "DB11187",
        "molecule": "1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphocholine",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11187",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "C1C(C2=NCCN2)C1(C1=CC=CC=C1)C1=CC=CC=C1",
        "id": "DB13358",
        "molecule": "Cibenzoline",
        "cas": "53267-01-9",
        "iupac_name": "2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole",
        "inchi": {
            "hash": "IPOBOOXFSRWSHL-UHFFFAOYSA-N",
            "id": "InChI=1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 262.356,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 262.146998588,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.",
        "link": "https://go.drugbank.com/drugs/DB13358",
        "type": "Small Molecule",
        "synonyms": [
            "Cibenzoline",
            "Cifenline"
        ],
        "is_stub": true
    },
    {
        "smiles": "C[C@H](OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=CC(O)=CC=C2C=C2C(=O)NC(=O)N=C12)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O",
        "id": "DB03913",
        "molecule": "Coenzyme F420",
        "cas": "64885-97-8",
        "iupac_name": "(2S)-2-[(4S)-4-carboxy-4-[(2S)-2-{[hydroxy({[(2R,3S,4S)-2,3,4-trihydroxy-5-{8-hydroxy-2,4-dioxo-2H,3H,4H,10H-pyrimido[4,5-b]quinolin-10-yl}pentyl]oxy})phosphoryl]oxy}propanamido]butanamido]pentanedioic acid",
        "inchi": {
            "hash": "GEHSZWRGPHDXJO-NALJQGANSA-N",
            "id": "InChI=1S/C29H36N5O18P/c1-12(25(42)31-17(28(46)47)4-6-21(38)30-16(27(44)45)5-7-22(39)40)52-53(49,50)51-11-20(37)23(41)19(36)10-34-18-9-14(35)3-2-13(18)8-15-24(34)32-29(48)33-26(15)43/h2-3,8-9,12,16-17,19-20,23,35-37,41H,4-7,10-11H2,1H3,(H,30,38)(H,31,42)(H,39,40)(H,44,45)(H,46,47)(H,49,50)(H,33,43,48)/t12-,16-,17-,19-,20+,23-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 773.5926,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 773.179295885,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB03913",
        "type": "Small Molecule",
        "synonyms": [
            "Coenzyme F(420)",
            "coenzyme -F420-2",
            "F420",
            "Factor F420",
            "N-{N-[O-(7,8-didemethyl-8-hydroxy-5-deazariboflavin phospho)-(S)-lactyl]--L-glutamyl}-L-glutamate"
        ]
    },
    {
        "smiles": "[H][C@]1(O)[C@]([H])(O)[C@@]2([H])N=C(O[C@@]2([H])[C@]1([H])CO)N(C)C",
        "id": "DB04404",
        "molecule": "Allosamizoline",
        "iupac_name": "(3aR,4R,5R,6R,6aS)-2-(dimethylamino)-6-(hydroxymethyl)-3aH,4H,5H,6H,6aH-cyclopenta[d][1,3]oxazole-4,5-diol",
        "inchi": {
            "hash": "MKJAYSJDHSEFRI-PVFLNQBWSA-N",
            "id": "InChI=1S/C9H16N2O4/c1-11(2)9-10-5-7(14)6(13)4(3-12)8(5)15-9/h4-8,12-14H,3H2,1-2H3/t4-,5-,6-,7-,8+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 216.2343,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 216.11100701,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oxazolines. These are organic compounds containing 1,3-oxazoline, a five-membered ring with a nitrogen and an oxygen atoms at the 1- and 3-position, respectively. Additionally, it contains two double bonds.",
        "link": "https://go.drugbank.com/drugs/DB04404",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UChitotriosidase-1"
            },
            {
                "action": "Not Available",
                "organism": "Serratia marcescens",
                "target": "UChitinase B"
            },
            {
                "action": "Not Available",
                "organism": "Serratia marcescens",
                "target": "UChitinase A"
            }
        ]
    },
    {
        "smiles": "[H]\\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\\[H])=C(/[H])[C@@]([H])(O)COC1=CC=CC(Cl)=C1",
        "id": "DB11507",
        "molecule": "Cloprostenol",
        "cas": "54276-21-0",
        "iupac_name": "(5Z)-7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid",
        "inchi": {
            "hash": "VJGGHXVGBSZVMZ-QIZQQNKQSA-N",
            "id": "InChI=1S/C22H29ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28)/b3-1-,11-10+/t16-,18-,19-,20+,21-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 424.92,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 424.1652664,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.",
        "link": "https://go.drugbank.com/drugs/DB11507",
        "type": "Small Molecule",
        "synonyms": [
            "Cloprostenol"
        ],
        "is_stub": true
    },
    {
        "smiles": "CCN1CCN(CC2=CC=C(C=C2)C2=CC3=C(N2)N=CN=C3N[C@H](C)C2=CC=CC=C2)CC1",
        "id": "DB12558",
        "molecule": "AEE-788",
        "cas": "497839-62-0",
        "iupac_name": "6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine",
        "background": "AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.\n",
        "inchi": {
            "hash": "OONFNUWBHFSNBT-HXUWFJFHSA-N",
            "id": "InChI=1S/C27H32N6/c1-3-32-13-15-33(16-14-32)18-21-9-11-23(12-10-21)25-17-24-26(28-19-29-27(24)31-25)30-20(2)22-7-5-4-6-8-22/h4-12,17,19-20H,3,13-16,18H2,1-2H3,(H2,28,29,30,31)/t20-/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 440.5832,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 440.268845054,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond.",
        "link": "https://go.drugbank.com/drugs/DB12558",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "NC1=NC2=C(NC=C2[C@@H]2N[C@H](CO)[C@@H](O)[C@H]2O)C(=O)N1",
        "id": "DB02230",
        "molecule": "Immucillin-G",
        "iupac_name": "2-amino-7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one",
        "inchi": {
            "hash": "KBIDJCVAURJXFG-PVEDRDFWSA-N",
            "id": "InChI=1S/C11H15N5O4/c12-11-15-5-3(1-13-7(5)10(20)16-11)6-9(19)8(18)4(2-17)14-6/h1,4,6,8-9,13-14,17-19H,2H2,(H3,12,15,16,20)/t4-,6+,8-,9+/m1/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 281.2679,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 281.112403993,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.",
        "link": "https://go.drugbank.com/drugs/DB02230",
        "type": "Small Molecule",
        "synonyms": [
            "(1S)-1,4-dideoxy-1,4-imino-1-(9-deazaguanin-9-yl)-D-ribitol"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPurine nucleoside phosphorylase"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CC(N)=O)C(O)=O",
        "id": "DB00174",
        "molecule": "Asparagine",
        "cas": "70-47-3",
        "iupac_name": "(2S)-2-amino-3-carbamoylpropanoic acid",
        "background": "A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)\n",
        "inchi": {
            "hash": "DCXYFEDJOCDNAF-REOHCLBHSA-N",
            "id": "InChI=1S/C4H8N2O3/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H2,6,7)(H,8,9)/t2-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 132.1179,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 132.053492132,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as asparagine and derivatives. These are compounds containing asparagine or a derivative thereof resulting from reaction of asparagine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB00174",
        "type": "Small Molecule",
        "synonyms": [
            "(2S)-2-amino-3-carbamoylpropanoic acid",
            "(2S)-2,4-diamino-4-oxobutanoic acid",
            "(S)-2-amino-3-carbamoylpropanoic acid",
            "(S)-Asparagine",
            "2-Aminosuccinamic acid",
            "alpha-aminosuccinamic acid",
            "Asn",
            "Asparagine",
            "Aspartamic acid",
            "L-2-aminosuccinamic acid",
            "L-Asparagine",
            "L-aspartic acid beta-amide",
            "L-aspartic acid -amide",
            "-aminosuccinamic acid"
        ],
        "indication": "Used for nutritional supplementation, also for treating dietary shortage or imbalance.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "A non-essential amino acid. Asparagine is critical for the production of the body's proteins, enzymes and muscle tissue. Supplements of this amino acid are claimed to balance nervous system function.\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "ASodium-coupled neutral amino acid transporters"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UNeutral amino acid transporter B(0)"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAsparagine synthetase [glutamine-hydrolyzing]"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UAsparagine--tRNA ligase, cytoplasmic"
            },
            {
                "action": "substrate",
                "organism": "Humans",
                "target": "NIsoaspartyl peptidase/L-asparaginase"
            },
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UProbable asparagine--tRNA ligase, mitochondrial"
            }
        ]
    },
    {
        "smiles": "[H]\\C(=C1\\N=C(N(CC(O)=O)C1=O)[C@@]([H])(N)CO)C1=CC=C(O)C=C1",
        "id": "DB03537",
        "molecule": "[4-(4-Hydroxy-Benzyl)-2-(2-Hydroxy-1-Methyl-Ethyl)-5-Oxo-Imidazolidin-1-Yl]-Acetic Acid",
        "iupac_name": "2-[(4Z)-2-[(1R)-1-amino-2-hydroxyethyl]-4-[(4-hydroxyphenyl)methylidene]-5-oxo-4,5-dihydro-1H-imidazol-1-yl]acetic acid",
        "inchi": {
            "hash": "XSUILVORURXWDH-QIMWGGGBSA-N",
            "id": "InChI=1S/C14H15N3O5/c15-10(7-18)13-16-11(14(22)17(13)6-12(20)21)5-8-1-3-9(19)4-2-8/h1-5,10,18-19H,6-7,15H2,(H,20,21)/b11-5-/t10-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 305.286,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 305.101170605,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB03537",
        "type": "Small Molecule"
    },
    {
        "smiles": "CCCOC1=CC2=C(NC=C2C[C@@H](NS(=O)(=O)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC2=CC=C(C=C2)C(N)=N)C=C1",
        "id": "DB04606",
        "molecule": "2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)",
        "iupac_name": "(2S)-N-[(4-carbamimidoylphenyl)methyl]-2-[(2R)-2-ethanesulfonamido-3-(5-propoxy-1H-indol-3-yl)propanamido]pentanediamide",
        "inchi": {
            "hash": "UHMORXPPNXDKHY-LOSJGSFVSA-N",
            "id": "InChI=1S/C29H39N7O6S/c1-3-13-42-21-9-10-23-22(15-21)20(17-33-23)14-25(36-43(40,41)4-2)29(39)35-24(11-12-26(30)37)28(38)34-16-18-5-7-19(8-6-18)27(31)32/h5-10,15,17,24-25,33,36H,3-4,11-14,16H2,1-2H3,(H2,30,37)(H3,31,32)(H,34,38)(H,35,39)/t24-,25+/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 613.728,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 613.268252705,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.",
        "link": "https://go.drugbank.com/drugs/DB04606",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UCoagulation factor VII"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06449"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00477"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02777"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11398"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09217"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01664"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06198"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04534"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01551"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05227"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12829"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07142"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01118"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02183"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14677"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07322"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03349"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15609"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02098"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03669"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03723"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13843"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01529"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07845"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01222"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04382"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13997"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07613"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01976"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06678"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11390"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12359"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00674"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06953"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07786"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12940"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04642"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00593"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07056"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04623"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02547"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02989"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07374"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18216"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16634"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11876"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01264"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04692"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08418"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07050"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13963"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01070"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05265"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07271"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11835"
    },
    {
        "smiles": "COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2",
        "id": "DB11586",
        "molecule": "Asunaprevir",
        "cas": "630420-16-5",
        "iupac_name": "tert-butyl N-[(2S)-1-[(2S,4R)-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-2-{[(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate",
        "background": "Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.2 It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.4\n",
        "inchi": {
            "hash": "XRWSZZJLZRKHHD-WVWIJVSJSA-N",
            "id": "InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1"
        },
        "summary": "Asunaprevir is an NS3 protease inhibitor used to treat hepatitis C genotype 1b.",
        "weight": [
            {
                "type": "average",
                "weight": 748.286,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 747.270476492,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.",
        "link": "https://go.drugbank.com/drugs/DB11586",
        "type": "Small Molecule",
        "synonyms": [
            "Asunaprevir"
        ],
        "indication": "Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.5 \nHepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.6 The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.7\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Studies in vitro demonstrated a significant antiviral activity in HCV replicon cell systems with an EC50 of 4nm and 1nm against the HCV genotype 1a and 1b respectively.2 These studies showed a limited activity against the genotypes 2 and 3. This property makes asunaprevir a highly selective anti-HCV agent that is not effective against HCV closely related virus.3 Asunaprevir produce robust declines in HCV RNA levels in patients with HCV genotype 1 infection.1In clinical studies, it has been shown that asunaprevir is well-tolerated and the mean maximum HCV RNA level reduction from baseline was of approximately 2.87 log10 IU/ml.2\nMonotherapy clinical studies with asunaprevir showed a mean maximum decline of HCV RNA in the range of 0.28-2.87 log10 IU/ml when administered in increasing doses from 10-600 mg. When asunaprevir was used as a combination product, it was possible to obtain a sustained virological response (aviremia 24 weeks after completion of therapy) in 83-92% of the patients.3\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Hepatitis C virus genotype 1b (isolate BK)",
                "target": "AGenome polyprotein"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08051"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05340"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01990"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18206"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18014"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08925"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11413"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04672"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08453"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05107"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12830"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11518"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14193"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07312"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15307"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01533"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18295"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09017"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03590"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07547"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03056"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11481"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02220"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18405"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04044"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03901"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09406"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02290"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03296"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07074"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11686"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07168"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04933"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04944"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08016"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12854"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06856"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00405"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03031"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17379"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00216"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07117"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00895"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00106"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06313"
    },
    {
        "smiles": "CCCCCCCCSCC(=O)C(F)(F)F",
        "id": "DB08612",
        "molecule": "1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE",
        "iupac_name": "1,1,1-trifluoro-3-(octylsulfanyl)propan-2-one",
        "inchi": {
            "hash": "WMQHRXUKAYSPPK-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H19F3OS/c1-2-3-4-5-6-7-8-16-9-10(15)11(12,13)14/h2-9H2,1H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 256.328,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 256.110870535,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha-haloketones. These are organic compounds contaning a halogen atom attached to the alpha carbon atom relative to C=O group.",
        "link": "https://go.drugbank.com/drugs/DB08612",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UPutative inactive carboxylesterase 4"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03016"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16703"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04492"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17240"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03417"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08745"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08562"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08260"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02850"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05882"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04710"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13737"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07648"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02857"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07935"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04212"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07171"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11637"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06089"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07950"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08576"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02015"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03736"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08688"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02506"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07153"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02189"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07888"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09169"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02705"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13663"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06138"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07850"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04563"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14913"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11273"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04259"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00389"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07297"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01289"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12774"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01407"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12947"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07485"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08166"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11704"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15933"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11867"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03311"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15173"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02324"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02210"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03697"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17382"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12900"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07684"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02491"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11109"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16049"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18551"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00673"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03816"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03480"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13619"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07716"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18502"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01364"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11723"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17197"
    },
    {
        "smiles": "C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@H]2[C@H](O)[C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)[C@@H](O)[C@H](O)[C@@H]1O",
        "id": "DB04678",
        "molecule": "H TYPE II TRISACCHARIDE",
        "iupac_name": "N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide",
        "inchi": {
            "hash": "PHTAQVMXYWFMHF-QVPNGJTFSA-N",
            "id": "InChI=1S/C20H35NO15/c1-5-10(25)13(28)15(30)19(32-5)36-17-14(29)11(26)7(3-22)34-20(17)35-16-8(4-23)33-18(31)9(12(16)27)21-6(2)24/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18+,19-,20-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 529.4896,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 529.200669455,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group.",
        "link": "https://go.drugbank.com/drugs/DB04678",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UHisto-blood group ABO system transferase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02952"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01487"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02310"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05475"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04149"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06831"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03061"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01804"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07422"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06723"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13885"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06689"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11556"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02300"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06974"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04285"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11672"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07359"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15493"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13845"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04814"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03675"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01120"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13468"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08347"
    },
    {
        "smiles": "COC1=CC(=CC(OC)=C1OC)C(CCCN(C)CCC1=CC(OC)=C(OC)C=C1)(C#N)C(C)C",
        "id": "DB12923",
        "molecule": "Gallopamil",
        "cas": "16662-47-8",
        "iupac_name": "5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)-2-(3,4,5-trimethoxyphenyl)pentanenitrile",
        "background": "Gallopamil has been used in trials studying the treatment of Asthma.\n",
        "inchi": {
            "hash": "XQLWNAFCTODIRK-UHFFFAOYSA-N",
            "id": "InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 484.637,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 484.293722396,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.",
        "link": "https://go.drugbank.com/drugs/DB12923",
        "type": "Small Molecule",
        "synonyms": [
            "Gallopamil"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18106"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09134"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08707"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14033"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04042"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02184"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14830"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07860"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02321"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13538"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14511"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07356"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12321"
    },
    {
        "smiles": "[H][C@@](CC(C)C)(NC(C)=O)C(=O)N[C@@]([H])(CC1=CC=CC=C1)C(=O)C(F)(F)F",
        "id": "DB08119",
        "molecule": "1,1,1-TRIFLUORO-3-((N-ACETYL)-L-LEUCYLAMIDO)-4-PHENYL-BUTAN-2-ONE(N-ACETYL-L-LEUCYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",
        "iupac_name": "(2S)-2-acetamido-4-methyl-N-[(2S)-4,4,4-trifluoro-3-oxo-1-phenylbutan-2-yl]pentanamide",
        "inchi": {
            "hash": "MZNXJCZDQRNGRC-GJZGRUSLSA-N",
            "id": "InChI=1S/C18H23F3N2O3/c1-11(2)9-15(22-12(3)24)17(26)23-14(16(25)18(19,20)21)10-13-7-5-4-6-8-13/h4-8,11,14-15H,9-10H2,1-3H3,(H,22,24)(H,23,26)/t14-,15-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 372.382,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 372.166077227,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as leucine and derivatives. These are compounds containing leucine or a derivative thereof resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.",
        "link": "https://go.drugbank.com/drugs/DB08119",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "UChymotrypsinogen B"
            }
        ]
    },
    {
        "smiles": "CC1=CC(NC2=NC(=NC3=CC=CC=C23)C(O)C2=CC=C(F)C=C2)=NN1",
        "id": "DB12535",
        "molecule": "AC-430",
        "cas": "1241914-87-3",
        "iupac_name": "(4-fluorophenyl)({4-[(5-methyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl})methanol",
        "background": "AC430 has been investigated for the treatment of Rheumatoid Arthritis.\n",
        "inchi": {
            "hash": "DCRWIATZWHLIPN-UHFFFAOYSA-N",
            "id": "InChI=1S/C19H16FN5O/c1-11-10-16(25-24-11)22-18-14-4-2-3-5-15(14)21-19(23-18)17(26)12-6-8-13(20)9-7-12/h2-10,17,26H,1H3,(H2,21,22,23,24,25)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 349.369,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 349.133888318,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.",
        "link": "https://go.drugbank.com/drugs/DB12535",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1",
        "id": "DB00801",
        "molecule": "Halazepam",
        "cas": "23092-17-3",
        "iupac_name": "7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one",
        "background": "Halazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.1,2 It has been shown to be less toxic than chlordiazepoxide or diazepam.1 This drug is no longer marketed in the United States, and was withdrawn by Schering, its manufacturer, in 2009.3,4\n",
        "inchi": {
            "hash": "WYCLKVQLVUQKNZ-UHFFFAOYSA-N",
            "id": "InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 352.738,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 352.059025338,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.",
        "link": "https://go.drugbank.com/drugs/DB00801",
        "type": "Small Molecule",
        "synonyms": [
            "Halazpam",
            "Halazepam",
            "Halazepamum"
        ],
        "indication": "Used to relieve anxiety, nervousness, and tension associated with anxiety disorders.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "moa": [
            {
                "action": "positive allosteric modulator",
                "organism": "Humans",
                "target": "AGABA(A) Receptor"
            },
            {
                "action": "ligand",
                "organism": "Humans",
                "target": "UGABA(A) Receptor Benzodiazepine Binding Site"
            }
        ]
    },
    {
        "smiles": "CNC(=O)C1=C(F)C=C(C=C1)C1=NN2C(CC3=CC4=C(C=C3)N=CC=C4)=CN=C2N=C1",
        "id": "DB11791",
        "molecule": "Capmatinib",
        "cas": "1029712-80-8",
        "iupac_name": "2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide",
        "background": "Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair.2 Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK.2 Mutations in MET have been detected in non-small cell lung cancer (NSCLC), and the prevalence of MET amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%.2 This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.\nManufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,4 for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.3 The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day.4 As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials.3 Capmatinib was approved by Health Canada on June 8, 2022.7\n",
        "inchi": {
            "hash": "LIOLIMKSCNQPLV-UHFFFAOYSA-N",
            "id": "InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)"
        },
        "summary": "Capmatinib is a kinase inhibitor targeting c-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer with MET exon 14 skipping.",
        "weight": [
            {
                "type": "average",
                "weight": 412.428,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 412.144787354,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as quinolines and derivatives. These are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.",
        "link": "https://go.drugbank.com/drugs/DB11791",
        "type": "Small Molecule",
        "synonyms": [
            "Capmatinib"
        ],
        "indication": "In the US, capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.3\nCapmatinib is approved to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations in Canada.6\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Capmatinib inhibits the overactivity of c-Met, a receptor tyrosine kinase encoded by the MET proto-oncogene.3 Mutations in MET are involved in the proliferation of many cancers, including non-small cell lung cancer (NSCLC).3,2 \nCapmatinib may cause photosensitivity reactions in patients following ultraviolet (UV) exposure - patients undergoing therapy with capmatinib should be advised to use sunscreen and protective clothing to limit exposure to UV radiation.3 Instances of interstitial lung disease/pneumonitis, which can be fatal, occurred in patients being treated with capmatinib. Patients presenting with signs or symptoms of lung disease (e.g. cough, dyspnea, fever) should have capmatinib immediately withheld, and capmatinib should be permanently discontinued if no other feasible causes of the lung-related symptoms are identified.3\n",
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AHepatocyte growth factor receptor"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07820"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12046"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07366"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08355"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00121"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02057"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03018"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08152"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11833"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12140"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06620"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13203"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12306"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01181"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06519"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16404"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07357"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00796"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12280"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03159"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15679"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13866"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01720"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04667"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08026"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05047"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12746"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06013"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02604"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01727"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18096"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14889"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06748"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11655"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14695"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02332"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12141"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02978"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01327"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07118"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12901"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04746"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01231"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03426"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03313"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12741"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17876"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08943"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14150"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06619"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00310"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14003"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12480"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02902"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14900"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01641"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04689"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11093"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11371"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04208"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04512"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08497"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15204"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04012"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07900"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13551"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07538"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05549"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15244"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01026"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03687"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14019"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14097"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07104"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04261"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03015"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04250"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01518"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07824"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00819"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05898"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11510"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07795"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08656"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07396"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05514"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08728"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08719"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06970"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08989"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05059"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07974"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05293"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04629"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00446"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02434"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04070"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13280"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03155"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02424"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02122"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07198"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13394"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01930"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01634"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11499"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08504"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07311"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13658"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02419"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07387"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01615"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02334"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03671"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13009"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00415"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02191"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11985"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16103"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02211"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12247"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03316"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11875"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06957"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09243"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02123"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07285"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00284"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07215"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00633"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06778"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02809"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17152"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07188"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16861"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04123"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03692"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02767"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03926"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01102"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04429"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04473"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13190"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12654"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09385"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB05449"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02932"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06701"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03283"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07046"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17834"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01871"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08861"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03857"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07529"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11740"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01498"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17927"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01873"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17077"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06997"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04279"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03199"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11846"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02035"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12187"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03117"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB17149"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13827"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12145"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15085"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01151"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04915"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06302"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07094"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03808"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14850"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01089"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03759"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06979"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11877"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01563"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01863"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04739"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13818"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01490"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15568"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07897"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12566"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02678"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06840"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01450"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11412"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02760"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02835"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11219"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13462"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01478"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03916"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13395"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06251"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB09473"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04317"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00217"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02807"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12067"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08553"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04687"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04610"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08295"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02950"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04115"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02106"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01982"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB00168"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02004"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03333"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14545"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14589"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15641"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14902"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07079"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02521"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB16933"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB15200"
    },
    {
        "id": "DB18021",
        "molecule": "BAP5191",
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB18021",
        "type": "Small Molecule",
        "is_stub": true
    },
    {
        "smiles": "CC[N+]1=C(C2=CC=CC=C2)C2=C(C=CC(N)=C2)C2=C1C=C(N)C=C2",
        "id": "DB17031",
        "molecule": "Homidium",
        "cas": "3546-21-2",
        "iupac_name": "3,8-diamino-5-ethyl-6-phenylphenanthridin-5-ium",
        "background": "Homidium is a group II compound with trypanocidal effects.1\n",
        "inchi": {
            "hash": "QTANTQQOYSUMLC-UHFFFAOYSA-O",
            "id": "InChI=1S/C21H19N3/c1-2-24-20-13-16(23)9-11-18(20)17-10-8-15(22)12-19(17)21(24)14-6-4-3-5-7-14/h3-13,23H,2,22H2,1H3/p+1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 314.411,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 314.165174076,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB17031",
        "type": "Small Molecule",
        "synonyms": [
            "2,7-diamino-10-ethyl-9-phenylphenanthridinium",
            "2,7-diamino-9-phenyl-10-ethylphenanthridinium",
            "3,8-diamino-5-ethyl-6-phenylphenanthridinium",
            "Babidium",
            "Ethidium",
            "Homidium cation",
            "Homidium ion",
            "Novidium"
        ],
        "is_stub": true
    },
    {
        "smiles": "COC1=CC=C(N2CCC3=C2N=C(C)C=C3N2C=CC(=N2)N2CCNC2=O)C(C)=C1",
        "id": "DB12910",
        "molecule": "Emicerfont",
        "cas": "786701-13-1",
        "iupac_name": "1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-1H,2H,3H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one",
        "background": "Emicerfont has been used in trials studying the diagnostic and treatment of Social Anxiety Disorder and Irritable Bowel Syndrome (IBS).\n",
        "inchi": {
            "hash": "JFHJGXQFESYQGY-UHFFFAOYSA-N",
            "id": "InChI=1S/C22H24N6O2/c1-14-12-16(30-3)4-5-18(14)26-9-6-17-19(13-15(2)24-21(17)26)28-10-7-20(25-28)27-11-8-23-22(27)29/h4-5,7,10,12-13H,6,8-9,11H2,1-3H3,(H,23,29)"
        },
        "weight": [
            {
                "type": "average",
                "weight": 404.474,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 404.196074037,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.",
        "link": "https://go.drugbank.com/drugs/DB12910",
        "type": "Small Molecule",
        "synonyms": [
            "Emicerfont"
        ],
        "is_stub": true
    },
    {
        "smiles": "CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O",
        "id": "DB09273",
        "molecule": "Doxofylline",
        "cas": "69975-86-6",
        "iupac_name": "7-[(1,3-dioxolan-2-yl)methyl]-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione",
        "background": "Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. In contrast with other xanthine derivatives, doxofylline does not significantly bind to adenosine alpha-1 or alpha-2 receptors and lacks stimulating effects. Decreased affinity for adenosine receptors may account for the better safety profile of doxofylline compared to theophylline 9. Unlike theophylline, doxofylline does not affect calcium influx and does not antagonize the actions of calcium channel blockers which could explain reduced cardiac adverse reactions associated with the drug 5. The anti-asthmatic effects of doxophylline are mediated by other mechanisms, primarily through inhibiting the activities of the phosphodiesterase (PDE) enzyme.\n",
        "inchi": {
            "hash": "HWXIGFIVGWUZAO-UHFFFAOYSA-N",
            "id": "InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3"
        },
        "summary": "Doxofylline is a methylxanthine derivative used in chronic obstructive pulmonary disease, asthma, and bronchospasms.",
        "weight": [
            {
                "type": "average",
                "weight": 266.257,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 266.101504947,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.",
        "link": "https://go.drugbank.com/drugs/DB09273",
        "type": "Small Molecule",
        "synonyms": [
            "doxofilina",
            "Doxofylline",
            "Doxophylline"
        ],
        "indication": "Indicated for the treatment of chronic obstructive pulmonary disease (COPD), bronchial asthma and pulmonary disease with spastic bronchial component.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Doxofylline is a methylxanthine bronchodilator with potent bronchodilator activity comparable to that of theophylline. In animal studies, doxofylline demonstrated to attenuate bronchoconstriction, inflammatory actions and the release of thromboxane A2 (TXA2) when challenged with platelet-activating factor 9. \nDoxofylline does not demonstrate direct inhibition of any histone deacetylase (HDAC) enzymes or known PDE enzyme isoforms and did not act as an antagonist at A2 or A2 receptors. The affinity for adenosine A1, A2A and A2B receptors are reported to be all higher than 100 M 6. It only displays an inhibitory action against PDE2A1 and antagonism at adenosine A(2A) at high concentrations 7. A study demonstrated that doxofylline interacts with 2-adrenoceptors to induce blood vessel relaxation and airway smooth muscle relaxation. In dog studies, doxofylline decreased airway responsiveness at a dose that did not affect heart rate and respiratory rate 6.\n",
        "moa": [
            {
                "action": "agonist",
                "organism": "Humans",
                "target": "ABeta-2 adrenergic receptor"
            },
            {
                "action": "antagonist",
                "organism": "Humans",
                "target": "UAdenosine receptor A2a"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AcGMP-dependent 3',5'-cyclic phosphodiesterase"
            }
        ]
    },
    {
        "smiles": "N[C@@H](CS\\C(N)=N\\CCC[C@H]([NH3+])C(O)=O)C(O)=O",
        "id": "DB04671",
        "molecule": "[(1S)-4-[[Amino-[(2R)-2-amino-2-carboxyethyl]sulfanylmethylidene]amino]-1-carboxybutyl]azanium",
        "iupac_name": "(1S)-4-[(E)-[amino({[(2R)-2-amino-2-carboxyethyl]sulfanyl})methylidene]amino]-1-carboxybutan-1-aminium",
        "inchi": {
            "hash": "FBDBZWJNHYXEKT-WDSKDSINSA-O",
            "id": "InChI=1S/C9H18N4O4S/c10-5(7(14)15)2-1-3-13-9(12)18-4-6(11)8(16)17/h5-6H,1-4,10-11H2,(H2,12,13)(H,14,15)(H,16,17)/p+1/t5-,6-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 279.337,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 279.112700806,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as l-cysteine-s-conjugates. These are compounds containing L-cysteine where the thio-group is conjugated.",
        "link": "https://go.drugbank.com/drugs/DB04671",
        "type": "Small Molecule",
        "moa": [
            {
                "action": "Not Available",
                "organism": "Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)",
                "target": "UArginine deiminase"
            }
        ]
    },
    {
        "smiles": "ClCCNC(=O)N(CCCl)N=O",
        "id": "DB00262",
        "molecule": "Carmustine",
        "cas": "154-93-8",
        "iupac_name": "1,3-bis(2-chloroethyl)-1-nitrosourea",
        "background": "A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)\n",
        "inchi": {
            "hash": "DLGOEMSEDOSKAD-UHFFFAOYSA-N",
            "id": "InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)"
        },
        "summary": "Carmustine is an alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others.",
        "weight": [
            {
                "type": "average",
                "weight": 214.05,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 213.007181961,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as nitrosoureas. These are compounds containing a nitro group and an urea group N-N linked together, with the general structure R1N(R2)C(=O)N(R3)N=O.",
        "link": "https://go.drugbank.com/drugs/DB00262",
        "type": "Small Molecule",
        "synonyms": [
            "BCNU",
            "bis-chloroethylnitrosourea",
            "Bischloroethyl nitrosourea",
            "Carmustina",
            "Carmustine",
            "Carmustinum",
            "N,N'-Bis(2-chloroethyl)-N-nitrosourea"
        ],
        "indication": "For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.\n",
        "moa": [
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "ARNA"
            },
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "AGlutathione reductase, mitochondrial"
            },
            {
                "action": "other/unknown",
                "organism": "Humans",
                "target": "ADNA"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03455"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB14522"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB04340"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12992"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07370"
    },
    {
        "smiles": "[H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1",
        "id": "DB08382",
        "molecule": "Gosogliptin",
        "cas": "869490-23-3",
        "iupac_name": "2-{4-[(3S,5S)-5-(3,3-difluoropyrrolidine-1-carbonyl)pyrrolidin-3-yl]piperazin-1-yl}pyrimidine",
        "background": "Gosogliptin has been used in trials studying the treatment of Renal Insufficiency, Chronic.\n",
        "inchi": {
            "hash": "QWEWGXUTRTXFRF-KBPBESRZSA-N",
            "id": "InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 366.4089,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 366.19796583,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.",
        "link": "https://go.drugbank.com/drugs/DB08382",
        "type": "Small Molecule",
        "synonyms": [
            "2-(4-{(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine",
            "Gosogliptin"
        ],
        "moa": [
            {
                "action": "Not Available",
                "organism": "Humans",
                "target": "ADipeptidyl peptidase 4"
            }
        ]
    },
    {
        "smiles": "CN[C@@H](C)CC1CCCCC1.CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1",
        "id": "DB09001",
        "molecule": "Barbexaclone",
        "cas": "4388-82-3",
        "iupac_name": "5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; [(2S)-1-cyclohexylpropan-2-yl](methyl)amine",
        "background": "Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. While barbexaclone has sedative properties, propylhexedrine has psychostimulant properties intended to offset these sedative effects. Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine. Several reports from Spanish and Italian literature suggest that barbexaclone is at least as effective as phenobarbital in adults and children, while being better tolerated and having less sedative properties. These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials. Despite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009. \nBarbexaclone exists in 25mg and 100mg tablets. 100mg of barbexaclone is equivalent to 60mg of phenobarbital. With this difference in potency in mind, other pharmacokinetic considerations such as dose titration, daily dosing, and optimal plasma concentration can be considered the same as for the equivalent amount of phenobarbital. \nThere has been a case of barbexaclone abuse due to the amphetamine like properties of propylhexedrine, although the comparative abuse potential is much lower than amphetamine.\n",
        "inchi": {
            "hash": "MJCBWPMBFCUHBP-NPULLEENSA-N",
            "id": "InChI=1S/C12H12N2O3.C10H21N/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;1-9(11-2)8-10-6-4-3-5-7-10/h3-7H,2H2,1H3,(H2,13,14,15,16,17);9-11H,3-8H2,1-2H3/t;9-/m.0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 387.524,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 387.252191935,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.",
        "link": "https://go.drugbank.com/drugs/DB09001",
        "type": "Small Molecule",
        "synonyms": [
            "Barbexaclon",
            "Barbexaclona",
            "Barbexaclone",
            "Barbexaclonum"
        ],
        "indication": "Created for the treatment for epilepsy, with the intent of creating an antiepileptic with less sedative properties than phenobarbital. \nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how"
    },
    {
        "smiles": "COC1=CC2=C(C=C1)C1=C(N2)C(C)=NCC1",
        "id": "DB13875",
        "molecule": "Harmaline",
        "cas": "304-21-2",
        "iupac_name": "7-methoxy-1-methyl-3H,4H,9H-pyrido[3,4-b]indole",
        "inchi": {
            "hash": "RERZNCLIYCABFS-UHFFFAOYSA-N",
            "id": "InChI=1S/C13H14N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-4,7,15H,5-6H2,1-2H3"
        },
        "weight": [
            {
                "type": "average",
                "weight": 214.2631,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 214.11061308,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as harmala alkaloids. These are compounds with a structure based on harmaline, harmine, harmalol, harman or a derivative of those parents. These parents are beta-carbolines, consisting of a pyrimidine fused to the pyrrole moiety of an indole to form a pyrido[3,4-b]indole.",
        "link": "https://go.drugbank.com/drugs/DB13875",
        "type": "Small Molecule",
        "is_stub": true,
        "moa": [
            {
                "action": "inhibitor",
                "organism": "Humans",
                "target": "UHistamine N-methyltransferase"
            }
        ]
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07996"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB13077"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07753"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01747"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11387"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB07803"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB02628"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB03363"
    },
    {
        "smiles": "OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC2=CC(CCC(O)=O)=CC=C2O)CC(O)=O)=C1)C(O)=O)C(O)=O",
        "id": "DB16303",
        "molecule": "Gallium-68 PSMA",
        "cas": "1366302-52-4",
        "iupac_name": "(2S)-2-({[(1S)-1-carboxy-5-(6-{3-[3-({[2-({[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl}(carboxymethyl)amino)ethyl](carboxymethyl)amino}methyl)-4-hydroxyphenyl]propanamido}hexanamido)pentyl]carbamoyl}amino)pentanedioic acid",
        "inchi": {
            "hash": "QJUIUFGOTBRHKP-LQJZCPKCSA-N",
            "id": "InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1"
        },
        "weight": [
            {
                "type": "average",
                "weight": 947.005,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 946.41714456,
                "units": "Da"
            }
        ],
        "link": "https://go.drugbank.com/drugs/DB16303",
        "type": "Small Molecule",
        "synonyms": [
            "Psma-hbed-cc"
        ],
        "is_stub": true
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB06847"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB11901"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08208"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB01706"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB12325"
    },
    {
        "inchi": {},
        "link": "https://go.drugbank.com/drugs/DB08672"
    },
    {
        "smiles": "ClC1=CC(Cl)=C(Cl)C=C1OCC#CI",
        "id": "DB00793",
        "molecule": "Haloprogin",
        "cas": "777-11-7",
        "iupac_name": "1,2,4-trichloro-5-[(3-iodoprop-2-yn-1-yl)oxy]benzene",
        "background": "Haloprogin is used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet). Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but it is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. Haloprogin is no longer available in the United States and has been discontinued. \n",
        "inchi": {
            "hash": "CTETYYAZBPJBHE-UHFFFAOYSA-N",
            "id": "InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2"
        },
        "weight": [
            {
                "type": "average",
                "weight": 361.391,
                "units": "Da"
            },
            {
                "type": "monoisotopic",
                "weight": 359.837241291,
                "units": "Da"
            }
        ],
        "description": "This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.",
        "link": "https://go.drugbank.com/drugs/DB00793",
        "type": "Small Molecule",
        "synonyms": [
            "Haloprogin",
            "Haloprogina",
            "Haloprogine",
            "Haloproginum"
        ],
        "indication": "Used to treat fungal (Tinea) skin infections such as athlete's foot, jock itch, ringworm, and tinea versicolor.\nReduce drug development failure ratesBuild, train, \u0026 validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, \u0026 validate predictive machine-learning models with structured datasets.See how",
        "pharmacodynamics": "Used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet).\n"
    }
]